PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	STRAUSS, JK; MAHER, LJ				STRAUSS, JK; MAHER, LJ			DNA BENDING BY ASYMMETRIC PHOSPHATE NEUTRALIZATION	SCIENCE			English	Article							INTRINSICALLY BENT DNA; CRYSTAL-STRUCTURE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATES; GENE-EXPRESSION; PROTEIN; OLIGONUCLEOTIDES; CURVATURE; COMPLEX; FLEXIBILITY; ADENINE	DNA is often bent when complexed with proteins. Understanding the forces responsible for DNA bending would be of fundamental Value in exploring the interplay of these macromolecules. A series of experiments was devised to test the hypothesis that proteins with cationic surfaces can induce substantial DNA bending by neutralizing phosphates on one DNA face. Repulsions between phosphates in the remaining anionic helix are predicted to result in an unbalanced compression force acting to deform the DNA toward the protein. This hypothesis is supported by the results of electrophoretic experiments in which DNA spontaneously bends when one helical face is partially modified by incorporation of neutral phosphate analogs. Phasing with respect to a site of intrinsic DNA curvature (hexadeoxyadenylate tract) permits estimation of the electrostatic bend angle, and demonstrates that such modified DNAs are deformed toward the neutralized surface, as predicted. Similar model systems may be useful in exploring the extent to which phosphate neutralization can account for DNA bending by particular proteins.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727-08] Funding Source: Medline; NIGMS NIH HHS [GM47814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.ge.23.120189.001303; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P2349, DOI 10.1021/bi00175a001; BOWER M, 1987, NUCLEIC ACIDS RES, V15, P4915, DOI 10.1093/nar/15.12.4915; CALLAHAN L, 1986, P NATL ACAD SCI USA, V83, P1617, DOI 10.1073/pnas.83.6.1617; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HAN F, 1990, NUCLEIC ACIDS RES, V18, P2759, DOI 10.1093/nar/18.9.2759; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HOGREFE RI, 1993, NUCLEIC ACIDS RES, V21, P2031, DOI 10.1093/nar/21.9.2031; IKEDA K, 1993, GENE, V136, P341; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KAN LS, 1980, BIOCHEMISTRY-US, V19, P2122, DOI 10.1021/bi00551a020; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MCGHEE JD, 1980, NUCLEIC ACIDS RES, V8, P2751, DOI 10.1093/nar/8.12.2751; MILLER PS, 1988, ANNU REP MED CHEM, V23, P295; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MILLER PS, 1990, HERPESVIRUSES IMMUNE, P343; NOBLE SA, 1984, NUCLEIC ACIDS RES, V12, P3387, DOI 10.1093/nar/12.7.3387; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; UHLMANN E, 1990, CHEM REV, V90, P544; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	50	268	274	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1829	1834		10.1126/science.7997878	http://dx.doi.org/10.1126/science.7997878			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997878				2022-12-01	WOS:A1994PX38300027
J	BLAU, JN				BLAU, JN			MIGRAINE IN DOCTORS - WORK LOSS AND CONSUMPTION OF MEDICATION	LANCET			English	Editorial Material							HEADACHE				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BOSANQUET N, 1992, BR J MED EC, V2, P82; HONKASALO ML, 1993, HEADACHE, V33, P403, DOI 10.1111/j.1526-4610.1993.hed3308403.x; Jarcho S, 1967, B N Y ACAD MED, V43, P1224; JONES A, 1980, J INT MED RES, V8, P321, DOI 10.1177/030006058000800503; LIPTON RB, 1993, NEUROLOGY, V43, P6; RASMUSSEN BK, 1991, HEADACHE, V31, P290, DOI 10.1111/j.1526-4610.1991.hed3105290.x	6	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1623	1624		10.1016/S0140-6736(94)90413-8	http://dx.doi.org/10.1016/S0140-6736(94)90413-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983999				2022-12-01	WOS:A1994PW05100016
J	CHANFREAU, G; JACQUIER, A				CHANFREAU, G; JACQUIER, A			CATALYTIC SITE COMPONENTS COMMON TO BOTH SPLICING STEPS OF A GROUP-II INTRON	SCIENCE			English	Article							RNA; SPLICEOSOME; MECHANISM; LARIAT	The splicing of group II introns occurs in two steps involving substrates with different chemical configurations. The question of whether these two steps are catalyzed by a single or two separate active sites is a matter of debate. Here, certain bases and phosphate oxygen atoms at conserved positions in domain V of a group II self-splicing intron are shown to be required for catalysis of both splicing steps. These results show that the active sites catalyzing the two steps must, at least, share common components, ruling out the existence of two completely distinct active sites in group II introns.	INST PASTEUR, DEPT BIOL MOLEC,UNITE GENET MOLEC LEVURES,CNRS, URA 1149, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				JACQUIER, ALAIN/0000-0001-5707-9184				BACHL J, 1990, J MOL BIOL, V212, P113, DOI 10.1016/0022-2836(90)90308-9; CHANFREAU G, UNPUB; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CONWAY L, 1989, METHOD ENZYMOL, V180, P369; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NILSEN T, COMMUNICATION; PEEBLES C, COMMUNICATION; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; PYLE AM, COMMUNICATION; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303	18	114	118	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1383	1387		10.1126/science.7973729	http://dx.doi.org/10.1126/science.7973729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973729				2022-12-01	WOS:A1994PT63200044
J	GUTTMAN, DS; DYKHUIZEN, DE				GUTTMAN, DS; DYKHUIZEN, DE			CLONAL DIVERGENCE IN ESCHERICHIA-COLI AS A RESULT OF RECOMBINATION, NOT MUTATION	SCIENCE			English	Article							MOLECULAR EVOLUTION; NATURAL-POPULATIONS; BACTERIA; CHROMOSOME; SEQUENCES; BOOTSTRAP; DNA	Nucleotide sequence analysis was performed on 12 natural isolates of Escherichia coli in four loci located in close proximity on the chromosome. A comparison of gene genealogies indicated that three recombination events have occurred in a subset of the strains (ECOR group A) in the time since their divergence from a common ancestor, while during the same time, no mutational divergence has occurred. The common ancestor of this subset existed no more than 2400 years ago, and recombination was shown to occur at a rate of 5.0 x 10(-9) changes per nucleotide per generation-50-fold higher than the mutation rate. Thus, recombination has been the dominant force driving the clonal divergence of the ECOR group A strains and must be considered a significant factor in structuring E. coli populations.			GUTTMAN, DS (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,DIV BIOL SCI,STONY BROOK,NY 11794, USA.		Guttman, David S/A-7839-2011	Guttman, David S/0000-0001-8479-3869	NIAID NIH HHS [AI32454] Funding Source: Medline; NIGMS NIH HHS [GM3020] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Drake J.W., 1970, MOL BASIS MUTATION; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; DYKHUIZEN DE, UNPUB; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GUTTMAN DS, IN PRESS GENETICS; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; HUDSON RR, 1985, GENETICS, V111, P147; LAWRENCE JG, 1992, GENETICS, V131, P753; LAWRENCE JG, 1992, GENETICS, V131, P9; MARGOLIN P, 1987, ESCHERICHIA COLI SAL, V2, P1154; MILKMAN R, 1988, GENETICS, V120, P359; MILKMAN R, 1990, GENETICS, V126, P505; MILKMAN R, 1993, GENETICS, V133, P455; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; RUDD KE, 1992, SHORT COURSE BACTERI; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SELANDER RK, 1987, ESCHERICHIA COLI SAL, V2, P1625; SMITH JM, 1993, P NATL ACAD SCI USA, V90, P4384, DOI 10.1073/pnas.90.10.4384; Swofford D. L., 1993, ILLINOIS NATURAL HIS; VALDES AM, 1992, EVOLUTION, V46, P641, DOI 10.1111/j.1558-5646.1992.tb02072.x; WHITTAM TS, 1983, P NATL ACAD SCI-BIOL, V80, P1751, DOI 10.1073/pnas.80.6.1751; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1980, NATURE, V283, P212, DOI 10.1038/283212a0	26	321	328	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1380	1383		10.1126/science.7973728	http://dx.doi.org/10.1126/science.7973728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973728				2022-12-01	WOS:A1994PT63200043
J	MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP				MOSBACHER, J; SCHOEPFER, R; MONYER, H; BURNASHEV, N; SEEBURG, PH; RUPPERSBERG, JP			A MOLECULAR DETERMINANT FOR SUBMILLISECOND DESENSITIZATION IN GLUTAMATE RECEPTORS	SCIENCE			English	Article							AMPA-KAINATE RECEPTORS; RAT HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; OPERATED CHANNELS; ION FLOW; PERMEABILITY; SUBUNITS; NEURONS; CELLS; CURRENTS	The decay of excitatory postsynaptic currents in central neurons mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors is likely to be shaped either by receptor desensitization or by offset after removal of glutamate from the synaptic cleft. Native AMPA receptors show desensitization time constants of 1 to about 10 milliseconds, but the underlying molecular determinants of these large differences are unknown. Cloned AMPA receptors carrying the ''flop'' splice variants of glutamate receptor subtype C (GluR-C) and GluR-D are shown to have desensitization time constants of around 1 millisecond, whereas those with the ''flip'' variants are about four ti mes slower. Cerebellar granule cells switch their expression of GluR-D splice variants from mostly flip forms in early stages to predominantly flop forms in the adult rat brain. These findings suggest that rapid desensitization of AM PA receptors can be regulated by the expression and alternative splicing of GluR-D gene transcripts.	UNIV TUBINGEN,EAR NOSE & THROAT HOSP,DEPT SENSORY BIOPHYS,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST MED RES,D-69028 HEIDELBERG,GERMANY; UNIV LONDON UNIV COLL,DEPT PHARMACOL,WELLCOME LAB MOLEC PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society; University of London; University College London; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1993, CELL PHYSIOL BIOCHEM, V3, P318, DOI 10.1159/000154696; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DUDEL J, 1987, NEUROSCI LETT, V77, P199; Edmonds B., 1993, Society for Neuroscience Abstracts, V19, P1515; GALLO V, 1992, J NEUROSCI, V12, P1010; HACKETT JT, 1982, NEUROSCIENCE, V7, P1455, DOI 10.1016/0306-4522(82)90257-3; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W	27	485	491	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1059	1062		10.1126/science.7973663	http://dx.doi.org/10.1126/science.7973663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973663				2022-12-01	WOS:A1994PQ92400050
J	BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS				BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS			TESTING RECKLESS DRIVERS FOR COCAINE AND MARIJUANA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-USE; ALCOHOL; ABSTINENCE; ABUSERS; TRAUMA	Background. Driving under the influence of intoxicating drugs other than alcohol may be an important cause of traffic injuries. We used a rapid urine test to identify reckless drivers who were under the influence of cocaine or marijuana. Methods. We conducted a consecutive-sample study in Memphis, Tennessee, in the summer of 1993. Subjects arrested for reckless driving who were not apparently impaired by alcohol (did not have an odor of alcohol, tested negative on breath analysis, or both) were tested for cocaine and marijuana at the scene of arrest. The results of the drug tests were compared with clinical evaluations of intoxication made at the scene by a police officer. Results. A total of 175 subjects were stopped for reckless driving, and 150 (86 percent) submitted urine samples for drug testing at the scene of arrest. Eighty-eight of the 150 (59 percent) tested positive: 20 (13 percent) for cocaine, 50 (33 percent) for marijuana, and 18 (12 percent) for both drugs. Ninety-four of the 150 tested drivers were clinically considered to be intoxicated, and 80 of them (85 percent) tested positive for cocaine or marijuana. The intoxicated drivers had a broad range of affects and appearances. Nearly half the drivers intoxicated with cocaine performed normally on standard sobriety tests. Conclusions. Over half of the reckless drivers who were not intoxicated with alcohol were found to be intoxicated with other drugs. Toxicologic testing at the scene is a practical means of identifying drivers under the influence of drugs and is a useful adjunct to standard behavioral sobriety testing.	UNIV TENNESSEE,METHODIST HOSP,DEPT EMERGENCY MED,MEMPHIS,TN; MEMPHIS POLICE DEPT,MEMPHIS,TN; MEMPHIS STATE UNIV,DEPT ANTHROPOL,MEMPHIS,TN	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis								BROOKOFF D, 1993, AM J PUBLIC HEALTH, V83, P369, DOI 10.2105/AJPH.83.3.369; BURKE WM, 1990, J CLIN PSYCHIAT, V51, P145; BYCK R, 1977, COCAINE OTHER STIMUL, P629; CHAVKIN W, 1991, JAMA-J AM MED ASSOC, V266, P1556, DOI 10.1001/jama.266.11.1556; DACKIS CA, 1982, AM J PSYCHIAT, V139, P1196; EVANS DG, 1990, DRUG TESTING LAW TEC; FELL JC, 1993, MMWR-MORBID MORTAL W, V42, P605; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GRANT BF, 1990, DRUG ALCOHOL DEPEN, V25, P97, DOI 10.1016/0376-8716(90)90147-7; KIRBY JM, 1992, SOUTHERN MED J, V85, P800, DOI 10.1097/00007611-199208000-00003; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P529, DOI 10.1001/jama.255.4.529; MARSDEN ME, 1988, PREV MED, V17, P366, DOI 10.1016/0091-7435(88)90011-4; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MOSKOWITZ H, 1976, ACCIDENT ANAL PREV, V8, P45, DOI 10.1016/0001-4575(76)90033-6; MOSKOWITZ H, 1993, 1993 P INT C ALC DRU, P612; PANNER MJ, 1986, HASTINGS CENT REP, V16, P7, DOI 10.2307/3562082; RAFAELSEN OJ, 1973, SCIENCE, V179, P920, DOI 10.1126/science.179.4076.920; REMALEY AT, 1988, CLIN CHEM, V34, P1933; RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307; SAYLOR KE, 1992, JAMA-J AM MED ASSOC, V267, P652, DOI 10.1001/jama.267.5.652; SKOLNICK A, 1990, JAMA-J AM MED ASSOC, V263, P3122; WEISS RD, 1988, AM J MED, V85, P879; WIDMARK EMP, 1981, PRINCIPLES APPLICATI; 1985, DHHS ADM851386 DEP H; 1985, JAMA-J AM MED ASSOC, V254, P2618; 1991, DRUNK DRIVING FACTS; 1986, FIELD EVALUATION LOS; 1988, FED REGISTER, V53, P970; 1992, DRUGS CRIME JUSTICE; 1988, USE CONTROLLED SUBST; 1992, DRUG EVALUATION CLAS	33	83	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					518	522		10.1056/NEJM199408253310807	http://dx.doi.org/10.1056/NEJM199408253310807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041419				2022-12-01	WOS:A1994PD07200007
J	MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP				MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP			REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR	NATURE			English	Article							MURINE TUMOR; MONO MAC-6; ACTIVATION; EXPRESSION; SECRETION; CLONING	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory agent produced primarily by activated monocytes and macrophages(1). TNF-alpha is synthesized as a precursor protein of M(r) 26,000 (26K) which is processed to a secreted 17K mature form by cleavage of an Ala-Val bond between residues 76-77. The enzyme(s) responsible for processing pro-TNF-alpha has yet to be identified. Here, we describe the capacity of a metalloproteinase inhibitor, GI 129471, to block TNF-alpha secretion both in vitro and in vivo. The inhibition is specific to TNF-alpha; the production of other secreted cytokines, such as the interleukins IL-1 beta, IL-2, or IL-6, is not inhibited. The mechanism of inhibition occurs at a post-translational step in TNF-alpha production. Our data suggest that TNF-alpha processing is mediated by a unique Zn2+ endopeptidase which is inhibited by GI 129471 and would represent a novel target for therapeutic intervention in TNF-alpha associated pathologies.	DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DEPT MED,DURHAM,NC 27710; MCGILL UNIV,JEWISH GEN HOSP,DEPT ONCOL,MONTREAL H3T 1E2,PQ,CANADA; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27516	Duke University; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	MCGEEHAN, GM (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Schoenen, Frank/0000-0003-2711-1117				BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLACK RA, 1992, CYTOKINE, V3, P480; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; CAMPION C, 1990, Patent No. 05719; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KIM KU, 1993, IMMUNOLOGY, V80, P134; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; NIEHORSTER M, 1990, BIOCHEM PHARMACOL, V40, P1601, DOI 10.1016/0006-2952(90)90461-S; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SCUDERI P, 1989, J IMMUNOL, V143, P168; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERGHESE MW, 1981, J IMMUNOL, V127, P288; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	26	546	607	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					558	561		10.1038/370558a0	http://dx.doi.org/10.1038/370558a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052311				2022-12-01	WOS:A1994PC53700055
J	CHAISSON, RE				CHAISSON, RE			SMOKING CESSATION IN PATIENTS WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CIGARETTE-SMOKING; HOMOSEXUAL MEN; INFECTION; PROGRESSION; SUBSETS; AIDS				CHAISSON, RE (corresponding author), JOHNS HOPKINS UNIV,BALTIMORE,MD, USA.							BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BUSHKIN SE, 1992, 8TH INT C AIDS 3 STD; CAIAFFA WT, 1993, 11TH INT C AIDS BERL; CRAIB KJP, 1992, CLIN INVEST MED, V15, P301; HIRSCHTICK R, 1993, AM REV RESPIR DIS, V147, pA1003; NIEMAN R, 1992, 8TH INT C AIDS 3 STD; NIEMAN RB, 1993, AIDS, V7, P705, DOI 10.1097/00002030-199305000-00015; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P612, DOI 10.1164/ajrccm/144.3_Pt_1.612	11	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	564						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046815				2022-12-01	WOS:A1994PB22900038
J	NIGHTINGALE, SL				NIGHTINGALE, SL			COMBINATION TUBERCULOSIS DRUG APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-01	WOS:A1994NY90300004
J	LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N				LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N			INTEGRATION AND GERM-LINE TRANSMISSION OF A PSEUDOTYPED RETROVIRAL VECTOR IN ZEBRAFISH	SCIENCE			English	Article							LEUKEMIA-VIRUS; CELLS; GENE; MICE	The zebrafish is rapidly becoming a popular model system for the study of vertebrate development because it is ideal for both embryological studies and genetic analysis. To determine if a retroviral vector pseudotyped with the envelope glycoprotein of the vesicular stomatitis virus could infect zebrafish embryos, and in particular, the cells destined to become the germ line, a pseudotyped virus was injected into blastula-stage zebrafish embryos. Fifty-one embryos were allowed to develop and eight transmitted proviral DNA to their progeny. Founders were mosaic, but as expected, transgenic F-1's transmitted proviral DNA in a Mendelian fashion to the F-2 progeny. Transgenic F-1 fish inherited a single integrated provirus, and a single founder could transmit more than one viral integration to its progeny. These results demonstrate that this pantropic pseudotyped vector, originally developed for human gene therapy, will make the use of retroviral vectors in zebrafish possible.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,SCH MED,DEPT PEDIAT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; University of California System; University of California San Diego			Burns, Jane C/J-6167-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020034] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001855] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NHLBI NIH HHS [HL-01855] Funding Source: Medline; NICHD NIH HHS [HD-20034] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CEPKO CL, 1993, METHOD ENZYMOL, V225, P933; CHEN J, 1994, METH MOL G, V4, P123; CULP P, UNPUB; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAIANO N, UNPUB; GRIDLEY T, 1987, TRENDS GENET, V3, P162, DOI 10.1016/0168-9525(87)90218-6; GRUNWALD DJ, 1992, GENET RES, V59, P103, DOI 10.1017/S0016672300030317; HUSZAR D, 1991, DEVELOPMENT, V113, P653; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; NJOLSTAD PR, 1988, FEBS LETT, V230, P25, DOI 10.1016/0014-5793(88)80634-3; RIGGLEMAN R, UNPUB; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	21	221	239	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					666	669		10.1126/science.8036514	http://dx.doi.org/10.1126/science.8036514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036514				2022-12-01	WOS:A1994NZ53800034
J	SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M				SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M			DIETARY N-3 POLYUNSATURATED FATTY-ACIDS AND SMOKING-RELATED CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; FISH-OIL; SUPPLEMENTATION; EMPHYSEMA; NEUTROPHIL; GENERATION; INVITRO; HEALTH	Background. Fish contain n-3 polyunsaturated fatty acids, principally eicosapentaenoic acid and docosahexaenoic acid, which are known to interfere with the body's inflammatory response and may be of benefit in chronic inflammatory conditions. Methods. We studied the relation between the dietary intake of n-3 fatty acids and chronic obstructive pulmonary disease (COPD) in 8960 current or former smokers participating in a population-based study of atherosclerosis. Intake of fatty acids was estimated with a dietary questionnaire. The presence of COPD was assessed by a questionnaire on respiratory symptoms and by spirometry. Three case definitions of COPD were used: symptoms of chronic bronchitis (667 subjects), physician-diagnosed emphysema reported by the subject (185 subjects), and spirometrically detected COPD (197 subjects). Results. After control for pack-years of smoking, age, sex, race, height, weight, energy intake, and educational level, the combined intake of eicosapentaenoic acid and docosahexaenoic acid was inversely related to the risk of COPD in a quantity-dependent fashion. The adjusted odds ratio for the highest quartile of intake as compared with the lowest quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85; P<0.001 for linear trend across the range of intake values), 0.31 for physician-diagnosed emphysema (95 percent confidence interval, 0.18 to 0.52; P for linear trend, 0.003), and 0.50 for spirometrically detected COPD (95 percent confidence interval, 0.32 to 0.79; P for linear trend, 0.007). Conclusions. A high dietary intake of n-3 fatty acids may protect cigarette smokers against COPD.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; IST NAZL RIC CANC, ENVIRONM EPIDEMIOL SERV, I-16132 GENOA, ITALY; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CTR COLLABORAT STUDIES COORDINATING, CHAPEL HILL, NC USA	Johns Hopkins University; University of Genoa; IRCCS AOU San Martino IST; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill	SHAHAR, E (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055022] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55022, N01-HC-55015, N01-HC-55016] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; AOKI M, 1989, CHEST, V96, pS343, DOI 10.1378/chest.96.3_Supplement.343S; COMSTOCK GW, 1973, ARCH ENVIRON HEALTH, V27, P143, DOI 10.1080/00039896.1973.10666343; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FISHER M, 1991, WORLD REV NUTR DIET, V66, P245; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOOGSTEDEN HC, 1991, MEDIATORS PULMONARY, P185; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MCGOWAN SE, 1989, NEW ENGL J MED, V321, P968, DOI 10.1056/NEJM198910053211410; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67, DOI 10.1093/oxfordjournals.aje.a115644; SILVERMAN DI, 1990, AM J CARDIOL, V66, P860, DOI 10.1016/0002-9149(90)90367-A; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SPERLING RI, 1987, J IMMUNOL, V139, P4186; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; TOCKMAN MS, 1985, CHRONIC OBSTRUCTIVE, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; ZAKRZEWSKI JT, 1987, PROSTAGLANDINS, V33, P663, DOI 10.1016/0090-6980(87)90033-5; 1990, SAS STAT USERS GUIDE; 1976, COMPOSITION FOODS RA; 1981, FOOD CONSUMPTION STA	30	143	151	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					228	233		10.1056/NEJM199407283310403	http://dx.doi.org/10.1056/NEJM199407283310403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015569				2022-12-01	WOS:A1994NY33500003
J	JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ				JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ			PHOSPHORYLATION AND ACTIVATION OF THE JAK-3 JANUS KINASE IN RESPONSE TO INTERLEUKIN-2	NATURE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; RECEPTOR-BETA; INTERFERON-ALPHA/BETA; IL-2; SUBUNIT; CHAIN; PATHWAY	LUTERLEUKIN-2 is an autocrine growth factor for T cells(1,2) which also activates other cells including B cells(3) and natural killer cells(4). The subunits of the interleukin-2 receptor (IL-2R) lack intrinsic enzymatic activity, but protein tyrosine phosphorylation is a critical event following ligand binding and src family kinases, such as Lck, are known to be activated by IL-2 (refs 5-9). However, IL-2 signalling can occur in the absence of receptor interaction with Lck, suggesting that other protein tyrosine kinases might be important(10). Here we report that a new member of the Janus family of kinases (Jak-3) is coupled to the IL-2R in human peripheral blood T cells and natural killer cells.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PRI DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS INC, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	JOHNSTON, JA (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, LEUKOCYTE CELL BIOL SECT, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015					ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENRY CS, 1981, NATURE, V291, P335; KAWAMURA M, IN PRESS P NATN ACAD; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANIGUCHI T, 1988, A REV IMMUN, V4, P69; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	546	569	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					151	153		10.1038/370151a0	http://dx.doi.org/10.1038/370151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022485	Green Submitted			2022-12-01	WOS:A1994NW80400060
J	COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ				COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ			DISRUPTION OF C-MOS CAUSES PARTHENOGENETIC DEVELOPMENT OF UNFERTILIZED MOUSE EGGS	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS EGGS; KINASE; GENE; FERTILIZATION; EXPRESSION; ACTIVATION; OOCYTES	THE c-mos proto-oncogene encodes a 37-39K cytoplasmic serine/threonine kinase(1) implicated in the meiotic maturation events during murine spermatogenesis(2) and oogenesis(3-6). In Xenopus, ectopic expression of pp39(mos) can promote both the meiotic maturation of oocytes(7-9) and also arrest the cleavage of blastomeres(10) To elucidate the role of pp39(mos) we have generated homozygous mutant mice by gene targeting in embryonic stem cells(11). These mice are viable and mutant males are fertile, demonstrating that pp39(mos) is not essential for spermatogenesis. In contrast, mutant females, have a reduced fertility because of the failure of mature eggs to arrest during meiosis. c-mos(-1-) oocytes undergo germinal vesicle breakdown and extrusion of both polar bodies followed in some cases by progression into cleavage. Mutant females also develop ovarian cysts. These results demonstrate that a major role for pp39(mos) is to prevent the spontaneous parthenogenetic activation of unfertilized eggs.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND; RUAKURA AGR CTR,HAMILTON,NEW ZEALAND	University of Cambridge; AgResearch - New Zealand	COLLEDGE, WH (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND.		Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Bradley A, 1991, Curr Opin Biotechnol, V2, P823, DOI 10.1016/S0958-1669(05)80114-4; EPPIG JJ, 1993, METHOD ENZYMOL, V225, P77; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hogan B., 1986, MANIPULATING MOUSE E; KAUFMAN MH, 1986, GAMETE RES, V14, P255, DOI 10.1002/mrd.1120140309; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1988, ONCOGENE, V2, P227; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Talerman A, 1992, Curr Top Pathol, V85, P165; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	23	403	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					65	68		10.1038/370065a0	http://dx.doi.org/10.1038/370065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015609				2022-12-01	WOS:A1994NV71100060
J	ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR				ALLAND, D; KALKUT, GE; MOSS, AR; MCADAM, RA; HAHN, JA; BOSWORTH, W; DRUCKER, E; BLOOM, BR			TRANSMISSION OF TUBERCULOSIS IN NEW-YORK-CITY - AN ANALYSIS BY DNA-FINGERPRINTING AND CONVENTIONAL EPIDEMIOLOGIC METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; COMPLEX STRAINS; INFECTION; OUTBREAK; HOMELESS; SHELTER; RISK; TOOL	Background. The incidence of tuberculosis and drug resistance is increasing in the United States, but it is not clear how much of the increase is due to reactivation of latent infection and how much to recent transmission. Methods. We performed DNA fingerprinting using restriction-fragment-length polymorphism (RFLP) analysis of at least one isolate from every patient with confirmed tuberculosis at a major hospital in the Bronx, New York, from December 1, 1989, through December 31, 1992. Medical records and census-tract data were reviewed for relevant clinical, social, and demographic data. Results. Of 130 patients with tuberculosis, 104 adults (80 percent) had complete medical records and isolates whose DNA fingerprints could be evaluated. Isolates from 65 patients (62.5 percent) had unique RFLP patterns, whereas isolates from 39 patients (37.5 percent) had RFLP patterns that were identical to those of an isolate from at least 1 other study patient; the isolates in the latter group were classified into 12 clusters. Patients whose isolates were included in one of the clusters were inferred to have recently transmitted disease. Independent risk factors for having a clustered isolate included seropositivity for the human immunodeficiency virus (HIV) (odds ratio for Hispanic patients, 4.31; P = 0.02; for non-Hispanic patients, 3.12; P = 0.07), Hispanic ethnicity combined with HIV seronegativity (odds ratio, 5.13; P = 0.05), infection with drug-resistant tuberculosis (odds ratio, 4.52; P = 0.005), and younger age (odds ratio, 1.59; P = 0.02). Residence in sections of the Bronx with a median household income below $20,000 was also associated with having a clustered isolate (odds ratio, 3.22; P = 0.04). Conclusions. In the inner-city community we studied, recently transmitted tuberculosis accounts for approximately 40 percent of the incident cases and almost two thirds of drug-resistant cases. Recent transmission of tuberculosis, and not only reactivation of latent disease, contributes substantially to the increase in tuberculosis.	MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10467; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; City University of New York (CUNY) System; Lehman College (CUNY)	ALLAND, D (corresponding author), MONTEFIORE MED CTR,N CENT BRONX HOSP,DEPT MED,DIV INFECT DIS,111 E 210 ST,BRONX,NY 10467, USA.		Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Kalkut, Gary/0000-0002-6160-2262	NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007183] Funding Source: NIH RePORTER; NCI NIH HHS [2T32CA09173-16] Funding Source: Medline; NIAID NIH HHS [T32AI07183-14, T32AI07183-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOBKIN J, 1993, 9 INT C AIDS JUN 6 1, P324; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Hewlett D. Jr., 1993, Morbidity and Mortality Weekly Report, V42, P427; Kent PT, 1985, GUIDE LEVEL 3 LAB; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STYBLO K, 1984, EPIDEMIOLOGY TUBERCU; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1993, TUBERCULOSIS NEW YOR; 1990, MMWR-MORBID MORTAL W, V39, P9; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, TUBERCULOSIS NEW YOR; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P703	28	760	778	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1710	1716		10.1056/NEJM199406163302403	http://dx.doi.org/10.1056/NEJM199406163302403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7993412	Bronze			2022-12-01	WOS:A1994NR10900003
J	PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC				PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC			NEW METHOD FOR MEASURING COMPLIANCE WITH LONG-TERM OXYGEN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,DEPT MED PHYS,LONDON SW17 0QT,ENGLAND; ST ALBANS HOSP,DEPT CHEST MED,ST ALBANS AL3 5PN,HERTS,ENGLAND	St Georges University London	PHILLIPS, GD (corresponding author), UNIV LONDON ST GEORGES HOSP,CHEST CLIN,LONDON SW17 0QT,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; Williams B, 1991, Health Trends, V23, P166; 1986, DHSS FPN398 DEP HLTH	4	6	6	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1544	1545		10.1136/bmj.308.6943.1544	http://dx.doi.org/10.1136/bmj.308.6943.1544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019312	Green Published			2022-12-01	WOS:A1994NR11000025
J	KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC				KIM, JS; URBAN, RG; STROMINGER, JL; WILEY, DC			TOXIC SHOCK SYNDROME TOXIN-1 COMPLEXED WITH A CLASS-II MAJOR HISTOCOMPATIBILITY MOLECULE HLA-DR1	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; HIGH-AFFINITY BINDING; RECEPTOR BETA-CHAIN; HLA-DR; T-CELLS; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; SUPERANTIGEN; ANTIGEN; IDENTIFICATION	The three-dimensional structure of a Staphylococcus aureus superantigen, toxic shock syndrome toxin-1 (TSST-1), complexed with a human class II major histocompatibility molecule (DR1), was determined by x-ray crystallography. The TSST-1 binding site on DR1 overlaps that of the superantigen S. aureus enterotoxin B (SEB), but the two binding modes differ. Whereas SEB binds primarily off one edge of the peptide binding site of DR1, TSST-1 extends over almost one-half of the binding site and contacts both the flanking alpha helices of the histocompatibility antigen and the bound peptide. This difference suggests that the T cell receptor (TCR) would bind to TSST-1:DR1 very differently than to DR1:peptide or SEB:DR1. It also suggests that TSST-1 binding may be dependent on the peptide, though less so than TCR binding, providing a possible explanation for the inability of TSST-1 to competitively block SEB binding to all DR1 molecules on cells (even though the binding sites of TSST-1 and SEB on DR1 overlap almost completely) and suggesting the possibility that T cell activation by superantigen could be directed by peptide antigen.	CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University								ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793, DOI 10.1128/IAI.61.3.793-799.1993; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; EDWIN C, 1991, J INFECT DIS, V163, P524, DOI 10.1093/infdis/163.3.524; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, EUR J IMMUNOL, V21, P1331, DOI 10.1002/eji.1830210537; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUDSON KR, COMMUNICATION; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MURRAY DL, 1993, 93RD GEN M AM SOC MI, V64; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SOOS JM, 1993, BIOCHEM BIOPH RES CO, V191, P1211, DOI 10.1006/bbrc.1993.1346; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, SCIENCE, V266, P1874, DOI 10.1126/science.7997881; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; WANG BC, 1985, METHOD ENZYMOL, V115, P90	44	249	258	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	1994	266	5192					1870	1874		10.1126/science.7997880	http://dx.doi.org/10.1126/science.7997880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997880				2022-12-01	WOS:A1994PX38300037
J	VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ				VARTIVARIAN, SE; PAPADAKIS, KA; PALACIOS, JA; MANNING, JT; ANAISSIE, EJ			MUCOCUTANEOUS AND SOFT-TISSUE INFECTIONS CAUSED BY XANTHOMONAS-MALTOPHILIA - A NEW SPECTRUM	ANNALS OF INTERNAL MEDICINE			English	Article							GRAM-NEGATIVE BACILLI; PSEUDOMONAS-MALTOPHILIA	Objective: To describe the mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia in patients with cancer. Design: A retrospective 15-month clinical study. Setting: Academic, referral-based cancer center. Patients: Of 237 patients with X. maltophilia isolated from all sites during the 15-month study period, 114 patients were judged to have true X. maltophilia infections. Only patients with mucocutaneous and soft tissue infections were included in the study. Results: 17 (15%) of the 114 patients with X. maltophilia infection had mucocutaneous and soft tissue infections: Six patients had metastatic cellulitis, 5 had primary cellulitis usually associated with catheter use, and 6 had infected mucocutaneous ulcers. The metastatic cellulitis consisted of previously undescribed multiple, hard, tender nodules with surrounding and distant cellulitis (5 patients) or ecthyma gangrenosum (1 patient). Four of these patients died of the infection. Metastatic cellulitis and mucocutaneous infections occurred in hospitalized, neutropenic patients who received broad-spectrum antibiotics (beta-lactams, quinolones), often with in vitro activity against the infecting organisms. Response usually correlated with recovery from myelosuppression and administration of trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate. Catheter removal contributed to response in the treatment of primary cellulitis. Conclusions: Mucocutaneous and soft tissue infections caused by X. maltophilia are not uncommon, and X. maltophilia can cause metastatic nodular skin lesions that mimic disseminated fungal infections. It also causes serious morbidity and high mortality in patients with metastatic skin nodules and can cause superinfections in patients receiving broad-spectrum beta-lactam or quinolone antibiotics to which the organisms are susceptible when the infections develop. Catheter removal contributes to a favorable outcome in patients with catheter-associated cellulitis without bacteremia. Xanthomonas maltophilia infection should be added to the differential diagnosis of mucocutaneous or soft tissue infection in patients with cancer. Trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate is the current treatment of choice for culture-proven infections, but early empiric therapy may improve outcome.			VARTIVARIAN, SE (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AGGER WA, 1986, REV INFECT DIS, V8, P927; BAGEL J, 1986, AM J MED, V80, P528, DOI 10.1016/0002-9343(86)90736-9; BALTIMORE RS, 1990, PEDIATR INFECT DIS J, V9, P143, DOI 10.1097/00006454-199002000-00017; BOTTONE EJ, 1986, J CLIN MICROBIOL, V24, P995, DOI 10.1128/JCM.24.6.995-997.1986; CALANDRA GB, 1992, CLIN INFECT DIS, V15, pS148, DOI 10.1093/clind/15.Supplement_1.S148; DYTE PH, 1977, MED J AUSTRALIA, V1, P444, DOI 10.5694/j.1326-5377.1977.tb130797.x; ELTING LS, 1990, MEDICINE, V69, P296, DOI 10.1097/00005792-199009000-00003; Fleming M G, 1987, Pediatr Dermatol, V4, P18, DOI 10.1111/j.1525-1470.1987.tb00746.x; GARDNER P, 1970, AM J MED, V48, P735, DOI 10.1016/S0002-9343(70)80009-2; GILARDI GL, 1972, ANN INTERN MED, V77, P211, DOI 10.7326/0003-4819-77-2-211; GILARDI GL, 1969, AM J CLIN PATHOL, V51, P58; HARLOWE HD, 1972, LARYNGOSCOPE, V82, P882, DOI 10.1288/00005537-197205000-00015; HOLMES B, 1979, J CLIN PATHOL, V32, P66, DOI 10.1136/jcp.32.1.66; Kealey G P, 1986, J Burn Care Rehabil, V7, P409, DOI 10.1097/00004630-198609000-00006; KERR KG, 1991, REV INFECT DIS, V13, P762; KHARDORI N, 1990, REV INFECT DIS, V12, P997; MARKLEY K, 1957, ANN SURG, V145, P175, DOI 10.1097/00000658-195702000-00005; MARSHALL WF, 1989, MAYO CLIN PROC, V64, P1097, DOI 10.1016/S0025-6196(12)64979-9; MORRISON AJ, 1986, J CLIN MICROBIOL, V24, P52, DOI 10.1128/JCM.24.1.52-55.1986; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; NAGAI T, 1984, J CLIN MICROBIOL, V20, P1003, DOI 10.1128/JCM.20.5.1003-1005.1984; PEDERSEN MM, 1970, AM J CLIN PATHOL, V54, P178; PHAM BN, 1992, ARCH DERMATOL, V128, P702, DOI 10.1001/archderm.128.5.702b; PICOU KA, 1979, ARCH DERMATOL, V115, P459, DOI 10.1001/archderm.115.4.459; REED RK, 1976, J PEDIATR-US, V88, P977, DOI 10.1016/S0022-3476(76)81054-2; ROBERTS R, 1982, JAMA-J AM MED ASSOC, V248, P2156, DOI 10.1001/jama.248.17.2156; SANGEORZAN JA, 1990, ARCH DERMATOL, V126, P832, DOI 10.1001/archderm.126.6.832; SCHLOSSBERG D, 1980, ARCH DERMATOL, V116, P446, DOI 10.1001/archderm.116.4.446; SOUTHERN PM, 1974, TEX REP BIOL MED, V32, P880; VARTIVARIAN S, 1994, ANTIMICROB AGENTS CH, V38, P624, DOI 10.1128/AAC.38.3.624; WISHART MM, 1976, MED J AUSTRALIA, V2, P710, DOI 10.5694/j.1326-5377.1976.tb128238.x; ZURAVLEFF JJ, 1982, REV INFECT DIS, V4, P1236	32	83	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					969	973		10.7326/0003-4819-121-12-199412150-00011	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978724				2022-12-01	WOS:A1994PW08300011
J	NIE, SM; CHIU, DT; ZARE, RN				NIE, SM; CHIU, DT; ZARE, RN			PROBING INDIVIDUAL MOLECULES WITH CONFOCAL FLUORESCENCE MICROSCOPY	SCIENCE			English	Article							SINGLE DNA-MOLECULES; CORRELATION SPECTROSCOPY; EXPERIMENTAL REALIZATION; GEL-ELECTROPHORESIS; OPTICAL MICROSCOPY; LIGHT-MICROSCOPY; PHYCOERYTHRIN; VISUALIZATION; MANIPULATION; DYES	Confocal fluorescence microscopy coupled with a diffraction-limited laser beam and a high-efficiency detection system has been used to study the diffusive movement and emission process of individual fluorescent molecules in the liquid phase at room temperature. The high detection sensitivity achieved at fast data acquisition speeds (greater than 1 kilohertz) allows real-time observation of single-molecule fluorescence without statistical analysis. The results show fluorescence-cycle saturation at the single-molecule level and multiple recrossings of a single molecule into and out of the probe volume as well as the triplet state.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University			Zare, Richard N./A-8410-2009; Nie, Shuming/E-4843-2011	Zare, Richard/0000-0001-5266-4253				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; ASIMOV MM, 1990, J LUMIN, V46, P243, DOI 10.1016/0022-2313(90)90020-C; AUZANNEAU I, 1993, CR ACAD SCI III-VIE, V316, P459; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.biophys.20.1.415; Dempster D. N., 1974, Journal of Photochemistry, V2, P343, DOI 10.1016/0047-2670(73)80032-2; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FELLER W, 1971, INTRO PROBABILITY TH, V1; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; MAGDE D, 1974, BIOPOLYMERS, V13, P1; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; NG KC, 1992, ANAL CHEM, V69, P2914; NGUYEN DC, 1987, ANAL CHEM, V59, P2158, DOI 10.1021/ac00144a032; ORRIT M, 1993, J PHYS CHEM-US, V97, P10256, DOI 10.1021/j100142a003; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185; RAMPINO NJ, 1991, ANAL BIOCHEM, V194, P278, DOI 10.1016/0003-2697(91)90230-Q; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNEIDER MB, 1981, APPL OPTICS, V20, P1382, DOI 10.1364/AO.20.001382; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOPER SA, 1993, PHOTOCHEM PHOTOBIOL, V57, P972, DOI 10.1111/j.1751-1097.1993.tb02957.x; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; WASHIZU M, 1990, IEEE T IND APPL, V26, P1165, DOI 10.1109/28.62403; WHITTEN WB, 1991, ANAL CHEM, V63, P1027, DOI 10.1021/ac00010a019; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361	36	518	584	3	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1018	1021		10.1126/science.7973650	http://dx.doi.org/10.1126/science.7973650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973650				2022-12-01	WOS:A1994PQ92400036
J	RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N				RODERICK, PJ; JONES, I; RALEIGH, VS; MCGEOWN, M; MALLICK, N			POPULATION NEED FOR RENAL REPLACEMENT THERAPY IN THAMES REGIONS - ETHNIC DIMENSION	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; PREVALENCE; FAILURE; INSULIN; CENSUS; ASIANS	Objectives-To determine the use of renal replacement therapy by ethnic origin and to ascertain the variation in provision of such therapy and to relate this to the distribution of ethnic minority populations. Design-Analysis of retrospective and cross sectional data from 19 renal units. Setting-All four Thames regional health authorities. Subjects-Patients resident in the Thames regions who were accepted as new patients for renal replacement therapy during 1991 and 1992 and the patients who were already undergoing such treatment between December 1992 and April 1993. Main outcome measures-Rates of acceptance for and prevalence of renal replacement therapy among white, black, and Asian people. Results-The average annual acceptance rates per million in 1991-2 were 61 for white people, 175 for black people, and 178 for Asians, and the prevalences per million were 351, 918, and 957 respectively. The relative risks increased with age. A threefold increase in the acceptance rate occurred in people aged under 55 in both the black and Asian populations, suggesting that the higher rates are probably not due to factors related to access alone. Treatment rates varied considerably among districts, reflecting both the distribution of ethnic minority populations and access to services. Conclusion-Black and Asian people receive and have a greater need for renal replacement therapy, and the need will increase as these populations age. These findings have important implications for the provision of renal services in districts with a high proportion of ethnic minorities and for the management of diabetes mellitus and hypertension, two important causes of end stage renal failure in these populations.	NW THAMES REG HLTH AUTHOR,LONDON,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON,ENGLAND; UNIV SURREY,INST PUBL HLTH,GUILDFORD,SURREY,ENGLAND; QUEENS UNIV BELFAST,BELFAST,ANTRIM,NORTH IRELAND; MANCHESTER ROYAL INFIRM,MANCHESTER,LANCS,ENGLAND	University of London; Queen Mary University London; University of Surrey; Queens University Belfast; University of Manchester				Jones, Ian/0000-0002-1682-9134				BALARAJAN R, 1978, OPCS SERIES DS, V9, P103; BEECH R, 1994, HLTH CARE NEEDS ASSE; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; COWIE CC, 1990, DIABETES, V321, P1074; CRUICKSHANK JK, 1991, LANCET, V338, P842, DOI 10.1016/0140-6736(91)91501-K; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; GARDNER MJ, 1989, STATISTICS CONFIDENC; GLOVER GR, 1993, BRIT MED J, V307, P506, DOI 10.1136/bmj.307.6902.506-a; HIATT RA, 1982, AM J PUBLIC HEALTH, V72, P829, DOI 10.2105/AJPH.72.8.829; HOPKINS A, 1993, ACCESSIBILITY HLTH C; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; MCGEOWN MG, 1990, BRIT MED J, V301, P900, DOI 10.1136/bmj.301.6757.900; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; PAZIANAS M, 1991, NEPHROL DIAL TRANSPL, V6, P931, DOI 10.1093/ndt/6.12.931; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SAMANTA A, 1986, BRIT MED J, V293, P366, DOI 10.1136/bmj.293.6543.366-a; SHULMAN NB, 1991, CIRCULATION, V83, P1477, DOI 10.1161/01.CIR.83.4.1477; THOMPSON EJ, 1993, BRIT MED J, V307, P803, DOI 10.1136/bmj.307.6907.803-b; 1991, PROVISION SERVICES A; [No title captured]; 1993, REPORT INDEPENDENT R; 1992, NEPHROL DIAL TRANSPL, V7, P10; 1994, 1991 CENSUS USER GUI	25	76	76	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1111	1114		10.1136/bmj.309.6962.1111	http://dx.doi.org/10.1136/bmj.309.6962.1111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987102	Green Published			2022-12-01	WOS:A1994PP69100018
J	CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM				CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM			EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED-STATES, 1985 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RACIAL-DIFFERENCES; SUSCEPTIBILITY; DISEASE; RISK	Objective.-To examine the distribution and sources of increased tuberculosis (TB) morbidity in the United States from 1985 through 1992. Design.-Review of TB surveillance data. Participants.-All incident TB cases in the United States reported to the Centers for Disease Control and Prevention from 1980 through 1992. Main Outcome Measures.-Changes in reported number of TB cases from 1985 through 1992 were analyzed by sex, race/ethnicity, age, country of birth (1986 through 1992), site of disease, geographic location; and socioeconomic status (through 1991). From 1985 through 1992, reported number of cases was compared with expected number of cases, extrapolated from 1980 through 1984 trends, to estimate excess cases by sex, race/ethnicity, and age. Results.-Increases in number of cases from 1985 through 1992 were concentrated among racial/ethnic minorities, persons 25 to 44 years of age, males, and the foreign-born. Excess cases occurred in both sexes, all racial/ethnic groups, and all age groups. Foreign-born cases accounted for 60% of the total increase in the number of US cases from 1986 through 1992 and had the greatest impact among Asians, Hispanics, females, and persons other than those 25 to 44 years of age. Human immunodeficiency virus infection had the greatest impact on TB morbidity among whites, blacks, males, and persons 25 to 44 years of age. From 1985 through 1992, the number of cases among children 4 years old or younger increased 36%, suggesting that transmission of TB increased during this period. Conclusions.-Multiple factors contributed to the recent increases in the number of TB cases. The effectiveness of TB screening in immigrants needs further evaluation. Intensified efforts to determine the human immunodeficiency virus status of persons with TB are needed. Screening of subpopulations at increased risk for tuberculous infection or TB should be expanded.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,OFF DIRECTOR,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	CANTWELL, MF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,1600 CLIFTON RD,E-10,ATLANTA,GA 30333, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; CAUTHEN GM, 1991, 7TH INT C AIDS FLOR; DRIVER CR, 1992, MAY AM LUNG ASS AM T; GLASSER D, 1978, MARYLAND PHARMAC JUL, P10; KUSHIGEMACHI M, 1984, J CHRON DIS, V37, P853, DOI 10.1016/0021-9681(84)90018-3; MANOFF SB, 1988, 4TH INT C AIDS STOCK; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; ONORATO I, 1993, 33RD INT C ANT AG NE; PITCHENIK AE, 1988, CLIN CHEST MED, V9, P425; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1986, CHEST, V90, P469, DOI 10.1378/chest.90.4.469; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1990, MMWR-MORBID MORTAL W, V39, P1; 1993, HIV AIDS SURVEILLANC, P1; 1992, CURRENT POPULATI P25; 1993, STATISTICAL YB IMMIG; [No title captured]; 1993, MMWR MORBID MORTAL W, V42, P696; 1991, TECHNICAL INSTRUCTIO; 1982, CENSUS POPULATION HO; 1992, AIDS PUBLIC INFORMAT; 1992, MMWR-MORBID MORTAL W, V41, P1	25	336	345	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					535	539		10.1001/jama.272.7.535	http://dx.doi.org/10.1001/jama.272.7.535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046808				2022-12-01	WOS:A1994PB22900031
J	CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH				CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH			T-CELL RECEPTOR-MHC CLASS-I PEPTIDE INTERACTIONS - AFFINITY, KINETICS, AND SPECIFICITY	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; BINDING; COMPLEX; ANTIGEN; MOLECULE; RECOGNITION; PROTEINS; ANTISERA	The critical discriminatory event in the activation of T lymphocytes bearing alpha beta T cell receptors (TCRs) is their interaction with a molecular complex consisting of a peptide bound to a major histocompatibility complex (MHC)-encoded class I or class II molecule on the surface of an antigen-presenting cell. The kinetics of binding were measured of a purified TCR to molecular complexes of a purified soluble analog of the murine MHC class I molecule H-2L(d) (sH-2L(d)) and a synthetic octamer peptide p2CL in a direct, real-time assay based on surface plasmon resonance. The kinetic dissociation rate of the MHC-peptide complex from the TCR was rapid (2.6 x 10(-2) second(-1), corresponding to a half-time for dissociation of approximately 27 seconds), and the kinetic association rate was 2.1 x 10(5) M(-1) second(-1). The equilibrium constant for dissociation was approximately 10(-7) M. These values indicate that TCRs must interact with a multivalent array of MHC-peptide complexes to trigger T cell signaling.	NIAID,MOLEC BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; Yale University				Margulies, David/0000-0001-8530-7375				Berzofsky Jay A., 1993, P421; BOYD LA, UNPUB; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; CORR M, UNPUB; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; JELONEK MT, UNPUB; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KHILKO S, UNPUB; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUBO RT, 1989, J IMMUNOL, V142, P2736; Margulies David H., 1993, Journal of Molecular Recognition, V6, P59, DOI 10.1002/jmr.300060204; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	30	307	320	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					946	949		10.1126/science.8052850	http://dx.doi.org/10.1126/science.8052850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052850				2022-12-01	WOS:A1994PB49900040
J	ROTHMAN, KJ; MICHELS, KB				ROTHMAN, KJ; MICHELS, KB			THE CONTINUING UNETHICAL USE OF PLACEBO CONTROLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; HEART-FAILURE; MAJOR DEPRESSION; CONTROLLED TRIAL; INDUCED NAUSEA; EFFICACY; CHEMOTHERAPY; METOCLOPRAMIDE; ONDANSETRON		HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	ROTHMAN, KJ (corresponding author), BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA 02118 USA.			Rothman, Kenneth/0000-0003-2398-1705				AMSTERDAM JD, 1989, PHARMACOPSYCHIATRY, V22, P137, DOI 10.1055/s-2007-1014596; ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P331; Annas GJ, 1992, NAZI DOCTORS NUREMBE, P339; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; CARR AA, 1991, J CLIN PHARMACOL, V31, P144, DOI 10.1002/j.1552-4604.1991.tb03698.x; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; CITRON ML, 1993, ANN INTERN MED, V118, P470, DOI 10.7326/0003-4819-118-6-199303150-00013; COWLEY AJ, 1993, INT J CARDIOL, V38, P167, DOI 10.1016/0167-5273(93)90176-H; COX R, 1982, CANCER CHEMOTH PHARM, V8, P133, DOI 10.1007/BF00292884; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, BRIT MED J, V295, P250, DOI 10.1136/bmj.295.6592.250; EDGE SB, 1987, AM J CLIN ONCOL-CANC, V10, P257, DOI 10.1097/00000421-198706000-00020; FABRE LF, 1990, J CLIN PSYCHIAT, V51, P55; FABRE LF, 1991, 5TH WORLD C BIOL PSY; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; GANDARA DR, 1992, SEMIN ONCOL, V19, P67; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; GREENE BM, 1985, NEW ENGL J MED, V313, P133, DOI 10.1056/NEJM198507183130301; Grodin MA., 1992, NAZI DOCTORS NUREMBE, P121; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; JOHNSEN V, 1989, SCAND J RHEUMATOL, V18, P251, DOI 10.3109/03009748909095027; KELBAEK H, 1993, EUR HEART J, V14, P692, DOI 10.1093/eurheartj/14.5.692; KIEV A, 1992, J CLIN PSYCHIAT, V53, P27; PACKER M, 1993, J AM COLL CARDIOL, V22, P65, DOI 10.1016/0735-1097(93)90816-J; RICKELS K, 1992, J CLIN PSYCHIAT, V53, P30; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; SILVERSTONE T, 1993, INT CLIN PSYCHOPHARM, V7, P133, DOI 10.1097/00004850-199300730-00002; SMITH WT, 1992, J CLIN PSYCHIAT, V53, P36; SPRIET A, 1994, CHOICE COMPARATOR PL; SVETKEY LP, 1988, CURR THER RES CLIN E, V43, P969; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; TORVIK D, 1986, BRIT J CLIN PHARMACO, V21, pS69, DOI 10.1111/j.1365-2125.1986.tb02856.x; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; WALKER AM, 1986, AM J PUBLIC HEALTH, V76, P556, DOI 10.2105/AJPH.76.5.556; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; 1988, GUIDELINES CLIN EVAL; 1987, FOOD DRUGS, V21	43	492	499	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					394	398		10.1056/NEJM199408113310611	http://dx.doi.org/10.1056/NEJM199408113310611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028622				2022-12-01	WOS:A1994PA37400011
J	MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS				MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS			INFECTIOUS-DISEASE SURVEILLANCE DURING EMERGENCY RELIEF TO BHUTANESE REFUGEES IN NEPAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENINGOCOCCAL MENINGITIS; DEVELOPING-COUNTRIES; MORTALITY TRENDS; VERBAL AUTOPSY; PUBLIC-HEALTH; POPULATIONS; THAILAND; SOMALIA; VALIDATION; INTERVIEWS	Objective.-To implement simplified infectious disease surveillance and epidemic disease control during the relocation of Bhutanese refugees to Nepal. Design.-Longitudinal observation study of mortality and morbidity. Setting.-Refugee health units in six refugee camps housing 73 500 Bhutanese refugees in the eastern tropical lowland between Nepal and India. Interventions.-Infectious disease surveillance and community-based programs to promote vitamin A supplementation, measles vaccination, oral rehydration therapy, and early use of antibiotics to treat acute respiratory infection. Main Outcome Measures.-Crude mortality rate, mortality rate for children younger than 5 years, and cause-specific mortality. Results.-Crude mortality rates up to 1.15 deaths per 10 000 persons per day were reported during the first 6 months of surveillance The leading causes of death were measles, diarrhea, and acute respiratory infections. Surveillance data were used to institute changes in public health management including measles vaccination, vitamin A supplementation, and control programs for diarrhea and acute respiratory infections and to ensure rapid responses to cholera, Shigella dysentery, and meningoencephalitis. Within 4 months of establishing disease control interventions, crude mortality rates were reduced by 75% and were below emergency levels. Conclusions.-Simple, sustainable disease surveillance in refugee populations is essential during emergency relief efforts. Data can be used to direct community-based public health interventions to control common infectious diseases and reduce high mortality rates among refugees while placing a minimal burden on health workers.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO USA; SAVE CHILDREN FUND UNITED KINGDOM, LONDON, ENGLAND; WHO, Kathmandu, NEPAL; CTR DIS CONTROL & PREVENT, INT HLTH PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Save the Children; World Health Organization; Centers for Disease Control & Prevention - USA			Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011	Moore, Patrick S./0000-0002-8132-858X				BANG AT, 1992, B WORLD HEALTH ORGAN, V70, P499; COCHI SL, 1987, INT J EPIDEMIOL, V16, P91, DOI 10.1093/ije/16.1.91; DESENCLOS JC, 1990, INT J EPIDEMIOL, V19, P367, DOI 10.1093/ije/19.2.367; ELIAS CJ, 1990, AM J PUBLIC HEALTH, V80, P824, DOI 10.2105/AJPH.80.7.824; GLASS RI, 1980, LANCET, V1, P868; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; KALTER HD, 1991, INT J EPIDEMIOL, V20, P193, DOI 10.1093/ije/20.1.193; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; KLAUCKE DN, 1988, MMWR S5, V37, P1; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OGAWA S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P37; PACQUEMARGOLIS S, 1990, SOC SCI MED, V31, P585, DOI 10.1016/0277-9536(90)90094-9; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, J TROP PEDIATRICS, V34, P218, DOI 10.1093/tropej/34.5.218; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TOOLE MJ, 1992, MMWR-MORBID MORTAL W, V41, P1; 1978, LAY REPORTING HLTH I	22	31	31	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					377	381		10.1001/jama.272.5.377	http://dx.doi.org/10.1001/jama.272.5.377			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028169				2022-12-01	WOS:A1994NY90300030
J	AOSAKI, T; GRAYBIEL, AM; KIMURA, M				AOSAKI, T; GRAYBIEL, AM; KIMURA, M			EFFECT OF THE NIGROSTRIATAL DOPAMINE SYSTEM ON ACQUIRED NEURAL RESPONSES IN THE STRIATUM OF BEHAVING MONKEYS	SCIENCE			English	Article							TERM SYNAPTIC DEPRESSION; PARKINSONS-DISEASE; PREFRONTAL CORTEX; RAT NEOSTRIATUM; NEURONS; PHYSIOLOGY; DEPLETION; LESIONS; ANATOMY; MATRIX	Dysfunction of the nigrostriatal dopamine system results in marked disorders of movement such as occur in Parkinson's disease. Functions of this dopamine-containing projection system were examined in monkeys trained in a classical conditioning task, and the effects of striatal dopamine depletion were tested. Unilateral dopamine loss substantially reduced the acquired sensory responsiveness of striatal neurons monitored electrophysiologically. This effect was ipsilateral and selective, and could be reversed by apomorphine. These results suggest that the primate nigrostriatal system modulates expression of neuronal response plasticity in the striatum during sensorimotor learning.	OSAKA UNIV,FAC HLTH & SPORT SCI,TOYONAKA,OSAKA 560,JAPAN; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Osaka University; Massachusetts Institute of Technology (MIT)				Graybiel, Ann/0000-0002-4326-7720	NINDS NIH HHS [R01 NS25529] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025529] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOSAKI T, UNPUB; AOSAKI T, IN PRESS; APICELLA P, 1991, EXP BRAIN RES, V84, P672; ARTIEDA J, 1992, BRAIN, V115, P199, DOI 10.1093/brain/115.1.199; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOOM FE, 1979, NEUROSCIENCES 4TH ST, P51; BROCHTIE JM, 1991, MOV DISORD, V6, P133; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, J NEUROSCI, V12, P4224; CARLI M, 1985, NATURE, V313, P679, DOI 10.1038/313679a0; COOLS AR, 1984, J NEUROL NEUROSUR PS, V47, P443, DOI 10.1136/jnnp.47.5.443; FLOWERS KA, 1976, BRAIN, V99, P269, DOI 10.1093/brain/99.2.269; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRAYBIEL AM, 1987, P NATL ACAD SCI USA, V84, P303, DOI 10.1073/pnas.84.1.303; Hornykiewicz O., 1966, BIOCH PHARM BASAL GA, P171; KAWAGUCHI Y, 1992, J NEUROPHYSIOL, V67, P1669, DOI 10.1152/jn.1992.67.6.1669; KIMURA M, 1990, EXP BRAIN RES, V82, P672; KIMURA M, 1984, P NATL ACAD SCI-BIOL, V81, P4998, DOI 10.1073/pnas.81.15.4998; KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LJUNGBERG T, 1993, J NEUROSCI, V13, P900; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; Mishkin M., 1984, NEUROBIOLOGY LEARNIN, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; MOORE RY, 1978, ANNU REV NEUROSCI, V1, P129, DOI 10.1146/annurev.ne.01.030178.001021; NAKAMURA T, 1988, BRAIN RES, V474, P327; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SCHULTZ W, 1982, PROG NEUROBIOL, V18, P121, DOI 10.1016/0301-0082(82)90015-6; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VONVOIGTLANDER PF, 1973, NEUROPHARMACOLOGY, V12, P451, DOI 10.1016/0028-3908(73)90061-0; WILSON CJ, 1990, J NEUROSCI, V10, P508	33	305	308	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					412	415		10.1126/science.8023166	http://dx.doi.org/10.1126/science.8023166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023166				2022-12-01	WOS:A1994NW81600046
J	LATTERICH, M; SCHEKMAN, R				LATTERICH, M; SCHEKMAN, R			THE KARYOGAMY GENE KAR2 AND NOVEL PROTEINS ARE REQUIRED FOR ER-MEMBRANE FUSION	CELL			English	Article							TRANSPORT VESICLE FORMATION; ENDOPLASMIC-RETICULUM; NUCLEAR-FUSION; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; GOLGI-APPARATUS; YEAST; TRANSLOCATION; RECONSTITUTION; BINDING	We have developed assays using cells and isolated membranes to identify factors mediating fusion of the ER-nuclear membrane network in yeast. When cells containing distinctly tagged ER-nuclear envelops membranes are observed during mating, the markers of both parental membranes become colocalized in a process sharing a genetic requirement with karyogamy. Using isolated membranes, we find that fusion between ER compartments requires ATP, but not cytosol, Sec17p (alpha-SNAP), or Sec18p (NSF), the latter two being required at the fusion step in vesicular transport. Proteins tightly associated with the ER membrane are essential for fusion, as is Kar2p (BiP), an ER lumenal hsp70 homolog. BiP may activate an ER-localized fusogen, allowing nuclear fusion and karyogamy in yeast.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BYERS B, 1982, MOL BIOL YEAST SACCH, P59; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ESMON B, 1984, J BIOL CHEM, V259, P322; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAISER CA, 1990, MOL CELL BIOL, V10, P3163, DOI 10.1128/MCB.10.6.3163; KURIHARA LJ, 1994, IN PRESS J CELL BIOL; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MORI K, 1993, CELL, V74, P743; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; REXACH M, 1994, IN PRESS J CELL BIOL; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROSE MD, 1990, METHDOS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATKINS JD, 1993, J BIOL CHEM, V268, P5182; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	59	99	99	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					87	98		10.1016/0092-8674(94)90575-4	http://dx.doi.org/10.1016/0092-8674(94)90575-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033215				2022-12-01	WOS:A1994NX32800011
J	SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE				SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE			POTENTIAL ROLE OF HUMAN CYTOMEGALOVIRUS AND P53 INTERACTION IN CORONARY RESTENOSIS	SCIENCE			English	Article							CELLULAR TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; NUCLEAR ANTIGEN; PROTEIN; VIRUS; EXPRESSION; CARCINOMA; PROLIFERATION; ANTIBODY	A subset of patients who have undergone coronary angioplasty develop restenosis, a vessel renarrowing characterized by excessive proliferation of smooth muscle cells (SMCs). Of 60 human restenosis lesions examined, 23 (38 percent) were found to have accumulated high amounts of the tumor suppressor protein p53, and this correlated with the presence of human cytomegalovirus (HCMV) in the lesions. SMCs grown from the lesions expressed HCMV protein IE84 and high amounts of p53. HCMV infection of cultured SMCs enhanced p53 accumulation, which correlated temporally with IE84 expression. IE84 also bound to p53 and abolished its ability to transcriptionally activate a reporter gene. Thus, HCMV, and IE84-mediated inhibition of p53 function, may contribute to the development of restenosis.	BIOSERVE BIOTECHNOL LTD,LAUREL,MD 20707; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; WASHINGTON HOSP CTR,WASHINGTON CARDIOL CTR,DIV CARDIOL,WASHINGTON,DC 20010; WASHINGTON ADVENTIST HOSP,DEPT CARDIOL,TAKOMA PK,MD 20912	University of North Carolina; University of North Carolina Chapel Hill; MedStar Washington Hospital Center	SPEIR, E (corresponding author), NIH,CARDIOL BRANCH,BLDG 10,BETHESDA,MD 20892, USA.							ALBRECHT T, 1993, FRONTIERS VIROLOGY, V2, pCH19; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENNETT WP, 1991, ONCOGENE, V6, P101; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FINKEL T, 1993, J BIOL CHEM, V268, P5; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; GUREVICH I, 1992, HEART LUNG, V21, P85; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HUANG ES, 1993, FRONTIERS VIROLOGY, V2, P247; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELNICK JL, 1993, FRONTIERS VIROLOGY, V2, pCH4; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NELSON JA, 1984, J VIROL, V49, P109, DOI 10.1128/JVI.49.1.109-115.1984; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SPEIR E, 1992, CIRCULATION, V86, P538, DOI 10.1161/01.CIR.86.2.538; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPEIR E, UNPUB; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TSUKADA T, 1987, AM J PATHOL, V126, P51; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	32	672	713	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					391	394		10.1126/science.8023160	http://dx.doi.org/10.1126/science.8023160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023160				2022-12-01	WOS:A1994NW81600039
J	MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S				MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S			ABILITY OF HIV TO PROMOTE A T(H)1 TO T(H)0 SHIFT AND TO REPLICATE PREFERENTIALLY IN T(H)2 AND T(H)0 CELLS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T-CELLS; LYMPHOKINE ACTIVITIES; CYTOKINE PRODUCTION; SELECTIVE DEFECT; LYMPHOCYTES-T; HELPER; ACTIVATION; INFECTION; PROFILES	Both interferon gamma (IFN-gamma) produced by T helper 1 (T(H)1) lymphocytes and interleukin-4 (IL-4) produced by T(H)2 lymphocytes were reduced in either bulk circulating mononuclear cells or mitogen-induced CD4(+) T cell clones from the peripheral blood of individuals infected with human immunodeficiency virus (HIV). There was a preferential reduction in clones producing IL-4 and IL-5 in the advanced phases of infection. However, enhanced proportions of CD4(+) T cell clones producing both T(H)1-type and T(H)2-type cytokines (T(H)0 clones) were generated from either skin-infiltrating T cells that had been activated in vivo or peripheral blood T cells stimulated by antigen in vitro when cells were isolated from HIV-infected individuals. All T(H)2 and most T(H)0 clones supported viral replication, although viral replication was not detected in any of the T(H)1 clones infected in vitro with HIV. These results suggest that HIV (i) does not induce a definite T(H)1 to T(H)2 switch, but can favor a shift to the T(H)0 phenotype in response to recall antigens, and (ii) preferentially replicates in CD4(+) T cells producing T(H)2-type cytokines (T(H)2 and T(H)0).	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGY,FLORENCE,ITALY; UNIV ROMA LA SAPIENZA,DIV CLIN IMMUNOL & ALLERGY,ROME,ITALY	University of Florence; Sapienza University Rome			Maggi, Enrico/AAA-8045-2019; Annunziato, Francesco/C-1155-2013	Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				AMELSEN JC, 1991, IMMUNOL TODAY, V12, P102; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CARBONARI M, 1993, TRENDS GENET, V9, P42; CHEHIMI J, IN PRESS J EXP MED; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; GRAZLOSI C, COMMUNICATION; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MACCHIA D, 1991, J IMMUNOL, V146, P3414; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MANETTI R, IN PRESS REV IMMUNOL; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MORETTA A, 1983, J EXP MED, V158, P571, DOI 10.1084/jem.158.2.571; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PALIARD X, 1990, J IMMUNOL, V144, P849; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, P13; ROMAGNANI S, IN PRESS IMMUNOL REV; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; STREET NE, 1990, J IMMUNOL, V144, P1629; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188	36	473	489	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					244	248		10.1126/science.8023142	http://dx.doi.org/10.1126/science.8023142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023142				2022-12-01	WOS:A1994NV95700040
J	LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB				LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB			MATERNAL RESCUE OF TRANSFORMING GROWTH-FACTOR-BETA-1 NULL MICE	SCIENCE			English	Article							FACTOR-BETA; EXPRESSION; MOUSE; RATS; LYMPHOCYTES; ANTIBODIES; DISEASE; ANTIGEN	Maternal sources of transforming growth factor-beta 1 (TGF-beta 1) are shown here to contribute to the normal appearance and perinatal survival of TGF-beta 1 null newborn mice. Labeled TGF-beta 1 crossed the placenta and was recovered intact from various tissues after oral administration to mouse pups. TGF beta-1 protein was also detected in cells recovered from breast milk. In immunohistochemical analyses, TGF-beta 1 null embryos and null newborn pups born to TGF-beta 1 heterozygotes stained positive for TGF-beta 1, whereas those born to a null female were negative and had severe cardiac abnormalities. These results suggest an important role for maternal sources of TGF-beta 1 during development and, more generally, provide evidence for maternal rescue of targeted gene disruption in the fetus.	NINCDS,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LETTERIO, JJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; ADENIYIJONES SCA, 1987, J IMMUNOL, V138, P1408; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; Brambell FWR., 1970, N HOLL RES MONOGR FR, V18; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; COX DA, 1991, EUR J BIOCHEM, V197, P353, DOI 10.1111/j.1432-1033.1991.tb15918.x; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DRESSER DW, 1990, J REPROD IMMUNOL, V18, P293, DOI 10.1016/0165-0378(90)90050-G; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; HANAFUSA T, 1983, LANCET, V2, P1111; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LETTERIO JJ, UNPUB; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; POPLIKER M, 1987, DEV BIOL, V119, P38, DOI 10.1016/0012-1606(87)90204-1; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; SEELIG LL, 1981, TRANSPLANTATION, V32, P308, DOI 10.1097/00007890-198110000-00010; SEELIG LL, 1987, J REPROD IMMUNOL, V10, P285, DOI 10.1016/0165-0378(87)90031-3; SHIMAMURA M, 1994, BLOOD, V83, P926, DOI 10.1182/blood.V83.4.926.bloodjournal834926; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STACH RM, 1993, J EXP MED, V17, P841; TOKUYAMA H, 1989, CELL BIOL INT REP, V13, P251, DOI 10.1016/0309-1651(89)90147-1; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; 1992, MOL REPROD DEV, V32	29	441	460	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1936	1938		10.1126/science.8009224	http://dx.doi.org/10.1126/science.8009224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009224				2022-12-01	WOS:A1994NT84700046
J	MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR				MALONEY, SA; PEARSON, ML; GORDON, MT; DELCASTILLO, R; BOYLE, JF; JARVIS, WR			EFFICACY OF CONTROL MEASURES IN PREVENTING NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT TUBERCULOSIS TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						RESISTANCE; MULTIPLE; CROSS INFECTION; DISEASE TRANSMISSION; TUBERCULOSIS; INFECTION CONTROL	MYCOBACTERIUM-TUBERCULOSIS; IMMUNODEFICIENCY-SYNDROME; INFECTION; OUTBREAK	Objective: To assess the efficacy of control measures in decreasing nosocomial transmission of multidrug-resistant tuberculosis. Design: Retrospective cohort study. Setting: A teaching hospital in New York City. Population: 40 patients hospitalized with multidrug-resistant tuberculosis (case-patients) and health care workers receiving tuberculin skin testing. Interventions: Centers for Disease Control and Prevention (CDC) 1990 guidelines for preventing transmission of tuberculosis, including 1) prompt isolation and treatment of patients with tuberculosis; 2) rapid diagnostic techniques for processing Mycobacterium tuberculosis specimens; 3) negative-pressure isolation rooms; and 4) molded surgical masks for health care workers. Measurements: Proportion of case-patients with nosocomially acquired tuberculosis and rate of tuberculin skin test conversion among health care workers before and after implementation of control measures. Results: The proportion of patients with multidrug-resistant strains of M. tuberculosis decreased after the interventions (10 of 70 [14%] compared with 30 of 95 [32%] patients before the intervention; relative risk [RR], 0.5; 95% CI, 0.2 to 0.9). Before onset of multidrug-resistant tuberculosis, case-patients in the intervention period were as likely to be hospitalized on high-risk wards containing patients with tuberculosis (4 of 10 compared with 17 of 30 patients; RR, 0.7; P = 0.5) but were less likely to be exposed to another case-patient with tuberculosis (1 of 10 compared with 20 of 30 patients; RR, 0.2; P = 0.003). Tuberculin skin test conversion rates for health care workers assigned to wards housing patients with tuberculosis were lower in the intervention period than in the preintervention period (4 of 78 [5%] compared with 15 of 90 [17%] conversions; P = 0.02), decreasing to levels observed for workers assigned to other wards (4 of 78 [5%] compared with 9 of 228 [4%] conversions; P = 0.7). Conclusions: Implementing control measures reduced nosocomial transmission of multidrug-resistant strains to patients and health care workers.	CTR DIS CONTROL, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CABRINI MED CTR, NEW YORK, NY 10003 USA	Centers for Disease Control & Prevention - USA								BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CHEN SK, 1994, AM J INFECT CONTROL, V22, P65, DOI 10.1016/0196-6553(94)90116-3; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DEAN AG, 1991, EPI INFO VERSION 5 0; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HUTTON MD, 1992, AM J INFECT CONTROL, V20, P24, DOI 10.1016/S0196-6553(05)80121-X; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; NOLAN CM, 1992, AM J INFECT CONTROL, V20, P30, DOI 10.1016/S0196-6553(05)80123-3; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PUGLIESE G, 1992, AM J INFECT CONTROL, V20, P37, DOI 10.1016/S0196-6553(05)80125-7; RAMIREZ JA, 1992, INFECT CONT HOSP EP, V13, P579, DOI 10.2307/30148459; SNIDER DE, 1985, JAMA-J AM MED ASSOC, V253, P3438, DOI 10.1001/jama.253.23.3438; VALWAY S, 1993, 33 INT C ANT AG CHEM, P231	20	143	144	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					90	95		10.7326/0003-4819-122-2-199501150-00002	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993001				2022-12-01	WOS:A1995QC05900002
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			PATENTS IN THE PUBLIC-INTEREST	NATURE			English	Article								The UH High Court has granted an injunction allowing Chiron Corporation a monopoly in selling hepatitis C virus test kits. The decision will be welcomed by the pharmaceutical and biotechnology industries.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.								0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					814	814						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997274				2022-12-01	WOS:A1994PY21200063
J	CHOO, Y; SANCHEZGARCIA, I; KLUG, A				CHOO, Y; SANCHEZGARCIA, I; KLUG, A			IN-VIVO REPRESSION BY A SITE-SPECIFIC DNA-BINDING PROTEIN DESIGNED AGAINST AN ONCOGENIC SEQUENCE	NATURE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR-IIIA; C-ABL PROTEIN; MAMMALIAN-CELLS; PHILADELPHIA-CHROMOSOME; DOMAINS; EXPRESSION; GENES; BCR	A DNA-binding peptide comprising three zinc-fingers has been engineered to bind specifically to a unique nine-base-pair region of a BCR-ABL fusion oncogene in preference to the parent genomic sequences. Binding to the target oncogene in chromosomal DNA is possible In transformed cells in culture, and results in blockage of transcription. Consequently, murine cells rendered independent of growth factors by the action of the oncogene revert to factor dependence upon transient transfection with a vector expressing the peptide.			CHOO, Y (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019	Choo, Yen/0000-0002-3348-9602; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COONEY M, 1988, SCIENCE, V245, P725; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOWELL PC, 1960, SCIENCE, V132, P1197; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515	37	235	300	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					642	645		10.1038/372642a0	http://dx.doi.org/10.1038/372642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990954	Green Submitted			2022-12-01	WOS:A1994PX30700076
J	DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D				DIMARZO, V; FONTANA, A; CADAS, H; SCHINELLI, S; CIMINO, G; SCHWARTZ, JC; PIOMELLI, D			FORMATION AND INACTIVATION OF ENDOGENOUS CANNABINOID ANANDAMIDE IN CENTRAL NEURONS	NATURE			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; RECEPTOR; BRAIN; GLYCEROPHOSPHOLIPIDS; AGONIST; BINDS; CELLS	ANANDAMIDE (N-arachidonoyl-ethanolamine) was recently identified as a brain arachidonate derivative that binds to and activates cannabinoid receptors(1-4), yet the mechanisms underlying formation, release and inactivation of this putative messenger molecule are still unclear. Were we report that anandamide is produced in and released from cultured brain neurons in a calcium ion-dependent manner when the neurons are stimulated with membrane-depolarizing agents. Anandamide formation occurs through phosphodiesterase-mediated cleavage of a novel phospholipid precursor, N-arachidonoyl-phosphatidylethanolamine. A similar mechanism also governs the formation of a family of anandamide congeners, whose possible roles in neuronal signalling remain unknown. Our results and those of others(5,6) indicate therefore that multiple biochemical pathways may participate in anandamide formation in brain tissue. The life span of extracellular anandamide is limited by a rapid and selective process of cellular uptake, which is accompanied by hydrolytic degradation to ethanolamine and arachidonate. Our results thus strongly support the proposed role of anandamide as an endogenous neuronal messenger.	INSERM,CTR PAUL BROCA,UNITE NEUROBIOL & PHARMACOL,PARIS,FRANCE; CNR,IST CHIM MOLEC INTERESSE BIOL,NAPLES,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); Consiglio Nazionale delle Ricerche (CNR)			Fontana, Angelo/AAO-2741-2021; Fontana, Angelo/C-3354-2012	Fontana, Angelo/0000-0002-5453-461X; Fontana, Angelo/0000-0002-5453-461X; Di Marzo, Vincenzo/0000-0002-1490-3070				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; COLODZIN M, 1963, BIOCHEM BIOPH RES CO, V10, P165, DOI 10.1016/0006-291X(63)90044-5; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EPPS DE, 1982, CELL CALCIUM, V3, P531, DOI 10.1016/0143-4160(82)90043-4; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; GULAYA NM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P280, DOI 10.1016/0005-2736(93)90259-3; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LU B, 1991, J NEUROSCI, V11, P318; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUMOTO M, 1973, BIOCHIM BIOPHYS ACTA, V296, P350, DOI 10.1016/0005-2760(73)90093-3; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; PERTWEE RG, 1993, BRIT J PHARMACOL, V110, P1483, DOI 10.1111/j.1476-5381.1993.tb13989.x; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; YUE TL, 1994, CRIT REV NEUROBIOL, V8, P11	22	1264	1293	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					686	691		10.1038/372686a0	http://dx.doi.org/10.1038/372686a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990962	Green Submitted			2022-12-01	WOS:A1994PX30700089
J	GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H				GRUNDEMANN, D; GORBOULEV, V; GAMBARYAN, S; VEYHL, M; KOEPSELL, H			DRUG EXCRETION MEDIATED BY A NEW PROTOTYPE OF POLYSPECIFIC TRANSPORTER	NATURE			English	Article							BASOLATERAL MEMBRANE-VESICLES; RENAL BRUSH-BORDER; ORGANIC CATIONS; TETRAETHYLAMMONIUM; PROTEIN; CLONING; MECHANISM; UPTAKE2; RNA	CATIONIC drugs of different types and structures (antihistaminics, antiarrhythmics, sedatives, opiates, cytostatics and antibiotics, for example) are excreted in mammals by epithelial cells of the renal proximal tubules and by hepatocytes in the liver(1-4). In the proximal tubules, two functionally disparate transport systems are involved which are localized in the basolateral and luminal plasma membrane and are different from the previously identified neuronal monoamine transporters and ATP-dependent multidrug exporting proteins(1-3,5-12). Here we report the isolation of a complementary DNA from rat kidney that encodes a 556-amino-acid membrane protein, OCT1, which has the functional characteristics of organic cation uptake over the basolateral membrane of renal proximal tubules and of organic cation uptake into hepatocytes. OCT1 is not homologous to any other known protein and is found in kidney, liver and intestine. As OCT1 translocates hydrophobic and hydrophilic organic cations of different structures, it is considered to be a new prototype of polyspecific transporters that are important for drug elimination.	UNIV WURZBURG,INST ANAT,D-97070 WURZBURG,GERMANY	University of Wurzburg			Gambaryan, Stepan/I-3940-2016; Gründemann, Dirk/AAD-2217-2022	Gambaryan, Stepan/0000-0002-1470-0791; 				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID D, 1994, K GESELLSCHAFT NEPHR, P472; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOHAGE H, 1994, J PHARMACOL EXP THER, V268, P897; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MEIJER DKF, 1990, J PHARMACOKINET BIOP, V18, P35, DOI 10.1007/BF01063621; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pritchard J.B., 1992, KIDNEY PHYSL PATHOPH, P2921; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; RUSS H, 1992, N-S ARCH PHARMACOL, V346, P158, DOI 10.1007/BF00165297; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SCHOMIG E, 1993, N-S ARCH PHARMACOL, V347, P379, DOI 10.1007/BF00165387; SCHOMIG E, 1990, N-S ARCH PHARMACOL, V341, P404; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; Trendelenburg U, 1988, HDB EXP PHARM, P279; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VEYHL M, 1993, J BIOL CHEM, V268, P25041; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040	27	558	574	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					549	552		10.1038/372549a0	http://dx.doi.org/10.1038/372549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990927	Green Submitted			2022-12-01	WOS:A1994PW08200052
J	MCGILL, JI; WHITE, JE				MCGILL, JI; WHITE, JE			ACYCLOVIR AND POSTHERPETIC NEURALGIA AND OCULAR INVOLVEMENT	BRITISH MEDICAL JOURNAL			English	Article							ZOSTER				MCGILL, JI (corresponding author), UNIV SOUTHAMPTON,GEN HOSP,EYE UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							MCGILL J, 1987, BRIT J OPHTHALMOL, V71, P118, DOI 10.1136/bjo.71.2.118; MCGILL J, 1983, J INFECTION, V6, P157, DOI 10.1016/S0163-4453(83)92787-1; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; PETERSLUND NA, 1981, LANCET, V2, P827; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003	5	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1124		10.1136/bmj.309.6962.1124	http://dx.doi.org/10.1136/bmj.309.6962.1124			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987104	Green Published			2022-12-01	WOS:A1994PP69100021
J	NAISH, J; BROWN, J; DENTON, B				NAISH, J; BROWN, J; DENTON, B			INTERCULTURAL CONSULTATIONS - INVESTIGATION OF FACTORS THAT DETER NON-ENGLISH SPEAKING WOMEN FROM ATTENDING THEIR GENERAL-PRACTITIONERS FOR CERVICAL SCREENING	BRITISH MEDICAL JOURNAL			English	Article							CYTOLOGY; RECALL	Objectives-To determine the factors that deter ethnic minority women living in east London from attending their general practitioner for cervical cytology screening. Design-Qualitative study by means of focus group discussions between October 1993 and March 1994. Setting-East London. Subjects-Non-health specific established community groups and specially convened groups of Bengali, Kurdish, Turkish, Urdu and Punjabi, and Chinese speaking women. Main outcome measures-The spontaneous views of non-English speaking women resident in east London on cervical screening, focusing on attitudes to screening, their experiences of the cervical cytology screening services as currently provided, and their knowledge and beliefs about cervical screening. Results-Some reported attitudinal barriers to cervical cytology screening such as fear of cancer were not deterrents. Administrative and language barriers were more important, as were inadequate surgery premises and concerns about sterility. Conclusion-Contrary to popular belief. among general practitioners in east London, women from ethnic minorities are enthusiastic about cervical cytology screening once they understand the purpose of the test and the call and recall procedures. It is possible to consult with community groups in their own language through focus group discussions, working with bilingual health advocates who have had a short practical training in facilitating small group discussions. This form of user consultation could be carried out focusing on other aspects of health promotion.	ROYAL LONDON HOSP,QUEEN MARY WESTFIELD COLL,LONDON E1 4NS,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	NAISH, J (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,JOINT ACAD DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							ALLMAN ST, 1974, HLTH TRENDS, V6, P39; BAILIE R, 1990, NZ MED J, V103, P292; BEARDOW R, 1989, BMJ-BRIT MED J, V299, P98, DOI 10.1136/bmj.299.6691.98; BOWLING A, 1989, BRIT MED J, V298, P545, DOI 10.1136/bmj.298.6673.545; CULLUM DE, 1983, BRIT MED J, V287, P329, DOI 10.1136/bmj.287.6388.329; DAVISON RL, 1971, MED OFFICER, V1, P329; ELKIND AK, 1988, SOC SCI MED, V27, P651, DOI 10.1016/0277-9536(88)90014-7; Gregory S, 1991, Nurs Stand, V5, P32; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; MCKIE L, 1990, PATTERNS TAKE UP ATT; NAISH J, 1992, GENERAL PRACTITIONER; NATHOO V, 1988, BRIT MED J, V296, P1041, DOI 10.1136/bmj.296.6628.1041; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Posner T, 1988, PREVENTION CERVICAL; ROSS SK, 1989, BRIT MED J, V299, P101, DOI 10.1136/bmj.299.6691.101; SANSOM CD, 1975, BRIT J PREV SOC MED, V29, P40; SCHWARTZ M, 1989, COMMUNITY MED, V11, P279; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317	18	86	87	2	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1126	1128						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987106				2022-12-01	WOS:A1994PP69100024
J	ZARRINKAR, PP; WILLIAMSON, JR				ZARRINKAR, PP; WILLIAMSON, JR			KINETIC INTERMEDIATES IN RNA FOLDING	SCIENCE			English	Article							GROUP-I INTRON; TETRAHYMENA-THERMOPHILA RIBOZYME; RIBOSOMAL-RNA; CONFORMATIONAL-CHANGES; TERTIARY STRUCTURE; ACTIVE-SITE; SUBSTRATE; CATALYSIS; BINDING; SEQUENCE	The folding pathways of large, highly structured RNA molecules are largely unexplored. Insight into both the kinetics of folding and the presence of intermediates was provided in a study of the Mg2+-induced folding of the Tetrahymena ribozyme by hybridization of complementary oligodeoxynucleotide probes. This RNA folds via a complex mechanism involving both Mg2+-dependent and Mg2+-independent steps. A hierarchical model for the folding pathway is proposed in which formation of one helical domain (P4-P6) precedes that of a second helical domain (P3-P7). The overall rate-limiting step is formation of P3-P7, and takes place with an observed rate constant of 0.72 +/- 0.14 minute(-1). The folding mechanism of large RNAs appears similar to that of many multidomain proteins in that formation of independently stable substructures precedes their association into the final conformation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X				BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1993, RNA WORLD, P239; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; EMERICK VL, 1993, BIOCHEMISTRY-US, V32, P14062, DOI 10.1021/bi00213a040; FELDEN B, 1994, RNA WORLD, V235, P508; Garel Jean-Renaud, 1992, P405; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LECUYER KA, 1994, P NATL ACAD SCI USA, V91, P3373, DOI 10.1073/pnas.91.8.3373; LYNCH DC, 1974, BIOCHEMISTRY-US, V13, P1841, DOI 10.1021/bi00706a012; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; Pan  T., 1993, RNA WORLD, P271; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RESTELAND RF, 1993, RNA WORLD; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SCHEFFLE.IE, 1968, J MOL BIOL, V36, P291, DOI 10.1016/0022-2836(68)90156-3; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; UHLENBEC.OC, 1970, NATURE, V225, P508, DOI 10.1038/225508a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG JF, 1994, J AM CHEM SOC, V116, P4178, DOI 10.1021/ja00089a005; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WESTHOF E, 1992, STRUCTURAL TOOLS ANA, P255; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	46	306	314	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					918	924		10.1126/science.8052848	http://dx.doi.org/10.1126/science.8052848			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052848				2022-12-01	WOS:A1994PB49900032
J	LI, YZ; HUNTER, RL; MCIVER, RT				LI, YZ; HUNTER, RL; MCIVER, RT			HIGH-RESOLUTION MASS-SPECTROMETER FOR PROTEIN CHEMISTRY	NATURE			English	Article							ASSISTED LASER-DESORPTION; ION-CYCLOTRON RESONANCE; BIOLOGICAL MOLECULES; SEQUENCE DATABASES; MATRIX; PEPTIDES; SPECTROSCOPY; FIELD	Matrix-assisted laser desorption/ionization is an accurate and sensitive method for measuring the molecular weights of peptides and proteins. Usually time-of-flight mass spectrometry is used to detect the laser-produced ions, but a new method called Fourier transform mass spectrometry offers greater sensitivity and much higher mass measurement accuracy.	IONSPEC CORP,IRVINE,CA 92714		LI, YZ (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							ARNOTT D, 1993, CLIN CHEM, V39, P2005; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BEAVIS RC, 1991, CHEM PHYS LETT, V181, P479, DOI 10.1016/0009-2614(91)90384-L; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BILLECI TM, 1993, ANAL CHEM, V65; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAMBERS DM, 1993, ANAL CHEM, V65, P14, DOI 10.1021/ac00049a005; COMISARO.MB, 1974, CHEM PHYS LETT, V26, P489, DOI 10.1016/0009-2614(74)80397-0; COMISAROW MB, 1978, J CHEM PHYS, V69, P4097, DOI 10.1063/1.437143; COTTER RJ, 1992, ANAL CHEM, V64, pA1027, DOI 10.1021/ac00045a002; EKSTROM P, 1980, SCI AM, V243, P105, DOI 10.1038/scientificamerican0880-104; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KARAS M, 1989, INT J MASS SPECTROM, V92, P231, DOI 10.1016/0168-1176(89)83030-7; Karas M., 1988, ANAL CHEM, V60, P2291; LEBRILLA CB, 1989, J AM CHEM SOC, V111, P8593, DOI 10.1021/ja00205a006; LEBRILLA CB, 1989, INT J MASS SPECTROM, V87, pR7, DOI 10.1016/0168-1176(89)80014-X; LI YZ, 1994, ANAL CHEM, V66, P2077, DOI 10.1021/ac00085a024; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MARSHALL AG, 1985, ACCOUNTS CHEM RES, V18, P316, DOI 10.1021/ar00118a006; MCIVER RT, 1990, INT J MASS SPECTROM, V98, P35, DOI 10.1016/0168-1176(90)85046-5; MCIVER RT, 1994, P NATL ACAD SCI USA, V91, P4801, DOI 10.1073/pnas.91.11.4801; MCIVER RT, 1994, INT J MASS SPECTROM, V132, pL1, DOI 10.1016/0168-1176(94)85003-8; MCIVER RT, 1981, INT J MASS SPECTROM, V39, P65, DOI 10.1016/0020-7381(81)80122-2; MCIVER RT, 1994, RAPID COMMUN MASS SP, V8, P237, DOI 10.1002/rcm.1290080303; MCIVER RT, 1985, INT J MASS SPECTROM, V64, P67, DOI 10.1016/0168-1176(85)85037-0; MEIVER R, 1985, Patent No. 4535235; PAN Y, 1992, ORG MASS SPECTROM, V27, P3, DOI 10.1002/oms.1210270103; SCHWARTZ JC, 1993, RAPID COMMUN MASS SP, V7, P27, DOI 10.1002/rcm.1290070107; SPENGLER B, 1991, RAPID COMMUN MASS SP, V5, P198, DOI 10.1002/rcm.1290050412; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; WINELAND D, 1973, PHYS REV LETT, V31, P1279, DOI 10.1103/PhysRevLett.31.1279; ZHOU J, 1992, RAPID COMMUN MASS SP, V6, P671, DOI 10.1002/rcm.1290061109	35	11	11	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					393	395		10.1038/370393a0	http://dx.doi.org/10.1038/370393a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047148				2022-12-01	WOS:A1994PA30400066
J	JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M				JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M			INHIBITION OF THE CARDIAC PROTEIN-KINASE A-DEPENDENT CHLORIDE CONDUCTANCE BY ENDOTHELIN-1	NATURE			English	Article							GUINEA-PIG ATRIA; AUTONOMIC REGULATION; MYOCYTES; CELLS; CONTRACTION; ACTIVATION; MECHANISM; RECEPTOR; SUBUNITS; ISOZYME	ENDOTHELIN-1 is a peptide hormone constitutively secreted by vascular and endocardial endothelial cells(1-3). Secretion of endothelin-1 is increased under certain pathophysiological conditions, including coronary vasospasm, cardiac ischaemia and myocardial infarction. We have examined the effect of endothelin-1 on the protein kinase A (PKA)-dependent chloride current in voltage-clamped guinea pig ventricular myocytes. This conductance, induced by catecholamines through beta-adrenergic receptors, counteracts the simultaneously increased L-type calcium current by shortening the action potential duration(4-6). We report here that endothelin-1, acting through ET(A) (endothelin-1-selective) receptors, inhibited the current through a pertussis toxin-sensitive mechanism, analogous to muscarinic receptors, by reducing the intracellular cyclic AMP concentration. This effect of endothelin-1 should help protect the ventricle against potentially arrhythmogenic shortening of the action potential during ischaemia when the circulating levels of catecholamines are increased.	KYOTO UNIV,FAC MED,DEPT INTERNAL MED 3,KYOTO 606,JAPAN; CIBA GEIGY JAPAN LTD,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN; NATL INST PHYSIOL SCI,DEPT CELLULAR & MOLEC PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Horie, Minoru/ABG-7128-2020					BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; HARVEY R D, 1990, Journal of Cardiovascular Electrophysiology, V1, P309, DOI 10.1111/j.1540-8167.1990.tb01072.x; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORIE M, 1992, J PHYSIOL-LONDON, V455, P235, DOI 10.1113/jphysiol.1992.sp019299; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; JAMES AF, 1993, CARDIOVASC DRUG REV, V11, P253, DOI 10.1111/j.1527-3466.1993.tb00190.x; JONES LG, 1992, AM J PHYSIOL, V263, pH1447, DOI 10.1152/ajpheart.1992.263.5.H1447; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; KOHMOTO O, 1993, AM J PHYSIOL, V265, pH793, DOI 10.1152/ajpheart.1993.265.3.H793; LAUER MR, 1992, J PHYSIOL-LONDON, V448, P729, DOI 10.1113/jphysiol.1992.sp019067; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; REID JJ, 1989, EUR J PHARMACOL, V168, P93, DOI 10.1016/0014-2999(89)90637-7; SOKOLOVSKY M, 1992, NEUROCHEMISTRY, V59, P809; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WANG JX, 1993, AM J PHYSIOL, V265, pH2168, DOI 10.1152/ajpheart.1993.265.6.H2168	26	83	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					297	300		10.1038/370297a0	http://dx.doi.org/10.1038/370297a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035878				2022-12-01	WOS:A1994NZ22900065
J	DJERASSI, C; LEIBO, SP				DJERASSI, C; LEIBO, SP			A NEW LOOK AT MALE CONTRACEPTION	NATURE			English	Editorial Material							UNITED-STATES MEN; PROSTATE-CANCER; VASECTOMY; SPERM; CRYOPRESERVATION; OLIGOSPERMIA; COHORT		UNIV GUELPH, ONTARIO VET COLL, GUELPH N1G 2W1, ON, CANADA	University of Guelph	DJERASSI, C (corresponding author), STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA.							ANDERSON NG, COMMUNICATION; ANDERSON NG, Patent No. 5092466; ASHWOODSMITH MJ, 1977, CIBA F S, V52, P251; BARWIN BN, 1986, ANDROLOGY MALE FERTI, P461; BELKER AM, 1987, UROL CLIN N AM, V14, P597; DJERASSI C, 1981, POLITICS CONTRACEPTI, pCH5; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GLENISTER PH, 1990, GENET RES, V56, P253, DOI 10.1017/S0016672300035357; HEALY B, 1993, JAMA-J AM MED ASSOC, V269, P2620, DOI 10.1001/jama.269.20.2620; IRITANI A, 1980, 9TH INT C AN REPR AI, V1, P115; IRVINE DS, 1986, HUM REPROD, V1, P539, DOI 10.1093/oxfordjournals.humrep.a136470; LEIBO SP, UNPUB; LELANNOU D, 1989, HUM REPROD, V4, P757; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LIU DY, 1992, FERTIL STERIL, V58, P465; MARTIN RH, 1991, MOL REPROD DEV, V30, P159, DOI 10.1002/mrd.1080300213; MUMFORD SD, 1977, VASECTOMY COUNSELING; Ross John A., 1993, FAMILY PLANNING POPU; SALAMON S, 1974, J REPROD FERTIL, V37, P433, DOI 10.1530/jrf.0.0370433; SHERMAN JK, 1977, TECHNIQUES HUMAN AND, P399; Short R.V., 1985, P24; SHULMAN S, 1986, ANDROLOGY MALE FERTI, P399; SILBER SJ, 1989, HUM REPROD, V4, P318, DOI 10.1093/oxfordjournals.humrep.a136896; SOKOL RZ, 1987, FERTIL STERIL, V47, P356; Triazolam's status in European Community, 1991, LANCET, V338, P1586; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; 1988, ARTIFICIAL INSEMINAT	28	8	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	1994	370	6484					11	12		10.1038/370011a0	http://dx.doi.org/10.1038/370011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015592				2022-12-01	WOS:A1994NV71100024
J	STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B				STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B			REGULATION OF MHC CLASS-II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GUANYLATE-BINDING-PROTEIN; TRANS-ACTING PROTEIN; TYROSINE PHOSPHORYLATION; IFN-GAMMA; TRANSCRIPTION; INDUCTION; CELLS; ALPHA; ACTIVATION	Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-gamma (IFN-gamma). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-gamma. A functional CI ITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-gamma. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,MOLEC GENET LAB,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U132,F-15015 PARIS,FRANCE	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			, Mühlethaler-Mottet/H-2848-2019	, Mühlethaler-Mottet/0000-0001-8274-0907				ALLEN JM, 1988, NUCLEIC ACIDS RES, V16, P11824, DOI 10.1093/nar/16.24.11824; AMALDI I, 1989, J IMMUNOL, V142, P999; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BONO MR, 1991, P NATL ACAD SCI USA, V88, P6077, DOI 10.1073/pnas.88.14.6077; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LISOWSKAGROSPIE.B, IN PRESS HUM MOL GEN; MAFFEI A, 1987, J IMMUNOL, V139, P942; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; STEIMLE V, UNPUB; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; ZIEGLER A, 1986, IMMUNOBIOLOGY, V171, P77, DOI 10.1016/S0171-2985(86)80019-5	30	684	703	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					106	109		10.1126/science.8016643	http://dx.doi.org/10.1126/science.8016643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016643				2022-12-01	WOS:A1994NV30100037
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			SHOULD YOU EAT MEAT, OR ARE YOU CONFOUNDED BY METHODOLOGICAL DEBATE	BRITISH MEDICAL JOURNAL			English	Article											VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BRESLOW NE, 1987, STATISTICAL METHODS, V2, P151; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P136; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P92; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P53; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P45; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; THOROGOOD M, 1994, BRIT MED J, V308, P1665	9	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1671	1671						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025459				2022-12-01	WOS:A1994NU48300018
J	CLELAND, WW; KREEVOY, MM				CLELAND, WW; KREEVOY, MM			LOW-BARRIER HYDROGEN-BONDS AND ENZYMATIC CATALYSIS	SCIENCE			English	Article							TRANSITION-STATE ANALOGS; DELTA-5-3-KETOSTEROID ISOMERASE; TRIOSEPHOSPHATE ISOMERASE; OROTIDYLATE DECARBOXYLASE; CARBOXYPEPTIDASE-A; INHIBITOR-BINDING; CRYSTAL-STRUCTURE; ACTIVE-SITE; MECHANISM; DEHYDROGENASE	Formation of a short (less than 2.5 angstroms), very strong, low-barrier hydrogen bond in the transition state, or in an enzyme-intermediate complex, can be an important contribution to enzymic catalysis. Formation of such a bond can supply 10 to 20 kilocalories per mole and thus facilitate difficult reactions such as enolization of carboxylate groups. Because low-barrier hydrogen bonds form only when the pK(a)'s (negative logarithm of the acid constant) of the oxygens or nitrogens sharing the hydrogen are similar, a weak hydrogen bond in the enzyme-substrate complex in which the pK(a)'s do not match can become a strong, low-barrier one if the pK(a)'s become matched in the transition state or enzyme-intermediate complex. Several examples of enzymatic reactions that appear to use this principle are presented.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	CLELAND, WW (corresponding author), UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018938, R01GM018938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUDARI K, 1979, J AM CHEM SOC, V101, P3688, DOI 10.1021/ja00507a059; ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; BRANT DA, 1963, J AM CHEM SOC, V85, P2204, DOI 10.1021/ja00898a003; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; Hibbert Frank., 1990, ADV PHYS ORG CHEM, V26, P255; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; KAPLAN AP, 1991, BIOCHEMISTRY-US, V30, P8165, DOI 10.1021/bi00247a011; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; KIM HD, 1991, BIOCHEMISTRY-US, V30, P8171, DOI 10.1021/bi00247a012; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KULIOPULOS A, 1991, BIOCHEMISTRY-US, V30, P3169, DOI 10.1021/bi00227a003; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; REMINGTON J, 1992, CURR OPIN STRUCT BIO, V2, P730; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SHOSTAK K, 1992, BIOCHEMISTRY-US, V31, P12155, DOI 10.1021/bi00163a026; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; TRONRUD DE, 1986, EUR J BIOCHEM, V157, P261, DOI 10.1111/j.1432-1033.1986.tb09664.x; USHER KC, IN PRESS BIOCHEMISTR; VIOLA RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P415, DOI 10.1016/0003-9861(84)90005-5; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZENG BF, 1991, J AM CHEM SOC, V113, P3838, DOI 10.1021/ja00010a028	36	1026	1035	3	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1887	1890		10.1126/science.8009219	http://dx.doi.org/10.1126/science.8009219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009219				2022-12-01	WOS:A1994NT84700034
J	BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB				BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB			USE OF COUGHING TEST TO DIAGNOSE PERITONITIS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter								DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; MOORE SW, 1958, SURG CLIN N AM, V38, P371; PROUT WG, 1970, BRIT J SURG, V57, P508, DOI 10.1002/bjs.1800570706	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1336	1336						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019222				2022-12-01	WOS:A1994NM98900023
J	MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB				MCCLAIN, KL; LEACH, CT; JENSON, HB; JOSHI, VV; POLLOCK, BH; PARMLEY, RT; DICARLO, FJ; CHADWICK, EG; MURPHY, SB			ASSOCIATION OF EPSTEIN-BARR-VIRUS WITH LEIOMYOSARCOMAS IN YOUNG-PEOPLE WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; CELL-LINES; DNA; AMPLIFICATION; NEOPLASIA; INFECTION; CHILDREN; LYMPHOMA	Background. Children with the acquired immunodeficiency syndrome (AIDS) have an unusually high incidence of smooth-muscle tumors (leiomyomas and leiomyosarcomas) in addition to malignant lymphomas. We tested the hypothesis that the smooth-muscle tumors in these children are associated with the Epstein-Barr virus (EBV). Methods. Tissue specimens of five leiomyosarcomas and two leiomyomas from five children and one young man with AIDS were studied for evidence of the human immunodeficiency virus (HIV) and EBV by in situ hybridization and quantitative polymerase chain reaction (PCR). Comparison specimens included samples of leiomyosarcoma and leiomyoma from HIV-negative children, EBV clonality of leiomyosarcomas was determined by Southern blot analysis with oligonucleotide probes for EBV terminal-repeat fragments, Tumor specimens were tested by immunoperoxidase staining for infiltration by B lymphocytes and expression of the EBV receptor, Serologic testing for EBV was performed. Results. In situ hybridization showed EBV genomes in all muscle cells of the five leiomyosarcomas and the two leiomyomas from the six HIV-infected patients, Quantitative PCR demonstrated strikingly high levels of EBV in tumor tissue, with as many as 4.3 genome copies per cell, Two colonic leiomyosarcomas obtained from different sites at different times from one patient contained different episomal EBV clones, signifying the presence of distinct monoclonal EBV-related tumors, We found biclonal EBV infection in the leiomyosarcoma of another patient, No EBV was detected in normal muscle or tumor specimens from HIV-negative patients, Immunostaining for the EBV receptor was strongly positive in six of the seven leiomyomas and leiomyosarcomas from the patients with AIDS. Conclusions. EBV can infect smooth-muscle cells, at least in patients with AIDS, and it may contribute to the pathogenesis of leiomyomas and leiomyosarcomas in patients with AIDS, EBV seems to play no part in smooth-muscle tumors in HIV-negative patients.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PEDIAT, SAN ANTONIO, TX 78284 USA; E CAROLINA UNIV, DEPT PATHOL & LAB MED, GREENVILLE, NC 27834 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; CHILDRENS HOSP NEW JERSEY, DEPT PATHOL, NEWARK, NJ USA; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; University of North Carolina; East Carolina University; State University System of Florida; University of Florida; Carolinas Medical Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago				McClain, Kenneth/0000-0003-0725-6263; Jenson, Hal/0000-0002-6549-860X	NCI NIH HHS [CA30969, CA55507, CA56296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056296, R01CA055507, U10CA030969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN GJ, 1989, VIROLOGY, V173, P489, DOI 10.1016/0042-6822(89)90561-8; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHADWICK EG, 1990, JAMA-J AM MED ASSOC, V263, P3182, DOI 10.1001/jama.263.23.3182; CHANG KL, 1993, BLOOD, V81, P496; CHEUNG A, 1982, J VIROL, V44, P286, DOI 10.1128/JVI.44.1.286-294.1982; CUNNINGHAM L, 1991, BRIT MED BULL, V47, P852, DOI 10.1093/oxfordjournals.bmb.a072516; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRICKHOFEN N, 1991, J VIROL METHODS, V35, P65, DOI 10.1016/0166-0934(91)90086-F; GAFFEY MJ, 1992, PATHOL ANNU, V27, P55; KARP JE, 1991, CANCER RES, V51, P4743; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LACK E E, 1986, Pediatric Pathology, V6, P181; LEE E, 1993, MODERN PATHOL, V6, pA127; LEVINE PH, 1992, LEUKEMIA, V6, pS54; MCLOUGHLIN LC, 1991, CANCER, V67, P2618, DOI 10.1002/1097-0142(19910515)67:10<2618::AID-CNCR2820671036>3.0.CO;2-5; MUELLER BU, 1994, PEDIATRIC AIDS CHALL, P603; NAKAMURA S, 1994, CANCER, V73, P2239, DOI 10.1002/1097-0142(19940501)73:9<2239::AID-CNCR2820730902>3.0.CO;2-#; ORLOW SJ, 1992, AM J PEDIAT HEMATOL, V14, P265; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1988, SCIENCE, V240, P130; PEIPER SC, 1990, ARCH PATHOL LAB MED, V114, P711; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; ROSS JS, 1992, HUM PATHOL, V23, P69, DOI 10.1016/0046-8177(92)90014-T; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STARASOLER L, 1991, AM J CLIN PATHOL, V95, P858, DOI 10.1093/ajcp/95.6.858; SUMAYA CV, 1992, MANUAL CLIN LABORATO, P568; TIMENS W, 1991, HISTOCHEMISTRY, V95, P605, DOI 10.1007/BF00266748; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011	32	416	430	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					12	18		10.1056/NEJM199501053320103	http://dx.doi.org/10.1056/NEJM199501053320103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990860				2022-12-01	WOS:A1995PZ49700003
J	RORTH, P				RORTH, P			SPECIFICATION OF C/EBP FUNCTION DURING DROSOPHILA DEVELOPMENT BY THE BZIP BASIC REGION	SCIENCE			English	Article							NF-KAPPA-B; LEUCINE ZIPPER; DNA-BINDING; SEQUENCE RECOGNITION; TRANSCRIPTION FACTOR; NUCLEAR-PROTEIN; FAMILY MEMBERS; GENE; EXPRESSION; CELLS	The biologically relevant interactions of a transcription factor are those that are important for function in the organism. Here, a transgenic rescue assay was used to determine which molecular functions of Drosophila CCAAT/enhancer binding protein (C/EBP), a basic region-leucine zipper transcription factor, are required for it to fulfill its essential role during development. Chimeric proteins that contain the Drosophila C/EBP (DmC/EBP) basic region, a heterologous zipper, and a heterologous activation domain could functionally substitute for DmC/EBP. Mammalian C/EBPs were also functional in Drosophila. In contrast, 9 of 25 single amino acid substitutions in the basic region disrupted biological function. Thus, the conserved basic region specifies DmC/EBP activity in the organism.			RORTH, P (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.		Rørth, Pernille/H-3020-2011					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; RORTH P, UNPUB; SCOTT LM, 1992, BLOOD, V80, P1725; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	30	28	30	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1878	1881		10.1126/science.7997882	http://dx.doi.org/10.1126/science.7997882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997882				2022-12-01	WOS:A1994PX38300039
J	BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE				BECKER, L; BADA, JL; WINANS, RE; BUNCH, TE			FULLERENES IN ALLENDE METEORITE	NATURE			English	Letter							CHEMISTRY		ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439; NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035	United States Department of Energy (DOE); Argonne National Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	BECKER, L (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.			Winans, Randall/0000-0002-7080-7673				BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BECKER L, 1993, NATURE, V361, P595, DOI 10.1038/361595a0; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; DEVRIES MS, 1993, GEOCHIM COSMOCHIM AC, V57, P933, DOI 10.1016/0016-7037(93)90179-Z; DIBROZOLO FR, 1994, NATURE, V369, P37, DOI 10.1038/369037a0; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; HEYMANN D, 1994, SCIENCE, V265, P645, DOI 10.1126/science.265.5172.645; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P275; POPE CJ, 1993, J PHYS CHEM-US, V97, P11001, DOI 10.1021/j100144a018; TIELENS AGGM, 1990, NASA CONF P, V3061, P59	10	60	61	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					507	507		10.1038/372507a0	http://dx.doi.org/10.1038/372507a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990921				2022-12-01	WOS:A1994PW08200033
J	GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K				GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K			PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES	NATURE			English	Article							COLLAGEN-INDUCED ARTHRITIS; TISSUE INHIBITOR; RABBIT BONE; CELLS; SECRETION; TIMP-2	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory and immunomodulatory cytokine implicated in inflammatory conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and the cachexia associated with cancer or human immunodeficiency virus infection(1). TNF-alpha is initially expressed as a 233-amino-acid membrane-anchored precursor which is proteolytically processed to yield the mature, 157-amino-acid cytokine(2). The processing enzyme(s) which cleave TNF-alpha are unknown. Here we show that the release of mature TNF-alpha from leukocytes cultured in vitro is specifically prevented by synthetic hydroxamic acid-based metalloproteinase inhibitors, which also prevent the release of TNF-alpha into the circulation of endotoxin challenged rats. A recombinant, truncated TNF-alpha precursor is cleaved to biologically active, mature TNF-alpha by several matrix metalloproteinase enzymes. These results indicate that processing of the TNF-alpha precursor is dependent on at least one matrix metalloproteinase-like enzyme, inhibition of which represents a novel therapeutic mechanism for interfering with TNF-alpha production.	BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND									CARMICHAEL DF, 1989, AGENTS ACTIONS, V27, P378, DOI 10.1007/BF01972827; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DEZUBE BJ, 1993, CANCER IMMUNOL IMMUN, V36, P57, DOI 10.1007/BF01789132; DIMARTINO MJ, 1991, J CELL BIOCH SE, V19, P179; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ENDRES S, 1991, IMMUNOLOGY, V72, P56; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519; GEE NS, 1987, BIOCHEM J, V246, P97, DOI 10.1042/bj2460097; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WILSON BMG, 1991, J IMMUNOL METHODS, V139, P233, DOI 10.1016/0022-1759(91)90193-J	21	1099	1151	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					555	557		10.1038/370555a0	http://dx.doi.org/10.1038/370555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052310				2022-12-01	WOS:A1994PC53700054
J	SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P				SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P			THE CRYSTAL-STRUCTURE OF A LOW-MOLECULAR-WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE	NATURE			English	Article							CYTOSOLIC ACID-PHOSPHATASE; BOVINE HEART; CATALYTIC MECHANISM; GROWTH; REFINEMENT	PROTEIN tyrosine phosphorylation and dephosphorylation are central reactions for control of cellular division, differentiation and development(1). Here we describe the crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase (PTPase)(2), a cytosolic phosphatase present in many mammalian cells. The enzyme catalyses the dephosphorylation of phosphotyrosine-containing substrates(3-6), and overexpression of the protein in normal and transformed cells inhibits cell. proliferation(7,8). The structure of the low-molecular-weight PTPase reveals an alpha/beta protein containing a phosphate-binding loop motif at the amino end of helix alpha 1. This motif includes the essential active-site residues Cys 12 and Arg 18 and bears striking similarities to the active-site motif recently described in the structure of human PTP1B(9). The structure ofthe low-molecular-weight PTPase supports a reaction mechanism involving the conserved Cys 12 as an attacking nucleophile in an in-line associative mechanism. The structure also suggests a catalytic role for Asp 129 in the reaction cycle.	UNIV FLORENCE,DEPT BIOCHEM SCI,FLORENCE,ITALY	University of Florence	SU, XD (corresponding author), UNIV STOCKHOLM,DEPT MOLEC BIOL,STOCKHOLM,SWEDEN.			Taddei, Niccolo/0000-0003-2513-1018; STEFANI, MASSIMO/0000-0002-4490-1922				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERTI A, IN PRESS FEBS LETT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIRAGA A, 1991, ADV PROTEIN PHOSPHAT, V6, P251; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; SU XD, 1994, FEBS LETT, V343, P107, DOI 10.1016/0014-5793(94)80299-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006	23	202	206	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					575	578		10.1038/370575a0	http://dx.doi.org/10.1038/370575a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052313				2022-12-01	WOS:A1994PC53700060
J	SEKUL, EA; CUPLER, EJ; DALAKAS, MC				SEKUL, EA; CUPLER, EJ; DALAKAS, MC			ASEPTIC-MENINGITIS ASSOCIATED WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY - FREQUENCY AND RISK-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						MENINGITIS, ASEPTIC; IMMUNOGLOBULINS; DOSE-RESPONSE RELATIONSHIP DRUG; INJECTIONS, INTRAVENOUS; MIGRAINE	IMMUNE GLOBULIN; CONTROLLED TRIAL; NEUROPATHY; INFUSIONS	Objective: Intravenous immunoglobulin is widely used to treat various autoimmune disorders. After observing instances of aseptic meningitis in treated patients, we studied the frequency and associated risk factors for aseptic meningitis in patients treated with high-dose intravenous immunoglobulin. Design: Retrospective analysis of a prospective cohort study. Setting: Tertiary research referral center. Patients: 54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin. Measurements: Analysis of patient records for evidence of aseptic meningitis, associated risk factors, penetration of serum IgG into the cerebrospinal fluid, and clearance of cerebrospinal fluid IgG. Results: Of 54 patients, 6 (11%; 95% CI, 4% to 23%) developed aseptic meningitis within 24 hours after completion of the infusions. Symptoms, lasting 3 to 5 days, included severe headache, meningismus, photophobia, and fever. Cerebrospinal fluid showed pleocytosis in 4 patients (leukocyte count as high as 1169 x 10(6)/L in one patient), eosinophilia in 3 patients, and IgG elevation in all patients (as great as 7 times the upper limit of normal in one patient). Repeat cerebrospinal fluid and serum studies after 24 hours showed a 46% cerebrospinal fluid IgG clearance compared with an 11% clearance of serum IgG in one patient. Cerebrospinal fluid cultures were negative. Aseptic meningitis developed in 4 of 8 patients (50%; CI, 16% to 84%) with a history of migraine but in only 2 of 46 (4%; CI, 0.5% to 15%) patients without such a history (P = 0.003). Aseptic meningitis recurred in patients who had migraine despite the use of different commercial intravenous immunoglobulin preparations and slower rates of infusion. Conclusion: Aseptic meningitis develops in patients receiving high-dose intravenous immunoglobulin therapy. patients with a history of migraine are more likely to develop aseptic meningitis while receiving intravenous immunoglobulin therapy, regardless of the type of commercial preparation or the infusion rate. Possible inciting factors include the IgG itself, various stabilizing products within each of the preparations, cytokine release triggered by the therapy, or cerebrovascular sensitivity in migraineurs.	NINCDS, NEUROMUSCULAR DIS SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Cupler, Edward/0000-0003-0958-8931				ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; ADAIR JC, 1991, NEUROLOGY, V41, P249, DOI 10.1212/WNL.41.2_Part_1.249; ARUSRA E, 1989, CLIN IMMUNOL IMMUNOP, V53, pS170; BALLOW M, 1991, CANCER, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4; BUCKLEY RH, 1980, IMMUNOGLOBULINS CHAR, P3; CASTEELSVANDAELE M, 1990, NEW ENGL J MED, V323, P614; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; CHEZ M, 1989, NEUROLOGY, V39, P1578, DOI 10.1212/WNL.39.12.1578; CONSTANTINESCU CS, 1993, NEW ENGL J MED, V329, P583, DOI 10.1056/NEJM199308193290820; COOK D, 1990, NEUROLOGY, V40, P212, DOI 10.1212/WNL.40.2.212; CUTLER RWP, 1970, J NEUROL SCI, V10, P259, DOI 10.1016/0022-510X(70)90154-1; DALAKAS MC, 1984, ANN NEUROL, V15, P590, DOI 10.1002/ana.410150612; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; DALAKAS MC, 1994, SEMIN NEUROL, V14, P97, DOI 10.1055/s-2008-1041065; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DALAKAS MC, 1994, IN PRESS ARCH NEUROL; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Fishman RA, 1992, CEREBROSPINAL FLUID, P198; GELFAND EW, 1984, CLIN IMMUNOL IMMUNOP, V53, P51; GORDON MF, 1990, NEUROLOGY, V40, P163, DOI 10.1212/WNL.40.1.163; KATO E, 1988, JAMA-J AM MED ASSOC, V259, P3269, DOI 10.1001/jama.1988.03720220017011; KREMER I, 1983, NEW ENGL J MED, V308, P1481; Martelletti P, 1991, Acta Neurol (Napoli), V13, P448; Covelli V, 1992, Acta Neurol (Napoli), V14, P313; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWLAND A C, 1991, P15; Raskin N, 1988, HEADACHE; ROBERTON DM, 1988, AUST PAEDIATR J, V24, P174; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SERGENT JS, 1978, JAMA-J AM MED ASSOC, V240, P529; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; TAN E, 1993, ARCH NEUROL-CHICAGO, V50, P137, DOI 10.1001/archneur.1993.00540020015010; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VERARAMIREZ M, 1992, NEUROLOGY, V42, P1636, DOI 10.1212/WNL.42.8.1636-a	34	286	293	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					259	262		10.7326/0003-4819-121-4-199408150-00004	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037406				2022-12-01	WOS:A1994PB10200004
J	KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA				KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA			FEATURES OF HIV-1 THAT COULD INFLUENCE MATERNAL-CHILD TRANSMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-ASSOCIATED RETROVIRUS; V3 LOOP PEPTIDES; VERTICAL TRANSMISSION; INFECTED INDIVIDUALS; TYPE-1 VARIANTS; UNITED-STATES; GP120; MOTHERS; ANTIBODIES	Objective.-To evaluate the biological and serological properties of the human immunodeficiency virus type 1 (HIV-1) for factors potentially involved in the mother-to-child transmission of HIV-1. Design.-Isolates of HIV-1 were recovered from the blood of 12 of 44 nontransmitting mothers and six of eight transmitting mothers and their corresponding infants. These 24 HIV-1 isolates were compared for their biological and immunologic properties to discern any parameters that correlate with vertical transmission of HIV-1. Main Outcome Measures.-Replication capabilities of the above-mentioned HIV-1 isolates in human peripheral blood mononuclear cells (PBMCs), human macrophages, and various T-cell lines and the susceptibilities of the viruses to neutralization or enhancement by anti-HIV-1 antibodies in autologous serum samples from mothers and infants. Setting.-San Francisco Bay Area, California. Participants.-A cohort of 52 HIV-1-infected women and their infants in a prospective study on perinatal HIV transmission by the Bay Area Perinatal AIDS Center. Results.-The viral isolates from the transmitting mothers and their infants differed from the isolates from the nontransmitting mothers in their efficient replication in human PBMCs and in their ability to infect one or more human T-lymphocytic cell lines. All the HIV-1 isolates were able to infect human macrophages with only low-level replication and were unable to form syncytia in the MTP-lymphocytic cells. No correlation between transmission and reactivity of maternal serum samples to the peptide corresponding to the principal neutralization domain of the third hypervariable region of the viral envelope was observed. However, the majority (9/12) of maternal isolates from the nontransmitters were neutralized by their autologous serum samples compared with only two among six in the transmitter group (P<.07). Moreover, five infant isolates were resistant to neutralization by their respective mothers' serum samples, and one was sensitive to infection enhancement by the mother's serum. Another infant isolate was enhanced by his autologous serum. Conclusions.-Viral factors that appeared to correlate with mother-to-child transmission of HIV-1 observed in a small cohort included rapid or high-titered replication in human PBMCs, T-cell line tropism, and resistance to neutralization or a sensitivity to enhancement of infection by the maternal Serum.	UNIV CALIF SAN FRANCISCO,SCH MED,DIV PEDIAT IMMUNOL,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT OBSTET & GYNECOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	KLIKS, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [R01 AI32446-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032446] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; CHU SY, 1991, PEDIATRICS, V87, P806; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EVANS LA, 1987, J IMMUNOL, V138, P3415; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOMSY J, 1988, LANCET, V1, P1285; HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990; KESSON AM, 1993, J INFECT DIS, V168, P571, DOI 10.1093/infdis/168.3.571; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LALLEMANT M, 1994, LANCET, V343, P1001, DOI 10.1016/S0140-6736(94)90126-0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; LYMAN WD, 1990, AIDS, V4, P917, DOI 10.1097/00002030-199009000-00014; MARKHAM RB, 1994, LANCET, V343, P390, DOI 10.1016/S0140-6736(94)91225-4; MCDOUGAL JS, 1985, J IMMUNOL METHODS, V76, P171, DOI 10.1016/0022-1759(85)90489-2; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; MOORE JP, 1993, AIDS RES HUM RETROV, V9, P209, DOI 10.1089/aid.1993.9.209; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAKAMOTO D, 1993, J CELL BIOCH E S, V17, P85; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STIEHM ER, 1991, J PEDIATR-US, V118, P410, DOI 10.1016/S0022-3476(05)82157-2; TATENO M, 1988, VIROLOGY, V167, P209; TERSMETTE M, 1989, LANCET, V1, P983; TUOFU Z, 1993, SCIENCE, V261, P1179; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VALENTIN A, 1990, VIROLOGY, V177, P790, DOI 10.1016/0042-6822(90)90551-2; WILLIAMSHERMAN D, 1993, 9TH P INT C AIDS BER, V1, P313; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P35; 1987, MMWR-MORBID MORTAL W, V36, P225	53	101	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					467	474		10.1001/jama.272.6.467	http://dx.doi.org/10.1001/jama.272.6.467			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040983				2022-12-01	WOS:A1994PA27800029
J	SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C				SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C			VITAMIN-D-3 THYROID-HORMONE RECEPTOR HETERODIMER POLARITY DIRECTS LIGAND SENSITIVITY OF TRANSACTIVATION	NATURE			English	Article							RETINOIC ACID RECEPTORS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; DIRECT REPEATS; X-RECEPTOR; RXR; BINDING; RAR; IDENTIFICATION	The nuclear receptors for 1,25-dihydroxyvitamin D-3 (VD) and 3,5,3'-triiodothyronine (T-3), that is, VDRs and T(3)Rs respectively, control aspects of homeostasis, cell growth and differentiation(1-4). They activate transcription from response elements consisting of direct repeats, palindromes and inverted palindromes(5-8) of a variety of hexameric core-binding motifs. VDRs bind preferentially to direct repeats spaced by three nucleotides, whereas T(3)Rs bind to direct repeats spaced by four nucleotides(9). VDRs and T(3)Rs can function as homodimers(5,6,10) but heterodimerization with retinoid X(11-14) Or retinoic acid receptors(15,16) increases their affinity for DNA in vitro and resulting transcriptional activity in vivo. We recently observed the formation of VDR-T(3)R heterodimers(17). Here we show that the polarity of the binding of such heterodimers to the VD response element of the rat 9K (relative molecular mass 9,000) calbindin's gene promoter was 5'-T(3)R-VDR-3', whereas on the mouse 28K calbindin VD response element(19) this polarity was reversed to 5'-VDR-T(3)R-3'. We also show that the ligand for the downstream receptor controls the transcriptional activity of the heterodimeric complex. Thus, polarity seems to be an important regulatory property of heterodimeric nuclear receptor complexes.			SCHRADER, M (corresponding author), UNIV GENEVA,HOP CANTONAL,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JWA, 1991, REV NUTR, V11, P189; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	125	126	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					382	386		10.1038/370382a0	http://dx.doi.org/10.1038/370382a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047145				2022-12-01	WOS:A1994PA30400059
J	BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM				BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM			CHARACTERIZATION AND RELATIONSHIP OF DPP RECEPTORS ENCODED BY THE SAXOPHONE AND THICK VEINS GENES IN DROSOPHILA	CELL			English	Article							GROWTH-FACTOR-BETA; PROTEIN-KINASE; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; CONSERVED FEATURES; GERM LAYERS; EXPRESSION; FAMILY; PATTERN; MELANOGASTER	The dpp/BMP family of TGF beta-related factors controls numerous events in pattern formation and morphogenesis. How these polypeptide signals are received and transduced by target cells is largely unknown. We combine molecular and genetic approaches to establish that the Drosophila saxophone (sax) gene encodes a dpp receptor. We compare the structural properties and expression patterns of sax with a second dpp receptor encoded by the thick veins (tkv) gene. While the sax gene is expressed ubiquitously, tkv is expressed in a highly localized and dynamic pattern during development. Some, but not all, of the tkv expression pattern parallels that of dpp. Ubiquitous expression of a tkv transgene rescues both tkv and sax loss-of function mutations. Thus, there is at least partial functional overlap of the sax and tkv receptors in vivo. We consider these observations in terms of possible ligand-receptor interactions during Drosophila development.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA; HARVARD UNIV, BIOL LABS, CAMBRIDGE, MA 02138 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	University of California System; University of California Irvine; Harvard University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BRUMMEL, TJ (corresponding author), UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA.		O'Connor, Michael B/C-9977-2014; Wrana, Jeffrey/F-8857-2013	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOENIG BB, 1994, IN PRESS MOL CELL BI; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHUPBACH T, 1989, GENETICS, V121, P101; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TERRACOL R, 1994, IN PRESS GENETICS; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wieschaus E., 1986, P199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	48	268	276	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					251	261		10.1016/0092-8674(94)90295-X	http://dx.doi.org/10.1016/0092-8674(94)90295-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044839				2022-12-01	WOS:A1994NZ24200009
J	SCHWARTZ, AB				SCHWARTZ, AB			DIRECT CORTICAL REPRESENTATION OF DRAWING	SCIENCE			English	Article							UNIT-ACTIVITY; MOVEMENTS; KINEMATICS; GEOMETRY; LEECH	How the intention to act results in movement is a fundamental question of brain organization. Recent work has shown that this operation involves the cooperative interaction of large neuronal populations. A population vector method, by transforming neuronal activity to the spatial domain, was used to visualize the motor cortical representation of the hand's trajectory made by rhesus monkeys as they drew spirals. Hand path was accurately reflected by a series of population vectors calculated throughout the task. A psychophysical rule relating speed to curvature, the ''power law,'' was found in this cortical representation. The relative timing between each population vector and the corresponding portion of the movement was variable. The population vectors only preceded the movement in a predictive manner in portions of the spiral where the radius of curvature was greater than 6 centimeters. These results show that the movement trajectory is an important determinant of motor cortical activity and that this aspect of motor cortical activity may contribute only to discrete portions of the drawing movement.			SCHWARTZ, AB (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NINDS NIH HHS [NS-26375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEV KV, 1991, NEUROSCIENCE, V43, P237, DOI 10.1016/0306-4522(91)90431-M; EDELMAN GM, 1978, MINDFUL BRAIN; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LUNDBERG A, 1971, EXP BRAIN RES, V12, P317; MASSEY JT, 1992, EXP BRAIN RES, V88, P685; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; SCHWARTZ AB, 1992, J NEUROPHYSIOL, V68, P528, DOI 10.1152/jn.1992.68.2.528; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; WANN J, 1988, J EXP PSYCHOL HUMAN, V14, P622, DOI 10.1037/0096-1523.14.4.622; WITTENBERG G, 1992, J NEUROPHYSIOL, V68, P1693, DOI 10.1152/jn.1992.68.5.1693; [No title captured]	16	241	242	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					540	542		10.1126/science.8036499	http://dx.doi.org/10.1126/science.8036499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY216	8036499				2022-12-01	WOS:A1994NY21600036
J	RIDDIHOUGH, G				RIDDIHOUGH, G			NO LIMITS ON RESTRICTION	NATURE			English	Note							CRYSTAL-STRUCTURE; ENDONUCLEASE											ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; CHENG X, IN PRESS EMBO J; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; RIDDIHOUGH G, 1994, NATURE, V368, P82, DOI 10.1038/368082a0; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	7	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					78	78		10.1038/370078a0	http://dx.doi.org/10.1038/370078a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015614	Bronze			2022-12-01	WOS:A1994NV71100064
J	BROMWICH, P; COHEN, J; STEWART, I; WALKER, A				BROMWICH, P; COHEN, J; STEWART, I; WALKER, A			DECLINE IN SPERM COUNTS - AN ARTIFACT OF CHANGED REFERENCE RANGE OF NORMAL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate a reported fall in sperm counts during 1940-90 in relation to the reduced lower reference value of ''normal'' during the same period by assuming the null hypothesis that no change had occurred in the probability distribution of the sperm concentration. Design-Analysis by using various mathematical models of the probability distribution of sperm concentration together with experimental data which supported a model employing a logarithmic distribution.	UNIV WARWICK,CTR ECOSYST ANAL & MANAGEMENT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; MIDLAND FERTIL SERV,ALDRIDGE WS9 8LT,STAFFS,ENGLAND; UNIV WARWICK,INST MATH,NONLINEAR SYST LAB,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick; University of Warwick								CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Cohen J., 1971, Adv comp Physiol Biochem, V4, P267; Feller W., 1957, INTRO PROBABILITY TH; MOORE DS, 1993, INTRO PRACTICE STATI; 1993, HORIZON         1031	5	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					19	22		10.1136/bmj.309.6946.19	http://dx.doi.org/10.1136/bmj.309.6946.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044061	Green Published			2022-12-01	WOS:A1994NV89100016
J	KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T				KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T			INVOLVEMENT OF THE IRF-1 TRANSCRIPTION FACTOR IN ANTIVIRAL RESPONSES TO INTERFERONS	SCIENCE			English	Article							REGULATORY FACTOR-I; GAMMA SIGNAL-TRANSDUCTION; CONSTITUTIVE EXPRESSION; INDUCIBLE GENES; BINDING PROTEIN; NITRIC-OXIDE; CELL-LINE; INHIBITION; ACTIVATION; ALPHA	The mechanisms underlying interferon (IFN)-induced antiviral states are not well understood. Interferon regulatory factor-1 (IRF-1) is an IFN-inducible transcriptional activator, whereas IRF-2 suppresses IRF-1 action. The inhibition of encephalomyocarditis virus (EMCV) replication by IFN-alpha and especially by IFN-gamma was impaired in cells from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice). The IRF-1(-/-) mice were less resistant than normal mice to EMCV infection, as revealed by accelerated mortality and a larger virus titer in target organs. The absence of IRF-1 did not clearly affect replication of two other types of viruses. Thus, IRF-1 is necessary for the antiviral action of IFNs against some viruses, but IFNs activate multiple activation pathways through diverse target genes to induce the antiviral state.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL & MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; University Health Network Toronto; New York University; New York University	KIMURA, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Nakayama, Katsutoshi/AAT-4536-2021; Harada, Hisashi/H-2815-2019; Penninger, Josef M/I-6860-2013	Kitagawa, Motoo/0000-0003-1036-840X; Nakayama, Katsutoshi/0000-0002-0141-7081; Harada, Hisashi/0000-0001-5993-1289; Penninger, Josef M/0000-0002-8194-3777; Kimura, Tohru/0000-0001-9227-0996; Tanaka, Nobuyuki/0000-0002-6373-2220	NCI NIH HHS [R35CA49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Anderson Sylvia L., 1992, Journal of Interferon Research, V12, pS86; BAIER LJ, 1993, NUCLEIC ACIDS RES, V21, P4830, DOI 10.1093/nar/21.20.4830; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Demaeyer E., 1988, INTERFERONS OTHER RE; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLASGOW L A, 1970, Journal of General Physiology, V56, P212, DOI 10.1085/jgp.56.1.212; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HESSEL BA, 1993, EMBO J, V12, P3297; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MURPHY BR, 1968, J EXP MED, V127, P1035, DOI 10.1084/jem.127.5.1035; NAKAYAMA K, UNPUB; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PENNINGER J, UNPUB; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, IN PRESS CELL; Vilcek J., 1990, HDB EXPT PHARM, V95, P3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WYNN TA, 1991, J IMMUNOL, V147, P4384; YAMAMOTO HM, UNPUB; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	52	267	273	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1921	1924		10.1126/science.8009222	http://dx.doi.org/10.1126/science.8009222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009222				2022-12-01	WOS:A1994NT84700042
J	NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI				NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI			IMPLICATIONS OF FRA16A STRUCTURE FOR THE MECHANISM OF CHROMOSOMAL FRAGILE SITE GENESIS	SCIENCE			English	Article							X-SYNDROME; HUNTINGTONS-DISEASE; MYOTONIC-DYSTROPHY; MENTAL-RETARDATION; MOLECULAR ANALYSIS; UNSTABLE ELEMENT; REPEAT SEQUENCE; FMR1 GENE; DNA; INSTABILITY	Fragile sites are chemically induced nonstaining gaps in chromosomes. Different fragile sites vary in frequency in the population and in the chemistry of their induction. DNA sequences encompassing and including the rare, autosomal, folate-sensitive fragile site, FRA16A, were isolated by positional cloning. The molecular basis of FRA16A was found to be expansion of a normally polymorphic p(CCG), repeat. This repeat was adjacent to a CpG island that was methylated in fragile site-expressing individuals. The FRA16A locus in individuals who do not express the fragile site is not a site of DNA methylation (imprinting), which suggests that the methylation associated with fragile sites may be a consequence and not a cause of their genesis.	WOMENS & CHILDRENS HOSP,CTR GENET MED,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; CTR ETUD POLYMORPHISME HUMAIN,F-750101 PARIS,FRANCE	Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory			Sutherland, Grant Robert/D-2606-2012; Kremer, Eric J/D-3734-2013; Callen, David F/G-1975-2012; Richards, Robert/ABE-6423-2020; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Le Paslier, Denis/0000-0003-4335-9956; Callen, David/0000-0002-6189-9991; Richards, Robert Ian/0000-0002-5978-6453				ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; BRUNNER HG, 1993, AM J HUM GENET, V53, P1016; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; JANSEN G, 1993, HUM MOL GENET, V2, P1221, DOI 10.1093/hmg/2.8.1221; KNIGHT SJL, 1993, CELL, V74, P27; KOZMAN H, 1992, GENET LIFE SCI ADV, V11, P229; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LAIRD CD, 1987, GENETICS, V117, P587; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; NANCARROW J, UNPUB; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENNIE J, 1993, SCI AM           MAR, P88; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1991, J MED GENET, V28, P856, DOI 10.1136/jmg.28.12.856; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHERMAN SL, 1986, HUM GENET, V72, P123; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1993, J MED GENET, V30, P978, DOI 10.1136/jmg.30.12.978; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	30	139	141	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1938	1941		10.1126/science.8009225	http://dx.doi.org/10.1126/science.8009225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009225				2022-12-01	WOS:A1994NT84700047
J	GRINSPOON, L; BAKALAR, JB				GRINSPOON, L; BAKALAR, JB			THE WAR ON DRUGS - A PEACE PROPOSAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROHIBITION				GRINSPOON, L (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							Austin J, 1989, NCCD PRISON POPULATI; DENNIS RJ, 1990, DRUG PROHIBITION CON; DINARDO J, 1991, ARE MARIHUANA ALCOHO; Erickson P. G., 1989, SOCIAL PHARM, V3, P249; GILL AM, 1992, IND LABOR RELAT REV, V45, P419, DOI 10.2307/2524269; GRINSPOON L, 1990, N C J INT LAW COMMER, V15, P505; Grinspoon L., 1993, MARIHUANA FORBIDDEN; HORGAN J, 1990, NEW REPUBLIC    0402, P22; Jolliffe N, 1936, SCIENCE, V83, P306, DOI 10.1126/science.83.2152.306-a; Kolb L, 1924, PUBLIC HEALTH REP, V39, P1179, DOI 10.2307/4577168; LEVINE HG, 1991, MILBANK Q, V69, P461, DOI 10.2307/3350105; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; MOORE MH, 1981, ALCOHOL PUBLIC POLIC; MOORE MH, 1977, BUY BUST EFFECTIVE R; NADELMANN EA, 1992, DAEDALUS, V121, P85; NADELMANN EA, 1988, FOREIGN POLICY, V70, P83; OMALLEY PM, 1985, NIDA RES MONOGRAPH, V61; POPE HG, 1990, AM J PSYCHIAT, V147, P998; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3177, DOI 10.1001/jama.268.22.3177; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TREBACH AS, 1987, GREAT DRUG WAR; Weil Andrew, 1980, MARRIAGE SUN MOON QU; WILSON JQ, 1990, DRUGS CRIME; WISOTSKY S, 1992, POLICY ANAL, V180; 1989, NATIONAL DRUG CONTRO; 1985, NATIONAL HOUSEHOLD S; 1991, CRIME US; 1992, NATIONAL DRUG CONTRO	30	19	19	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					357	360		10.1056/NEJM199402033300513	http://dx.doi.org/10.1056/NEJM199402033300513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU489	8043062				2022-12-01	WOS:A1994MU48900013
J	LAFONT, F; BURKHARDT, JK; SIMONS, K				LAFONT, F; BURKHARDT, JK; SIMONS, K			INVOLVEMENT OF MICROTUBULE MOTORS IN BASOLATERAL AND APICAL TRANSPORT IN KIDNEY-CELLS	NATURE			English	Article							DARBY CANINE KIDNEY; INTESTINAL EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; CYTOPLASMIC DYNEIN; SURFACE POLARITY; ACTIN-FILAMENTS; CACO-2; IDENTIFICATION; GLYCOPROTEIN	THE maintenance of a polarized cell surface requires vectorial transport of vesicles to the apical and the basolateral membrane domains(1). Transport of newly synthesized apical proteins and trans-cytosis from the basolateral to the apical surface have Motors been demonstrated to depend on microtubules(2-9). In contrast, movement of membrane proteins to the basolateral surface has been claimed to occur by diffusion and to be microtubule- and actin-independent(2,4,5,7,10-12). We have re-examined the role of microtubules using a recently developed polarized transport assay in permeabilized Madin-Darby canine kidney cells(13,14). Here we report that both apical and basolateral transport is inhibited by nocodazole treatment. Transport to the basolateral surface was inhibited by immunodepletion of cytosolic kinesin. In contrast, apical transport involved both dynein and kinesin. Our data demonstrate that in epithelial cells, microtubule motors are involved in the movement of apical and basolateral vesicles. Moreover, we propose that the differential requirement for microtubule-based motors is related to the microtubule organization.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69112 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				Burkhardt, Janis/0000-0002-8176-1375; Simons, Kai/0000-0002-9231-9996; Lafont, frank/0000-0001-8668-2580				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BACALLAO R, 1989, METHOD CELL BIOL, V31, P437; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.neuro.17.1.267; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; GIBBONS IR, 1978, J BIOL CHEM, V25, P2780; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; OJAKIAN GK, 1992, J CELL SCI, V103, P677; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VANZEIJL MJAH, 1990, CELL REGUL, V1, P921, DOI 10.1091/mbc.1.12.921	30	168	169	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					801	803						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997271				2022-12-01	WOS:A1994PY21200059
J	ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE				ZIEGLER, A; JONASON, AS; LEFFELL, DJ; SIMON, JA; SHARMA, HW; KIMMELMAN, J; REMINGTON, L; JACKS, T; BRASH, DE			SUNBURN AND P53 IN THE ONSET OF SKIN-CANCER	NATURE			English	Article							ULTRAVIOLET RADIATION; SOLAR KERATOSES; CELL; SUNLIGHT; MUTATION; APOPTOSIS; PROMOTION; EXPOSURE; GENE; DNA	SQUAMOUS cell carcinoma of the skin (SCC) can progress by stages: sun-damaged epidermis, with individual disordered keratinocytes; actinic keratosis (AK), spontaneously regressing keratinized patches having aberrant cell differentiation and proliferation; carcinoma in situ; SCC and metastasis(1-3). To understand how sunlight acts as a carcinogen, we determined the stage at which sunlight mutates the p53 tumour-suppressor gene and identified a function for p53 in skin. The p53 mutations induced by ultraviolet radiation and found in >90% of human SCCs4,5 were present in AKs. Inactivating p53 in mouse skin reduced the appearance of sunburn cells(6), apoptotic keratinocytes generated by overexposure to ultraviolet. Skin thus appears to possess a p53-dependent 'guardian-of-the-tissue' response to DNA damage which aborts precancerous cells. If this response is reduced in a single cell by a prior p53 mutation, sunburn can select for clonal expansion of the p53-mutated cell into the AK. Sunlight can act twice: as tumour initiator and tumour promoter.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,HOWARD HUGHES MED INST,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Yale University; Yale University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	ZIEGLER, A (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510, USA.			Ziegler, Annemarie/0000-0003-0018-7031				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS FJ, 1976, CANCER RES, V36, P1422; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EPSTEIN JH, 1962, J INVEST DERMATOL, V39, P455, DOI 10.1038/jid.1962.142; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA., 1984, SKIN AGING PROCESSES; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRICKER A, 1991, INT J CANCER, V48, P650, DOI 10.1002/ijc.2910480504; LEY RD, 1985, J INVEST DERMATOL, V85, P365, DOI 10.1111/1523-1747.ep12276992; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS R, 1990, MED J AUSTRALIA, V152, P62, DOI 10.5694/j.1326-5377.1990.tb124456.x; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; POTTER VR, 1984, CANCER RES, V44, P2733; ROSARIO R, 1979, BRIT J DERMATOL, V101, P299; SCHWARTZ RA, 1993, DERMATOLOGY GEN MED, P804; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; URBACH F, 1972, ENV CANCER, P355; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	30	1238	1270	2	97	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					773	776		10.1038/372773a0	http://dx.doi.org/10.1038/372773a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997263				2022-12-01	WOS:A1994PY21200051
J	LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D				LURIE, P; AVINS, AL; PHILLIPS, KA; KAHN, JG; LOWE, RA; CICCARONE, D			THE COST-EFFECTIVENESS OF VOLUNTARY COUNSELING AND TESTING OF HOSPITAL INPATIENTS FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; NEEDLESTICK INJURIES; UNITED-STATES; UNIVERSAL PRECAUTIONS; SURGICAL-PROCEDURES; RISK; POPULATION; ANTIBODY; BLOOD	Objective.-To evaluate the cost-effectiveness of voluntary counseling and testing of US hospital inpatients for the human immunodeficiency virus (HIV). Data Sources.-Data for entry into the model were derived from a review of the literature, consultation with experts, and consensus of the authors. Data Extraction.-We rated our confidence in these probabilities and costs by grading the data inputs using methods adapted from those of the US Preventive Services Task Force. Data Synthesis.-Decision analysis models were developed to evaluate two outcomes: (1) cost per health care worker (HCW) HIV infection averted if measures are taken by the HCW to reduce his or her risk of acquiring HIV; and (2) cost per inpatient HIV infection detected, Sensitivity analyses were also conducted, Using baseline input values, testing to avert HCW infection may prevent 3.6 HIV infections per year at a total program cost of $2.7 billion, or a cost of $753 million per infection averted. At baseline assumptions (seroprevalence=1%), testing to detect inpatient HIV infection would cost $16104 per year per infection detected. Cost-effectiveness at baseline drops to $8353 per HIV infection detected if the seroprevalence is 10%. If testing is limited to hospitals with inpatient seroprevalences of at least 1%, approximately 5400 persons per year will be falsely labeled HIV-positive. Conclusions.-This analysis provides no justification for testing inpatients to prevent HIV infection of HCWs. Screening inpatients to detect HIV infection may be justified at seroprevalences exceeding 1%, but issues of medical or social discrimination, false-positive results, informed consent, and logistics must be resolved first.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California Berkeley	LURIE, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA, USA.		Lowe, Robert A/A-4926-2008; Ciccarone, Daniel/I-5404-2013	Lowe, Robert A/0000-0002-4732-9634; Ciccarone, Daniel/0000-0002-2355-5477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P50MH042459] Funding Source: NIH RePORTER; AHRQ HHS [HS07373-01] Funding Source: Medline; NIMH NIH HHS [P50 MH42459, MH19105-02] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ARNO PS, 1991, SEP IMP REG GUID LEG; ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; BARTON JJ, 1989, AM J OBSTET GYNECOL, V160, P1316, DOI 10.1016/0002-9378(89)90850-8; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; COLOMBOTOS J, 1991, PHYSICIANS NURSES AI; FREEMAN HE, 1991, MED CARE, V29, P87, DOI 10.1097/00005650-199102000-00001; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GERBERT B, 1993, ARCH INTERN MED, V153, P313, DOI 10.1001/archinte.153.3.313; HAGEN MD, 1988, JAMA-J AM MED ASSOC, V259, P1357, DOI 10.1001/jama.259.9.1357; Hamory B H, 1984, Am J Infect Control, V12, P68, DOI 10.1016/0196-6553(84)90080-4; HAMORY BH, 1983, AM J INFECT CONTROL, V11, P174, DOI 10.1016/0196-6553(83)90077-9; HARDY LM, 1991, HIV SCREENING PREGNA, P91; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HEDLUND K, 1990, 6TH INT C AIDS SAN F; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HENDERSON DK, 1990, PRINCIPLES PRACTICE, P2221; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HORVITZ DG, 1990, P SECTION SURV S218, V150; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; HULL HF, 1988, JAMA-J AM MED ASSOC, V260, P935, DOI 10.1001/jama.260.7.935; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JANSSEN RS, 1992, NEW ENGL J MED, V327, P445, DOI 10.1056/NEJM199208133270701; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LAWRENCE VA, 1993, J CLIN EPIDEMIOL, V46, P1219, DOI 10.1016/0895-4356(93)90084-E; LINDAN CP, 1994, AIDS, V8, P1149, DOI 10.1097/00002030-199408000-00018; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LINNEMANN CC, 1991, INFECT CONT HOSP EP, V12, P214, DOI 10.2307/30146994; LURIE P, 1992, NEW ENGL J MED, V327, P1815, DOI 10.1056/NEJM199212173272512; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PETERSEN LR, 1990, AM J PUBLIC HEALTH, V80, P1087, DOI 10.2105/AJPH.80.9.1087; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; PHILLIPS KA, IN PRESS PUBLIC HLTH; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SCHOCHETMAN G, 1992, AIDS TESTING METHODS; SCHWARCZ SK, 1993, AM J EPIDEMIOL, V137, P600, DOI 10.1093/oxfordjournals.aje.a116717; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; TANDBERG D, 1991, ANN EMERG MED, V20, P66, DOI 10.1016/S0196-0644(05)81122-9; TOKARS J, 1990, 6TH INT C AIDS SAN F; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; WEISS R, 1988, NEW ENGL J MED, V319, P1010, DOI 10.1056/NEJM198810133191509; Yawn B P, 1992, Fam Med, V24, P355; 1993, AIDS ALERT, V8, P49; 1991, ESTIMATES RISK ENDEM; 1994, ANN INTERN MED, V120, P310; 1990, NATIONAL HIV SEROPRE; 1989, GUIDELINES PREVENTIO; 1990, MMWR-MORBID MORTAL W, V39, P380; 1991, NATIONAL HOSPITAL DI; 1991, HIV SCREENING PREGNA; 1993, MMWR-MORBID MORTAL W, V42, P5; 1992, STATISTICAL ABSTRACT; 1991, MMWR-MORBID MORTAL W, V40, P1	73	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1832	1838		10.1001/jama.272.23.1832	http://dx.doi.org/10.1001/jama.272.23.1832			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990217				2022-12-01	WOS:A1994PW98000031
J	FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD				FEAVER, WJ; SVEJSTRUP, JQ; HENRY, NL; KORNBERG, RD			RELATIONSHIP OF CDK-ACTIVATING KINASE AND RNA-POLYMERASE-II CTD KINASE TFIIH/TFIIK	CELL			English	Article							CARBOXYL-TERMINAL-DOMAIN; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; INITIATION-FACTORS; CATALYTIC SUBUNIT; SEQUENCE; DNA; PHOSPHORYLATION; YEAST	KIN28, a member of the p34(cdc2/CDC28) family of protein kinases, is identified as a subunit of yeast RNA polymerase transcription factor IIH (TFIIH) on the basis of sequence determination, immunological reactivity, and copurification. KIN28 is, moreover, one of three subunits of TFIIK, a subassembly of TFIIH with protein kinase activity directed toward the C-terminal repeat domain (CTD) of the largest subunit of RNA polymerase II. Itself a phosphoprotein, KIN28 interacts specifically with the two largest subunits of RNA polymerase II. Previous work of others points to two further associations: KIN28 interacts in vivo with the cyclin CCL1, and KIN28 and CCL1 are homologous to human MO15 and cyclin H, which form the cyclin-dependent kinase-activating kinase (CAK). We show that human CAK possesses the CTD kinase activity characteristic of TFIIH.			FEAVER, WJ (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305, USA.			Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HENRY NL, 1994, IN PRESS GENES DEV; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROY R, 1994, CELL, V79; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TSUJI JN, 1991, P NATL ACAD SCI USA, V88, P9006; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU LT, 1994, ONCOGENE, V9, P2089; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	48	376	381	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1103	1109		10.1016/0092-8674(94)90040-X	http://dx.doi.org/10.1016/0092-8674(94)90040-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001136				2022-12-01	WOS:A1994PY08600019
J	LIU, HP; KOHLER, J; FINK, GR				LIU, HP; KOHLER, J; FINK, GR			SUPPRESSION OF HYPHAL FORMATION IN CANDIDA-ALBICANS BY MUTATION OF A STE12 HOMOLOG	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; YEAST; PROTEIN	A Candida albicans gene (CPH1) was cloned that encodes a protein homologous to Saccharomyces cerevisiae Ste12p, a transcription factor that is the target of the pheromone response mitogen-activated protein kinase cascade. CPH1 complements both the mating defect of ste12 haploids and the filamentous growth defect of ste12/ste12 diploids. Candida albicans strains without a functional CPH1 gene (cph1/cph1) show suppressed hyphal formation on solid medium. However, cph1/cph1 strains can still form hyphae in liquid culture and in response to serum. Thus, filamentous growth may be activated in C. albicans by the same signaling kinase cascade that activates Ste12p in S. cerevisiae; however, alternative pathways may exist in C. albicans.	CHILDRENS HOSP, BOSTON, MA 02115 USA; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute					NIGMS NIH HHS [GM402661] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANUETT F, 1994, GENE DEV, V8, P1367, DOI 10.1101/gad.8.12.1367; BARLOW AJE, 1974, J GEN MICROBIOL, V82, P261, DOI 10.1099/00221287-82-2-261; BUFFO J, 1984, MYCOPATHOLOGIA, V85, P21, DOI 10.1007/BF00436698; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FONZI WA, 1993, DIMORPHIC FUNGI IN BIOLOGY AND MEDICINE, P37; FONZI WA, 1993, GENETICS, V134, P717; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOSHORN AK, 1989, GENETICS, V123, P667; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MALATHI K, 1994, J BIOL CHEM, V269, P22945; SCHERER S, 1990, MICROBIOL REV, V54, P226, DOI 10.1128/MMBR.54.3.226-241.1990; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	24	674	707	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1723	1726		10.1126/science.7992058	http://dx.doi.org/10.1126/science.7992058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992058				2022-12-01	WOS:A1994PW30800045
J	MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W				MINVIELLESEBASTIA, L; PREKER, PJ; KELLER, W			RNA14 AND RNA15 PROTEINS AS COMPONENTS OF A YEAST PRE-MESSENGER-RNA 3'-END PROCESSING FACTOR	SCIENCE			English	Article							CYC1 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; 3' END; GENE; SEQUENCE; POLYADENYLATION; MUTATIONS; INVITRO; BINDING	Most eukaryotic pre-messenger RNAs are processed at their 3' ends by endonucleolytic cleavage and polyadenylation. In yeast, this processing requires polyadenylate [poly(A)] polymerase (PAP) and other proteins that have not yet been characterized. Here, mutations in the PAP1 gene were shown to be synergistically lethal with previously identified mutations in the RNA14 and RNA15 genes, which suggests that their encoded proteins participate in 3'-end processing. Indeed, extracts from ma14 and ma15 mutants were shown to be deficient in both steps of processing. Biochemical complementation experiments and reconstitution of both activities with partially purified cleavage factor I (CF I) validated the genetic prediction.			MINVIELLESEBASTIA, L (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014					BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BONNEAUD N, 1994, J CELL SCI, V107, P913; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; HOU W, 1994, EMBO J, V13, P446, DOI 10.1002/j.1460-2075.1994.tb06279.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, UNPUB; MINVIELLESEBAST.L, 1992, THESIS PARIS U; MINVIELLESEBAST.L, UNPUB; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J., 1989, MOL CLONING LAB MANU; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	26	137	139	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1702	1705		10.1126/science.7992054	http://dx.doi.org/10.1126/science.7992054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992054				2022-12-01	WOS:A1994PW30800039
J	KASAHARA, N; DOZY, AM; KAN, YW				KASAHARA, N; DOZY, AM; KAN, YW			TISSUE-SPECIFIC TARGETING OF RETROVIRAL VECTORS THROUGH LIGAND-RECEPTOR INTERACTIONS	SCIENCE			English	Article							MURINE LEUKEMIA-VIRUS; HUMAN ERYTHROPOIETIN; EXPRESSION; CLONING; CELLS; GENE; INFECTION; MUTANT; MOUSE	The development of retroviral vectors that target specific cell types could have important implications for the design of gene therapy strategies. A chimeric protein containing the polypeptide hormone erythropoietin and part of the env protein of ecotropic Moloney murine leukemia virus was engineered into the virus. This murine virus became several times more infectious for murine cells bearing the erythropoietin receptor, and it also became infectious for human cells bearing the erythropoietin receptor. This type of tissue-specific targeting by means of ligand-receptor interactions may have broad applications to a variety of gene delivery systems.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM ENDOCRINOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Kasahara, Noriyuki/0000-0002-6069-9082	NHLBI NIH HHS [HL 20985] Funding Source: Medline; NIADDK NIH HHS [AM16666] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM016666] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ETIENNEJULAN M, 1992, J GEN VIROL, V73, P3251, DOI 10.1099/0022-1317-73-12-3251; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KASAHARA N, 1994, THESIS U CALIFORNIA; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; NEDA H, 1991, J BIOL CHEM, V266, P14143; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMONSEN CC, 1988, NUCLEIC ACIDS RES, V16, P2235, DOI 10.1093/nar/16.5.2235; VALSESIAWITTMANN S, 1994, J VIROL, V68, P4609, DOI 10.1128/JVI.68.7.4609-4619.1994; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEISS R, 1984, RNA TUMOR VIRUSES MO; WILSON C, 1989, J VIROL, V63, P2374, DOI 10.1128/JVI.63.5.2374-2378.1989; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	23	385	424	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1373	1376		10.1126/science.7973726	http://dx.doi.org/10.1126/science.7973726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973726				2022-12-01	WOS:A1994PT63200041
J	DISCHER, DE; MOHANDAS, N; EVANS, EA				DISCHER, DE; MOHANDAS, N; EVANS, EA			MOLECULAR MAPS OF RED-CELL DEFORMATION - HIDDEN ELASTICITY AND IN-SITU CONNECTIVITY	SCIENCE			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; BLOOD-CELLS; PROTEIN 4.1; SPECTRIN; SKELETON; BAND-3	Fluorescence-imaged micropipette aspiration was used to map redistribution of the proteins and lipids in highly extended human red blood cell membranes. Whereas the fluid bilayer distributed uniformly (+/-10 percent), the underlying, solidlike cytoskeleton of spectrin, actin, and protein 4.1 exhibited a steep gradient in density along the aspirated projection, which was reversible on release from deformation. Quantitation of the cytoskeletal protein density gradients showed that skeletal elasticity is well represented by a grafted polymer network with a ratio of surface dilation modulus to shear modulus of approximately 2:1. Fractionally mobile integral proteins, such as band 3, and highly mobile receptors, such as CD59 as well as glycophorin C in protein 4.1-deficient cells, appeared to be squeezed out of areas dense in the underlying network and enriched in areas of network dilation. This complementary segregation demonstrates patterning of cell surface components by cytoskeletal dilation.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PHYS, VANCOUVER V6T 1W5, BC, CANADA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of British Columbia; University of British Columbia	DISCHER, DE (corresponding author), UNIV CALIF BERKELEY, JOINT GRAD GRP BIOENGN, BERKELEY, CA 94720 USA.			discher, dennis/0000-0001-6163-2229	NHLBI NIH HHS [R01 HL31579-13] Funding Source: Medline; NIDDK NIH HHS [R01 DK26263-15, P01 DK32094-09] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026263, P01DK032094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOM JA, 1983, BIOPHYS J, V42, P295, DOI 10.1016/S0006-3495(83)84397-5; BOAL DH, 1994, BIOPHYS J, V67, P521, DOI 10.1016/S0006-3495(94)80511-9; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; de Gennes P.G., 1988, SCALING CONCEPTS POL; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1993, THESIS U CALIFORNIA; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; EVANS EA, 1989, METHOD ENZYMOL, V173, P3; EVANS EA, 1980, MECHANICS THERMODYNA; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819; GOLAN DE, 1980, P NATL ACAD SCI-BIOL, V77, P2537, DOI 10.1073/pnas.77.5.2537; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; HAGELBERG C, 1990, BIOCHEM J, V271, P831, DOI 10.1042/bj2710831; HAMASAKI N, 1980, ANION TRANSPORT PROT; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; HOFFMAN JF, 1992, USE RESEALED ERYTHRO, P1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NAKASHIMA K, 1978, P NATL ACAD SCI USA, V75, P3823, DOI 10.1073/pnas.75.8.3823; PINDER JC, 1993, BLOOD, V82, P3482; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1990, BLOOD, V75, P2229; SCOTT MD, 1990, J LAB CLIN MED, V115, P470; SPENCER M, 1990, DEV BIOL, V139, P279, DOI 10.1016/0012-1606(90)90297-V; STOKKE BT, 1986, J THEOR BIOL, V123, P205, DOI 10.1016/S0022-5193(86)80154-0; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VIITALA J, 1985, TRENDS BIOCHEM SCI, V10, P392, DOI 10.1016/0968-0004(85)90067-2; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WAYS P, 1964, J LIPID RES, V5, P318; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4	33	279	287	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1032	1035		10.1126/science.7973655	http://dx.doi.org/10.1126/science.7973655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973655				2022-12-01	WOS:A1994PQ92400041
J	ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK				ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK			AN OUTBREAK OF FATAL FLUORIDE INTOXICATION IN A LONG-TERM HEMODIALYSIS UNIT	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODIALYSIS UNITS, HOSPITAL; FLUORIDE POISONING; HEMODIALYSIS; DEIONIZATION SYSTEMS; WATER	HYPERKALEMIA	Objective: To determine the cause of an outbreak of acute illness and death in a long-term hemodialysis unit. Design: A retrospective cohort and case-control study of patients receiving hemodialysis and a laboratory study of a model deionization system to purify water for hemodialysis. Setting: An outpatient hemodialysis unit of a university hospital. Patients: 12 patients who became severely ill after hemodialysis treatment and 20 patients who did not become ill after receiving hemodialysis treatment in the same unit. Measurements: Medical and dialysis unit records were reviewed to identify and characterize cases. Fluids for dialysis were tested for toxic substances, and fluoride was measured in patients' serum. Resistivity and fluoride were measured in effluent from a model deionization system operated in the same way as the system associated with illness. Results: During five consecutive hemodialysis shifts, 12 of 15 patients receiving dialysis treatment in one room became acutely ill, with severe pruritus, multiple nonspecific symptoms, and/or fatal ventricular fibrillation (3 patients). None of 17 patients treated in the adjacent room became ill (P < 0.0001). Death was associated with longer hemodialysis time and increased age compared with other patients who became ill. Serum concentrations of fluoride in the sick patients were markedly increased to as high as 716 mu mol/L, and the source of fluoride was the temporary deionization system used to purify water for hemodialysis only in the affected room. Operation of a model deionization system showed how fluoride was adsorbed and then displaced in a massive efflux. Conclusions: Because deionization systems are used widely in hemodialysis and can cause fatal fluoride intoxication, careful design and monitoring are essential.	CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ARNOW, PM (corresponding author), UNIV CHICAGO HOSP & CLIN, DEPT MED MC5065, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							ABUELO JG, 1993, SEMIN DIALYSIS, V6, P59, DOI 10.1111/j.1525-139X.1993.tb00257.x; ABUKURAH AR, 1972, J AMER MED ASSOC, V222, P816; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Arduino MJ, 1989, DIALYSIS TRANSPLANT, V18, P655; ARMSTRONG W D, 1964, J Clin Invest, V43, P555; BALTAZAR RF, 1980, CHEST, V78, P660, DOI 10.1378/chest.78.4.660; BERMAN L, 1973, NEW ENGL J MED, V289, P922; Clifford D., 1990, WATER QUALITY TREATM; FLAHERTY JP, 1993, ANN INTERN MED, V119, P1072, DOI 10.7326/0003-4819-119-11-199312010-00003; FUCHS C, 1975, CLIN CHIM ACTA, V60, P157, DOI 10.1016/0009-8981(75)90121-7; HANES CM, 1990, J DENT RES, V69, P282, DOI 10.1177/00220345900690S110; JOHNSON WJ, 1974, KIDNEY INT, V5, P451, DOI 10.1038/ki.1974.64; KESHAVIAH PR, 1989, REPLACEMENT RENAL FU, P189; KUO HC, 1975, ARCH ORAL BIOL, V20, P235, DOI 10.1016/0003-9969(75)90117-X; LEVIN NW, 1990, CLIN DIALYSIS, P172; LUEHMAN DA, 1989, MANUAL WATER TREATME, P109; MCIVOR M, 1983, AM J CARDIOL, V51, P901, DOI 10.1016/S0002-9149(83)80153-2; MCIVOR ME, 1987, ANN EMERG MED, V16, P1165; MCIVOR ME, 1987, ANN EMERG MED, V16, P777; Murray J. J., 1986, APPROPRIATE USE FLUO, P131; PARSONS V, 1975, BMJ-BRIT MED J, V1, P128, DOI 10.1136/bmj.1.5950.128; SCHIFFL HH, 1980, NEPHRON, V26, P69, DOI 10.1159/000181954; SIDDIQUI JY, 1970, P EUR DIAL TRANS, V7, P110; SNEDECOR GW, 1980, STATISTICAL METHODS, P107; TAVES DR, 1968, T AM SOC ART INT ORG, V14, P412; TEPPERMAN PB, 1980, J OCCUP ENVIRON MED, V22, P691, DOI 10.1097/00043764-198010000-00018; Tokars J I, 1993, ASAIO J, V39, P966, DOI 10.1097/00002480-199310000-00027; VLCHEK DL, 1991, QUALITY ASSURANCE GU; YOLKEN R, 1976, PEDIATRICS, V58, P90; 1993, ANSIAAMI RD51992 ASS, P5; 1980, MMWR-MORBID MORTAL W, V29, P134	31	47	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					339	344		10.7326/0003-4819-121-5-199409010-00005	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042823				2022-12-01	WOS:A1994PD70100005
J	RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J				RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J			PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTOR; DIFFERENT SIGNALING PATHWAYS; SH3 DOMAIN; 3-KINASE; BIND; ASSOCIATION; EXPRESSION; 3'-KINASE; COMPLEX	Ras (p21(ras)) interacts directly with the catalytic subunit of phosphatidylinositol-3-OH kinase in a GTP-dependent manner through the Ras effector site. In vivo, dominant negative Ras mutant N17 inhibits growth factor induced production of 3' phosphorylated phosphoinositides in PC12 cells, and transfection of Ras, but not Raf, into COS cells results in a large elevation in the level of these lipids. Therefore Ras can probably regulate phosphatidylinositol-3-OH kinase, providing a point of divergence in signalling pathways downstream of Ras.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Fry, Michael/0000-0001-8518-1370				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOWNWARD J, 1991, Current Biology, V1, P353, DOI 10.1016/0960-9822(91)90190-8; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REIF K, 1993, J BIOL CHEM, V268, P10780; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VATANI A, 1990, CELL, V61, P769; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAME PH, 1993, NATURE, V364, P352; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	1629	1661	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					527	532		10.1038/370527a0	http://dx.doi.org/10.1038/370527a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052307				2022-12-01	WOS:A1994PC53700046
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA TO SPONSOR WORKSHOP ON HIV DETECTION DURING WINDOW PERIOD IN DONOR SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-01	WOS:A1994NY90300006
J	CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW				CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW			NEUTROPHIL AND B-CELL EXPANSION IN MICE THAT LACK THE MURINE IL-8 RECEPTOR HOMOLOG	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; OXYGEN METABOLITES; CYTOKINE FAMILY; CLONING; LUNG; ACCUMULATION; ACTIVATION; INHIBITOR; BINDING; INJURY	Interleukin-8 (IL-8) is a preinflammatory cytokine that specifically attracts and activates human neutrophils. A murine gene with a high degree of homology to the two known human IL-8 receptors was cloned and then deleted from the mouse genome by homologous recombination in embryonic stem (ES) cells. These mice, although outwardly healthy, had lymphadenopathy, resulting from an increase in B cells, and splenomegaly, resulting from an increase in metamyelocytes, band, and mature neutrophils. Thus, this receptor may participate in the expansion and development of neutrophils and B cells. This receptor was the major mediator of neutrophil migration to sites of inflammation and may provide a potential therapeutic target in inflammatory disease.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Huang, H/E-9490-2010					BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; COLDITZ I, 1989, AM J PATHOL, V134, P755; DAVEY FR, 1984, CLIN DIAGNOSIS MANAG, P857; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; KIKLY K, UNPUB; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RAMPART M, 1989, AM J PATHOL, V135, P21; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; WATANABE K, 1993, EUR J BIOCHEM, V214, P267, DOI 10.1111/j.1432-1033.1993.tb17920.x; WATANABE K, 1989, J BIOL CHEM, V264, P18907; WOOD WB, UNPUB	30	555	565	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					682	684		10.1126/science.8036519	http://dx.doi.org/10.1126/science.8036519			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036519				2022-12-01	WOS:A1994NZ53800040
J	ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M				ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M			ENDOTHELIN-A RECEPTOR MEDIATES CARDIAC INHIBITION BY REGULATING CALCIUM AND POTASSIUM CURRENTS	NATURE			English	Article							GENE-RELATED PEPTIDE; VASOCONSTRICTOR PEPTIDE; CELLS; CLONING; HEART; CDNA; EXPRESSION; SUBTYPES; MYOCYTES; BINDING	VOLTAGE-SENSITIVE ion channels play fundamental roles in the regulation of cardiac function by various neurotransmitters(1,2). Endothelins(3) have strong positive inotropic(4) and chronotropic(5) effects, for,which recent studies have implicated various intracellular mechanisms(6,7). However, very little is known about the underlying ion-channel regulation by the peptide. We report here that endothelin-1 consistently hyperpolarizes the membrane and shortens the duration of the action potential in mammalian atrial myocytes, leading to suppression of electrical excitability of the heart. Endothelin-1, but not endothelin(3), inhibited the L-type calcium current by decreasing cyclic AMP accumulation and activated the muscarinic potassium current by stimulating a pertussis toxin-sensitive GTP-binding protein. Consistent with these results, endothelin-1 strongly reduced the heart rate when it was increased by beta-adrenoceptor stimulation. These effects were blocked by an ET(A) (endothelin-1-selective) receptor-selective antagonist, BQ123 (refs 8-11). The ET(A) receptor-mediated regulation of cardiac ion channels gives new insight into our understanding of the physiological and pathophysiological roles of endothelins in the control of cardiac function.	NATL CHILDRENS MED RES CTR,DIV MOLEC & CELLULAR PHARMACOL,SETAGAYA KU,TOKYO 154,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN	National Center for Child Health & Development - Japan; Kyoto University	ONO, K (corresponding author), NATL INST HLTH SCI,DIV CHEM PHARMACOL & PHYTOCHEM,SETAGAYA KU,1-18-1 KAMI YOHGA,TOKYO 158,JAPAN.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTZELL HC, 1987, J PHYSIOL-LONDON, V389, P411, DOI 10.1113/jphysiol.1987.sp016663; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HURI S, 1992, ENDOCRINOLOGY, V130, P1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1991, CIRC RES, V69, P918, DOI 10.1161/01.RES.69.4.918; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; ONO K, 1991, J PHYSIOL-LONDON, V436, P195, DOI 10.1113/jphysiol.1991.sp018546; ONO K, 1989, NATURE, V340, P721, DOI 10.1038/340721a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REID JJ, 1991, EUR J PHARMACOL, V194, P173, DOI 10.1016/0014-2999(91)90102-V; REUTER H, 1979, ANNU REV PHYSIOL, V41, P413, DOI 10.1146/annurev.ph.41.030179.002213; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; TANAKA T, 1994, MOL PHARMACOL, V45, P724; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WENNMALM A, 1991, J PHYSIOL-LONDON, V435, P163, DOI 10.1113/jphysiol.1991.sp018503; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	27	144	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					301	304		10.1038/370301a0	http://dx.doi.org/10.1038/370301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035879				2022-12-01	WOS:A1994NZ22900066
J	HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ				HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ			CONTRIBUTION OF EARLY CELLS TO THE FATE MAP OF THE ZEBRAFISH GASTRULA	SCIENCE			English	Article							EMBRYO; LINEAGE; BLASTOMERES; MOVEMENTS	Previously, a tissue-specific fate map was compiled for the gastrula stage of the zebrafish embryo, indicating that development subsequent to this stage follows a reproducible pattern. Here it is shown that each early zebrafish blastomere normally contributes to a subset of the gastrula and thus gives rise to a limited array of tissues. However, the final contribution that any early blastomere makes to the fate map in the gastrula cannot be predicted because of variability in both the position of the future dorsoventral axis with respect to the early cleavage blastomeres and the scattering of daughter cells as the gastrula is formed. Therefore, early cell divisions of the zebrafish embryo cannot reproducibly segregate determinants of tissue fates.			HELDE, KA (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Cretekos, Chris J/D-8350-2013					ABDELILAH S, IN PRESS NATURE; HO RK, 1993, SCIENCE, V261, P109, DOI 10.1126/science.8316841; KANE DA, 1992, NATURE, V360, P735, DOI 10.1038/360735a0; KANE DA, 1993, DEVELOPMENT, V119, P447; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KIMMEL CB, 1985, DEV BIOL, V108, P94, DOI 10.1016/0012-1606(85)90012-0; NUSSLEINVOLHARD C, 1992, DEVELOPMENT, V116, P1021; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; WARGA RM, 1990, DEVELOPMENT, V108, P569; WETERFIELD M, 1993, ZEBRAFISH BOOK; WILSON ET, 1993, TRENDS GENET, V9, P348, DOI 10.1016/0168-9525(93)90039-K	19	72	74	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					517	520		10.1126/science.8036493	http://dx.doi.org/10.1126/science.8036493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036493				2022-12-01	WOS:A1994NY21600028
J	MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA				MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA			PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOR-NECROSIS-FACTOR PROCESSING	NATURE			English	Article							MOLECULAR-CLONING; EMERGING FAMILY; TNF; PURIFICATION; LIGAND; LIPOPOLYSACCHARIDE; INTERLEUKIN-1-BETA; CYTOKINES; PRECURSOR; HOMOLOGY	TUMOUR necrosis factor (tumour necrosis factor-alpha/cachectin) plays a critical role in certain physiological defensive responses but causes severe damage to the host organism when produced in excess(1). There are two forms of tumour necrosis factor, a type II membrane protein of relative molecular mass 26,000 (26K) and a soluble, 17K form generated from the cell-bound protein by proteolytic cleavage(2,3). The two forms of tumour necrosis factor and lymphotoxin-alpha (tumour necrosis factor-beta/lymphotoxin), a related protein, have similar but apparently not identical biological activities(4-6). A therapeutic agent which inhibited the release of tumour necrosis factor, but did not reduce the cell-associated activity or the level of lymphotoxin-alpha, might preserve the benefits of these cytokines while preventing tumour necrosis factor-induced damage. Here we describe a potent inhibitor of tumour necrosis factor processing and report that it protects mice from a lethal dose of endotoxin.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965									AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; BLACK RA, 1988, J BIOL CHEM, V263, P9437; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LIBBY RT, 1987, DNA-J MOLEC CELL BIO, V6, P221, DOI 10.1089/dna.1987.6.221; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MALISZEWSKI CR, 1988, MOL IMMUNOL, V25, P429, DOI 10.1016/0161-5890(88)90162-9; MOHLER KM, 1993, J IMMUNOL, V151, P1548; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; 1992, 12TH P AM PEPT S CAM	24	566	598	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					218	220		10.1038/370218a0	http://dx.doi.org/10.1038/370218a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028669				2022-12-01	WOS:A1994NX97100053
J	HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L				HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L			RISK OF ACUTE CHILDHOOD LEUKEMIA IN SWEDEN AFTER THE CHERNOBYL REACTOR ACCIDENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the risk of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident in April 1986. Design-Population based study of childhood leukaemia diagnosed during 1980-92. Setting-Coordinates for places of residence of all 1.6 million children aged 0-15 years; aerial mapped areas of Sweden heavily contaminated after the Chernobyl accident. Subjects-888 children aged 0-15 years with acute leukaemia diagnosed in Sweden during 1980-92, identified with place of birth and residence at diagnosis. Main outcome measures-Risk of leukaemia in areas contaminated after the Chernobyl accident compared with the rest of Sweden and in the same areas before the accident. Results-During six and a half years of follow up after the accident the odds ratio for acute leukaemia was 0.9 (95% confidence interval 0.6 to 1.4) in highly contaminated areas (greater than or equal to 10 kBq/m(2)) compared with the same areas before the accident. For the subgroup acute lymphoblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.5 (0.8 to 2.6). For all cases diagnosed after May 1986 in highly contaminated areas compared with areas of low contamination the odds ratio was 0.9 (0.7 to 1.3). For acute lymphblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.2 (0.8 to 1.9) in highly contaminated areas compared with areas of low contamination. Dose-response analysis showed no correlation between the degree of contamination and the incidence of childhood leukaemia. Conclusion-There has been no significant increase in the incidence of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident.	UPPSALA UNIV,DEPT STAT,UPPSALA,SWEDEN	Uppsala University	HJALMARS, U (corresponding author), CENT HOSP,DEPT PAEDIAT,S-83183 OSTERSUND,SWEDEN.		Kulldorff, Martin/H-4282-2011					BITHELL JF, 1988, STAT MED, V7, P857, DOI 10.1002/sim.4780070804; Edvarson K, 1991, CHERNOBYL FALLOUT SW, P527; Hosmer D, 2013, APPL LOGISTIC REGRES; JOSEPH L, 1981, STATISTICAL METHODS; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; Knox E. G., 1987, J SOC RADIOL PROT, V7, P3; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; PRISYAZHIUK A, 1991, LANCET, V338, P1334, DOI 10.1016/0140-6736(91)92632-C; 1991, INT PROGRAMME HLTH E; 1991, ANN ICRP, V21, P1; 1989, SUMMARY REPORT CONSU	11	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					154	157		10.1136/bmj.309.6948.154	http://dx.doi.org/10.1136/bmj.309.6948.154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044093	Green Published			2022-12-01	WOS:A1994NY22900018
J	STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P				STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P			CRYSTAL-STRUCTURE OF P22 TAILSPIKE PROTEIN - INTERDIGITATED SUBUNITS IN A THERMOSTABLE TRIMER	SCIENCE			English	Article							TAIL SPIKE PROTEIN; SENSITIVE FOLDING MUTATIONS; MOLECULAR-PROPERTIES; GLOBAL SUPPRESSORS; MUTANT PROTEINS; PHAGE-P22; BACTERIOPHAGE-P22; ENDORHAMNOSIDASE; PATHWAY; INVITRO	The tailspike protein (TSP) of Salmonella typhimurium phage P22 is a part of the apparatus by which the phage attaches to the bacterial host and hydrolyzes the O antigen. It has served as a model system for genetic and biochemical analysis of protein folding. The x-ray structure of a shortened TSP (residues 109 to 666) was determined to a 2.0 angstrom resolution. Each subunit of the homotrimer contains a large parallel beta helix. The interdigitation of the polypeptide chains at the carboxyl termini is important to protrimer formation in the folding pathway and to thermostability of the mature protein.	UNIV REGENSBURG,D-93040 REGENSBURG,GERMANY	University of Regensburg	STEINBACHER, S (corresponding author), MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Steipe, Boris/ABE-3813-2020	Steipe, Boris/0000-0002-1134-6758				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P20071; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DANNER M, UNPUB; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; ISRAEL JV, 1967, P NATL ACAD SCI USA, V57, P284, DOI 10.1073/pnas.57.2.284; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LEE SC, 1991, J BIOL CHEM, V266, P23191; MAURIDES PA, 1990, GENETICS, V125, P673; MESSERSCHMIDT A, 1990, J APPL CRYSTALLOGR, V23, P436, DOI 10.1107/S0021889890005301; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MESSERSCHMIDT A, 1991, CRYSTALLOGRAPHIC COM, V5, P115; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	34	274	278	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					383	386		10.1126/science.8023158	http://dx.doi.org/10.1126/science.8023158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023158				2022-12-01	WOS:A1994NW81600037
J	FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU				FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU			FOLDING OF NASCENT POLYPEPTIDE-CHAINS IN A HIGH-MOLECULAR-MASS ASSEMBLY WITH MOLECULAR CHAPERONES	NATURE			English	Article							T-COMPLEX POLYPEPTIDE-1; ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; STRESS PROTEINS; BINDING-SPECIFICITY; PEPTIDE-BINDING; CENTRAL CAVITY; GROEL; TRANSLOCATION; CELL	The folding of polypeptides emerging from ribosomes was analysed in a mammalian translation system using firefly luciferase as a model protein. The growing polypeptide interacts with a specific set of molecular chaperones, including Hsp70, the DnaJ homologue Hsp40 and the chaperonin TRiC. The ordered assembly of these components on the nascent chain forms a high molecular mass complex that allows the cotranslational formation of protein domains and the completion of folding once the chain is released from the ribosome.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIPHYS PROGRAM,NEW YORK,NY 10021; AICHI CANC CTR,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Aichi Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CZERMELY P, 1991, J BIOL CHEM, V266, P4943; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HATTORI H, 1993, J CELL SCI, V104, P629; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARCO S, IN PRESS BIOPHYS J; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	50	569	582	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					111	117		10.1038/370111a0	http://dx.doi.org/10.1038/370111a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022479				2022-12-01	WOS:A1994NW80400047
J	BUCKMAN, R; LEWITH, G				BUCKMAN, R; LEWITH, G			WHAT DOES HOMEOPATHT DO AND HOW	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	Robert Buckman, a medical oncologist, and George Lewith, a homoeopathic physician, met in Southampton while filming ''Magic or Medicine?,'' a television series of four programmes about what can and might be learnt from the popularity of complementary medicine. In particular, the series showed how the effect of the patient's and the doctor's beliefs affected the relationship between them. The two doctors so enjoyed talking with each other that they carried on their debate in letters to each other over the next year. We think that their exchange merits a wider readership.	CTR STUDY COMPLEMENTARY MED,SOUTHAMPTON SO15 2DT,HANTS,ENGLAND		BUCKMAN, R (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Lewith, George/0000-0002-2364-3960				BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Brigo B, 1991, BERL J RES HOM, V1, P98; BUCKMAN R, 1993, MAGIC MED; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEWITH G, 1987, COMPLEMENTAYR MED RE, V2, P11; PETO R, 1984, LANCET, V2, P1205; REILLY DT, 1986, LANCET, V2, P881; REILLY DT, 1993, COMPLEMENTARY THE S1, V1, P24; SPIEGEL D, 1989, LANCET, V2, P888	11	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					103	106		10.1136/bmj.309.6947.103	http://dx.doi.org/10.1136/bmj.309.6947.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038642	Green Published			2022-12-01	WOS:A1994NW71600027
J	SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G				SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G			ACTIVE CASCADE TESTING FOR CARRIERS OF CYSTIC-FIBROSIS GENE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; CFTR GENE; DNA; PRACTITIONERS; MUTATIONS	Objective-To examine the acceptability, practicability, efficiency, and application of active screening for carriers of the cystic fibrosis gene in the extended families of those in whom the disease is present (cascade screening). Design-Paediatricians and physicians provide details of their affected patients, pedigrees are drawn up, and relatives offered tests after initial contact by the affected nuclear families. Affected patients are genotyped in a laboratory with a special interest in the genetics of cystic fibrosis. Setting-North Western health region. Subjects-Relatives and partners of 607 people with cystic fibrosis.	UNIV MANCHESTER,MANCHESTER M27 1HA,LANCS,ENGLAND	University of Manchester	SUPER, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,REG GENET SERV,MANCHESTER M27 1HA,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BURN J, 1993, BRIT MED J, V306, P1558, DOI 10.1136/bmj.306.6892.1558; CASKEY CT, 1990, AM J HUM GENET, V46, P393; DANKS DM, 1965, ANN HUM GENET, V28, P323, DOI 10.1111/j.1469-1809.1965.tb00489.x; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HANDYSIDE AH, NEW ENGL J MED, V905, P92; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; MORRAL N, 1992, HUM GENET, V88, P356; SCHWARZ MJ, 1990, HUM GENET, V85, P428, DOI 10.1007/BF02428298; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SUPER M, 1987, LANCET, V2, P782; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; SUPER M, 1992, J ROY SOC MED, V85, P6; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; 1992, LANCET, V340, P209; 1992, CYSTIC FIBROSIS DNA; 1990, CYSTIC FIBROSIS ADUL	25	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1462	1467		10.1136/bmj.308.6942.1462	http://dx.doi.org/10.1136/bmj.308.6942.1462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019278	Green Published			2022-12-01	WOS:A1994NQ22900013
J	KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J				KRISHNA, TSR; KONG, XP; GARY, S; BURGERS, PM; KURIYAN, J			CRYSTAL-STRUCTURE OF THE EUKARYOTIC DNA-POLYMERASE PROCESSIVITY FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; AUXILIARY PROTEIN; ESCHERICHIA-COLI; III HOLOENZYME; DELTA; BACTERIOPHAGE-T4; REFINEMENT	The crystal structure of the processivity factor required by eukaryotic DNA polymerase delta, proliferating cell nuclear antigen (PCNA) from S. cerevisiae, has been determined at 2.3 Angstrom resolution. Three PCNA molecules, each containing two topologically identical domains, are tightly associated to form a closed ring. The dimensions and electrostatic properties of the ring suggest that PCNA encircles duplex DNA, providing a DNA-bound platform for the attachment of the polymerase. The trimeric PCNA ring is strikingly similar to the dimeric ring formed by the beta subunit (processivity factor) of E. coli DNA polymerase III holoenzyme, with which it shares no significant sequence identity. This structural correspondence further substantiates the mechanistic connection between eukaryotic and prokaryotic DNA replication that has been suggested on biochemical grounds.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Rockefeller University; Washington University (WUSTL)	KRISHNA, TSR (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, NEW YORK, NY 10021 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431, GM45547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHA TA, 1988, EUKARYOTIC DNA REPLI, P1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER F, 1994, J BIOL CHEM, V269, P17086; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PODUST VN, 1993, J BIOL CHEM, V25, P841; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROOS G, 1993, LAB INVEST, V68, P204; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TINKER RL, 1994, IN PRESS EMBO J; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wells A.F., 1984, STRUCTURAL INORGANIC; WOLD MS, 1988, CANCER CELL, V6, P133; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	56	765	784	27	183	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1233	1243		10.1016/0092-8674(94)90014-0	http://dx.doi.org/10.1016/0092-8674(94)90014-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001157				2022-12-01	WOS:A1994PZ86000014
J	WATANABE, S; TAKAHASHI, H				WATANABE, S; TAKAHASHI, H			TREATMENT OF NEVUS OF OTA WITH THE Q-SWITCHED RUBY-LASER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUINEA-PIG SKIN; SELECTIVE PHOTOTHERMOLYSIS; IRRADIATION; PULSES; INJURY	Background. Nevus of Ota is a benign bluish gray-brown lesion of the eye and the surrounding skin that has been reported to occur in about 1 in 200 people in Japan. Prior treatments have either been ineffective or caused scarring. The Q-switched ruby laser can produce very short high-energy pulses and can selectively target cells that contain pigment, such as dermal melanocytes. Methods. We treated the skin lesions of 114 patients (25 male and 89 female) with nevi of Ota with a Q-switched ruby laser set to deliver pulses of 6 J per square centimeter of body-surface area at a wavelength of 694.3 nm, with a pulse duration of 30 nanoseconds. The interval between treatments ranged from three to four months. Five dermatologists who were not familiar with the patients independently compared a full set of pretreatment and post-treatment photographs of each patient and determined the percentage of pigment lightening of the affected areas using standard criteria. Results. Of the 35 patients who received four or five treatments, 33 had an excellent response (lightening of 70 percent or more), and 2 had a good response (lightening of 40 to 69 percent). Of the 31 patients who received three treatments, 4 had an excellent response, 26 a good response, and 1 a fair response (lightening of 10 to 39 percent). Of the 25 patients who received two treatments, 2 had an excellent response, 16 a good response, and 7 a fair response. Of the 23 patients who received one treatment, 3 had a good response, 13 a fair response, and 7 no response (lightening of 9 percent or less). No patient had hypertrophic or atrophic scarring; eight patients had postinflammatory hyperpigmentation for up to two months after the first treatment. Conclusions. Selective photothermolysis with the Q-switched ruby laser is a safe and effective method for lightening nevi of Ota. Multiple treatments increase the response rate.			WATANABE, S (corresponding author), TEIKYO UNIV,SCH MED,DEPT DERMATOL,ITABASHI KU,11-1 KAGA,2 CHOME,TOKYO 173,JAPAN.							Anderson R R, 1981, Lasers Surg Med, V1, P263; ANDERSON RR, 1989, J INVEST DERMATOL, V93, P28, DOI 10.1111/1523-1747.ep12277339; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191; APFELBERG DB, 1981, JAMA-J AM MED ASSOC, V245, P2073, DOI 10.1001/jama.245.20.2073; DOVER JS, 1989, ARCH DERMATOL, V125, P43, DOI 10.1001/archderm.125.1.43; GERONEMUS RG, 1992, ARCH DERMATOL, V128, P1618, DOI 10.1001/archderm.128.12.1618; GOLDBERG DJ, 1992, J DERMATOL SURG ONC, V18, P817, DOI 10.1111/j.1524-4725.1992.tb03040.x; HIDANO A, 1967, ARCH DERMATOL, V95, P187, DOI 10.1001/archderm.95.2.187; HRUZA GJ, 1991, ARCH DERMATOL, V127, P1799, DOI 10.1001/archderm.127.12.1799; LOWE NJ, 1993, J AM ACAD DERMATOL, V29, P997, DOI 10.1016/0190-9622(93)70280-7; MARGOLIS RJ, 1989, LASER SURG MED, V9, P389, DOI 10.1002/lsm.1900090412; MOSHER DB, 1987, DERMATOLOGY GENERAL, V1, P854; MURPHY GF, 1983, LAB INVEST, V49, P680; POLLA LL, 1987, J INVEST DERMATOL, V89, P281, DOI 10.1111/1523-1747.ep12471397; TAYLOR CR, 1990, ARCH DERMATOL, V126, P893, DOI 10.1001/archderm.126.7.893; TAYLOR CR, 1994, J AM ACAD DERMATOL, V30, P743, DOI 10.1016/S0190-9622(08)81505-8; WATANABE S, 1991, PHOTOCHEM PHOTOBIOL, V53, P757, DOI 10.1111/j.1751-1097.1991.tb09889.x	18	108	112	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1745	1750		10.1056/NEJM199412293312604	http://dx.doi.org/10.1056/NEJM199412293312604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984195				2022-12-01	WOS:A1994PZ26600004
J	KASTELER, JS; CALLEN, JP				KASTELER, JS; CALLEN, JP			SCALP INVOLVEMENT IN DERMATOMYOSITIS - OFTEN OVERLOOKED OR MISDIAGNOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IDIOPATHIC INFLAMMATORY MYOPATHIES; SINE MYOSITIS; POLYMYOSITIS	Objective.-To characterize scalp involvement in patients with dermatomyositis. Design.-Case series. Patients.-All patients with dermatomyositis seen in our office between 1988 and mid 1993. Patient inclusion in this study required fulfillment of three or more of Bohan and Peter's criteria for dermatomyositis. Results.-Of 17 patients with the diagnosis of dermatomyositis, scalp involvement was present in 14. Five of the 14 patients with scalp involvement were diagnosed as having scalp psoriasis or seborrheic dermatitis before progression of their disease or tissue examination revealed the diagnosis of dermatomyositis. In all patients, the scalp involvement was manifested as atrophic, erythematous, scaly plaques. In addition, alopecia was noted in six of the 14 patients. Treatment of cutaneous involvement included sun avoidance, topical corticosteroids and/or antimalarials, and/or methotrexate. Conclusions.-Recognition of this process is important because scalp involvement is often overlooked, may be misdiagnosed initially, and can be the presenting complaint in some patients with dermatomyositis.	UNIV LOUISVILLE,SCH MED,DIV DERMATOL,LOUISVILLE,KY 40292	University of Louisville								BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; CALLEN JP, 1993, J AM ACAD DERMATOL, V28, P477, DOI 10.1016/S0190-9622(08)81757-4; CALLEN JP, 1987, DM-DIS MON, V33, P242; EUWER RL, 1991, J AM ACAD DERMATOL, V24, P959, DOI 10.1016/0190-9622(91)70153-S; FAFALAK RG, 1994, J RHEUMATOL, V21, P643; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; JOFFE MM, 1993, AM J MED, V94, P379, DOI 10.1016/0002-9343(93)90148-I; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; SCHWIETERMAN WD, 1993, ARTHRITIS RHEUM, V36, pS118; SINOWAY PA, 1994, J RHEUMATOL, V21, P353; STONECIPHER MR, 1993, J AM ACAD DERMATOL, V28, P951, DOI 10.1016/0190-9622(93)70136-H; URBANOMARQUEZ A, 1991, ANN RHEUM DIS, V50, P191, DOI 10.1136/ard.50.3.191	13	50	50	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1939	1941		10.1001/jama.272.24.1939	http://dx.doi.org/10.1001/jama.272.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990247				2022-12-01	WOS:A1994PX92700040
J	SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM				SLOANLANCASTER, J; SHAW, AS; ROTHBARD, JB; ALLEN, PM			PARTIAL T-CELL SIGNALING - ALTERED PHOSPHO-ZETA AND LACK OF ZAP70 RECRUITMENT IN APL-INDUCED T-CELL ANERGY	CELL			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR-ZETA; LYMPHOKINE PRODUCTION; CYTOPLASMIC TAIL; CROSS-LINKING; ACTIVATION; KINASE; CHAIN; TRANSDUCTION; ASSOCIATION	Studies of T cell responses to altered peptide ligands (APLs) have provided functional evidence that a T cell receptor (TCR) can interpret subtle changes in its ligand, resulting in different phenotypic outcomes. One dramatic effect of APL stimulation with live antigen-presenting cells (APCs) is the induction of energy as opposed to proliferation. We investigated the intracellular signaling events involved in generating this unresponsiveness by comparing protein-tyrosine phosphorylation patterns after stimulation with anergy-inducing APL or the immunogenic peptide. In resting T cell clones, presentation with APL/live APC stimulated a unique pattern of TCR phospho-zeta species and a subsequent lack of association with zap70. This demonstrates that the TCR-CD3 complex can engage selective intracellular biochemical signaling pathways as a direct consequence of the nature of the ligand recognized and the initial phosphotyrosine pattern of the TCR-CD3 proteins, leading to different phenotypes.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; IMMULOG, PALO ALTO, CA 94304 USA	Washington University (WUSTL)								ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS LS, 1989, J IMMUNOL, V142, P1084; DIANZANI U, 1992, J IMMUNOL, V148, P678; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HERMANS MHA, 1993, EUR J IMMUNOL, V23, P2257, DOI 10.1002/eji.1830230931; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LORENZ RG, 1989, NATURE, V340, P557, DOI 10.1038/340557a0; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; NORTON SD, 1991, J IMMUNOL, V146, P1125; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; QUILL H, 1987, J IMMUNOL, V138, P3704; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	587	593	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					913	922		10.1016/0092-8674(94)90080-9	http://dx.doi.org/10.1016/0092-8674(94)90080-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001128				2022-12-01	WOS:A1994PW05400018
J	HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA				HECK, SD; SIOK, CJ; KRAPCHO, KJ; KELBAUGH, PR; THADEIO, PF; WELCH, MJ; WILLIAMS, RD; GANONG, AH; KELLY, ME; LANZETTI, AJ; GRAY, WR; PHILLIPS, D; PARKS, TN; JACKSON, H; AHLIJANIAN, MK; SACCOMANO, NA; VOLKMANN, RA			FUNCTIONAL CONSEQUENCES OF POSTTRANSLATIONAL ISOMERIZATION OF SER(46) IN A CALCIUM-CHANNEL TOXIN	SCIENCE			English	Article							GLUTAMATE RACEMASE; OMEGA-CONOTOXIN; CA2+ CHANNELS; PERIPHERAL NEURONS; EXPRESSION; PEPTIDE; NEUROPEPTIDES; DIVERSITY; MECHANISM; CLONING	The venom of the funnel-web spider Agelenopsis aperta contains several peptides that paralyze prey by blocking voltage-sensitive calcium channels. Two peptides, omega-Aga-IVB (IVB) and omega-Aga-IVC (IVC), have identical amino acid sequences, yet have opposite absolute configurations at serine 46. These toxins had similar selectivities for blocking voltage-sensitive calcium channel subtypes but different potencies for blocking P-type voltage-sensitive calcium channels in rat cerebellar Purkinje cells as well as calcium-45 influx into rat brain synaptosomes. An enzyme purified from venom converts IVC to IVB by isomerizing serine 46, which is present in the carboxyl-terminal tail, from the L to the D configuration. Unlike the carboxyl terminus of IVC, that of IVB was resistant to the major venom protease. These results show enzymatic activities in A. aperta venom being used in an unprecedented strategy for coproduction of necessary neurotoxins that possess enhanced stability and potency.	NPS PHARMACEUT INC,SALT LAKE CITY,UT 84108; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT ANAT,SALT LAKE CITY,UT 84112; PFIZER RES INC,GROTON,CT 06340	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Pfizer								ADAMS ME, 1993, MOL PHARMACOL, V44, P681; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BRANTON WD, 1993, NATURE, V365, P496, DOI 10.1038/365496a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; FORD R, 1986, COMP BIOCHEM PHYS C, V85, P61, DOI 10.1016/0742-8413(86)90052-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GANONG AH, 1993, SOC NEUR ABSTR, V19, P7212; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; HECK SD, IN PRESS J AM CHEM S; HORNBERG U, 1991, J COMP NEUROL, V303, P35; KREIL G, 1994, J BIOL CHEM, V269, P10967; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PHILLIPS D, 1992, Patent No. 5122596; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOOFS L, 1988, GEN COMP ENDOCR, V69, P1, DOI 10.1016/0016-6480(88)90046-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SPEDDING M, 1992, PHARMACOL REV, V44, P363; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TANNER ME, 1993, BIOCHEMISTRY-US, V32, P3998, DOI 10.1021/bi00066a021; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WALSH C, 1979, ENZYMATIC REACTION M, P828; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	39	130	133	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1065	1068		10.1126/science.7973665	http://dx.doi.org/10.1126/science.7973665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973665				2022-12-01	WOS:A1994PQ92400052
J	HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF				HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF			AN EPIDEMIC OF PNEUMOCOCCAL DISEASE IN AN OVERCROWDED, INADEQUATELY VENTILATED JAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICK BUILDING SYNDROME; RESISTANT STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE VACCINE; OUTBREAK; TUBERCULOSIS; TRANSMISSION; CARRIAGE; FAMILIES; SYMPTOMS; EFFICACY	Background. In the United States many correctional facilities now operate at far over capacity, with the potential for living conditions that permit outbreaks of respiratory infections. We investigated an outbreak that was identified in an overcrowded Houston jail after two inmates died of pneumococcal sepsis on the same day. Outbreaks of pneumococcal disease have been rare in the era of antibiotics. Methods. We assessed risk factors for pneumococcal disease in both a case-control and a cohort study. Ventilation was evaluated by measuring carbon dioxide levels and air flow to the living areas of the jail. The extent of asymptomatic infection was determined by culturing pharyngeal specimens from a random sample of inmates. Type-specific immunity was determined with an enzyme immunoassay. Results. Over a four-week period, 46 inmates had either acute pneumonia or invasive pneumococcal disease due to Streptococcus pneumoniae serotype 12F. The jail's capacity had been set at 3500 inmates, but it housed 6700 at the time of the outbreak; the inmates had a median living area of only 34 ft(2) (3.2 m(2)) (interquartile range, 28 to 56 ft(2) [2.6 to 5.2 m(2)]) per person. There were significantly fewer cases of disease among inmates with 80 ft(2) (7.4 m(2)) per person or more (P = 0.030). Carbon dioxide levels ranged from 1100 to 2500 ppm (acceptable, <1000), and the ventilation system delivered a median of only 6.1 ft(3) of outside air per minute per person (interquartile range, 4.4 to 8.5 ft(3); recommended, greater than or equal to 20 ft(3)). The attack rate was highest among inmates in cells with the highest carbon dioxide levels and the lowest volume of outside air delivered by the ventilation system (relative risk, 1.94; 95 percent confidence interval, 1.08 to 3.48). Of underlying medical conditions, intravenous drug use was most strongly associated with disease (odds ratio, 4.50). The epidemic strain (serotype 12F) was cultured from 7 percent of the asymptomatic inmates. Of 11 case patients tested with the enzyme immunoassay, 9 (82 percent) lacked preexisting immunity to this strain. Conclusions. Severe overcrowding, inadequate ventilation, and altered host susceptibility all contributed to this outbreak of pneumococcal disease in a large urban jail.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,ATLANTA,GA; VET AFFAIRS MED CTR,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; HARRIS CTY HLTH DEPT,HOUSTON,TX; TEXAS DEPT HLTH,AUSTIN,TX	Centers for Disease Control & Prevention - USA; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Texas Department of State Health Services			Dominguez, Edward A./AAL-6119-2020					AUSTRIAN R, 1992, INFECTIOUS DISEASES; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1990, EPIINFO VERSION 5 WO; DOWLING JN, 1971, J INFECT DIS, V124, P9, DOI 10.1093/infdis/124.1.9; ERDMAN DD, 1990, J CLIN MICROBIOL, V28, P2744, DOI 10.1128/JCM.28.12.2744-2749.1990; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; Heffron R, 1979, PNEUMONIA SPECIAL RE; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; HUGHES RT, 1986, AM IND HYG ASSOC J, V47, P207, DOI 10.1080/15298668691389630; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; MACKENZIE GM, 1940, T ASSOC AM PHYSICIAN, V55, P199; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; REICHLER M, 1991, 31ST INT C ANT AG CH, P107; RIEDO F, 1991, 31ST INT C ANT AG CH, P106; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Smillie WG, 1936, AM J HYG, V24, P522, DOI 10.1093/oxfordjournals.aje.a118281; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; 1989, MMWR-MORBID MORTAL W, V38, P635; 1992, ANN INTERN MED, V117, P71; 1981, ASHRAE551981 AM SOC; 1989, MMWR-MORBID MORTAL W, V38, P64; 1989, ASHRAE621989 AM SOC; 1985, MMWR-MORBID MORTAL W, V34, P615; 1988, AM C GOVT IND HYGIEN; 1981, STANDARDIZED DIAGNOS; 1989, MMWR-MORBID MORTAL W, V38, P73; 1992, MMWR-MORBID MORTAL W, V41, P927; 1989, MMWR-MORBID MORTAL W, V38, P733; 1992, MMWR-MORBID MORTAL W, V41, P507; 1989, MMWR-MORBID MORTAL W, V38, P641	51	184	187	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					643	648		10.1056/NEJM199409083311004	http://dx.doi.org/10.1056/NEJM199409083311004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052273				2022-12-01	WOS:A1994PE38200004
J	SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P				SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P			EFFECTS OF LIMITING MEDICAID DRUG-REIMBURSEMENT BENEFITS ON THE USE OF PSYCHOTROPIC AGENTS AND ACUTE MENTAL-HEALTH-SERVICES BY PATIENTS WITH SCHIZOPHRENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECONOMIC COSTS; PAYMENT; THERAPY; POLICY; NEED; CARE; ILL	Background. We examined the effects of a three-prescription monthly payment limit (cap) on the use of psychotropic drugs and acute mental health care by noninstitutionalized patients with schizophrenia. We hypothesized that reducing access to such drugs would increase the use of emergency mental health services and the rate of partial hospitalizations (full-day or half-day treatment programs) and psychiatric-hospital admissions. Methods. We linked Medicaid claims data for a period of 42 months with clinical records from two community mental health centers (CMHCs) and the single state psychiatric hospital in New Hampshire, where Medicaid imposed a three-prescription limit on reimbursement for drugs during 11 months (months 15 through 25) of the study. For comparison, we used Medicaid claims for a period of 42 months in New Jersey, which had no limit on drug reimbursement. The study patients (n = 268) and the comparison patients (n = 1959) were permanently disabled, noninstitutionalized patients with schizophrenia, 19 through 60 years of age, who were insured by Medicaid. We conducted interrupted time-series regression analyses to estimate the effects of the cap on the use of medications and mental health services. Results. The cap resulted in immediate reductions (range, 15 to 49 percent) in the use of antipsychotic drugs, antidepressants and lithium, and anxiolytic and hypnotic drugs (P<0.01). It also resulted in coincident increases of one to two visits per patient per month to CMHCs (range of increase, 43 to 57 percent; P<0.001) and sharp increases in the use of emergency mental health services and partial hospitalization (1.2 to 1.4 episodes per patient per month), but no change in the frequency of hospital admissions. After the cap was discontinued, the use of medications and most mental health services reverted to base-line levels (measured in the first 14 months of the study). The estimated average increase in mental health care costs per patient during the cap ($1,530) exceeded the savings in drug costs to Medicaid by a factor of 17. Conclusions. Limits on coverage for the costs of prescription drugs can increase the use of acute mental health services among low-income patients with chronic mental illnesses and increase costs to the government, even aside from the increases caused in pain and suffering on the part of patients.	HARVARD UNIV,SCH MED,DEPT PREVENT & SOCIAL MED,BOSTON,MA; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; INT ORG MIGRAT,GENEVA,SWITZERLAND	Harvard University; Harvard Medical School; International Organization for Migration	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE,BOSTON,MA, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044881] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH44881] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREWS G, 1985, ARCH GEN PSYCHIAT, V42, P537; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; Cook T.D., 1979, QUASIEXPERIMENTATION; CRANE GE, 1973, SCIENCE, V181, P124, DOI 10.1126/science.181.4095.124; DAVIS JM, 1984, TREATMENT CARE SCHIZ; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; ENNA SJ, 1983, NEUROLEPTICS NEUROCH, P1; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; HAAIJERRUSKAMP FM, 1991, DRUGS MONEY PROBLEM; JABLENSKY A, 1988, SCHIZOPHRENIA MAJOR, P19; JOHNSON DAW, 1988, SCHIZOPHRENIA MAJOR, P158; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; LIEBERMAN AA, 1986, COMMUNITY MENT HLT J, V22, P104, DOI 10.1007/BF00754549; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MCGUIRE TG, 1991, SCHIZOPHRENIA BULL, V17, P375, DOI 10.1093/schbul/17.3.375; MECHANIC D, 1992, HEALTH AFFAIR, V11, P128, DOI 10.1377/hlthaff.11.1.128; Mohr L., 1992, IMPACT ANAL PROGRAM; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SHAPIRO S, 1985, MED CARE, V23, P1033, DOI 10.1097/00005650-198509000-00002; SHARFSTEIN SS, 1992, HEALTH AFFAIR, V11, P84, DOI 10.1377/hlthaff.11.3.84; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Torrey EF, 1990, CARE SERIOUSLY MENTA; 1979, SCHIZOPHRENIA INT FO; 1973, INT PILOT STUDY SCHI, V1; 1984, MED CARE S, V22, pS1	32	403	404	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					650	655		10.1056/NEJM199409083311006	http://dx.doi.org/10.1056/NEJM199409083311006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PE382	8052275	Green Published			2022-12-01	WOS:A1994PE38200006
J	KIM, SG; UGURBIL, K; STRICK, PL				KIM, SG; UGURBIL, K; STRICK, PL			ACTIVATION OF A CEREBELLAR OUTPUT NUCLEUS DURING COGNITIVE PROCESSING	SCIENCE			English	Article							MOTOR CORTEX; ARCUATE PREMOTOR; EYE-MOVEMENTS; MENTAL SKILLS; CELL ACTIVITY; BRAIN; DISCHARGE; NEURONS; MONKEY; ORGANIZATION	Magnetic resonance imaging was used to examine the involvement of the dentate nucleus of the cerebellum in cognitive operations. All seven people examined displayed a large bilateral activation in the dentate during their attempts to solve a pegboard puzzle. The area activated was three to four times greater than that activated during simple movements of the pegs. These results provide support for the concept that the computational power of the cerebellum is applied not only to the control of movement but also to cognitive functions.	VET ADM MED CTR, RES SERV 151, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; UNIV MINNESOTA, SCH MED, DEPT RADIOL, CTR MAGNET RESONANCE RES, MINNEAPOLIS, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities			Ugurbil, Kamil/AAD-6058-2022		NCRR NIH HHS [RR08079] Funding Source: Medline; NINDS NIH HHS [NS24328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRACKETOLKMITT R, 1989, BEHAV NEUROSCI, V103, P442, DOI 10.1037/0735-7044.103.2.442; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DAVIS R, 1984, CEREBELLAR STIMULATI; DECETY J, 1990, BRAIN RES, V535, P313, DOI 10.1016/0006-8993(90)91615-N; Dow RS, 1942, BIOL REV CAMB PHILOS, V17, P179, DOI 10.1111/j.1469-185X.1942.tb00437.x; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; GARDNER EP, 1975, J NEUROPHYSIOL, V38, P627, DOI 10.1152/jn.1975.38.3.627; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; HU XP, 1994, MAGN RESON MED, V31, P495, DOI 10.1002/mrm.1910310505; Ito M., 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEINER HC, 1987, ITAL J NEUROL SCI, V8, P425; LEINER HC, 1989, BEHAV NEUROSCI, V103, P998, DOI 10.1037/0735-7044.103.5.998; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; MUSHIAKE H, 1993, J NEUROPHYSIOL, V70, P2660, DOI 10.1152/jn.1993.70.6.2660; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PASSINGHAM RE, 1975, BRAIN BEHAV EVOLUT, V11, P73, DOI 10.1159/000123626; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHIEBER MH, 1985, J NEUROPHYSIOL, V54, P1228, DOI 10.1152/jn.1985.54.5.1228; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1993, REV NEUROL, V149, P607; THACH WT, 1975, BRAIN RES, V88, P233, DOI 10.1016/0006-8993(75)90387-X; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1970, J NEUROPHYSIOL, V33, P527, DOI 10.1152/jn.1970.33.4.527; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; WOOTEN GF, 1981, J NEUROSCI, V1, P285; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023	51	409	418	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					949	951		10.1126/science.8052851	http://dx.doi.org/10.1126/science.8052851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052851				2022-12-01	WOS:A1994PB49900041
J	WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ				WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ			STRUCTURE AND MECHANISM OF INTERLEUKIN-1-BETA CONVERTING-ENZYME	NATURE			English	Article							RECEPTOR ANTAGONIST PROTEIN; COLLAGEN-INDUCED ARTHRITIS; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; SIDE-CHAIN; PAPAIN; RESOLUTION; IL-1-BETA	Interleukin-1 beta converting enzyme (ICE) processes an inactive precursor to the proinflammatory cytokine, Interleukln-1 beta, and may regulate programmed cell death in neuronal cells. The high-resolution structure of human ICE In complex with an inhibitor has been determined by X-ray diffraction. The structure confirms the relationship between human ICE and cell-death proteins in other organisms. The active site spans both the 10 and 20K subunits, which associate to form a tetramer, suggesting a mechanism for ICE autoactivation.			WILSON, KP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							BENDER PE, 1989, A REP MED CHEM, V25, P185; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1992, IMMUNOL REV, V127, P119, DOI 10.1111/j.1600-065X.1992.tb01411.x; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Drenth J., 1987, BIOL MACROMOL, V3, P312; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEIGER T, 1993, CLIN EXP RHEUMATOL, V11, P515; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NETTGIORDALISI MA, 1993, J CELL BIOCH B, V17, P117; NORONHA IL, 1993, KIDNEY INT, V43, P682, DOI 10.1038/ki.1993.98; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; POLGAR L, 1973, EUR J BIOCHEM, V33, P104, DOI 10.1111/j.1432-1033.1973.tb02660.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SANDBERG JO, 1993, DIABETES, V42, P1845, DOI 10.2337/diabetes.42.12.1845; SHIVERS BD, 1993, J CELL BIOCH B, V17, P119; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1979, SUITE PROGRAMS PROTE; 1992, QUANTA VERSION 4 0B	45	734	779	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					270	275		10.1038/370270a0	http://dx.doi.org/10.1038/370270a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035875				2022-12-01	WOS:A1994NZ22900055
J	TOYOSHIMA, H; HUNTER, T				TOYOSHIMA, H; HUNTER, T			P27, A NOVEL INHIBITOR OF G1 CYCLIN-CDK PROTEIN-KINASE ACTIVITY, IS RELATED TO P21	CELL			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TGF-BETA; DEPENDENT KINASES; G(1); PHASE; PHOSPHORYLATION; PROLIFERATION; SUPPRESSION; FIBROBLASTS	Using a yeast interaction screen to search for proteins that interact with cyclin D1-Cdk4, we identified a 27 kDa mouse protein related to the p21 cyclin-Cdk inhibitor. p27 interacts strongly with D-type cyclins and Cdk4 in vitro and more weakly with cyclin E and Cdk2. In mouse fibroblasts, p27 is associated predominantly with cyclin D1-Cdk4. Recombinant p27 is a potent inhibitor of cyclin D1-Cdk4 and cyclin A-Cdk2 protein kinase activity and a weaker inhibitor of cyclin B1-Cdc2. Overexpression of p27 in Saos-2 cells causes G1 arrest. p27 protein levels do not change as serum-stimulated quiescent mouse fibroblasts progress through the cell cycle. p27 is identical to p27(Kip1), a cyclin-Cdk inhibitor present in TGF beta-treated cells. p27 has the hallmarks of a negative regulator of G1 progression and may mediate TGF beta-induced G1 arrest.			TOYOSHIMA, H (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	1957	2040	0	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					67	74		10.1016/0092-8674(94)90573-8	http://dx.doi.org/10.1016/0092-8674(94)90573-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033213				2022-12-01	WOS:A1994NX32800009
J	COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL				COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL			STIMULATION OF GAL4 DERIVATIVE BINDING TO NUCLEOSOMAL DNA BY THE YEAST SWI/SNF COMPLEX	SCIENCE			English	Article							TRANSCRIPTION FACTOR ACCESS; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; ASSEMBLY INVITRO; GLUCOCORTICOID RECEPTOR; HISTONE COMPLEXES; GENES; PROTEINS; ACTIVATORS	The SWI/SNF protein complex is required for the enhancement of transcription by many transcriptional activators in yeast. Here it is shown that the purified SWI/SNF complex is composed of 10 subunits and includes the SWI1, SW12/SNF2, SWI3, SNF5, and SNF6 gene products. The complex exhibited DNA-stimulated adenosine triphosphatase (ATPase) activity, but lacked helicase activity. The SWI/SNF complex caused a 10- to 30-fold stimulation in the binding of GAL4 derivatives to nucleosomal DNA in a reaction that required adenosine triphosphate (ATP) hydrolysis but was activation domain-independent. Stimulation of GAL4 binding by the complex was abolished by a mutant SWI2 subunit, and was increased by the presence of a histone-binding protein, nucleoplasmin. A direct ATP-dependent interaction between the SWI/SNF complex and nucleosomal DNA was detected. These observations suggest that a primary role of the SWI/SNF complex is to promote activator binding to nucleosomal DNA.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, University Pk, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, University Pk, PA 16802 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Massachusetts System; University of Massachusetts Worcester			Quinn, Janet/AAR-9957-2021; Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X	NIGMS NIH HHS [R01 GM049650, GM49650-01, R37 GM049650, GM47867-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867, R37GM047867, R37GM049650, R01GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1991, MOL CELL BIOL, V11, P655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JUAN LJ, IN PRESS COLD SPRING; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLADDE MP, 1994, P NATL ACAD SCI USA, V91, P1361, DOI 10.1073/pnas.91.4.1361; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON C, UNPUB; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; RHODES D, 1989, METHOD ENZYMOL, V170, P575; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEALY L, 1989, METHOD ENZYMOL, V170, P612; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	727	739	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					53	60		10.1126/science.8016655	http://dx.doi.org/10.1126/science.8016655			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016655				2022-12-01	WOS:A1994NV30100024
J	GONCZY, P; THOMAS, BJ; DINARDO, S				GONCZY, P; THOMAS, BJ; DINARDO, S			ROUGHEX IS A DOSE-DEPENDENT REGULATOR OF THE 2ND MEIOTIC DIVISION DURING DROSOPHILA SPERMATOGENESIS	CELL			English	Article							MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; ACTIVATES P34CDC2; STERILE MUTATIONS; GENETIC-ANALYSIS; MITOTIC CONTROL	During spermatogenesis, germ cells execute two meiotic divisions, then withdraw from the cell cycle and initiate postmeiotic differentiation. We show that the gene roughex (rux) is a dose-dependent regulator of meiosis II during Drosophila spermatogenesis. rux mutant germ cells execute the two meiotic divisions, but then undergo an additional M phase resembling an extra meiosis II. Conversely, germ cells with excess rux function fail to undergo meiosis II. rux does not appear to act directly at meiosis II. Rather, rux appears to act through cyclin A during premeiotic G2 to regulate meiosis II. We propose that cyclin A-cdc2 kinase at the G2 to M transition of meiosis I activates a target necessary for meiosis II, thereby coupling the two meiotic divisions.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	GONCZY, P (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Gonczy, Pierre/0000-0002-6305-6883; DiNardo, Stephen/0000-0003-4131-5511				ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BONACCORSI S, 1988, GENETICS, V120, P1015; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CASTRILLON DH, 1993, GENETICS, V135, P489; Cooper KW, 1950, BIOL DROSOPHILA, P1; COURTOT C, 1992, DEVELOPMENT, V116, P405; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FERELL JE, 1991, MOL CELL BIOL, V11, P1965; FRITZNIGGLI H, 1972, CYTOBIOLOGIE, V5, P12; FULLER MT, 1993, DEV DROSOPHILA MELAN, V1, P71; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONCZY P, 1992, DEVELOPMENT, V114, P89; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT T, 1993, CELL CYCLE, P167; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIFSCHYTZ E, 1977, DEV BIOL, V58, P276, DOI 10.1016/0012-1606(77)90092-6; LIFSCHYTZ E, 1977, CHROMOSOMA, V64, P371, DOI 10.1007/BF00294944; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHUPBACH T, 1991, GENETICS, V129, P1119; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tates AD, 1971, THESIS RIJKSUNIVERSI; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; WHITECOOPER H, 1993, J CELL SCI, V106, P1035; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	75	49	50	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1015	1025		10.1016/0092-8674(94)90441-3	http://dx.doi.org/10.1016/0092-8674(94)90441-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020092				2022-12-01	WOS:A1994NV42500010
J	HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP				HO, MF; CHELLY, J; CARTER, N; DANEK, A; CROCKER, P; MONACO, AP			ISOLATION OF THE GENE FOR MCLEOD SYNDROME THAT ENCODES A NOVEL MEMBRANE-TRANSPORT PROTEIN	CELL			English	Article							BLOOD-GROUP SYSTEM; AMINO-ACID TRANSPORTER; X-LINKED MYOPATHY; GLUTAMATE TRANSPORTER; MUSCULAR-DYSTROPHY; RAT-BRAIN; EXPRESSION; CLONING; DNA; PHENOTYPE	Mcleod syndrome is an X-linked multisystem disorder characterized by abnormalities in the neuromuscular and hematopoietic systems. We have assembled a cosmid contig of 360 kb that encompasses the McLeod gene locus. A 50 kb deletion was detected by screening DNA from patients with radiolabeled whole cosmids, and two transcription units were identified within this deletion. The mRNA expression pattern of one of them, designated as XK, correlates closely to the McLeod phenotype. XK encodes a novel protein with structural characteristics of prokaryotic and eukaryotic membrane transport proteins. Nucleotide sequence analysis of XK from two unrelated McLeod patients has identified point mutations at conserved splice donor and acceptor sites. These findings provide direct evidence that XK is responsible for McLeod syndrome.	UNIV LONDON ST GEORGES HOSP, SCH MED, MED GENET UNIT, LONDON SW17 0RE, ENGLAND; UNIV MUNICH, NEUROL KLIN, D-81366 MUNICH 70, GERMANY	St Georges University London; University of Munich	HO, MF (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND, OXFORD OX3 9DU, ENGLAND.		Danek, Adrian/G-7339-2011; Chelly, Jamel/J-7528-2015; Monaco, Anthony P/A-4495-2010	Danek, Adrian/0000-0001-8857-5383; Chelly, Jamel/0000-0002-0939-8719; Monaco, Anthony P/0000-0001-7480-3197; Crocker, Paul/0000-0001-6230-0293				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BERTELSON CJ, 1986, AM J HUM GENET, V423, P703; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BRADLEY WG, 1978, NEUROLOGY, V28, P670, DOI 10.1212/WNL.28.7.670; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CALLENDER R, 1977, ANNU REV BIOPHYS BIO, V6, P33, DOI 10.1146/annurev.bb.06.060177.000341; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CARTER ND, 1990, J MED GENET, V27, P345, DOI 10.1136/jmg.27.6.345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE WG, 1990, J BIOL CHEM, V265, P17070; COULSON AFW, 1987, COMPUT J, V30, P420, DOI 10.1093/comjnl/30.5.420; DANEK A, 1994, NEUROLOGY, V44, P117, DOI 10.1212/WNL.44.1.117; DANEK A, 1990, ANN NEUROL, V28, P720, DOI 10.1002/ana.410280521; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GALEY WR, 1978, VOX SANG, V34, P152, DOI 10.1111/j.1423-0410.1978.tb02458.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARDIE RJ, 1989, Q J MED, V71, P291; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HO MF, 1991, J HUM GENET, V50, P317; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRK K, 1994, J BIOL CHEM, V269, P3339; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUYPERS FA, 1985, FEBS LETT, V184, P20, DOI 10.1016/0014-5793(85)80644-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEE S, 1993, BLOOD, V81, P2804; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Marsh W L, 1987, Transfus Med Rev, V1, P4; MARSH WL, 1981, VOX SANG, V40, P403, DOI 10.1111/j.1423-0410.1981.tb00728.x; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; ORKIN SH, 1984, ANNU REV GENET, V18, P131; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIINES G, 1992, NATURE, V360, P464; REDMAN CM, 1986, J BIOL CHEM, V261, P9521; REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x; REDMAN CM, 1993, SEMIN HEMATOL, V30, P209; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; STECK TL, 1989, CELL SHAPE DETERMINA; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SWASH M, 1983, BRAIN, V106, P717, DOI 10.1093/brain/106.3.717; SYMMANS WA, 1979, BRIT J HAEMATOL, V42, P575, DOI 10.1111/j.1365-2141.1979.tb01170.x; TREISMAN R, 1982, CELL, V29, P90; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANHEIJNE G, 1986, EMBO J, V6, P3021; WEIL D, 1988, J BIOL CHEM, V263, P8561; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503; WIMER BM, 1977, BRIT J HAEMATOL, V36, P219, DOI 10.1111/j.1365-2141.1977.tb00642.x; WITT TN, 1992, J NEUROL, V239, P302, DOI 10.1007/BF00867584; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	76	197	208	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					869	880		10.1016/0092-8674(94)90136-8	http://dx.doi.org/10.1016/0092-8674(94)90136-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004674				2022-12-01	WOS:A1994NT33100012
J	KLEYMAN, TR; ROBERTS, C; LING, BN				KLEYMAN, TR; ROBERTS, C; LING, BN			A MECHANISM FOR PENTAMIDINE-INDUCED HYPERKALEMIA - INHIBITION OF DISTAL NEPHRON SODIUM-TRANSPORT	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERKALEMIA; PENTAMIDINE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ION TRANSPORT; POTASSIUM	PNEUMOCYSTIS-CARINII PNEUMONIA; CORTICAL COLLECTING TUBULE; POTASSIUM CHANNELS; PRIMARY CULTURES; THERAPY; AIDS	Objectives: To determine whether pentamidine directly affects the transport of renal ions and thus provides a mechanism for hyperkalemia, which develops in as many as 100% of patients with the acquired immunodeficiency syndrome (AIDS) who receive pentamidine for more than 6 days. Design: Transepithelial and single-channel electrical measurements were made on two models of distal-nephron ion transport: an amphibian distal-nephron cell line (A6) and primary cultures of rabbit cortical collecting tubules. Results: Luminal bath application of pentamidine to A6 monolayers inhibited the amiloride-sensitive, short-circuit current with a 50% inhibitory concentration of 700 mu M (five experiments). In the principal cell apical membranes of cortical collecting tubule primary cultures, amiloride-sensitive, 4-picosiemen Na+ channels in cell-attached patches were also identified. When the luminal membrane was directly exposed to 1.0 mu M of pentamidine in the patch pipette solution, channel activity decreased by 40% (11 experiments). Channel inhibition rapidly reversed with washout of intrapipette pentamidine (four experiments). In contrast, replacement of either the luminal bath outside the patch pipette (four experiments) or the serosal bath (five experiments) with pentamidine did not significantly affect Na+ channel activity in the patches. Conclusions: Luminal or ''urinary'' pentamidine inhibits distal nephron reabsorption of Na+ by blocking apical Na+ channels in a manner similar to ''potassium-sparing'' diuretics (for example, amiloride and triamterene). This results in a decrease in the electrochemical gradients that drive secretion of distal nephron K+. Because pentamidine is eliminated through urinary excretion, this renal tubular effect provides a mechanism for pentamidine-induced hyperkalemia.	EMORY UNIV, SCH MED, DIV RENAL, ATLANTA, GA 30322 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002111] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08-DK02111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; BUFF DD, 1990, AM J MED, V88, P552, DOI 10.1016/0002-9343(90)90446-K; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CONTE JE, 1987, J INFECT DIS, V156, P885, DOI 10.1093/infdis/156.6.885; DEVITA VT, 1969, NEW ENGL J MED, V280, P287, DOI 10.1056/NEJM196902062800602; EATON DC, 1988, ION CHANNELS, P251; EATON DC, 1994, IN PRESS KIDNEY INT; KLEYMAN TR, 1988, SEMIN NEPHROL, V8, P242; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; LING BN, 1991, KIDNEY INT, V40, P441, DOI 10.1038/ki.1991.231; MARINO PL, 1990, AM J MED, V89, P397, DOI 10.1016/0002-9343(90)90364-J; PELTZ S, 1989, AM J MED, V87, P698, DOI 10.1016/S0002-9343(89)80411-5; PONCE SP, 1985, MEDICINE, V64, P357, DOI 10.1097/00005792-198511000-00001; SANDS M, 1985, REV INFECT DIS, V7, P625; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; Schlanger Lynn E., 1993, Journal of the American Society of Nephrology, V4, P878; SMALDONE GC, 1991, CHEST, V100, P1219, DOI 10.1378/chest.100.5.1219; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WESTERN KA, 1970, ANN INTERN MED, V73, P695, DOI 10.7326/0003-4819-73-5-695	22	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					103	106		10.7326/0003-4819-122-2-199501150-00004	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992983				2022-12-01	WOS:A1995QC05900004
J	FRANCOMANO, CA				FRANCOMANO, CA			THE GENETIC-BASIS OF DWARFISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; FIBROBLAST				FRANCOMANO, CA (corresponding author), NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.			Francomano, Clair/0000-0002-4032-7425				FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; LEMERRER M, 1994, NAT GENET, V6, P318; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314	10	33	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					58	59		10.1056/NEJM199501053320113	http://dx.doi.org/10.1056/NEJM199501053320113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990869				2022-12-01	WOS:A1995PZ49700013
J	ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE				ROBINSON, CV; GROSS, M; EYLES, SJ; EWBANK, JJ; MAYHEW, M; HARTL, FU; DOBSON, CM; RADFORD, SE			CONFORMATION OF GROEL-BOUND ALPHA-LACTALBUMIN PROBED BY MASS-SPECTROMETRY	NATURE			English	Article							MOLTEN GLOBULE STATE; GROUP HYDROGEN-EXCHANGE; EGG-WHITE LYSOZYME; STRUCTURAL CHARACTERIZATION; 2-DIMENSIONAL NMR; CHAPERONIN GROEL; 1.7-A RESOLUTION; CENTRAL CAVITY; HEN LYSOZYME; PROTEIN	The conformation of a three-disulphide derivative of bovine alpha-lactalbumin bound to the molecular chaperone GroEL has been investigated by monitoring directly its hydrogen exchange kinetics using electrospray ionization mass spectrometry. The bound protein is weakly protected from exchange to an extent closely similar to that of an uncomplexed molten globule state of the three-disulphide protein. Binding to GroEL in this system appears to involve relatively disordered partly folded states resembling intermediates formed in the very early stages of kinetic folding of many proteins in vitro.	UNIV OXFORD,OXFORD CTR MOLEC SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,DYSON PERRINS LAB,OXFORD OX1 3QT,ENGLAND; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	University of Oxford; University of Oxford; European Molecular Biology Laboratory (EMBL); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Eyles, Stephen/F-4077-2010; Hartl, F. Ulrich/Y-8206-2019; Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862; Radford, Sheena/0000-0002-3079-8039; Eyles, Stephen/0000-0003-0451-2903; robinson, carol/0000-0001-7829-5505				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; ARAMINI JM, 1992, BIOCHEMISTRY-US, V31, P6761, DOI 10.1021/bi00144a016; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCK M, 1994, J MOL BIOL, V237, P247, DOI 10.1006/jmbi.1994.1228; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; CREIGHTON TE, 1992, BIOCHEMISTRY-US, V31, P12695; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EYLES SJ, 1994, BIOCHEMISTRY-US, V333, P1534; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1992, BIOCHEMISTRY-US, V31, P12695, DOI 10.1021/bi00165a021; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIGHTWAHL KJ, 1993, J AM CHEM SOC, V115, P5869, DOI 10.1021/ja00066a083; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; LOO JA, 1991, RAPID COMMUN MASS SP, V5, P101, DOI 10.1002/rcm.1290050303; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PEDERSEN TG, 1993, J MOL BIOL, V230, P651, DOI 10.1006/jmbi.1993.1176; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RADFORD SE, 1991, BIOCHEM J, V273, P211, DOI 10.1042/bj2730211; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; WANG M, 1989, J BIOL CHEM, V264, P21116; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	51	202	202	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					646	651		10.1038/372646a0	http://dx.doi.org/10.1038/372646a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990955				2022-12-01	WOS:A1994PX30700077
J	TYCOWSKI, KT; SHU, MD; STEITZ, JA				TYCOWSKI, KT; SHU, MD; STEITZ, JA			REQUIREMENT FOR INTRON-ENCODED U22 SMALL NUCLEOLAR RNA IN 18S RIBOSOMAL-RNA MATURATION	SCIENCE			English	Article							EXTERNAL TRANSCRIBED SPACER; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL RNA; PRE-RRNA; YEAST; U3; CLEAVAGE; DISRUPTION; PRECURSOR	The nucleoli of vertebrate cells contain a number of small RNAs that are generated by the processing of intron fragments of protein-coding gene transcripts. The host gene (UHG) for intron-encoded human U22 is unusual in that it specifies a polyadenylated but apparently noncoding RNA. Depletion of U22 from Xenopus oocytes by oligonucleotide-directed ribonuclease H targeting prevented the processing of 18S ribosomal RNA (rRNA) at both ends. The appearance of 18S rRNA was restored by injection of in vitro-synthesized U22 RNA. These results identify a cellular function for an intronencoded small RNA.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BOWMAN LH, 1983, MOL CELL BIOL, V3, P1501, DOI 10.1128/MCB.3.8.1501; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HADJIOLOVA KV, 1993, EUR J BIOCHEM, V212, P211, DOI 10.1111/j.1432-1033.1993.tb17652.x; HADJIOLOVA KV, 1984, BIOCHIM BIOPHYS ACTA, V782, P195, DOI 10.1016/0167-4781(84)90024-1; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HOGAN NC, 1994, J CELL BIOL, V125, P21, DOI 10.1083/jcb.125.1.21; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JENSEN R, 1993, EMBO J, V12, P2549; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; Sambrook J., 1989, MOL CLONING LAB MANU; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; SOLLNERWEBB B, IN PRESS RIBOSOMAL R; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; TYCOWSKI KT, UNPUB; WELLAUER PK, 1974, J MOL BIOL, V89, P379, DOI 10.1016/0022-2836(74)90526-9	41	132	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1558	1561		10.1126/science.7985025	http://dx.doi.org/10.1126/science.7985025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985025				2022-12-01	WOS:A1994PV01500043
J	KISELEV, A; SUBRAMANIAM, S				KISELEV, A; SUBRAMANIAM, S			ACTIVATION AND REGENERATION OF RHODOPSIN IN THE INSECT VISUAL CYCLE	SCIENCE			English	Article							INVERTEBRATE PHOTORECEPTORS; ARRESTIN; PROTEIN; PIGMENT; MEMBRANES; PHOSPHORYLATION; TRANSDUCTION	Light absorption by rhodopsin generates metarhodopsin, which activates heterotrimeric guanine nucleotide-binding proteins (G proteins) in photoreceptor cells of vertebrates and invertebrates. In contrast to vertebrate metarhodopsins, most invertebrate metarhodopsins are thermally stable and regenerate rhodopsin by absorption of a second photon. In experiments with Rh1 Drosophila rhodopsin, the thermal stability of metarhodopsin was found not to be an intrinsic property of the visual pigment but a consequence of its interaction with arrestin (49 kilodaltons). The Stabilization of metarhodopsin resulted in a large decrease in the efficiency of G protein activation. Light absorption by thermally stable metarhodopsin initially regenerated an inactive rhodopsin-like intermediate, which was subsequently converted in the dark to active rhodopsin. The accumulation of inactive rhodopsin at higher light levels may represent a mechanism for gain regulation in the insect visual cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Subramaniam, Sriram/0000-0003-4231-4115				BENTROP J, 1993, EUR J BIOCHEM, V216, P67, DOI 10.1111/j.1432-1033.1993.tb18117.x; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HAMDORF K, 1977, BIOPHYS STRUCT MECH, V3, P163, DOI 10.1007/BF00535813; Hamdorf K., 1979, HDB SENSORY PHYSL, V7/6A, P145; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; KISELEV AD, UNPUB; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; OSTROY SE, 1978, J GEN PHYSIOL, V72, P717, DOI 10.1085/jgp.72.5.717; PAK WL, 1974, J GEN PHYSIOL, V63, P740, DOI 10.1085/jgp.63.6.740; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; TANIMURA T, 1986, PHOTOCHEM PHOTOBIOL, V43, P225, DOI 10.1111/j.1751-1097.1986.tb09519.x; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	26	46	47	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1369	1373		10.1126/science.7973725	http://dx.doi.org/10.1126/science.7973725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973725				2022-12-01	WOS:A1994PT63200040
J	STEVENS, J				STEVENS, J			JAPAN PICKS A WINNER IN THE RICE GENOME PROJECT	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1186	1187		10.1126/science.7973698	http://dx.doi.org/10.1126/science.7973698			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973698				2022-12-01	WOS:A1994PT13200037
J	KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW				KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW			A SWIMMING-ASSOCIATED OUTBREAK OF HEMORRHAGIC COLITIS CAUSED BY ESCHERICHIA-COLI O157-H7 AND SHIGELLA-SONNEI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; WATERBORNE OUTBREAK; GEL-ELECTROPHORESIS; NURSING-HOME; TOXIN-II; O157-H7; INFECTIONS; DIARRHEA; TRANSMISSION; CONSUMPTION	Background. In the summer of 1991, simultaneous outbreaks of bloody diarrhea and hemolytic-uremic syndrome caused by Escherichia coli O157:H7 and of bloody diarrhea caused by Shigella sonnei were traced to a lakeside park near Portland, Oregon. Methods. We identified cases primarily from routine surveillance reports. In case-control studies, the activities of persons with park-associated E. coli O157:H7 or S. sonnei infections were compared independently with those of three sets of controls. We also evaluated environmental conditions at the park and subtyped the bacterial isolates. Results. We identified 21 persons with park-associated E. coli O157:H7 infections (all of them children; median age, six years) and 38 persons with S. sonnei infections (most of them children). These 59 people had visited the park over a 24-day period. Their illnesses were not associated with food or beverage consumption. All the case patients reported swimming, however, and in case-control studies swimming was strongly associated with both types of infection (P = 0.015 or less). The case patients were more likely than the controls to report having swallowed lake water, and they had spent more time in the lake. Numbers of enterococci indicative of substantial fecal contamination (geometric mean, > 50 per deciliter) were detected in the swimming area during some but not all of the outbreak period. Park-associated E. coli O157:H7 isolates were identical by pulsed-field gel electrophoresis and were distinguishable from other isolates in the Portland area. Conclusions. Lake water that was fecally contaminated by bathers was the most likely vehicle for the transmission of both the E. coli O157:H7 and the S. sonnei infections. The unusually prolonged outbreak suggests both the survival of these enteric organisms in lake water and a low infectious dose.	CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, ENTER DIS BRANCH, ATLANTA, GA 30341 USA; MULTNOMAH CTY HLTH DEPT, PORTLAND, OR USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Oregon Health & Science University	KEENE, WE (corresponding author), OREGON HLTH DIV, CTR DIS PREVENT & EPIDEMIOL, 800 NE OREGON ST, SUITE 772, PORTLAND, OR 97232 USA.							[Anonymous], 1992, STANDARD METHODS EXA, V18; Balows A, 1991, MANUAL CLIN MICROBIO; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BLOSTEIN J, 1991, PUBLIC HEALTH REP, V106, P317; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; BRENNIMAN GR, 1981, AM J PUBLIC HEALTH, V71, P283, DOI 10.2105/AJPH.71.3.283; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DUFOUR AP, 1984, EPA600184004 REP; Duncan L., 1987, Canada Diseases Weekly Report, V13, P5; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1990, J CLIN MICROBIOL, V28, P1088; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HARTSTEIN AI, 1990, INFECT CONT HOSP EP, V11, P531; KEENE WE, 1993, 33 INT C ANT AG CHEM, P354; MAKINTUBEE S, 1987, AM J PUBLIC HEALTH, V77, P166, DOI 10.2105/AJPH.77.2.166; MCGOWAN KL, 1989, LANCET, V1, P967; Mitscherlich E., 1984, MICROBIAL SURVIVAL E; MORGAN D, 1993, EPIDEMIOL INFECT, V111, P181, DOI 10.1017/S0950268800056880; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROSENBERG ML, 1976, JAMA-J AM MED ASSOC, V236, P1849, DOI 10.1001/jama.236.16.1849; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SORVILLO FJ, 1988, AM J TROP MED HYG, V38, P613, DOI 10.4269/ajtmh.1988.38.613; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; Zar JH., 1999, BIOSTAT ANAL, V4; 1981, EPI80922 CTR DIS CON; 1982, MMWR-MORBID MORTAL W, V30, P633; 1986, EPA440584002 REP; 1986, CAN MED ASSOC J, V134, P50; 1982, MMWR-MORBID MORTAL W, V30, P623; 1993, MMWR-MORBID MORTAL W, V42, P85; 1969, MMWR-MORBID MORTAL W, V18, P403	43	240	243	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					579	584		10.1056/NEJM199409013310904	http://dx.doi.org/10.1056/NEJM199409013310904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047082				2022-12-01	WOS:A1994PD69900004
J	HARDY, LM; HAYNES, BF; VOLBERDING, PA				HARDY, LM; HAYNES, BF; VOLBERDING, PA			GENE-THERAPY FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,SCH MED,ROUNDTABLE DEV DRUGS & VACCINES AGAINST AIDS,DURHAM,NC 27706; SAN FRANCISCO GEN HOSP,AIDS PROGRAM & CLIN ONCOL,SAN FRANCISCO,CA 94110	Duke University; San Francisco General Hospital Medical Center									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					423	423						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040965				2022-12-01	WOS:A1994PA27800005
J	MAHAJANMIKLOS, S; COOLEY, L				MAHAJANMIKLOS, S; COOLEY, L			THE VILLIN-LIKE PROTEIN ENCODED BY THE DROSOPHILA QUAIL GENE IS REQUIRED FOR ACTIN BUNDLE ASSEMBLY DURING OOGENESIS	CELL			English	Article							BRUSH-BORDER CYTOSKELETON; SEVERING PROTEINS; BICAUDAL-D; GELSOLIN; MELANOGASTER; SEQUENCE; DOMAINS; ORGANIZATION; MORPHOLOGY; RESIDUES	Mutations in the Drosophila quail gene result in female sterility due to the disruption of cytoplasmic transport from the nurse cells into the oocyte late in oogenesis. Nurse cells from quail mutant egg chambers fail to assemble cytoplasmic actin filament bundles correctly. We have cloned the quail gene and found that it encodes a protein with homology to the vertebrate actin-regulating protein villin. Unlike vertebrate villin, which is restricted to specialized absorptive epithelial cells, the villin-like protein encoded by quail is germline specific in adult flies. Antibodies directed against the quail protein show a striking colocalization with filamentous actin in the nurse cells and the oocyte. Our results demonstrate that the villin-like product of quail is required for the formation of cytoplasmic actin filament bundles in nurse cells, possibly by regulating both the polymerization and organization of actin filaments as demonstrated for vertebrate villin in vitro.			MAHAJANMIKLOS, S (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.				NIGMS NIH HHS [GM43301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DIMITRIADIS VK, 1984, CAN J ZOOL, V62, P659, DOI 10.1139/z84-097; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; GUTZEIT HO, 1986, J CELL SCI, V80, P159; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFMANN A, 1993, FEBS LETT, V328, P71, DOI 10.1016/0014-5793(93)80968-Z; King RC., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PATERSON J, 1991, GENETICS, V129, P1073; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; Spradling Allan C., 1993, P1; STELLA MC, 1994, J CELL BIOL, V125, P607, DOI 10.1083/jcb.125.3.607; STEWARD R, 1986, GENETICS, V113, P665; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; TOWER J, 1993, GENETICS, V133, P3347; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WRIGHT TRF, 1976, GENETICS, V84, P267; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	54	120	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					291	301		10.1016/0092-8674(94)90298-4	http://dx.doi.org/10.1016/0092-8674(94)90298-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044841				2022-12-01	WOS:A1994NZ24200012
J	CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF				CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF			THE ECONOMIC-IMPACT OF MULTIPLE-GESTATION PREGNANCIES AND THE CONTRIBUTION OF ASSISTED-REPRODUCTION TECHNIQUES TO THEIR INCIDENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO FERTILIZATION; INTRAFALLOPIAN TRANSFER; INFANT-MORTALITY; UNITED-STATES; BIRTH-WEIGHT; MANAGEMENT; PREVENTION; OVULATION; TRIPLETS; TWINS	Background. Although the medical complications associated with multiple-gestation pregnancies have been well documented, little is known about the effects of such pregnancies on the use of health care resources and the associated costs. This is an important issue because of the increasing use of assisted-reproduction techniques, which commonly result in multiple-gestation pregnancies. Methods. We determined hospital charges and the use of assisted-reproduction techniques (such as induction of ovulation, in vitro fertilization, and gamete intrafallopian transfer) for 13,206 pregnant women (11,986 with singleton pregnancies, 1135 with twin pregnancies, and 85 with more than two fetuses) who were admitted for delivery to Brigham and Women's Hospital, Boston, in 1986 through 1991 and their 14,033 neonates (11,671 singletons, 2144 twins, and 218 resulting from higher-order multiple gestations). Results. After we controlled for variables known to affect hospital charges, the predicted total charges to the family in 1991 for a singleton delivery were $9,845, as compared with $37,947 for twins ($18,974 per baby) and $109,765 for triplets ($36,588 per baby). Assisted-reproduction techniques were used in 2 percent of singleton, 35 percent of twin, and 77 percent of higher-order multiple-gestation pregnancies; such procedures were approximately equally divided between induction of ovulation alone and in vitro fertilization or gamete intrafallopian transfer. Conclusions. Multiple-gestation pregnancies, a high proportion of which result from the use of assisted-reproduction techniques, dramatically increase hospital charges. If all the multiple gestations resulting from assisted-reproduction techniques had been singleton pregnancies, the predicted savings to the health care delivery system in the study hospital alone would have been over $3 million per year. Although assisted reproduction provides tremendous benefits to families with infertility, the increased medical risks entailed by multiple-gestation pregnancies and the associated costs cannot be ignored. We suggest that more attention be paid to approaches to infertility that reduce the likelihood of multiple gestation.	MASSACHUSETTS GEN HOSP,NATL CTR INFERTIL RES,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OBSTET GYNECOL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Hall, Janet E/F-3516-2019	Hall, Janet E/0000-0003-4644-3061; Christiansen, Cindy/0000-0001-9951-480X	NCRR NIH HHS [MO1-RR-01066] Funding Source: Medline; NICHD NIH HHS [U54-HD-29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERKI SE, 1987, PEDIATRICS, V79, P874; BERKOWITZ RL, 1993, AM J OBSTET GYNECOL, V169, P17, DOI 10.1016/0002-9378(93)90124-2; BOLLEN N, 1991, FERTIL STERIL, V55, P314; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; CORSON SL, 1989, FERTIL STERIL, V51, P644; DEMUYLDER X, 1982, ACTA GENET MED GEMEL, V31, P149, DOI 10.1017/S0001566000008230; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; FAUSER BCJM, 1993, BAILLIERE CLIN OB GY, V7, P309, DOI 10.1016/S0950-3552(05)80133-6; Gennaro S, 1992, Image J Nurs Sch, V24, P191; GILSTRAP LC, 1988, CLIN PERINATOL, V15, P71, DOI 10.1016/S0095-5108(18)30725-5; GRUTZNERKONNECKE H, 1990, ACTA GENET MED GEMEL, V39, P491, DOI 10.1017/S000156600000372X; GUTTMACHER AF, 1953, OBSTET GYNECOL, V2, P22; HARRIS J, 1979, BELL J ECON, V1, P224; HECHT BR, 1993, ASSIST REPROD REV, V3, P75; HOWIE PW, 1988, BMJ-BRIT MED J, V297, P433, DOI 10.1136/bmj.297.6646.433; JACKSONBEECK M, 1983, JAMA-J AM MED ASSOC, V250, P2826, DOI 10.1001/jama.250.20.2826; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LEROY F, 1990, ACTA GENET MED GEMEL, V39, P371, DOI 10.1017/S0001566000005298; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LIPITZ S, 1989, AM J OBSTET GYNECOL, V161, P1279, DOI 10.1016/0002-9378(89)90683-2; LIPITZ S, 1990, OBSTET GYNECOL, V76, P215; LUKE B, 1992, J REPROD MED, V37, P661; MACLENNAN AH, 1990, LANCET, V335, P267, DOI 10.1016/0140-6736(90)90079-K; MALMSTROM PM, 1990, ACTA GENET MED GEMEL, V39, P507, DOI 10.1017/S0001566000003755; MARTIN KA, 1993, J CLIN ENDOCR METAB, V77, P125, DOI 10.1210/jc.77.1.125; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; NEWMAN RB, 1989, AM J OBSTET GYNECOL, V161, P547, DOI 10.1016/0002-9378(89)90354-2; NIJS M, 1993, FERTIL STERIL, V59, P1245; POLSON DW, 1987, CLIN ENDOCRINOL, V26, P205, DOI 10.1111/j.1365-2265.1987.tb00778.x; REIN MS, 1990, INT J FERTIL, V35, P154; RESNICK MB, 1986, PEDIATRICS, V78, P820; SCHENKER JG, 1981, FERTIL STERIL, V35, P105; WAPNER RJ, 1990, LANCET, V335, P90, DOI 10.1016/0140-6736(90)90550-O; WEEKES ARL, 1977, BRIT J OBSTET GYNAEC, V84, P161, DOI 10.1111/j.1471-0528.1977.tb12549.x; 1990, BRIT MED J, V300, P1229; 1993, FERTIL STERIL, V59, P956; 1988, INFERTILITY MED SOCI	40	328	332	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					244	249		10.1056/NEJM199407283310407	http://dx.doi.org/10.1056/NEJM199407283310407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY335	8015572	Bronze			2022-12-01	WOS:A1994NY33500007
J	BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC				BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC			BLOOD LEAD LEVELS IN THE US POPULATION - PHASE-1 OF THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES-III, 1988 TO 1991)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EXPOSURE; CHILDREN; IMPAIRMENT; TOXICOLOGY	Objective.-To determine mean blood lead levels and their sociodemographic correlates in the US population. Design.-Nationally representative cross-sectional health examination survey that included measurements of venous blood lead. Participants.-A total of 13 201 persons aged 1 year and older examined during phase 1 of the third National Health and Nutrition Examination Survey (1988 to 1991). Results.-The overall mean blood lead level for the US population was 0.14 mu mol/L (2.8 mu g/dL). Blood lead levels were consistently higher for younger children than for older children, for older adults than for younger adults, for males than for females, for blacks than for whites, and for central-city residents than for non-central-city residents. Other correlates of higher blood lead levels included low income, low educational attainment, and residence in the Northeast region of the United States, National estimates for children 1 to 5 years of age indicate that 8.9%, or approximately 1.7 million children, have blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater. These levels are high enough to be of health concern under 1991 Centers for Disease Control and Prevention guidelines. Conclusions.-The low overall mean blood lead levels demonstrate a major public health success in primary prevention efforts. However, exposure to lead at levels that may adversely affect the health of children remains a problem especially for those who are minority, urban, and from low-income families. Strategies to identify the most vulnerable risk groups are necessary to further reduce lead exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BRODY, DJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,ROOM 900,HYATTSVILLE,MD 20782, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				[Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BINDER S, 1991, STRATEGIC PLAN ELIMI; BINNS HJ, 1994, PEDIATRICS, V93, P164; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; DAVIS JM, 1987, NATURE, V329, P298; DIETRICH KN, 1993, PEDIATRICS, V91, P301; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628; GELLERT GA, 1993, JAMA-J AM MED ASSOC, V270, P69, DOI 10.1001/jama.270.1.69; GUNTER EW, 1986, HHANES1982 1984 CTR; HUNTER JM, 1977, SOC SCI MED, V11, P691, DOI 10.1016/0037-7856(77)90155-X; Johnson B L, 1993, Ann Epidemiol, V3, P175; LANDRIGAN PJ, 1990, ENVIRON HEALTH PERSP, V89, P61, DOI 10.2307/3430898; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MARINO PE, 1990, AM J PUBLIC HEALTH, V80, P1183, DOI 10.2105/AJPH.80.10.1183; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; MUSHAK P, 1989, ENVIRON RES, V50, P11, DOI 10.1016/S0013-9351(89)80046-5; NEEDLEMAN HL, 1981, ANNU REV PUBL HEALTH, V2, P277, DOI 10.1146/annurev.pu.02.050181.001425; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RIFAI N, 1993, THER DRUG MONIT, V15, P71, DOI 10.1097/00007691-199304000-00001; SCHAFFER SJ, 1994, PEDIATRICS, V93, P159; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300, DOI 10.1080/00039896.1991.9934391; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; SCHWARTZ J, 1987, ARCH ENVIRON HEALTH, V42, P153, DOI 10.1080/00039896.1987.9935814; Sempos CT., 1991, MONITORING DIETARY I, P99; SHAH BV, 1991, SUDAAN USERS MANUAL; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SILBERGELD EK, 1990, ENVIRON HEALTH PERSP, V89, P49, DOI 10.2307/3430896; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; TEJEDA DM, 1994, PEDIATRICS, V93, P192; WEITZMAN M, 1993, JAMA-J AM MED ASSOC, V269, P1647, DOI 10.1001/jama.269.13.1647; 1988, CURRENT POPULATI P60, V163; 1993, MMWR-MORBID MORTAL W, V42, P522; 1987, ANN HIST REV FNS PRO; 1990, SAS LANGUAGE REFEREN; 1992, MMWR-MORBID MORTAL W, V41, P715; 1989, CURRENT POPULATI P60, V171; 1991, CURRENT POPULATI P60, V175	43	463	474	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					277	283		10.1001/jama.272.4.277	http://dx.doi.org/10.1001/jama.272.4.277			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028140				2022-12-01	WOS:A1994NX80600029
J	MILLER, M; HUTCHINS, GM				MILLER, M; HUTCHINS, GM			HEMOCHROMATOSIS, MULTIORGAN HEMOSIDEROSIS, AND CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LOW-DENSITY-LIPOPROTEIN; ISCHEMIC-HEART-DISEASE; IRON; RISK; AUTOPSY	Objective.-To examine the prevalence of coronary artery disease (CAD) in autopsies of patients with iron-overload syndromes. Design.-Retrospective autopsy study of CAD in cases of hemochromatosis and multiorgan hemosiderosis. Setting.-Registry of nearly 48 000 autopsies performed at The Johns Hopkins Hospital between 1889 and 1992. Subjects.-One hundred twenty-three subjects were studied. In a 2:1 control-case ratio, 82 controls matched by age, race, and sex were compared with 41 cases with iron overload. Main Outcome Measure.-Severity of CAD. Results.-Pathological description of the coronary arteries were recorded as advanced or severe in 12% of iron-overload cases (n=41) (mean age, 57.6+/-13.2 years) compared with 38% of controls (n=82) (mean age, 57.0+/-13.8 years) (P=.01). The prevalence of three-vessel disease assessed by postmortem coronary arteriography was 11.1% in iron-overload cases (n=18) (mean age, 61.7+/-12.2 years) compared with 33.3% in controls (n=36) (mean age, 61.1+/-12.5 years) (P=.04). The odds ratio of CAD with iron overload was 0.18 (95% confidence interval, 0.04 to 0.73). Conclusions.-Iron overload resulting from hemochromatosis or multiorgan hemosiderosis is not associated with an increased prevalence of CAD.	UNIV MARYLAND,MED SYST,DIV CARDIOL,BALTIMORE,MD 21201; JOHNS HOPKINS MED INST,DEPT PATHOL,DIV AUTOPSY PATHOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine			Miller, Michael/AGX-6773-2022	Miller, Michael/0000-0002-1679-2095	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002263] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO7-HL-02263-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; CUTLER DJ, 1980, AM J MED, V69, P923, DOI 10.1016/S0002-9343(80)80020-9; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; Hennekens CH., 1987, EPIDEMIOLOGY MED CHA, P54; HUTCHINS GM, 1973, JOHNS HOPKINS MED J, V133, P96; KUZUYA M, 1990, BIOCHEM INT, V22, P567; MACDONALD RA, 1960, ARCH INTERN MED, V105, P686, DOI 10.1001/archinte.1960.00270170024004; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MCINTOSH HD, 1991, ERA CARDIOVASCULAR M, P316; MOORE GW, 1984, AM J PATHOL, V115, P36; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SULLIVAN JL, 1981, LANCET, V1, P1293; VONRECKLINGHAUS.F, 1889, HEIDELBERG J, V52, P324	17	70	72	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					231	233		10.1001/jama.272.3.231	http://dx.doi.org/10.1001/jama.272.3.231			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022042				2022-12-01	WOS:A1994NW18500025
J	TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N				TARDIFF, K; MARZUK, PM; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N			HOMICIDE IN NEW-YORK-CITY - COCAINE USE AND FIREARMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-EXCRETION; UNITED-STATES; RECENT TRENDS; VIOLENCE; HANDGUNS; COUNTY; DEATH; ABUSE; BENZOYLECGONINE; COMPLICATIONS	Objective.-To determine differences between racial/ethnic groups in overall rates of death by homicide, proportion of firearm homicides, and the use of cocaine prior to death. Design.-Descriptive epidemiologic survey of a complete 2-year sample of homicides. Setting.-New York City, NY (population 7 322 564). Subjects.-All residents (N=4298) of New York City who were victims of homicide during 1990 and 1991. Main Outcome Measures.-Using medical examiner data, age- and gender-specific rates of homicide were calculated for African Americans, Latinos, and whites. Separate logistic regression analyses were conducted to examine the association between demographic variables and both recent cocaine use and firearm-related homicides. Results.-Young African-American and Latino men were more likely to be victims of homicide than all other demographic groups. Approximately three fourths of all homicides involved firearms. In the subset of homicide victims dying within 48 hours (n=3890), 31.0% were positive for cocaine metabolites. African Americans (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2 to 2.1), Latinos (OR, 1.4; 95% CI, 1.1 to 1.9), and victims 25 through 34 years of age (OR, 2.9; 95% CI, 2.5 to 3.5) and 35 through 44 years of age (OR, 2.7; 95% CI, 2.2 to 3.4) were more likely to be positive for cocaine metabolites than other groups. Young males and females were equally likely to have used cocaine before death. Victims 15 through 24 years of age were more likely than other age groups to be killed by a firearm. African Americans (OR, 1.7; 95% CI, 1.3 to 2.3), Latinos (OR, 1.5; 95% CI, 1.2 to 2.0), and Asians (OR, 2.2; 95% CI, 1.4 to 3.6) were more likely than whites to be killed by a firearm. Men (OR, 4.8; 95% CI, 4.0 to 5.9) were more likely than women to be killed by a firearm. There was no association between having used cocaine before death and being killed by a firearm. Conclusions.-The high rates of death by homicide among young African Americans and Latinos may be due to the increased involvement with both cocaine use and firearms. New efforts must be made to decrease cocaine use and firearm availability.	CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA	Cornell University; New York University	TARDIFF, K (corresponding author), CORNELL UNIV, COLL MED,DEPT PSYCHIAT,EPIDEMIOL SECT, 525 E 68TH ST, BOX 147, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMBRE J, 1988, J ANAL TOXICOL, V12, P301, DOI 10.1093/jat/12.6.301; AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BASELT RC, 1974, DISPOSITION TOXIC DR; BUDD RD, 1989, AM J DRUG ALCOHOL AB, V15, P375, DOI 10.3109/00952998908992798; CALLAHAN CM, 1992, JAMA-J AM MED ASSOC, V267, P3038, DOI 10.1001/jama.267.22.3038; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; CENTERWALL BS, 1984, AM J PUBLIC HEALTH, V74, P813, DOI 10.2105/AJPH.74.8.813; Collins JJ, 1985, CRIMINOLOGY, V23, P743, DOI 10.1111/j.1745-9125.1985.tb00372.x; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; Fagan J, 1990, NIDA Res Monogr, V103, P8; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1990, JAMA-J AM MED ASSOC, V263, P3292, DOI 10.1001/jama.263.24.3292; Gerstein D. R., 1993, PREVENTING DRUG ABUS; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; GOLDSTEIN PJ, 1991, J DRUG ISSUES, V21, P345, DOI 10.1177/002204269102100207; GOLDSTEIN PJ, 1985, J DRUG ISSUES, V15, P493, DOI 10.1177/002204268501500406; Goldstein PJ, 1979, PROSTITUTION DRUGS; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HAMID A, 1990, CONTEMP DRUG PROBL, V17, P31; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; HOUSER HB, 1991, AM J EPIDEMIOL, V134, P1261, DOI 10.1093/oxfordjournals.aje.a116028; INCIARDI JA, 1990, NATIONAL I DRUG ABUS, V103; JATLOW PI, 1987, CLIN CHEM, V33, pB66; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK PM, 1992, JAMA-J AM MED ASSOC, V267, P2635; MENDOZA R, 1992, HOSP COMMUNITY PSYCH, V43, P677; MESSNER SF, 1986, CRIMINOLOGY, V24, P297, DOI 10.1111/j.1745-9125.1986.tb01497.x; OCARROLL PW, 1991, AM J PUBLIC HEALTH, V81, P576, DOI 10.2105/AJPH.81.5.576; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TRENT B, 1991, CAN MED ASSOC J, V145, P1332; WALLACE JE, 1977, J ANAL TOXICOL, V1, P20, DOI 10.1093/jat/1.1.20; WEBSTER DW, 1993, AM J PUBLIC HEALTH, V83, P1604, DOI 10.2105/AJPH.83.11.1604; WETLI CV, 1985, J FORENSIC SCI, V30, P873; Wolfgang M. E., 1967, SUBCULTURE VIOLENCE; ZAHN M, 1989, HOMICIDE 20TH CENTUR, P1; 1993, SMA931980 US DEP MEN; 1993, UNDERSTANDING PREVEN; 1990, VITAL HLTH STAT, V11; 1990, MMWR-MORBID MORTAL W, V39, P869; 1990, TREATING DRUG PROBLE, V1, P220; 1991, MMWR-MORBID MORTAL W, V40, P681	50	58	59	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					43	46		10.1001/jama.272.1.43	http://dx.doi.org/10.1001/jama.272.1.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007078				2022-12-01	WOS:A1994NU48500028
J	PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P				PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P			BREAST-FEEDING AND MULTIPLE-SCLEROSIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED ANTONIO CARDARELLI,DIV NEUROL,NAPLES,ITALY; ASSOC ITALIANA SCLEROSI MULTIPLA,NAPLES,ITALY	Antonio Cardarelli Hospital	PISACANE, A (corresponding author), UNIV NAPLES FEDERICO II,DIPARTIMENTO PEDIAT,VIA PANSINI 5,I-80131 NAPLES,ITALY.							AGRANOFF BW, 1974, LANCET, V2, P1061; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSON LA, 1985, PEDIATRICS, V75, P172; MARTYN CN, 1991, CIBA F SYMP, V156, P93; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302	5	47	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1411	1412		10.1136/bmj.308.6941.1411	http://dx.doi.org/10.1136/bmj.308.6941.1411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019251	Green Published			2022-12-01	WOS:A1994NP42000016
J	CHREN, MM; LANDEFELD, CS				CHREN, MM; LANDEFELD, CS			A COST-ANALYSIS OF TOPICAL DRUG REGIMENS FOR DERMATOPHYTE INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERDIGITAL TINEA-PEDIS; TERBINAFINE; 1-WEEK; CREAM	Objective.-To examine the extra cost of using higher-priced drugs as initial therapy for dermatophyte infections, because the many available effective drugs vary considerably in cost. Design.-Cost analysis from the purchaser's perspective, comparing two prototypical regimens to treat tinea pedis: one in which all patients initially receive a fewer-priced drug and those with unresponsive infections receive a higher-priced drug at a follow-up office visit, and one in which all patients receive the higher-priced drug from the outset. The reference drug was miconazole, an imidazole available without a prescription, for which reported overall efficacy rates are 70% to 100%. Main Outcome Measures.-The threshold efficacy rate (the efficacy rate of miconazole below which it is always less expensive to use a specific higher-priced drug first) and the extra cost (of beginning therapy with a higher-priced drug). Results.-Assuming the Medicare-approved charge for a follow-up visit ($21.98), it is less expensive to begin therapy with a prescription drug only if the efficacy rate of miconazole is less than 55%; this threshold efficacy rate varied from 26% (for a $0 total cost of the follow-up visit) to 79% (for an $89 total cost of the follow-up visit). If the efficacy rate of miconazole is 70%, the extra cost per patient for all patients to receive the least expensive prescription antifungal drug instead of miconazole first was $15.23 and $8.64 if total visit costs were $0 and $21.98, miconazole remained the less expensive alternative as long as the total cost of the follow-up visit was less than $50.76. Conclusion.-For reported efficacy rates and standard costs of a follow-up office visit, using miconazole first and then treating only those patients with unresponsive infections with a higher-priced prescription drug is less expensive than treating ail patients with the higher-priced drug.	VET AFFAIRS MED CTR,PROGRAM HLTH CARE RES,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,DEPT MED,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	CHREN, MM (corresponding author), VET AFFAIRS MED CTR,DEPT DERMATOL,11-GW,10701 EAST BLVD,CLEVELAND,OH 44106, USA.							BERGSTRESSER PR, 1993, J AM ACAD DERMATOL, V28, P648, DOI 10.1016/S0190-9622(08)81787-2; BERMAN B, 1992, J AM ACAD DERMATOL, V26, P956, DOI 10.1016/0190-9622(92)70141-2; BLOOM BS, 1986, JAMA-J AM MED ASSOC, V256, P2523, DOI 10.1001/jama.256.18.2523; CHREN MM, 1994, J AM ACAD DERMATOL, V31, pS103, DOI 10.1016/S0190-9622(08)81278-9; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELDAROUTI MA, 1990, INT J DERMATOL, V29, P521, DOI 10.1111/j.1365-4362.1990.tb04851.x; FULTON JE, 1975, ARCH DERMATOL, V111, P596, DOI 10.1001/archderm.111.5.596; HAY RJ, 1990, SEMIN DERMATOL, V9, P309; HAY RJ, 1992, CLIN EXP DERMATOL, V17, P2, DOI 10.1111/j.1365-2230.1992.tb00268.x; JONES HE, 1982, MED CLIN N AM, V66, P873, DOI 10.1016/S0025-7125(16)31399-2; MANDY SJ, 1974, JAMA-J AM MED ASSOC, V230, P72, DOI 10.1001/jama.230.1.72; ORTIZ LG, 1978, CLIN THER, V1, P444; SAWYER PR, 1975, DRUGS, V9, P406, DOI 10.2165/00003495-197509060-00002; Smith E B, 1976, Cutis, V17, P54; STERN RS, 1993, DERMATOLOGY GEN MED, P7; SVEJGAAR.E, 1973, ACTA DERM-VENEREOL, V53, P497; 1984, CAN MED ASSOC J, V130, P1428; 1993, MED LETT DRUGS THER, V35, P76; 1993, 1993 RED BOOK; 1984, CAN MED ASSOC J, V130, P1542	20	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	1994	272	24					1922	1925		10.1001/jama.272.24.1922	http://dx.doi.org/10.1001/jama.272.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX927	7990244				2022-12-01	WOS:A1994PX92700037
J	BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N				BATTISTUTTA, D; PALMER, J; WALTERS, M; WALKER, G; NANCARROW, D; HAYWARD, N			INCIDENCE OF FAMILIAL MELANOMA AND MLM2 GENE	LANCET			English	Note							INCREASING INCIDENCE; LINKAGE; LOCUS	The overall incidence of melanoma is increasing world wide. We investigated whether there has been an increase in familial melanoma by studying age at onset among different birth cohorts in 18 melanoma kindreds linked to a predisposition gene (MLM2) on chromosome 9. The cumulative incidence of melanoma was 21-fold higher (95% CI 5.2-84.6) among subjects born after 1959 than in those born before 1900. The expected age of onset of the group born after 1959 was 24 years earlier (21.0 vs 45.0 years). These data support the notion that phenotypic penetrance of the MLM2 gene is increasing, presumably as a result of the interaction of sunlight exposure and mutation at this locus.	QUEENSLAND INST MED RES,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	hayward, nicholas k/0000-0003-4760-1033; 				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9; RING IT, 1989, T MENZIES F, V15, P157; WALKER GJ, 1994, ONCOGENE, V9, P819; WLKER GJ, 1993, MELANOMA RES, V4, P29	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1607	1608		10.1016/S0140-6736(94)90408-1	http://dx.doi.org/10.1016/S0140-6736(94)90408-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983995				2022-12-01	WOS:A1994PW05100011
J	LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S				LANGERMANN, S; PALASZYNSKI, S; SADZIENE, A; STOVER, CK; KOENIG, S			SYSTEMIC AND MUCOSAL IMMUNITY INDUCED BY BCG VECTOR EXPRESSING OUTER-SURFACE PROTEIN-A OF BORRELIA-BURGDORFERI	NATURE			English	Article							ANTIBODY-SECRETING CELLS; ORAL IMMUNIZATION; CHOLERA-TOXIN; OSPA; MICE; ENUMERATION; VACCINE	THE bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis which offers potential advantages as a vector for mucosal delivery of antigens(1-3). Recombinant BCG elicits protective humoral immune responses to a variety of antigens(4). Furthermore, BCG binds specifically to microfold cells(5) present in the epithelium overlying lymphoid follicles throughout the mucosal immune system(6-8). Here we show that a single intranasal vaccination with recombinant BCG expressing the outersurface protein A antigen from B. burgdorferi(9) results in a prolonged (more than one year) protective systemic IgG response and a highly sustained secretory IgA response which is disseminated throughout the mucosal immune system. Furthermore, intranasal immunization induces marked, organized lymphocyte accumulation in the proximal nasopharyngeal lymphoid tissue as well as at distal mucosal sites; the appearance and persistence of lymphoid aggregates correlates with the secretory immune responses. Thus intranasal immunization with recombinant BCG is a powerful method for inducing long-lasting secretory and systemic immune responses.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	LANGERMANN, S (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.			Stover, Charles/0000-0002-7406-1696				ABRAHAM E, 1992, J IMMUNOL, V149, P3719; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; FUJIMURA Y, 1986, Gastroenterologia Japonica, V21, P325; HANEBERG B, 1994, INFECT IMMUN, V62, P15, DOI 10.1128/IAI.62.1.15-23.1994; JACOBS WR, 1990, CURR TOP MICROBIOL, V155, P153; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KUPER CF, 1992, IMMUNOL TODAY, V13, P219; LANGERMANN S, 1993, CURR OPIN GASTROEN, V8, P983; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9; OHAGAN DT, 1993, VACCINE, V11, P149, DOI 10.1016/0264-410X(93)90011-L; QULDING M, 1991, J CLIN INVEST, V88, P143; SADZIENE A, 1993, J INFECT DIS, V167, P165, DOI 10.1093/infdis/167.1.165; SCHWAN TG, 1988, J CLIN MICROBIOL, V26, P893, DOI 10.1128/JCM.26.5.893-895.1988; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STOVER CK, 1994, RECOMBINANT VECTORS, P153; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; VAJDY M, 1992, IMMUNOLOGY, V75, P488; Young J T, 1981, Fundam Appl Toxicol, V1, P309, DOI 10.1016/S0272-0590(81)80037-1	26	143	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					552	555		10.1038/372552a0	http://dx.doi.org/10.1038/372552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990928	Bronze			2022-12-01	WOS:A1994PW08200053
J	ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM				ZHANG, YY; PROENCA, R; MAFFEI, M; BARONE, M; LEOPOLD, L; FRIEDMAN, JM			POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOG	NATURE			English	Article							ARTIFICIAL-CHROMOSOME LIBRARIES; POLYMERASE CHAIN-REACTION; DNA FRAGMENTS; MESSENGER-RNA; OB MUTATION; YEAST; IDENTIFICATION; MICE	The mechanisms that balance food intake and energy expenditure determine who will be obese and who will be lean. One of the molecules that regulates energy balance in the mouse is the obese (ob) gene. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University								ADOLPH EF, 1947, AM J PHYSIOL, V151, P110, DOI 10.1152/ajplegacy.1947.151.1.110; BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRAY GA, 1990, INT J OBESITY, V14, P909; BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; BROBECK JR, 1948, YALE J BIOL MED, V20, P545; BRUBECK JR, 1946, PHYSIOL REV, V25, P541; BURMEISTER M, 1989, TRENDS GENET, V5, P41, DOI 10.1016/0168-9525(89)90019-X; BURROS M, 1994, NY TIMES        0717; Cannon WB, 1912, AM J PHYSIOL, V29, P441, DOI 10.1152/ajplegacy.1912.29.5.441; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dickie M. M., 1957, MOUSE NEWS LETT, V17, P52; DIETRICH W, 1992, GENETICS, V131, P423; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRUNDY SM, 1990, DM-DIS MON, V36, P645; HARTI DL, 1993, BIOTECHNIQUES, V15, P201; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1969, NATURE, V222, P629, DOI 10.1038/222629a0; Hetherington AW, 1942, AM J PHYSIOL, V136, P609, DOI 10.1152/ajplegacy.1942.136.4.609; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MAYER J, 1955, ANN NY ACAD SCI, V63, P15, DOI 10.1111/j.1749-6632.1955.tb36543.x; NEEL JV, 1962, AM J HUM GENET, V14, P353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Rubner M., 1894, Z BIOL, V30, P73; SABATINI D, 1989, METABOLIC BASIS INHE, P177; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; VENTER CJ, 1993, AUTOMATED DNA SEQUEN; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	49	10597	11474	30	1115	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					425	432		10.1038/372425a0	http://dx.doi.org/10.1038/372425a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984236				2022-12-01	WOS:A1994PV01200046
J	HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A				HENDERSON, CE; PHILLIPS, HS; POLLOCK, RA; DAVIES, AM; LEMEULLE, C; ARMANINI, M; SIMPSON, LC; MOFFET, B; VANDLEN, RA; KOLIATSOS, VE; ROSENTHAL, A			GDNF - A POTENT SURVIVAL FACTOR FOR MOTONEURONS PRESENT IN PERIPHERAL-NERVE AND MUSCLE	SCIENCE			English	Article							NEUROTROPHIC FACTOR; EMBRYONIC MOTONEURONS; MOTOR NEURONS; SCHWANN-CELLS; EXPRESSION; DEATH; RAT; INVITRO; INVIVO; CHICK	For survival, embryonic motoneurons in vertebrates depend on as yet undefined neurotrophic factors present in the limb bud. Members of the neurotrophin family are currently the best candidates for such neurotrophic factors, but inactivation of their receptor genes leads to only partial loss of motoneurons, which suggests that other factors are involved. Glial cell line-derived neurotrophic factor (GDNF), originally identified as a trophic factor specific for dopaminergic neurons, was found to be 75-fold more potent than the neurotrophins in supporting the survival of purified embryonic rat motoneurons in culture. GDNF messenger RNA was found in the immediate vicinity of motoneurons during the period of cell death in development. In vivo, GDNF rescues and prevents the atrophy of facial motoneurons that have been deprived of target-derived survival factors by axotomy. GDNF may therefore be a physiological trophic factor for spinal motoneurons. Its potency and specificity in vitro and in vivo also make it a good candidate for treatment of motoneuron disease.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; IBDM,INSERM,U382,F-13288 MARSEILLE 9,FRANCE; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; SCH BIOL & MED SCI ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL NEUROL & NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,BALTIMORE,MD 21205	Roche Holding; Genentech; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Roche Holding; Genentech; Roche Holding; Genentech; University of St Andrews; Johns Hopkins University; Johns Hopkins University			Davies, Alun M/A-4334-2010	Davies, Alun M/0000-0001-5841-8176; Henderson, Christopher/0000-0002-9936-3279	NINDS NIH HHS [NS 10580] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAMU W, 1993, NEUROPROTOCOLS, V2, P191; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; HALLER FR, 1971, AM J ANAT, V131, P1, DOI 10.1002/aja.1001310102; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1993, RESTOR NEUROL NEUROS, V5, P15, DOI 10.3233/RNN-1993-5105; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES GE, 1990, J CELL SCI, V97, P659; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; POULSEN KT, IN PRESS NEURON; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YANSURA DG, 1990, METHOD ENZYMOL, V185, P54	29	1119	1210	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1062	1064		10.1126/science.7973664	http://dx.doi.org/10.1126/science.7973664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973664				2022-12-01	WOS:A1994PQ92400051
J	TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ				TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ			HERPES-SIMPLEX VIRUS-INFECTION AS A CAUSE OF BENIGN RECURRENT LYMPHOCYTIC MENINGITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES SIMPLEX; MENINGITIS, VIRAL; CEREBROSPINAL FLUID; HERPES GENITALIS; CENTRAL NERVOUS SYSTEM	POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; MOLLARETS MENINGITIS; GENITAL HERPES; ENCEPHALITIS; TYPE-2; DIAGNOSIS; DNA; HERPESVIRUSES; PATIENT	Objective: To identify the role of herpes simplex virus (HSV) in causing benign recurrent lymphocytic meningitis. Design: Prospective cohort study. Setting: Tertiary referral center. Patients: 20 consecutive patients with a provisional diagnosis of benign recurrent lymphocytic meningitis had cerebrospinal fluid specimens submitted between 1990 and 1993 to the diagnostic virology laboratory. Thirteen patients met our criteria for benign recurrent lymphocytic meningitis. Measurements: Herpes simplex virus DNA was detected in cerebrospinal fluid specimens using the polymerase chain reaction, followed by hybridization with a HSV-specific DNA probe. Herpes simplex virus type 1 and type 2 DNA products were distinguished by digestion with restriction enzymes and analysis by gel electrophoresis. Anti-HSV antibodies in cerebrospinal fluid were detected by immunoblot. Results: The patients had 3 to 9 attacks (mean, 4.6 attacks) of benign recurrent lymphocytic meningitis during periods ranging from 2 to 21 years (mean, 8.4 years). Three of 13 patients had known recurrent genital herpes. Cerebrospinal fluid analysis showed 48 to 1600 cells/mu L, glucose levels of more than 2.22 mmol/L (40 mg/dL), and protein levels of 41 to 240 mg/dL (0.41 to 2.4 g/L). Herpes simplex virus DNA and anti-HSV antibodies were detected in cerebrospinal fluid samples in 11 of 13 patients (84.6%; 95% CI, 55% to 98%). Ten of these 11 patients had HSV type 2 DNA and HSV type 2 antibodies. One patient had HSV type 1 DNA and HSV type 1 antibodies in the cerebrospinal fluid. The remaining two patients had only anti-HSV type 2 antibodies. Conclusions: Herpes simplex virus, predominantly HSV type 2, was the major agent causing benign recurrent lymphocytic meningitis that met our specified diagnostic criteria.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT INFECT DIS, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, DENVER, CO 80220 USA; UNIV WASHINGTON, CHILDRENS HOSP & MED CTR, DEPT LAB MED, VIROL LAB, SEATTLE, WA 98105 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; US Department of Veterans Affairs; Veterans Health Administration (VHA); Seattle Children's Hospital; University of Washington; University of Washington Seattle			Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS032228, R01NS032228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20381] Funding Source: Medline; NINDS NIH HHS [NINCDS P1NS32228A] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCHARD JM, 1992, NEW ENGL J MED, V326, P893; ASHLEY R, 1992, ADV HOST DEFENSE MEC, V8, P201; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; AURELIUS E, 1993, J MED VIROL, V39, P179, DOI 10.1002/jmv.1890390302; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BARINGER JR, 1974, NEW ENGL J MED, V291, P828, DOI 10.1056/NEJM197410172911606; BERGER JR, 1991, LANCET, V337, P1360, DOI 10.1016/0140-6736(91)93051-A; BERGSTROM T, 1990, J INFECT DIS, V162, P322, DOI 10.1093/infdis/162.2.322; BERGSTROM T, 1990, SCAND J INFECT DIS, V22, P239, DOI 10.3109/00365549009037909; BRUYN GW, 1962, NEUROLOGY, V12, P745, DOI 10.1212/WNL.12.11.745; COHEN BA, 1992, ANN NEUROL, V32, P295; DAVISON AJ, 1983, J GEN VIROL, V64, P1927, DOI 10.1099/0022-1317-64-9-1927; FREDERIKS JAM, 1978, HDB CLIN NEUROLOGY, V34, P545; GRAMAN PS, 1987, ARCH NEUROL-CHICAGO, V44, P1204, DOI 10.1001/archneur.1987.00520230084023; HERMANS PE, 1972, AM J MED, V52, P128, DOI 10.1016/0002-9343(72)90014-9; KAHLON J, 1987, J INFECT DIS, V155, P38, DOI 10.1093/infdis/155.1.38; KIMURA H, 1991, J INFECT DIS, V164, P289, DOI 10.1093/infdis/164.2.289; KLAPPER PE, 1990, J MED VIROL, V32, P261, DOI 10.1002/jmv.1890320413; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Mollaret MP, 1944, REV NEUROL-FRANCE, V76, P57; MOLLARET P, 1977, REV NEUROL, V133, P225; MOLLARET P, 1952, Bull Mem Soc Med Hop Paris, V68, P946; MOLLARET P, 1945, ANN I PASTEUR PARIS, V71, P1; PAL GS, 1987, BRIT MED J, V295, P367, DOI 10.1136/bmj.295.6594.367; PICARD FJ, 1993, NEUROLOGY, V43, P1722, DOI 10.1212/WNL.43.9.1722; PLUMMER G, 1973, J INFECT DIS, V128, P345, DOI 10.1093/infdis/128.3.345; PRICE RW, 1986, CRC CR REV CL NEUROB, V2, P61; PUCHHAMMERSTOCKL E, 1990, J MED VIROL, V32, P77, DOI 10.1002/jmv.1890320202; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SKOLDENBERG B, 1975, SCAND J INFECT DIS, V7, P227, DOI 10.3109/inf.1975.7.issue-4.01; STALDER H, 1973, NEW ENGL J MED, V289, P1296, DOI 10.1056/NEJM197312132892409; STEEL JG, 1982, ANN NEUROL, V11, P17, DOI 10.1002/ana.410110104; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; STRAUS SE, 1990, PRINCIPLES PRACTICE, P1139; TYLER KL, 1983, ARCH NEUROL-CHICAGO, V40, P42, DOI 10.1001/archneur.1983.04050010062017; VONHOFF DD, 1975, WESTERN J MED, V123, P490; WARREN KG, 1977, LANCET, V2, P637; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; WHITLEY RJ, 1991, INFECTIONS CENTRAL N, P41; YAMAMOTO LJ, 1991, NEW ENGL J MED, V325, P1082, DOI 10.1056/NEJM199110103251507	41	130	133	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					334	338		10.7326/0003-4819-121-5-199409010-00004	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042822				2022-12-01	WOS:A1994PD70100004
J	KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR				KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR			NUCLEOSOME DISRUPTION AND ENHANCEMENT OF ACTIVATOR BINDING BY A HUMAN SW1/SNF COMPLEX	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; YEAST; GAL4; DNA; SNF2/SWI2; PROTEINS; INVITRO; FAMILY; CHROMATIN; DOMAINS	CHROMATIN structure can affect the transcriptional activity of eukaryotic structural genes by blocking access of sequence-specific activator proteins (activators) to their promoter-binding sites(1). For example, the DNA-binding domain of the yeast GAL4 protein interacts very poorly with nucleosome cores compared with naked DNA(2) (and see below), and binding of other activators is even more strongly inhibited(2,3). The way in which activators bind to nucleosomal DNA is therefore a critical aspect of transcriptional activation. Genetic studies have suggested that the multi-component SWI/SNF complex of Saccharomyces cerevisiae facilitates transcription by altering the structure of the chromatin(4,5). Here we identify and partially purify a human homologue of the yeast SWI/SNF complex (hSWI/SNF complex). We show that a partially purified hSWI/SNF complex mediates the ATP-dependent disruption of a nucleosome, thereby enabling the activators, GAL4-VP16 and GAL4-AH, to bind within a nucleosome core. We conclude that the hSWI/SNF complex acts directly to reorganize chromatin structure so as to facilitate binding of transcription factors.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; STANFORD UNIV,CTR MOILEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Stanford University								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	24	647	655	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					477	481		10.1038/370477a0	http://dx.doi.org/10.1038/370477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047169				2022-12-01	WOS:A1994PB40700061
J	DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A				DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A			2 STEPS IN THE ASSEMBLY OF COMPLEXES AT YEAST REPLICATION ORIGINS IN-VIVO	CELL			English	Article							CEREVISIAE CELL-CYCLE; DNA-BINDING FACTORS; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPLEX; TRANSCRIPTIONAL REPRESSION; SUBCELLULAR-LOCALIZATION; CHROMATIN ORGANIZATION; MULTIPROTEIN COMPLEX; CHROMOSOMAL ORIGIN; LICENSING FACTOR	The integration of chromosomal DNA replication into the eukaryotic cell cycle might involve temporal regulation of interactions between cellular factors and replication origins. We show here that yeast replication origins exist in two chromatin states during the cell cycle. In the postreplicative state, genomic footprints closely resemble those produced in vitro by the purified ORC and ABF1 proteins, indicating that the binding of these proteins to replication origins is not sufficient to drive the initiation of DNA replication. The prereplicative state is characterized by an additional region of protection overlapping the ORC footprint. This prereplicative complex appears near the end of mitosis and persists through G1. After entry into S phase, origins return to the postreplicative state. Similarities in temporal regulation of the prereplicative state and the Xenopus licensing factor suggest that mechanisms limiting DNA replication to once per cell cycle may be conserved among eukaryotes.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680; Dowell, Simon/0000-0001-6499-7573				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1992, MOL BIOL SACCHAROMYC, P25; DORSMAN JC, 1990, NUCLEIC ACIDS RES, V18, P2769, DOI 10.1093/nar/18.9.2769; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; ESTES HG, 1992, P NATL ACAD SCI USA, V89, P11156, DOI 10.1073/pnas.89.23.11156; FAGRELIUS TJ, 1984, J MOL BIOL, V173, P1, DOI 10.1016/0022-2836(84)90400-5; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; RIVIN CJ, 1980, J CELL BIOL, V85, P96, DOI 10.1083/jcb.85.1.96; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VEIT BE, 1985, MOL CELL BIOL, V5, P2190, DOI 10.1128/MCB.5.9.2190; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; [No title captured]	62	479	487	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					303	316		10.1016/0092-8674(94)90299-2	http://dx.doi.org/10.1016/0092-8674(94)90299-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044842				2022-12-01	WOS:A1994NZ24200013
J	CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P				CROWTHER, RA; KISELEV, NA; BOTTCHER, B; BERRIMAN, JA; BORISOVA, GP; OSE, V; PUMPENS, P			3-DIMENSIONAL STRUCTURE OF HEPATITIS-B VIRUS CORE PARTICLES DETERMINED BY ELECTRON CRYOMICROSCOPY	CELL			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ANTIGENIC DETERMINANTS; CAPSID PARTICLES; MICROSCOPY; PROTEIN; SURFACE; RNA; EXPRESSION; MODEL	Human hepatitis B virus core protein expressed in E. coli assembles into two sizes of particle. We have determined their three-dimensional structures by electron cryomicroscopy and image processing. The large and small particles correspond to triangulation number T = 4 and T = 3 dimer clustered packings, containing 240 and 180 protein subunits, respectively. The local packing of subunits is very similar in the two sizes of particle and shows holes or channels through the shell. The native viral core particle packages RNA and is active in reverse transciption to DNA. The holes we observe may provide access for the necessary small molecules. Shells assembled from the intact core protein contain additional material, probably RNA, which appears as an icosahedrally ordered inner shell in the three-dimensional map.	RUSSIAN ACAD SCI,INST CRYSTALLOG,MOSCOW 117333,RUSSIA; UNIV LATVIA,CTR BIOMED RES & STUDY,RIGA 1065,LATVIA	Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Latvian Biomedical Research & Study Centre; University of Latvia	CROWTHER, RA (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Bottcher, Bettina/E-9397-2010; Kiselev, Nikolay/H-2534-2014; Pumpens, Paul/A-2163-2008	Bottcher, Bettina/0000-0002-7962-4849; Kiselev, Nikolay/0000-0001-8130-8629; 	NIGMS NIH HHS [GM41449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, EMBO J, V7, P819, DOI 10.1002/j.1460-2075.1988.tb02880.x; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BORISOVA G, 1993, J VIROL, V67, P3696, DOI 10.1128/JVI.67.6.3696-3701.1993; BORISOVA GP, 1984, DOKL AKAD NAUK SSSR+, V279, P1245; BORISOVA GP, 1988, DOKL AKAD NAUK SSSR+, V298, P1474; BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; CROWTHER RA, 1971, PHILOS T ROY SOC B, V261, P2211; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EDMAN JC, 1981, NATURE, V291, P503, DOI 10.1038/291503a0; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HULL R, 1987, J CELL SCI S, V7, P213; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; METCALF P, 1991, EMBO J, V10, P3129, DOI 10.1002/j.1460-2075.1991.tb04874.x; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NASSAL M, 1993, HEPATITS B VIRUS NUC, P41; ONODERA S, 1982, J MED VIROL, V10, P147, DOI 10.1002/jmv.1890100209; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; ULRICH R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P323; VIGERS GPA, 1986, THESIS U CAMBRIDGE; ZHENG J, 1992, J BIOL CHEM, V267, P9422; ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046	28	416	451	3	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					943	950		10.1016/0092-8674(94)90142-2	http://dx.doi.org/10.1016/0092-8674(94)90142-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004680				2022-12-01	WOS:A1994NT33100018
J	TONTONOZ, P; HU, ED; SPIEGELMAN, BM				TONTONOZ, P; HU, ED; SPIEGELMAN, BM			STIMULATION OF ADIPOGENESIS IN FIBROBLASTS BY PPAR-GAMMA-2, A LIPID-ACTIVATED TRANSCRIPTION FACTOR	CELL			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HORMONE RECEPTOR SUPERFAMILY; PEROXISOME PROLIFERATOR; GENE-EXPRESSION; RETINOIC ACID; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; NUCLEAR RECEPTORS	Peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) is an adipocyte-specific nuclear hormone receptor that has recently been identified as a key regulator of two fat cell enhancers. Transcriptional activation by PPAR gamma 2 is potentiated by a variety of lipids and lipid-like compounds, including naturally occurring polyunsaturated fatty acids. We demonstrate here that retroviral expression of PPAR gamma 2 stimulates adipose differentiation of cultured fibroblasts. PPAR activators promote the differentiation of PPAR gamma 2-expressing cells in a dose-dependent manner. C/EBP alpha, a second transcription factor induced during adipocyte differentiation, can cooperate with PPAR gamma 2 to stimulate the adipocyte program dramatically. Our results suggest that the physiologic role of PPAR gamma 2 is to regulate development of the adipose lineage in response to endogenous activators and that this factor may serve to link the process of adipocyte differentiation to systemic lipid metabolism.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	TONTONOZ, P (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31405] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32 GM07753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BENNETT PH, 1990, DIABETES MELLITUS TH, P357; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; FINEBERG AP, 1984, ANAL BIOCHEM, V137, P266; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHARBICHIHI J, 1993, BIOCHIM BIOPHYS ACTA, V1177, P8, DOI 10.1016/0167-4889(93)90150-N; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, DECONTAMINATION DILU; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1995, IN PRESS NUCL ACIDS; TONTONOZ P, 1909, IN PRESS MOL CELL BI; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	3017	3145	4	187	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1147	1156		10.1016/0092-8674(94)90006-X	http://dx.doi.org/10.1016/0092-8674(94)90006-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001151				2022-12-01	WOS:A1994PZ86000006
J	COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS				COVINSKY, KE; GOLDMAN, L; COOK, EF; OYE, R; DESBIENS, N; REDING, D; FULKERSON, W; CONNORS, AF; LYNN, J; PHILLIPS, RS			THE IMPACT OF SERIOUS ILLNESS ON PATIENTS FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS; SYSTEM; SERVICES	Objective.-To examine the impact of illness on the families of seriously ill adults and to determine the correlates of adverse economic impact. Design.-Data were collected during the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT), a prospective cohort study of outcomes, preferences, and decision making in seriously ill hospitalized adults and their families. Setting.-Five tertiary care hospitals in the United States. Participants.-The 2661 seriously ill patients in nine diagnostic categories who survived their index hospitalization and were discharged home were eligible for this analysis, Surrogate and/or patient interviews about the impact of illness on the family were obtained for 2129 (80%) of these patients (mean age, 62 years; 43% women; 6-month survival, 75%). Outcome Measures.-Surrogates and patients were surveyed to determine the frequency of adverse caregiving and economic burdens, Multivariable analyses were performed to determine correlates of loss of family savings. Results.-One third (34%) of patients required considerable caregiving assistance from a family member. In 20% of cases, a family member had to quit work or make another major life change to provide care for the patient. Loss of most or all of the family savings was reported by 31% of families, whereas 29% reported loss of the major source of income. Patient factors independently associated with loss of the family's savings on multivariable analysis included poor functional status (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.10 to 1.78 for patients needing assistance with three or more activities of daily living), lower family income (OR, 1.74; 95% CI, 1.37 to 2.21 for those with annual incomes below $25 000), and young age (OR, 2.85; 95% CI, 2.13 to 3.82 for those younger than 45 years compared with those 65 years or older). Conclusions.-Many families of seriously ill patients experience severe caregiving and financial burdens. Families of younger, poorer, and more functionally dependent patients are most likely to report loss of most or all of the family's savings.	BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,LOS ANGELES,CA 90024; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI 54449; DUKE UNIV,MED CTR,DURHAM,NC; METROHLTH MED CTR,CASE WESTERN RESERVE UNIV,CLEVELAND,OH; DARTMOUTH HITCHCOCK MED CTR,HANOVER,NH; GEORGE WASHINGTON UNIV,CTR SUPPORT COORDINATION,WASHINGTON,DC	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Marshfield Clinic; Duke University; Case Western Reserve University; MetroHealth System; Dartmouth College; George Washington University				Connors, Alfred F./0000-0001-7123-3360				ALTMAN B, 1993, 930040 AG HLTH CAR P; ANDOLSEK KM, 1988, ARCH INTERN MED, V148, P2177, DOI 10.1001/archinte.148.10.2177; BODKIN CM, 1982, BRIT MED J, V284, P1542, DOI 10.1136/bmj.284.6328.1542; Hamel M., 1994, Journal of General Internal Medicine, V9, P43; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; Hosmer D, 2013, APPL LOGISTIC REGRES; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MUI AC, 1992, GERONTOLOGIST, V32, P205; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PRUNCHO RA, 1989, J AM GERIATR SOC, V37, P697; Rosner B., 1995, FUNDAMENTALS BIOSTAT; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; STANLEY MJB, 1988, HEART LUNG, V17, P677; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	20	372	379	1	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1839	1844		10.1001/jama.272.23.1839	http://dx.doi.org/10.1001/jama.272.23.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990218				2022-12-01	WOS:A1994PW98000032
J	ORRELL, RW; DEBELLEROCHE, JS				ORRELL, RW; DEBELLEROCHE, JS			SUPEROXIDE-DISMUTASE AND ALS	LANCET			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS		CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London	ORRELL, RW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON,ENGLAND.		Orrell, Richard/L-2123-2013					BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ELSHAFEY A, 1994, HUM MOL GENET, V3, P363, DOI 10.1093/hmg/3.2.363; ESTEBAN J, 1994, HUM MOL GENET, V3, P997, DOI 10.1093/hmg/3.6.997; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; JONES CT, 1994, HUM MOL GENET, V3, P649, DOI 10.1093/hmg/3.4.649; KING AW, 1994, BIOCHEM SOC T, V22, pS149, DOI 10.1042/bst022149s; NAKANO R, 1994, BIOCHEM BIOPH RES CO, V200, P695, DOI 10.1006/bbrc.1994.1506; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	15	13	13	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1651	1652		10.1016/S0140-6736(94)90452-9	http://dx.doi.org/10.1016/S0140-6736(94)90452-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996955				2022-12-01	WOS:A1994PX30200003
J	KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA				KARLSSON, L; PELERAUX, A; LINDSTEDT, R; LILJEDAHL, M; PETERSON, PA			RECONSTITUTION OF AN OPERATIONAL MHC CLASS-II COMPARTMENT IN NONANTIGEN-PRESENTING CELLS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN; MICE LACKING; MOLECULES; PEPTIDE; ANTIGENS; TRANSPORT; BIOSYNTHESIS; ASSOCIATION; EXPRESSION	Professional antigen-presenting cells (APCs) have a distinct compartment in which class II molecules are proposed to acquire antigenic peptides. Genetic evidence suggests that human leukocyte antigen (HLA)-DM, an unusual class II molecule, participates in this process. Peptide acquisition was reconstituted in nonprofessional APCs by transfection of class II, invariant chain (Ii), and H-2M, the murine equivalent of DM. The H-2M heterodimer appeared in an endosomal compartment, not at the cell surface, and the localization was independent of Ii. The data presented show that H-2M, class II, and Ii are the minimally required components for efficient formation of stable class II-peptide complexes, and thus for a functional class II compartment.			KARLSSON, L (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026610] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CARRINGTON M, 1993, IMMUNOGENETICS, V38, P446; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; DORNMAIR K, 1989, COLD SH Q B, V54, P409; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KARLSSON L, UNPUB; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OWEN MJ, 1981, J BIOL CHEM, V256, P8987; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SANDERSON F, 1994, IMMUNOGENETICS, V39, P56; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	42	137	138	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1569	1573		10.1126/science.7985028	http://dx.doi.org/10.1126/science.7985028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985028				2022-12-01	WOS:A1994PV01500046
J	KINOSHITA, J				KINOSHITA, J			AGRICULTURAL BIOTECH BLOOMS LATE	SCIENCE			English	Editorial Material																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1184	1185		10.1126/science.7973697	http://dx.doi.org/10.1126/science.7973697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973697				2022-12-01	WOS:A1994PT13200035
J	UNGERMANN, C; NEUPERT, W; CYR, DM				UNGERMANN, C; NEUPERT, W; CYR, DM			THE ROLE OF HSP70 IN CONFERRING UNIDIRECTIONALITY ON PROTEIN TRANSLOCATION INTO MITOCHONDRIA	SCIENCE			English	Article							YEAST MITOCHONDRIA; MEMBRANE TRANSLOCATION; INTERMEMBRANE SPACE; PRECURSOR PROTEIN; INNER MEMBRANE; IMPORT; CYTOCHROME-B2; RECOGNITION; PREPROTEINS; REQUIREMENT	The entry of segments of preproteins of defined lengths into the matrix space of mitochondria was studied. The mitochondrial chaperone Hsp70 (mtHsp70) interacted with proteins emerging from the protein import channel and stabilized translocation intermediates across the membranes in an adenosine triphosphate-dependent fashion. The chaperone bound to the presequence and mature parts of preproteins. In the absence of mtHsp70 binding, preproteins with less than 30 to 40 residues in the matrix diffused out of mitochondria. Thus, protein translocation was reversible up to a late stage. The import channels in both mitochondrial membranes constitute a passive pore that interacts weakly with polypeptide chains entering the matrix.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Cyr, Douglas/0000-0002-4928-3414				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANNAVY K, 1993, CURR OPIN CELL BIOL, V5, P594; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SANDERS SL, 1992, J BIOL CHEM, V267, P9881; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, IN PRESS NATURE; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.biochem.60.1.101; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	30	222	224	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1250	1253		10.1126/science.7973708	http://dx.doi.org/10.1126/science.7973708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973708				2022-12-01	WOS:A1994PT13200056
J	MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T				MIYAZAKI, T; KAWAHARA, A; FUJII, H; NAKAGAWA, Y; MINAMI, Y; LIU, ZJ; OISHI, I; SILVENNOINEN, O; WITTHUHN, BA; IHLE, JN; TANIGUCHI, T			FUNCTIONAL ACTIVATION OF JAK1 AND JAK3 BY SELECTIVE ASSOCIATION WITH IL-2 RECEPTOR SUBUNITS	SCIENCE			English	Article							INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; TYROSINE KINASE; CYTOPLASMIC REGION; LIGAND-BINDING; BETA-SUBUNIT; COMPONENT; FAMILY; SUPERFAMILY	The interleukin-2 receptor (IL-2) consists of three subunits: the IL-2R alpha, IL-2R beta, and IL-2R gamma chains, the last of which is also used in the receptors for IL-4, IL-7, and IL-9. Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3. Jak1 and Jak3 were found to be selectively associated with the ''serine-rich'' region of IL-2R beta and the carboxyl-terminal region of IL-2R gamma, respectively. Both regions were necessary for IL-2 signaling. Furthermore, Jak3-negative fibroblasts expressing reconstituted IL-2R became responsive to IL-2 after the additional expression of Jak3 complementary DNA. Thus, activation of Jak1 and Jak3 may be a key event in IL-2 signaling.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	MIYAZAKI, T (corresponding author), OSAKA UNIV, INST MOLEC & CELLULAR BIOL, 1-3 YAMADA OKA, SUITA, OSAKA 565, JAPAN.		witthuhn, bruce/GSE-3193-2022; Oishi, Isao/L-8639-2018; Fujii, Hodaka/N-9792-2019; Miyazaki, Tadaaki/D-9368-2012; Fujii, Hodaka/A-2420-2008	Oishi, Isao/0000-0003-3682-5349; Fujii, Hodaka/0000-0003-1296-4256; Fujii, Hodaka/0000-0003-1296-4256	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUNG MR, 1991, J IMMUNOL, V147, P1253; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAHARA A, UNPUB; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Minami Y., UNPUB; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WITTHUHN BA, UNPUB; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	520	532	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1045	1047		10.1126/science.7973659	http://dx.doi.org/10.1126/science.7973659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973659				2022-12-01	WOS:A1994PQ92400045
J	KOPP, E; GHOSH, S				KOPP, E; GHOSH, S			INHIBITION OF NF-KAPPA-B BY SODIUM-SALICYLATE AND ASPIRIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TUMOR NECROSIS FACTOR; EXPRESSION; BINDING; CELLS; GENE; RESISTANCE; INDUCTION; DRUGS; HSP70	The transcription factor nuclear factor-kappa B (NF-kappa B) is critical for the inducible expression of multiple cellular and viral genes involved in inflammation and infection including interleukin-1 (IL-1), IL-6, and adhesion molecules. The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs. This inhibition prevented the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B was retained in the cytosol. Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 33443-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V14; BEGG AA, 1993, GENE DEV, V7, P2064; BROOKS PM, 1986, CLIN PHARM ANTIINFLA, P32; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAMAEY JP, 1992, THERAPEUTIC APPLICAT; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; MACILWAIN C, 1993, NATURE, V364, P369; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; PALMOSKI MJ, 1984, ARTHRITIS RHEUM, V27, P398, DOI 10.1002/art.1780270406; PALMOSKI MJ, 1985, ARTHRITIS RHEUM, V28, P237, DOI 10.1002/art.1780280226; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Rainsford K.D., 1984, ASPIRIN SALICYLATES; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; VANE JR, 1990, STROKE S, V4, P12; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84	27	1532	1603	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					956	959		10.1126/science.8052854	http://dx.doi.org/10.1126/science.8052854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052854				2022-12-01	WOS:A1994PB49900044
J	ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W				ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W			IMPLICATIONS FOR DORSOVENTRAL AXIS DETERMINATION FROM THE ZEBRAFISH MUTATION JANUS	NATURE			English	Article							OCCURRING DIBLASTODERMIC EGGS; XENOPUS-LAEVIS; CELL LINEAGE; FATE MAP; CLEAVAGE; EMBRYOS; EXPRESSION; ORGANIZER; PATTERN; GENES	THE mechanisms underlying the formation of dorsoventral polarity in the zebrafish Danio rerio are unknown. Here we describe the zebrafish recessive maternal-effect mutation janus(m55). The mutant phenotype is a division of the blastoderm along the first cleavage plane into two detached half-sized blastoderms. Partial-axis bifurcation occurs in a subset of mutants. Analysis of goosecoid expression in the mutant embryos indicates that only one organizer region is present in each embryo. Furthermore, the position of this organizer region is random with respect to the first cleavage plant bisecting the two blastoderms. Finally, cell tracing in wild-type embryos demonstrates that there is no strict correlation of the dorsoventral axis with early cleavage planes in zebrafish. These findings support the notion that the establishment of the dorsoventral axis and the first cleavage planes are determined by separate mechanisms in the zebrafish embryo.	HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School	ABDELILAH, S (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,13TH ST,BLDG 149,BOSTON,MA 02129, USA.			Stainier, Didier/0000-0002-0382-0026; Driever, Wolfgang/0000-0002-9551-9141				BLACK SD, 1988, DEV BIOL, V128, P65, DOI 10.1016/0012-1606(88)90267-9; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CARROLL CR, 1973, DEV BIOL, V32, P155, DOI 10.1016/0012-1606(73)90227-3; CARTER CA, 1993, J MORPHOL, V215, P301, DOI 10.1002/jmor.1052150309; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DANILCHIK MV, 1988, DEV BIOL, V128, P58, DOI 10.1016/0012-1606(88)90266-7; DROIN A, 1984, ROUX ARCH DEV BIOL, V193, P86, DOI 10.1007/BF00848635; GERHART J, 1981, NATURE, V292, P511, DOI 10.1038/292511a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GEVERS P, 1992, ROUX ARCH DEV BIOL, V201, P275, DOI 10.1007/BF00592108; HELDE KA, 1994, SCIENCE, V265, P517, DOI 10.1126/science.8036493; IKENISHI K, 1988, DEV BIOL, V125, P458, DOI 10.1016/0012-1606(88)90227-8; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KUBOTA HY, 1991, DEV BIOL, V144, P145, DOI 10.1016/0012-1606(91)90486-M; LAALE HW, 1984, CAN J ZOOL, V62, P386, DOI 10.1139/z84-060; MALACINSKI GM, 1974, SCIENCE, V184, P1142, DOI 10.1126/science.184.4142.1142; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; SCHIRONE RC, 1968, J EXP ZOOL, V169, P43, DOI 10.1002/jez.1401690106; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; Westerfield M., 1993, ZEBRAFISH BOOK	24	43	46	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					468	471		10.1038/370468a0	http://dx.doi.org/10.1038/370468a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047167				2022-12-01	WOS:A1994PB40700058
J	PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD				PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD			THE DECLINE IN BLOOD LEAD LEVELS IN THE UNITED-STATES - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS (NHANES)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe trends in blood lead levels for the US population and selected population subgroups during the time period between 1976 and 1991. Design.-Two nationally representative cross-sectional surveys and one cross-sectional survey representing Mexican Americans in the southwestern United States. Setting/Participants.-Participants in two national surveys that included blood lead measurements: the second National Health and Nutrition Examination Survey, 1976 to 1980 (n=9832), and phase 1 of the third National Health and Nutrition Examination Survey, 1988 to 1991 (n=12119). Also, Mexican Americans participating in the Hispanic Health and Nutrition Examination Survey, 1982 to 1984 (n=5682). Results.-The mean blood lead level of persons aged 1 to 74 years dropped 78%, from 0.62 to 0.14 mu mol/L (12.8 to 2.8 mu g/dL). Mean blood lead levels of children aged 1 to 5 years declined 77% (0.66 to 0.15 mu mol/L [13.7 to 3.2 mu g/dL]) for non-Hispanic white children and 72% (0.97 to 0.27 mu mol/L [20.2 to 5.6 mu g/dL]) for non-Hispanic black children. The prevalence of blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater for children aged 1 to 5 years declined from 85.0% to 5.5% for non-Hispanic white children and from 97.7% to 20.6% for non-Hispanic black children. Similar declines were found in population subgroups defined by age, sex, race/ethnicity, income level, and urban status. Mexican Americans also showed similar declines in blood lead levels of a slightly smaller magnitude over a shorter time. Conclusions.-The results demonstrate a substantial decline in blood lead levels of the entire US population and within selected subgroups of the population. The major cause of the observed decline in blood lead levels is most likely the removal of 99.8% of lead from gasoline and the removal of lead from soldered cans. Although these data indicate major progress in reducing lead exposure, they also show that the same sociodemographic factors continue to be associated with higher blood lead levels, including younger age, male sex, non-Hispanic black race/ethnicity, and low income level. Future efforts to remove other lead sources (eg, paint, dust, and soil) are needed but will be more difficult than removing lead from gasoline and soldered cans.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	PIRKLE, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ADAMS M A, 1991, Chemical Speciation and Bioavailability, V3, P37; ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; ANNEST JL, 1984, VITAL HLTH STAT 11, V223; [Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BOLGER P M, 1991, Chemical Speciation and Bioavailability, V3, P31; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SHAH BV, 1991, SUDAAN USERS MANUAL; [No title captured]; 1990, SAS LANGUAGE VERSION; 1981, LABORATORY PROCEDURE; 1992, FOOD SOFT DRINK CAN; 1991, H15089 US DEP COMM C; 1986, EPA600883028AF REP; 1982, H15080 US DEP COMM C; 1985, VITAL HLTH STAT 1, V19; 1981, VITAL HLTH STAT 1, V15; 1991, Q SUMMARY LEAD PHASE	22	692	714	1	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					284	291		10.1001/jama.272.4.284	http://dx.doi.org/10.1001/jama.272.4.284			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028141				2022-12-01	WOS:A1994NX80600030
J	WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG				WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG			LANGERHANS-CELL HISTIOCYTOSIS (HISTIOCYTOSIS-X) - A CLONAL PROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOSOME INACTIVATION; METHYLATION PATTERNS; DENDRITIC CELLS; HUMAN-TUMORS; M27-BETA; ORIGIN; PROBE; POLYMORPHISMS; LESIONS	Background. The lesions of Langerhans'-cell histiocytosis (histiocytosis X), a proliferative histiocytic disorder of unknown cause, contain histiocytes similar in phenotype to dendritic Langerhans' cells. The disease ranges in severity from a fatal leukemia-like disorder to an isolated lytic lesion of bone. Intermediate forms of the disease are usually characterized by multiorgan involvement, diabetes insipidus, and a chronic course. Methods. To determine whether Langerhans' histiocytosis is a polyclonal reactive disease or a clonal disorder, we used X-linked polymorphic DNA probes (HUMARA, PGK, M27 beta[DXS255], and HPRT) to assess clonality in lesional tissues and control leukocytes from 10 female patients with various forms of the disease. Lymphoid clonality was also assessed by analysis of rearrangements at immunoglobulin and T-cell-receptor gene loci. Results. The HUMARA assay detected clonal cells in the lesions of 9 of the 10 patients: 3 patients had acute disseminated disease, 3 had unifocal disease, and 3 had intermediate forms. The percentage of clonal cells closely approximated the percentage of CD1a-positive histiocytes in each lesion. Clonality was also confirmed in two of nine cases with the PGK or M27 beta probe. Extreme constitutional lyonization precluded assessment of clonality in the 10th case. Lymphoid clonality was ruled out in all cases. Conclusions. The detection of clonal histiocytes in all forms of Langerhans'-cell histiocytosis indicates that this disease is probably a clonal neoplastic disorder with highly variable biologic behavior. Thus, genetic mutations that promote clonal expansion of Langerhans' cells or their precursors may now be identified.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PEDIAT,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,CTR MOLEC & CELLULAR DIAGNOST,ALBUQUERQUE,NM 87131; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; ALL CHILDRENS HOSP,DEPT PATHOL & LAB MED,ST PETERSBURG,FL; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	University of New Mexico; University of New Mexico; University of New Mexico; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Baylor College of Medicine	WILLMAN, CL (corresponding author), UNIV NEW MEXICO,SCH MED,CTR CANC,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.			McClain, Kenneth/0000-0003-0725-6263				ABRAHAMSON G, 1990, BRIT J HAEMATOL, V74, P371, DOI 10.1111/j.1365-2141.1990.tb02601.x; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, LANCET, V1, p[208, 209]; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BROADBENT V, 1984, LANCET, V1, P253; BUSQUE L, 1994, NUCLEIC ACIDS RES, V22, P697, DOI 10.1093/nar/22.4.697; BUSQUE L, 1993, BLOOD, V82, P337; CACHIA PG, 1992, GENOMICS, V14, P70, DOI 10.1016/S0888-7543(05)80285-X; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; FAVARA BE, 1990, LEUKEMIA LYMPHOMA, V2, P141, DOI 10.3109/10428199009053518; FAVARA BE, 1991, SEMIN ONCOL, V18, P3; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; GREENBERGER JS, 1981, MEDICINE, V60, P311, DOI 10.1097/00005792-198109000-00001; HAGE C, 1993, HUM PATHOL, V24, P840, DOI 10.1016/0046-8177(93)90133-2; Hand. A., 1893, ARCH PEDIAT, V10, P673; HODGES E, 1991, BRIT J HAEMATOL, V77, P315, DOI 10.1111/j.1365-2141.1991.tb08577.x; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KURAHASHI H, 1991, BLOOD, V77, P1161; LAHEY ME, 1962, J PEDIATR-US, V60, P664, DOI 10.1016/S0022-3476(62)80091-2; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEAHY MA, 1993, J INVEST DERMATOL, V101, P642, DOI 10.1111/1523-1747.ep12371669; MCCLAIN K, IN PRESS AM J HEMATO; MIERAU GW, IN PRESS PEDIATR PAT; NEZELOF C, 1973, BIOMEDICINE, V18, P365; NEZELOF C, 1979, CANCER, V44, P1824, DOI 10.1002/1097-0142(197911)44:5<1824::AID-CNCR2820440542>3.0.CO;2-J; STARZL TE, 1984, LANCET, V1, P583; VANDERVALK P, 1984, VIRCHOWS ARCH B, V45, P169; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEISS LM, 1986, NEW ENGL J MED, V315, P475, DOI 10.1056/NEJM198608213150802; WEISS LM, 1985, NEW ENGL J MED, V313, P539, DOI 10.1056/NEJM198508293130903; WEISS LM, 1986, HUM PATHOL, V17, P179, DOI 10.1016/S0046-8177(86)80291-X; WILLMAN CL, 1990, CLIN LAB MED, V10, P119, DOI 10.1016/S0272-2712(18)30585-7	36	728	762	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					154	160		10.1056/NEJM199407213310303	http://dx.doi.org/10.1056/NEJM199407213310303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008029				2022-12-01	WOS:A1994NW79700003
J	KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C				KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C			THE ETS TRANSCRIPTION FACTORS ENCODED BY THE DROSOPHILA GENE POINTED DIRECT GLIAL-CELL DIFFERENTIATION IN THE EMBRYONIC CNS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; AXON PATHWAYS; NEURONAL DIFFERENTIATION; SPINAL-CORD; MELANOGASTER; MIGRATION; PATTERN; MIDLINE; PROTEIN	The Drosophila gene pointed (pnt) encodes two putative transcription factors (P1 and P2) of the Ets family, which in the embryonic CNS are found exclusively in glial cells. Loss of pnt function leads to poorly differentiated glial cells and a marked decrease in the expression of the neuronal antigen 22C10 in the MP2 neurons, which are known to interact intimately with the pnt(P1)-expressing longitudinal glial cells. Ectopic expression of pnt(P1) RNA forces additional CNS cells to enter the glial differentiation pathway. Interestingly, the additional glial-like cells are often flanked by cells that ectopically express the neuronal antigen 22C10. Therefore, both the pnt loss-of-function as well as the gain-of-function phenotype suggest that glial cells are able to induce 22C10 expression on neighboring neurons. This was further verified by cell transplantation experiments. Thus, pnt is not only required but also sufficient for several aspects of glial differentiation.			KLAES, A (corresponding author), UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY.		Scholz, Henrike/ABE-1063-2020					BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOSSING T, 1994, IN PRESS DEVELOPMENT; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; CHOI KW, 1994, NEURON, V12, P423, DOI 10.1016/0896-6273(94)90282-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FISHELL G, 1991, DEVELOPMENT, V113, P755; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FUJITA CS, 1982, P NATL ACAD SCI USA, V79, P59; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; IP TY, 1992, GENE DEV, V6, P1728; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLODKIN AL, 1994, IN PRESS DEVELOPMENT; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MENNE TV, 1994, DEVELOPMENT, V120, P123; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOLZ H, 1993, GENETICS, V135, P455; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; TYTELL M, 1984, BRAIN RES, V324, P223, DOI 10.1016/0006-8993(84)90032-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILSON MA, 1988, DEVELOPMENT, V102, P537; WINBERG ML, 1992, DEVELOPMENT, V115, P903	55	212	214	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					149	160		10.1016/0092-8674(94)90581-9	http://dx.doi.org/10.1016/0092-8674(94)90581-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033206				2022-12-01	WOS:A1994NX32800017
J	LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH				LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH			STIMULATED ANOXIC BIODEGRADATION OF AROMATIC-HYDROCARBONS USING FE(III) LIGANDS	NATURE			English	Article							DENITRIFYING CONDITIONS; AQUIFER MICROORGANISMS; DISSIMILATORY FE(III); MICROBIAL-DEGRADATION; ORGANIC CONTAMINANTS; REDUCING CONDITIONS; HYDROGEN-PEROXIDE; IRON REDUCTION; SHALLOW SAND; GROUNDWATER	CONTAMINATION of ground waters with water-soluble aromatic hydrocarbons, common components of petroleum pollution, often produces anoxic conditions under which microbial degradation of the aromatics is slow(1-7). Oxygen is often added to contaminated ground water to stimulate biodegradation, but this can be technically difficult and expensive(1,5-8). Insoluble Fe(III) oxides, which are generally abundant in shallow aquifers, are alternative potential oxidants, but are difficult for microorganisms to access(9). Here we report that adding organic ligands that bind to Fe(III) dramatically increases its bioavailability, and that in tbe presence of these ligands, rates of degradation of aromatic hydrocarbons in anoxic aquifer sediments are comparable to those in oxic sediments. We find that even benzene, which is notoriously refractory in the absence of oxygen, can be rapidly degraded. Our results suggest that increasing the bioavailability of Fe(III) by adding suitable ligands provides a potential alternative to oxygen addition for the bioremediation of petroleum-contaminated aquifers.	US GEOL SURVEY, DIV WATER RESOURCES, COLUMBIA, SC 29210 USA	United States Department of the Interior; United States Geological Survey	LOVLEY, DR (corresponding author), US GEOL SURVEY, DIV WATER RESOURCES, 430 NATL CTR, RESTON, VA 22092 USA.							ACTON DW, 1992, J CONTAM HYDROL, V9, P325, DOI 10.1016/0169-7722(92)90002-V; ANID PJ, 1993, WATER RES, V27, P685, DOI 10.1016/0043-1354(93)90178-K; ARNOLD RG, 1988, BIOTECHNOL BIOENG, V32, P1081, DOI 10.1002/bit.260320902; BAEDECKER MJ, 1993, APPL GEOCHEM, V8, P569, DOI 10.1016/0883-2927(93)90014-8; BARBARO JR, 1992, J CONTAM HYDROL, V11, P245, DOI 10.1016/0169-7722(92)90019-B; BARKER JF, 1987, GROUND WATER MONIT R, V7, P64, DOI 10.1111/j.1745-6592.1987.tb01063.x; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P2663, DOI 10.1128/AEM.58.8.2663-2666.1992; FLYVBJERG J, 1993, J CONTAM HYDROL, V12, P133, DOI 10.1016/0169-7722(93)90018-N; GILLHAM RW, 1990, GROUND WATER, V28, P858, DOI 10.1111/j.1745-6584.1990.tb01720.x; GRBICGALIC D, 1987, APPL ENVIRON MICROB, V53, P254; HUTCHINS S R, 1991, Environmental Toxicology and Chemistry, V10, P1437, DOI 10.1897/1552-8618(1991)10[1437:OBBUDC]2.0.CO;2; HUTCHINS SR, 1991, ENVIRON SCI TECHNOL, V25, P68, DOI 10.1021/es00013a005; KUHN EP, 1988, APPL ENVIRON MICROB, V54, P490, DOI 10.1128/AEM.54.2.490-496.1988; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LOVLEY DR, 1989, NATURE, V339, P297, DOI 10.1038/339297a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; LOVLEY DR, 1987, APPL ENVIRON MICROB, V53, P2636, DOI 10.1128/AEM.53.11.2636-2641.1987; LOVLEY DR, IN PRESS ENV SCI TEC; LYNGKILDE J, 1992, J CONTAM HYDROL, V10, P291, DOI 10.1016/0169-7722(92)90012-4; MAJOR DW, 1988, GROUND WATER, V26, P8, DOI 10.1111/j.1745-6584.1988.tb00362.x; MORGAN P, 1992, WATER RES, V26, P73, DOI 10.1016/0043-1354(92)90113-I; PARDIECK DL, 1992, J CONTAM HYDROL, V9, P221, DOI 10.1016/0169-7722(92)90006-Z; RODEN EE, 1993, APPL ENVIRON MICROB, V59, P734, DOI 10.1128/AEM.59.3.734-742.1993; SALANITRO JP, 1993, GROUND WATER MONIT R, V13, P150, DOI 10.1111/j.1745-6592.1993.tb00459.x; THOMAS JM, 1989, ENVIRON SCI TECHNOL, V23, P760, DOI 10.1021/es00065a004; VROBLESKY DA, 1994, WATER RESOUR RES, V30, P1561, DOI 10.1029/94WR00067; WILSON BH, 1986, ENVIRON SCI TECHNOL, V20, P997, DOI 10.1021/es00152a005	28	249	264	5	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					128	131		10.1038/370128a0	http://dx.doi.org/10.1038/370128a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022480				2022-12-01	WOS:A1994NW80400052
J	CRAIG, AD; BUSHNELL, MC				CRAIG, AD; BUSHNELL, MC			THE THERMAL GRILL ILLUSION - UNMASKING THE BURN OF COLD PAIN	SCIENCE			English	Article							DORSAL HORN; SKIN; CAT; PRIMATE; STIMULATION; RESPONSES; NEURONS; SENSITIVITY; MECHANISMS; AFFERENTS	In Thunberg's thermal grill illusion, first demonstrated in 1896, a sensation of strong, often painful heat is elicited by touching interlaced warm and cool bars to the skin. Neurophysiological recordings from two classes of ascending spinothalamic tract neurons that are sensitive to innocuous or noxious cold showed differential responses to the grill. On the basis of these results, a simple model of central disinhibition, or unmasking, predicted a quantitative correspondence between grill-evoked pain and cold-evoked pain, which was verified psychophysically. This integration of pain and temperature can explain the thermal grill illusion and the burning sensation of cold pain and may also provide a basis for the cold-evoked, burning pain of the classic thalamic pain syndrome.	BARROW NEUROL INST,DIV NEUROSURG,PHOENIX,AZ 85013; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA	Barrow Neurological Institute; Universite de Montreal; Universite de Montreal	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007402] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07402] Funding Source: Medline; NINDS NIH HHS [NS25616] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALRUTZ S, 1897, UPPSALA LAKFOREN FOR, V2, P445; BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BORING EG, 1942, SENSATION PERCEPTION, P504; BROMAGE PR, 1980, PAIN, V9, P145, DOI 10.1016/0304-3959(80)90003-2; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; BUSHNELL MC, 1993, SOC NEUR ABSTR, V19, P1573; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; Craig A. D., 1992, Society for Neuroscience Abstracts, V18, P385; CRAIG AD, 1991, J COMP NEUROL, V313, P377, DOI 10.1002/cne.903130212; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, BRAIN RES, V636, P233, DOI 10.1016/0006-8993(94)91022-7; CRAIG AD, 1991, BRAIN RES, V558, P93, DOI 10.1016/0006-8993(91)90719-C; CRAIG AD, 1991, PAIN CENTRAL NERVOUS, P157; CRAIG AG, UNPUB; DARIANSMITH I, 1984, HDB PHYSL 1, V3, P879; DOSTROVSKY JO, 1978, J PHYSIOL-LONDON, V277, P29, DOI 10.1113/jphysiol.1978.sp012258; FERRINGTON DG, 1988, J NEUROPHYSIOL, V59, P886, DOI 10.1152/jn.1988.59.3.886; GELDARD FA, 1972, HUMAN SENSES, P359; GEORGOPOULOS AP, 1976, J NEUROPHYSIOL, V39, P71, DOI 10.1152/jn.1976.39.1.71; HARDY JD, 1951, SCIENCE, V114, P149, DOI 10.1126/science.114.2954.149; HELLON R, 1983, HDB PHYSL 2, P659; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES SF, 1988, PAIN, V34, P117, DOI 10.1016/0304-3959(88)90156-X; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; KURU M, 1949, SENSORY PATHS SPINAL; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; NORRSELL U, 1989, EXP BRAIN RES, V78, P369; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; STRASSMAN AM, 1993, J NEUROPHYSIOL, V70, P1811, DOI 10.1152/jn.1993.70.5.1811; SUGIURA Y, 1986, SCIENCE, V234, P358, DOI 10.1126/science.3764416; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TAYLOR DJ, 1993, SOMATOSENS MOT RES, V10, P455, DOI 10.3109/08990229309028850; THURBERG T, 1896, UPPSALA LAKFOREN FOR, V2, P489; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; Willis William D., 1985, PAIN SYSTEM; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	42	300	308	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					252	255		10.1126/science.8023144	http://dx.doi.org/10.1126/science.8023144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023144				2022-12-01	WOS:A1994NV95700042
J	OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT				OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT			PHOSPHORYLATION OF RNA-POLYMERASE-II C-TERMINAL DOMAIN AND TRANSCRIPTIONAL ELONGATION	NATURE			English	Article							TATA-BINDING PROTEIN; DROSOPHILA-MELANOGASTER; LARGEST SUBUNIT; HEAT-SHOCK; NONPHOSPHORYLATED FORM; IN-VIVO; 5' END; GENES; INITIATION; COMPLEX	THE carboxy-terminal domain (CTD) of the large subunit of RNA polymerase II is essential in vivo(1-4), and is found in either an unphosphorylated (IIa) or hyperphosphorylated (IIo) form(5,6). The Drosophila uninduced hsp70 and hsp26 genes, and the constitutively expressed beta-1 tubulin and Gapdh-2 genes, contain an RNA polymerase II complex which pauses after synthesizing a short transcript(7-10). We report here that, using an in vivo ultraviolet crosslinking technique(11) and antibodies directed against the IIa and IIo forms of the CTD12, these paused polymerases have an unphosphorylated CTD. For genes containing a 5' paused polymerase, passage of the paused RNA polymerase into an elongationally competent mode in vivo coincides with phosphorylation of the CTD. Also, the level of phosphorylation of the CTD of elongating polymerases is shown not to be related to the level of transcription, but is promoter specific.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Cornell University; Duke University								ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CADENA DL, 1987, J BIOL CHEM, V262, P12468; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR D, 1991, METHODS CELL BIOL FU, P369; HACKETT RW, 1983, NUCLEIC ACIDS RES, V11, P7011, DOI 10.1093/nar/11.20.7011; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; ROUGVIE A, 1989, THESIS CORNELL U ITH; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	24	299	300	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					75	77		10.1038/370075a0	http://dx.doi.org/10.1038/370075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015613				2022-12-01	WOS:A1994NV71100063
J	LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N				LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N			SEQA - A NEGATIVE MODULATOR OF REPLICATION INITIATION IN ESCHERICHIA-COLI	CELL			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; CHROMOSOMAL REPLICATION; DAM METHYLTRANSFERASE; FLOW-CYTOMETRY; GATC SITES; ORIGIN; METHYLATION; GENE; MEMBRANE	In E. coli, replication initiates at a genetically unique origin, oriC. Rapidly growing cells contain multiple oriC copies. Initiation occurs synchronously, once and only once per cell cycle at all origins present. Secondary initiations are prevented by a sequestration process that acts uniquely on newly replicated origins, which are marked because they are hemimethylated at GATC sites. We report the identification of a gene required for sequestration and demonstrate that this gene, seqA, also serves as a negative modulator of the primary initiation process. All previously identified in vivo initiation factors play positive roles. Thus, precise control of replication initiation may involve a balance between positive and negative elements. We suggest that SeqA might be a cooperativity factor, acting to make the replication initiation process dependent upon cooperative interactions among components.	INST CANC RES,DEPT BIOPHYS,N-0310 OSLO,NORWAY		LU, M (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM25326, GM15405] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015405, R37GM025326, R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; ATLUNG T, 1993, J BACTERIOL, V175, P6573; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1992, ANNU REV GENET, V26, P447; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYE E, 1991, RES MICROBIOL, V142, P131, DOI 10.1016/0923-2508(91)90020-B; BOYE E, 1991, J BACTERIOL, V173, P4537, DOI 10.1128/JB.173.14.4537-4539.1991; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BOYE E, 1992, DNA REPLICATION CELL, V43, P15; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1991, THESIS HARVARD U CAM; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HUGHES P, 1984, J MOL BIOL, V176, P155, DOI 10.1016/0022-2836(84)90386-3; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1992, J BIOL CHEM, V267, P2209; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KELTENBERGERGUJ.G, 1978, MOL GEN GENET, V162, P9; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kornberg A., 1991, DNA REPLICATION; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOUARN J, 1984, MOL GEN GENET, V195, P170, DOI 10.1007/BF00332741; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; Miller JH., 1972, EXPT MOL GENETICS; MORRISON DA, 1977, J BACTERIOL, V132, P349, DOI 10.1128/JB.132.1.349-351.1977; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; Radman M., 1980, PROGR ENV MUTAGENESI, P121; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RUDD KE, 1992, SHORT COURSE BACTERI; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J., 1989, MOL CLONING LAB MANU; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SINGER M, 1989, MICROBIOL REV, V53, P1; SKARSTAD K, 1983, J BACTERIOL, V154, P656, DOI 10.1128/JB.154.2.656-662.1983; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VINELLA D, 1992, J BACTERIOL, V174, P2388, DOI 10.1128/JB.174.7.2388-2390.1992; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	60	413	420	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					413	426		10.1016/0092-8674(94)90156-2	http://dx.doi.org/10.1016/0092-8674(94)90156-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8011018				2022-12-01	WOS:A1994NK97000012
J	MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB				MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB			THE SPECTRUM OF SEVERE RHEUMATIC MITRAL-VALVE DISEASE IN A DEVELOPING-COUNTRY - CORRELATIONS AMONG CLINICAL PRESENTATION, SURGICAL PATHOLOGICAL FINDINGS, AND HEMODYNAMIC SEQUELAE	ANNALS OF INTERNAL MEDICINE			English	Article							NATURAL-HISTORY; UNITED-STATES; FEVER; REGURGITATION; PENICILLIN; CARDITIS; PROLAPSE	Objective: To describe the demographic, pathologic, and hemodynamic profiles of patients with severe rheumatic mitral valve disease in a developing country and to assess their relation to uncontrolled rheumatic disease activity. Design: Retrospective, cross-sectional, cohort study. Setting: Tertiary medical center in Soweto, South Africa. Patients: 714 of 737 consecutive black patients, 4 to 73 years old, with pure mitral regurgitation, pure mitral stenosis, or mixed mitral disease who had mitral valve surgery and in whom preoperative and surgical data were concordant. Measurements: Valve lesions were evaluated on the basis of clinical, echocardiographic, hemodynamic, and surgical pathologic data. Active rheumatic carditis was diagnosed according to clinical evidence for concurrent acute rheumatic fever (Jones criteria), macroscopic appearances at surgery, and histologic findings. Results: 219 patients had pure mitral regurgitation, 275 had pure mitral stenosis, and 220 had mixed lesions. Ongoing rheumatic activity was diagnosed in 106 patients with pure regurgitation (47%) and in only 5 patients with pure stenosis (2%). Pure regurgitation was the most common lesion in the first and second decades; the relative prevalence of pure stenosis increased with age. Purely regurgitant valves had pliable, unscarred leaflets (95%), dilated mitral annuli (95%), elongated chordae tendineae (92%), and anterior leaflet prolapse (81%). In contrast, purely stenotic valves had fused leaflet commissures (100%) and rigid leaflets (38%) but no evidence of prolapse. Conclusions: The spectrum of rheumatic mitral valve disease that is hemodynamically severe in developing countries differs from that currently reported in the United States. Severe, pure rheumatic mitral regurgitation is as prevalent as pure stenosis but has an entirely different time course, surgical anatomy, and relation to disease activity, suggesting a separate pathophysiologic mechanism.	UNIV WITWATERSRAND, SCH MED, DEPT MED, JOHANNESBURG 2193, SOUTH AFRICA	University of Witwatersrand								BAILEY C P, 1956, N Y State J Med, V56, P825; BARLOW JB, 1990, S AFR MED J, V78, P181; BARLOW JB, 1975, AM HEART J, V90, P636, DOI 10.1016/0002-8703(75)90229-X; BARLOW JB, 1987, PERSPECTIVES MITRAL, P227; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; BORMAN JB, 1961, AM HEART J, V61, P763, DOI 10.1016/0002-8703(61)90460-4; BRAUNWALD E, 1988, HEART DISEASE, P1039; BULKLEY BH, 1975, AM J MED, V59, P457, DOI 10.1016/0002-9343(75)90252-1; CARPENTIER A, 1980, J THORAC CARDIOV SUR, V79, P338; CHERIAN G, 1964, BRIT HEART J, V26, P157; CHESLER E, 1966, S AFR MED J, V40, P99; Clawson BJ, 1940, AM HEART J, V20, P454, DOI 10.1016/S0002-8703(40)90878-X; DUPLESSIS LA, 1969, J THORAC CARDIOV SUR, V58, P730, DOI 10.1016/S0022-5223(19)42553-1; EDWARDS WD, 1978, CIRCULATION, V57, P181, DOI 10.1161/01.CIR.57.1.181; GORDIS L, 1969, J AMER MED ASSOC, V210, P862, DOI 10.1001/jama.210.5.862; GOTSMAN MS, 1973, THORAX, V28, P453, DOI 10.1136/thx.28.4.453; GOTSMAN MS, 1975, AM HEART J, V90, P685, DOI 10.1016/0002-8703(75)90456-1; GROSSMAN W, 1986, CARDIAC CATHETERIZAT, P364; HALL RJ, 1989, DISEASES CARDIAC VAL, P143; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; KAPLAN EL, 1988, INT J CARDIOL, V21, P3, DOI 10.1016/0167-5273(88)90003-4; Kinsley R H, 1981, Surg Annu, V13, P299; KLIBANOFF E, 1966, J AMER MED ASSOC, V195, P895, DOI 10.1001/jama.195.11.895; LEMBO NJ, 1988, CIRCULATION, V77, P830, DOI 10.1161/01.CIR.77.4.830; MARCUS R, 1989, CIRCULATION S2, V80, P507; MARCUS RH, 1989, AM J CARDIOL, V63, P577, DOI 10.1016/0002-9149(89)90902-8; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; PADMAVATI S, 1978, B WORLD HEALTH ORGAN, V56, P543; SELZER A, 1972, CIRCULATION, V45, P878, DOI 10.1161/01.CIR.45.4.878; SELZER A, 1972, MEDICINE, V51, P337, DOI 10.1097/00005792-197209000-00001; STOLLERMAN GH, 1975, RHEUMATIC FEVER STRE, P127; TOMARU T, 1987, CIRCULATION, V76, P68, DOI 10.1161/01.CIR.76.1.68; TOMPKINS DG, 1972, CIRCULATION, V45, P543, DOI 10.1161/01.CIR.45.3.543; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WHITE PD, 1951, HEART DISEASE, P670; WOOD PH, 1957, DISEASES HEART CIRCU, P517; ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077; 1965, CIRCULATION, V32, P64	39	132	134	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					177	183		10.7326/0003-4819-120-3-199402010-00001	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8043061				2022-12-01	WOS:A1994MU30300001
J	PHILLIPS, DM				PHILLIPS, DM			ENTEROCOCCUS-FAECALIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					26	26		10.1056/NEJM199501053320105	http://dx.doi.org/10.1056/NEJM199501053320105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990862				2022-12-01	WOS:A1995PZ49700005
J	JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C				JOHNSON, RL; LAUFER, E; RIDDLE, RD; TABIN, C			ECTOPIC EXPRESSION OF SONIC HEDGEHOG ALTERS DORSAL-VENTRAL PATTERNING OF SOMITES	CELL			English	Article							FLOOR PLATE; CHICK-EMBRYO; CELL PATTERN; NEURAL-TUBE; DIFFERENTIATION; NOTOCHORD; SIGNALS; GENE; MORPHOGENESIS; SPECIFICATION	Differentiation of somites into sclerotome, dermatome, and myotome is controlled by a complex set of inductive interactions. The ability of axial midline tissues, the notochord and floor plate, to induce sclerotome has been well documented and has led to models in which ventral somite identity is specified by signals derived from the notochord and floor plate. Herein, we provide evidence that Sonic hedgehog, a vertebrate homolog of the Drosophila segment polarity gene hedgehog, is a signal produced by the notochord and floor plate that directs ventral somite differentiation. Sonic hedgehog is expressed in ventral midline tissues at critical times during somite specification and has the ability, when ectopically expressed, to enhance the formation of sclerotome and antagonize the development of dermatome.			JOHNSON, RL (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				AOYAMA H, 1988, DEVELOPMENT, V104, P15; BOBER E, 1994, DEVELOPMENT, V120, P603; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; DANTO SI, 1984, J CELL BIOL, V98, P2179, DOI 10.1083/jcb.98.6.2179; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FAN CM, 1994, CELL, V79; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JACOB H J, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P581; JEFFS P, 1992, ANAT EMBRYOL, V185, P589; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	46	380	406	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1165	1173		10.1016/0092-8674(94)90008-6	http://dx.doi.org/10.1016/0092-8674(94)90008-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001152				2022-12-01	WOS:A1994PZ86000008
J	LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C				LAUFER, E; NELSON, CE; JOHNSON, RL; MORGAN, BA; TABIN, C			SONIC HEDGEHOG AND FGF-4 ACT THROUGH A SIGNALING CASCADE AND FEEDBACK LOOP TO INTEGRATE GROWTH AND PATTERNING OF THE DEVELOPING LIMB BUD	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARITY GENE HEDGEHOG; RETROVIRAL VECTORS; HOX-4 GENES; EXPRESSION; CELLS; ACTIVATION; HOMOLOG	Proper limb growth and patterning requires signals from the zone of polarizing activity in the posterior mesoderm and from the overlying apical ectodermal ridge (AER). Sonic hedgehog and Fgf-4, respectively, have recently been identified as candidates for these signals. We have dissected the roles of these secreted proteins in early limb development by ectopically regulating their activities in a number of surgical contexts. Our results indicate that Sonic hedgehog initiates expression of secondary signaling molecules, including Bmp-2 in the mesoderm and Fgf-4 in the ectoderm. The mesoderm requires ectodermally derived competence factors, which include Fgf-4, to activate target gene expression in response to Sonic hedgehog. The expression of Sonic hedgehog and Fgf-4 is coordinately regulated by a positive feedback loop operating between the posterior mesoderm and the overlying AER. Taken together, these data provide a basis for understanding the integration of growth and patterning in the developing limb.			LAUFER, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Laufer, Edward/0000-0002-4933-1017				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON R, 1993, DEVELOPMENT, V117, P1421; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIETZ M, 1995, IN PRESS DEVELOPME S; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KOYAMA E, 1993, PROG CLIN BIOL RES, V383, P51; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1993, CURR BIOL, V3, P306, DOI 10.1016/0960-9822(93)90187-S; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACCABE JA, 1979, J EMBRYOL EXP MORPH, V53, P67; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TICKLE C, 1991, DEVELOPMENT, P113; TODT WL, 1987, DEVELOPMENT, V101, P501; VOGEL A, 1993, DEVELOPMENT, V119, P199; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	48	708	730	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					993	1003		10.1016/0092-8674(94)90030-2	http://dx.doi.org/10.1016/0092-8674(94)90030-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001146				2022-12-01	WOS:A1994PY08600009
J	ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G				ZANARIA, E; MUSCATELLI, F; BARDONI, B; STROM, TM; GUIOLI, S; GUO, WW; LALLI, E; MOSER, C; WALKER, AP; MCCABE, ERB; MEITINGER, T; MONACO, AP; SASSONECORSI, P; CAMERINO, G			AN UNUSUAL MEMBER OF THE NUCLEAR HORMONE-RECEPTOR SUPERFAMILY RESPONSIBLE FOR X-LINKED ADRENAL HYPOPLASIA CONGENITA	NATURE			English	Article							COUP TRANSCRIPTION FACTOR; DNA-BINDING DOMAINS; RETINOIC ACID; GENE SUPERFAMILY; GLYCEROL KINASE; GENOMIC ORGANIZATION; EXPRESSION; CLONING; PROTEIN; XP21	X-linked adrenal hypoplasia congenita is a developmental disorder of the human adrenal gland that results in profound hormonal deficiencies and is,lethal if untreated. We have isolated the gene responsible for the disease, DAX-1, which is deleted or mutated in X-linked adrenal hypoplasia patients. DAX-1 encodes a new member of the nuclear hormone receptor superfamily displaying a novel DNA-binding domain. The DAX-1 product acts as a dominant negative regulator of transcription mediated by the retinoic acid receptor.	UNIV PAVIA,I-27100 PAVIA,ITALY; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; LMU,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ULP,CNRS,INSERM,INST GENET & BIOL MOLEC CELLULAIRE,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV SASSARI,IST ISTOL & EMBRIOL,I-07100 SASSARI,ITALY	University of Pavia; Cancer Research UK; University of Oxford; University of Munich; Baylor College of Medicine; Baylor College of Medicine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Sassari			Muscatelli, Françoise/P-4650-2016; Monaco, Anthony P/A-4495-2010; Bardoni, Barbara/F-9918-2013; Lalli, Enzo/F-7052-2013; Moser, Claudio/B-4686-2010; Walker, Ann P/C-1628-2008	Muscatelli, Françoise/0000-0003-4001-6528; Monaco, Anthony P/0000-0001-7480-3197; Lalli, Enzo/0000-0002-0584-5681; Moser, Claudio/0000-0002-9141-7850; Meitinger, Thomas/0000-0002-8838-8403; Bardoni, Barbara/0000-0001-6411-1517; Guioli, Silvana/0000-0002-4920-7745	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Kastner P., 1994, Vitamin A in health and disease., P189; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KLETTER GB, 1991, TRENDS ENDOCRIN MET, V2, P123, DOI 10.1016/1043-2760(91)90001-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU C, 1992, MOL ENDOCRIN, V7, P651; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin M.M., 1985, INT J ADOLESC MED HL, V1, P119; MATHARU PJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P331, DOI 10.1016/0167-4781(92)90512-X; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; McKusick V.A., 1992, MENDELIAN INHERITANC; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J., 1989, MOL CLONING LAB MANU; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WORLEY KC, 1992, GENOMICS, V13, P957, DOI 10.1016/0888-7543(92)90007-F; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204	45	690	719	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					635	641		10.1038/372635a0	http://dx.doi.org/10.1038/372635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990953				2022-12-01	WOS:A1994PX30700075
J	GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E				GORLICH, D; PREHN, S; LASKEY, RA; HARTMANN, E			ISOLATION OF A PROTEIN THAT IS ESSENTIAL FOR THE FIRST STEP OF NUCLEAR-PROTEIN IMPORT	CELL			English	Article							GTP-BINDING PROTEIN; 2 STEPS; SEQUENCE; PORE; TRANSLOCATION; IDENTIFICATION; LOCALIZATION; REPLICATION; ENVELOPE; SIGNALS	We have purified a cytosolic protein from Xenopus eggs that is essential for selective protein import into the cell nucleus. The purified protein, named importin, promotes signal-dependent binding of karyophilic proteins to the nuclear envelope. We have cloned, sequenced, and expressed a corresponding cDNA. Importin shows 44% sequence identity with SRP1p, a protein associated with the yeast nuclear pore complex. Complete, signal-dependent import into HeLa nuclei can be reconstituted by combining importin purified from Xenopus eggs or expressed in E. coli with Ran/TC4. Evidence for additional stimulatory factors is provided.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; HUMBOLDT UNIV BERLIN, INST BIOCHEM, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY	University of Cambridge; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Hartmann, Enno/C-5687-2013; Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUPREE P, 1992, GENE, V120, P325, DOI 10.1016/0378-1119(92)90118-9; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	33	627	635	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					767	778		10.1016/0092-8674(94)90067-1	http://dx.doi.org/10.1016/0092-8674(94)90067-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001116				2022-12-01	WOS:A1994PW05400005
J	SUN, XH				SUN, XH			CONSTITUTIVE EXPRESSION OF THE ID1 GENE IMPAIRS MOUSE B-CELL DEVELOPMENT	CELL			English	Article							NF-KAPPA-B; IMMUNOGLOBULIN LIGHT CHAIN; DNA-BINDING SUBUNIT; LOOP-HELIX PROTEINS; HEAVY-CHAIN; BONE-MARROW; TARGETED DISRUPTION; V(D)J RECOMBINATION; MEMBRANE EXON; TRANSCRIPTION	The Id proteins are inhibitors of the basic-helix-loop-helix (bHLH) transcription factors. In the B cell lineage, the Id1 and Id2 genes are expressed in pro-B cells and down-regulated during differentiation. To determine the role of bHLH proteins and the significance of downregulation of ld genes in B cell development, transgenic mice constitutively expressing the Id1 gene were generated. Their phenotype suggests that B cell development is impaired at an early stage. Primarily, these mice have few B220(+) IgM(+) mature B or B220(+) CD43(-) pre-B cells in the bone marrow, reduced frequencies of V(D)J and V(kappa)J(kappa) recombination of the immunoglobulin loci, and lower expression levels of the immunoglobulin, RAG-1, RAG-2, and lambda 5 genes.			SUN, XH (corresponding author), NYU,MED CTR,KAPLAN COMPREHENSIVE CANC CTR,DEPT CELL BIOL,NEW YORK,NY 10016, USA.							ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blackwell T. K., 1988, Molecular Immunology., P1; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HARA E, 1994, J BIOL CHEM, V269, P2139; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHAPIRO AM, 1993, MOL CELL BIOL, V13, P5679, DOI 10.1128/MCB.13.9.5679; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIN XQ, 1993, J IMMUNOL, V151, P5398; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	57	249	254	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					893	900		10.1016/0092-8674(94)90078-7	http://dx.doi.org/10.1016/0092-8674(94)90078-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001126				2022-12-01	WOS:A1994PW05400016
J	KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ				KESSLER, F; BLOBEL, G; PATEL, HA; SCHNELL, DJ			IDENTIFICATION OF 2 GTP-BINDING PROTEINS IN THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							PRECURSOR PROTEINS; SEQUENCE-ANALYSIS; ENVELOPE; LOCALIZATION; MEMBRANES; REQUIRES; PATHWAY	Two of four proteins that associated with translocation intermediates during protein import across the outer chloroplast envelope membrane were identified as guanosine triphosphate (GTP)-binding proteins. Both proteins are integral membrane proteins of the outer chloroplast membrane, and both are partially exposed on the chloroplast surface where they were accessible to thermolysin digestion. Engagement of the outer membrane's import machinery by an import substrate was inhibited by slowly hydrolyzable or non-hydrolyzable GTP analogs. Thus, these GTP-binding proteins may function in protein import into chloroplasts.	RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Rutgers State University Newark; Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rockefeller University			Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MARSTON FAO, 1987, DNA CLONING PRACTICA, V3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNELL D, UNPUB; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P100; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	22	251	264	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1035	1039		10.1126/science.7973656	http://dx.doi.org/10.1126/science.7973656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973656				2022-12-01	WOS:A1994PQ92400042
J	WARK, NC				WARK, NC			30 YEARS LATER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					497	498						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046787				2022-12-01	WOS:A1994PB22900001
J	NUDLER, E; GOLDFARB, A; KASHLEV, M				NUDLER, E; GOLDFARB, A; KASHLEV, M			DISCONTINUOUS MECHANISM OF TRANSCRIPTION ELONGATION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CLEAVAGE; DNA	During transcription elongation, three flexibly connected parts of RNA polymerase of Escherichia coli advance along the template so that the front-end domain is followed by the catalytic site which in turn is followed by the RNA product binding site. The advancing enzyme was found to maintain the same conformation throughout extended segments of the transcribed region. However, when the polymerase traveled across certain DNA sites that seemed to briefly anchor the front-end domain, cyclic shifting of the three parts, accompanied by buildup and relief of internal strain, was observed. Thus, elongation proceeded in alternating laps of monotonous and inchworm-like movement with the flexible RNA polymerase configuration being subject to direct sequence control.	PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016					Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1994, HARVEY LECTURES 88, P1; GU WG, 1993, J BIOL CHEM, V268, P25604; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LUSE DS, COMMUNICATION; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, UNPUB; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; YAGER TD, 1987, CELLULAR MOL BIOL, P1241	14	141	141	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					793	796		10.1126/science.8047884	http://dx.doi.org/10.1126/science.8047884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047884				2022-12-01	WOS:A1994PA37200036
J	NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K				NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K			THYROID-DISEASES AMONG ATOMIC-BOMB SURVIVORS IN NAGASAKI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECK IRRADIATION; HODGKINS-DISEASE; RADIATION; CARCINOMA; HEAD; CHILDHOOD; CANCER; THYROGLOBULIN; EXPOSURE; INFANCY	Objective.-To elucidate the current thyroid disease status for the Nagasaki Adult Health Study cohort of the Radiation Effects Research Foundation. Design.-Survey study. Setting.- Nagasaki, Japan. Participants.-Cohort members of the Nagasaki Adult Health Study who received biennial health examinations from October 1984 to April 1987 (n=2856). A total of 2587 subjects remained after exclusion of persons exposed in Hiroshima or in utero and those who were not in Nagasaki at the time of the bombing. Thyroid radiation dose by the dosimetry system established in 1986 was available for 1978 of the 2587 subjects. Main Outcome Measures.-Thyroid diseases were diagnosed using uniform procedures including ultrasonic scanning. The relationship of the prevalence of each thyroid disease with thyroid radiation dose, sex, and age was analyzed using logistic models. Results.-A significant dose-response relationship was observed for solid nodules, which include cancer, adenoma, adenomatous goiter, and nodules without histological diagnosis, and for antibody-positive spontaneous hypothyroidism (autoimmune hypothyroidism) but not for other diseases. The prevalence of solid nodules showed a monotonic dose-response relationship, yet that of autoimmune hypothyroidism displayed a concave dose-response relationship reaching a maximum (+/-SE) level of 0.7 +/- 0.2 Sv. Conclusions.-The present study confirmed the results of previous studies by showing a significant increase in solid nodules with dose to the thyroid and demonstrated for the first time a significant increase in autoimmune disease among atomic bomb survivors. A concave dose-response relationship indicates the necessity for further studies on the effects of relatively low doses of radiation on thyroid disease.	RADIAT EFFECTS RES FDN, NAGASAKI, JAPAN	Radiation Effects Research Foundation - Japan	NAGATAKI, S (corresponding author), NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, SAKAMOTO 1-7-1, NAGASAKI 852, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AKIBA S, 1991, 591 RAD EFF RES F RE; DEGROOT L, 1973, JAMA-J AM MED ASSOC, V225, P487, DOI 10.1001/jama.225.5.487; DIXON WJ, 1983, BMDP STATISTICAL SOF; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; HEGEDUS L, 1983, J CLIN ENDOCR METAB, V56, P260, DOI 10.1210/jcem-56-2-260; HEMPELMANN LH, 1975, J NATL CANCER I, V55, P519, DOI 10.1093/jnci/55.3.519; JOENSUU H, 1986, ACTA RADIOL ONCOL, V25, P167, DOI 10.3109/02841868609136397; JOHNSON KG, 1965, 1065 AT BOMB CAS COM; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KOTANI T, 1982, CLIN IMMUNOL IMMUNOP, V24, P111, DOI 10.1016/0090-1229(82)90094-0; LESSARD E, 1985, BNL51882 REP; MODAN B, 1974, LANCET, V1, P277; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1989, LANCET, V2, P385; NAGATAKI S, 1993, 80 YEARS HASHIMOTO D; NELDER JA, 1983, GENERALIZED LINEAR M; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; OKAJIMA S, 1990, HEALTH PHYS, V58, P591, DOI 10.1097/00004032-199005000-00004; PARKER LN, 1974, ANN INTERN MED, V80, P600, DOI 10.7326/0003-4819-80-5-600; PARKER LN, 1973, J CLIN ENDOCR METAB, V37, P797, DOI 10.1210/jcem-37-5-797; PINCUS RA, 1967, ANN INTERN MED, V66, P1154, DOI 10.7326/0003-4819-66-6-1154; PRAGER D, 1972, CANCER, V29, P458, DOI 10.1002/1097-0142(197202)29:2<458::AID-CNCR2820290232>3.0.CO;2-N; Rasmussen S N, 1974, J Clin Ultrasound, V2, P143, DOI 10.1002/jcu.1870020211; REFETOFF S, 1975, NEW ENGL J MED, V292, P171, DOI 10.1056/NEJM197501232920402; Roesch WC, 1987, US JAPAN JOINT REASS, V1; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCHNEIDER AB, 1977, ANN INTERN MED, V86, P29, DOI 10.7326/0003-4819-86-1-29; SHAFER RB, 1975, ARCH INTERN MED, V135, P843, DOI 10.1001/archinte.135.6.843; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SOCOLOW EL, 1963, NEW ENGL J MED, V268, P406, DOI 10.1056/NEJM196302212680803; TAMURA K, 1981, CANCER-AM CANCER SOC, V47, P2704, DOI 10.1002/1097-0142(19810601)47:11<2704::AID-CNCR2820471129>3.0.CO;2-G; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; YOKOYAMA N, 1986, J NUCL MED, V27, P1475	34	109	112	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					364	370		10.1001/jama.272.5.364	http://dx.doi.org/10.1001/jama.272.5.364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028167				2022-12-01	WOS:A1994NY90300028
J	SIMOONS, ML				SIMOONS, ML			MYOCARDIAL-INFARCTION - ACE-INHIBITORS FOR ALL - FOR EVER	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; CAPTOPRIL; THERAPY; ENALAPRIL; REPERFUSION; DILATATION; TRIAL				SIMOONS, ML (corresponding author), ERASMUS UNIV ROTTERDAM,THORAXCTR,3000 DR ROTTERDAM,NETHERLANDS.							Acute Infarction Ramipril Efficacy (AIRE) Study Inves- tigators, 1993, LANCET, V342, P821; BALL SG, 1994, LANCET, V343, P1632, DOI 10.1016/S0140-6736(94)93083-X; BONARJEE VVS, 1993, AM J CARDIOL, V72, P1004, DOI 10.1016/0002-9149(93)90853-5; DEGRAEFF PA, 1987, J CARDIOVASC PHARM, V9, pS37, DOI 10.1097/00005344-198700002-00009; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; HOCK CE, 1985, AM HEART J, V109, P222, DOI 10.1016/0002-8703(85)90587-3; KINGMA JH, IN PRESS EUR HEART J; KINGMA JH, 1989, CURRENT ADV ACE INHI, P291; NABEL EG, 1991, J AM COLL CARDIOL, V17, P467, DOI 10.1016/S0735-1097(10)80117-2; OLDROYD KG, 1991, AM J CARDIOL, V68, P713, DOI 10.1016/0002-9149(91)90641-W; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1992, NEW ENGL J MED, V327, P369; SCHOEMAKER RG, 1991, J MOL CELL CARDIOL, V23, P187, DOI 10.1016/0022-2828(91)90105-U; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SIGURDSSON A, 1991, INT J CARDIOL, V33, P115, DOI 10.1016/0167-5273(91)90159-M; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TOGNONI G, 1994, LANCET, V343, P1633; VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429; 1991, AM J CARDIOL, V68, pD87	23	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					279	281		10.1016/S0140-6736(94)91333-1	http://dx.doi.org/10.1016/S0140-6736(94)91333-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7980780	Green Submitted			2022-12-01	WOS:A1994NZ23300002
J	CARRIER, DR; HEGLUND, NC; EARLS, KD				CARRIER, DR; HEGLUND, NC; EARLS, KD			VARIABLE GEARING DURING LOCOMOTION IN THE HUMAN MUSCULOSKELETAL SYSTEM	SCIENCE			English	Article							MUSCLE; FOOT	Human feet and toes provide a mechanism for changing the gear ratio of the ankle extensor muscles during a running step. A variable gear ratio could enhance muscle performance during constant-speed running by applying a more effective prestretch during landing, while maintaining the muscles near the high-efficiency or high-power portion of the force-velocity curve during takeoff. Furthermore, during acceleration, variable gearing may allow muscle contractile properties to remain optimized despite rapid changes in running speed. Forceplate and kinematic analyses of running steps show low gear ratios at touchdown that increase throughout the contact phase.	PHAROS SYST INC, S CHELMSFORD, MA 01824 USA		CARRIER, DR (corresponding author), BROWN UNIV, DEPT ECOL & EVOLUTIONARY BIOL, PROVIDENCE, RI 02912 USA.							ALEXANDER RMN, 1977, J ZOOL, V183, P125, DOI 10.1111/j.1469-7998.1977.tb04177.x; [Anonymous], 1982, ANAL VERTEBRATE STRU; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1993, J BIOMECH, V26, P294; CARRIER DR, 1983, J ZOOL, V201, P27; CARRIER DR, 1980, AM ZOOL, V20, P895; CAVAGNA GA, 1986, AM J PHYSIOL, V251, pC571, DOI 10.1152/ajpcell.1986.251.4.C571; COATES MI, 1990, NATURE, V347, P66, DOI 10.1038/347066a0; GANS C, 1991, J BIOMECH, V24, P53, DOI 10.1016/0021-9290(91)90377-Y; HAYASHI T, 1987, BIOMECHANICS A, V7, P203; HENNIG EM, 1982, J BIOMED ENG, V4, P213, DOI 10.1016/0141-5425(82)90005-X; HILDEBRAND M, 1982, ANAL VERTEBRATE STRU, P417; Hill A. V., 1950, Science Progress London, V38, P209; LORD M, 1986, J BIOMED ENG, V8, P283, DOI 10.1016/0141-5425(86)90060-9; NALBACH G, 1989, J COMP PHYSIOL A, V165, P321, DOI 10.1007/BF00619351; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; Schaeffer Bobb, 1947, AMER MUS NOVITATES, V1356, P1; WISSER A, 1988, ZOOMORPHOLOGY, V107, P359, DOI 10.1007/BF00312219	18	129	131	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					651	653		10.1126/science.8036513	http://dx.doi.org/10.1126/science.8036513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036513				2022-12-01	WOS:A1994NZ53800030
J	KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL				KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL			INCREASING PREVALENCE OF OVERWEIGHT AMONG US ADULTS - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS, 1960 TO 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; UNITED-STATES ADULTS; WEIGHT-LOSS; ANTHROPOMETRIC MEASUREMENTS; SOCIOECONOMIC-FACTORS; SKINFOLD THICKNESS; SECULAR TRENDS; RISK-FACTORS; OBESITY; WOMEN	Objective.-To examine trends in overweight prevalence and body mass index of the US adult population. Design.-Nationally representative cross-sectional surveys with an in-person interview and a medical examination, including measurement of height and weight. Setting/Participants.-Between 6000 and 13000 adults aged 20 through 74 years examined in each of four separate national surveys during 1960 to 1962 (the first National Health Examination Survey [NHES I]), 1971 to 1974 (the first National Health and Nutrition Examination Survey [NHANES I]), 1976 to 1980 (NHANES II), and 1988 to 1991 (NHANES III phase 1). Results.-In the period 1988 to 1991, 33.4% of US adults 20 years of age or older were estimated to be overweight. Comparisons of the 1988 to 1991 overweight prevalence estimates with data from earlier surveys indicate dramatic increases in all race/sex groups. Overweight prevalence increased 8% between the 1976 to 1980 and 1988 to 1991 surveys. During this period, for adult men and women aged 20 through 74 years, mean body mass index increased from 25.3 to 26.3; mean body weight increased 3.6 kg. Conclusions.-These nationally representative data document a substantial increase in overweight among US adults and support the findings of other investigations that show notable increases in overweight during the past decade. These observations suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000. Understanding the reasons underlying the increase in the prevalence of overweight in the United States and elucidating the potential consequences in terms of morbidity and mortality present a challenge to our understanding of the, etiology, treatment, and prevention of overweight.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH EXAMINAT STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)			Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BEGLEY CE, 1991, J AM DIET ASSOC, V91, P1255; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; CHUMLEA WC, 1990, AM J CLIN NUTR, V51, pS902, DOI 10.1093/ajcn/51.5.902; CHUNG CS, 1992, AM J PUBLIC HEALTH, V82, P1544, DOI 10.2105/AJPH.82.11.1544; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; Emery E M, 1993, Am J Health Promot, V7, P342; EZZATI RM, 1992, VITAL HLTH STAT 113, V2; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P544, DOI 10.1093/ajcn/48.3.544; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P535, DOI 10.1093/ajcn/48.3.535; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; FULWOOD R, 1981, VITAL HLTH STAT 224, V11; GOODRICK GK, 1991, J AM DIET ASSOC, V91, P1243; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JARRETT RJ, 1986, BRIT MED J, V293, P493, DOI 10.1136/bmj.293.6545.493; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1990, ANTHROPOMETRIC ASSES; KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8; KUMANYIKA SK, 1991, ETHNIC DIS, V2, P166; KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; LEVY BT, 1988, J FAM PRACTICE, V27, P285; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lohman TG, 1988, ANTROPOMETRIC STANDA; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; MAURER KR, 1985, VITAL HLTH STAT 19, V1; MCARTOR RE, 1992, INT J OBESITY, V16, P335; MCDOWELL A, 1981, VITAL HLTH STAT 15, V1; MCGINNIS JM, 1992, MED SCI SPORT EXER, V24, pS196; NAJJAR MF, 1989, VITAL HLTH STAT 239, V11; NAJJAR MF, 1987, VITAL HLTH STAT 238, V11; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PETITTI DB, 1988, AM J PREV MED, V4, P327, DOI 10.1016/S0749-3797(18)31141-3; PIANI A, 1993, VITAL HLTH STAT 185, V10; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PISUNYER FX, 1992, ANN INTERN MED, V55, pS503; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHOENBORN CA, 1987, EVAL HEALTH PROF, V10, P438, DOI 10.1177/016327878701000405; SCHOENBORN CA, 1988, VITAL HLTH STAT 163, V10; SEIDELL JC, 1992, INT J OBESITY, V16, pS31; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; SHAH BV, 1991, SUDAAN USERS MANUAL; SHAH M, 1991, INT J OBESITY, V15, P499; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STOUDT HW, 1965, VITAL HLTH STAT 8, V11; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEIGLE DS, 1990, WESTERN J MED, V153, P421; White A, 1993, HLTH SURVEY ENGLAND; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; 1973, VITAL HLTH STAT 10, V1; 1993, MMWR-MORBID MORTAL W, V42, P576; 1993, NIH931088 NAT HEART; 1990, SAS STAT USERS GUIDE; 1965, VITAL HLTH STAT 4, V1; 1981, PC801B1 US DEP COMM, V1, pCHB; [No title captured]; 1990, PHS9050212 US DEP HL	64	2144	2180	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					205	211		10.1001/jama.272.3.205	http://dx.doi.org/10.1001/jama.272.3.205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022039				2022-12-01	WOS:A1994NW18500021
J	REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY				REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY			ACTIVATION OF THE CLONED MUSCARINIC POTASSIUM CHANNEL BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							COUPLED RECEPTOR KINASES; K+-CHANNEL; ION CHANNELS; MECHANISM; EXPRESSION; ALPHA; CLONING; CYCLASE; HEART	ACETYLCHOLINE released during parasympathetic stimulation of the vagal nerve slows the heart rate through the activation of muscarinic receptors and subsequent opening of an inwardly rectifying potassium channel(1) The activation of these muscarinic potassium channels is mediated by a pertussis toxin-sensitive heterotrimeric GTP-binding protein (G protein)(2,3). It has not been resolved whether exogenously applied G(alpha)(4,5) or G(beta gamma)(6,7), Or both, activate the channel. Using a heterologous expression system, we have tested the ability of different G protein subunits to activate the cloned muscarinic potassium channel, GIRK1(8,9). We report here that coexpression of GIRK1 with G(beta gamma) but not G(alpha beta gamma) in Xenopus oocytes results in channel activity that persists in the absence of cytoplasmic GTP. This activity is reduced by fusion proteins of the beta-adrenergic receptor kinase and of recombinant G(alpha i)-GDP, both of which are known to interact with G(beta gamma)(10,11). Moreover, application of recombinant G(beta gamma), but not G(alpha i)-GTP-gamma S, activates GIRK1 channels. Thus G(beta gamma) appears to be sufficient for the activation of GIRK1 muscarinic potassium channels.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	REUVENY, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143, USA.		Lefkowitz, Robert/AAW-2649-2021	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Iniguez-Lluhi, Jorge/0000-0001-7010-089X				BIRNBAUMER L, 1987, NATURE, V327, P21, DOI 10.1038/327021a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1991, J GEN PHYSIOL, V97, P1279, DOI 10.1085/jgp.97.6.1279; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	432	443	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					143	146		10.1038/370143a0	http://dx.doi.org/10.1038/370143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022483				2022-12-01	WOS:A1994NW80400058
J	JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG				JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG			FACTORS IN CHILDHOOD AS PREDICTORS OF ASTHMA IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							NATURAL-HISTORY; DISEASE; AGE; FOLLOW; BIRTH	Objective-To determine which factors measured in childhood predict asthma in adult life. Design-Prospective study over 25 years of a birth cohort initially studied at the age of 7. Setting-Tasmania, Australia. Subjects-1494 men and women surveyed in 1991-3 when aged 29 to 32 (75% of a random stratified sample from the 1968 Tasmanian asthma survey of children born in 1961 and at school in Tasmania). Main outcome measures-Self reported asthma or wheezy breathing in the previous 12 months (current asthma). Result-Of the subjects with asthma or wheezy breathing by the age of 7, as reported by their parents 25.6% (190/741) reported current asthma as an adult compared with 10.8% (81/753) of subjects without parent reported childhood asthma (P<0.001). Factors measured at the age of 7 that independently predicted current asthma as an adult were being female (odds ratio 1.57; 95% confidence interval 1.19 to 2.08); having a history of eczema (1.45; 1.04 to 2.03); having a low mild forced expiratory flow rate (interquartile odds ratio 1.40; 1.15 to 1.71); having a mother or father with a history of asthma (1.74 (1.23 to 2.47) and 1.68 (1.18 to 2.38) respectively); and having childhood asthma (1.59; 1.10 to 2.29) and, if so, having the first attack after the age of 2 (1.66; 1.17 to 2.36) or having had more than 10 attacks (1.70; 1.17 to 2.48). Conclusion-Children with asthma reported by their parents in 1968 were more likely than not to be free of symptoms as adults. The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult. These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies, and understanding the onset of asthma in adult life.	UNIV MELBOURNE,DEPT PUBL HLTH & COMMUNITY MED,CARLTON,VIC 3053,AUSTRALIA; ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,CTR ADOLESCENT HLTH,PARKVILLE,VIC 3052,AUSTRALIA; ANTICANC COUNCIL VICTORIA,CTR CANC EPIDEMIOL,CARLTON,VIC 3053,AUSTRALIA	University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Jenkins, Mark/P-7803-2015; Carlin, John/AAG-4332-2020; Carlin, John B/B-3492-2012	Jenkins, Mark/0000-0002-8964-6160; Carlin, John/0000-0002-2694-9463; Carlin, John B/0000-0002-2694-9463; Giles, Graham/0000-0003-4946-9099; Flander, Louisa/0000-0003-0824-9364				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BAKER RJ, 1978, GLIM SYSTEM; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURR ML, 1993, MONOGR ALLERGY, V31, P80; DAY NE, 1976, TISSUE ANTIGENS, V8, P109; FLANDER LB, 1983, 111TH P ANN M AM PUB, P181; GIBSON T, 1969, J BIOMECH, V2, P201, DOI 10.1016/0021-9290(69)90032-3; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; HOSMER DW, 1980, APPLIED LOGISTIC REG; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KENDALL MG, 1973, ADV THEORY STAT, V2, P231; PETO J, 1980, BANBURY REPORT, V4, P203; PHELAN PD, 1982, RESPIRATORY ILLNESS; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; STECENKO AA, 1991, AM REV RESPIR DIS, V144, P1008, DOI 10.1164/ajrccm/144.5.1008; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012	23	188	195	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					90	93		10.1136/bmj.309.6947.90	http://dx.doi.org/10.1136/bmj.309.6947.90			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038673	Green Published			2022-12-01	WOS:A1994NW71600016
J	DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS				DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS			AN EYE-SPECIFIC G-BETA SUBUNIT ESSENTIAL FOR TERMINATION OF THE PHOTOTRANSDUCTION CASCADE	NATURE			English	Article							PROTEIN-KINASE-C; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; ADENYLYL CYCLASE; ALPHA-SUBUNITS; RECEPTORS; TRANSDUCTION; ASSOCIATION	HETEROTRIMERIC G proteins couple various receptors to intracellular effector molecules. Although the role of the G alpha subunit in effector activation, guanine nucleotide exchange and GTP hydrolysis has been well studied(1-4), the cellular functions of the G beta subunits are less well understood(5,6). G beta gamma dimers bind G alpha subunits and anchor them to the membrane for presentation to the receptor(7,9). Tn specific systems, the G beta subunits have also been implicated in direct coupling to ion channels and to effector molecules(10-19). We have isolated Drosophila melanogaster mutants defective in an eye-specific G-protein beta-subunit (G beta e), and show here that the beta-subunit is essential for G-protein-receptor coupling in vivo. Remarkably, G beta mutants are also severely defective in the deactivation of the light response, demonstrating an essential role for the G beta subunit in terminating the active state of this signalling cascade.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Washington; University of Washington Seattle					NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	33	52	53	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					59	61		10.1038/370059a0	http://dx.doi.org/10.1038/370059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015606				2022-12-01	WOS:A1994NV71100058
J	LINDENSTROM, E; BOYSEN, G; NYBOE, J				LINDENSTROM, E; BOYSEN, G; NYBOE, J			INFLUENCE OF TOTAL CHOLESTEROL, HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDES ON RISK OF CEREBROVASCULAR-DISEASE - THE COPENHAGEN CITY HEART-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; FOLLOW-UP; CEREBRAL INFARCTION; STROKE INCIDENCE; CORONARY; MEN; FRAMINGHAM; DENMARK; JAPAN	Objective-To estimate the influence of plasma total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease. Design-The Copenhagen city heart study is a prospective observational survey with two cardiovascular examinations at five year intervals. Non-fasting plasma lipids were measured in participants once at each examination, along with other variables. The Cox regression model was used to establish the effect of the factors recorded on cerebrovascular events of mostly, but not exclusively, ischaemic origin. Subjects-19 698 women and men at least 20 years old, randomly selected after age stratification from an area of central Copenhagen. Main outcome measures-Initial cases of stroke and transient ischaemic attack recorded from hospital records and death certificates from 1976 through 1988. Results-660 non-haemorrhagic and 33 haemorrhagic events were recorded. Total cholesterol was positively associated with risk of non-haemorrhagic events, but only for levels > 8 mmol/l, corresponding to the upper 5% of the distribution in the study population. For lower plasma cholesterol values the relative risk remained nearly constant. Plasma triglyceride concentration was significantly, positively associated with risk of non-haemorrhagic events. The relative risk corresponding to an increase of 1 mmol/l was 1.12 (95% confidence interval 1.07 to 1.16). There was a negative, log linear association between high density lipoprotein cholesterol and risk of non-haemorrhagic events (0.53 (0.34 to 0.83)). There was no indication that the effects of plasma lipids were different in women and men. Conclusions-The pattern of the association between plasma cholesterol and risk of ischaemic cerebrovascular disease was not log linear, and the increased risk was confined to the upper 5% of the cholesterol distribution. Further studies should concentrate on the association between plasma cholesterol and verified haemorrhagic stroke.	RIGSHOSP, COPENHAGEN CITY HEART STUDY, DK-2200 COPENHAGEN N, DENMARK	Rigshospitalet	LINDENSTROM, E (corresponding author), HVIDOVRE UNIV HOSP, DEPT NEUROL, 433, KETTEGARDS ALLE 30, DK-2650 HVIDOVRE, DENMARK.							Appleyard M., 1989, SCAND J SOC MED, V41, P1; ARONOW WS, 1988, ANGIOLOGY, V39, P563, DOI 10.1177/000331978803900701; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P73; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; Gatchev O, 1993, Ann Epidemiol, V3, P403, DOI 10.1016/1047-2797(93)90068-F; GERTLER MM, 1968, GERIATRICS, V23, P135; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JAKOBSON T, 1967, ACTA MED SCAND, V182, P233; JENSEN G, 1983, ACTA MED SCAND S682, V214, P18; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1976, CEREBRAL ARTERIAL DI, P1; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P37, DOI 10.1159/000110297; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P43, DOI 10.1159/000110298; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MEYER JS, 1959, ARCH NEUROL-CHICAGO, V1, P303, DOI 10.1001/archneur.1959.03840030061006; MUI K, 1989, Osaka City Medical Journal, V35, P145; MURAI A, 1981, STROKE, V12, P167, DOI 10.1161/01.STR.12.2.167; NUBIOLA AR, 1981, ARCH NEUROL-CHICAGO, V38, P468, DOI 10.1001/archneur.1981.00510070102026; PATERSON J C, 1960, Can Med Assoc J, V82, P6; PRENTICE RL, 1982, BIOMETRIKA, V69, P331, DOI 10.2307/2335407; QUIZIBLASH N, 1991, BRIT MED J, V303, P605; QUIZIBLASH N, 1992, CEREBROVASC DIS, V2, P127; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROBINSON RW, 1963, ANN INTERN MED, V59, P180, DOI 10.7326/0003-4819-59-2-180; ROSSNER S, 1978, LANCET, V1, P577; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SIDHARAM R, 1992, NEUROEPIDEMIOLOGY, V11, P24; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STOKES J, 1987, CIRCULATION, V75, P65; STRACHAN D, 1991, J CLIN EPIDEMIOL, V44, P1187, DOI 10.1016/0895-4356(91)90151-X; TAGGART H, 1979, EUR J CLIN INVEST, V9, P219, DOI 10.1111/j.1365-2362.1979.tb00926.x; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILHELMSEN L, 1990, CLIN EXP HYPERTENS A, V12, P845, DOI 10.3109/10641969009073504; Wolf P A, 1978, Adv Neurol, V19, P107; WOLF PA, 1986, SEMIN NEUROL, V6, P243, DOI 10.1055/s-2008-1041467; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YATSU FM, 1989, ANN NEUROL, V26, P3, DOI 10.1002/ana.410260102	51	275	290	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					11	15		10.1136/bmj.309.6946.11	http://dx.doi.org/10.1136/bmj.309.6946.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044059	Green Published			2022-12-01	WOS:A1994NV89100013
J	KURAHASHI, T; LOWE, G; GOLD, GH				KURAHASHI, T; LOWE, G; GOLD, GH			SUPPRESSION OF ODORANT RESPONSES BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	SCIENCE			English	Article							NUCLEOTIDE-GATED CONDUCTANCE; SENSITIVE ADENYLATE-CYCLASE; ADAPTIVE PROPERTIES; TRANSDUCTION; CHANNELS; NEURONS; SALAMANDER; MEMBRANE; CILIA; ACTIVATION	Odorants activate an inward current in vertebrate olfactory receptor cells. Here it is shown, in receptor cells from the newt, that odorants can also suppress this current, by a mechanism that is distinct from inhibition and adaptation. Suppression provides a simple explanation for two seemingly unrelated phenomena: the anomalously long latency of olfactory transduction and the existence of an ''off response'' at the end of a prolonged stimulus. Suppression may influence the perception of odorants by masking odorant responses and by sharpening the odorant specificities of single cells.	MONELL CHEM SENSES CTR,PHILADELPHIA,PA 19104	Monell Chemical Senses Center								ANHOLT RRH, 1987, BIOCHEMISTRY-US, V26, P788, DOI 10.1021/bi00377a020; ARZT AH, 1986, J COMP PHYSIOL A, V158, P479, DOI 10.1007/BF00603794; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAIN WS, 1975, CHEM SENS FLAV, V1, P339, DOI 10.1093/chemse/1.3.339; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GESTELAND RC, 1965, J PHYSIOL-LONDON, V181, P525, DOI 10.1113/jphysiol.1965.sp007781; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P521, DOI 10.1113/jphysiol.1978.sp012479; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1993, NEURON, V11, P123, DOI 10.1016/0896-6273(93)90276-W; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; KURAHASHI T, 1989, ZOOL SCI, V6, P19; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; MENINI A, 1993, J PHYSIOL-LONDON, V468, P1; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SHIBUYA TATSUAKI, 1960, JAPANESE JOUR PHYSIOL, V10, P317; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1989, CHEM SENSES, V1, P469; TAKAGI SADAYUKI F., 1960, JAPANESE JOUR PHYSIOL, V10, P385; TAKAGI SF, 1959, NATURE, V184, P60, DOI 10.1038/184060a0; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	46	88	88	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					118	120		10.1126/science.8016645	http://dx.doi.org/10.1126/science.8016645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016645				2022-12-01	WOS:A1994NV30100040
J	KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P				KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P			MODERATE ALCOHOL-CONSUMPTION AND LOSS OF CEREBELLAR PURKINJE-CELLS	BRITISH MEDICAL JOURNAL			English	Article							BRAIN ATROPHY; DRINKING; VALIDITY; AUTOPSY; DEGENERATION; NEURONS; LESIONS; DAMAGE; DEATH	Objective-To examine the dose-response effect of alcohol consumption on the number of cerebellar Purkinje cells. Design-A prospective necropsy study combined with detailed reports on use of alcohol from a relative or friend. The number of Purkinje cells was counted in the anterior midsagittal section of the cerebellar vermis, the area of which was measured by computer assisted morphometry. Setting-Department of forensic medicine, University of Helsinki. Subjects-66 men, aged 35 to 69 years, subjected to medicolegal necropsy because of sudden or violent death. The average all year daily alcohol consumption over the year was 0 to 10 g in 17 men, 11 to 80 g in 24 men, and more than 80 g in 25 men. Main outcome measures-Number of Purkinje cells, alcohol consumption. Results-The numbers and density of Purkinje cells in the cross section of vermis showed a consistent but weak decrease with increasing daily alcohol intake but not with age. A wide variation in the cell counts was observed, especially in men drinking more than 80 g, suggesting differences in the susceptibility to effects of alcohol. Compared with men drinking 40 g or less, a long term moderate consumption of an average of 41 to 80 g daily was associated with a significant average loss of 242 (95% confidence interval 45 to 439) Purkinje cells (15.2%) from a mean of 1583 to 1341 cells. In those drinking 81 to 180 g the average loss was 535 (259 to 811) cells (33.4%) to a mean of 1048 cells. The density of cells in the cross section of vermis also fell significantly by 0.9 cell/mm (0.1 to 1.7) when the daily consumption exceeded 40 g and by 1.4 cell/mm (0.3 to 2.5) when the intake was 81 to 180 g. Only three cases (4.5%); in the series showed macroscopical cerebellar atrophy. Conclusion-Long term intake of moderate doses of alcohol daily for 20-30 years may damage the cerebellum before the onset of macroscopical atrophy. Despite distinct individual differences an all year average daily alcohol intake of 41-80 g results in a risk of significant loss of Purkinje cells.	UNIV HELSINKI,DEPT FORENS MED,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,DEPT NEUROL,MED RES UNIT,HELSINKI,FINLAND	University of Helsinki; University of Helsinki	KARHUNEN, PJ (corresponding author), UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,PL 607,SF-33101 TAMPERE,FINLAND.							ACKER W, 1982, J NEUROL NEUROSUR PS, V45, P984, DOI 10.1136/jnnp.45.11.984; ALTERMAN AI, 1989, ALCOHOL CLIN EXP RES, V13, P799, DOI 10.1111/j.1530-0277.1989.tb00425.x; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; CALA LA, 1978, AUST NZ J MED, V8, P147, DOI 10.1111/j.1445-5994.1978.tb04502.x; ESTRIN WJ, 1987, ALCOHOL CLIN EXP RES, V11, P372, DOI 10.1111/j.1530-0277.1987.tb01327.x; FULLER RK, 1988, ALCOHOL CLIN EXP RES, V12, P201, DOI 10.1111/j.1530-0277.1988.tb00180.x; GURLING HMD, 1991, BRIT J ADDICT, V86, P151; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1988, J NEUROL NEUROSUR PS, V51, P909, DOI 10.1136/jnnp.51.7.909; HILLBOM M, 1986, J NEUROL SCI, V73, P45, DOI 10.1016/0022-510X(86)90062-6; KARHUNEN PJ, 1990, ALCOHOL ALCOHOLISM, V25, P25; KERR JT, 1989, ALCOHOL CLIN EXP RES, V13, P730, DOI 10.1111/j.1530-0277.1989.tb00412.x; MIDANIK LT, 1989, BRIT J ADDICT, V84, P1419; MUURONEN A, 1989, ALCOHOL CLIN EXP RES, V13, P137, DOI 10.1111/j.1530-0277.1989.tb00298.x; PHILLIPS SC, 1987, BRAIN, V110, P301, DOI 10.1093/brain/110.2.301; SAVOLAINEN VT, 1992, ALCOHOL CLIN EXP RES, V16, P661, DOI 10.1111/j.1530-0277.1992.tb00655.x; SAVOLAINEN VT, 1993, ALCOHOL CLIN EXP RES, V17, P1112, DOI 10.1111/j.1530-0277.1993.tb05673.x; SKULLERUD K, 1991, INT J LEGAL MED, V104, P209, DOI 10.1007/BF01369809; SORENSEN TIA, 1989, LIVER, V9, P189; SUN GY, 1985, ALCOHOLISM CLIN EXP, V9, P95; TAVARES MA, 1987, ALCOHOL CLIN EXP RES, V11, P315, DOI 10.1111/j.1530-0277.1987.tb01315.x; THOMSON AD, 1988, HUM TOXICOL, V7, P455, DOI 10.1177/096032718800700513; TORVIK A, 1986, J NEUROL SCI, V75, P43, DOI 10.1016/0022-510X(86)90049-3; TORVIK A, 1982, J NEUROL SCI, V56, P233, DOI 10.1016/0022-510X(82)90145-9; VICTOR M, 1959, ARCH NEUROL-CHICAGO, V1, P579, DOI 10.1001/archneur.1959.03840060001001; VICTOR M, 1978, ADV NEUROLOGY; WATSON CG, 1984, J STUD ALCOHOL, V45, P344, DOI 10.15288/jsa.1984.45.344; 1987, MED CONSEQUENCES ALC, P125	28	76	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1663	1667		10.1136/bmj.308.6945.1663	http://dx.doi.org/10.1136/bmj.308.6945.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU483	8025457	Green Published			2022-12-01	WOS:A1994NU48300016
J	PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ				PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ			CHANGING PREVALENCE OF ASTHMA IN AUSTRALIAN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; SCHOOLCHILDREN; CHILDHOOD; POPULATION; ALLERGENS; ATOPY; EXPOSURE	Objective-To investigate whether prevalence of asthma in children increased in 10 years. Design-Serial cross sectional studies of two populations of children by means of standard protocol. Setting-Two towns in New South Wales: Belmont (coastal and humid) and Wagga Wagga (inland and dry). Subjects-Children aged 8-10 years: 718 in Belmont and 769 in Wagga Wagga in 1982; 873 in Belmont and 795 in Wagga Wagga in 1992. Main outcome measures-History of respiratory illness recorded by parents in self administered questionnaire; airway hyperresponsiveness by histamine inhalation test; atopy by skin prick tests; counts of house dust mites in domestic dust. Results-Prevalence of wheeze in previous 12 months increased in Belmont, from 10.4% (75/718) in 1982 to 27.6% (240/873) in 1992 (P<0.001), and in Wagga Wagga, from 15.5% (119/769) to 23.1% (183/795) (P<0.001). The prevalence of airway hyperresponsiveness increased twofold in Belmont to 19.8% (173/873) (P<0.001) and 1.4-fold in Wagga Wagga to 18.1% (P<0.05). The prevalence of airway hyperresponsiveness increased mainly in atopic children only, but the prevalence of atopy was unchanged (about 28.5% in Belmont and about 32.5% in Wagga Wagga). Numbers of house dust mites increased 5.5-fold in Belmont and 4.5-fold in Wagga Wagga. Conclusions-We suggest that exposure to higher allergen levels has increased airway abnormalities in atopic children or that mechanisms that protected airways of earlier generations of children have been altered by new environmental factors.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; ROYAL PRINCE ALFRED HOSP, INST RESP MED, ALLEN & HANBURYS EPIDEMIOL UNIT, SYDNEY, NSW 2050, AUSTRALIA; WESTMEAD HOSP, DEPT COMMUNITY MED, WESTMEAD, NSW 2145, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FEATHER IH, 1993, THORAX, V48, P5, DOI 10.1136/thx.48.1.5; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GREEN WF, 1978, CLIN ALLERGY, V8, P135, DOI 10.1111/j.1365-2222.1978.tb00458.x; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1992, SEARCH, V23, P252; PEAT JK, 1994, IN PRESS EUR RESPIR; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; WOOLCOCK AJ, 1991, EUR RESPIR REV, V1, P243; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1985, SAS USERS GUIDE STAT	37	424	427	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	1994	308	6944					1591	1596		10.1136/bmj.308.6944.1591	http://dx.doi.org/10.1136/bmj.308.6944.1591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025424	Green Published			2022-12-01	WOS:A1994NT52800015
J	TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T				TANAKA, N; ISHIHARA, M; KITAGAWA, M; HARADA, H; KIMURA, T; MATSUYAMA, T; LAMPHIER, MS; AIZAWA, S; MAK, TW; TANIGUCHI, T			CELLULAR COMMITMENT TO ONCOGENE-INDUCED TRANSFORMATION OR APOPTOSIS IS DEPENDENT ON THE TRANSCRIPTION FACTOR IRF-1	CELL			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; IFN-INDUCIBLE GENES; INTERFERON SYSTEM; PROTEIN-KINASE; P53 GENE; MALIGNANT TRANSFORMATION; MYELOGENOUS LEUKEMIA	The transcriptional activator interferon regulatory factor 1 (IRF-1) and its antagonistic repressor IRF-2 are regulators of the interferon (IFN) system and of cell growth. Here we report that embryonic fibroblasts (EFs) from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice) can be transformed by expression of an activated c-Ha-ras oncogene. This property is not observed in EFs from wild-type or IRF-2(-/-) mice but is still observed in EFs from mice deficient in both genes. The transformed phenotype of ras-expressing IRF-1(-/-) EFs could be suppressed by the expression of the IRF-1 cDNA. Thus, IRF-1 functions as a tumor suppressor. Furthermore, expression of the c-Ha-ras oncogene causes wild-type but not IRF-1(-/-) EFs to undergo apoptosis when combined with a block to cell proliferation or treated by anticancer drugs or ionizing radiation. Hence, IRF-1 may be a critical determinant of oncogene-induced cell transformation or apoptosis.	UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL & MED BIOPHYS,AMGEN INST,TORONTO M4X 1K9,ON,CANADA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; RIKEN	TANAKA, N (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Harada, Hisashi/H-2815-2019	Kitagawa, Motoo/0000-0003-1036-840X; Harada, Hisashi/0000-0001-5993-1289; Kimura, Tohru/0000-0001-9227-0996; Tanaka, Nobuyuki/0000-0002-6373-2220				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BOS JL, 1989, CANCER RES, V49, P4682; BOULTWOOD J, 1993, BLOOD, V82, P2611; Carter Graham, 1992, Critical Reviews in Oncogenesis, V3, P339; CLRKE AR, 1993, NATURE, V362, P849; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demaeyer E., 1988, INTERFERONS OTHER RE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENAUX P, 1991, BLOOD, V78, P1652; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KASTAN MB, 1991, CANCER RES, V51, P6304; KERIM S, 1990, LEUKEMIA, V4, P12; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBEAU MM, 1992, CANCER SURV, V15, P143; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA T, 1993, WATA, V75, P83; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA K, 1975, CELL, V5, P131, DOI 10.1016/0092-8674(75)90021-5; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFNER H, 1993, P NATL ACAD SCI USA, V90, P11503; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shin S, 1979, Methods Enzymol, V58, P370; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; SUGIMOTO K, 1993, BLOOD, V81, P3022; SUGIMOTO K, 1991, BLOOD, V77, P1153; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VOGELSTEIN B, 1992, CELL, V70, P623; WATANABE N, CELL, V83, P93; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1990, P NATL ACAD SCI USA, V88, P532; YAMAMOTO H, 1994, IN PRESS ONCOGENE; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YOSHIDA K, 1988, CANCER RES, V48, P5503; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	92	473	486	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					829	839		10.1016/0092-8674(94)90132-5	http://dx.doi.org/10.1016/0092-8674(94)90132-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004672				2022-12-01	WOS:A1994NT33100008
J	WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J				WHITE, RH; MCKITTRICK, T; HUTCHINSON, R; TWITCHELL, J			TEMPORARY DISCONTINUATION OF WARFARIN THERAPY - CHANGES IN THE INTERNATIONAL NORMALIZED RATION	ANNALS OF INTERNAL MEDICINE			English	Note							ANTICOAGULANT-THERAPY; SURGERY; OPERATIONS	Objective: To measure the rate of decrease of the international normalized ratio (INR) after temporary discontinuation of warfarin therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University medical center anticoagulation clinic. Patients: 22 patients receiving a fixed evening dose of warfarin for whom temporary discontinuation of therapy was deemed safe. Measurements: Serial plasma samples were drawn for INR measurements approximately 20, 65, 115, and 185 hours after patients received the last dose of warfarin. in five patients, INR was measured twice daily for 5 days. Results: For patients with a mean steady-state INR of 2.6, the mean INR 65 hours (2.7 days) after discontinuation of warfarin therapy was 1.6 (range, 1.11 to 2.16); 20 of 22 patients (98%) had an INR greater than 1.2. The mean INR 115 hours (4.7 days) after discontinuation of warfarin therapy was 1.1; 5 of 22 patients (23%) had an INR of 1.2 or greater. in 5 patients studied in detail, the INR decreased exponentially and had a half-life that ranged from 0.52 to 1.2 days; the onset of maximal decrease began 24 to 36 hours after discontinuation of warfarin therapy. In the total cohort, age was a significant (P < 0.005) independent predictor of smaller decreases in the INR between day 1 and day 3 (regression coefficient = -6.8% +/- 2%/2 days per decade of age; R(2) = 0.34). Conclusions: By simulating preoperative discontinuation of warfarin therapy, we found that the INR decreases exponentially, with wide interpatient variation in the rate of decrease. Age is associated with a slower rate of decrease. To be certain that the INR at the time of the surgery is less than 6.2, warfarin should be withheld for 96 to 115 hours (4 doses) in patients with a steady-state INR between 2.0 and 3.0. For patients with a higher steady-state INR, a longer wait is necessary.	UNIV CALIF DAVIS, DAVIS, CA 95616 USA	University of California System; University of California Davis								CADE JF, 1979, MED J AUSTRALIA, V2, P292, DOI 10.5694/j.1326-5377.1979.tb125717.x; GAINEY SP, 1989, AM J OPHTHALMOL, V108, P142, DOI 10.1016/0002-9394(89)90008-1; KATHOLI RE, 1978, AM HEART J, V96, P163, DOI 10.1016/0002-8703(78)90080-7; MCINTYRE H, 1966, LANCET, V2, P99; MOLL AC, 1989, DOC OPHTHALMOL, V72, P367, DOI 10.1007/BF00153505; MUNGALL DR, 1985, J PHARMACOKINET BIOP, V13, P213, DOI 10.1007/BF01065653; OREILLY RA, 1963, J CLIN INVEST, V42, P1542, DOI 10.1172/JCI104839; OREILLY RA, 1987, PRINCIPLES PHARM THE, P1344; RAMSTROM G, 1993, J ORAL MAXIL SURG, V51, P1211, DOI 10.1016/S0278-2391(10)80291-5; ROSE SD, 1987, MED EVALUATION SURGI, P253; SELVIN S, 1991, STATISTICAL ANAL EPI; TINKER JH, 1978, JAMA-J AM MED ASSOC, V239, P738, DOI 10.1001/jama.239.8.738; TRAVIS S, 1989, BRIT J SURG, V76, P1107, DOI 10.1002/bjs.1800761102	13	189	193	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					40	42		10.7326/0003-4819-122-1-199501010-00006	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985894				2022-12-01	WOS:A1995PY50200006
J	JIN, YS; HOSKINS, R; HORVITZ, HR				JIN, YS; HOSKINS, R; HORVITZ, HR			CONTROL OF TYPE-D GABAERGIC NEURON DIFFERENTIATION BY C-ELEGANS UNC-30 HOMEODOMAIN PROTEIN	NATURE			English	Article							CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; GENE ENCODES	THE Caenorhabditis elegans gene unc-30 is required for the develop ment and functioning of the 19 inhibitory GABAergic (gamma-aminobutyric-acid-secreting) type D motor neurons, which control locomotion(1-4). In unc-30 mutants the D neurons lack GABA(2) and have defects in axonal pathfinding and synaptic connections (J. White, personal communication). We report here that unc-30 encodes a homeodomain protein that is present in the nuclei of the D neurons at high levels in young larvae, in which the motor circuitry is formed, and at low levels in older animals. The UNC-30 protein is also present in six non-GABAergic neurons and is absent from the seven non-D-type GABAergic neurons. Ectopic expression of unc-30 induced GABA expression in cells that are normally not GABAergic. We propose that unc-30 functions as a transcriptional regulator within the type D neurons to control their terminal differentiation and that unc-30 is sufficient in some but not all cell types to induce GABA expression.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); MRC Laboratory Molecular Biology				Jin, Yishi/0000-0002-9371-9860				BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1993, GUIDEBOOK HOMEOBOX G, P25; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HODGKIN J, 1983, GENETICS, V103, P43; HOSKINS R, 1990, THESIS U CAMBRIDGE; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3957; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; RUVKUN G, 1989, GENETICS, V121, P501; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; TREISMAN J, 1989, CELL, V59, P553; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; [No title captured]	30	179	183	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					780	783		10.1038/372780a0	http://dx.doi.org/10.1038/372780a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997265				2022-12-01	WOS:A1994PY21200053
J	LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR				LEE, JC; LAYDON, JT; MCDONNELL, PC; GALLAGHER, TF; KUMAR, S; GREEN, D; MCNULTY, D; BLUMENTHAL, MJ; HEYS, JR; LANDVATTER, SW; STRICKLER, JE; MCLAUGHLIN, MM; SIEMENS, IR; FISHER, SM; LIVI, GP; WHITE, JR; ADAMS, JL; YOUNG, PR			A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RNA-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; MURINE MACROPHAGES; ENDOTOXIN; IL-1; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; PURIFICATION; EXPRESSION	Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compounds. Using radiolabelled and radio-photoaffinity-labelled chemical probes, the target of these compounds was identified as a pair of closely related mitogen-activated protein kinase homologues, termed CSBPs. Binding of the pyridinyl-imidazole compounds inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine production, suggesting that the CSBPs are critical for cytokine production.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT RADIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	LEE, JC (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406, USA.			White, John R/0000-0003-2998-1626				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; ERICKSON RL, 1991, J BIOL CHEM, V266, P6007; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KASPAR RL, 1994, J IMMUNOL, V153, P277; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1992, CELL IMMUNOL, V144, P155, DOI 10.1016/0008-8749(92)90233-F; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1990, INT J IMMUNOTHER, V6, P1; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAHKOV AN, 1990, J EXP MED, V171, P35; SCHINDLER R, 1990, BLOOD, V76, P1631; SETH A, 1991, J BIOL CHEM, V266, P23521; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	3055	3188	0	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					739	746		10.1038/372739a0	http://dx.doi.org/10.1038/372739a0			8	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997261				2022-12-01	WOS:A1994PY21200042
J	ISNER, JM; FELDMAN, LJ				ISNER, JM; FELDMAN, LJ			GENE-THERAPY FOR ARTERIAL-DISEASE	LANCET			English	Editorial Material							INTIMAL HYPERPLASIA; EXPRESSION INVIVO; CELLS; WALL		TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02111	St. Elizabeth's Medical Center; Tufts University	ISNER, JM (corresponding author), TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED CARDIOL,BOSTON,MA 02111, USA.		Feldman, Laurent/AGM-4472-2022					FELDMAN LJ, 1994, CIRCULATION, V90, P1; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; RIESSEN R, 1993, HUM GENE THER, V4, P749, DOI 10.1089/hum.1993.4.6-749; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; TAKESHITA S, IN PRESS P NATL ACAD; 1994, MINUTES RECOMBINANT	16	34	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1653	1654		10.1016/S0140-6736(94)90454-5	http://dx.doi.org/10.1016/S0140-6736(94)90454-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996957				2022-12-01	WOS:A1994PX30200005
J	LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S				LIAN, JP; STONE, S; JIANG, Y; LYONS, P; FERRONOVICK, S			YPT1P IMPLICATED IN V-SNARE ACTIVATION	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; VESICULAR TRANSPORT; SECRETORY PATHWAY; YEAST; FUSION; ER; ENCODES; IDENTIFICATION	SYNAPTOBREVIN-LIKE membrane proteins that reside on transport vesicles, called the vesicle SNARE (v-SNARE), play a key role in ensuring that a vesicle targets and fuses with its correct acceptor compartment(1-3). Here we show that Bos1p, the v-SNARE of yeast endoplasmic reticulum-to-Golgi transport vesicles, pairs with another integral membrane protein of similar topology (Sec22p) on vesicles. This pairing, which appears to require functional Ypt1p (Rab in mammalian cells), may aid the activity of Bos1p on this compartment. These findings suggest that Rabs regulate the specificity of membrane fusion by selectively activating the v-SNARE on carrier vesicles. Because the v-SNARE resides on more than one membrane, such a regulated activation step may be necessary to prevent the premature fusion of donor and acceptor compartments(4).	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GROESCH ME, 1992, METHOD ENZYMOL, V219, P137; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WARREN G, 1993, NATURE, V362, P297, DOI 10.1038/362297a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	21	175	177	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					698	701		10.1038/372698a0	http://dx.doi.org/10.1038/372698a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990964				2022-12-01	WOS:A1994PX30700092
J	LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y				LIUZZI, M; DEZIEL, R; MOSS, N; BEAULIEU, P; BONNEAU, AM; BOUSQUET, C; CHAFOULEAS, JG; GARNEAU, M; JARAMILLO, J; KROGSRUD, RL; LAGACE, L; MCCOLLUM, RS; NAWOOT, S; GUINDON, Y			A POTENT PEPTIDOMIMETIC INHIBITOR OF HSV RIBONUCLEOTIDE REDUCTASE WITH ANTIVIRAL ACTIVITY IN-VIVO	NATURE			English	Article							HERPES-SIMPLEX VIRUS; COLORIMETRIC ASSAY; CARBOXYL TERMINUS; DNA-POLYMERASE; MUTANTS; SUBUNIT; TYPE-1; ACYCLOVIR; ASSOCIATION; SENSITIVITY	HERPES simplex viruses (HSV) types 1 and 2 encode their own ribonucleotide reductases (RNRs) (EC 1.17.4.1) to convert ribonucleoside diphosphates into the corresponding deoxyribonucleotides(1). Like other iron-dependent RNRs, the viral enzyme is formed by the reversible association of two distinct homodimeric subunits(2). The carboxy terminus of the RNR small subunit (R2) is critical for subunit association(3,4) and synthetic peptides containing these amino-acid sequences selectively inhibit the viral enzyme by preventing subunit association(4-9). Increasing evidence indicates that the HSV RNR is important for virulence and reactivation from latency(10-14). Previously, we reported on the design of HSV RNR inhibitors with enhanced inhibitory potency in vitro(4,15,16). We now report on BILD 1263, which to our knowledge is the first HSV RNR subunit-association inhibitor with antiviral activity in vivo. This compound suppresses the replication of HSV-1, HSV-2 and acyclovir-resistant HSV strains in cell culture, and also strongly potentiates the antiviral activity of acyclovir. Most importantly, its anti-herpetic activity is shown in a murine ocular model of HSV-1-induced keratitis, providing an example of potent nonsubstrate-based antiviral agents that prevent protein-protein inter actions. The unique antiviral properties of BILD 1263 may lead to the design of new strategies to treat herpesvirus infections in humans.			LIUZZI, M (corresponding author), BIO MEGA BOEHRINGER INGELHEIM RES INC,2100 CUNARD ST,LAVAL H7S 2G5,PQ,CANADA.		Deziel, Robert/ABA-9629-2020					BRANDT CR, 1992, J VIROL METHODS, V36, P209, DOI 10.1016/0166-0934(92)90052-F; BRANDT CR, 1991, J GEN VIROL, V72, P2043, DOI 10.1099/0022-1317-72-9-2043; BRAZEAU P, 1982, P NATL ACAD SCI-BIOL, V79, P7909, DOI 10.1073/pnas.79.24.7909; CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607; CHATIS PA, 1992, ANTIMICROB AGENTS CH, V36, P1589, DOI 10.1128/AAC.36.8.1589; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; COEN DM, 1989, ANTIMICROB AGENTS CH, V33, P1395, DOI 10.1128/AAC.33.8.1395; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FILATOV D, 1992, J BIOL CHEM, V267, P15816; FURMAN PA, 1981, J VIROL, V40, P936, DOI 10.1128/JVI.40.3.936-941.1981; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; IDOWU AD, 1992, ANTIVIR RES, V17, P145, DOI 10.1016/0166-3542(92)90048-A; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; KNIPE DM, 1982, J VIROL, V43, P314, DOI 10.1128/JVI.43.1.314-324.1982; KROGSRUD RL, 1993, ANAL BIOCHEM, V213, P386, DOI 10.1006/abio.1993.1436; LANGLOIS M, 1986, J BIOL STAND, V14, P201, DOI 10.1016/0092-1157(86)90004-1; Liuzzi Michel, 1993, P225; MCCLEMENTS W, 1988, VIROLOGY, V162, P270, DOI 10.1016/0042-6822(88)90421-7; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; PARADIS H, 1988, J BIOL CHEM, V263, P16045; Reardon J E, 1991, Adv Pharmacol, V22, P1, DOI 10.1016/S1054-3589(08)60031-9; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SUHNEL J, 1990, ANTIVIR RES, V13, P23, DOI 10.1016/0166-3542(90)90042-6; YAMADA Y, 1991, J INFECT DIS, V164, P1091, DOI 10.1093/infdis/164.6.1091	30	122	134	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					695	698		10.1038/372695a0	http://dx.doi.org/10.1038/372695a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990963				2022-12-01	WOS:A1994PX30700091
J	TOTH, EL				TOTH, EL			NEVER AGAIN, LISA - CHILDHOOD DIABETES IN A DYSFUNCTIONAL FAMILY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											TOTH, EL (corresponding author), UNIV ALBERTA, WALTER C MACKENZIE HLTH SCI CTR 2F129, DEPT MED, EDMONTON T6G 2R7, AB, CANADA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					979	980		10.7326/0003-4819-121-12-199412150-00014	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7978726				2022-12-01	WOS:A1994PW08300014
J	DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML				DRENNAN, CL; HUANG, S; DRUMMOND, JT; MATTHEWS, RG; LUDWIG, ML			HOW A PROTEIN BINDS B-12 - A 3.0-ANGSTROM X-RAY STRUCTURE OF B-12-BINDING DOMAINS OF METHIONINE SYNTHASE	SCIENCE			English	Article							METHYLMALONYL-COA MUTASE; CYTOCHROME-C PEROXIDASE; ESCHERICHIA-COLI; METH GENE; CLONING; ACTIVATION; FLAVODOXIN; SEQUENCE; MODELS; ENZYME	The crystal structure of a 27-kilodalton methylcobalamin-containing fragment of methi onine synthase from Escherichia coli was determined at 3.0 Angstrom resolution. This structure depicts cobalamin-protein interactions and reveals that the corrin macrocycle lies between a helical amino-terminal domain and an alpha/beta carboxyl-terminal domain that is a variant of the Rossmann fold. Methylcobalamin undergoes a conformational change on binding the protein; the dimethylbenzimidazole group, which is coordinated to the cobalt in the free cofactor, moves away from the corrin and is replaced by a histidine contributed by the protein. The sequence Asp-X-His-X-X-Gly, which contains this histidine ligand, is conserved in the adenosylcobalamin-dependent enzymes methylmalonyl-coenzyme A mutase and glutamate mutase, suggesting that displacement of the dimethylbenzimidazole will be a feature common to many cobalamin-binding proteins. Thus the cobalt ligand, His(759), and the neighboring residues Asp(757) and Ser(810), may form a catalytic quartet, Co-His-Asp-Ser, that modulates the reactivity of the B-12 prosthetic group in methionine synthase.	UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University					NIGMS NIH HHS [GM24908, GM16429, GM08570] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008570, R37GM024908, R01GM024908] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babior B. M., 1982, B12, V2, P263; Baker J. J., 1982, B12 BIOCH MED, V2, P203; BANERJEE RV, 1989, J BIOL CHEM, V264, P13888; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Blakley R.L., 1982, B12, V2, P381; BRINKSHOEMAKER C, 1964, PROC R SOC LON SER-A, V278, P1, DOI 10.1098/rspa.1964.0042; BRUNGER AT, 1993, X PLOR VERSION 3 1 M; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9282, DOI 10.1021/bi00087a004; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HALPERN J, 1982, B12, V1, P501; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HODGKIN DC, 1956, NATURE, V178, P64, DOI 10.1038/178064a0; HODGKIN DC, 1959, PROC R SOC LON SER-A, V251, P306, DOI 10.1098/rspa.1959.0111; HODGKIN DC, 1957, PROC R SOC LON SER-A, V242, P228, DOI 10.1098/rspa.1957.0174; HODGKIN DC, 1962, PROC R SOC LON SER-A, V266, P494, DOI 10.1098/rspa.1962.0074; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIMURA N, 1994, J AM CHEM SOC, V116, P4087, DOI 10.1021/ja00088a058; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUTLER B, 1987, HELV CHIM ACTA, V70, P1268, DOI 10.1002/hlca.19870700506; LENHERT PG, 1968, PROC R SOC LON SER-A, V303, P45, DOI 10.1098/rspa.1968.0039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; LEXA D, 1988, J AM CHEM SOC, V110, P7617, DOI 10.1021/ja00231a006; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; LUSCHINSKY CL, 1992, J MOL BIOL, V225, P557, DOI 10.1016/0022-2836(92)90940-L; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARSH N, 1988, J MOL BIOL, V200, P421, DOI 10.1016/0022-2836(88)90252-5; MATTHEWS RG, 1984, FOLATES PTERINS, V1, P497; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; OLD IG, 1990, GENE, V87, P15, DOI 10.1016/0378-1119(90)90490-I; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; POULOS TL, 1980, J BIOL CHEM, V255, P575; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Retey J., 1982, B12, VII, P357; ROSSI M, 1985, J AM CHEM SOC, V107, P1729, DOI 10.1021/ja00292a046; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; SCHRAUZER GN, 1969, J AM CHEM SOC, V91, P3341, DOI 10.1021/ja01040a041; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SMITH DR, 1994, U00017 GENBA; STEIGEMANN W, 1974, THESIS TU MUNICH; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; SUMMERS MF, 1984, J AM CHEM SOC, V106, P4478, DOI 10.1021/ja00328a030; SWITZER RL, 1982, B12, V2, P289; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAYLOR RT, 1982, B12, V2, P307; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Toraya T., 1982, B12, P233; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; WHITE JG, 1962, PROC R SOC LON SER-A, V266, P440, DOI 10.1098/rspa.1962.0072; WIRT MD, 1992, BIOPHYS J, V63, P412, DOI 10.1016/S0006-3495(92)81605-3	62	519	529	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1669	1674		10.1126/science.7992050	http://dx.doi.org/10.1126/science.7992050			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992050				2022-12-01	WOS:A1994PW30800029
J	SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK				SPECHLER, SJ; ZEROOGIAN, JM; ANTONIOLI, DA; WANG, HH; GOYAL, RK			PREVALENCE OF METAPLASIA AT THE GASTROESOPHAGEAL JUNCTION	LANCET			English	Article							BARRETTS-ESOPHAGUS; INCREASING INCIDENCE; ADENOCARCINOMA; CARDIA	Specialised columnar epithelium (SCE), a form of intestinal metaplasia usually found in Barrett's oesophagus, cannot be distinguished endoscopically from normal gastric epithelium. Endoscopists seldom obtain biopsy specimens from a normal-appearing gastro-oesophageal junction, and therefore short segments of SCE in this region may go unrecognised. We studied patients who had short segments of SCE at the gastro-oesophageal junction. All patients scheduled for elective endoscopic examinations in our general endoscopy unit, irrespective of indication, were questioned for symptoms of gastro-oesophageal reflux disease. At endoscopy, severity of oesophagitis was graded, and biopsy specimens obtained from the squamocolumnar junction, irrespective of its appearance or location in the oesophagus. Among 142 patients without endoscopically apparent Barrett's oesophagus, 26 (18%) were found to have SCE. All patients with SCE were white, and the male/female ratio was 1.9. In contrast, non-whites accounted for 14% of the 114 patients without SCE and the male/female ratio was 0.8. The groups did not differ significantly in the frequency of symptoms and endoscopic signs of gastrooesophageal reflux. We conclude that adults frequently have unrecognised segments of SCE at the gastro-oesophageal junction; this may underlie the rising frequency of cancer of the gastrooesophageal junction in the USA and Europe.	BETH ISRAEL HOSP, DEPT PATHOL, CTR SWALLOWING DISORDERS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	SPECHLER, SJ (corresponding author), BETH ISRAEL HOSP, DEPT MED, CTR SWALLOWING DISORDERS, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NIDDK NIH HHS [DK31092] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031092, R37DK031092] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT NR, 1950, BRIT J SURG, V38, P175, DOI 10.1002/bjs.18003815005; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; BONELLI L, 1991, INT J CANCER, V48, P364; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DELAPAVA S, 1964, NEW YORK STATE J MED, V64, P1831; GOYAL RK, 1970, NEW ENGL J MED, V282, P1298, DOI 10.1056/NEJM197006042822305; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; HAGGITT RC, 1992, HUM PATHOL, V23, P475, DOI 10.1016/0046-8177(92)90121-I; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; HASSALL E, 1993, J PEDIATR GASTR NUTR, V16, P345, DOI 10.1097/00005176-199305000-00001; KIM SL, 1994, GASTROENTEROLOGY, V107, P945, DOI 10.1016/0016-5085(94)90217-8; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; Moller H, 1992, Eur J Cancer Prev, V1, P159; MORSON BC, 1955, BRIT J CANCER, V9, P365, DOI 10.1038/bjc.1955.35; OVASKA J, 1989, DIGEST DIS SCI, V34, P1336, DOI 10.1007/BF01538065; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RAPHAEL HA, 1966, ANN SURG; REID BJ, 1987, ANNU REV MED, V38, P477, DOI 10.1146/annurev.med.38.1.477; ROTHERY GA, 1986, GUT, V27, P1062, DOI 10.1136/gut.27.9.1062; SCHMIDT HG, 1985, J CANCER RES CLIN, V110, P145, DOI 10.1007/BF00402729; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; TRIER JS, 1985, BARRETTS ESOPHAGUS P, P19; Tuyns A J, 1992, Eur J Cancer Prev, V1, P275, DOI 10.1097/00008469-199204000-00010; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X	30	492	500	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1533	1536		10.1016/S0140-6736(94)90349-2	http://dx.doi.org/10.1016/S0140-6736(94)90349-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983953				2022-12-01	WOS:A1994PV01700009
J	JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ				JAFFE, HW; MCCURDY, JM; KALISH, ML; LIBERTI, T; METELLUS, G; BOWMAN, BH; RICHARDS, SB; NEASMAN, AR; WITTE, JJ			LACK OF HIV TRANSMISSION IN THE PRACTICE OF A DENTIST WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; DENTISTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT	HUMAN-IMMUNODEFICIENCY-VIRUS; TO-PATIENT TRANSMISSION; DENTAL PRACTICE; INFECTED DENTIST; SEQUENCES	Objectives: To determine whether dentist-to-patient or patient-to-patient transmission of human immunodeficiency virus (HIV) occurred in the practice of a dentist who had the acquired immunodeficiency syndrome (AIDS). Design: Retrospective epidemiologic investigation supported by molecular virology studies. Setting: The practice of a dentist with AIDS in an area with a high AIDS prevalence. Participants: A dentist with AIDS, his former employees, and his former patients, including 28 patients with HIV infection. Measurements: Identification of potential risks for acquisition of HIV infection-control practices. Results: A dentist with known behavioral risks for HIV infection, who was practicing in an area of Miami, Florida, that had a high rate of reported AIDS cases, disclosed that he frequently did invasive procedures and did not always follow recommended infection-control procedures. Of 6474 patients who had records of receiving care from the dentist during the last 5 years of practice, 1279 (19.8%) were known to have been tested for HIV infection and 24 of those (1.9%) were seropositive. Four other patients with HIV infection were identified through additional case-finding activities. Of these 28 patients with HIV infection, all but 4 had potential behavioral risk factors for infection. Phylogenetic tree analysis of HIV genetic sequences from the dentist and 24 of the patients with HIV infection showed an absence of strong bootstrap support for any grouping and therefore did not indicate that the virus strains were linked. Conclusions: Despite identifying numerous patients with HIV infection, we found no evidence of dentist-to-patient or patient-to-patient transmission of HIV during dental care. Our findings are consistent with those of all previous studies in this area, with the exception of one that did identify such transmission.	FLORIDA DEPT HLTH & REHABIL SERV, TALLAHASSEE, FL 32399 USA; ROCHE MOLEC SYST INC, ALAMEDA, CA 94501 USA	Florida Department of Health	JAFFE, HW (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS G29, ATLANTA, GA 30333 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Favero M., 1991, DISINFECTION STERILI, P617; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GOOCH B, 1993, J AM DENT ASSOC, V124, P38, DOI 10.14219/jada.archive.1993.0006; Heuer M A, 1992, J Dent Educ, V56, P528; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; LEWIS DL, 1992, J CLIN MICROBIOL, V30, P401, DOI 10.1128/JCM.30.2.401-406.1992; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; Taylor M, 1992, J Dent Educ, V56, P540; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141; 1991, MMWR-MORBID MORTAL W, V40, P377; 1991, MMWR-MORBID MORTAL W, V40, P221; 1991, MMWR-MORBID MORTAL W, V40, P233; 1993, MMOWR MORB MORTAL WK, V42, P337; 1990, MMWR MROB MORTAL WKL, V39, P489; 1993, MMWR-MORBID MORTAL W, V42, P329	28	54	55	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					855	+		10.7326/0003-4819-121-11-199412010-00005	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978698				2022-12-01	WOS:A1994PT62800005
J	MCDONALD, DB; POTTS, WK				MCDONALD, DB; POTTS, WK			COOPERATIVE DISPLAY AND RELATEDNESS AMONG MALES IN A LEK-MATING BIRD	SCIENCE			English	Article							LONG-TAILED MANAKIN; SEXUAL SELECTION; LEKKING BIRD; RECIPROCITY; EVOLUTION; MAMMALS; KINSHIP	Long-tailed manakins mate in leks and cooperate in multiyear male-male partnerships. An alpha male is responsible for virtually all mating, whereas a beta male assists in the courtship displays. Such altruism by the beta male poses a problem for evolutionary theory because most theoretical treatments and empirical examples of cooperative behavior involve kin selection or reciprocity. Here it is shown that alpha and beta partners are not relatives and that reciprocity is not involved. Instead, direct, though long-delayed benefits to beta males are demonstrated, which include rare copulations, ascension to alpha status, and female lek fidelity. These benefits maintain this unusual form of male-male cooperation.	ARCHBOLD BIOL STN, LAKE PLACID, FL 33852 USA; SMITHSONIAN INST, MOLEC SYSTEMAT LAB, WASHINGTON, DC 20025 USA; UNIV FLORIDA, DEPT PATHOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, CTR MAMMALIAN GENET, GAINESVILLE, FL 32610 USA	Smithsonian Institution; State University System of Florida; University of Florida; State University System of Florida; University of Florida			McDonald, David Bartelle/C-3195-2008	McDonald, David Bartelle/0000-0001-8582-3775; Potts, Wayne/0000-0003-4137-0326				Boucher Douglas H., 1985, BIOL MUTUALISM ECOLO; Brown J. L., 1987, HELPING COMMUNAL BRE; ELGAR MA, 1989, BIOL REV, V64, P13, DOI 10.1111/j.1469-185X.1989.tb00636.x; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; FOSTER MS, 1985, NEOTROPICAL ORNITHOL, V36, P817; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Kruuk H., 1989, SOCIAL BADGER; LIGON JD, 1983, AM NAT, V121, P366, DOI 10.1086/284066; MCDONALD DB, 1993, BEHAV ECOL, V4, P297, DOI 10.1093/beheco/4.4.297; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MCDONALD DB, 1993, ETHOLOGY, V94, P31; MCDONALD DB, 1989, AM NAT, V134, P709, DOI 10.1086/285007; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI 10.1111/j.1558-5646.1989.tb04226.x; QUELLER DC, 1989, P NATL ACAD SCI USA, V86, P3224, DOI 10.1073/pnas.86.9.3224; REYER HU, 1980, BEHAV ECOL SOCIOBIOL, V6, P219, DOI 10.1007/BF00569203; Sambrook J., 1989, MOL CLONING LAB MANU; Sherman P.W., 1991, BIOL NAKED MOLE RAT; Sokal R.R., 1981, BIOMETRY; SULLIVAN KA, 1984, BEHAVIOUR, V91, P294, DOI 10.1163/156853984X00128; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRAINER JM, 1993, CONDOR, V95, P769, DOI 10.2307/1369416; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILEY RH, 1984, EVOLUTION, V38, P609, DOI 10.1111/j.1558-5646.1984.tb00326.x; Wiley RH, 1991, ADV STUD BEHAV, V20, P201	26	175	178	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1030	1032		10.1126/science.7973654	http://dx.doi.org/10.1126/science.7973654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973654				2022-12-01	WOS:A1994PQ92400040
J	BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW				BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW			EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHELATION-THERAPY; CARDIAC-FUNCTION; DESFERRIOXAMINE; STORES; ANEMIA; SURVIVAL	Background. To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death. Methods. At each follow-up visit, we performed a detailed clinical and laboratory evaluation and measured hepatic iron stores with a noninvasive magnetic device. Results. The body iron burden as assessed by magnetic measurement of hepatic iron stores was closely correlated (R = 0.89, P < 0.001) with the ratio of cumulative transfusional iron load to cumulative deferoxamine use (expressed in millimoles of iron per kilogram of body weight, in relation to grams of deferoxamine per kilogram, transformed into the natural logarithm). Each increase of one unit in the natural logarithm of the ratio (transfusional iron load to deferoxamine use) was associated with an increased risk of impaired glucose tolerance (relative risk, 19.3; 95 percent confidence interval, 4.8 to 77.4), diabetes mellitus (relative risk, 9.2; 95 percent confidence interval, 1.8 to 47.7), cardiac disease (relative risk, 9.9; 95 percent confidence interval, 1.9 to 51.2), and death (relative risk, 12.6; 95 percent confidence interval, 2.4 to 65.4). All nine deaths during the study occurred among the 23 patients who had begun chelation therapy later and used less deferoxamine in relation to their transfusional iron load (P < 0.001). Conclusions. The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.	CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHYS, CLEVELAND, OH 44106 USA; MOORHEAD STATE UNIV, DEPT MATH, MOORHEAD, MN 56560 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Minnesota State Colleges & Universities; Minnesota State University Moorhead; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NIADDK NIH HHS [AM-25105] Funding Source: Medline; NIDDK NIH HHS [DK-14370] Funding Source: Medline; FDA HHS [FD-U-000532] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM025105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K06DK014370] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FDA HHS; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BORGNAPIGNATTI C, 1985, J PEDIATR-US, V106, P150, DOI 10.1016/S0022-3476(85)80488-1; BRITTENHAM GM, 1988, ANN NY ACAD SCI, V526, P199, DOI 10.1111/j.1749-6632.1988.tb55506.x; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRITTENHAM GM, 1992, BLOOD, V80, P569; BRITTENHAM GM, 1994, IRON METABOLISM HLTH, P31; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COHEN A, 1990, J PEDIATR-US, V117, P326, DOI 10.1016/S0022-3476(05)80556-6; COX DR, 1972, J R STAT SOC B, V34, P187; DESANCTIS V, 1988, ARCH DIS CHILD, V63, P58, DOI 10.1136/adc.63.1.58; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FOSBURG MT, 1990, BLOOD, V76, P435; FREEDMAN MH, 1990, AM J DIS CHILD, V144, P565, DOI 10.1001/archpedi.1990.02150290059028; FREEMAN AP, 1989, CLIN LAB HAEMATOL, V11, P299, DOI 10.1111/j.1365-2257.1989.tb00227.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P740; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; MARCUS RE, 1984, LANCET, V1, P392; Modell B., 1984, CLIN APPROACH THALAS; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIOMELLI S, 1993, BAILLIERE CLIN HAEM, V6, P287, DOI 10.1016/S0950-3536(05)80073-3; Pippard M J, 1989, Prog Clin Biol Res, V309, P85; POOTRAKUL P, 1988, BLOOD, V71, P1124; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; PROPPER RD, 1976, NEW ENGL J MED, V294, P1421, DOI 10.1056/NEJM197606242942603; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SMITH RS, 1962, BMJ-BRIT MED J, P1577, DOI 10.1136/bmj.2.5319.1577; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	32	647	667	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					567	573		10.1056/NEJM199409013310902	http://dx.doi.org/10.1056/NEJM199409013310902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047080	Bronze			2022-12-01	WOS:A1994PD69900002
J	WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF				WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF			EQUILIBRATION OF HEMOGLOBIN CONCENTRATION AFTER TRANSFUSION IN MEDICAL INPATIENTS NOT ACTIVELY BLEEDING	ANNALS OF INTERNAL MEDICINE			English	Note							UNITED-STATES; BLOOD; COLLECTION		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								Barnes A, 1993, HEMATOLOGY CLIN LAB, P1653; GREENFIELD RH, 1989, ANN EMERG MED, V18, P51, DOI 10.1016/S0196-0644(89)80312-9; GROVERASMUSSEN M, 1961, NEW ENGL J MED, V264, P1034, DOI 10.1056/NEJM196105182642006; HUBER H, 1964, BRIT J HAEMATOL, V10, P567, DOI 10.1111/j.1365-2141.1964.tb00733.x; Johnston M, 1985, TRANSFUSION THERAPY, P35; Jones J, 1993, BLOOD TRANSFUSION CL, P423; KEELING RP, 1987, FUNDAMENTALS CLIN HE, P932; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; MOLLISON PL, 1947, CLIN SCI, V6, P137; NADLER SB, 1962, SURGERY, V51, P224; OCONNELL B, 1988, TRANSFUSION, V28, P66, DOI 10.1046/j.1537-2995.1988.28188127957.x; Rovin BH., 1989, MANUAL MED THERAPEUT, P221; Sekhsaria S, 1991, J Perinatol, V11, P161; Simon TL, 1991, PRINCIPLES TRANSFUSI, P97; SIMPSON MB, 1984, LABORATORY HEMATOLOG, P1149; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WIDMANN FK, 1985, TECHNICAL MANUAL AM, P7; WINTROBE MM, 1981, CLIN HEMATOLOGY, P8	19	64	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					278	280		10.7326/0003-4819-121-4-199408150-00009	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037410	Green Submitted			2022-12-01	WOS:A1994PB10200009
J	PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH				PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH			HIGH-SPECIFICITY DNA CLEAVAGE AGENT - DESIGN AND APPLICATION TO KILOBASE AND MEGABASE DNA SUBSTRATES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; TRIPLE-HELIX FORMATION; SITE-SPECIFIC CLEAVAGE; ESCHERICHIA-COLI; SINGLE-SITE; DUPLEX DNA; CRYSTAL-STRUCTURE; TRANSCRIPTION ACTIVATION; NUCLEASE ACTIVITY; RECEPTOR PROTEIN	Strategies to cleave double-stranded DNA at specific DNA sites longer than those of restriction endonucleases (longer than 8 base pairs) have applications in chromosome mapping, chromosome cloning, and chromosome sequencing-provided that the strategies yield high DNA-cleavage efficiency and high DNA-cleavage specificity. In this report, the DNA-cleaving moiety copper:o-phenanthroline was attached to the sequence-specific DNA binding protein catabolite activator protein (CAP) at an amino acid that, because of a difference in DNA bending, is close to DNA in the specific CAP-DNA complex but is not close to DNA in the nonspecific CAP-DNA complex. The resulting CAP derivative, OP(26)CAP, cleaved kilobase and megabase DNA substrates at a 22- base pair consensus DNA site with high efficiency and exhibited no detectable nonspecific DNA-deavage activity.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTAGLIA LP, 1977, ACTA CRYSTALLOGR B, V33, P3886, DOI 10.1107/S0567740877012321; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; CHEN CHB, 1987, SCIENCE, V237, P1197, DOI 10.1126/science.2820056; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; KANG C, 1993, BIOTECHNIQUES, V15, P659; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; KOOB M, 1992, NUCLEIC ACIDS RES, V20, P5831, DOI 10.1093/nar/20.21.5831; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI D, 1991, J AM CHEM SOC, V113, P9398, DOI 10.1021/ja00024a072; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P118, DOI 10.1073/pnas.91.1.118; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; TAKAHASHI M, 1979, NUCLEIC ACIDS RES, V7, P1699, DOI 10.1093/nar/7.6.1699; VIPOND IB, 1993, MOL MICROBIOL, V9, P225, DOI 10.1111/j.1365-2958.1993.tb01685.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1984, NUCLEIC ACIDS RES, V12, P8475, DOI 10.1093/nar/12.22.8475; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	45	51	52	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					959	962		10.1126/science.8052855	http://dx.doi.org/10.1126/science.8052855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052855				2022-12-01	WOS:A1994PB49900045
J	WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD				WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD			PREFERENTIAL NUCLEOSOME ASSEMBLY AT DNA TRIPLET REPEATS FROM THE MYOTONIC-DYSTROPHY GENE	SCIENCE			English	Article							FRAGILE-X; MUTATIONS; SEQUENCE; INSTABILITY; EXPANSION; DISEASE	The expansion of CTG repeats in DNA occurs in or near genes involved in several human diseases, including myotonic dystrophy and Huntington's disease. Nucleosomes, the basic structural element of chromosomes, consist of 146 base pairs of DNA coiled about an octamer of histone proteins and mediate general transcriptional repression. Electron microscopy was used to examine in vitro the nucleosome assembly of DNA containing repeating CTG triplets. The efficiency of nucleosome formation increased with expanded triplet blocks, suggesting that such blocks may repress transcription through the creation of stable nucleosomes.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM030822] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819, GM 30822, GM42342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRHAERI S, UNPUB; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; Kang S.-G., UNPUB; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG Y, UNPUB; 1993, CELL, V72, P971	25	203	208	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					669	671		10.1126/science.8036515	http://dx.doi.org/10.1126/science.8036515			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036515				2022-12-01	WOS:A1994NZ53800035
J	LIAO, H; LI, G; YEN, TJ				LIAO, H; LI, G; YEN, TJ			MITOTIC REGULATION OF MICROTUBULE CROSS-LINKING ACTIVITY OF CENP-E KINETOCHORE PROTEIN	SCIENCE			English	Article							TAU-PROTEIN; MAP2; SEQUENCE; MITOSIS; TUBULIN; CELLS; DNA	CENP-E is a kinesin-like protein that is transiently bound to kinetochores during early mitosis, becomes redistributed to the spindle midzone at anaphase, and is degraded after cytokinesis. At anaphase, CENP-E may cross-link the interdigitating microtubules in the spindle midzone through a motor-like binding site at the amino terminus and a 99-amino acid carboxyl-terminal domain that bound microtubules in a distinct manner. Phosphorylation of the carboxyl terminus by the mitotic kinase maturation promoting factor (MPF) inhibited microtubule-binding activity before anaphase. Thus, MPF suppresses the microtubule cross-linking activity of CENP-E until anaphase, when its activity is lost.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center				JOHNSON, HEATHER/0000-0001-7468-0705; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-44762-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MCINTOSH JR, 1989, SCIENCE, V246, P622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	15	117	120	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					394	398		10.1126/science.8023161	http://dx.doi.org/10.1126/science.8023161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023161				2022-12-01	WOS:A1994NW81600040
J	BERO, LA; GLANTZ, SA; RENNIE, D				BERO, LA; GLANTZ, SA; RENNIE, D			PUBLICATION BIAS AND PUBLIC-HEALTH POLICY ON ENVIRONMENTAL TOBACCO-SMOKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the tobacco industry's claim that publication bias against negative studies invalidates the risk assessment of environmental tobacco smoke (ETS) conducted by the US Environmental Protection Agency and other reviews of the health effects of ETS. Design.-Determination of the number of published original research articles that tested the hypothesis that ETS exposure is associated with adverse health effects and that reported statistically significant (''positive'') or nonsignificant (''negative'') results; the number of articles that concluded that ETS is a health risk; and unpublished studies on the effects of ETS on health. Participants.-Articles identified by a computerized search of the medical literature supplemented with material obtained from the tobacco industry and hand searching. Articles were classified as peer-reviewed journal articles or articles from sponsored symposia. Main Outcome Measure.-The statistical significance of results reported in the article and whether or not the article concluded that ETS exposure is a health risk. Results.-More symposium articles than journal articles were reviews (46% vs 6%; P=.0001). More original journal articles than original symposium articles reported the use of statistical tests (96% vs 54%; P=.0001). Of articles with statistical analyses, similar proportions of journal articles and symposium articles reported statistically significant results (57% vs 47%; P=.329). The conclusions of 80% of the original journal articles were positive, compared with 51% of the original symposium articles (P=.006). Conclusions.-There is no publication bias against statistically nonsignificant results on ETS in the peer-reviewed literature. The high proportion of articles in symposia that reach the conclusion that ETS is not harmful primarily results from the inclusion of review articles.	UNIV CALIF SAN FRANCISCO, SCH MED, DIV CARDIOL, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DIV CLIN PHARM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERO, LA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1993, TOB CONTROL, V2, P103; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BUTLER TL, 1988, THESIS U CALIFORNIA; CALDWELL ADS, 1992, J SMOKING REL DISORD, V4, P1; CATANOSO J, 1992, NEWS REC        0926, pA1; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CHALMERS TC, 1982, T AM CLIN CLIMAT ASS, V8, P388; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FEUER G, UNPUB ASSESSMENT HLT; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HUBER GL, 1991, CONSUMERS RES    JUL, P10; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; KILPATRICK SJ, 1992, INT SURG, V77, P131; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Lam W. K., 1985, THESIS U HONG KONG; LEE PN, 1992, ENV TOBACCO SMOKE MO; MANTEL N, 1989, INT CONGR SER, V860, P155; MCNAMEE R, 1989, BRIT J IND MED, V46, P143; OLDAKER GB, 1989, J NATL CANCER I, V81, P1424, DOI 10.1093/jnci/81.18.1424; OLDAKER GB, UNPUB ETS PASSENGER; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STERLING T, UNPUB COMP RISK CHRO; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STERLING TD, 1992, EPIDEMIOLOGY, V3, P11, DOI 10.1097/00001648-199201000-00004; STERLING TD, UNPUB BIAS DIAGNOSIS; SUGITA M, 1992, JPN J CLIN ONCOL, V22, P354; SVENSSON C, 1988, SMOKING PASSIVE SMOK; SZKLO M, 1991, J CLIN EPIDEMIOL, V44, pS109; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; VARELA LR, 1987, THESIS YALE U; WEETMAN DF, 1992, INDOOR ENVIRON, V1, P197; WELLS AJ, 1988, BRIT MED J, V296, P1128, DOI 10.1136/bmj.296.6629.1128-a; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; WU AHT, 1988, CASE CONTROL STUDY L; 1990, MAILING TOBACCO ACTI; 1984, CIGARETTE SMOKE NONS; SMOKING RESTRICTIONS; 1986, DHHS CDC878398 US DE, P332; 1990, HLTH EFFECTS PASSIVE; 1990, SCI DOES NOT SUPPORT; ENV TOBACCO SMOKE HL; SMOKERS RIGHTS WORKP; SMOKING WORKPLACE SO; 1992, RESPIRATORY HLTH EFF; 1986, TOBACCO SMOKE NONSMO	55	45	46	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					133	136		10.1001/jama.272.2.133	http://dx.doi.org/10.1001/jama.272.2.133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015124				2022-12-01	WOS:A1994NV42400014
J	POOLE, CJM; MILLER, S; FILLINGHAM, G				POOLE, CJM; MILLER, S; FILLINGHAM, G			IMMUNITY TO HEPATITIS-B AMONG HEALTH-CARE WORKERS PERFORMING EXPOSURE PRONE PROCEDURES	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,OCCUPAT HLTH SERV,LONDON W12 0HS,ENGLAND	Imperial College London	POOLE, CJM (corresponding author), DUDLEY HLTH AUTHOR,CENT CLIN,OCCUPAT HLTH SERV,DUDLEY DY2 7BX,W MIDLANDS,ENGLAND.							ALEXANDER G, 1986, BRIT MED J, V293, P956, DOI 10.1136/bmj.293.6552.956-a; BOXALL EH, 1993, BRIT MED J, V306, P652, DOI 10.1136/bmj.306.6878.652-c; Gupta H L, 1989, J Assoc Physicians India, V37, P618; 1992, IMMUNISATION INFECTI, P114; 1993, PROTECTING HLTH CARE	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					94	95		10.1136/bmj.309.6947.94a	http://dx.doi.org/10.1136/bmj.309.6947.94a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038675	Green Published			2022-12-01	WOS:A1994NW71600018
J	JAMESON, SC; HOGQUIST, KA; BEVAN, MJ				JAMESON, SC; HOGQUIST, KA; BEVAN, MJ			SPECIFICITY AND FLEXIBILITY IN THYMIC SELECTION	NATURE			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; POSITIVE SELECTION; PEPTIDE BINDING; BETA-2-MICROGLOBULIN; THYMOCYTES; EXPRESSION; DEFICIENT; TOLERANCE; ANTIGEN	DURING positive selection, developing thymocytes are rescued from programmed cell death by T-cell receptor (TCR)-mediated recognition of major histocompatibility complex (MHC) molecules(1-3). MHC-bound peptides contribute to this process(4-8). Recently we identified individual MHC-binding peptides which can induce positive selection of a single TCR(9). Here we examine peptide fine specificity in positive selection. These data suggest that a direct TCR-peptide interaction occurs during this event, and strengthens the correlation between selecting peptides and TCR antagonists(9,10). Certain positively selecting peptides are weakly antigenic(9). We demonstrate that thymocytes 'educated' on such a peptide are specifically non-responsive to it and have decreased CD8 expression levels. Similar reduction of CD8 expression on mature T cells converts a TCR agonist into a TCR antagonist. These data indicate that thymocytes may maintain self-tolerance towards a positively selecting ligand by regulating co-receptor expression.			JAMESON, SC (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.		Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146; Hogquist, Kristin/0000-0001-9963-5687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335, R01 AI019335-19] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1993, J IMMUNOL, V150, P1; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HAMMERLING GJ, 1991, IMMUNOL REV, V122, P47, DOI 10.1111/j.1600-065X.1991.tb00596.x; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MOLLER G, 1993, IMMUNOL REV, V135; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1990, NATURE, V344, P65	25	209	209	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					750	752		10.1038/369750a0	http://dx.doi.org/10.1038/369750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008067	Green Accepted			2022-12-01	WOS:A1994NU58100062
J	AUSTOKER, J; SANDERS, D; FOWLER, G				AUSTOKER, J; SANDERS, D; FOWLER, G			CANCER PREVENTION IN PRIMARY-CARE - SMOKING AND CANCER - SMOKING CESSATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Smoking is the single most important cause of cancer. The risk of developing cancer is reduced by stopping smoking and decreases substantially after five years. Reduction in smoking must be central to any programme aimed seriously at the prevention of cancer. An individual approach, based in primary care, has the potential to bring about modest but important reductions in risk. Many randomised trials have shown the effectiveness of various smoking cessation interventions in primary care. Given resource limitations in primary care, individual effort should be focused on those at highest risk who are motivated to stop smoking. A population strategy has considerable advantages over the high risk approach as the potential for reducing morbidity and mortality in the whole population is much greater. The government must acknowledge its major responsibility; the outstanding example of its failure to do this is its persistent refusal to ban outright all forms of advertising and promotion of tobacco. There is clear evidence that a ban would contribute to a reduction in smoking prevalence and especially in the uptake of smoking by children.	UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, IMPERIAL CANC RES FUND, GEN PRACTICE RES GRP, OXFORD OX2 6PE, ENGLAND	University of Oxford; University of Oxford	AUSTOKER, J (corresponding author), UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, CANC RES CAMPAIGN, PRIMARY CARE EDUC RES GRP, OXFORD OX2 6PE, ENGLAND.							DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; FOWLER G, 1993, PREVENTION GENERAL P, P106; FOWLER G, IN PRESS PREVENTIVE; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; RAW M, 1994, GUIDELINES SMOKING P; SANDERS D, 1992, PHP DEP PUBLICATION, V6; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; WALD N, 1991, UK SMOKING STATISTIC; 1992, STOPPING SMOKING MAD; 1993, GIVING UP SMOKING DO; [No title captured]; 1993, EUROPEAN CODE CANCER; [No title captured]; 1992, 11 CANC RES CAMP FAC; 1992, EFFECT TOBACCO ADVER	16	37	37	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	1994	308	6942					1478	1482		10.1136/bmj.308.6942.1478	http://dx.doi.org/10.1136/bmj.308.6942.1478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019283	Green Published			2022-12-01	WOS:A1994NQ22900020
J	HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG				HABETS, GGM; SCHOLTES, EHM; ZUYDGEEST, D; VANDERKAMMEN, RA; STAM, JC; BERNS, A; COLLARD, JG			IDENTIFICATION OF AN INVASION-INDUCING GENE, TIAM-1, THAT ENCODES A PROTEIN WITH HOMOLOGY TO GDP-GTP EXCHANGERS FOR RHO-LIKE PROTEINS	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MURINE LEUKEMIA-VIRUS; T-LYMPHOMA CELLS; BINDING-PROTEIN; HEMATOPOIETIC-CELLS; ACTIVATING PROTEIN; SIGNALING PROTEINS; CDC42HS PROTEIN; HUMAN ONCOGENE; BCR	Using proviral tagging in combination with in vitro selection for invasiveness, we have identified a gene, designated Tiam-1, that affects invasion. In the selected invasive T lymphoma variants, proviral insertions were found within coding exons of the Tiam-1 gene, resulting in both truncated 5'-end and 3'-end transcripts that give rise to N- and C-terminal Tiam-1 protein fragments. In one invasive variant, amplification of the Tiam-1 locus was observed with concomitant increase in the amount of normal Tiam-1 protein. Cell clones that were invasive in vitro produced experimental metastases in nude mice, and transfection of truncated Tiam-1 cDNAs into noninvasive cells made these cells invasive. The predicted Tiam-1 protein harbors a Dbl- and Pleckstrin-homologous domain, which it shares with GDP-GTP exchangers for Rho-like proteins that have been implicated in cytoskeletal organization.	ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	HABETS, GGM (corresponding author), ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DIV CELL BIOL,121 PLESMANLAAN,1066 CX AMSTERDAM,NETHERLANDS.							ADAMS JM, 1992, ONCOGENE, V7, P611; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; COLLARD JG, 1987, CANCER RES, V47, P754; COLLARD JG, 1987, CANCER RES, V47, P6666; COLLARD JG, 1988, CANCER SURV, V7, P692; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUYPERS HT, 1984, CELL, V37, P141; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1990, CLIN EXP METASTAS, V8, P567, DOI 10.1007/BF00135878; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1993, MOL CELL BIOL, V11, P9106; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1984, SCIENCE, V37, P1043; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1076; ROOS E, 1985, CANCER RES, V45, P6238; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIELENGA VJM, 1993, CANCER RES, V53, P4754	48	467	502	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					537	549		10.1016/0092-8674(94)90216-X	http://dx.doi.org/10.1016/0092-8674(94)90216-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7999144				2022-12-01	WOS:A1994NM83200009
J	HARRIES, AD; CULLINAN, T				HARRIES, AD; CULLINAN, T			HERBIS ET ORBIS - THE DANGERS OF TRADITIONAL EYE MEDICINES	LANCET			English	Editorial Material									COLL MED,DEPT COMMUNITY HLTH,BLANTYRE,MALAWI	University of Malawi	HARRIES, AD (corresponding author), COLL MED,DEPT MED,BLANTYRE,MALAWI.							CHIRAMBO MC, 1976, BRIT J OPHTHALMOL, V60, P665, DOI 10.1136/bjo.60.9.665; COURTRIGHT P, 1994, BRIT J OPHTHALMOL, V74, P810; MCMOLI TE, 1984, BRIT J OPHTHALMOL, V68, P401, DOI 10.1136/bjo.68.6.401; YORSTON D, 1994, J TROP MED HYG, V97, P211	4	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1588	1588		10.1016/S0140-6736(94)90403-0	http://dx.doi.org/10.1016/S0140-6736(94)90403-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983991				2022-12-01	WOS:A1994PW05100006
J	KINOSHITA, J; MERVIS, J				KINOSHITA, J; MERVIS, J			SEND IN THE CLONES	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1187	1187		10.1126/science.7973699	http://dx.doi.org/10.1126/science.7973699			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973699				2022-12-01	WOS:A1994PT13200038
J	ADLEMAN, LM				ADLEMAN, LM			MOLECULAR COMPUTATION OF SOLUTIONS TO COMBINATORIAL PROBLEMS	SCIENCE			English	Article								The tools of molecular biology were used to solve an instance of the directed Hamiltonian path problem. A small graph was encoded in molecules of DNA, and the ''operations'' of the computation were performed with standard protocols and enzymes. This experiment demonstrates the feasibility of carrying out computations at the molecular level.	UNIV SO CALIF,INST MOLEC & MED TECHNOL,LOS ANGELES,CA 90089	University of Southern California	ADLEMAN, LM (corresponding author), UNIV SO CALIF,DEPT COMP SCI,941 W 37TH PL,LOS ANGELES,CA 90089, USA.							BRADLEY D, 1993, SCIENCE, V259, P890, DOI 10.1126/science.259.5097.890; CRANDALL BC, 1992, NANOTECHNOLOGY; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Feynman RP, 1961, MINIATURIZATION, P282, DOI DOI 10.1201/9781315217178; Garey M.R., 1979, COMPUTERS INTRACTABI; Karp R.M., 1972, P COMPL COMP, P85, DOI 10.1007/978-1-4684-2001-29; Merkle R. C., 1993, Nanotechnology, V4, P21, DOI 10.1088/0957-4484/4/1/002; Rogers H., 1987, THEORY RECURSIVE FUN; Sambrook J., 1989, MOL CLONING; SCHNEIDER TD, 1991, J THEOR BIOL, V148, P125, DOI 10.1016/S0022-5193(05)80467-9; Watson J. D., 1987, MOL BIOL GENE	11	2659	2987	20	421	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1021	1024		10.1126/science.7973651	http://dx.doi.org/10.1126/science.7973651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973651				2022-12-01	WOS:A1994PQ92400037
J	COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC				COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC			ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAMMOGRAPHIC PARENCHYMAL PATTERNS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE STEROIDS; ADJUVANT CHEMOTHERAPY; TAMOXIFEN THERAPY; HORMONE USE; RISK; CARCINOMA		HEMATOL ONCOL ASSOCIATES, DENVER, CO USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21205 USA; FAIRFAX ONCOL ASSOCIATES, ANNANDALE, VA USA; ALBERT EINSTEIN CANC CTR, BRONX, NY USA; EASTERN COOPERAT ONCOL GRP, OPERAT OFF, DENVER, CO USA; EMORY UNIV, SCH MED, ATLANTA, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Emory University	COBLEIGH, MA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT INTERNAL MED, DIV HEMATOL ONCOL, MED ONCOL SECT, CHICAGO, IL 60612 USA.							ADAMI HO, 1987, NEW ENGL J MED, V316, P752; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; [Anonymous], 1992, Lancet, V339, P1; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BONADONNA G, 1979, ADJUVANT THERAPY CAN, V2, P227; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1993, EPIDEMIOL REV, V15, P233, DOI 10.1093/oxfordjournals.epirev.a036110; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIDSON JA, 1992, MED J AUSTRALIA, V157, P429, DOI 10.5694/j.1326-5377.1992.tb137283.x; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DISAIA PJ, 1993, CANCER-AM CANCER SOC, V71, P1490, DOI 10.1002/cncr.2820710414; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; EDEN JA, IN PRESS MED J AUST; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1989, NEW ENGL J MED, V320, P474; FORNANDER T, 1989, LANCET, V1, P117; GAMBRELL RD, 1984, AM J OBSTET GYNECOL, V150, P119; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1993, CANCER-AM CANCER SOC, V71, P2127, DOI 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2; HENRICH JB, 1992, JAMA-J AM MED ASSOC, V268, P1900, DOI 10.1001/jama.268.14.1900; HEUSON JC, 1976, CANCER TREAT REP, V60, P1463; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOGSTRATEN B, 1982, CANCER RES, V42, P4788; HOOGSTRATEN B, 1984, CANCER, V54, P2248, DOI 10.1002/1097-0142(19841115)54:10<2248::AID-CNCR2820541031>3.0.CO;2-D; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HUG V, 1985, J CLIN ONCOL, V3, P1672, DOI 10.1200/JCO.1985.3.12.1672; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSONWILLIAMS KA, 1991, YALE J BIOL MED, V64, P607; JORDAN VC, 1987, CANCER RES, V47, P624; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOBO RA, 1990, OBSTET GYNECOL, V75, pS18; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MANNI A, 1980, CANCER TREAT REP, V64, P779; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MARCHANT DJ, 1993, CANCER, V71, P2169, DOI 10.1002/1097-0142(19930315)71:6+<2169::AID-CNCR2820711608>3.0.CO;2-B; MARGREITER R, 1984, BREAST CANCER RES TR, V4, P45, DOI 10.1007/BF01806987; MATTHEWS PN, 1981, BRIT MED J, V282, P774, DOI 10.1136/bmj.282.6266.774; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MEHTA RR, 1992, BREAST CANCER RES TR, V20, P125; MERRILL JM, 1992, JAMA-J AM MED ASSOC, V267, P568; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OBRIAN CA, 1985, CANCER RES, V45, P2462; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PLANTING AST, 1985, CANCER TREAT REP, V69, P363; POWLES TJ, 1988, LANCET, V2, P344; POWLES TJ, 1990, LANCET, V336, P48, DOI 10.1016/0140-6736(90)91555-O; PRITCHARD KI, 1980, CANCER TREAT REP, V64, P787; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SAWKA CA, 1986, CANCER RES, V46, P3152; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SHERMAN BM, 1979, J CLIN INVEST, V64, P398, DOI 10.1172/JCI109475; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SPENCER JD, 1978, BRIT MED J, V1, P1024, DOI 10.1136/bmj.1.6119.1024; SPICER DV, 1991, J NATL CANCER I, V83, P63, DOI 10.1093/jnci/83.1.63; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STOLL BA, 1988, LANCET, V1, P1278; STOLL BA, 1967, BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5533.150; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; THERIAULT RL, 1991, ANN ONCOL, V2, P709, DOI 10.1093/oxfordjournals.annonc.a057847; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WADA T, 1981, CANCER TREAT REP, V65, P728; WILE AG, 1993, AM J SURG, V165, P372, DOI 10.1016/S0002-9610(05)80848-7; WILE AG, 1991, P AN M AM SOC CLIN, V10, P58; WILKUND I, 1992, MATURITAS, V14, P211; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YOSHIDA M, 1982, JPN J CLIN ONCOL, V12, P57; 1992, HORMONE REPLACEMENT, P166; 1989, N ENGL JMED, V320, P491	107	135	136	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					540	545		10.1001/jama.272.7.540	http://dx.doi.org/10.1001/jama.272.7.540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046809				2022-12-01	WOS:A1994PB22900032
J	HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA				HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA			PROTON MIGRATION ALONG THE MEMBRANE-SURFACE AND RETARDED SURFACE TO BULK TRANSFER	NATURE			English	Article							HALOBACTERIUM-HALOBIUM; PURPLE-MEMBRANE; BACTERIORHODOPSIN; WATER; TRANSLOCATION; PHOTOCYCLE	Since the proposal of the chemiosmotic theory(1) there has been a continuing debate about how protons that have been pumped across membranes reach another membrane protein that utilizes the established pH gradient. Evidence has been gathered in favour of a 'delocalized' theory, in which the pumped protons equilibrate with the aqueous bulk phase before being consumed, and a 'localized' one, in which protons move exclusively along the membrane surface(2,3). We report here that after proton release by an integral membrane protein, long-range proton transfer along the membrane surface is faster than proton exchange with the bulk water phase. The rate of lateral proton diffusion can be calculated by considering the buffer capacity of the membrane surface. Our results suggest that protons can efficiently diffuse along the membrane surface between a source and a sink (for example H+-ATP synthase) without dissipation losses into the aqueous bulk.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; TH DARMSTADT, INST BIOCHEM, D-64287 DARMSTADT, GERMANY; HAHN MEITNER INST BERLIN GMBH, D-14109 BERLIN, GERMANY	Max Planck Society; Technical University of Darmstadt; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)			Dencher, Norbert/G-6640-2014; Heberle, Joachim/D-8605-2016	Heberle, Joachim/0000-0001-6321-2615				ANTONENKO YN, 1993, BIOCHIM BIOPHYS ACTA, V1150, P45, DOI 10.1016/0005-2736(93)90119-K; BAUER PJ, 1976, BIOPHYS STRUCT MECH, V2, P79, DOI 10.1007/BF00535654; BURGHAUS PA, 1989, ARCH BIOCHEM BIOPHYS, V275, P395, DOI 10.1016/0003-9861(89)90387-1; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; GRZESIEK S, 1986, BIOPHYS J, V50, P265, DOI 10.1016/S0006-3495(86)83460-9; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; GUTMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P391, DOI 10.1016/0005-2728(90)90073-D; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HEBERLE J, 1990, FEBS LETT, V277, P277, DOI 10.1016/0014-5793(90)80864-F; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; HEBERLE J, 1992, NATO ADV SCI I B-PHY, V291, P187; JUNGE W, 1987, BIOCHIM BIOPHYS ACTA, V890, P1, DOI 10.1016/0005-2728(87)90061-2; KASIANOWICZ J, 1987, J MEMBRANE BIOL, V99, P227; LEBERLE K, 1989, BIOPHYS J, V55, P637, DOI 10.1016/S0006-3495(89)82861-9; LECHNER RE, 1994, BIOPHYS CHEM, V49, P91, DOI 10.1016/0301-4622(93)E0086-K; MICHEL H, 1980, BIOCHEMISTRY-US, V19, P4607, DOI 10.1021/bi00561a011; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; OESTERHELT D, 1973, FEBS LETT, V36, P72, DOI 10.1016/0014-5793(73)80339-4; POLLE A, 1989, BIOPHYS J, V56, P27, DOI 10.1016/S0006-3495(89)82649-9; PRATS M, 1986, NATURE, V322, P756, DOI 10.1038/322756a0; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019	21	277	281	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					379	382		10.1038/370379a0	http://dx.doi.org/10.1038/370379a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047144				2022-12-01	WOS:A1994PA30400058
J	WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J				WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J			MECHANISM OF ACTIVATION OF THE TGF-BETA RECEPTOR	NATURE			English	Article							TRANSFORMING GROWTH-FACTOR; TRANSMEMBRANE SERINE KINASE; EXPRESSION CLONING; ACTIVIN RECEPTOR; II RECEPTORS; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; THREONINE KINASE; IDENTIFICATION; INHIBITION	Transforming growth factor-beta (TGF-beta) signals by contacting two distantly related transmembrane serine/threonine kinases called receptors I and II. The role of these molecules in signalling has now been determined. TGF-beta binds directly to receptor II, which is a constitutively active kinase. Bound TGF-beta is then recognized by receptor I which is recruited into the complex and becomes phosphorylated by receptor II. Phosphorylation allows receptor I to propagate the signal to downstream substrates. This provides a mechanism by which a cytokine can generate the first step of a signalling cascade.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Wrana, Jeffrey/F-8857-2013; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408; Wieser, Rotraud/0000-0003-4384-6658				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, IN PRESS MOL CELL BI; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	43	2045	2141	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	1994	370	6488					341	347		10.1038/370341a0	http://dx.doi.org/10.1038/370341a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047140				2022-12-01	WOS:A1994PA30400046
J	JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR				JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR			ALLELIC LOSS OF CHROMOSOME 18Q AND PROGNOSIS IN COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SURGICAL ADJUVANT THERAPY; GENETIC ALTERATIONS; P53 GENE; MICROSATELLITE INSTABILITY; ADHESION MOLECULES; FLOW-CYTOMETRY; RECTAL-CANCER; CARCINOMA; DNA	Background. Colorectal cancer occurs in approximately 150,000 people each year in the United States. Prognostic assessment influences the treatment of patients with colorectal cancer, including decisions about adjuvant therapy. We evaluated chromosome 18q allelic loss, a genetic event associated with tumor progression, as a prognostic marker for this disease. Methods. We developed procedures to examine the status of chromosome 18q with microsatellite markers and DNA from formalin-fixed, paraffin-embedded tumors. Allelic loss of chromosome 18q was assessed in 145 consecutively resected stage II or III colorectal carcinomas.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, BALTIMORE, MD 21205 USA; FINNISH RED CROSS & BLOOD TRANSFUS SERV, HELSINKI, FINLAND	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA-47527, CA-09243, CA-35494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047527, R37CA035494, R01CA035494, T32CA009243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; [Anonymous], 1985, NEW ENGL J MED, V312, P1465; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CRISSMAN JD, 1989, PATHOL ANNU, V24, P103; CRISSMAN JD, 1993, COLORECTAL CANCER, P57; DEANS GT, 1992, BRIT J SURG, V79, P608, DOI 10.1002/bjs.1800790706; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; ENSLEY JF, 1993, CYTOMETRY, V14, P550, DOI 10.1002/cyto.990140515; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRUIS NA, 1993, BRIT J CANCER, V68, P308, DOI 10.1038/bjc.1993.333; GUYER M, 1992, SCIENCE, V258, P67; HAHN M, 1993, CLIN CHEM, V39, P549; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMILTON SR, 1993, GASTROENTEROLOGY, V105, P3, DOI 10.1016/0016-5085(93)90003-U; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; KIM HG, 1994, AM J PATHOL, V145, P148; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; LITT M, 1993, BIOTECHNIQUES, V15, P280; LOUIS DN, 1992, AM J PATHOL, V141, P777; MANTEL N, 1959, J NATL CANCER I, V22, P719; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIBATA D, 1992, AM J PATHOL, V141, P539; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; 1993, CANCER FACTS FIGURES	57	639	653	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					213	221		10.1056/NEJM199407283310401	http://dx.doi.org/10.1056/NEJM199407283310401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015568				2022-12-01	WOS:A1994NY33500001
J	MARKO, JF; SIGGIA, ED				MARKO, JF; SIGGIA, ED			FLUCTUATIONS AND SUPERCOILING OF DNA	SCIENCE			English	Article							HELICAL REPEAT; CIRCULAR DNAS; RING-CLOSURE; FLEXIBILITY; ELASTICITY; DIFFUSION; MOLECULES; DYNAMICS; TWIST	Frequently, DNA in vivo is organized into loops that are partially underwound and consequently form interwound helical supercoils. Methods from polymer statistical mechanics are used to show how the competition between entropy (thermal fluctuations) and elastic energy determines supercoil radius and pitch, in good agreement with recent experiments and simulations. Supercoil reorganization by means of slithering (reptation) of the DNA along the supercoil is argued to be a slow process. Extension of supercoiled DNA by an applied force shows a number of unexpected features, including coexistence of interwound and helical states.	CORNELL UNIV,ATOM & SOLID STATE PHYS LAB,ITHACA,NY 14853	Cornell University			Marko, John F./AAY-7111-2021	Marko, John F./0000-0003-4151-9530				BATES AD, 1993, DNA TOPOLOGY, pCH4; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BENHAM CJ, 1983, BIOPOLYMERS, V22, P2477, DOI 10.1002/bip.360221112; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; COZZARELLI NR, 1990, DNA TOPOLOGY ITS BIO, pCH4; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DAOUD M, 1981, J PHYS-PARIS, V42, P1359, DOI 10.1051/jphys:0198100420100135900; DOI M, 1975, CHEM PHYS, V11, P115, DOI 10.1016/0301-0104(75)80044-9; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LEIBLER S, 1989, STATISTICAL MECHANIC, V5, P81; MARK JE, UNPUB; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TANAKA F, 1985, J CHEM PHYS, V83, P6017, DOI 10.1063/1.449637; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WOLFF AP, 1993, CHROMATIN	27	190	190	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					506	508		10.1126/science.8036491	http://dx.doi.org/10.1126/science.8036491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036491				2022-12-01	WOS:A1994NY21600024
J	ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A				ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A			BIOLOGICAL MAGNETIC-RESONANCE-IMAGING USING LASER POLARIZED XE-129	NATURE			English	Article							NUCLEAR-SPIN RELAXATION; PROJECTION RECONSTRUCTION; XENON; GAS; EXCHANGE; NMR; SOLUBILITY; LIQUIDS; BRAIN	AS currently implemented, magnetic resonance imaging (MRI) relies on the protons of water molecules in tissue to provide the NMR signal. Protons are, however, notoriously difficult to image in some biological environments of interest, notably the lungs(1) and lipid bilayer membranes such as those in the brain(2). Here we show that Xe-129 gas can be used for high-resolution MRI when the nuclear-spin polarization of the atoms is increased by laser optical pumping and spin exchange(3-6). This process produces hyperpolarized Xe-129, in which the magnetization is enhanced by a factor of about 10(5). By introducing hyperpolarized Xe-129 into mouse lungs we have obtained images of the lung gas space with a speed and a resolution better than those available from proton MRI(1,7) or emission tomography(8,9). As xenon (a safe general anaesthetic) is rapidly-and safely transferred from the lungs to blood and thence to other tissues(8,9), where it is concentrated in lipid(10-15) and protein(13,15-18) components, images of the circulatory system, the brain and other vital organs can also be obtained. Because the magnetic behaviour of Xe-129 is very sensitive to its environment, and is different from that of (H2O)-H-1, MRI using hyperpolarized Xe-129 should involve distinct and sensitive mechanisms for tissue contrast.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544	Princeton University	ALBERT, MS (corresponding author), SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794, USA.			Driehuys, Bastiaan/0000-0002-1236-4210; Springer, Charles/0000-0002-5966-2135				ALBERT MS, 1993, MAGNET RESON MED, V29, P700, DOI 10.1002/mrm.1910290520; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P2104; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P4710; BARANY M, 1987, MAGN RESON IMAGING, V5, P393, DOI 10.1016/0730-725X(87)90128-7; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; BHASKAR ND, 1982, PHYS REV LETT, V49, P25, DOI 10.1103/PhysRevLett.49.25; BLUMGART HL, 1927, J CLIN INVEST, V4, P423; BLUMGART HL, 1927, J CLIN INVEST, V4, P339; CATES GD, 1992, PHYS REV A, V45, P4631, DOI 10.1103/PhysRevA.45.4631; CATES GD, 1990, PHYS REV LETT, V65, P2591, DOI 10.1103/PhysRevLett.65.2591; DIEHL P, 1990, J MAGN RESON, V88, P660, DOI 10.1016/0022-2364(90)90299-O; FULLERTON GD, 1988, BIOMEDICAL MAGNETIC, P147; GATZKE M, 1993, PHYS REV LETT, V70, P690, DOI 10.1103/PhysRevLett.70.690; GEWALT SL, 1993, MAGNET RESON MED, V29, P99, DOI 10.1002/mrm.1910290117; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HAPPER W, 1984, PHYS REV A, V29, P3092, DOI 10.1103/PhysRevA.29.3092; JAMESON CJ, 1988, J CHEM PHYS, V89, P4074, DOI 10.1063/1.454842; KNUDSEN GM, IN PRESS AM J PHYSL; MAYO JR, 1987, RADIOLOGY, V163, P507, DOI 10.1148/radiology.163.2.3562834; MILLER KW, 1981, P NATL ACAD SCI-BIOL, V78, P4946, DOI 10.1073/pnas.78.8.4946; NEWBURY NR, 1993, PHYS REV A, V48, P4411, DOI 10.1103/PhysRevA.48.4411; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; POLLACK GL, 1984, J CHEM PHYS, V81, P3239, DOI 10.1063/1.448032; RAFTERY D, 1991, PHYS REV LETT, V66, P584, DOI 10.1103/PhysRevLett.66.584; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; Susskind H, 1978, Prog Nucl Med, V5, P144; Susskind H, 1978, Prog Nucl Med, V5, P13; TILTON RF, 1982, BIOCHEMISTRY-US, V21, P6850, DOI 10.1021/bi00269a035; WILCOCK RJ, 1978, J CHEM THERMODYN, V10, P817, DOI 10.1016/0021-9614(78)90154-4; WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/cr60306a003; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5064, DOI 10.1021/bi00840a058; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059	32	833	862	3	148	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					199	201		10.1038/370199a0	http://dx.doi.org/10.1038/370199a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028666				2022-12-01	WOS:A1994NX97100045
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING AND SELF-EXAMINATION FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; MAMMOGRAPHY; ATTENDANCE; ATTITUDES	Breast cancer is the major form of cancer in women, with nearly 30 000 new cases and over 15 000 deaths in the United Kingdom each year. Breast screening by mammography has been shown in randomised trials to reduce mortality from breast cancer in women aged 50 and over. An NHS breast screening programme has been in operation in the United Kingdom since 1988. Its aim is to reduce mortality from breast cancer by 25% in the population of women invited to be screened. The uptake of mammography among the eligible population may be the single most important determinant if the programme is to be effective. Primary care teams have an important part to play in encouraging women to attend for screening and in providing information, advice, and reassurance at all stages of the screening process. To date, routine breast self examination has not been shown to be an effective method of screening for breast cancer and should not therefore be promoted as a primary screening procedure. There is, however, a case to be made for women to become more ''breast aware.''			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							AUSTOKER J, 1990, INVOLVING PRIMARY CA; AUSTOKER J, 1993, BREAST SCREENING ACC, P34; AUSTOKER J, 1992, BREAST CANCER SCREEN; Baines C. J., 1988, SCREENING BREAST CAN, P85; BAINES CJ, 1992, CANCER, V69, P1942, DOI 10.1002/1097-0142(19920401)69:7+<1942::AID-CNCR2820691712>3.0.CO;2-K; BAINES CJ, 1983, CAN MED ASSOC J, V128, P255; BERAL V, 1993, LANCET, V341, P1509, DOI 10.1016/0140-6736(93)90639-X; CHAMBERLAIN J, 1993, EUR J CANCER, V29A, P1804, DOI 10.1016/0959-8049(93)90524-J; CHAMBERLAIN J, BMJ, V353; CHAMPION V, 1992, CANCER, V69, P1985, DOI 10.1002/1097-0142(19920401)69:7+<1985::AID-CNCR2820691720>3.0.CO;2-C; CLOVER KA, 1991, MED J AUSTRALIA, V156, P91; COCKBURN J, 1989, MED J AUSTRALIA, V151, P391, DOI 10.5694/j.1326-5377.1989.tb101221.x; Coleman E A, 1991, J Cancer Educ, V6, P83; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; FALLOWFIELD LJ, 1990, J ROY SOC MED, V83, P547, DOI 10.1177/014107689008300905; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRANK JW, 1985, LANCET, V2, P654; FRENCH K, 1982, BRIT MED J, V285, P617, DOI 10.1136/bmj.285.6342.617; HILL D, 1988, BRIT MED J, V297, P271, DOI 10.1136/bmj.297.6643.271; Kee F, 1992, Eur J Cancer Prev, V1, P231, DOI 10.1097/00008469-199204000-00004; KRUSE J, 1987, OBSTET GYNECOL, V70, P744; MACHARDY L, 1991, BREAST SCREENING PRI; MACLEAN U, 1984, J EPIDEMIOL COMMUN H, V38, P278, DOI 10.1136/jech.38.4.278; MANT D, 1991, BRIT MED BULL, V47, P455, DOI 10.1093/oxfordjournals.bmb.a072483; MANT D, 1992, BREAST, V1, P108; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; RIMER BK, 1989, RADIOLOGY, V172, P243, DOI 10.1148/radiology.172.1.2740510; SEMIGLAZOV VF, 1992, EUR J EPIDEMIOL, V8, P498, DOI 10.1007/BF00146366; WALD NJ, 1994, CONSENSUS C BREAST C; 1993, NHS BREAST SCREENING; 1991, FACTSHEET 7 BREAST C	31	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					168	174		10.1136/bmj.309.6948.168	http://dx.doi.org/10.1136/bmj.309.6948.168			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044097	Green Published			2022-12-01	WOS:A1994NY22900023
J	KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM				KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM			NEGATIVE REGULATION OF THE GROWTH-PROMOTING TRANSCRIPTION FACTOR E2F-1 BY A STABLY BOUND CYCLIN A-DEPENDENT PROTEIN-KINASE	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; S-PHASE; VIRAL ONCOPROTEINS; COMPLEX-FORMATION; BINDING PROTEIN; IDENTIFICATION; CLONING; P107	Cyclin A-kinase, an enzyme required for coordinating S phase progression, forms stable in vivo complexes with E2F-1, a growth-promoting transcription factor, which binds to the retinoblastoma gene product and is involved in the timely activation of genes whose products contribute to G1 exit and S phase traversal. Complex formation results in a negative biochemical effect of cyclin A-kinase: the shut-off of E2F-1-dependent DNA binding function in S/G2. Thus, specific and timely cell cycle-dependent interactions of E2F-1 with proteins that inhibit its function (i.e., RB during G1 and cyclin A-kinase during S/G2) may contribute to the periodicity of expression of certain E2F-1-responsive genes at the G1/S transition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KREK, W (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FLEMINGTON EK, 1993, IN PRESS P NATL ACAD; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MARIDOR G, 1993, J CELL SCI, V106, P535; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	44	445	457	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					161	172		10.1016/0092-8674(94)90582-7	http://dx.doi.org/10.1016/0092-8674(94)90582-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033208				2022-12-01	WOS:A1994NX32800018
J	SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E				SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E			A NOVEL HETERODIMERIC TRANSFERRIN RECEPTOR ENCODED BY A PAIR OF VSG EXPRESSION SITE-ASSOCIATED GENES IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM FORM; TRYPANOSOMA-BRUCEI; AFRICAN TRYPANOSOMES; MEDIATED ENDOCYTOSIS; FLAGELLAR POCKET; TRANSCRIPTION; MEMBRANE; IDENTIFICATION; LOCALIZATION	In T. brucei, a transferrin-binding protein has been found to share sequence homology with pESAG-7 and -6, the products of two related genes present in the VSG gene polycistronic transcription unit. When expressed in Xenopus oocytes, they appear as N-glycosylated proteins secreted in the medium (pESAG-7) and GPI anchored to the membrane (pESAG-6). These proteins are able to homo- or heterodimerize, probably through association in the same orientation. Only heterodimers can bind Tf, possibly two molecules per dimer. A comparison of Tf binding to pESAG-7/6-expressing oocytes and trypanosomes suggests that pESAG-7/6 is the Tf receptor of the parasite. In trypanosomes, the majority of pESAG-7/6 is released from the membrane and associates, together with Tf, with a glycosylated matrix present in the lumen of the flagellar pocket. Both pESAG-7/6 and Tf are internalized via coated pits and vesicles. These observations suggest a novel mode of Tf binding and uptake in trypanosomes.	SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275	Southern Methodist University	SALMON, D (corresponding author), UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM.		Salmon, Didier/M-5670-2013	Nolan, Derek/0000-0002-3742-4304				ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BULOW R, 1989, J CELL SCI, V93, P233; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GEUSKENS M, 1982, ONCODEV BIOL MED, V3, P291; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; KARIN M, 1981, J BIOL CHEM, V256, P3245; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; SCHELL D, 1993, EMBO J, V12, P2990; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; STANLEY KK, 1984, EMBO J, V3, P1420; THIERY JP, 1967, J MICROSC-PARIS, V6, P987; THIERY JP, 1974, J MICROSC-PARIS, V21, P225; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; Vijayaraghavan P, 1992, Clin Physiol Biochem, V9, P138; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, INFECT IMMUN, V61, P4540, DOI 10.1128/IAI.61.11.4540-4545.1993; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	38	155	155	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					75	86		10.1016/0092-8674(94)90574-6	http://dx.doi.org/10.1016/0092-8674(94)90574-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033214				2022-12-01	WOS:A1994NX32800010
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION - SETTING THE SCENE	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Each year in the United Kingdom there are over 300 000 new cases of cancer and nearly 165 000 deaths from cancer. It is widely believed that as many as four fifths of all cancers are preventable by means that are already available. The Health of the Nation and the Europe Against Cancer programme have set targets and strategies for reducing the risk of cancer. An approach based on the whole population will achieve the greatest reductions in morbidity and mortality. Complementary to this is the individual approach, which can be based in primary care and targeted at high risk subjects, Health promotion and screening in primary care are not in themselves self evidently valuable. Their effectiveness must be tested rigorously and scientifically. Furthermore, because of limited time and resources, health education in primary care should be focused on interventions that are likely to achieve the greatest benefit, such as helping people to stop smoking.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							CALNAN M, 1989, SOCIAL DILEMMAS CANC, P91; CALNAN M, 1992, CORONARY HEART DISEA; COULTER A, 1993, PREVENTION GENERAL P, P19; DELAMOTHE T, 1991, BRIT MED J, V303, P1046, DOI 10.1136/bmj.303.6809.1046; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; DOLL R, 1993, REDUCING RISK CANCER, P14; Doll R, 1981, THE CAUSES OF CANCER; KELLY MP, 1992, BRIT J GEN PRACT, V42, P223; Love R R, 1988, J Cancer Educ, V3, P71; MANT D, 1994, BRIT J GEN PRACT, V44, P51; Prochaska JO, 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; Rose G., 1992, STRATEGY PREVENTIVE; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; WILSON JMJ, 1968, WHO PUBLIC HLTH PAPE, P34; WRIGH L, 1992, HLTH LIFESTYLES OXFO; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1993, CANCER RES CAMPAIGN; 1994, BRIT MED J, V308, P308; 1993, EUROPEAN CODE CANCER; 1992, CRC11 CANC RES CAMP; 1994, SCI YB	25	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1415	1420		10.1136/bmj.308.6941.1415	http://dx.doi.org/10.1136/bmj.308.6941.1415			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019255	Green Published			2022-12-01	WOS:A1994NP42000021
J	BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ				BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ			LOW-CHOLESTEROL CONCENTRATIONS AND SEVERE DEPRESSIVE SYMPTOMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							LOW SERUM-CHOLESTEROL; PRIMARY PREVENTION; MORTALITY; MEN; PROGRESS	Objective-To investigate the reported association between low serum cholestrol concentration and severe depressive symptoms in an elderly population. Design-Cross sectional analysis of pooled data from three communities of the established populations for epidemiologic studies of the elderly. Participants who completed their interview, including the Centers for Epidemiologic Studies' depression scale and consented to measurement of their cholesterol concentration were included in the study. Subjects-3939 men and women aged greater than or equal to 71. Methods-chi(2) analysis, t tests, and multivariate regression analysis of the association between low cholesterol concentration and severe depressive symptoms. All analyses were stratified by sex, and multivariate analyses were adjusted for age, self reported health, physical function, number of drugs used, and weight loss. Main outcome measure-Score of depressive symptoms on the Centers for Epidemiologic Studies' depression scale. Results-Depressive symptoms, cholesterol concentration, weight, and use of drugs were all associated with age in men and women. The relative odds of severe depressive symptoms (score greater than or equal to 16) for those with low cholesterol concentrations (<4.14 mmol/l) were 1.9 (95% confidence interval, 1.1 to 3.3) for the older group of men and 1.8 (1.1 to 2.9) for the older group of women. This association was also observed when depressive symptoms were analysed as a continuous rather than a categorical variable. In multivariate models that adjusted for age, self reported health, physical function, number of drugs used, and weight loss, the association was substantially weakened. Conclusions-After several factors relating to health had been controlled for, no significant association between low cholesterol concentration and severe depressive symptoms was found.	UNIV IOWA,COLL DENT,IOWA CITY,IA 52242	University of Iowa	BROWN, SL (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WINSCONSIN AVE,SUITE 3C309,BETHESDA,MD 20892, USA.		Simonsick, Eleanor/W-6864-2019					ASBERG M, 1976, ARCH GEN PSYCHIAT, V9, P51; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORNONIHUNTLEY J, 1986, US PHS NIH862443 PUB; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Harris T, 1992, Ann Epidemiol, V2, P35, DOI 10.1016/1047-2797(92)90035-O; Hooker K., 1992, BEHAV HLTH AGING, V2, P81; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PALINKAS LA, 1993, LANCET, V341, P563, DOI 10.1016/0140-6736(93)90328-E; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SMITH GD, 1993, LANCET, V341, P434; TRAN ZV, 1985, JAMA-J AM MED ASSOC, V254, P919, DOI 10.1001/jama.254.7.919	20	103	103	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1328	1332		10.1136/bmj.308.6940.1328	http://dx.doi.org/10.1136/bmj.308.6940.1328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019218	Green Published			2022-12-01	WOS:A1994NM98900019
J	TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB				TAIRA, M; OTANI, H; SAINTJEANNET, JP; DAWID, IB			ROLE OF THE LIM CLASS HOMEODOMAIN PROTEIN XLIM-1 IN NEURAL AND MUSCLE INDUCTION BY THE SPEMANN ORGANIZER IN XENOPUS	NATURE			English	Article							MESSENGER-RNAS; DNA-BINDING; GENE; EXPRESSION; MESODERM; DOMAIN; LAEVIS; EMBRYOS; NOGGIN; PLATE	LIKE all known LIM class homeobox genes, Xlim-1 encodes a protein with two tandemly repeated cysteine-rich LIM domains upstream of the homeodomain(1). In Xenopus laevis, Xlim-1 is specifically expressed in the Spemann organizer, whose major functions include neural induction and dorsalization of ventral mesoderm(2-4). From RNA injection experiments we conclude here that: (1) the LIM domains behave as negative regulatory domains; (2) LIM domain mutants of Xlim-1 elicited neural differentiation in animal explants; (3) mutant, and to a lesser extent wild-type, Xlim-1 enhanced muscle formation after coinjection with Xbra; (4) both of these activities are mediated by extracellular signals as seen in combined explant experiments;. (5) Xlim-1 mutants activated goosecoid (gsc) expression in animal explants, but not expression of noggin or follistatin; (6) mutant Xlim-1 elicited formation of partial secondary axes, and cooperated with gsc in notochord formation. Thus Xlim-1 has latent activities, implicating it in organizer functions.	UNIV TOULOUSE 3,CNRS,UNITE MIXTE RECH 9925,CTR DEV BIOL,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	TAIRA, M (corresponding author), NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892, USA.							BOICE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GILBERT SF, 1993, MECH DEVELOP, V41, P73, DOI 10.1016/0925-4773(93)90039-Z; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; JAMRICH M, 1989, DEVELOPMENT, V105, P779; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; SAINTJEANNET JP, 1994, P NATL ACAD SCI USA, V91, P3049, DOI 10.1073/pnas.91.8.3049; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	28	181	183	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					677	679		10.1038/372677a0	http://dx.doi.org/10.1038/372677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990959				2022-12-01	WOS:A1994PX30700086
J	BONITA, R; BEAGLEHOLE, R				BONITA, R; BEAGLEHOLE, R			CARDIOVASCULAR-DISEASE EPIDEMIOLOGY IN DEVELOPING-COUNTRIES - ETHICS AND ETIQUETTE	LANCET			English	Editorial Material									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,GERIATR UNIT,AUCKLAND,NEW ZEALAND.							[Anonymous], 1994, MED GLOBAL SURVIVAL; [Anonymous], 1993, WORLD DEV REPORT INV; LI N, 1994, J CLIN EPIDEMIOL, V47, P599, DOI 10.1016/0895-4356(94)90208-9; LINDEBERG S, 1993, J INTERN MED, V233, P269, DOI 10.1111/j.1365-2796.1993.tb00986.x; LINDEBERG S, 1994, J INTERN MED, V236, P331, DOI 10.1111/j.1365-2796.1994.tb00804.x; PETO R, 1994, MORTALITY SMOKING; Snow J., 1855, MODE COMMUNICATION C; Wessen A., 1992, MIGRATION HLTH SMALL; 1994, CIRCULATION, V90, P583; 1992, J CLIN EPIDEMIOL, V45, P841	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1586	1587		10.1016/S0140-6736(94)90401-4	http://dx.doi.org/10.1016/S0140-6736(94)90401-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983989				2022-12-01	WOS:A1994PW05100004
J	DIERMAYER, M; HEDBERG, K; FLEMING, D				DIERMAYER, M; HEDBERG, K; FLEMING, D			BACKING OFF UNIVERSAL CHILDHOOD LEAD SCREENING IN THE USA - OPPORTUNITY OR PITFALL	LANCET			English	Editorial Material											DIERMAYER, M (corresponding author), OREGON HLTH DIV,PORTLAND,OR 97207, USA.							[Anonymous], 1991, PREVENTING LEAD POIS; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; DIERMAYER M, 1994, 43RD ANN EP INT SERV, P72; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1587	1588		10.1016/S0140-6736(94)90402-2	http://dx.doi.org/10.1016/S0140-6736(94)90402-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW051	7983990				2022-12-01	WOS:A1994PW05100005
J	NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM				NOURSE, J; FIRPO, E; FLANAGAN, WM; COATS, S; POLYAK, K; LEE, MH; MASSAGUE, J; CRABTREE, GR; ROBERTS, JM			INTERLEUKIN-2-MEDIATED ELIMINATION OF THE P27(KIP1) CYCLIN-DEPENDENT KINASE INHIBITOR PREVENTED BY RAPAMYCIN	NATURE			English	Article							CATALYTIC SUBUNIT; PROTEIN-KINASE; CDK2 ACTIVITY; PHOSPHORYLATION; FIBROBLASTS; LYMPHOCYTES; ACTIVATION; P40(MO15); P34(CDC2); FK506	THE cyclin-dependent kinase (Cdk) enzymes, when associated with the G1 cycIins D and E, are rate-limiting for entry into the S phase of the cell cycle(1,2). During T-cell mitogenesis, antigen-receptor signalling promotes synthesis of cyclin E and its catalytic partner, Cdk2, and interleukin-2 (IL-2) signalling activates cyclin E/Cdk2 complexes(3). Rapamycin is a potent immunosuppressant which specifically inhibits G1-to-S-phase progression, leading to cell-cycle arrest in yeast and mammals(4-7) Here we report that IL-2 allows Cdk activation by causing the elimination of the Cdk inhibitor protein p27(Kip1), and that this is prevented by rapamycin. By contrast, the Cdk inhibitor p21 is induced by IL-2 and this induction is blocked by rapamycin. Our results show that p27(Kip1) governs Cdk activity during the transition from quiescence to S phase in T lymphocytes and that p21 function may be restricted to cycling cells.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Stanford University; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center	NOURSE, J (corresponding author), STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305, USA.			Massague, Joan/0000-0001-9324-8408; Lee, Mong-Hong/0000-0001-8675-8215				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KATO JY, IN PRESS CELL; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MORICE WG, 1993, J BIOL CHEM, V268, P22737; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	903	933	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					570	573		10.1038/372570a0	http://dx.doi.org/10.1038/372570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990932				2022-12-01	WOS:A1994PW08200058
J	GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A				GUCKENBERGER, R; HEIM, M; CEVC, G; KNAPP, HF; WIEGRABE, W; HILLEBRAND, A			SCANNING-TUNNELING-MICROSCOPY OF INSULATORS AND BIOLOGICAL SPECIMENS BASED ON LATERAL CONDUCTIVITY OF ULTRATHIN WATER FILMS	SCIENCE			English	Article							MEMBRANE; PROTEIN	Scanning tunneling microscopy is based on the flow of an electrical current and thus cannot be used to directly image insulating material. It has been found, however, that a very thin film of water (about one monolayer) adsorbed to a surface exhibits a surprisingly high conductivity that is sufficient to allow scanning tunneling microscope imaging at currents below 1 picoampere. Hydrophilic insulators, such as glass and mica, can thus be imaged in humid air. The same is true for biological specimens deposited on such surfaces, as demonstrated by the scanning tunneling microscope imaging of plasmid DNA on mica.	TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,D-81675 MUNICH,GERMANY	Technical University of Munich	GUCKENBERGER, R (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.							BEAGLEHOLE D, 1991, PHYS REV LETT, V66, P2084, DOI 10.1103/PhysRevLett.66.2084; CEVC G, 1990, BIOCHIM BIOPHYS ACTA, V1031, P311, DOI 10.1016/0304-4157(90)90015-5; CEVC G, 1992, J ELECTROANAL CHEM, V330, P407, DOI 10.1016/0022-0728(92)80321-T; CEVC G, 1993, HYDRATION BIOL MACRO, P338; GATHERCOLE LJ, 1993, J CHEM SOC FARADAY T, V89, P2589, DOI 10.1039/ft9938902589; GUCKENBERGER R, 1988, ULTRAMICROSCOPY, V25, P111, DOI 10.1016/0304-3991(88)90218-5; GUCKENBERGER R, 1989, ULTRAMICROSCOPY, V31, P327, DOI 10.1016/0304-3991(89)90055-7; GUCKENBERGER R, 1991, J VAC SCI TECHNOL B, V9, P1227, DOI 10.1116/1.585210; GUCKENBERGER R, 1994, J VAC SCI TECHNOL B, V12, P1508, DOI 10.1116/1.587274; GUCKENBERGER R, UNPUB; GUCKENBERGER R, 1992, SCANNING TUNNELING M, V2, P52; HACKER B, 1992, ULTRAMICROSCOPY, V42, P1514, DOI 10.1016/0304-3991(92)90475-Y; HELM ML, UNPUB; KELL DB, 1992, BIOELECTROCH BIOENER, V27, P235, DOI 10.1016/0302-4598(92)87047-X; LEGGETT GJ, 1993, J PHYS CHEM-US, V97, P8852, DOI 10.1021/j100137a006; SCHAPER A, 1993, NUCLEIC ACIDS RES, V21, P6004, DOI 10.1093/nar/21.25.6004; WANG ZH, 1990, P NATL ACAD SCI USA, V87, P9343, DOI 10.1073/pnas.87.23.9343; YUAN JY, 1991, PHYS REV LETT, V67, P863, DOI 10.1103/PhysRevLett.67.863; [No title captured]	19	214	217	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1538	1540		10.1126/science.7985024	http://dx.doi.org/10.1126/science.7985024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985024				2022-12-01	WOS:A1994PV01500036
J	KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V				KAUSHAL, S; SCHNEIDER, JW; NADALGINARD, B; MAHDAVI, V			ACTIVATION OF THE MYOGENIC LINEAGE BY MEF2A, A FACTOR THAT INDUCES AND COOPERATES WITH MYOD	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; MUSCLE-SPECIFIC EXPRESSION; CREATINE-KINASE GENE; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; MYOCARDIAL-CELLS; FACTOR MEF-2; FACTOR-II; PROTEINS; SKELETAL	Muscle enhancer factor-2A (MEF2A), a member of the MADS family, induced myogenic development when ectopically expressed in clones of nonmuscle cells of human clones, a function previously limited to the muscle basic helix-loop-helix (bHLH) proteins. During myogenesis, MEF2A and bHLH proteins cooperatively activate skeletal muscle genes and physically interact through the MADS domain of MEF2A and the three myogenic amino acids of the muscle bHLH proteins. Thus, skeletal myogenesis is mediated by two distinct families of mutually inducible and interactive muscle transcription factors, either of which can initiate the developmental cascade.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School								ANDRES V, UNPUB; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Martin J., UNPUB; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WOLD JH, 1990, P NATL ACAD SCI USA, V87, P1089; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	52	206	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1236	1240		10.1126/science.7973707	http://dx.doi.org/10.1126/science.7973707			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973707				2022-12-01	WOS:A1994PT13200053
J	KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M				KONDO, T; TSINOREMAS, NF; GOLDEN, SS; JOHNSON, CH; KUTSUNA, S; ISHIURA, M			CIRCADIAN CLOCK MUTANTS OF CYANOBACTERIA	SCIENCE			English	Article							CHLAMYDOMONAS; EXPRESSION; RHYTHMS; STRAIN; GENE	A diverse set of circadian clock mutants was isolated in a cyanobacterial strain that carries a bacterial luciferase reporter gene attached to a clock-controlled promoter. Among 150,000 clones of chemically mutagenized bioluminescent cells, 12 mutants were isolated that exhibit a broad spectrum of periods (between 16 and 60 hours), and 5 mutants were found that show a variety of unusual patterns, including arrhythmia. These mutations appear to be clock-specific. Moreover, it was demonstrated that in this cyanobacterium it is possible to clone mutant genes by complementation, which provides a means to genetically dissect the circadian mechanism.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235; NAGOYA UNIV,GRAD SCH HUMAN INFORMAT,NAGOYA,AICHI 465,JAPAN	Texas A&M University System; Texas A&M University College Station; Vanderbilt University; Nagoya University	KONDO, T (corresponding author), NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN.		Johnson, Carl H/I-4655-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043836, R01MH043836] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37040] Funding Source: Medline; NIMH NIH HHS [MH43836] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BINDER BJ, 1990, J BACTERIOL, V172, P2313, DOI 10.1128/jb.172.5.2313-2319.1990; BRUCE VG, 1972, GENETICS, V70, P537; Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; FELDMAN JF, 1982, ANNU REV PLANT PHYS, V33, P583, DOI 10.1146/annurev.pp.33.060182.003055; HALL JC, 1990, ANNU REV GENET, V24, P659; HUANG TC, 1993, CURR MICROBIOL, V27, P249, DOI 10.1007/BF01575987; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1991, PLANT PHYSIOL, V95, P197, DOI 10.1104/pp.95.1.197; KONDO T, UNPUB; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; MERGENHAGEN D, 1986, EUR J CELL BIOL, V33, P13; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; SUGIURA M, COMMUNICATION; TSINOREMAS NF, 1994, J BACTERIOL, V176, P6764, DOI 10.1128/JB.176.21.6764-6768.1994; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	18	240	252	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1233	1236		10.1126/science.7973706	http://dx.doi.org/10.1126/science.7973706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973706				2022-12-01	WOS:A1994PT13200052
J	HAJNOCZKY, G; THOMAS, AP				HAJNOCZKY, G; THOMAS, AP			THE INOSITOL TRISPHOSPHATE CALCIUM-CHANNEL IS INACTIVATED BY INOSITOL TRISPHOSPHATE	NATURE			English	Article							PERMEABILIZED HEPATOCYTES; CA2+ MOBILIZATION; RELEASE; 1,4,5-TRISPHOSPHATE; STORES; CELLS	ACTIVATION Of intracellular Ca2+ channels by inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) represents the initial Ca2+ mobilization step in response to many extracellular signals(1). Here we report that Ins(1,4,5)P-3-induced channel activation in permeabilized hepatocytes is followed by a time-dependent inactivation, which is a direct consequence of ligand binding. The inactivation by Ins(1,4,5)P-3 parallels the quantal character of channel opening, giving rise to a unique process of incremental inactivation whereby discrete channel populations are inhibited at each Ins(1,4,5)P-3 dose. Ins(1,4,5)P-3 can induce inactivation in the absence of stored Ca2+, but the inactivation rate is enhanced by increases of cytosolic Ca2+. The inhibitory effect of Ins(1,4,5)P-3 can be reversed by Ins(1,4,5)P-3 washout, or by chelation of cytosolic Ca2+. Thus, Ins(1,4,5)P-3 and Ca2+ act as coinhibitors of the Ins(1,4,5)P-3-sensitive Ca2+ channel. Inactivation is an inherent consequence of Ins(1,4,5)P-3-induced channel opening which can terminate increases of cytosolic Ca2+.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601	16	156	157	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					474	477		10.1038/370474a0	http://dx.doi.org/10.1038/370474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047168				2022-12-01	WOS:A1994PB40700060
J	DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U				DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U			STIMULATION OF RNA-POLYMERASE-II ELONGATION BY CHROMOSOMAL PROTEIN HMG-14	SCIENCE			English	Article							ASSEMBLED CHROMATIN TEMPLATES; MOBILITY GROUP PROTEIN-14; ACCURATE TRANSCRIPTION; NUCLEOSOMES; GENES; DNA; EXPRESSION; SEQUENCE; INVITRO; CELLS	The high-mobility group protein 14 (HMG-14) is a non-histone chromosomal protein that is preferentially associated with transcriptionally active chromatin. To assess the effect of HMG-14 on transcription by RNA polymerase II, in vivo-assembled chromatin with elevated amounts of HMG-14 was obtained. Here it is shown that HMG-14 enhanced transcription on chromatin templates but not on DNA templates. This protein stimulated the rate of elongation by RNA polymerase II but not the level of initiation of transcription. These findings suggest that the association of HMG-14 with nucleosomes is part of the cellular process involved in the generation of transcriptionally active chromatin.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; Ding, Han-Fei/0000-0001-5702-3439; Rimsky, Sylvie/0000-0003-2654-3014; Hansen, Ulla/0000-0001-9803-4185	NIGMS NIH HHS [GM-36667] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; AUSUBEL FM, 1989, CURRENT PROTOCOLSIN; BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BATSON SC, 1992, MOL CELL BIOL, V12, P1639, DOI 10.1128/MCB.12.4.1639; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; Ding H, UNPUB; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; GIRI C, 1987, J BIOL CHEM, V262, P9839; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Johns EW, 1982, HMG CHROMOSOMAL PROT; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; NICOLAS RH, 1983, NUCLEIC ACIDS RES, V11, P753, DOI 10.1093/nar/11.3.753; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PASH JM, 1993, J BIOL CHEM, V268, P13632; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; STEIN A, 1983, NUCLEIC ACIDS RES, V11, P6803, DOI 10.1093/nar/11.19.6803; SWERDLOW PS, 1983, NUCLEIC ACIDS RES, V11, P387, DOI 10.1093/nar/11.2.387; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WEISBROD S, 1979, P NATL ACAD SCI USA, V76, P630, DOI 10.1073/pnas.76.2.630	33	76	77	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					796	799		10.1126/science.8047885	http://dx.doi.org/10.1126/science.8047885			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047885				2022-12-01	WOS:A1994PA37200037
J	DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA				DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA			THE 3-DIMENSIONAL CRYSTAL-STRUCTURE OF THE CATALYTIC CORE OF CELLOBIOHYDROLASE-I FROM TRICHODERMA-REESEI	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; ENDOGLUCANASE-I; ACTIVE-SITE; X-RAY; CELLULASE; SYNERGISM; QM-9414; DOMAIN; INTACT; OLIGOSACCHARIDES	Cellulose is the major polysaccharide of plants where it plays a predominantly structural role. A variety of highly specialized microorganisms have evolved to produce enzymes that either synergistically or in complexes can carry out the complete hydrolysis of cellulose. The structure of the major cellobiohydrolase, CBHI, of the potent cellulolytic fungus Trichoderma reesei has been determined and refined to 1.8 angstrom resolution. The molecule contains a 40 angstrom long active site tunnel that may account for many of the previously poorly understood macroscopic properties of the enzyme and its interaction with solid cellulose. The active site residues were identified by solving the structure of the enzyme complexed with an oligosaccharide, o-iodobenzyl-1-thio-beta-cellobioside. The three-dimensional structure is very similar to a family of bacterial beta-glucanases with the main-chain topology of the plant legume lectins.	UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND; UNIV UPPSALA, CTR BIOMED, DEPT BIOCHEM, S-75123 UPPSALA, SWEDEN; GLAXO INST MOLEC BIOL SA, CH-1228 PLAN LES OUATES, SWITZERLAND	Uppsala University; VTT Technical Research Center Finland; Uppsala University; GlaxoSmithKline			Divne, Christina/E-8646-2010; Teeri, Tuula T/E-7509-2013; Stahlberg, Jerry/D-4163-2013	Divne, Christina/0000-0002-5805-2693; Stahlberg, Jerry/0000-0003-4059-8580				ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANZY H, 1983, FEBS LETT, V153, P113, DOI 10.1016/0014-5793(83)80129-X; CHANZY H, 1985, FEBS LETT, V184, P285, DOI 10.1016/0014-5793(85)80623-2; CLAEYSSENS M, 1989, BIOCHEM J, V261, P819, DOI 10.1042/bj2610819; CLAEYSSENS M, 1990, FEBS LETT, V263, P89, DOI 10.1016/0014-5793(90)80712-R; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; DIVNE C, 1993, J MOL BIOL, V234, P905, DOI 10.1006/jmbi.1993.1640; DURAND H, 1988, ENZYME MICROB TECH, V10, P341, DOI 10.1016/0141-0229(88)90012-9; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; FAGERSTAM LG, 1980, FEBS LETT, V119, P97, DOI 10.1016/0014-5793(80)81006-4; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Gritzali M., 1979, HYDROLYSIS CELLULOSE, V181, P237, DOI DOI 10.1021/BA-1979-0181.CH012; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; JKCWLES K, 1988, J CHEM SOC CHEM COMM, P1401; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KONSTANTINIDIS AK, 1993, BIOCHEM J, V291, P883, DOI 10.1042/bj2910883; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; MARLE I, 1993, J CHROMATOGR, V648, P333, DOI 10.1016/0021-9673(93)80415-5; NIDETZKY B, 1994, BIOCHEM J, V298, P705, DOI 10.1042/bj2980705; NIDETZKY B, 1994, ENZYME MICROB TECH, V16, P43, DOI 10.1016/0141-0229(94)90108-2; NIKU-PAAVOLA M-L, 1986, Biotechnology and Applied Biochemistry, V8, P449; NUMMI M, 1983, BIOCHEM J, V215, P677, DOI 10.1042/bj2150677; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; STAHLBERG J, 1993, BIOCHIM BIOPHYS ACTA, V1157, P107, DOI 10.1016/0304-4165(93)90085-M; STAHLBERG J, 1993, CELLULASES OTHER HYD, P273; SUOMINEN PL, 1993, MOL GEN GENET, V241, P523, DOI 10.1007/BF00279894; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; VRSANSKA M, 1992, CARBOHYD RES, V227, P19, DOI 10.1016/0008-6215(92)85058-8; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WOOD TM, 1989, ENZYME SYSTEMS LIGNO, P19; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	536	550	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					524	528		10.1126/science.8036495	http://dx.doi.org/10.1126/science.8036495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036495				2022-12-01	WOS:A1994NY21600030
J	HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P				HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P			SLEEP DISORDERS AND MELATONIN RHYTHMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,SLEEP LAB,IL-31096 HAIFA,ISRAEL; NEURIM PHARMACEUT LTD,TEL AVIV,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; MACCABI PHARMACEUT LTD,TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University			Laudon, Moshe/GXH-1907-2022; Lavie, Peretz/AAC-2736-2020					Dement W, 1985, HDB BIOL AGING, P692; GWINNER E, 1978, J COMP PHYSIOL, V127, P209, DOI 10.1007/BF01350111; Sadeh A., 1989, J AMBUL MONITOR, V2, P209; SHARMA M, 1989, BIOL PSYCHIAT, V25, P305, DOI 10.1016/0006-3223(89)90178-9; WISBERG J, 1990, SLEEP RES, V19, P384	5	246	251	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					167	167		10.1136/bmj.309.6948.167	http://dx.doi.org/10.1136/bmj.309.6948.167			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044096	Green Published			2022-12-01	WOS:A1994NY22900022
J	AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P				AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P			RISKING EVERYTHING - RISK BEHAVIOR, BEHAVIOR-CHANGE, AND AIDS	SCIENCE			English	Article							CONDOM PROMOTION; MODEL; HIV; TRANSMISSION; AFRICA; WOMEN; SEX	Inquiry into the determinants of risk-related sexual behavior is important for the development of interventions to reduce the incidence of new cases of human immunodeficiency virus infection. Recent social and behavioral research has revealed much about the individual and social factors influencing risk-taking. Findings from these studies have been important in the development of new educational and community-based interventions for communities at risk in the developed and developing worlds.	UNIV PORTSMOUTH, SCH HLTH STUDIES, PORTSMOUTH, HANTS, ENGLAND	University of Portsmouth	AGGLETON, P (corresponding author), WHO, GLOBAL PROGRAMME AIDS, CH-1211 GENEVA, SWITZERLAND.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALTMAN D, 1991, AIDS FACING 2ND DECA, P1; Altman D., 1986, AIDS NEW PURITANISM; ANDERSON R M, 1991; ANKRAH EM, 1991, SOC SCI MED, V32, P967, DOI 10.1016/0277-9536(91)90155-6; [Anonymous], 1988, NEW PUBLIC HLTH; Bandura A, 1977, SOCIAL LEARNING THEO; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; Becker MH, 1974, HLTH BELIEF MODEL PE; Biberfeld G, 1991, AIDS, V5 Suppl 2, pS129, DOI 10.1097/00002030-199101001-00018; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P880; CLEARY PD, 1987, TAKING CARE UNDERSTA, P119, DOI DOI 10.1017/CBO9780511527760.009; DAVIES P, 1991, SOC AS AIDS, P111; Davies P, 1993, SEX GAY MEN AIDS; DEZALDUONDO BO, 1991, J SEX RES, V28, P223, DOI 10.1080/00224499109551607; FEE N, 1993, YOUNG PEOPLE AIDS ST; Fetscherin M, 2008, J ELECTRON COMMER RE, V9, P231; Finger W R, 1991, Netw Res Triangle Park N C, V12, P16; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; FORD NJ, 1993, 9TH INT C AIDS BERL; GILADA IS, 1993, WOMEN HIV AIDS, P276; HAYS RB, 1993, 9TH INT C AIDS BERL; Herdt G.H., 2018, SAME SEX DIFFERENT C; HOLLAND J, 1992, SOC AS AIDS, P142; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOB RFS, 1988, AM J PUBLIC HEALTH, V78, P163, DOI 10.2105/AJPH.78.2.163; KAPLAN BJ, 1993, AIDS EDUC PREV, V5, P294; KATLAMA C, 1993, AIDS, V7, pS185, DOI 10.1097/00002030-199301001-00024; Kippax S., 1993, SUSTAINING SAFE SEX; KREPCHO MA, 1993, J PSYCHOACTIVE DRUGS, V25, P135, DOI 10.1080/02791072.1993.10472243; LAMPTEY P, 1993, 9TH INT C AIDS BERL, P18; Mann J., 1992, AIDS WORLD GLOBAL RE; MANN J, 1992, AIDS WORLD GLOBAL RE, P228; MCKUSICK L, 1985, SEX TRANSM DIS, V12, P229, DOI 10.1097/00007435-198510000-00012; MOULI VC, 1992, ALL AIDS COPPERBELT; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; POLLAK M, 1992, ASSESSING AIDS PREVE, P137; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SILVERMAN M, 1992, AIDS PREVENTION ED W, P352; SMALLMANRAYNOR M, 1992, ATLAS AIDS, P210; STIMSON G, 1991, SOC AS AIDS, P225; STIMSON G V, 1991, International Review of Psychiatry, V3, P401, DOI 10.3109/09540269109072146; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; Weinstein N. D., 1987, TAKING CARE UNDERSTA; WILLIAMS G, 1993, WORK AIDS WORKPLACE; Yeboah-Afari A, 1988, AIDSWATCH, V4, P4; ZWI A, 1993, BRIT MED J, V303, P1527; 1993, HIV DEV AFRICA; 1993, BEHAVIORAL SOCIAL SC, P41; 1993, 1993 WORLD BANK WORL, P99; 1993, GLOBAL AIDS NEWS, V3, P1; 1993, EFFECTIVE APPROACHES; 1994, CURRENT GLOBAL SITUA	56	96	97	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					341	345		10.1126/science.8023156	http://dx.doi.org/10.1126/science.8023156			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023156				2022-12-01	WOS:A1994NW81600026
J	NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW				NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW			CHANGES IN LONG-TERM PROGNOSIS FOR BREAST-CANCER IN A DUTCH CANCER REGISTRY	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; TRENDS; WOMEN; CURABILITY	Objectives-To assess whether the long term survival of patients with breast cancer has changed with time. Design-Population based descriptive study. Setting-Eindhoven Cancer Registry in south east Netherlands. Subjects-2O52 patients with first primary breast cancer diagnosed between 1955 and 1974. Main outcome measures-Overall survival and relative survival. Results-Overall survival was 35% (727 patients) after 10 years, 21% (267) after 20 years, and 15% (25) after 30 years. The corresponding relative survival rates were 43%, 34%, and 34%, respectively. Survival improved from 1955 onwards for all ages and all tumour stages, Improvement was observed in both overall and relative survival. Prognosis was strongly related to the stage at diagnosis in the first 10 years of follow up but independent of stage after 10 years. Survival of patients still alive after 19 years became similar to that of the general female population, Conclusions-Both short and long term survival improved considerably in all age groups. This improvement was most marked for patients who were diagnosed with a localised tumour. Patients who survive for 19 years may be considered cured,	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	NAB, HW (corresponding author), COMPREHENS CANC CTR S,REG BREAST CANC STUDY GRP,POB 231,5600 AE EINDHOVEN,NETHERLANDS.			Coebergh, Jan Willem/0000-0002-2419-3930				ADAMI HO, 1986, JNCI-J NATL CANCER I, V76, P653, DOI 10.1093/jnci/76.4.653; BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; BRINKLEY D, 1984, LANCET, V1, P1118; CASCINELLI N, 1991, CANCER-AM CANCER SOC, V68, P427, DOI 10.1002/1097-0142(19910715)68:2<427::AID-CNCR2820680236>3.0.CO;2-Y; CAYGILL CPJ, 1991, TUMORI, V77, P126, DOI 10.1177/030089169107700207; COX DR, 1972, J R STAT SOC B, V34, P187; DANFORTH DN, 1986, J CLIN ONCOL, V4, P655, DOI 10.1200/JCO.1986.4.5.655; DUNCAN W, 1976, BRIT MED J, V2, P781, DOI 10.1136/bmj.2.6039.781; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; HAKULINEN T, 1981, ANN CLIN RES S31, V13, P48; HAKULINEN T, 1987, APPL STAT-J ROY ST C, V36, P309; HIBBERD AD, 1983, BRIT MED J, V286, P1777, DOI 10.1136/bmj.286.6380.1777; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; LANGLANDS AO, 1979, BRIT MED J, V2, P1247, DOI 10.1136/bmj.2.6200.1247; LAVECCHIA C, 1992, EUR J CANCER, V28A, P927, DOI 10.1016/0959-8049(92)90153-S; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; NAB HW, 1994, EUR J CANCER, V30A, P50, DOI 10.1016/S0959-8049(05)80018-8; NAB HW, 1993, EUR J CANCER, V29A, P1557, DOI 10.1016/0959-8049(93)90294-P; PARKIN DM, 1992, CANCER INVIDENCE 5 C, V6; RUTQVIST LE, 1985, CANCER-AM CANCER SOC, V55, P658, DOI 10.1002/1097-0142(19850201)55:3<658::AID-CNCR2820550331>3.0.CO;2-P; 1992, ATLAS CANCER MORTALI; NIH882789 NCI PUBL, P69	23	26	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					83	86		10.1136/bmj.309.6947.83	http://dx.doi.org/10.1136/bmj.309.6947.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038671	Green Published			2022-12-01	WOS:A1994NW71600014
J	CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J				CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J			PDGF-DEPENDENT AND INSULIN-DEPENDENT PP70(S6K) ACTIVATION MEDIATED BY PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; S6 PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; 3-KINASE; INHIBITION; P70(S6K); 3,4,5-TRISPHOSPHATE; EXPRESSION; WORTMANNIN	PLATELET-DERIVED growth factor receptor (PDGF-R) phosphorylation at tyrosines 740/751 and insulin receptor phosphorylation of insulin receptor substrate-1 effects the recruitment and activation of phosphatidylinositol-3-OH kinase (PI(3)K)(1-5). Changes in PI(3)K activity correlate with cell growth but its downstream signal transducers are unknown(4,5). Activation of the 70/85K S6 kinases (pp70(S6k)) by serine phosphorylation(6,7) results in 40S ribosomal protein S6 phosphorylation and is important for G1 cell-cycle transition in a variety of cells(8-11). Although receptor tyrosine kinases activate the microtubule-associated protein kinase cascade through SH2-/SH3-adaptor proteins, Sos and c-Ras(12), it is unclear how tyrosine kinases are coupled to the pp70(S6k) phosphorylation cascade. Here we report that PI(3)K mediates PDGF or insulin receptor signalling to pp70(S6k). PI(3)K-mediated activation of pp70(S6k) is independent of conventional protein kinase C isoforms. Additionally, rapamycin blocks pp70(S6k) activation by all mitogens(8-10), without inhibiting PI(3)M, and acts downstream this signalling system.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Harvard University; Harvard Medical School; National Jewish Health								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEATHAM B, IN PRESS MOL CELL BI; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2354; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YANO H, 1993, J BIOL CHEM, V268, P25846	30	687	695	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					71	75		10.1038/370071a0	http://dx.doi.org/10.1038/370071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015612				2022-12-01	WOS:A1994NV71100062
J	BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP				BIKKINA, M; LEVY, D; EVANS, JC; LARSON, MG; BENJAMIN, EJ; WOLF, PA; CASTELLI, WP			LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTROPHY; ECHOCARDIOGRAPHY; CRITERIA; DISEASE; EVENTS	Objective.-To evaluate the association of echocardiographically determined left ventricular mass (LVM) with incidence of stroke or transient ischemic attack in an elderly cohort. Design.-Cohort study with a follow-up period of 8 years. Setting.-Population-based sample. Subjects.-Elderly original cohort subjects of the Framingham Heart Study who were free of cerebrovascular disease and atrial fibrillation at the 16th biennial examination and who had adequate echocardiograms. This group consisted of 447 men (mean age, 67.8 years; range, 60 to 90 years) and 783 women (mean age, 69.2 years; range 59 to 90 years). Main Outcome Measures.-Age-adjusted 8 year incidence of stroke was examined as a function of baseline quartiles of LVM-to-height ratio. Proportional hazards regression was used in multivariate analyses to assess risk of stroke as a function of LVM-to-height ratio quartile, adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and blood lipid levels. Results.-Among the 1230 subjects eligible, 89 cerebrovascular disease events (62 strokes and 27 transient ischemic attacks) occurred during follow-up. In men, 8-year age-adjusted incidence of cerebrovascular events was 18.4% in the highest quartile of LVM-to-height ratio and 5.2% in the lowest quartile. Corresponding values in women were 12.2% and 2.9%. The hazard ratio for cerebrovascular events comparing highest to lowest quartile of LVM-to-height ratio was 2.72 (95% confidence interval [CI], 1.39 to 5.36) after adjusting for age, sex, systolic blood pressure, hypertension treatment, diabetes, cigarette smoking, and the ratio of total cholesterol to high-density lipoprotein cholesterol. After adjusting for age, sex, and cardiovascular disease risk factors, the hazard ratio for cerebrovascular events was 1.45 (95% CI, 1.17 to 1.80) for each quartile increment of LVM-to-height ratio. Conclusions.-Echocardiographically determined LVM-to-height ratio offers prognostic information beyond that provided by traditional cerebrovascular disease risk factors. Echocardiography provides information that facilitates identification of individuals at high risk for stroke and transient ischemic attack.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA 01701; NHLBI,BETHESDA,MD; BOSTON UNIV,SCH MED,DIV EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV CARDIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DIV NEUROL,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center			Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021	Benjamin, Emelia/0000-0003-4076-2336; Larson, Martin/0000-0002-9631-1254; Levy, Daniel/0000-0003-1843-8724; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-12] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOW WS, 1988, AM J CARDIOL, V61, P1130, DOI 10.1016/0002-9149(88)90145-2; BAHEMUKA M, 1987, STROKE, V18, P531, DOI 10.1161/01.STR.18.2.531; BAHEMUKA M, 1988, Q J MED, V67, P467; BENJAMIN EJ, 1992, NEW ENGL J MED, V327, P374, DOI 10.1056/NEJM199208063270602; BHALI JK, 1992, ANN INTERN MED, V117, P831; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CUPPLES LA, 1988, NIH882969 US DEP HLT; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FROHLICH ED, 1971, CIRCULATION, V44, P446, DOI 10.1161/01.CIR.44.3.446; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MILLER JT, 1988, AM HEART J, V116, P1048, DOI 10.1016/0002-8703(88)90158-5; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SAVAGE DD, 1987, HYPERTENSION, V9, P40; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1975, CEREBRAL VASCULAR DI, P105; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1993, MONTHLY VITAL STAT R, V42, P1; 1992, ANN INTERN MED, V116, P6	30	254	259	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	1994	272	1					33	36		10.1001/jama.272.1.33	http://dx.doi.org/10.1001/jama.272.1.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU485	8007076				2022-12-01	WOS:A1994NU48500026
J	LIU, FY; ALTMAN, S				LIU, FY; ALTMAN, S			DIFFERENTIAL EVOLUTION OF SUBSTRATES FOR AN RNA ENZYME IN THE PRESENCE AND ABSENCE OF ITS PROTEIN COFACTOR	CELL			English	Article							4.5 S-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-P; INVITRO; PRECURSOR; SEQUENCE; MOIETY; MODEL; GENE; LIFE	Selection of substrates for an RNA enzyme, the catalytic subunit of RNAase P from E. coli, has been carried out by simulation of evolution in vitro in the presence and absence of the protein cofactor of the enzyme. In the presence of the protein, substrates resembling precursor tRNAs, which were readily cleaved by the catalytic RNA, were selected in addition to others, with different sequences and structures (one of which resembled the precursor to 4.5S RNA) that were not readily cleaved by the catalytic RNA alone. The ribonucleoprotein enzyme is more versatile than the RNA enzyme, and our results suggest that it and 4.5S RNA may have evolved after ancestral tRNAs.			LIU, FY (corresponding author), YALE UNIV,DEPT BIOL,POB 6666,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM19422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019422, R01GM019422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CECH TR, 1993, RNA WORLD, P239; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; FEDOR M, 1993, BIOCHEMISTRY-US, V31, P12042; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KOMINE Y, 1994, IN PRESS P NATL ACAD; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Moore M., 1993, RNA WORLD, P303; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OKIMOTO R, 1990, EMBO J, V9, P3405, DOI 10.1002/j.1460-2075.1990.tb07542.x; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; YUAN Y, 1994, SCIENCE, V263, P1269, DOI 10.1126/science.8122108	33	72	75	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1093	1100		10.1016/0092-8674(94)90448-0	http://dx.doi.org/10.1016/0092-8674(94)90448-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020097				2022-12-01	WOS:A1994NV42500017
J	HOLLAND, BK				HOLLAND, BK			PROSPECTING FOR DRUGS IN ANCIENT TEXTS	NATURE			English	Editorial Material							PENNYROYAL OIL; HEPATOTOXICITY; MENTHOFURAN; GLUTATHIONE; PULEGONE				HOLLAND, BK (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103, USA.							ATHERTON DJ, 1991, LANCET, V338, P510, DOI 10.1016/0140-6736(91)90580-I; BURTON JL, 1990, LANCET, V336, P1565, DOI 10.1016/0140-6736(90)93326-K; FARNSWORTH NR, 1983, NATURAL PRODUCTS DRU; FELLOWS L, 1992, LANCET, V339, P1330, DOI 10.1016/0140-6736(92)91967-D; FROEHLICH O, 1990, Journal of Agricultural and Food Chemistry, V38, P2057, DOI 10.1021/jf00101a012; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; REYNOLDS T, 1991, J NATL CANCER I, V83, P594, DOI 10.1093/jnci/83.9.594; RIDDLE JM, 1992, AM SCI, V80, P226; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; VILLASENOR IM, 1993, CARCINOGENESIS, V14, P123, DOI 10.1093/carcin/14.1.123	14	46	48	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					702	702		10.1038/369702a0	http://dx.doi.org/10.1038/369702a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008059				2022-12-01	WOS:A1994NU58100027
J	COUPLAND, RM				COUPLAND, RM			EPIDEMIOLOGIC APPROACH TO SURGICAL-MANAGEMENT OF THE CASUALTIES OF WAR	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; FALKLANDS WAR; EXPERIENCE; TRIAGE; INJURIES	The nature of modern conflicts precludes adequate medical care for most people wounded in wars. The traditional military approach of echeloned care for those wounded on the battlefield has limited relevance. I present an alternative, epidemiological approach whereby some affective care may reach many more. For a surgical facility to have a positive impact by using surgical and anaesthetic competence there must be access to the wounded; security for staff and patients; and a functioning hospital infrastructure. These all depend on respect for the first Geneva convention. Early hospital admission for urgent surgery is not so important if there is adequate first aid beforehand. The hospitals of the International Committee of the Red Cross have provided surgical care for thousands of wounded people by fulfilling these conditions. People wounded in modern conflicts would fare better if these priorities were recognised and less emphasis was placed on the more spectacular aspects of surgical care that benefit only a few.			COUPLAND, RM (corresponding author), RED CROSS,INT COMM,DIV MED,AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; BELLAMY RF, 1984, MIL MED, V149, P55; BOWEN TE, 1988, EMERGENCY WAR SURGER; CLYNE A J, 1955, J R Army Med Corps, V101, P33; COUPLAND RM, 1988, INJURY, V19, P259, DOI 10.1016/0020-1383(88)90041-1; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1992, INJURY, V23, P507, DOI 10.1016/0020-1383(92)90146-J; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; CUTTING PA, 1992, INJURY, V23, P405, DOI 10.1016/0020-1383(92)90018-N; DANON YL, 1984, ISRAEL J MED SCI, V20, P300; DEWIND CM, 1987, ANN ROY COLL SURG, V69, P193; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FRASER I, 1984, BRIT MED J, V289, P1723, DOI 10.1136/bmj.289.6460.1723; GERTSCH, 1987, BRIT J SURG, V74, P831; HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004; JACKSON DS, 1983, ANN ROY COLL SURG, V65, P281; LLEWELLYN CH, 1992, WORLD J SURG, V16, P904, DOI 10.1007/BF02066990; MALPASS CP, 1976, BRIT J SURG, V63, P482, DOI 10.1002/bjs.1800630621; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MELSOM MA, 1975, ANN R COLL SURG ENGL, V56, P287; MUCKART DJJ, 1990, BRIT J SURG, V77, P652, DOI 10.1002/bjs.1800770620; Perrin P, 1991, INT REV RED CROSS, V284, P494; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; Rogov M, 1982, ISRAEL J MED SCI, V20, P369; ROZIN R, 1988, INJURY, V19, P193, DOI 10.1016/0020-1383(88)90014-9; ROZIN RR, 1987, J TRAUMA, V27, P656; Ryan J M, 1990, J R Army Med Corps, V136, P27; RYAN JM, 1984, ANN ROY COLL SURG, V66, P195; SMITH AM, 1989, FEB US NAV I P, P40; SMITH MSO, 1981, J R ARMY MED CORPS, V127, P31; TROUWBORST A, 1987, INJURY, V18, P96, DOI 10.1016/0020-1383(87)90181-1; 1986, 1949 GEN CONV AUG 12	33	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1693	1697		10.1136/bmj.308.6945.1693	http://dx.doi.org/10.1136/bmj.308.6945.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025468	Green Published			2022-12-01	WOS:A1994NU48300033
J	RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF				RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF			NEONATAL SCREENING FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS - 4 YEARS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article							MUTATION; DELTA-F508; POPULATION; GENOTYPE	Objective-To assess the performance and impact of a two tier neonatal screening programme for cystic fibrosis based on an initial estimation of immunoreactive trypsinogen followed by direct gene analysis. Design-Four year prospective study of two tier screening strategy. First tier: immunoreactive trypsinogen measured in dried blood spot samples from neonates aged 3-5 days. Second tier: direct gene analysis of cystic fibrosis mutations (Delta F-508, Delta I-506, G(551)D, G(542)X, and R(553)X) in samples with immunoreactive trypsinogen concentrations in highest 1% and in all neonates with meconium ileus or family history of cystic fibrosis. Setting-South Australian Neonatal Screening Programme, Adelaide. Subjects-All 88752 neonates born in South Australia between December 1989 and December 1993. Interventions-Neonates with two identifiable mutations were referred directly for clinical assessment and confirmatory sweat test; infants with only one identifiable mutation were recalled for sweat test at age 3-4 weeks. Parents of neonates identified as carriers of cystic fibrosis mutation were counselled and offered genetic testing. Main outcome measures-Identification of all children with cystic fibrosis in the screened population. Results-Of 1004 (1.13%) neonates with immunoreactive trypsinogen greater than or equal to 99th centile, 912 (90.8%) had no identifiable mutation. 23 neonates were homozygotes or compound heterozygotes; 69 carried one identifiable mutation, of whom six had positive sweat tests. Median age at clinical assessment for the 29 neonates with cystic fibrosis was 3 weeks; six had meconium ileus and two had affected siblings. 63 neonates were identified as carriers of a cystic fibrosis mutation. Extra laboratory costs for measuring immunoreactive trypsinogen and direct gene analysis were $A1.50 per neonate screened. Conclusion-This strategy results in early and accurate diagnosis of cystic fibrosis and performs better than screening strategies based on immunoreactive trypsinogen measurement alone.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE NEONATAL SCREENING SERV,ADELAIDE,SA 5006,AUSTRALIA; WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia	RANIERI, E (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA.			Morris, Phillip/0000-0001-8976-619X				[Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CULARD JF, 1994, HUM GENET, V93, P167; Dankert-Roelse J E, 1990, Acta Univ Carol Med (Praha), V36, P99; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Farrell P M, 1992, Adv Pediatr, V39, P35; GIBSON LE, 1959, PEDIATRICS, V23, P545; GREEN MR, 1993, ARCH DIS CHILD, V68, P464, DOI 10.1136/adc.68.4.464; GREGG RG, 1993, AM J HUM GENET, V52, P616; HAMMOND K, 1987, ADV NEONATAL SCREENI, P337; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; HEELEY AF, 1992, ANN CLIN BIOCHEM, V29, P361, DOI 10.1177/000456329202900401; HENRY RL, 1990, J PAEDIATR CHILD H, V26, P150, DOI 10.1111/j.1440-1754.1990.tb02413.x; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRAMER R, 1977, HELV PAEDIATR ACTA, V32, P107; LAROUCHE D, 1991, LANCET, V339, P55; Mischler E, 1989, Wis Med J, V88, P14; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; RANIERI E, 1991, BRIT MED J, V302, P1237, DOI 10.1136/bmj.302.6787.1237; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROSENSTEIN BJ, 1982, JOHNS HOPKINS MED J, V150, P113; RYALL RG, 1993, CLIN CHEM, V39, P224; RYLEY HC, 1992, BRIT MED BULL, V48, P805, DOI 10.1093/oxfordjournals.bmb.a072579; SPENCE WC, 1993, BIOCHEM MED METAB B, V49, P200, DOI 10.1006/bmmb.1993.1022; TLUCZEK A, 1992, J DEV BEHAV PEDIATR, V13, P181; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILCKEN B, 1993, SCREENING, V2, P43	32	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1469	1472		10.1136/bmj.308.6942.1469	http://dx.doi.org/10.1136/bmj.308.6942.1469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019280	Green Published			2022-12-01	WOS:A1994NQ22900016
J	HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M				HOSODA, K; HAMMER, RE; RICHARDSON, JA; BAYNASH, AG; CHEUNG, JC; GIAID, A; YANAGISAWA, M			TARGETED AND NATURAL (PIEBALD-LETHAL) MUTATIONS OF ENDOTHELIN-B RECEPTOR GENE PRODUCE MEGACOLON ASSOCIATED WITH SPOTTED COAT COLOR IN MICE	CELL			English	Article							HIRSCHSPRUNGS-DISEASE; AGANGLIONIC MEGACOLON; NERVOUS-SYSTEM; BINDING-SITES; NEURAL CREST; DELETION; CLONING; PROTEIN; LIGAND; IRIDES	Endothelins act on two subtypes of G protein-coupled receptors, termed endothelin-A and endothelin-B receptors. We report a targeted disruption of the mouse endothelin-B receptor (EDNRB) gene that results in aganglionic megacolon associated with coat color spotting, resembling a hereditary syndrome of mice, humans, and other mammalian species. Piebald-lethal (s') mice exhibit a recessive phenotype identical to that of the EDNRB knockout mice. In crossbreeding studies, the two mutations show no complementation. Southern blotting revealed a deletion encompassing the entire EDNRB gene in the s(1) chromosome. A milder allele, piebald (s), which produces coat color spotting only, expresses low levels of structurally intact EDNRB mRNA and protein. These findings indicate an essential role for EDNRB in the development of two neural crest-derived cell lineages, myenteric ganglion neurons and epidermal melanocytes. We postulate that defects in the human EDNRB gene cause a hereditary form of Hirschsprung's disease that has recently been mapped to human chromosome 13, in which EDNRB is located.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	HOSODA, K (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.							ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; BAYNASH AG, 1994, CELL, V79; BOLGER GT, 1990, J CARDIOVASC PHARM, V16, P367, DOI 10.1097/00005344-199009000-00004; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEOL MS, 1967, J EMBRYOL EXP MORPH, V17, P535; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIANG JC, 1983, ARCH OPHTHALMOL-CHIC, V101, P69, DOI 10.1001/archopht.1983.01040010071011; LYON MF, 1988, GENETIC VARIANTS STR; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; METALLINOS DL, 1994, GENETICS, V136, P217; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHAH KN, 1981, J PEDIATR-US, V99, P432, DOI 10.1016/S0022-3476(81)80339-3; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEEL KP, 1992, DEVELOPMENT, V115, P1111; WEBSTER W, 1973, J EMBRYOL EXP MORPH, V30, P573; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YADA Y, 1991, J BIOL CHEM, V266, P18352; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	48	804	835	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1267	1276		10.1016/0092-8674(94)90017-5	http://dx.doi.org/10.1016/0092-8674(94)90017-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001159				2022-12-01	WOS:A1994PZ86000017
J	JENNEY, MEM				JENNEY, MEM			LANGERHANS CELL HISTIOCYTOSIS - WHERE DO WE GO FROM HERE	LANCET			English	Editorial Material							EPIPODOPHYLLOTOXINS; LEUKEMIA; CHILDREN				JENNEY, MEM (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND.							BROADBENT V, 1989, MED PEDIATR ONCOL, V17, P97, DOI 10.1002/mpo.2950170205; CARSTENSEN H, 1923, MED PEDIATR ONCOL, V21, P387; CHU T, 1987, LANCET, V1, P208; EGELER RM, 1994, MED PEDIATR ONCOL, V23, P81, DOI 10.1002/mpo.2950230204; EGELER RM, 1993, CANCER, V71, P565; GADNER H, 1994, MED PEDIATR ONCOL, V23, P72, DOI 10.1002/mpo.2950230203; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; KANNOURAKIS G, 1994, BRIT J CANCER, V70, pS37; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KOMP DM, 1980, MED PEDIATR ONCOL, V8, P35, DOI 10.1002/mpo.2950080106; Langerhans P., 1868, ARCH PATHOL ANAT PH, V44, P325, DOI [10.1007/BF01959006, DOI 10.1007/BF01959006]; MATUSRIDLEY M, 1983, MED PEDIATR ONCOL, V11, P99, DOI 10.1002/mpo.2950110206; PRITCHARD J, 1994, BR J CANCER S23, V70; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RANEY RB, 1989, MED PEDIATR ONCOL, V17, P20, DOI 10.1002/mpo.2950170106; SIMS DG, 1977, ARCH DIS CHILD, V52, P433, DOI 10.1136/adc.52.6.433; WILLMAN CL, 1994, BRIT J CANCER, V70, pS29	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1717	1718		10.1016/S0140-6736(94)92882-7	http://dx.doi.org/10.1016/S0140-6736(94)92882-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996998				2022-12-01	WOS:A1994PY28100005
J	FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ				FOSTER, JW; DOMINGUEZSTEGLICH, MA; GUIOLI, S; KWOK, C; WELLER, PA; STEVANOVIC, M; WEISSENBACH, J; MANSOUR, S; YOUNG, ID; GOODFELLOW, PN; BROOK, JD; SCHAFER, AJ			CAMPOMELIC DYSPLASIA AND AUTOSOMAL SEX REVERSAL CAUSED BY MUTATIONS IN AN SRY-RELATED GENE	NATURE			English	Article							CAMPTOMELIC DWARFISM; DETERMINING REGION; Y-CHROMOSOME; DELETION; PROTEIN; INHERITANCE; SEQUENCES; ENCODES; SOX-4; MOUSE	Induction of testis development in mammals requires the presence of the Y-chromosome gene SRY. This gene must exert its effect by interacting with other genes in the sex-determination pathway. Cloning of a translocation chromosome breakpoint from a sex-reversed patient with campomelic dysplasia, followed by mutation analysis of an adjacent gene, indicates that SOX9, an SRY-related gene, is involved in both bone formation and control of testis development.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; CITY HOSP,CTR MED GENET,NOTTINGHAM,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND; LAB GENETHON,F-91002 EVRY,FRANCE; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Cambridge; University of Nottingham; University of Nottingham; University of London; University College London				Stevanovic, Milena/0000-0003-4286-7334; Brook, John David/0000-0002-5946-6740; Guioli, Silvana/0000-0002-4920-7745	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BENNETT CP, 1993, J MED GENET, V30, P518, DOI 10.1136/jmg.30.6.518; BERNSTEIN R, 1980, J MED GENET, V17, P291, DOI 10.1136/jmg.17.4.291; BIANCHINE JW, 1971, LANCET, V1, P1017; BLACK DM, 1993, AM J HUM GENET, V52, P702; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BRIDGE J, 1985, AM J MED GENET, V21, P225, DOI 10.1002/ajmg.1320210204; BUEHR M, 1993, DEVELOPMENT, V117, P273; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; CREMIN BJ, 1973, LANCET, V1, P488; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DILLON N, 1994, CURR OPIN GENET DEV, V5, P260; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HOEFNAGEL D, 1978, CLIN GENET, V13, P489; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LEHRACH H., 1990, GENOME ANAL, P39; LENZINI E, 1988, ANN GENET-PARIS, V31, P175; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH SA, 1993, J MED GENET, V30, P683, DOI 10.1136/jmg.30.8.683; MANSOUR S, 1994, THESIS U LONDON; MARAIA R, 1991, CLIN GENET, V39, P401; McKusick V.A., 1992, MENDELIAN INHERITANC; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; THURMON TF, 1973, J PEDIATR-US, V83, P841, DOI 10.1016/S0022-3476(73)80384-1; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; TOMMERUP N, 1993, J MED GENET, V30, P713, DOI 10.1136/jmg.30.9.713; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WALTER MA, 1993, TRENDS GENET, V9, P352, DOI 10.1016/0168-9525(93)90040-O; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; WILKIE AOM, 1993, AM J MED GENET, V46, P597, DOI 10.1002/ajmg.1320460527; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG ID, 1992, J MED GENET, V29, P251, DOI 10.1136/jmg.29.4.251	44	1251	1313	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					525	530		10.1038/372525a0	http://dx.doi.org/10.1038/372525a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990924				2022-12-01	WOS:A1994PW08200044
J	FORGACS, I				FORGACS, I			ESCAPING GAS - IMMORTALITY, DEFLATION, AND TOXIC DILATION	LANCET			English	Editorial Material							MEGACOLON				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON,ENGLAND.							GARRETT JM, 1967, GASTROENTEROLOGY, V53, P93; GREENSTEIN AJ, 1985, J CLIN GASTROENTEROL, V7, P137, DOI 10.1097/00004836-198504000-00007; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KRAMER P, 1981, GASTROENTEROLOGY, V80, P433; MCINERNEY GT, 1962, GASTROENTEROLOGY, V42, P244; PANOS MZ, 1993, GUT, V34, P1726, DOI 10.1136/gut.34.12.1726; PRESENT DH, 1988, J CLIN GASTROENTEROL, V10, P485, DOI 10.1097/00004836-198810000-00004	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1521	1521		10.1016/S0140-6736(94)90344-1	http://dx.doi.org/10.1016/S0140-6736(94)90344-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983949				2022-12-01	WOS:A1994PV01700004
J	KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A				KELNER, GS; KENNEDY, J; BACON, KB; KLEYENSTEUBER, S; LARGAESPADA, DA; JENKINS, NA; COPELAND, NG; BAZAN, JF; MOORE, KW; SCHALL, TJ; ZLOTNIK, A			LYMPHOTACTIN - A CYTOKINE THAT REPRESENTS A NEW CLASS OF CHEMOKINE	SCIENCE			English	Article							EXPRESSION; FAMILY; RECEPTOR; CLONING; CELLS	In this study, the cytokine-producing profile of progenitor T cells (pro-T cells) was determined. During screening of a complementary DNA library generated from activated mouse pro-T cells, a cytokine designated lymphotactin was discovered. Lymphotactin is similar to members of both the Cys-Cys and Cys-X-Cys chemokine families but lacks two of the four cysteine residues that are characteristic of the chemokines. Lymphotactin is also expressed in activated CD8(+) T cells and CD4(-)CD8(-) T cell receptor alpha beta(+) thymocytes. It has chemotactic activity for lymphocytes but not for monocytes or neutrophils. The gene encoding lymphotactin maps to chromosome one. Taken together, these observations suggest that lymphotactin represents a novel addition to the chemokine superfamily.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Largaespada, David/C-9832-2014; Zlotnik, Albert/C-3791-2011; Bazan, J. Fernando/B-4562-2010					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KENNEDY JD, UNPUB; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	18	590	631	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1395	1399		10.1126/science.7973732	http://dx.doi.org/10.1126/science.7973732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973732				2022-12-01	WOS:A1994PT63200047
J	GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W				GESSLER, K; KRAUSS, N; STEINER, T; BETZEL, C; SANDMANN, C; SAENGER, W			CRYSTAL-STRUCTURE OF BETA-D-CELLOTETRAOSE HEMIHYDRATE WITH IMPLICATIONS FOR THE STRUCTURE OF CELLULOSE-II	SCIENCE			English	Article							PACKING ANALYSIS; POLYSACCHARIDES	The crystal structure of beta-D-cellotetraose shows the same molecular packing as cellulose II, with two antiparallel molecules in the unit cell. For cellulose II, the orientation of the C6-O6 bonds has been described as gauche-trans and trans-gauche, respectively, for the two antiparallel molecules, which otherwise have identical conformations. In contrast, in beta-D-cellotetraose all C6-O6 bonds are gauche-trans, but the conformations of the two antiparallel molecules are different. Energy minimization and molecular dynamics studies suggest that the structure of cellulose II should be reinvestigated in light of these findings.	FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY; DESY,EUROPEAN MOLEC BIOL LAB OUTSTN,D-22603 HAMBURG,GERMANY	Free University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Krauss, Norbert/0000-0002-7128-4632				ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X; BLACKWELL J, 1980, FIBER DIFFRACTION ME, P315; CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011; DUDLEY RL, 1983, J AM CHEM SOC, V105, P2469, DOI 10.1021/ja00346a059; ISOGAI A, 1989, MACROMOLECULES, V22, P3168, DOI 10.1021/ma00197a045; KOLPAK FJ, 1976, MACROMOLECULES, V9, P273, DOI 10.1021/ma60050a019; PERTSIN AJ, 1987, ATOM ATOM POTENTIAL, P204; POLANYI M, 1921, NATURWISSENSCHAFTEN, V18, P337; SARKO A, 1974, MACROMOLECULES, V7, P486, DOI 10.1021/ma60040a016; SHELDRICK GM, 1976, SHELX PROGRAM CRYSTA; STEINER T, 1994, CARBOHYD RES, V259, P1, DOI 10.1016/0008-6215(94)84192-6; STEINER T, IN PRESS CARBOHYD RE; STIPANOVIC AJ, 1976, MACROMOLECULES, V9, P851, DOI 10.1021/ma60053a027; 1993, DISCOVER VERSION 310; [No title captured]	15	59	59	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1027	1029		10.1126/science.7973653	http://dx.doi.org/10.1126/science.7973653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973653				2022-12-01	WOS:A1994PQ92400039
J	IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE				IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE			FACILITATED BINDING OF TATA-BINDING PROTEIN TO NUCLEOSOMAL DNA	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; CRYSTAL-STRUCTURE; MINOR-GROOVE; TFIID BINDS; BOX COMPLEX; MAJOR LATE; YEAST; INVITRO	BINDING of the TATA-binding protein (TBP) to the TATA box is required for transcription from many eukaryotic promoters in gene expression. Regulation of this binding is therefore likely to be an important determinant of promoter activity. Incorporation of the TATA sequence into nucleosomes dramatically reduces transcription initiation(1-3), presumably because of stereochemical constraints on binding of general transcription factors. Biochemical and genetic studies imply that cellular factors such as yeast SWI/SNF are required for activator function and might alter chromatin structure(4-11). One step that could be regulated during the activation process is TBP binding in chromatin(12,13) We show here that binding of TBP to the TATA sequence is severely inhibited by incorporation of this sequence into a nucleosome. Inhibition can be overcome by ATP-dependent alterations in nucleosomal DNA structure mediated by hSWI/SNF, a putative human homologue of the yeast SWI/SNF complex. Additionally, the orientation of the TATA sequence relative to the surface of the histone core affects the access of TBP. We propose that the dynamic remodelling of chromatin structure to allow TBP binding is a key step in the regulation of eukaryotic gene expression.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	30	527	535	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					481	485		10.1038/370481a0	http://dx.doi.org/10.1038/370481a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047170				2022-12-01	WOS:A1994PB40700062
J	BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C				BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C			THE ETS DOMAIN PROTEIN POINTED-P2 IS A TARGET OF MAP KINASE IN THE SEVENLESS SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; FUNCTIONS DOWNSTREAM; GENETIC DISSECTION; DROSOPHILA EYE; GROWTH-FACTOR; ACTIVATION; EXPRESSION; CELLS; LOCALIZATION; PATTERN	The fate of the R7 photoreceptor cell in the developing eye of Drosophila is controlled by the Sevenless (Sev) receptor tyrosine kinase(1,2). Sev activates a highly conserved signal transduction cascade involving the proteins Ras1 and Raf and the Rolled/mitogen-activated protein (Rl/hlAP) kinase(3). Here we show that the ETS domain protein encoded by the P2 transcript of the pointed (pnt) gene is a nuclear target of this signalling cascade which acts downstream of RI/MAP kinase. The PntP2 protein is phosphorylated by Rl/MAP kinase in vitro at a single site and this site is required for its function in vivo. Furthermore, we present genetic and biochemical data suggesting that MAP kinase controls neural development through phosphorylation of two antagonizing transcription factors of the ETS family, Yan and PntP2.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND; UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Zurich; University of Cologne			Scholz, Henrike/ABE-1063-2020; Brunner, Damian/F-2024-2011	Brunner, Damian/0000-0001-5250-492X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1993, DEV DROSOPHILA; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JURGENS G, 1984, W ROUXS ARCH DEV BIO, V193, P183; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	30	317	319	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					386	389		10.1038/370386a0	http://dx.doi.org/10.1038/370386a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047146				2022-12-01	WOS:A1994PA30400060
J	NELLEN, D; AFFOLTER, M; BASLER, K				NELLEN, D; AFFOLTER, M; BASLER, K			RECEPTOR SERINE/THREONINE KINASES IMPLICATED IN THE CONTROL OF DROSOPHILA BODY PATTERN BY DECAPENTAPLEGIC	CELL			English	Article							TGF-BETA FAMILY; POSTERIOR COMPARTMENT BOUNDARY; DORSAL-VENTRAL PATTERN; POLARITY GENE HEDGEHOG; 2ND CHROMOSOME; GERM LAYERS; II RECEPTOR; CYTOGENETIC ANALYSIS; SPATIAL EXPRESSION; BICOID PROTEIN	Members of the TGF beta superfamily of secreted signaling molecules regulate growth and cellular patterning during development and interact with specific type I and type II membrane receptors possessing a cytoplasmic serine/threonine kinase domain. We describe two members of the type I receptor family in Drosophila and demonstrate that they are encoded by the genes saxophone (sax) and thick veins (tkv). Further, we show that mutations that abolish sex or tkv activity cause phenotypes similar to partial or complete loss of activity, respectively, of the TGF beta homolog decapentaplegic (dpp). We propose that specification of distinct cell fates in response to different concentrations of dpp may be achieved combinatorially by the sax and tkv receptors.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel				Affolter, Markus/0000-0002-5171-0016; Basler, Konrad/0000-0003-3534-1529				AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; ARORA K, 1992, DEVELOPMENT, V114, P1003; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CHASAN R, 1993, DEV DROSOPHILA MELAN, V1, P387; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DEFRUTOS R, 1990, METHODS MOL CELL BIO, V2, P32; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RAY RP, 1991, DEVELOPMENT, V113, P35; Rushlow C, 1990, Adv Genet, V27, P277; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1989, GENETICS, V121, P101; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TOROK T, 1993, GENETICS, V135, P71; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wieschaus E., 1986, P199; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223	69	249	253	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					225	237		10.1016/0092-8674(94)90293-3	http://dx.doi.org/10.1016/0092-8674(94)90293-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044837	Green Accepted			2022-12-01	WOS:A1994NZ24200007
J	BODEN, G; MURER, E; MOZZOLI, M				BODEN, G; MURER, E; MOZZOLI, M			GLUCOSE-TRANSPORTER PROTEINS IN HUMAN INSULINOMA	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-CELL LINE; GENE-EXPRESSION; MESSENGER-RNA; RAT; SEQUENCE; LIVER	Objective: To determine the reason patients with insulinoma are unable to cease insulin secretion during hypoglycemia. Patients: Five patients with insulinoma. Design: All patients fasted for up to 25 hours, during which blood was obtained serially for determination of glucose and insulin concentrations. Insulinomas were surgically removed from all patients and Glut 1 and Glut 2 transporter proteins were measured in solubilized tumor membranes by immune blotting. Results: in all patients, serum insulin concentrations failed to decrease to less than 30.0 pmol/L (<5.0 mu U/mL) and C-peptide concentrations to less than 0.08 nmol/L during hypoglycemia (glucose concentration, <2.2 mmol/L) that was induced by fasting. The islet cell tumors from all five patients contained Glut 1, a low-K-m glucose transporter protein, which is not normally present in beta-cells. Glut 2, a high-K-m glucose transporter protein, which is normally prevalent in beta-cells, was undetectable in one patient and was present in what appeared to be low concentrations in the remaining four patients. Conclusions: Our data are compatible with the concept that continued glucose transport, mediated by the low-K-m Glut 1 glucose transporter, was responsible for continued insulin release during hypoglycemia in these patients.			BODEN, G (corresponding author), TEMPLE UNIV HOSP & MED SCH, 3401 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIA NIH HHS [R01 AG-07988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BODEN G, 1989, GASTROENTEROL CLIN N, V18, P831; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GERSGIBU, 1990, METHOD BIOCHEM ANAL, V33, P1; GORUS FK, 1984, J BIOL CHEM, V259, P1196; HARRIS V, 1979, METHOD HORM RADIOIMM, P643; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RASTOGI GK, 1970, DIABETOLOGIA, V6, P445, DOI 10.1007/BF01212080; SALTIS J, 1991, J BIOL CHEM, V266, P261; SEINO Y, 1993, J CLIN ENDOCR METAB, V76, P75, DOI 10.1210/jc.76.1.75; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; YASUNAMI Y, 1987, J CLIN ENDOCR METAB, V65, P110, DOI 10.1210/jcem-65-1-110	24	31	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					109	112		10.7326/0003-4819-121-2-199407150-00005	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017722				2022-12-01	WOS:A1994NW18600005
J	ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM				ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM			THE ACTIVITIES OF 2 ETS-RELATED TRANSCRIPTION FACTORS REQUIRED FOR DROSOPHILA EYE DEVELOPMENT ARE MODULATED BY THE RAS/MAPK PATHWAY	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SUBSTRATE RECOGNITION; TYROSINE KINASE; DOMAIN PROTEIN; GENE; PHOSPHORYLATION; RAS1; IDENTIFICATION; PHOTORECEPTOR; EXPRESSION	We show that the activities of two Ets-related transcription factors required for normal eye development in Drosophila, pointed and yan, are regulated by the Ras1/MAPK pathway. The pointed gene codes for two related proteins, and we show that one form is a constitutive activator of transcription, while the activity of the other form is stimulated by the Ras1/MAPK pathway. Mutation of the single consensus MARK phosphorylation site in the second form abrogates this responsiveness. yan is a negative regulator of photoreceptor determination, and genetic data suggest that it acts as an antagonist of Ras1. We demonstrate that yan can repress transcription and that this repression activity is negatively regulated by the Ras1/MAPK signal, most likely through direct phosphorylation of yan by MAPK.			ONEILL, EM (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703	NIGMS NIH HHS [GM33135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033135, R01GM033135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KARPEN GH, 1992, GENETICS, V132, P737; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, THESIS U CALIFORNIA; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	39	582	588	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					137	147		10.1016/0092-8674(94)90580-0	http://dx.doi.org/10.1016/0092-8674(94)90580-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033205				2022-12-01	WOS:A1994NX32800016
J	STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF				STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF			TESTING THE EXON THEORY OF GENES - THE EVIDENCE FROM PROTEIN-STRUCTURE	SCIENCE			English	Article							TRIOSEPHOSPHATE ISOMERASE GENE; MULTIPLE SEQUENCE ALIGNMENT; INTRON-DEPENDENT EVOLUTION; ALCOHOL-DEHYDROGENASE GENE; PYRUVATE-KINASE GENE; ASPERGILLUS-NIDULANS; MOLECULAR ANALYSIS; SPLICE SITES; IN-PIECES; CHICKEN	A tendency for exons to correspond to discrete units of protein structure in protein-coding genes of ancient origin would provide clear evidence in favor of the exon theory of genes, which proposes that split genes arose not by insertion of introns into unsplit genes, but from combinations of primordial mini-genes (exons) separated by spacers (introns). Although putative examples of such correspondence have strongly influenced previous debate on the origin of introns, a general correspondence has not been rigorously proved. Objective methods for detecting correspondences were developed and applied to four examples that have been cited previously as evidence of the exon theory of genes. No significant correspondence between exons and units of protein structure was detected, suggesting that the putative correspondence does not exist and that the exon theory of genes is untenable.	WASHINGTON UNIV,CANADIAN INST ADV RES,INST BIOMED COMP,PROGRAM EVOLUT BIOL,ST LOUIS,MO 63110; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Washington University (WUSTL); Indiana University System; Indiana University Bloomington	STOLTZFUS, A (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,DEPT BIOCHEM,PROGRAM EVOLUT BIOL,HALIFAX B3H 4H7,NS,CANADA.		Logsdon, John M/B-7812-2009; Stoltzfus, Arlin/D-8551-2011	Stoltzfus, Arlin/0000-0002-0963-1357; Doolittle, W. Ford/0000-0002-4675-8832	NIGMS NIH HHS [GM-35087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BOLTON W, 1970, NATURE, V228, P551, DOI 10.1038/228551a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P142; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; COLE KP, 1992, GENE, V122, P255, DOI 10.1016/0378-1119(92)90213-9; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DEGRAAFF L, 1988, CURR GENET, V14, P553, DOI 10.1007/BF00434080; DENNIS ES, 1984, NUCLEIC ACIDS RES, V12, P3983, DOI 10.1093/nar/12.9.3983; DIBB NJ, 1989, EMBO J, V8, P2015, DOI 10.1002/j.1460-2075.1989.tb03609.x; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1991, SCIENCE, V253, P677, DOI 10.1126/science.1871603; DOOLITTLE WF, 1993, NATURE, V361, P403, DOI 10.1038/361403a0; DOOLITTLE WF, 1987, AM NAT, V130, P915, DOI 10.1086/284755; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; DUESTER G, 1986, NUCLEIC ACIDS RES, V14, P1931, DOI 10.1093/nar/14.5.1931; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILBERT W, 1994, GENE, V135, P137; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HICKEY DA, 1989, J THEOR BIOL, V137, P41, DOI 10.1016/S0022-5193(89)80148-1; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; LONBERG N, 1985, CELL, V40, P81, DOI 10.1016/0092-8674(85)90311-3; MICHELSON AM, 1985, P NATL ACAD SCI USA, V82, P6965, DOI 10.1073/pnas.82.20.6965; MOENS L, 1993, FEBS LETT, V320, P284, DOI 10.1016/0014-5793(93)80604-S; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NAKANO T, 1991, BIOCHIM BIOPHYS ACTA, V1090, P273, DOI 10.1016/0167-4781(91)90118-6; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTHY L, 1991, BIOESSAYS, V13, P187, DOI 10.1002/bies.950130408; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; POHAJDAK B, 1993, FEBS LETT, V320, P281, DOI 10.1016/0014-5793(93)80603-R; PRESS WH, 1992, NUMERICAL RECIPES C, P282; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; STOLTZFUS A, 1993, CURR BIOL, V3, P215, DOI 10.1016/0960-9822(93)90336-M; STONE EM, 1985, NATURE, V313, P498, DOI 10.1038/313498a0; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; TITTIGER C, 1993, NATURE, V361, P470, DOI 10.1038/361470a0; WATSON JD, 1987, MOL BIOL GENE, P1145; ZUKER M, UNPUB; [No title captured]	56	194	198	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					202	207		10.1126/science.8023140	http://dx.doi.org/10.1126/science.8023140			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023140				2022-12-01	WOS:A1994NV95700027
J	ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR				ALMOHANNA, FA; CADDY, KWT; BOLSOVER, SR			THE NUCLEUS IS INSULATED FROM LARGE CYTOSOLIC CALCIUM-ION CHANGES	NATURE			English	Article							SMOOTH-MUSCLE CELLS; C-FOS EXPRESSION; INTRACELLULAR CALCIUM; CONFOCAL MICROSCOPY; PORE COMPLEX; NEURONS; TRANSCRIPTION; TRANSIENTS; GRADIENTS; DYNAMICS	EXTRACELLULAR events regulate functions in the cell nucleus by means of calcium ions acting through effector enzymes1-5. Recently, the traditional view of the nuclear pore as freely permeable to small ions6,7 has been questioned as a result of reports that nuclear calcium can be regulated independently of cytosolic calcium8-12. We have used confocal microscopy of fluorescent Ca2+ indicators to investigate the Ca2+ dynamics between cytosol and nucleus in neurons. We find that a previously reported amplification of Ca2+ changes in the nucleus13-16 is a measurement artefact. Small changes of cytosolic Ca2+ cause equally rapid changes in nuclear Ca2+, consistent with the free diffusion of Ca2+ through nuclear pores. In contrast, large cytosolic Ca2+ increases (above 300 nM) are attempted in the nucleus. Our results show the nuclear envelope shapes but does not block the passage of Ca2+ signals from cytosol to nucleus.	UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMOHANNA FA, 1992, DEV BRAIN RES, V70, P287, DOI 10.1016/0165-3806(92)90209-F; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; MEHMET H, 1991, BRIT MED BULL, V47, P76, DOI 10.1093/oxfordjournals.bmb.a072463; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; WAHL M, 1992, J CELL PHYSIOL, V150, P593, DOI 10.1002/jcp.1041500321; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	25	228	232	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					745	750		10.1038/367745a0	http://dx.doi.org/10.1038/367745a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7993399				2022-12-01	WOS:A1994MX63100061
J	AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D				AMOR, JC; HARRISON, DH; KAHN, RA; RINGE, D			STRUCTURE OF THE HUMAN ADP-RIBOSYLATION FACTOR-1 COMPLEXED WITH GDP	NATURE			English	Article							PHOSPHOLIPASE-D; PROTEIN; BINDING; RESOLUTION; COFACTOR; ARF	ADP-ribosylation factors (ARFs) are essential and ubiquitous in eukaryotes, being involved in vesicular transport and functioning as an activator of phospholipase D (refs 1, 2) and cholera toxin(3,4). The functions of ARF proteins in membrane traffic and organelle integrity(5,6) are intimately tied to its reversible association with membranes and specific interactions with membrane phospholipids. One common feature of these functions is their regulation by the binding and hydrolysis of GTP. Here we report the three-dimensional structure of full-length human ARF1 (M(r) 21,000) in its GDP-bound non-myristoylated form. The presence of a unique amino-terminal alpha-helix and loop, together with differences in Mg2+ ligation and the existence of a non-crystallographic dimer, set this structure apart from other GTP-binding proteins. These features provide a structural basis for the GTP-dependent modulation of membrane affinity, the lack of intrinsic GTPase activity, and the nature of effector binding surfaces.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,PROGRAM BIOORGAN CHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM & BIOCHEM,WALTHAM,MA 02254; NCI,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892	Brandeis University; Brandeis University; Brandeis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				Barbacid M., 1987, REV BIOCH, V56, P779; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALKIDES CJ, 1994, BIOCHEMISTRY-US, V33, P4019, DOI 10.1021/bi00179a031; JOHN J, 1989, J BIOL CHEM, V264, P13086; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, IN PRESS J BIOL CHEM; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; ROSENWALD AG, 1994, GTPASE CONTROLLED MO; SEUELL JL, 1988, P NATL ACAD SCI USA, V85, P4620; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; PROGRAM MANUAL GCG P	29	241	246	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					704	708						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990966				2022-12-01	WOS:A1994PX30700094
J	ZHENG, B; XUE, W; KELSOE, G				ZHENG, B; XUE, W; KELSOE, G			LOCUS-SPECIFIC SOMATIC HYPERMUTATION IN GERMINAL CENTER T-CELLS	NATURE			English	Article							IMMUNOGLOBULIN GENES; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; CHAIN GENES; MUTATION; GENERATION; SEQUENCES; CENTERS; MEMORY; DNA	SOMATIC hypermutation and affinity-driven selection of active immunoglobulin genes occur in germinal centres (GCs), resulting in the generation of high-affinity memory B cells(1-3). In contrast, T lymphocytes do not require the germinal centre microenvironment to establish memory and the T-cell antigen receptor (TCR) genes, though homologous to immunoglobulin genes, are believed to be incapable of hypermutation(5-7). Here we present direct evidence that the small population of antigen-specific T cells that are recruited into splenic GCs acquire mutations in the variable region of genes encoding TCR alpha-chains (V alpha) but not those of beta-chains. These locus-specific mutations reach frequencies comparable to mutated inmunoglobulin V-H exons recovered from the same site and exhibit similar substitution biases and DNA strand polarity. T cells bearing identical mutations appear in multiple GCs, raising the possibility that some cells bearing mutant TCRs may re-enter the peripheral lymphocyte pool.			ZHENG, B (corresponding author), UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.			Kelsoe, Garnett/0000-0002-8770-040X				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BLOMBERG B, 1982, P NATL ACAD SCI-BIOL, V79, P530, DOI 10.1073/pnas.79.2.530; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER K, 1993, J IMMUNOL, V9, P4505; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P678; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LUNDBERG KS, 1991, GENE, V106, P1; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; TAO W, 1990, J IMMUNOL, V145, P3216; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEISS U, 1990, J EXP MED, V172, P1680; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	30	115	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					556	559		10.1038/372556a0	http://dx.doi.org/10.1038/372556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990929				2022-12-01	WOS:A1994PW08200054
J	SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J				SANDERSON, F; KLEIJMEER, MJ; KELLY, A; VERWOERD, D; TULP, A; NEEFJES, JJ; GEUZE, HJ; TROWSDALE, J			ACCUMULATION OF HLA-DM, A REGULATOR OF ANTIGEN PRESENTATION, IN MHC CLASS-II COMPARTMENTS	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; RNA-POLYMERASE; DR MOLECULES; CLONED GENES; EXPRESSION; LOCUS	The HLA-DM genes encode an unconventional HLA (human leukocyte antigen) class II molecule that is required for appropriate binding of peptide to classical HLA class II products. In the absence of DM, other class II molecules are unstable upon electrophoresis in sodium dodecyl sulfate and are largely associated with a nested set of peptides derived from the invariant chain called CLIP, for class Ii-associated invariant chain peptides. DMA and DMB associated and accumulated in multilaminar, intracellular compartments with classical class II molecules, but were found infrequently, if at all, at the cell surface. Thus, DM may facilitate peptide binding to class II molecules within these intracellular compartments.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Cancer Research UK; Utrecht University; Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARLOW E, 1988, ANTIBODIES LABORATOR; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LIOU W, 1994, P INT C ELECTRON MIC, V13; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THORPE C, COMMUNICATION; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	29	232	235	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1566	1569		10.1126/science.7985027	http://dx.doi.org/10.1126/science.7985027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985027				2022-12-01	WOS:A1994PV01500045
J	SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA				SOMERS, W; ULTSCH, M; DEVOS, AM; KOSSIAKOFF, AA			THE X-RAY STRUCTURE OF A GROWTH-HORMONE PROLACTIN RECEPTOR COMPLEX	NATURE			English	Article							EXTRACELLULAR DOMAIN; BINDING DETERMINANTS; RATIONAL DESIGN; DIMERIZATION; SUPERFAMILY; ANTAGONISTS; REFINEMENT; VARIANTS; CRYSTALS; DETECTOR	THE human pituitary hormones, growth hormone (hGH) and prolactin (hPRL), regulate a large variety of physiological processes, among which are growth and differentiation of muscle, bone and cartilage cells, and lactation(1). These activities are initiated by hormone-receptor binding. The hGH and hPRL receptors (hGH(R) and hPRL(R), respectively) are single-pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily(2,3). This classification is based on sequence similarity in their extracellular domains, notably a highly conserved pentapeptide, the so-called 'WSXWS box', the function of which is controversial. All ligands in class 1 activate their respective receptors by clustering mechanisms(4). In the case of hGH, activation involves receptor homodimerization in a sequential process: the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1:1 complex(5-8). hPRL does not bind to the hGH receptor, but hGH binds to both the hGH(R) and hPRL(R), and mutagenesis studies have shown that the receptor-binding sites on hGH overlap(9). We present here the crystal structure of the 1:1 complex of hGH bound to the extracellular domain of the hPRL(R). Comparisons with the hGH-hGH(R) complex(10) reveal how hGH can bind to the two distinctly different receptor binding surfaces.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRUNER AT, 1992, X PLOR REFERENCE MAN; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135	24	339	350	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					478	481		10.1038/372478a0	http://dx.doi.org/10.1038/372478a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984244				2022-12-01	WOS:A1994PV01200061
J	BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF				BURTON, DR; PYATI, J; KODURI, R; SHARP, SJ; THORNTON, GB; PARREN, PWHI; SAWYER, LSW; HENDRY, RM; DUNLOP, N; NARA, PL; LAMACCHIA, M; GARRATTY, E; STIEHM, ER; BRYSON, YJ; CAO, YZ; MOORE, JP; HO, DD; BARBAS, CF			EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SOLUBLE CD4; COMBINATORIAL LIBRARIES; TYPE-1; GP120; ASSAY; VACCINE; BINDING; GP160; GENES	The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; CALIF DEPT HLTH SERV, VIRAL & RICKETTSIAL DIS LAB, BERKELEY, CA 94704 USA; NCI, FREDERICK CANC RES & DEV CTR, TUMOR CELL BIOL LAB, VIRUS BIOL SECT, FREDERICK, MD 21702 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; NYU, SCH MED, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; California Department of Health Care Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York University	BURTON, DR (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Dr. Peter L. Nara, M.Sc./I-7432-2019	Thornton, George/0000-0002-8744-4987; Parren, Paul/0000-0002-4365-3859	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, R37AI033292, R01AI033292] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35168, AI27742, AI33292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9939; Bender Eckhard, 1993, Human Antibodies and Hybridomas, V4, P74; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BRYSON Y, 1993, J CELL BIOCH SE, V17, P95; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; COHEN J, 1994, SCIENCE, V264, P1072, DOI 10.1126/science.8178162; COHEN J, 1993, SCIENCE, V262, P980, DOI 10.1126/science.8235635; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DSOUZA MP, 1994, AIDS, V8, P169; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSON CV, 1990, J CLIN MICROBIOL, V28, P2030, DOI 10.1128/JCM.28.9.2030-2034.1990; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P633; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1989, AIDS, V3, P155, DOI 10.1097/00002030-198903000-00006; MOORE JS, UNPUB; NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; SAWYER LSW, 1994, J VIROL, V68, P1342, DOI 10.1128/JVI.68.3.1342-1349.1994; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; 1993, AIDS CLIN TRIALS GRO	38	956	1041	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1024	1027		10.1126/science.7973652	http://dx.doi.org/10.1126/science.7973652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973652				2022-12-01	WOS:A1994PQ92400038
J	CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ				CALDER, SJ; ANDERSON, GH; HARPER, WM; GREGG, PJ			ETHNIC VARIATION IN EPIDEMIOLOGY AND REHABILITATION OF HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							OSTEOMALACIA				CALDER, SJ (corresponding author), UNIV LEICESTER,GLENFIELD GEN HOSP,DEPT ORTHOPAED SURG,LEICESTER LE3 9QP,LEICS,ENGLAND.							ANDERSON GH, 1993, J BONE JOINT SURG BR, V75, P441, DOI 10.1302/0301-620X.75B3.8496217; ROBINSON CM, 1992, INJURY, V23, P300, DOI 10.1016/0020-1383(92)90172-O; STAMP TCB, 1980, CLIN ENDOCRINOL META, V9, P81, DOI 10.1016/S0300-595X(80)80022-3; STEPHENS WP, 1982, Q J MED, V202, P171; WILTON TJ, 1987, J BONE JOINT SURG BR, V69, P388, DOI 10.1302/0301-620X.69B3.3584190	5	11	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1124	1125		10.1136/bmj.309.6962.1124a	http://dx.doi.org/10.1136/bmj.309.6962.1124a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987105	Green Published			2022-12-01	WOS:A1994PP69100022
J	PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP				PATEL, P; MENDALL, MA; KHULUSI, S; NORTHFIELD, TC; STRACHAN, DP			HELICOBACTER-PYLORI INFECTION IN CHILDHOOD - RISK-FACTORS AND EFFECT ON GROWTH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNIDENTIFIED CURVED BACILLI; CAMPYLOBACTER-PYLORI; GASTRITIS; SEROEPIDEMIOLOGY; SYMPTOMS; HEIGHT	Objective-To investigate the current prevalence of Helicobacter pylori infection in childhood, the risk factors for infection, and the effect of infection on growth in preadolescent schoolchildren. Design-Population based sample of 7 year old schoolchildren followed up at age 11; data on risk factors for infection collected at age 7; presence of infection at age 11 determined by measurement of salivary IgG against H pylori by a newly developed: enzyme linked immunosorbent assay (ELISA). Height was measured at 7 and 11 years of age. Subjects-554 schoolchildren from Edinburgh. Results-62 (11%) children had H pylori infection. Independent risk factors for infection were single parent families (adjusted odds ratio=2.5; 95% confidence interval 1.1 to 5.7), the 10% most crowded homes (3.1; 1.3 to 7.2), and schools serving predominantly rented housing estates (2.5; 1.0 to 6.5). School catchment area was more important than parental social class or housing tenure. Growth in height between 7 and 11 was diminished in infected children by a mean of 1.1 cm (0.3 to 2.0 cm) over four years. This growth reduction was largely confined to girls (1.6 cm over four years), among whom it correlated with salivary IgG (P=0.015). Conclusion-Data from salivary assay to investigate the epidemiology of H pylori suggest that factors relating to the type of community in which the child lives may now be as important for acquisition of this infection as features of the family home. The greater reduction of growth among infected girls raises the possibility that H pylori infection may delay or diminish the pubertal growth spurt.	ST GEORGE HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	PATEL, P (corresponding author), ST GEORGE HOSP, SCH MED, DIV BIOCHEM MED, LONDON SW17 0RE, ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BIRKHOLZ S, 1993, FEMS IMMUNOL MED MIC, V6, P317, DOI 10.1016/0928-8244(93)90008-R; CAMPBELL AGM, 1992, FORFAR ARNEILS TXB P, P423; CRABTREE JE, 1993, SCAND J IMMUNOL, V37, P65, DOI 10.1111/j.1365-3083.1993.tb01666.x; CROWNE EC, 1991, EUR J PEDIATR, V150, P708, DOI 10.1007/BF01958760; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HILL ID, 1987, ARCH DIS CHILD, V62, P1215, DOI 10.1136/adc.62.12.1215; JIVANI SKM, 1973, ARCH DIS CHILD, V48, P109, DOI 10.1136/adc.48.2.109; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KUH DL, 1991, INT J EPIDEMIOL, V20, P1001, DOI 10.1093/ije/20.4.1001; MARSHALL BJ, 1984, LANCET, V1, P1311; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MENDALL M, 1994, GUT               S1, V35, pS4; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1993, GUT, V34, pS3; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATEL D, 1994, GUT, V35, pS64; PATEL P, IN PRESS LANCET; RAYMOND J, 1994, J CLIN MICROBIOL, V32, P461, DOI 10.1128/JCM.32.2.461-463.1994; ROTHWELL NJ, 1991, J ENDOCRINOL, V128, P171, DOI 10.1677/joe.0.1280171; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; TANNER JM, 1973, NATURE, V243, P95, DOI 10.1038/243095a0; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; THOMAS J, 1988, GUT, V29, pA707; WARREN JR, 1983, LANCET, V1, P1273; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; 1991, ITALIAN J GASTROE S2, V23, P19	31	210	215	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	1994	309	6962					1119	1123		10.1136/bmj.309.6962.1119	http://dx.doi.org/10.1136/bmj.309.6962.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7987103	Green Published			2022-12-01	WOS:A1994PP69100020
J	SCHWARTZ, TB				SCHWARTZ, TB			ASK, AND IT SHALL BE GIVEN YOU	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					376	376		10.7326/0003-4819-121-5-199409010-00011	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042828				2022-12-01	WOS:A1994PD70100011
J	GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC				GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC			ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS	ANNALS OF INTERNAL MEDICINE			English	Article						ASPIRIN; COLORECTAL NEOPLASMS; ADENOMA; RISK; HEALTH PERSONNEL	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; COLON CANCER; LARGE-BOWEL; INDOMETHACIN TREATMENT; ALCOHOL-CONSUMPTION; INTESTINAL TUMORS; REDUCED RISK; POLYPOSIS; SULINDAC	Objective: To determine whether regular use of aspirin decreases the risk for colorectal cancer. Design: Prospective cohort study. Setting: Male health professionals throughout the United States. Patients: 47 900 male respondents to a mailed questionnaire in 1986, who were 40 to 75 years of age. Measurements: Questionnaires in 1986, 1988, and 1990 about use of aspirin and other variables including occurrence of cancer. Results: 251 new patients were diagnosed with colorectal cancer during the study period. Regular users of aspirin (greater than or equal to 2 times per week) in 1986 had a lower risk for total colorectal cancer (relative risk [RR] = 0.68; 95% CI, 0.52 to 0.92) and advanced (metastatic and fatal) colorectal cancer (RR = 0.51; CI, 0.32 to 0.84) after controlling for age; history of polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; physical activity; and intakes of red meat, vitamin E, and alcohol. The incremental association was greater among men who reported regular use of aspirin consistently on subsequent questionnaires. The total number of colorectal adenomas discovered among aspirin users was lower with or without overt or occult fecal blood. Thus, earlier diagnosis and treatment of adenomas did not account for the inverse association between aspirin and cancer. Conclusions: These results support laboratory, clinical, and other epidemiologic evidence that regular use of aspirin is associated with a decreased risk for colorectal cancer.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARON JA, 1991, NEW ENGL J MED, V325, P1644, DOI 10.1056/NEJM199112053252309; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GONZAGA RAF, 1985, LANCET, V1, P751; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MARNETT LJ, 1992, CANCER RES, V52, P5575; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; 1989, CANCER STATISTICS RE	34	681	711	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					241	246		10.7326/0003-4819-121-4-199408150-00001	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037405				2022-12-01	WOS:A1994PB10200001
J	ZOHARY, E; SHADLEN, MN; NEWSOME, WT				ZOHARY, E; SHADLEN, MN; NEWSOME, WT			CORRELATED NEURONAL DISCHARGE RATE AND ITS IMPLICATIONS FOR PSYCHOPHYSICAL PERFORMANCE	NATURE			English	Article							VISUAL AREA MT; CORTICAL-NEURONS; SINGLE NEURONS; MONKEY; DISCRIMINATION; MICROSTIMULATION; ORIENTATION; FREQUENCY; STIMULI; MOTION	SINGLE neurone can signal subtle changes in the sensory environment with surprising fidelity, often matching the perceptual sensitivity of trained psychophysical observers This similarity poses an intriguing puzzle: why is psychophysical sensitivity not greater than that of single neurons? Pooling responses across neurons should average out noise in the activity of single cells, leading to substantially improved psychophysical performance. If, however, noise is correlated among these neurons, the beneficial effects of pooling would be diminished(10-12). To assess correlation within a pool, the responses of pairs of neurons were recorded simultaneously during repeated stimulus presentations. We report here that the observed covariation in spike count was relatively weak, the correlation coefficient averaging 0.12. A theoretical analysis revealed, however, that weak correlation can limit substantially the signalling capacity of the pool. In addition, theory suggests a relationship between neuronal responses and psychophysical decisions which may prove useful for identifying cell populations underlying specific perceptual capacities.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Newsome, William T./W-7171-2019; Shadlen, Michael Neil/AAL-1870-2020	Shadlen, Michael/0000-0002-2002-2210				Anderson T.W., 1958, INTRO MULTIVARIATE S, V2nd ed; BRADLEY A, 1987, J NEUROPHYSIOL, V57, P755, DOI 10.1152/jn.1987.57.3.755; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CELEBRINI S, IN PRESS J NEUROSCI; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; Hawken M.J., 1990, P103; JOHNSON KO, 1980, J NEUROPHYSIOL, V43, P1793, DOI 10.1152/jn.1980.43.6.1793; JOHNSON KO, 1979, J NEUROPHYSIOL, V42, P1332, DOI 10.1152/jn.1979.42.5.1332; JOHNSON KO, 1973, J NEUROPHYSIOL, V36, P347, DOI 10.1152/jn.1973.36.2.347; MOUNTCASTLE VB, 1972, J NEUROPHYSIOL, V35, P122, DOI 10.1152/jn.1972.35.1.122; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; NEWSOME WT, 1989, NEURAL MECHANISMS VI, P171; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; VANKAN P, 1985, EXPL BRAIN RES, P559; VOGELS R, 1990, J NEUROSCI, V10, P3543; WORGOTTER F, 1986, J NEUROSCI METH, V17, P141, DOI 10.1016/0165-0270(86)90067-1; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	22	855	856	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					140	143		10.1038/370140a0	http://dx.doi.org/10.1038/370140a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022482				2022-12-01	WOS:A1994NW80400057
J	DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML				DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML			PURSUIT AND PRACTICE OF COMPLEMENTARY THERAPIES BY CANCER-PATIENTS RECEIVING CONVENTIONAL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine what proportion of oncology patients receiving conventional medical treatment also use complementary treatments; to assess which complementary treatments are the most popular and to assess patients' motivation for using them; to evaluate associated advantages and risks. Design-Postal screening questionnaire followed by semistructured interview. Setting-Two hospitals in inner London. Subjects-600 unselected oncology patients aged 18 or over who had known their diagnosis of cancer for at least three months. Main outcome measures-Prevalence and demography of use of complementary therapies; patients' motivation and expectations of complementary therapies; areas of satisfaction and dissatisfaction associated with conventional and complementary therapies. Results-415 (69%) patients returned the questionnaire. 16% had used complementary therapies. The most popular were healing, relaxation, visualisation, diets, homoeopathy, vitamins, herbalism, and the Bristol approach. Patients using complementary therapies tended to be younger, of higher social class, and female. Three quarters used two or more therapies. Therapies were mostly used for anticipated antitumour effect. Ill effects of diets and herb treatments were described. Satisfaction with both conventional and complementary therapies was high, although diets often caused difficulties. Patients using complementary therapies were less satisfied with conventional treatments, largely because of side effects and lack of hope of cure. Benefits of complementary therapies were mainly psychological. Conclusions-A sizeable percentage of patients receiving conventional treatments for cancer also use complementary therapies. Patient satisfaction with complementary therapies, other than dietary therapies, was high even without the hoped for anticancer effect. Patients reported psychological benefits such as hope and optimism.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			McCluskey, Peter J/H-7607-2013	McCluskey, Peter J/0000-0002-8177-1637				ALDRIDGE D, 1989, BRIT MED J, V299, P1211; BAGENAL FS, 1990, LANCET, V336, P1185; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Dickson A C, 1985, Oncol Nurs Forum, V12, P49; FULDER S, 1982, STATUS COMPLEMENTARY; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; SIKORA K, 1970, CANCER CARE, V7, P9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1986, ALTERNATIVE THERAPY	11	245	246	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					86	89		10.1136/bmj.309.6947.86	http://dx.doi.org/10.1136/bmj.309.6947.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038672	Green Published			2022-12-01	WOS:A1994NW71600015
J	LAND, MF; LEE, DN				LAND, MF; LEE, DN			WHERE WE LOOK WHEN WE STEER	NATURE			English	Article							COORDINATION	STEERING a car requires visual information from the changing pattern of the road ahead. There are many theories about what features a driver might use(1-3), and recent attempts to engineer self-steering vehicles have sharpened interest in the mechanisms involved(4,5). However, there is little direct information linking steering performance to the driver's direction of gaze(3). We have made simultaneous recordings of steering-wheel angle and drivers' gaze direction during a series of drives along a tortuous road. We found that drivers rely particularly on the 'tangent point' an the inside of each curve, seeking this point 1-2 s before each bend and returning to it throughout the bend. The direction of this point relative to the car's heading predicts the curvature of the road ahead, and we examine the way this information is used.	UNIV EDINBURGH, DEPT PSYCHOL, PERCEPT ACT LABS, EDINBURGH EH8 9JZ, SCOTLAND	University of Edinburgh	LAND, MF (corresponding author), UNIV SUSSEX, SCH BIOL SCI, SUSSEX CTR NEUROSCI, BRIGHTON BN1 9QG, ENGLAND.							BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; Carpenter RHS, 1988, MOVEMENTS EYES; Dickmanns E. D., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P608, DOI 10.1109/ICCV.1993.378155; LAND MF, 1992, NATURE, V359, P318, DOI 10.1038/359318a0; LAND MF, 1993, P IEEE SYST MAN CYB, V3, P490; LANDWEHR K, 1991, VISION VEHICLES, V3, P187; LEE DN, 1977, SCAND J PSYCHOL, V18, P224, DOI 10.1111/j.1467-9450.1977.tb00281.x; OKUNO A, 1992, VISION BASED VEHICLE, P222; Raviv D., 1991, Proceedings of the IEEE Workshop on Visual Motion (Cat. No.91TH0390-5), P217, DOI 10.1109/WVM.1991.212804; RIEMERSMA JBJ, 1991, VISION VEHICLES, V3, P163; SERAFIN C, 1993, UMTRI9329163 U MICH; WARREN WH, 1991, J EXP PSYCHOL HUMAN, V17, P28, DOI 10.1037/0096-1523.17.1.28	12	653	671	1	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					742	744		10.1038/369742a0	http://dx.doi.org/10.1038/369742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008066				2022-12-01	WOS:A1994NU58100059
J	YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC				YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC			NEGATIVE FEEDBACK-REGULATION OF IGE SYNTHESIS BY MURINE CD23	NATURE			English	Article							LOW-AFFINITY RECEPTOR; FC-EPSILON-RII; B-CELLS; T-CELLS; FC-EPSILON-RII/CD23; LYMPHOCYTES; INHIBITION; ACTIVATION; RESPONSES; CLONES	IMMUNOGLOBULIN E is found in nanogram amounts in normal human and mouse serum. It is increased during parasitic infestations(1) and mediates allergy. CD23, the low-affinity receptor for IgE (Fc epsilon RII), has been proposed as an important regulator of IgE synthesis(2-4). The type-II transmembrane lectin(4) CD23 is expressed in the mouse on B cells and follicular dendritic cells. In humans there are two forms of CD23 which differ in their intracellular amino-terminal 6/7 amino acids(4); expression of the A-form corresponds to that of murine CD23, whereas the B-form is also found on T and other haematopoietic cells(4). CD23 has been implicated in cellular adhesion(5), antigen presentation(6), as a growth and differentiation factor for human B, T and plasma cells, and as a signal transduction molecule(7) (reviewed in refs 3, 8). Here we disrupt the gene coding for murine CD23 (ref. 9) to clarify the role of CD23 in vivo and find that B- and T-cell development is normal in these CD23-deficient mice. Immune responses to the helminth Nippostrongylus brasiliensis are unaffected, In contrast, immunization with thymus-dependent antigens leads to increased and sustained specific IgE antibody titres compared with controls. Formation of germinal centres is normal. These results suggest that murine CD23 acts as a negative feedback component of IgE regulation.	MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; MED BIOL INST,LA JOLLA,CA 92037	Max Planck Society				Yu, Philipp/0000-0003-2629-6690				ADAMCZEWSKI M, 1991, EUR J IMMUNOL, V21, P617, DOI 10.1002/eji.1830210313; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; AYANE MP, 1990, NUCLEIC ACIDS RES, V17, P6722; BERTHO JM, 1991, EUR J IMMUNOL, V21, P1073, DOI 10.1002/eji.1830210433; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; GORDON J, 1991, MONOGR ALLERGY CD23, V29; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; KEEGAN AD, 1989, J IMMUNOL, V142, P3868; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KOLB JP, 1993, J IMMUNOL, V150, P4798; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEBRUN P, 1987, J IMMUNOL, V139, P1459; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUO H, 1991, J IMMUNOL, V146, P2125; MAEDA K, 1992, J IMMUNOL, V148, P2340; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; RAO M, 1987, J IMMUNOL, V138, P1845; RICHARDS ML, 1991, J IMMUNOL, V147, P1067; SAXON A, 1991, J IMMUNOL, V147, P4000; SHERR E, 1989, J IMMUNOL, V142, P481; SINCLAIR NRS, 1983, IMMUNOL TODAY, V4, P35, DOI 10.1016/0167-5699(83)90107-X; STREET NE, 1990, J IMMUNOL, V144, P1629; SUUTTON BJ, 1993, NATURE, V366, P421; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	29	196	200	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					753	756		10.1038/369753a0	http://dx.doi.org/10.1038/369753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008068				2022-12-01	WOS:A1994NU58100063
J	CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B				CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B			RISK OF BREAST-CANCER IN RELATION TO THE INTERVAL SINCE LAST FULL-TERM PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							INCREASE; AGE	Objective-To examine whether the risk of breast cancer is increased by a recent term pregnancy. Design-Population based case-control study. Setting-Eight areas in the United States. Subjects-Cases were 2279 multiparous women residents of the eight areas aged 25-49 who were diagnosed as having breast cancer during 1980-2. Controls were 2357 multiparous women selected from the same areas by random digit dialling. Main outcome measure-Relative risk of developing breast cancer according to the time interval since last full term pregnancy. Results-The distribution of intervals since the last term pregnancy was similar in cases and controls. Adjusted for age, parity, and age at first term pregnancy, the odds ratios observed for categories of years since the last full term pregnancy were: 0-2 years, odds ratio 1.16 (95% confidence interval 0.84 to 1.59); 3-6 years, odds ratio 1.21 (0.95 to 1.54); 7-9 years, odds ratio 1.04 (0.84 to 1.38); greater than or equal to 10 years, odds ratio 1.00 (reference). Conclusions-Among multiparous women aged 25-49 years there was no association between the risk of breast cancer and the time interval since the last full term pregnancy.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98112	University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [T32CA009168, R35CA039779] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA01364, R35CA39779, T32CA09168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; BRESLOW N. E., 1980, STATISTICAL METHODS; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; JANERICH DT, 1982, AM J EPIDEMIOL, V116, P737, DOI 10.1093/oxfordjournals.aje.a113462; Kelsey JL, 1983, BREAST GYNECOLOGIC C; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LOGAN WPD, 1953, LANCET, V2, P1199; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1983, JAMA-J AM MED ASSOC, V249, P1591; 1986, NEW ENGL J MED, V315, P401	14	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1672	1674		10.1136/bmj.308.6945.1672	http://dx.doi.org/10.1136/bmj.308.6945.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025460	Green Published			2022-12-01	WOS:A1994NU48300019
J	KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA				KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA			STRUCTURE OF THE RGD PROTEIN DECORSIN - CONSERVED MOTIF AND DISTINCT FUNCTION IN LEECH PROTEINS THAT AFFECT BLOOD-CLOTTING	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITORS; AMINO-ACID-SEQUENCE; RECOMBINANT HIRUDIN; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; ALPHA-THROMBIN; CELL-ADHESION; FACTOR-XA	The structure of the leech protein decorsin, a potent 39-residue antagonist of glycoprotein IIb-IIIa and inhibitor of platelet aggregation, was determined by nuclear magnetic resonance. In contrast to other disintegrins, the Arg-Gly-Asp (RGD)-containing region of decorsin is well defined. The three-dimensional structure of decorsin is similar to that of hirudin, an anticoagulant leech protein that potently inhibits thrombin. Amino acid sequence comparisons suggest that ornatin, another glycoprotein IIb-IIIa antagonist, and antistasin, a potent Factor Xa inhibitor and anticoagulant found in leeches, share the same structural motif. Although decorsin, hirudin, and antistasin all affect the blood clotting process and appear similar in structure, their mechanisms of action and epitopes important for binding to their respective targets are distinct.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech								ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BANG NU, 1992, TRENDS CARDIOVAS MED, V2, P183, DOI 10.1016/1050-1738(92)90047-V; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, UNPUB; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MAZUR P, 1991, EUR J BIOCHEM, V202, P1073, DOI 10.1111/j.1432-1033.1991.tb16472.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NUTT E, 1988, J BIOL CHEM, V263, P10162; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAWYER RT, 1991, BIO-TECHNOL, V9, P513, DOI 10.1038/nbt0691-513; SEEMULLER U, 1986, PROTEINASE INHIBITOR, P337; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SEYMOURULMER J, UNPUB; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; STEINER V, 1992, BIOCHEMISTRY-US, V31, P2294, DOI 10.1021/bi00123a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SZYPERSKI T, 1992, J MOL BIOL, V228, P1206, DOI 10.1016/0022-2836(92)90326-F; SZYPERSKI T, 1992, J MOL BIOL, V228, P1193, DOI 10.1016/0022-2836(92)90325-E; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VITALI J, 1992, J BIOL CHEM, V267, P17670; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9	48	131	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1944	1947		10.1126/science.8009227	http://dx.doi.org/10.1126/science.8009227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009227				2022-12-01	WOS:A1994NT84700049
J	BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M				BEDOS, JP; CHASTANG, C; LUCET, JC; KALO, T; GACHOT, B; WOLFF, M			EARLY PREDICTORS OF OUTCOME FOR HIV PATIENTS WITH NEUROLOGICAL FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTENSIVE-CARE; RESPIRATORY-FAILURE; MECHANICAL VENTILATION; CONTROLLED TRIAL; VIRUS INFECTION; AIDS; SURVIVAL; CORTICOSTEROIDS	Objective.-To carry out a descriptive study of human immunodeficiency virus (HIV)-infected patients admitted to an intensive care unit (ICU) with neurological failure and to identify parameters that are predictive of death within 3 months. Design.-Case series study. Population and Setting.-A total of 84 consecutive HIV-infected patients admitted to an infectious disease ICU in a university hospital for neurological failure. A thorough clinical, laboratory, and brain computed tomography (CT) scan workup was done within 48 hours of admission. Main Results.-The mean (+/-SD) CD4(+) lymphocyte count was 0.067 (+/-0.086) x10(9)/L. Mechanical ventilation was necessary within 48 hours of admission in 67 cases (80%). The brain CT scan revealed abscesses in 51 patients (61%). The abscesses were attributed to probable toxoplasmosis in 47 patients. A total of 57 patients died, yielding a 3-month survival rate of 32%. By the log-rank test, the following factors were predictive of death within 3 months of admission to the ICU: Glasgow Coma Scale score less than 7 (P=.01), signs of brain stem involvement (P=.001), and need for mechanical ventilation in the 48 hours after admission (P=.02). In a Cox model, only Glasgow Coma Scale score less than 7 (P=.006) and clinical signs of brain stem involvement (P=.02) were predictive of death within 3 months of admission to the ICU. Conclusions.-Despite a thorough examination, no initial HIV-specific parameters were identified as predictive of death. The prognostic factors found simply reflected the severity of neurological involvement in the various etiologies.	HOP ST LOUIS,DEPT BIOSTAT & MED COMP,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	BEDOS, JP (corresponding author), UNIV LYON 1,HOP BICHAT,REANIMAT MALAD INFECT CLIN,INFECT INTENS CARE UNIT,48 RUE HENRI HUCHARD,F-75018 PARIS,FRANCE.							BEDOS JP, 1992, SCAND J INFECT DIS, V24, P309, DOI 10.3109/00365549209061336; BISHBURG E, 1989, ARCH INTERN MED, V149, P941, DOI 10.1001/archinte.149.4.941; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BREW BJ, 1992, MED CLIN N AM, V76, P63, DOI 10.1016/S0025-7125(16)30371-6; CASALINO E, 1993, 9TH INT C AIDS BERL; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; DEPALO VA, 1993, AM REV RESPIR DIS, V147, pA1004; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; FISCHER PA, 1987, J NEUROL, V234, P269, DOI 10.1007/BF00314279; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LEVY RM, 1988, ANN NEUROL, V23, pS7, DOI 10.1002/ana.410230706; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MASON GR, 1987, AM REV RESPIR DIS, V139, P1336; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MILLER RF, 1990, THORAX, V45, P140, DOI 10.1136/thx.45.2.140; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; NIELSEN TL, 1991, SCAND J INFECT DIS, V23, P37, DOI 10.3109/00365549109023372; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEINBROOK R, 1985, ANN INTERN MED, V103, P787, DOI 10.7326/0003-4819-103-5-787; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; ZAMAN MK, 1985, AM REV RESPIR DIS, V137, P796; 1992, LANCET, V340, P1135; 1990, NEW ENGL J MED, V323, P1500	38	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	1995	273	1					35	40		10.1001/jama.273.1.35	http://dx.doi.org/10.1001/jama.273.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ042	7996648				2022-12-01	WOS:A1995PZ04200025
J	DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP				DAKE, MD; MILLER, DC; SEMBA, CP; MITCHELL, RS; WALKER, PJ; LIDDELL, RP			TRANSLUMINAL PLACEMENT OF ENDOVASCULAR STENT-GRAFTS FOR THE TREATMENT OF DESCENDING THORACIC AORTIC-ANEURYSMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; GRAFT PLACEMENT; FEASIBILITY	Background. The usual treatment for thoracic aortic aneurysms is surgical replacement with a prosthetic graft, but the associated morbidity and mortality are considerable. We studied the use of transluminally placed endovascular stent-graft devices as an alternative to surgical repair. Methods. We evaluated the feasibility, safety, and effectiveness of transluminally placed stent-grafts to treat descending thoracic aortic aneurysms in 13 patients over a 24-month period. Atherosclerotic, anastomotic, and post-traumatic true or false aneurysms and aortic dissections were treated. The mean diameter of the aneurysms was 6.1 cm (range, 5 to 8). The endovascular stent-grafts were custom-designed for each patient and were constructed of self-expanding stainless-steel stents covered with woven Dacron grafts. Results. Endovascular placement of the stent-graft prosthesis was successful in all patients. There was complete thrombosis of the thoracic aortic aneurysm surrounding the stent-graft in 12 patients, and partial thrombosis in 1. Two patients initially had small, residual patent proximal tracts into the aneurysm sac, but both tracts thrombosed within two months after the procedure. in four patients, two prostheses were required to bridge the aneurysm adequately. There have been no deaths or instances of paraplegia, stroke, distal embolization, or infection during an average follow-up of 11.6 months. One patient with an extensive chronic aortic dissection required open surgical graft replacement four months later because of progressive dilatation of the arch. Conclusions. These preliminary results demonstrate that endovascular stent-graft repair is safe in highly selected patients with descending thoracic aortic aneurysms. This new method of treatment will, however, require careful long-term evaluation.	STANFORD UNIV,SCH MED,DEPT RADIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT CARDIOVASC SURG,STANFORD,CA 94305	Stanford University; Stanford University			Walker, Philip J/F-3034-2010	Miller, D. Craig/0000-0001-7619-0080				BALKO A, 1986, J SURG RES, V40, P305, DOI 10.1016/0022-4804(86)90191-5; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; CHUTER TAM, 1993, J VASC SURG, V18, P185, DOI 10.1016/0741-5214(93)90598-G; CRAGG AH, 1993, RADIOLOGY, V187, P643, DOI 10.1148/radiology.187.3.8497609; DOTTER CT, 1969, INVEST RADIOL, V4, P329, DOI 10.1097/00004424-196909000-00008; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; JOYCE JW, 1964, CIRCULATION, V29, P176, DOI 10.1161/01.CIR.29.2.176; LABORDE JC, 1992, RADIOLOGY, V184, P185, DOI 10.1148/radiology.184.1.1535160; LAWRENCE DD, 1987, RADIOLOGY, V163, P357, DOI 10.1148/radiology.163.2.2951767; MARIN ML, 1993, J VASC SURG, V18, P299, DOI 10.1016/0741-5214(93)90611-O; MAY J, 1993, J VASC SURG, V18, P1056, DOI 10.1016/0741-5214(93)90562-Z; MCNAMARA JJ, 1978, ANN THORAC SURG, V26, P468, DOI 10.1016/S0003-4975(10)62927-X; MIRICH D, 1989, RADIOLOGY, V170, P1033, DOI 10.1148/radiology.170.3.2916054; MITCHELL RS, 1983, J THORAC CARDIOV SUR, V86, P400; MORENOCABRAL CE, 1984, J THORAC CARDIOV SUR, V88, P1020; Najafi H, 1980, World J Surg, V4, P553; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PRESSLER V, 1980, J THORAC CARDIOV SUR, V79, P489; YOSHIOKA T, 1988, AM J ROENTGENOL, V151, P673, DOI 10.2214/ajr.151.4.673	19	1161	1364	2	53	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1729	1734		10.1056/NEJM199412293312601	http://dx.doi.org/10.1056/NEJM199412293312601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984192				2022-12-01	WOS:A1994PZ26600001
J	YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ				YAN, MH; DAI, TN; DEAK, JC; KYRIAKIS, JM; ZON, LI; WOODGETT, JR; TEMPLETON, DJ			ACTIVATION OF STRESS-ACTIVATED PROTEIN-KINASE BY MEKK1 PHOSPHORYLATION OF ITS ACTIVATOR SEK1	NATURE			English	Article							RAF; TYROSINE	A KINASE distinct from the MEK activator Raf(1-3), termed MEK kinase-1 (MEKK), was originally identified by virtue of its homology to kinases involved in yeast mating signal cascades(4). Like Raf, MEKK is capable of activating MEK in vitro(4,5). High-level expression of MEKK in COS-7 cells(4) or using vaccinia virus vectors(5) also activates MEK and MAPK, indicating that MEKK and Raf provide alternative means of activating the MAPK signalling pathmay. We have derived NIH3T3 cell sublines that can be induced to express active MEKK. Here we show that induction of MEKK does not result in the activation of MAPK, but instead stimulates the stress-activated protein kinases (SAPKs)(6-8) which are identical to a Jun amino-terminal kinase(9,10). We find that MEKK regulates a new signalling cascade by phosphorylating an SAPK activator, SEK1 which in turn phosphorylates and activates SAPK.	CASE WESTERN RESERVE UNIV HOSP, SCH MED, CELL BIOL PROGRAM, CLEVELAND, OH 44106 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP EAST, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST, DIV HEMATOL, BOSTON, MA 02115 USA	Case Western Reserve University; Case Western Reserve University Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	YAN, MH (corresponding author), CASE WESTERN RESERVE UNIV HOSP, SCH MED, INST PATHOL, 10900 E EUCLID AVE, CLEVELAND, OH 44106 USA.		Woodgett, Jim/F-1087-2010; Templeton, Dennis J/F-7695-2011	Woodgett, Jim/0000-0003-3731-5797; 				DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; YAN MH, 1994, J BIOL CHEM, V269, P19067	20	706	723	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					798	800						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997270				2022-12-01	WOS:A1994PY21200058
J	HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA				HEINZE, HJ; MANGUN, GR; BURCHERT, W; HINRICHS, H; SCHOLZ, M; MUNTE, TF; GOS, A; SCHERG, M; JOHANNES, S; HUNDESHAGEN, H; GAZZANIGA, MS; HILLYARD, SA			COMBINED SPATIAL AND TEMPORAL IMAGING OF BRAIN ACTIVITY DURING VISUAL SELECTIVE ATTENTION IN HUMANS	NATURE			English	Article							PET IMAGES; CORTEX	VISUAL-SPATIAL attention is an essential brain function that enables os to select and preferentially process high priority information in the visual fields. Several brain areas have been shown to participate in the control of spatial attention in humans(3-5), but little is known about the underlying selection mechanisms. Non-invasive scalp recordings of event-related potentials (e.r.ps) in humans have shown that attended visual stimuli are preferentially selected as early as 80-90 ms after stimulus onset(6,7), but current e.r.p. methods do not permit a- precise localization of the participating cortical areas. In this study we combined neuroimaging (positron emission tomography) with e.r.p. recording in order to describe both the cortical anatomy and time course of attentional selection processes. Together these methods showed that visual inputs from attended locations receive enhanced processing in the extrastriate cortex (fusiform gyrus) at 80-130 ms after stimulus onset. These findings reinforce early selection models of attention(8-10).	UNIV CALIF DAVIS, DEPT PSYCHOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, CTR NEUROSCI, DAVIS, CA 95616 USA; HANNOVER MED SCH, DEPT NUCL MED, W-3000 HANNOVER, GERMANY; UNIV HEIDELBERG, DEPT NEUROL, HEIDELBERG, GERMANY; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; Hannover Medical School; Ruprecht Karls University Heidelberg; University of California System; University of California San Diego	HEINZE, HJ (corresponding author), UNIV MAGDEBURG, DEPT CLIN NEUROPHYSIOL, D-39120 MAGDEBURG, GERMANY.		Burchert, Wolfgang/ABF-4194-2020; Münte, Thomas/C-2077-2014					[Anonymous], 1992, SELECTIVE ATTENTION; Broadbent D.E., 1958, PERCEPTION COMMUNICA; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; DESIMONE R, 1992, COLD SPRING HARB SYM, P963; FISCHER B, 1985, BRAIN RES, V345, P111, DOI 10.1016/0006-8993(85)90841-8; FOX PT, 1989, J NUCL MED, V30, P141; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GONZALEZ G, IN PRESS BRAIN TOPOG; HAWKINS HL, 1990, J EXP PSYCHOL HUMAN, V16, P802, DOI 10.1037/0096-1523.16.4.802; HEINZE HJ, 1994, PERCEPT PSYCHOPHYS, V56, P42, DOI 10.3758/BF03211689; HILLYARD SA, 1993, CURR OPIN NEUROBIOL, V3, P217, DOI 10.1016/0959-4388(93)90213-I; JEFFREYS DA, 1972, EXP BRAIN RES, V16, P1; Laberge D, 1990, J Cogn Neurosci, V2, P358, DOI 10.1162/jocn.1990.2.4.358; MANGUN GR, 1993, ATTENTION PERFORM, V14, P219; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Petersen S E, 1992, Curr Opin Neurobiol, V2, P217, DOI 10.1016/0959-4388(92)90016-E; PETERSEN SE, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P413; Posner M I, 1992, Curr Opin Neurobiol, V2, P165, DOI 10.1016/0959-4388(92)90006-7; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; SCHERG M, 1991, Brain Topography, V4, P143, DOI 10.1007/BF01132771; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; Tournoux P., 1988, COPLANAR STEREOTACTI; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI S, 1991, J NEUROSCI, V11, P641	30	757	769	0	46	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					543	546		10.1038/372543a0	http://dx.doi.org/10.1038/372543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990926				2022-12-01	WOS:A1994PW08200050
J	TAKAGAKI, Y; MANLEY, JL				TAKAGAKI, Y; MANLEY, JL			A POLYADENYLATION FACTOR SUBUNIT IS THE HUMAN HOMOLOG OF THE DROSOPHILA SUPPRESSOR OF FORKED PROTEIN	NATURE			English	Article							PRE-MESSENGER-RNAS; POLY(A) POLYMERASE; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; BINDING DOMAIN; MELANOGASTER; CLEAVAGE; EXPRESSION; SEQUENCE; GENES	POLYADENYLATION of messenger RNA precursors is a complex process that requires multiple protein factors (for reviews, see refs 1, 2). Cleavage stimulation factor (CstF) is one of these, functioning together with cleavage-polyadenylation specificity factor, two cleavage factors, and poly(A)(+) polymerase(3-7) CstF is composed of three subunits of M(r) 77, 64 and 50K(8,9). The 64K(10) and 50K(11) subunits contain, respectively, an RNP-type RNA-binding domain that contacts the pre-mRNA and transducin repeats characteristic of G-protein beta-subunits. Here we report the cloning and characterization of the 77K subunit of human CstF (referred to as 77K). We show that the 77K subunit is required for formation of active CstF and bridges the 64K and 50K subunits. Sequence analyses indicate that the 77K subunit is the homologue of the protein encoded by the Drosophila melanogaster suppressor of forked (su(f)) gene(12). Mutations in su(f) can enhance or suppress the effects of transposable element insertions(13), and our data indicate that this is due to changes in polyadenylation. Both the 77K subunit and the su(f) protein share homology with Saccharomyces cerevisiae RNA14 previously shown to be involved in mRNA metabolism(14). Our results thus also indicate that components of the complex polyadenylation machinery are conserved from yeast to man.			TAKAGAKI, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DORSETT D, 1989, GENE DEV, V3, P454, DOI 10.1101/gad.3.4.454; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; DUDICK ME, 1974, GENETICS, V76, P487; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLOW E, 1988, ANTIBODIES LABORATOR; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUTLEDGE BJ, 1988, GENETICS, V119, P391; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON TG, 1980, J EMBRYOL EXP MORPH, V55, P247; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x	30	118	119	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					471	474		10.1038/372471a0	http://dx.doi.org/10.1038/372471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984242				2022-12-01	WOS:A1994PV01200059
J	PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA				PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA			AN EFFICIENT MIMIC OF CYTOCHROME-P-450 FROM A ZEOLITE ENCAGED IRON COMPLEX IN A POLYMER MEMBRANE	NATURE			English	Article							ALIPHATIC HYDROXYLATION; PORPHYRIN COMPLEXES; HYDROGEN-PEROXIDE; ALKANE OXIDATION; CATALYSTS; MANGANESE; MECHANISM; PYRIDINE	MANY attempts have been made to mimic the catalytic oxidative properties of the enzyme cytochrome P-450. For homogeneous systems' the mechanisms of oxidation can be readily determined but proper mimicry of the protein environment is difficult to achieve. Heterogeneous mimics have been designed that use organometallic complexes encapsulated in the supercages of zeolites(2,3), which enables control of selectivity and inhibition of auto-oxidation. But these systems do not show any mechanistic analogy with the enzymatic process, and the oxidation rates tend to be low. Here we report a composite catalytic system that achieves realistic mimicry of cytochrome P-450 as well as catalytic turnover rates that make the system industrially viable. Our catalyst incorporates iron phthalocyanine complexes encapsulated in crystals of zeolite Y, which are in turn embedded ina polydimethylsiloxane membrane. The polymer acts as a mimic of the phospholipid membrane in which cytochrome P-450 resides(4), acting as an interface between two immiscible phases and avoiding the need for solvents or phase-transfer agents. This system oxidizes alkanes at room temperature at rates comparable to those of the enzyme(5). The observation of a large kinetic isotope effect and the preferential oxidation of tertiary C-H bonds suggest close mechanistic similarities to the enzymatic process.			PARTON, RF (corresponding author), KATHOLIEKE UNIV LEUVEN, CENTRUM OPPERVLAKTECHEM KATALYSE, DEPT INTERFACE CHEM, B-3001 HEVERLEE, BELGIUM.		Vankelecom, Ivo/AAL-5006-2020; Nanozymes, Nanozymes/D-8197-2019					ARMOR JN, 1989, APPL CATAL, V102, P1; ASADA T, 1991, MEMBRANE SCI TECHNOL, V1, P439; BARTON DHR, 1991, TETRAHEDRON LETT, V32, P3811; BELL RP, 1974, CHEM SOC REV, V3, P513, DOI 10.1039/cs9740300513; BOWERS C, 1990, J CATAL, V122, P271, DOI 10.1016/0021-9517(90)90281-N; CAMBLOR MA, 1993, J ZEOLITES, V13, P82; CHE CM, 1993, J CHEM SOC DA, P1259; CORMA A, 1994, J CHEM SOC CHEM COMM, P147, DOI 10.1039/c39940000147; DEVOS DE, 1994, MACROMOL SYMP, V80, P157, DOI 10.1002/masy.19940800112; GROVES JT, 1990, J AM CHEM SOC, V112, P7796, DOI 10.1021/ja00177a050; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HUYBRECHTS DRC, 1990, NATURE, V345, P240, DOI 10.1038/345240a0; ICHIKAWA M, 1991, STUD SURF SCI CATAL, V60, P335; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; KHENKIN AM, 1989, NEW J CHEM, V13, P659; KNOPSGERRITS PP, 1994, NATURE, V369, P543, DOI 10.1038/369543a0; KWART H, 1982, ACCOUNTS CHEM RES, V15, P401, DOI 10.1021/ar00084a004; LEISING RA, 1993, J AM CHEM SOC, V115, P9524, DOI 10.1021/ja00074a017; Mansuy D., 1989, ACTIVATION FUNCTIONA, P195; MENAGE S, 1993, INORG CHEM, V32, P4766, DOI 10.1021/ic00074a019; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; NAKAMURA M, 1990, B CHEM SOC JPN, V63, P3334, DOI 10.1246/bcsj.63.3334; NAM W, 1989, NEW J CHEM, V13, P677; PARTON R, 1992, NATO ADV SCI I C-MAT, V352, P555; PARTON RF, 1991, STUD SURF SCI CATAL, V59, P395; PENNERHAHN JE, 1983, J BIOL CHEM, V258, P2761; SOROKIN A, 1993, J AM CHEM SOC, V115, P7293, DOI 10.1021/ja00069a031; SOROKIN AB, 1990, J CHEM SOC CHEM COMM, P45, DOI 10.1039/c39900000045; TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0; Tolman C. A., 1989, ACTIVATION FUNCTIONA, P303; Ullrich V, 1979, Top Curr Chem, V83, P67	32	255	258	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					541	544		10.1038/370541a0	http://dx.doi.org/10.1038/370541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	PC537	8052309				2022-12-01	WOS:A1994PC53700049
J	YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K				YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K			RELATIONSHIP BETWEEN DROSOPHILA GAP GENE TAILLESS AND A VERTEBRATE NUCLEAR RECEPTOR TLX	NATURE			English	Article							9-CIS RETINOIC ACID; EMBRYONIC TERMINI; DNA-BINDING; SUPERFAMILY; EXPRESSION; CLONING; REGION; BRAIN; SITES; CELL	We report here the identification of a unique vertebrate nuclear receptor, Tlx, which is expressed exclusively in the neuroepithelium of the embryonic brain. Sequence comparison reveals striking similarity to the product of the Drosophila terminal/gap gene tailless (tll)(1), which is expressed in the embryonic brain and is required for brain development in flies. In vitro DNA-binding assays demonstrated that Tlx and Tll proteins share a target gene specificity that, is unique among the nuclear receptor superfamily. Ectopic expression of Tlx in fly embryos caused a repression of segmentation comparable to that elicited by Tll. The similarities in structure, expression pattern, target gene specificity and phenotypes in transgenic flies suggest conservation of genetic programs upstream and downstream of this Tlx/Tll class of nuclear receptors during embryogenesis.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,GRAD PROGRAM MOLEC PATHOL,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Salk Institute; Salk Institute; University of California System; University of California San Diego			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; KAKIZUKA A, 1993, ESSENTIAL DEV BIOL P, P223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; ORO AE, 1992, DEVELOPMENT, V115, P449; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUZ D, 1989, CHROMOSOMA, V98, P81; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418	28	162	173	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					375	379		10.1038/370375a0	http://dx.doi.org/10.1038/370375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047143				2022-12-01	WOS:A1994PA30400057
J	DORER, DR; HENIKOFF, S				DORER, DR; HENIKOFF, S			EXPANSIONS OF TRANSGENE REPEATS CAUSE HETEROCHROMATIN FORMATION AND GENE SILENCING IN DROSOPHILA	CELL			English	Article							POSITION EFFECT VARIEGATION; P-ELEMENT TRANSPOSITION; WHITE GENE; MELANOGASTER; EXPRESSION; CHROMOSOME; TRANSVECTION; CHROMATIN; TRANSCRIPTION; INSERTIONS	Closely linked repeats of a Drosophila P transposon carrying a white transgene were found to cause white variegation. Arrays of three or more transgenes produced phenotypes similar to classical heterochromatin-induced position-effect variegation (PEV), and these phenotypes were modified by known modifiers of PEV. This effect on the repeated transgenes was much stronger for a site near centric heterochromatin than it was for a medial site, and it strengthened with increasing copy number. Differences between variegated phenotypes could be accounted for if different topological structures were generated by pairing between closely linked repeat sequences. We propose that pairing of repeats underlies heterochromatin formation and is responsible for diverse gene silencing phenomena in animals and plants.			DORER, DR (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,DIV BASIC SCI,SEATTLE,WA 98104, USA.			Henikoff, Steven/0000-0002-7621-8685				ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COOLEY L, 1990, P NATL ACAD SCI USA, V87, P3170, DOI 10.1073/pnas.87.8.3170; DANIELS SB, 1993, GENETICS, V133, P623; DAVIS BP, 1988, GENE DEV, V2, P13, DOI 10.1101/gad.2.1.13; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; Ephrussi B, 1944, P NATL ACAD SCI USA, V30, P183, DOI 10.1073/pnas.30.8.183; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Gans M., 1953, B BIOL FRANCE BELG S, V38, P1; GRIGLIATTI T, 1991, FUNCTIONAL ORG NUCLE, P587; GUBB D, 1990, GENETICS, V126, P167; HAWLEY RS, 1988, GENETICS, V119, P85; HAWLEY RS, 1993, DEV GENET, V13, P440; HENIKOFF S, 1993, CHROMOSOME, P183; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; KASSIS JA, 1991, GENETICS, V128, P751; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KKOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503; LAIRD CD, 1987, GENETICS, V117, P587; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Matzke M., 1994, Homologous recombination and gene silencing in plants., P271; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; Rabl C., 1885, MORPHOL JB, V10, P214; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROBERTSON HM, 1988, GENETICS, V118, P461; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SMABROOK J, 1989, MOL CLONING LABORATO; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STUART GW, 1990, DEVELOPMENT, V109, P577; TALBERT PB, 1994, GENETICS, V136, P559; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TOWER J, 1993, GENETICS, V133, P347; WAKIMOTO BT, 1990, GENETICS, V125, P141; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WINES DR, 1992, GENETICS, V131, P683; ZACHAR Z, 1985, COLD SPRING HARB SYM, V50, P337, DOI 10.1101/SQB.1985.050.01.043; ZHANG P, 1993, GENETICS, V133, P361	52	452	473	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					993	1002		10.1016/0092-8674(94)90439-1	http://dx.doi.org/10.1016/0092-8674(94)90439-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020105				2022-12-01	WOS:A1994NV42500008
J	THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL				THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL			CELL-CYCLE PROGRESSION IN THE DEVELOPING DROSOPHILA EYE - ROUGHEX ENCODES A NOVEL PROTEIN REQUIRED FOR THE ESTABLISHMENT OF G1	CELL			English	Article							POLARITY GENE HEDGEHOG; MAMMALIAN FIBROBLASTS; SEVENLESS PROTEIN; G2-M TRANSITION; TYROSINE-KINASE; TGF-BETA; HOMOLOG; RETINA; DIFFERENTIATION; PROLIFERATION	The onset of pattern formation in the developing Drosophila eye is marked by the simultaneous synchronization of all cells in the G1 phase of the cell cycle. These cells will then either commit to another round of cell division or differentiate into neurons. Although cell cycle synchronization occurs in rougher (rux) mutants, cells circumvent G1 and all cells enter S phase, including cells that would normally differentiate. This leads to defects in early steps of pattern formation and cell fate determination. rux is suppressed by mutations in genes that promote cell cycle progression (i.e., cyclin A and string) and enhanced by mutations in genes that promote differentiation (i.e., Ras1 and Star). rux encodes a novel protein of 335 amino acids. We propose that rux functions as a negative regulator of G1 progression in the developing eye.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	THOMAS, BJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, DROSOPHILA LABORATOR; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Cagan Ross Leigh, 1992, P189; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEYETTE BNR, 1994, NEURON, V12, P1; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P1; KAFATOS FC, 1991, TRENDS GENET, V7, P155, DOI 10.1016/0168-9525(91)90379-5; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLODKIN A, 1993, IN PRESS DEVELOPMENT; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Murray A., 1993, CELL CYCLE INTRO; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WEN ME, 1993, CELL, V74, P1009; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	42	166	170	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1003	1014		10.1016/0092-8674(94)90440-5	http://dx.doi.org/10.1016/0092-8674(94)90440-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020091				2022-12-01	WOS:A1994NV42500009
J	BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL				BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL			A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX	NATURE			English	Article							P70 S6 KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; LYMPHOCYTES-T; YEAST; IMMUNOPHILIN; ACTIVATION; ARREST; FK506; PROLIFERATION	THE structurally related natural products rapamycin and FK506 bind to the same intracellular receptor, FKBP12, yet the resulting complexes interfere with distinct signalling pathways(1,2). FKBP12- rapamycin inhibits progression through the G1 phase of the cell cycle in osteosarcoma(3), liver(4,5) and T cells(6,7) as well as in yeasts, and interferes with mitogenic signalling pathways that are involved in G1 progressiong(9,10), namely with activation of the protein p70(S6k) (refs 5, 11-13) and cyclin-dependent kinases(3,14-16). Here we isolate a mammalian FKBP-rapamycin-associated protein (FRAP) whose binding to structural variants of rapamycin complexed to FKBP12 correlates with the ability of these ligands to inhibit cell-cycle progression. Peptide sequences from purified bovine FRAP were used to isolate a human cDNA clone that is highly related to the DRR1/TOR1 and DRR2/TOR2 gene products from Saccharomyces cerevisiae(8,17,18). Although it has not been previously demonstrated that either of the DRR/TOR gene products can bind the FKBP-rapamycin complex directly(17,19), these yeast genes have been genetically linked to a rapamycin-sensitive pathway and are thought to encode lipid kinases(17-20).	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FOOR F, 1992, NATURE, V360, P682; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HAYWARD CM, 1993, J AM CHEM SOC, V115, P9345, DOI 10.1021/ja00073a083; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HULTSCH T, 1992, MOL BIOL CELL, V3, P981, DOI 10.1091/mbc.3.9.981; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9	27	1577	1685	5	134	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					756	758		10.1038/369756a0	http://dx.doi.org/10.1038/369756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008069				2022-12-01	WOS:A1994NU58100064
J	JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW				JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW			3-DIMENSIONAL STRUCTURE OF BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ALPHA-COMPLEMENTATION; WEISSENBERG CAMERA; DIFFRACTION DATA; LACZ GENE; CRYSTALLOGRAPHY; REFINEMENT; EXPRESSION; PROGRAM	THE beta-galactosidase from Escherichia coli was instrumental in the development of the operon model(1), and today is one of the most commonly used enzymes in molecular biology. Here we report the structure of this protein and show that it is a tetramer with 222- point symmetry. The 1,023-amino-acid polypeptide chain(2,3) folds into five sequential domains, with an extended segment at the amino terminus. The participation of this amino-terminal segment in a subunit interface, coupled with the observation that each active site is made up of elements from two different subunits, provides a structural rationale for the phenomenon of alpha-complementation. The structure represents the longest polypeptide chain for which an atomic structure has been determined. Our results show that it is possible successfully to study non-viral protein crystals with unit cell dimensions in excess of 500 Angstrom and with relative molecular masses in the region of 2,000K per asymmetric unit. Non-crystallographic symmetry averaging proved to be a very powerful tool in the structure determination, as has been shown in other contexts(31,32).	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon								ADAMS RM, 1994, J BIOL CHEM, V269, P5666; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CELADA F, 1974, BIOCHEMISTRY-US, V13, P5543, DOI 10.1021/bi00724a014; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HEINZ DW, 1994, PROTEIN ENG, V7, P301, DOI 10.1093/protein/7.3.301; HENDERSON DR, 1986, CLIN CHEM, V32, P1637; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOBSON RH, 1992, J MOL BIOL, V223, P1177, DOI 10.1016/0022-2836(92)90269-P; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; ROSSMANN MG, 1985, NATURE, V317, P153; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; STOKES HW, 1985, MOL BIOL EVOL, V2, P469; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Weinstock G M, 1983, Gene Amplif Anal, V3, P27; ZABIN I, 1982, MOL CELL BIOCHEM, V49, P87	32	538	550	1	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					761	766		10.1038/369761a0	http://dx.doi.org/10.1038/369761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008071				2022-12-01	WOS:A1994NU58100066
J	HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR				HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR			RATES OF ADMISSION TO HOSPITAL FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CHILDHOOD ASTHMA; TRENDS; CHILDREN; INCREASE; HEALTH; CARE	Objective-To describe trends in hospital admission rates for asthma in England and Wales (1976-85), the East Anglian region (from 1976 to 1991-2), and Wales (1980-90). Design-Descriptive study. Setting-Hospitals in England and Wales; hospitals in the East Anglian Regional Health Authority; hospitals in Wales. Main outcome measures-Hospital admissions for asthma as principal diagnosis in England and Wales (Hospital In-patient Enquiry, 1976-85), for the East Anglian region (Hospital In-patient Enquiry, 1976-7; Hospital Activity Analysis, 1978-86; Regional Information System, 1987-8 to 1991-2), and for Wales (Hospital Activity Analysis, l980-90). Results-Rates for England and Wales as a whole showed a steady upward trend throughout the period examined. Rates in East Anglia, though they were similar to the national trends in the early years, showed a peak in 1985 (for males and females) with some indication of a decline in rates thereafter. Rates for Wales showed an upward trend until 1988 (for both males and females) after which they showed a decline. Conclusions-Interpretation of the East Anglian trends is made more difficult by the change in England in 1987 of the system for the collection of hospital admission data. The fact that the rates for the East Anglian region seem to decline before this change and other considerations suggest that the observed trends, although partly reflecting the disruption of the coding during the changeover in systems, may not be entirely artefactual. The possible roles of diagnostic transfer and changes in the delivery of care, asthma treatment, admission and readmission policies, and the severity and prevalence of asthma in changing admission rates are considered. The changing bends in admission rates for East Anglia and Wales reflect recently published trends for mortality from asthma in England.			HYNDMAN, SJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,UNIV FORVIE SITE,CAMBRIDGE CB2 2SR,CAMBS,ENGLAND.							ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1980, BRIT MED J, V281, P1191, DOI 10.1136/bmj.281.6249.1191; [Anonymous], 1990, BMJ, V301, P797; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CLARK TJH, 1990, OCCURRENCE COST ASTH; GARDNER MJ, 1989, STATISTICS CONFIDENC; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; 1993, HOSPITAL EPISODE STA, V1; 1980, HOSPITAL INPATIENT E; 1990, BRIT MED J, V301, P651	22	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1596	1600		10.1136/bmj.308.6944.1596	http://dx.doi.org/10.1136/bmj.308.6944.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025425	Green Published			2022-12-01	WOS:A1994NT52800016
J	SAWYER, SM; BOWES, G; PHELAN, PD				SAWYER, SM; BOWES, G; PHELAN, PD			VULVO-VAGINAL CANDIDIASIS IN YOUNG-WOMEN WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								BLUM RW, 1991, PEDIATRICIAN, V18, P1010; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; O'Neill S, 1989, Aust Fam Physician, V18, P99; SPARKS JM, 1991, J REPROD MED, V36, P745	4	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1609	1609		10.1136/bmj.308.6944.1609	http://dx.doi.org/10.1136/bmj.308.6944.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025429	Green Published			2022-12-01	WOS:A1994NT52800020
J	SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM				SEMPOS, CT; LOOKER, AC; GILLUM, RF; MAKUC, DM			BODY IRON STORES AND THE RISK OF CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING PROTEINS; MORTALITY; DEFICIENCY; HEMATOCRIT; PROGRAM; CANCER; MEN; INFORMATION; FRAMINGHAM; SMOKING	Background. Recent studies have suggested an association between higher body iron stores and the risk of coronary heart disease. To assess these findings, we examined the association between transferrin saturation and the risk of coronary heart disease, myocardial infarction, overall mortality, and mortality from cardiovascular causes in a large population. Methods. We studied a total of 4518 men and women from the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, using a multivariate Cox proportional-hazards model. Base-line data were collected from 1971 to 1974, with follow-up through 1987. Transferrin saturation (serum iron concentration divided by total iron-binding capacity) was used as a measure of the amount of circulating iron available to tissues. Results. The risk of coronary heart disease was not related to transferrin-saturation levels in white men or women. Estimates of the relative risk of coronary heart disease for the fifth quintile of transferrin saturation as compared with the first quintile were 0.72 (95 percent confidence interval, 0.51 to 1.00) for men and 0.85 (95 percent confidence interval, 0.60 to 1.21) for women. The results were similar for myocardial infarction. A significant inverse association with transferrin saturation was found for overall mortality and for mortality from cardiovascular causes in white men and women. Transferrin saturation was not associated with any of the clinical outcomes in blacks, possibly owing to the small sample. Conclusions. Higher transferrin-saturation levels were not associated with an increased risk of coronary heart disease or myocardial infarction. On the contrary, the results indicate that there may be an inverse association of iron stores with overall mortality and with mortality from cardiovascular causes.			SEMPOS, CT (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 1070, HYATTSVILLE, MD 20782 USA.							ABELL LL, 1952, J BIOL CHEM, V195, P357; ABRAHAM S, 1978, VITAL HLTH STAT, V11, P1; ABUZEID HAH, 1976, J CHRON DIS, V29, P395, DOI 10.1016/0021-9681(76)90060-6; BAKER IA, 1982, BRIT HEART J, V47, P490, DOI 10.1136/hrt.47.5.490; BEATON GH, 1989, AM J CLIN NUTR, V50, P575, DOI 10.1093/ajcn/50.3.575; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; BRAND RJ, 1976, CIRCULATION, V53, P348, DOI 10.1161/01.CIR.53.2.348; BURCH GE, 1962, JAMA-J AM MED ASSOC, V180, P63, DOI 10.1001/jama.1962.03050140065017b; Campbell M J, 1983, Stat Med, V2, P223, DOI 10.1002/sim.4780020217; CAMPBELL MJ, 1985, J CHRON DIS, V38, P881, DOI 10.1016/0021-9681(85)90113-4; CARTER C, 1983, AM HEART J, V105, P674, DOI 10.1016/0002-8703(83)90493-3; Clayton D., 1993, STAT MODELS EPIDEMIO, P249; Cohen B B, 1987, Vital Health Stat 1, P1; COOPER RS, 1993, CIRCULATION, V87, P686; COX CS, 1992, VITAL HLTH STAT, V1, P1; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN KJ, 1981, LANCET, V2, P1288; DEPASQUALE NP, 1963, JAMA-J AM MED ASSOC, V183, P142; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; EAVENSON E, 1966, J AM OIL CHEM SOC, V43, P652, DOI 10.1007/BF02682563; ELWOOD PC, 1974, LANCET, V1, P891; FINCH CA, 1982, NEW ENGL J MED, V306, P1520, DOI 10.1056/NEJM198206243062504; FINCH CA, 1984, AM J CLIN NUTR, V39, P471, DOI 10.1093/ajcn/39.3.471; Finucane F F, 1990, Vital Health Stat 1, P1; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GIOVANNIELLO TJ, 1968, J LAB CLIN MED, V71, P874; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; INGRAM DD, IN PRESS VITAL HLTH, V2; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; KNOTTNERUS JA, 1988, J CLIN EPIDEMIOL, V41, P67, DOI 10.1016/0895-4356(88)90010-8; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAUFFER RB, 1991, MED HYPOTHESES, V35, P96, DOI 10.1016/0306-9877(91)90030-3; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MAYER GA, 1965, CAN MED ASSOC J, V93, P1151; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLIMAN JD, 1973, BIOL GEOLOGY CORAL R, V1, P1; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; RAMSAY WNM, 1957, CLIN CHIM ACTA, V2, P221, DOI 10.1016/0009-8981(57)90106-7; RIMM EB, 1993, CIRCULATION, V87, P692; ROBERTS J, 1977, VITAL HLTH STAT, V11, P1; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCHATZKIN A, 1984, AM J EPIDEMIOL, V120, P888, DOI 10.1093/oxfordjournals.aje.a113960; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; SHAH BV, 1991, SUDAAN USERS MANUAL; SORLIE PD, 1981, AM HEART J, V101, P456, DOI 10.1016/0002-8703(81)90136-8; STAMPFER MJ, 1993, CIRCULATION, V87, P688; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1983, AM J EPIDEMIOL, V118, P550, DOI 10.1093/oxfordjournals.aje.a113660; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; STUART J, 1988, J CLIN PATHOL, V41, P1203; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TAKKUNEN H, 1974, LANCET, V2, P523; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; Wintrobe MM, 1935, AM J MED SCI, V189, P102, DOI 10.1097/00000441-193501000-00012; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; 1986, SGI SUPPLEMENTAL LIB; 1971, TECHNICON AUTO ANAL; 1979, HANES 1 HEMATOLOGY C	63	225	227	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1119	1124		10.1056/NEJM199404213301604	http://dx.doi.org/10.1056/NEJM199404213301604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7993405				2022-12-01	WOS:A1994NF69900004
J	PAPAVASSILIOU, AG				PAPAVASSILIOU, AG			TRANSCRIPTION FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											PAPAVASSILIOU, AG (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Karamouzis, Michalis/AAD-2860-2020					LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P931, DOI 10.1056/NEJM199410063311408; Travers A., 1993, DNA PROTEIN INTERACT	3	79	84	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 5	1995	332	1					45	47		10.1056/NEJM199501053320108	http://dx.doi.org/10.1056/NEJM199501053320108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ497	7990864				2022-12-01	WOS:A1995PZ49700008
J	SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI				SANCHEZ, I; HUGHES, RT; MAYER, BJ; YEE, K; WOODGETT, JR; AVRUCH, J; KYRIAKIS, JM; ZON, LI			ROLE OF SAPK/ERK KINASE-1 IN THE STRESS-ACTIVATED PATHWAY REGULATING TRANSCRIPTION FACTOR C-JUN	NATURE			English	Article							MAP KINASE; PROTEIN-KINASE; PHOSPHORYLATION; EXPRESSION; TYROSINE; CLONING; FAMILY; MEK	THE stress-activated protein kinases (SAPKs), which are distantly related to the MAP kinases, are the dominant c-Jun amino-terminal protein kinases activated in response to a variety of cellular stresses, including treatment with tumour-necrosis factor-a and interleukin-beta (refs 1, 2). SAPK phosphorylation of c-Jun probably activates the c-Jun transactivation function(3). SAPKs are part of a signal transduction cascade related to, but distinct from, the MAPK pathway(1). We have now identified a novel protein kinase, called SAPK/ERK kinase-1 (SEK1), which is structurally related to the MAP kinase kinases (MEKs)(4). SEK1 is a potent activator of the SAPKs in vitro and in vivo. An inactive SEK1 mutant blocks SAPK activation by extracellular stimuli without interfering with the MAPK pathway. Although alternative mechanisms of SAPK activation may exist, as an immediate upstream activator of the SAPKs, SEK1 further defines a signalling cascade that couples cellular stress agonists to the c-Jun transcription factor.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	SANCHEZ, I (corresponding author), MASSACHUSETTS GEN HOSP E, MED SERV, DIABET RES LAB, 149 13TH ST, BOSTON, MA 02129 USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	28	961	982	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					794	798						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997269				2022-12-01	WOS:A1994PY21200057
J	WHITCOMB, DC; BLOCK, GD				WHITCOMB, DC; BLOCK, GD			ASSOCIATION OF ACETAMINOPHEN HEPATOTOXICITY WITH FASTING AND ETHANOL USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED HEPATIC NECROSIS; ENHANCED TOXICITY; N-ACETYLCYSTEINE; PROTECTIVE ROLE; FREE-RADICALS; HUMAN-LIVER; METABOLISM; PARACETAMOL; ALCOHOL; OVERDOSE	Objectives.-To evaluate the association of fasting and alcohol use with hepatotoxicity from acetaminophen ingested for therapeutic reasons. Design.-Retrospective case series. Setting.-Hospitals of the University of Pittsburgh (Pa) Medical Center. Patients.-A total of 126779 discharge summaries from January 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity. These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested. Main Outcomes Measured.-The independent variables of chronic alcohol use, recent alcohol use, and recent fasting were determined for all patients. Results.-Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase > 1000 U/L) were identified. Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes. All patients with hepatotoxicity took more than the recommended limit of 4 g/d. Recent fasting was more common than recent alcohol use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day (P=.02). Recent alcohol use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d (P=.004). Conclusion.-Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was associated with fasting and less commonly with alcohol use. Patients who developed hepatoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alcohol users. Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addition to alcohol ingestion.	UNIV PITTSBURGH,DEPT MED,DIV GASTROENTEROL & HEPATOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,DEPT PHYSIOL & CELL BIOL,PITTSBURGH,PA; DEPT VET AFFAIRS MED CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALTOMARE E, 1984, ALCOHOL CLIN EXP RES, V8, P405, DOI 10.1111/j.1530-0277.1984.tb05688.x; ALTOMARE E, 1984, BIOCHEM PHARMACOL, V33, P2207, DOI 10.1016/0006-2952(84)90655-5; BARKER JD, 1977, ANN INTERN MED, V87, P299, DOI 10.7326/0003-4819-87-3-299; BENSON GD, 1983, CLIN PHARMACOL THER, V33, P95, DOI 10.1038/clpt.1983.14; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P139, DOI 10.3109/15563659309000383; BRENT JA, 1993, J TOXICOL-CLIN TOXIC, V31, P173, DOI 10.3109/15563659309000384; CLARK R, 1973, LANCET, V1, P66; CRITCHLEY JAJH, 1986, BRIT J CLIN PHARMACO, V22, P649, DOI 10.1111/j.1365-2125.1986.tb02953.x; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; DEMORAIS SMF, 1989, HEPATOLOGY, V10, P163, DOI 10.1002/hep.1840100207; EDWARDS D, 1986, ANN EMERG MED, V5, P1314; EMBY DJ, 1977, S AFR MED J, V51, P208; GOLDFINGER R, 1978, AM J GASTROENTEROL, V70, P385; GREGUS Z, 1988, DRUG METAB DISPOS, V16, P527; GREGUS Z, 1990, DRUG METAB DISPOS, V18, P10; HALL AH, 1986, JAMA-J AM MED ASSOC, V256, P1893, DOI 10.1001/jama.1986.03380140063015; HALL AH, 1986, ANN INTERN MED, V105, P624, DOI 10.7326/0003-4819-105-4-624_2; HALL AH, 1987, DIGEST DIS SCI, V32, P558, DOI 10.1007/BF01296042; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; JOHNSON MW, 1981, AM J GASTROENTEROL, V76, P530; JOLLOW DJ, 1974, PHARMACOLOGY, V12, P251, DOI 10.1159/000136547; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KARTSONIS A, 1986, ANN INTERN MED, V105, P138, DOI 10.7326/0003-4819-105-1-138_2; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEIST MH, 1985, J CLIN GASTROENTEROL, V7, P55, DOI 10.1097/00004836-198502000-00008; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; LIEBER CS, 1991, J AM COLL NUTR, V10, P602; MADDREY WC, 1987, J CLIN GASTROENTEROL, V9, P180, DOI 10.1097/00004836-198704000-00014; MADHU C, 1989, J PHARMACOL EXP THER, V248, P1069; MCCLAIN CJ, 1980, JAMA-J AM MED ASSOC, V244, P251, DOI 10.1001/jama.244.3.251; MITCHELL JR, 1974, CLIN PHARMACOL THER, V16, P676; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MROCHEK JE, 1974, CLIN CHEM, V20, P1086; PATEL M, 1992, PHARMACOGENETICS, V2, P28; PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x; PESSAYRE D, 1979, GASTROENTEROLOGY, V77, P264; PESSAYRE D, 1980, BIOCHEM PHARMACOL, V29, P2219, DOI 10.1016/0006-2952(80)90201-4; PETERSON RG, 1977, JAMA-J AM MED ASSOC, V237, P2406, DOI 10.1001/jama.237.22.2406; PRESCOTT LF, 1971, LANCET, V1, P519; PRESCOTT LF, 1983, AM J MED, V75, P113, DOI 10.1016/0002-9343(83)90241-3; PRESCOTT LF, 1977, LANCET, V2, P432; PRESCOTT LF, 1980, BR J CLIN PHARM, V10, P2915; PRICE VF, 1989, BIOCHEM PHARMACOL, V38, P289, DOI 10.1016/0006-2952(89)90039-7; PRICE VF, 1987, BIOCHEM PHARMACOL, V36, P427, DOI 10.1016/0006-2952(87)90346-7; PRICE VF, 1988, BIOCHEM PHARMACOL, V37, P1067, DOI 10.1016/0006-2952(88)90512-6; PRICE VF, 1984, XENOBIOTICA, V7, P533; READ RB, 1986, HUM TOXICOL, V5, P201, DOI 10.1177/096032718600500309; REINKE LA, 1979, RES COMMUN CHEM PATH, V23, P185; RUMACK BH, 1981, ARCH INTERN MED, V141, P380, DOI 10.1001/archinte.141.3.380; RUMACK BH, 1983, AM J MED, V75, P104, DOI 10.1016/0002-9343(83)90240-1; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SEEFF LB, 1986, ANN INTERN MED, V105, P624; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; Thurman R. G, 1980, PHARMACOL REV, V31, P229; TREDGER JM, 1985, TOXICOLOGY, V36, P341, DOI 10.1016/0300-483X(85)90035-6; TREDGER JM, 1986, XENOBIOTICA, V16, P661, DOI 10.3109/00498258609043556; YANG CS, 1992, FASEB J, V6, P737, DOI 10.1096/fasebj.6.2.1537464; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	60	322	334	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1845	1850		10.1001/jama.272.23.1845	http://dx.doi.org/10.1001/jama.272.23.1845			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7990219				2022-12-01	WOS:A1994PW98000033
J	MILLER, HI				MILLER, HI			A NEED TO REINVENT BIOTECHNOLOGY REGULATION AT THE EPA	SCIENCE			English	Editorial Material									STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305	Stanford University	MILLER, HI (corresponding author), STANFORD UNIV,HOOVER INST,STANFORD,CA 94305, USA.							BIDINOTTO RJ, 1990, READERS DIGEST   OCT, P55; COOK RJ, 1992, COMMUNICATION   0917; FALK BW, 1994, SCIENCE, V263, P1395, DOI 10.1126/science.8179685; FISHER LJ, 1992, COMMUNICATION   0821; Fumento M., 1993, SCI SIEGE BALANCING, P19; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; HOYLE R, 1992, BIO-TECHNOL, V10, P742; HUTTNER SL, IN PRESS BIOTECHNOLO; MILLER HI, 1990, SCIENCE, V250, P490, DOI 10.1126/science.2237398; MILLER HI, IN PRESS BIOTECHNOLO; MOFFAT AS, 1994, SCIENCE, V265, P1804, DOI 10.1126/science.8091208; NAJ AK, 1989, WALL STREET J   0130; National Academy of Science Committee on the Introduction of Genetically Engineered Organisms into the Environment, 1987, INTRO RECOMBINANT DN; SEIDLER RJ, 1988, SPECIAL REPORT RELEA; STEWART RB, 1991, GENETIC REVOLUTION, P219; 1994, FINAL RULE TESTING M; 1992, EPA600991050 DOC; 1992, NATIONAL BIOTECHNOLO; 1989, FIELD TESTING GENETI; 1989, NY TIMES        0202, pA1; 1989, APPL MICROBIOL BIOT, V30, P541; 1994, FED REGISTER, V59, P45600; 1988, BIOSAFETY MICROBIOLO; 1992, FED REGISTER, V57, P6753	24	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1815	1818		10.1126/science.7997875	http://dx.doi.org/10.1126/science.7997875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997875				2022-12-01	WOS:A1994PX38300024
J	VONARNIM, AG; DENG, XW				VONARNIM, AG; DENG, XW			LIGHT INACTIVATION OF ARABIDOPSIS PHOTOMORPHOGENIC REPRESSOR COP1 INVOLVES A CELL-SPECIFIC REGULATION OF ITS NUCLEOCYTOPLASMIC PARTITIONING	CELL			English	Article							NF-KAPPA-B; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; PROTEIN-KINASE; BINDING-PROTEIN; PHYTOCHROME; THALIANA; ENCODES; TRANSDUCTION; DROSOPHILA	Arabidopsis COP1 acts as a repressor of photomorphogenesis in darkness, and light stimuli abrogate this suppressive action. COP1, when fused to beta-glucuronidase (GUS), is enriched in the nucleus in darkness, but not in the light, in hypocotyl cells of Arabidopsis seedlings and epidermal cells of onion bulbs. In Arabidopsis hypocotyl cells, the nuclear GUS-COP1 level changes in response to dark-light transitions and quantitatively correlates with the extent of repression of photomorphogenic development. In root cells, GUS-COP1 is constitutively nuclear, consistent with an established role of COP1 in suppressing root chloroplast development in both light and darkness. We conclude that COP1 acts inside the nucleus to suppress photomorphogenesis and that light inactivation of COP1 involves a cell type-specific control of its nucleocytoplasmic partitioning.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University			Deng, Xing Wang/ABF-4107-2020	von Arnim, Albrecht/0000-0003-3472-3357	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047850] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R29-GM47850] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUTTER PS, 1994, BIOCHEM J, V300, P609, DOI 10.1042/bj3000609; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GOPLDFARB DS, 1994, CURR BIOL, V4, P57; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MCCURDY DW, 1986, J CELL BIOL, V103, P2541, DOI 10.1083/jcb.103.6.2541; MCNELLIS T, 1994, IN PRESS PLANT CEL; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; ROMERO LC, 1991, FEBS LETT, V282, P342; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	51	363	375	1	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1035	1045		10.1016/0092-8674(94)90034-5	http://dx.doi.org/10.1016/0092-8674(94)90034-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001131				2022-12-01	WOS:A1994PY08600013
J	HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML				HINKLE, G; WETTERER, JK; SCHULTZ, TR; SOGIN, ML			PHYLOGENY OF THE ATTINE ANT FUNGI BASED ON ANALYSIS OF SMALL-SUBUNIT RIBOSOMAL-RNA GENE-SEQUENCES	SCIENCE			English	Article								Complete 16S-like ribosomal RNA coding regions were obtained from the fungal symbiont of five genera of attine (leaf-cutting) ants and two free-living fungi. Phylogenetic analyses with distance matrix, maximum likelihood, and parsimony methods revealed that the attine fungal symbionts are homobasidiomycetes in the order Agaricales. Comparison of the topology of the attine fungal symbiont phylogenetic tree with a tree based on attine ant morphology revealed a congruent branching pattern of the more derived attine ants and their fungal symbionts. The parallel branching pattern suggests a long-term coevolution of derived leaf-cutting attine ants and their fungal symbionts.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA; CORNELL UNIV, DEPT ENTOMOL, ITHACA, NY 14853 USA	Marine Biological Laboratory - Woods Hole; Harvard University; Cornell University			Sogin, Mitchell/AAE-7186-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032964] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32964] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baroni Urbani C., 1980, STUTTGARTER BEITRA B, V54, P1; CHAPELA IH, 1994, SCIENCE, V266, P1691, DOI 10.1126/science.266.5191.1691; Cherrett J.M., 1989, P93; ELWOOD HJ, 1985, MOL BIOL EVOL, V2, P399; HERVEY A, 1977, BRITTONIA, V29, P226, DOI 10.2307/2805856; Holldobler B., 1990, pi; Kermarrec A., 1986, P231; KREISEL H, 1975, INDEX FUNGI 10, V4; Lee SB, 1990, PCR PROTOCOLS GUIDE, P282, DOI [10.1016/B978-0-12-372180-8.50038-X, DOI 10.1016/B978-0-12-372180-8.50038-X]; MARTIN MM, 1987, INVERTEBRATE MICROBI, P91; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Mitter C., 1983, P65; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; POWELL RJ, 1986, T BRIT MYCOL SOC, V87, P205, DOI 10.1016/S0007-1536(86)80022-5; SCHULTZ TR, IN PRESS SYSTEM ENTO; STRADLING DJ, 1986, EXPERIENTIA, V42, P962, DOI 10.1007/BF01941781; Swofford D., 1990, B ILL NAT HIST SURV; Weber N.A., 1972, Memoirs Am phil Soc, V92, P1; Weber N.A., 1979, P77; Weber N.A., 1938, REV ENTOMOLOGIA, V9, P154; WEBER NA, 1966, SCIENCE, V153, P587, DOI 10.1126/science.153.3736.587; Weber NA, 1958, P 10 INT C ENT, V2, P459; Wetterer James K., 1994, P309; Wilson E.O., 1986, P1; WILSON EO, 1985, SCIENCE, V229, P265, DOI 10.1126/science.229.4710.265	26	68	72	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1695	1697		10.1126/science.7992052	http://dx.doi.org/10.1126/science.7992052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992052				2022-12-01	WOS:A1994PW30800037
J	MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C				MULLER, U; CRISTINA, N; LI, ZW; WOLFER, DP; LIPP, HP; RULICKE, T; BRANDNER, S; AGUZZI, A; WEISSMANN, C			BEHAVIORAL AND ANATOMICAL DEFICITS IN MICE HOMOZYGOUS FOR A MODIFIED BETA-AMYLOID PRECURSOR PROTEIN GENE	CELL			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; STEM-CELLS; TARGETED DISRUPTION; TYPE-4 ALLELE; MESSENGER-RNA; MOUSE HOMOLOG; WATER-MAZE; RAT; PROTOONCOGENE	The beta-amyloid precursor protein (beta APP) gene of the mouse was disrupted by inserting into exon 2 a cassette containing a neomycin resistance gene and a putative transcription termination sequence. Contrary to expectation, brain and other tissues from mice homozygous for the insertion still contained beta APP-specific RNA, albeit at a level 5- to 10-fold lower than wild type and lacking the disrupted exon, which had been spliced out. The brain contained shortened beta APP-specific protein at a low level. Mutant mice were severely impaired in spatial learning and exploratory behavior and showed increased incidence of agenesis of the corpus callosum.	UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; UNIV SPITAL ZURICH, INST NEUROPATHOL, BIOL ZENT LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital	MULLER, U (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		; Brandner, Sebastian/J-4562-2014	Aguzzi, Adriano/0000-0002-0344-6708; Brandner, Sebastian/0000-0002-9821-0342				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BERNASCONIGUASTALLA S, 1994, HIPPOCAMPUS, V4, P53, DOI 10.1002/hipo.450040107; BEYREUTHER K, 1991, ANN NY ACAD SCI, V640, P129; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; Gallyas F, 1979, Neurol Res, V1, P203; GANDY S, 1992, TRENDS PHARMACOL SCI, V13, P108, DOI 10.1016/0165-6147(92)90039-9; GENNARINI G, 1984, EUR J BIOCHEM, V142, P65, DOI 10.1111/j.1432-1033.1984.tb08251.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HARDY J, 1994, SCIENCE, V263, P454, DOI 10.1126/science.8290946; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HESS DT, 1983, J NEUROSCI METH, V8, P95, DOI 10.1016/0165-0270(83)90055-9; HILBICH C, 1993, J BIOL CHEM, V268, P26571; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEITINGER B, 1994, BEHAV GENET, V24, P273, DOI 10.1007/BF01067194; Lipp H.-P., 1993, Society for Neuroscience Abstracts, V19, P799; Lipp H.-P., 1992, GENETICALLY DEFINED, P217; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; REBECK GW, 1993, NEURON, V11, P575; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	55	271	282	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					755	765		10.1016/0092-8674(94)90066-3	http://dx.doi.org/10.1016/0092-8674(94)90066-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001115				2022-12-01	WOS:A1994PW05400004
J	FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J				FISHEL, R; EWEL, A; LEE, S; LESCOE, MK; GRIFFITH, J			BINDING OF MISMATCHED MICROSATELLITE DNA-SEQUENCES BY THE HUMAN MSH2 PROTEIN	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; GENETIC INSTABILITY; REPAIR; CARCINOGENESIS; HETERODUPLEXES; TUMORIGENESIS; CARCINOMA; HOMOLOG	Alteration of the human mismatch repair gene hMSH2 has been linked to the microsatellite DNA instability found in hereditary nonpolyposis colon cancer and several sporadic cancers. This microsatellite DNA instability is thought to arise from defective repair of DNA replication errors that create insertion-deletion loop-type (IDL) mismatched nucleotides. Here, it is shown that purified hMSH2 protein efficiently and specifically binds DNA containing IDL mismatches of up to 14 nucleotides. These results support a direct role for hMSH2 in mutation avoidance and microsatellite stability in human cells.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT MICROBIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	FISHEL, R (corresponding author), UNIV VERMONT,MARKEY CTR MOLEC GENET,SCH MED,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405, USA.				NCI NIH HHS [CA56542, R01 CA067007] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM42342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, UNPUB; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BISHOP DT, 1990, CANCER SURV, V9, P585; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CHI W, IN PRESS J BIOL CHEM; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, UNPUB; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P10; GRIFFITH JP, UNPUB; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEARN BA, 1989, J BACTERIOL, V171, P6473, DOI 10.1128/jb.171.12.6473-6481.1989; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; LOEB LA, 1991, CANCER RES, V51, P3075; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHOENBERG MP, 1994, BIOCHEM BIOPH RES CO, V198, P74, DOI 10.1006/bbrc.1994.1011; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, IN PRESS SCIENCE; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WANG YH, 1992, J BIOL CHEM, V267, P4911; WETNUR JG, 1968, J MOL BIOL, V31, P349; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	54	162	173	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1403	1405		10.1126/science.7973733	http://dx.doi.org/10.1126/science.7973733			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973733				2022-12-01	WOS:A1994PT63200049
J	BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM				BOUSSIOTIS, VA; BARBER, DL; NAKARAI, T; FREEMAN, GJ; GRIBBEN, JG; BERNSTEIN, GM; DANDREA, AD; RITZ, J; NADLER, LM			PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CTLA-4 COUNTER-RECEPTOR; HUMAN LYMPHOCYTES-T; CLONAL ANERGY; FUNCTIONAL COMPONENT; INTERLEUKIN-2; INDUCTION; ANTIGEN; MICE; PROLIFERATION	When stimulated through their antigen receptor without requisite costimulation, T cells enter a state of antigen-specific unresponsiveness, termed anergy. In this study, signaling through the common gamma chain of the interleukin-2 (IL-2), IL-4, and IL-7 receptors in the presence of antigen was found to be sufficient to prevent the induction of anergy. After culture with IL-2, IL-4, or IL-7, Jak3 kinase was tyrosine-phosphorylated, which correlated with the prevention of anergy. Therefore, a signal through the common gamma chain may regulate the decision of T cells to either clonally expand or enter a state of anergy.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BOUSSIOTIS, VA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,44 BINNEY ST,BOSTON,MA 02115, USA.		Ritz, Jerome/C-7929-2009; Freeman, Gordon/AAC-5380-2019	Ritz, Jerome/0000-0001-5526-4669; Freeman, Gordon/0000-0002-7210-5616; Barber, Dwayne/0000-0001-5528-8150	NCI NIH HHS [CA 40216] Funding Source: Medline; NIAID NIH HHS [AI 35225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; BOUSSIOTIS VA, UNPUB; BOUSSIOTIS VA, IN PRESS J EXP MED; DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FANSLOW WC, 1993, BLOOD, V81, P2998; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOX DA, 1984, J IMMUNOL, V133, P1250; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GO C, 1992, J EXP MED, V175, P1327, DOI 10.1084/jem.175.5.1327; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMIO M, 1990, INT IMMUNOL, V2, P521, DOI 10.1093/intimm/2.6.521; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LOMBARDI G, 1994, J EXP MED, V264, P1587; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON JD, 1994, NATURE, V369, P333; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WHITTHUHN BA, 1994, NATURE, V370, P153; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	51	318	325	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1039	1042		10.1126/science.7973657	http://dx.doi.org/10.1126/science.7973657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973657				2022-12-01	WOS:A1994PQ92400043
J	RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ				RUSSELL, SM; JOHNSTON, JA; NOGUCHI, M; KAWAMURA, M; BACON, CM; FRIEDMANN, M; BERG, M; MCVICAR, DW; WITTHUHN, BA; SILVENNOINEN, O; GOLDMAN, AS; SCHMALSTIEG, FC; IHLE, JN; OSHEA, JJ; LEONARD, WJ			INTERACTION OF IL-2R-BETA AND GAMMA(C) CHAINS WITH JAK1 AND JAK3 - IMPLICATIONS FOR XSCID AND XCID	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COMBINED IMMUNODEFICIENCY DISEASE; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; LYMPHOCYTES-T; BETA; EXPRESSION	Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta (IL-2R beta) and common gamma (gamma(c)) chains. Mutations of gamma(c) can result in X-linked severe combined immunodeficiency (XSCID). IL-2, IL-4, IL-7 (whose receptors are known to contain gamma(c)) and IL-9 (whose receptor is shown here to contain gamma(c)) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3. Jak1 and Jak3 associated with IL-2R beta and gamma(c), respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma(c) associations. Truncations of gamma(c), and a gamma(c), point mutation causing moderate X-linked combined immunodeficiency (XCID), decreased gamma(c)-Jak3 association. Thus, gamma(c) mutations in at least some XSCID and XCID patients prevent normal Jak3 activation, suggesting that mutations of Jak3 may result in an XSCID-like phenotype.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV TEXAS, MED BRANCH, DEPT PEDIAT, DIV IMMUNOL & ALLERGY, GALVESTON, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; St Jude Children's Research Hospital; University of Texas System; University of Texas Medical Branch Galveston	RUSSELL, SM (corresponding author), NHLBI, MOLEC IMMUNOL LAB, BLDG 10, BETHESDA, MD 20892 USA.		Leonard, Warren/AAA-1397-2022; McVicar, Daniel/G-1970-2015; Russell, Sarah M/B-9341-2009; witthuhn, bruce/GSE-3193-2022	Russell, Sarah M/0000-0001-5826-9641; Bacon, Chris/0000-0002-8268-2812	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROOKS EG, 1990, J CLIN INVEST, V86, P1623, DOI 10.1172/JCI114884; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDMAN AS, 1992, EUR J IMMUNOL, V22, P1103, DOI 10.1002/eji.1830220435; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSSELL SM, UNPUB; SALTZMAN EM, 1990, J BIOL CHEM, V265, P10138; SCHMALSTIEG FC, 1992, CLIN IMMUNOL IMMUNOP, V64, P71, DOI 10.1016/0090-1229(92)90061-R; SCHMALSTIEG FC, UNPUB; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	616	647	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1042	1045		10.1126/science.7973658	http://dx.doi.org/10.1126/science.7973658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973658	Green Submitted			2022-12-01	WOS:A1994PQ92400044
J	KINLEN, LJ; JOHN, SM				KINLEN, LJ; JOHN, SM			WARTIME EVACUATION AND MORTALITY FROM CHILDHOOD LEUKEMIA IN ENGLAND AND WALES IN 1945-9	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; EXCESS	Objective-To discover whether the wartime government evacuation of children from London and other population centres to rural districts was associated with any increase in childhood leukaemia. Design-Observational study of mortality from leukaemia among the childhood population of England and Wales in relation to the unique population movements during the second world war. The 476 rural districts of England and Wales were ranked according to the ratio of government evacuees (two thirds of them children) to local children in September 1941. The districts were divided into three categories, each with similar numbers of children in 1947 but with different ratios of evacuees to local children (''low,'' ''intermediate,'' ''high''). Mortality from childhood leukaemia was examined in these three rural categories in 1945-9. Urban areas were also examined according to their exposure to evacuees. Setting-Local authority areas of England and Wales. Subjects-Children aged under 15. Results-47% excess of leukaemia at ages 0-14 years occurred in 1945-9 in the rural ''high'' category for evacuees relative to the ''low'' category, with a significant trend across the three categories. There were increases in both the 0-4 and 5-14 year age groups, but these were larger in the older age group. Rates 25% lower than average occurred in rural areas with few evacuees. Conclusion-These findings suggest that wartime evacuation increased the incidence of childhood leukaemia in rural areas and that other forms of population mixing may have contributed to the increases in past decades. Overall, they add to the appreciable evidence for an infective basis in childhood leukaemia.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							BRADBEER G, 1993, LAND CHANGED ITS FAC; BROWN WMC, 1960, BRIT MED J, V2, P1539, DOI 10.1136/bmj.2.5212.1539; CALDER A, 1986, PEOPLES WAR BRITAIN; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KNEALE GW, 1971, BRIT J PREV SOC MED, V25, P152; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; ROOTES A, 1980, FRONT LINE COUNTY; Stocks P, 1941, J R STAT SOC, V104, P311, DOI 10.2307/2980120; Stocks P, 1942, J R STAT SOC, V105, P259, DOI 10.2307/2980435; TITMUSS RM, 1950, HIST 2ND WORLD WAR U; WOLFF SP, 1991, NATURE, V349, P23, DOI 10.1038/349023a0; 1951, STATISTICAL REV ENGL, V2; 1940, STATISTICS POPULATIO; 1949, ESTIMATES SEX AGE DI; 1947, STATISTICAL REV EN 1	19	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1197	1202		10.1136/bmj.309.6963.1197	http://dx.doi.org/10.1136/bmj.309.6963.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987150	Green Published			2022-12-01	WOS:A1994PQ66200019
J	MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP				MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP			CUSHINGS-SYNDROME IN CHILDREN AND ADOLESCENTS - PRESENTATION, DIAGNOSIS, AND THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; STIMULATION TEST; FREE CORTISOL; DISEASE; CHILDHOOD; MICROADENOMAS	Background and Methods. Cushing's syndrome is rare in children and adolescents. We analyzed the clinical presentation, diagnostic evaluation, and treatment of 59 patients with Cushing's syndrome between the ages of 4 and 20 years who were admitted to the National Institutes of Health during the period from 1982 to 1992. The cause of hypercortisolism was identified by low- and high-dose dexamethasone suppression tests, the ovine corticotropin-releasing hormone (CRH) stimulation test, imaging studies, and bilateral sampling of the inferior petrosal sinuses combined with administration of CRH. Results. Fifty patients had Cushing's disease, six had primary adrenal disease, and three had ectopic corticotropin secretion. The initial signs were excessive weight gain in 90 percent of the patients and growth retardation in 83 percent. Most patients (81 percent) had normal bone age at the time of diagnosis. Forty-seven percent had hypertension, whereas only 19 percent had mental or behavioral problems. The high-dose dexamethasone suppression test and the CRH stimulation test identified 68 and 80 percent, respectively, of the patients with Cushing's disease. Magnetic resonance imaging of the pituitary indicated the presence of tumor in 52 percent of the patients with pituitary adenomas. The maximal central-to-peripheral ratio of plasma corticotropin during sampling of the interior petrosal sinuses was greater than or equal to 2.5 in all the patients with Cushing's disease and <2.5 in those with ectopic corticotropin secretion. Remission of hypercortisolism was achieved in 48 of the 49 patients who underwent transsphenoidal surgery for Cushing's disease, in all 6 of the patients who underwent adrenalectomy for primary adrenal disease, and in the 2 patients in whom the ectopic source of corticotropin could be identified. Conclusions. Weight gain and growth retardation are common clinical characteristics of Cushing's syndrome in children and adolescents. Diagnostic evaluation of such patients with CRH stimulation alone and combined with inferior petrosal sinus sampling and imaging studies is accurate, and therapy is usually successful.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; NIH,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA	MAGIAKOU, MA (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; DANON M, 1975, J PEDIATR-US, V87, P917, DOI 10.1016/S0022-3476(75)80905-X; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; FRANKS RC, 1973, J CLIN ENDOCR METAB, V36, P702, DOI 10.1210/jcem-36-4-702; FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; JOB JC, 1981, PEDIATRIC ENDOCRINOL, P275; JONES KL, 1990, PEDIATR CLIN N AM, V37, P1313; KAO M, 1975, CLIN CHEM, V21, P1644; KAPLAN SA, 1979, PEDIATR CLIN N AM, V26, P65; KORTHSCHUTZ S, 1984, ADRENAL DISEASES CHI, V13, P185; KRIEGER DT, 1982, CUSHINGS SYNDROME; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCARTHUR RG, 1972, MAYO CLIN PROC, V47, P318; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NEW MI, 1989, CLIN PEDIATRIC ENDOC, P181; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; NIEMAN LK, 1989, J CLIN ENDOCR METAB, V69, P165, DOI 10.1210/jcem-69-1-165; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1978, METHOD HORM RADIOIMM, P245; SILBER RH, 1954, J BIOL CHEM, V210, P923; STREETEN DHP, 1975, PEDIATRICS, V56, P797; STRICKLAND AL, 1972, AM J DIS CHILD, V123, P207, DOI 10.1001/archpedi.1972.02110090077007; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; THOMAS CG, 1984, ANN SURG, V199, P538, DOI 10.1097/00000658-198405000-00008; TYRRELL JB, 1978, NEW ENGL J MED, V298, P753, DOI 10.1056/NEJM197804062981401	33	292	300	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					629	636		10.1056/NEJM199409083311002	http://dx.doi.org/10.1056/NEJM199409083311002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052272				2022-12-01	WOS:A1994PE38200002
J	UHLIN, U; EKLUND, H				UHLIN, U; EKLUND, H			STRUCTURE OF RIBONUCLEOTIDE REDUCTASE PROTEIN R1	NATURE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; BARREL ENZYMES; INHIBITION; REFINEMENT; MUTANT; SITE; R2	Ribonucleotide reductase is the only enzyme that catalyses de novo formation of deoxyribonucleotides and is thus a key enzyme in DNA synthesis. The radical-based reaction involves five cysteines. Two redox-active cysteines are located at adjacent antiparallel strands in a new type of ten-stranded alpha/beta-barrel, and two others at the carboxyl end in a flexible arm. The fifth cysteine, in a loop in the centre of the barrel, is positioned to initiate the radical reaction.			UHLIN, U (corresponding author), SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.							ABERG A, 1989, J BIOL CHEM, V264, P12249; ABERG A, 1993, THESIS U STOCKHOLM; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BOOKER S, 1993, BIOCHEM SOC T, V21, P727, DOI 10.1042/bst0210727; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ERIKSSON S, 1986, J BIOL CHEM, V261, P1878; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KNIGHT S, 1989, THESIS SWEDISH U AGR; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Nyborg J., 1977, ROTATION METHOD CRYS, P139; OTWINOWSKI Z, 1991, DENZO MANUAL; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PRONGAY AJ, 1990, J BIOL CHEM, V265, P18968; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TUGGLE CK, 1990, J BACTERIOL, V172, P1711, DOI 10.1128/jb.172.4.1711-1718.1990; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	505	515	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					533	539		10.1038/370533a0	http://dx.doi.org/10.1038/370533a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052308				2022-12-01	WOS:A1994PC53700047
J	OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG				OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG			GENE-THERAPY FOR VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION AFTER ARTERIAL INJURY	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; TRANSLUMINAL CORONARY ANGIOPLASTY; ENDOTHELIAL-CELLS; BALLOON ANGIOPLASTY; INTIMAL HYPERPLASIA; EXPRESSION INVIVO; RETROVIRAL VECTOR; ADENOVIRAL VECTOR; CONTROLLED TRIAL; MODEL	Accumulation of vascular smooth muscle cells as a consequence of arterial injury is a major feature of vascular proliferative disorders. Molecular approaches to the inhibition of smooth muscle cell proliferation in these settings could potentially limit intimal expansion. This problem was approached by introducing adenoviral vectors encoding the herpesvirus thymidine kinase (tk) into porcine arteries that had been injured by a balloon on a catheter. These smooth muscle cells were shown to be infectable with adenoviral vectors, and introduction of the tk gene rendered them sensitive to the nucleoside analog ganciclovir. When this vector was introduced into porcine arteries immediately after a balloon injury, intimal hyperplasia decreased after a course of ganciclovir treatment. No major local or systemic toxicities were observed. These data suggest that transient expression of an enzyme that catalyzes the formation of a cytotoxic drug locally may limit smooth muscle cell proliferation in response to balloon injury.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	OHNO, T (corresponding author), UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL143507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI033355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43507] Funding Source: Medline; NIAID NIH HHS [AI33355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCON R, 1992, CIRCULATION, V86, P100; BARR E, 1994, GENE THER, V1, P51; BAUMGARTNER HR, 1976, THROMB HAEMOSTASIS, V35, P124, DOI 10.1055/s-0038-1647919; BLOCK PC, 1981, NEW ENGL J MED, V305, P382, DOI 10.1056/NEJM198108133050706; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FAXON DP, 1992, CIRCULATION, V86, P53; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; FRENCH J. E., 1965, ANN N Y ACAD SCI, V127, P780, DOI 10.1111/j.1749-6632.1965.tb49444.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GINSBURG D, 1992, BLOOD, V79, P2507; GONCHOROFF NJ, 1986, J IMMUNOL METHODS, V93, P97, DOI 10.1016/0022-1759(86)90438-2; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; ISIK FF, 1992, AM J PATHOL, V141, P1139; KNUDTSON ML, 1990, J AM COLL CARDIOL, V15, P691, DOI 10.1016/0735-1097(90)90648-9; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MOOLTEN FL, 1990, HUM GENE THER, V1, P125, DOI 10.1089/hum.1990.1.2-125; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; OHNO T, UNPUB; OKEEFE JH, 1992, J AM COLL CARDIOL, V19, P1597, DOI 10.1016/0735-1097(92)90624-V; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; PLAUTZ G, 1991, NEW BIOL, V3, P709; POMPILI VJ, UNPUB; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; REKHTER MD, 1993, AM J PATHOL, V143, P1634; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SCHWARTZ RS, 1994, ARTERIOSCLER THROMB, V14, P395, DOI 10.1161/01.ATV.14.3.395; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V19, P267, DOI 10.1016/0735-1097(92)90476-4; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1992, CIRCULATION, V86, P100; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIMS FH, 1989, PATHOLOGY, V21, P115, DOI 10.3109/00313028909059547; SMITH KO, 1982, ANTIMICROB AGENTS CH, V22, P55, DOI 10.1128/AAC.22.1.55; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; WEINER BH, 1986, NEW ENGL J MED, V315, P841, DOI 10.1056/NEJM198610023151401; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; Winer BJ, 1971, STATISTICAL PRINCIPL, P261; WISSLER RW, 1968, ANN NY ACAD SCI, V149, P907	68	424	467	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					781	784		10.1126/science.8047883	http://dx.doi.org/10.1126/science.8047883			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047883				2022-12-01	WOS:A1994PA37200033
J	KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D				KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D			DEPENDENCE ON REM-SLEEP OF OVERNIGHT IMPROVEMENT OF A PERCEPTUAL SKILL	SCIENCE			English	Article							PARADOXICAL SLEEP; CORTEX; MEMORY; DISCRIMINATION; CONSOLIDATION; ACETYLCHOLINE; PLASTICITY	Several paradigms of perceptual learning suggest that practice can trigger long-term, experience-dependent changes in the adult visual system of humans. As shown here, performance of a basic visual discrimination task improved after a normal night's sleep. Selective disruption of rapid eye movement (REM) sleep resulted in no performance gain during a comparable sleep interval, although non-REM slow-wave sleep disruption did not affect improvement. On the other hand, deprivation of REM sleep had no detrimental effects on the performance of a similar, but previously learned, task. These results indicate that a process of human memory consolidation, active during sleep, is strongly dependent on REM sleep.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT NEUROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,OSCAR SAGER SLEEP RES LAB,IL-52621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center			Sagi, Dov/A-5454-2008; Tanne, David/F-2560-2010	Sagi, Dov/0000-0002-8446-9230; Tanne, David/0000-0002-6699-2220				AGNEW HW, 1967, PERCEPT MOTOR SKILL, V24, P851, DOI 10.2466/pms.1967.24.3.851; AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; BALL K, 1987, VISION RES, V27, P935; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CASTALDO V, 1974, PERCEPT MOTOR SKILL, V39, P1023, DOI 10.2466/pms.1974.39.3.1023; CHERNIK DA, 1972, PERCEPT MOTOR SKILL, V34, P283, DOI 10.2466/pms.1972.34.1.283; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; EMPSON JAC, 1970, NATURE, V227, P287, DOI 10.1038/227287a0; FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1; FISHBEIN W, 1977, BEHAV BIOL, V19, P425, DOI 10.1016/S0091-6773(77)91903-4; FOWLER MJ, 1973, SCIENCE, V179, P302, DOI 10.1126/science.179.4070.302; Hobson J A, 1992, Curr Opin Neurobiol, V2, P759, DOI 10.1016/0959-4388(92)90130-D; HOBSON JA, 1990, J NEUROSCI, V10, P371; HORNE JA, 1984, BIOL PSYCHOL, V18, P165, DOI 10.1016/0301-0511(84)90001-2; JASPER HH, 1971, SCIENCE, V172, P601, DOI 10.1126/science.172.3983.601; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KARNI A, 1990, Investigative Ophthalmology and Visual Science, V31, P562; KARNI A, 1994, MATURATIONAL WINDOWS; KARNI A, 1992, THESIS WEIZMANN I SC; KOVACS I, COMMUNICATION; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MISHKIN M, 1952, J EXP PSYCHOL, V43, P43, DOI 10.1037/h0061361; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; MOSES JM, 1975, PSYCHOPHYSIOLOGY, V12, P141, DOI 10.1111/j.1469-8986.1975.tb01264.x; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; POLAT U, 1994, MATURATIONAL WINDOWS; Rechtschaffen A., 1968, MANUAL STANDARDIZED; SHIU LP, 1992, PERCEPT PSYCHOPHYS, V52, P282; SMITH C, 1982, PHYSIOL BEHAV, V29, P469, DOI 10.1016/0031-9384(82)90268-2; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SQUIRE LR, 1987, MEMORY BRAIN, P164; TILLEY AJ, 1978, BIOL PSYCHOL, V6, P293, DOI 10.1016/0301-0511(78)90031-5; Winson J, 1993, Curr Opin Neurobiol, V3, P243, DOI 10.1016/0959-4388(93)90217-M	35	683	703	3	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					679	682		10.1126/science.8036518	http://dx.doi.org/10.1126/science.8036518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ538	8036518				2022-12-01	WOS:A1994NZ53800039
J	HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD				HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD			TRANSCRIPTIONAL REPRESSION DIRECTED BY THE YEAST ALPHA-2 PROTEIN IN-VITRO	NATURE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; ACTIVATION; DROSOPHILA; BINDS; NUCLEOSOMES; OPERATOR; COMPLEX; DOMAIN	THE alpha 2 protein, a homeodomain protein involved in specifying cell type in the budding yeast Saccharomyces cerevisiae, is a transcriptional repressor(1,2). alpha 2 binds cooperatively with Mcm1, a serum response factor-related protein, to the a-specific gene operator(3-6). The alpha 2-Mcm1 complex in turn recruits Ssn6 and Tup1 to the operator, and we believe that these latter two proteins are responsible for the transcriptional repression(7-9). Placement of the a-specific gene operator in any of a variety of positions upstream of a test promoter leads to repression of that promoter in vivo(9-11). In this respect, the a-specific gene operator resembles a negatively acting enhancer. Here we describe the in vitro reconstitution of this example of negative control from a distance. We observe repression in vitro in the absence of exogenously added activator protein and on templates that lack binding sites for known activator proteins, and we infer that alpha 2-directed repression acts on the general transcription machinery.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	HERSCHBACH, BM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HERSCHBACH BM, 1993, MOL CELL BIOL, V13, P4029, DOI 10.1128/MCB.13.7.4029; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON AD, 1985, CELL, V53, P927; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; Johnson SL, 1991, THESIS U WASHINGTON; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; WOOTNER M, 1991, MOL CELL BIOL, V11, P4555	30	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					309	311		10.1038/370309a0	http://dx.doi.org/10.1038/370309a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035881				2022-12-01	WOS:A1994NZ22900069
J	LEE, PR				LEE, PR			IRRADIATION TO PREVENT FOODBORNE ILLNESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service									0	12	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					261	261		10.1001/jama.272.4.261	http://dx.doi.org/10.1001/jama.272.4.261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028126				2022-12-01	WOS:A1994NX80600004
J	SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M				SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M			SIGNIFICANT INCREASE IN TRISOMY-21 IN BERLIN 9 MONTHS AFTER THE CHERNOBYL REACTOR ACCIDENT - TEMPORAL CORRELATION OR CAUSAL RELATION	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; RISK; ABNORMALITIES; RADIATION; EUROPE	Objective-To assess whether the increased prevalence of trisomy 21 in West Berlin in January 1987 might have been causally related to exposure to ionising radiation as a result of the Chernobyl reactor accident or was merely a chance event. Design-Analysis of monthly prevalence of trisomy 21 in West Berlin from January 1980 to December 1989. Setting-Confines of West Berlin. Results-Owing to the former ''island'' situation of West Berlin and its well organised health services, ascertainment of trisomy 21 was thought to be almost complete. A cluster of 12 cases occurred in January 1987 as compared with two or three expected. After exclusion of factors that might have explained the increase, including maternal age distribution, only exposure to radiation as a result of the Chernobyl reactor accident remained. In six of seven cases that could be studied cytogenetically the extra chromosome was of maternal origin, confirming that nondisjunction had occurred at about the time of conception. Conclusion-On the basis of two assumptions -(a) that maternal meiosis is an error prone process susceptible to exogenous factors at the time of conception; (b) that owing to the high prevalence of iodine deficiency in Berlin a large amount of iodine-131 would have been accumulated over a short period-it is concluded that the increased prevalence of trisomy 21 in West Berlin in January 1987 was causally related to a short period of exposure to ionising radiation as a result of the Chernobyl reactor accident.	INST GESCHICHTE MED,D-79104 FREIBURG,GERMANY; FREE UNIV BERLIN,KINDERKLIN,D-14059 BERLIN,GERMANY; JOHN F KENNEDY INST,DK-2600 GLOSTRUP,DENMARK	Free University of Berlin	SPERLING, K (corresponding author), FREE UNIV BERLIN,INST HUMAN GENET,D-14059 BERLIN,GERMANY.							ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; ANTONARAKIS SE, 1993, TRENDS GENET, V9, P142, DOI 10.1016/0168-9525(93)90210-9; CZEIZEL A, 1989, HUM GENET, V82, P359; CZEIZEL A, 1988, ACTA MORPHOL HUNG, V36, P63; CZEIZEL AE, 1993, LANCET, V341, P539, DOI 10.1016/0140-6736(93)90293-P; DELANGE F, 1989, B WORLD HEALTH ORGAN, V67, P317; DELANGE F, 1986, BIOL NEONATE, V49, P322, DOI 10.1159/000242547; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; Diggle P. J., 1990, TIME SERIES BIOSTATI; DULK H, 1991, EUROCAT REGISTRY DES; FIALKOW PJ, 1970, ANN NY ACAD SCI, V171, P500, DOI 10.1111/j.1749-6632.1970.tb39359.x; GERMAN J, 1968, NATURE, V217, P516, DOI 10.1038/217516a0; HANSMANN I, 1990, TRENDS CHROMOSOME RE, P165; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HELLER CG, 1963, SCIENCE, V140, P184, DOI 10.1126/science.140.3563.184; HOOK EB, 1989, AM J HUM GENET, V45, P855; JANERICH DT, 1977, LANCET, V1, P515; JORGBLOET PH, 1982, HUM GENET, V62, P134; KALLEN B, 1989, HEREDITAS, V110, P55, DOI 10.1111/j.1601-5223.1989.tb00417.x; KLINE J, 1985, ANEUPLOIDY ETIOLOGY, P149; KOCHUPILLAI N, 1976, NATURE, V262, P60, DOI 10.1038/262060a0; LIENERT GA, 1978, VERTEILUNGSFREIE MET, V2; LINDSTEN J, 1981, TRISOMY, V21, P1195; RAMSAY CN, 1991, BIOMED PHARMACOTHER, V45, P267, DOI 10.1016/0753-3322(91)90028-R; SPERLING K, 1991, BIOMED PHARMACOTHER, V45, P255, DOI 10.1016/0753-3322(91)90026-P; SPERLING K, 1984, MUTATIONS MAN, P128; SPERLING K, 1987, ANN U SARAVIENSIS S, V7, P307; SPERLING K, 1987, ANN U SARAV MED S, V7, P305; STEINMETZ KH, 1987, RADIOAKTIVITATSMESSU, P439; THIEME C, 1989, KINDERARZT, V20, P857; TORFS CP, 1990, AM J HUM GENET, V47, P727; VOGEL F, 1992, HUM GENET, V89, P127; WINTER M, 1986, RADIOAKTIVITAZ BRD S; WITOWSKI R, 1987, Z KLINISCHE MED, V24, P2203; 1985, LANCET, V1, P1289; 1980, SCIENCE, V209, P877	36	74	77	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					158	162		10.1136/bmj.309.6948.158	http://dx.doi.org/10.1136/bmj.309.6948.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044094	Green Published			2022-12-01	WOS:A1994NY22900020
J	CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM				CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM			HIGH-RESOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ISOTOPICALLY ENRICHED PROTEINS; RESTRAINED MOLECULAR-DYNAMICS; MULTIPLE QUANTUM COHERENCE; DNA-BINDING; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; J COUPLINGS; PEPTIDE COMPLEX; LARGER PROTEINS	The three-dimensional structure of the oligomerization domain (residues 319 to 360) of the tumor suppressor p53 has been solved by multidimensional heteronuclear magnetic resonance (NMR) spectroscopy. The domain forms a 20-kilodalton symmetric tetramer with a topology made up from a dimer of dimers. The two primary dimers each comprise two antiparallel helices linked by an antiparallel beta sheet. One beta strand and one helix are contributed from each monomer. The interface between the two dimers forming the tetramer is mediated solely by helix-helix contacts. The overall result is a symmetric, four-helix bundle with adjacent helices oriented antiparallel to each other and with the two antiparallel beta sheets located on opposing faces of the molecule. The tetramer is stabilized not only by hydrophobic interactions within the protein core but also by a number of electrostatic interactions. The implications of the structure of the tetramer for the biological function of p53 are discussed.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Sakamoto, Hiroshi/A-3181-2011; Zambrano, Nicola/B-9352-2014; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Zambrano, Nicola/0000-0001-9395-3481; Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAMICO D, 1992, ONCOGENE, V7, P339; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; DELANO W, 1993, AVS XPLOR USERS MANU; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GRZESIEK S, 1992, J MAGN RESON, V96, P215, DOI 10.1016/0022-2364(92)90307-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, 1993, SCIENCE, V262, P1980; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1993, SCIENCE, V261, P438; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MIYAMOTO H, 1993, ONCOL RES, V5, P245; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NISHIDA N, 1993, CANCER RES, V53, P368; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO H, IN PRESS P NATL ACAD; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, METHOD ENZYMOL, V239, P79; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	69	299	306	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					386	391		10.1126/science.8023159	http://dx.doi.org/10.1126/science.8023159			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023159				2022-12-01	WOS:A1994NW81600038
J	POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J				POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J			CLONING OF P27(KIP1), A CYCLIN-DEPENDENT KINASE INHIBITOR AND A POTENTIAL MEDIATOR OF EXTRACELLULAR ANTIMITOGENIC SIGNALS	CELL			English	Article							FC-GAMMA-RIII; CELL-CYCLE; GROWTH-FACTOR; TGF-BETA; GENE-EXPRESSION; CDK2 ACTIVITY; G1 CYCLIN; FIBROBLASTS; PROTEIN; PHASE	We cloned p27(Kip1), a cyclin-dependent kinase inhibitor implicated in G1 phase arrest by TGF beta and cell-cell contact. p27(Kip1) associates with cyclin E-Cdk2 complexes in vivo and in vitro, prevents their activation, and inhibits previously activated complexes, and p27(Kip1) overexpression obstructs cell entry into S phase. p27(Kip1) potently inhibits Rb phosphorylation by cyclin E-Cdk2, cyclin A-Cdk2, and cyclin D2-Cdk4. p27(Kip1) is highly conserved and broadly expressed in human tissues, and its mRNA levels are similar in proliferating and quiescent cells. p27(Kip1) has a region of sequence similarity to p21(Cip1/WAF1), the Cdk inhibitor whose transcription is stimulated by p53. A p27(Kip1) peptide corresponding to this region retains Cdk inhibitory activity. We suggest that cell contact, TGF beta, and p53 all restrain cell proliferation through related Cdk inhibitors.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center	POLYAK, K (corresponding author), HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; Massague, Joan/0000-0001-9324-8408; Lee, Mong-Hong/0000-0001-8675-8215				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELICONE C, 1994, IN PRESS J CHROMATOG; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	2068	2207	3	57	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					59	66		10.1016/0092-8674(94)90572-X	http://dx.doi.org/10.1016/0092-8674(94)90572-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033212				2022-12-01	WOS:A1994NX32800008
J	TZAMARIAS, D; STRUHL, K				TZAMARIAS, D; STRUHL, K			FUNCTIONAL DISSECTION OF THE YEAST CYC8-TUP1 TRANSCRIPTIONAL CO-REPRESSOR COMPLEX	NATURE			English	Article							DNA-BINDING SPECIFICITY; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; GLUCOSE REPRESSION; ACTIVATION DOMAIN; ESCHERICHIA-COLI; SHUTTLE VECTORS; PROTEIN; GENES; PURIFICATION	DNA-BINDING repressor proteins mediate regulation of yeast genes by cell type (Mcm1/alpha 2 and a1/alpha 2), glucose (Mig1) and oxygen (Rox1) (refs 1-4 respectively). An unusual feature of all these regulatory pathways is that transcriptional repression requires two physically associated proteins(5) that do not bind DNA Cyc8(Ssn6) and Tup1. The Cyc8-Tup1 complex has been proposed to be a corepressor that is recruited to target promoters by pathway-specific DNA-binding proteins(6), but the specific functions of the individual proteins are unknown. Here we show that when it is bound upstream of a functional promoter through the LexA DNA-binding domain, Tup1 represses transcription in the absence of Cyc8. Deletion analysis indicates that Tup1 contains at least two non-overlapping transcriptional repression regions with minimal primary sequence similarity, and a separable Cyc8-interaction domain. These Tup1 domains, which do not include the beta-transducin motifs(7), are necessary and partially sufficient for Tup1 function. We suggest that Tup1 performs the repression function of the Cyc8-Tup1 co-repressor complex, and that Cyc8 serves as a link with the pathway-specific DNA-binding proteins.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	30	286	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					758	761		10.1038/369758a0	http://dx.doi.org/10.1038/369758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008070				2022-12-01	WOS:A1994NU58100065
J	SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N				SIGURDSSON, E; THORGEIRSSON, G; SIGVALDASON, H; SIGFUSSON, N			UNRECOGNIZED MYOCARDIAL-INFARCTION - EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND THE PROGNOSTIC ROLE OF ANGINA-PECTORIS - THE REYKJAVIK STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; ANGINA PECTORIS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; RISK ASSESSMENT	CORONARY-ARTERY DISEASE; AUTONOMIC NEUROPATHY; WARNING SYSTEM; HEART-DISEASE; CHEST PAIN; FOLLOW-UP; SILENT; PREVALENCE; ISCHEMIA; MEN	Objective: To evaluate the incidence, prevalence, characteristics, and prognosis associated with clinically unrecognized myocardial infarction as diagnosed by electrocardiographic changes. Design: Prospective, population-based cohort study with 4- to 20-year follow-up. Setting: Icelandic Heart Association Preventive Clinic. Participants: 9141 men residing in the Reykjavik area who were born between 1907 and 1934. Measurements: Patients were assigned to categories of coronary heart disease at first visit on the basis of hospital records, Rose chest pain questionnaire, standardized 12-lead electrocardiogram, and history and physical examination. Incidence and prevalence of unrecognized myocardial infarction were determined, survival was measured, and causes of death were determined from death certificates and autopsy records. Results: Prevalence was strongly influenced by age. Nearly undetectable in the youngest age group, it increased to more than 5% in the group aged 75 to 79 years. Incidence was almost zero up to age 40, then increased steeply to more than 300 cases per year per 100 000 persons at age 60, and decreased with age after age 65. Ten- and 15-year survival probabilities were 51% and 45%, respectively, and were similar to those for patients with recognized myocardial infarction. One third of men with unrecognized and 58% of men with recognized myocardial infarction had a history of angina pectoris (P < 0.001). Angina pectoris had a greater effect on coronary heart disease mortality in the former group than in the latter. The risk ratio for unrecognized myocardial infarction was 4.6 without angina (95% CI, 2.4 to 8.6) and 16.9 with angina (CI, 9.4 to 30.3); the risk ratio for recognized myocardial infarction was 6.3 without angina (CI, 3.7 to 10.6) and 8.5 with angina (CI, 5.8 to 12.6). Conclusion: At least one third of all myocardial infarctions were unrecognized. Prognosis and risk factor profiles for patients with recognized and unrecognized myocardial infarction were similar. Although those with unrecognized myocardial infarction were less likely than those with recognized myocardial infarction to have a history of angina pectoris, angina in these cases was usually associated with ischemic electrocardiographic changes and a poor prognosis, suggesting severe coronary heart disease.	NATL UNIV HOSP REYKJAVIK, DEPT MED, IS-121 REYKJAVIK, ICELAND; GOTHENBURG UNIV, GOTHENBURG, SWEDEN; HLTH CTR MARIESTAD, MARIESTAD, SWEDEN; ICELAND HEART ASSOC, HEART PREVENT CLIN, IS-108 REYKJAVIK, ICELAND; NATL UNIV HOSP REYKJAVIK, DEPT MED LANDSPITALINN, IS-121 REYKJAVIK, ICELAND	Landspitali National University Hospital; University of Gothenburg; Icelandic Heart Association; Landspitali National University Hospital								AIRAKSINEN KEJ, 1992, DIABETES CARE, V15, P288, DOI 10.2337/diacare.15.2.288; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Bertolet B D, 1989, Cardiovasc Clin, V20, P173; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COHN PF, 1980, AM J CARDIOL, V45, P697, DOI 10.1016/S0002-9149(80)80024-5; COHN PF, 1988, AM J CARDIOL, V61, pB4; DROSTE C, 1983, J AM COLL CARDIOL, V1, P940, DOI 10.1016/S0735-1097(83)80214-9; DROSTE C, 1986, PAIN, V26, P199, DOI 10.1016/0304-3959(86)90075-8; HEDBLAD B, 1989, EUR HEART J, V10, P149, DOI 10.1093/oxfordjournals.eurheartj.a059455; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1987, CIRCULATION, V75, P4; KANNEL WB, 1990, ADV CARDIOL, V37, P202; KOISTINEN MJ, 1992, ACTA DIABETOL, V28, P199, DOI 10.1007/BF00778998; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NIAKAN E, 1986, ARCH INTERN MED, V146, P2229, DOI 10.1001/archinte.146.11.2229; OSULLIVAN JJ, 1991, BRIT HEART J, V66, P313; PYORALA K, 1974, ANN CLIN RES, V6, P137; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE GA, 1968, CARDIOVASCULAR SURVE, P56; ROSEMAN MD, 1954, ANN INTERN MED, V41, P1, DOI 10.7326/0003-4819-41-1-1; ROSENMAN RH, 1970, J CHRON DIS, V23, P173, DOI 10.1016/0021-9681(70)90094-9; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1990, EGRET REFERENCE MANU	28	187	190	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					96	102		10.7326/0003-4819-122-2-199501150-00003	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7993002				2022-12-01	WOS:A1995QC05900003
J	SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P				SCHLAEPFER, DD; HANKS, SK; HUNTER, T; VANDERGEER, P			INTEGRIN-MEDIATED SIGNAL-TRANSDUCTION LINKED TO RAS PATHWAY BY GRB2 BINDING TO FOCAL ADHESION KINASE	NATURE			English	Article							PROTEIN-TYROSINE KINASE; CELL-ADHESION; SH3 DOMAIN; PHOSPHORYLATION; RECEPTOR	THE cytoplasmic focal adhesion protein-tyrosine kinase (FAK) localizes with surface integrin receptors at sites where cells attach to the extracellular matrix. Increased FAK tyrosine phosphorylation occurs upon integrin engagement with fibronectin. Here we show that adhesion of murine NIH3T3 fibroblasts to fibronectin promotes SH2-domain-mediated association of the GRB2 adaptor protein and the c-Src protein-tyrosine kinase (PTK) with FAK in vivo, and also results in activation of mitogen-activated protein kinase (MAPK). In v-Src-transformed NIH3T3, the association of v-Src, GRB2 and Sos with FAK is independent of cell adhesion to fibronectin. The GRB2 SH2 domain binds directly to tyrosine-phosphorylated FAK. Mutation of tyrosine residue 925 of FAK (YENV motif) to phenylalanine blocks GRB2 SH2-domain binding to PAK in vitro. Our results show that fibronectin binding to integrins on NIH3T3 fibroblasts promotes c-Src and FAK association and formation of an integrin-activated signalling complex. Phosphorylation of FAK at Tyr 925 upon fibronectin stimulation creates an SH2-binding site for GRB2 which may link integrin engagement to the activation of the Ras/MAPK signal transduction pathway.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University	SCHLAEPFER, DD (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB M, IN PRESS MOL CELL BI; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	1443	1471	2	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					786	791						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997267				2022-12-01	WOS:A1994PY21200055
J	VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R				VASSAR, R; CHAO, SK; SITCHERAN, R; NUNEZ, JM; VOSSHALL, LB; AXEL, R			TOPOGRAPHIC ORGANIZATION OF SENSORY PROJECTIONS TO THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; MARKER PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; RAT; FAMILY; EPITHELIUM; NEURONS; MOLECULES	The detection of odorant receptor mRNAs within the axon terminals of sensory neurons has permitted us to ask whether neurons expressing a given receptor project their axons to common glomeruli within the olfactory bulb. In situ hybridization with five different receptor probes demonstrates that axons from neurons expressing a given receptor converge on one, or at most, a few glomeruli within the olfactory bulb. Moreover, the position of specific glomeruli is bilaterally symmetric and is constant in different individuals within a species. These data support a model in which exposure to a given odorant may result in the stimulation of a spatially restricted set of glomeruli, such that the individual odorants would be associated with specific topographic patterns of activity within the olfactory bulb.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	VASSAR, R (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Sitcheran, Raquel/0000-0001-8916-9707; Vosshall, Leslie/0000-0002-6060-8099; Axel, Richard/0000-0002-3141-4076	NIGMS NIH HHS [T32 GM07367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTIC L, 1986, BRAIN RES BULL, V16, P445, DOI 10.1016/0361-9230(86)90172-3; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BAIER H, 1994, J NEUROSCI, V14, P219; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BERKLEY KJ, 1985, DEV ORG PROCESSING S, P191; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUONVISO N, 1991, EUR J NEUROSCI, V3, P493, DOI 10.1111/j.1460-9568.1991.tb00836.x; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATO.M, 1990, ANN REV NEUROSCI, V13, P129; DYKES RW, 1982, J NEUROPHYSIOL, V47, P389, DOI 10.1152/jn.1982.47.3.389; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN CS, 1993, NEURON S, V10, P77; HABERLY LB, 1977, BRAIN RES, V129, P152, DOI 10.1016/0006-8993(77)90978-7; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P516; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LANDRY C, 1992, J NEUROBIOL, V23, P89, DOI 10.1002/neu.480230109; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LUSKIN MB, 1982, J COMP NEUROL, V209, P249, DOI 10.1002/cne.902090304; MARGOLIS FL, 1978, SOC NEUR ABSTR, V4, P88; MEISAMI E, 1989, DEV BRAIN RES, V46, P9, DOI 10.1016/0165-3806(89)90139-9; MEISAMI E, 1979, NEURAL GROWTH DIFFER; MELTON DA, 1984, NUCLEIC ACIDS RES, V13, P7035; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NADI NS, 1981, BRAIN RES, V213, P365, DOI 10.1016/0006-8993(81)90241-9; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; OJIMA H, 1984, J COMP NEUROL, V230, P77, DOI 10.1002/cne.902300107; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PERL ER, 1962, J NEUROPHYSIOL, V25, P337, DOI 10.1152/jn.1962.25.3.337; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; ROYET JP, 1987, BRAIN RES, V417, P1, DOI 10.1016/0006-8993(87)90173-9; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWOB JE, 1978, BRAIN RES, V151, P369, DOI 10.1016/0006-8993(78)90891-0; SCOTT JW, 1980, J COMP NEUROL, V194, P519, DOI 10.1002/cne.901940304; Shepherd G. M., 1991, OLFACTION MODEL SYST; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VERHAAGEN J, 1990, J NEUROSCI RES, V26, P31, DOI 10.1002/jnr.490260105; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	64	981	996	0	34	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					981	991		10.1016/0092-8674(94)90029-9	http://dx.doi.org/10.1016/0092-8674(94)90029-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001145				2022-12-01	WOS:A1994PY08600008
J	ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A				ADOLPHS, R; TRANEL, D; DAMASIO, H; DAMASIO, A			IMPAIRED RECOGNITION OF EMOTION IN FACIAL EXPRESSIONS FOLLOWING BILATERAL DAMAGE TO THE HUMAN AMYGDALA	NATURE			English	Article							CIRCUMPLEX MODEL; IDENTITY; LESIONS; MONKEY	STUDIES in animals have shown that the amygdala receives highly processed visual input(1,2), contains neurons that respond selectively to faces(3), and that it participates in emotion(4,5) and social behaviour(6). Although studies in epileptic patients support its role in emotion(7), determination of the amygdala's function in humans has been hampered by the rarity of patients with selective amygdala lesions(8). Here, with the help of one such rare patient, we report findings that suggest the human amygdala may be indispensable to: (1) recognize fear in facial expressions; (2) recognize multiple emotions in a single facial expression; but (3) is not required to recognize personal identity from faces. These results suggest that damage restricted to the amygdala causes very specific recognition impairments, and thus constrains the broad notion that the amygdala is involved in emotion.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	ADOLPHS, R (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,DIV COGNIT NEUROSCI,IOWA CITY,IA 52242, USA.		Tudusciuc, Oana/C-1339-2011; Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				AGGLETON J P, 1992, P485; AMARAL D G, 1992, P1; Amaral DG, 1992, AMYGDALA NEUROBIOLOG, P465; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; DAMASIO AR, 1990, ANNU REV NEUROSCI, V13, P89, DOI 10.1146/annurev.ne.13.030190.000513; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 1989, ANAL NEUROPSYCHOLOGY; Darwin Charles, 1965, EXPRESSION EMOTIONS; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Ekman P, 1976, PICTURES FACIAL AFFE; Ekman Paul, 1973, DARWIN FACIAL EXPRES; GUTTMAN L, 1968, PSYCHOMETRIKA, V33, P469, DOI 10.1007/BF02290164; HALGREN E, 1978, BRAIN, V101, P83, DOI 10.1093/brain/101.1.83; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HERZOG AG, 1976, BRAIN RES, V115, P57, DOI 10.1016/0006-8993(76)90822-2; HOFER PA, 1973, ACTA DERM-VENEREOL, V53, P5; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; KLING A S, 1992, P353; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P115, DOI 10.1007/BF02289694; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROLLS E T, 1992, P143; RUSSELL JA, 1989, J PERS SOC PSYCHOL, V57, P848, DOI 10.1037/0022-3514.57.5.848; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; RUSSELL JA, 1991, PSYCHOL BULL, V110, P426, DOI 10.1037/0033-2909.110.3.426; RUSSELL JA, 1985, J PERS SOC PSYCHOL, V48, P1290, DOI 10.1037/0022-3514.48.5.1290; TRANEL D, 1988, NEUROLOGY, V38, P690, DOI 10.1212/WNL.38.5.690; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	29	1564	1593	2	215	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					669	672		10.1038/372669a0	http://dx.doi.org/10.1038/372669a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PX307	7990957				2022-12-01	WOS:A1994PX30700084
J	FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L				FROLOVA, L; LEGOFF, X; RASMUSSEN, HH; CHEPEREGIN, S; DRUGEON, G; KRESS, M; ARMAN, I; HAENNI, AL; CELIS, JE; PHILIPPE, M; JUSTESEN, J; KISSELEV, L			A HIGHLY CONSERVED EUKARYOTIC PROTEIN FAMILY POSSESSING PROPERTIES OF POLYPEPTIDE-CHAIN RELEASE FACTOR	NATURE			English	Article							TRANSFER RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE; TRANSLATION FIDELITY; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; YEAST; TERMINATION; SUP45; HOMOLOGY; CLONING	THE termination of protein synthesis in ribosomes is governed by termination (stop) codons in messenger RNAs and by polypeptide chain release factors (RFs). Although the primary structure of prokaryotic RFs and yeast mitochrondrial RF is established(1-4), that of the only known eukaryotic RF (eRF)(5) remains obscure. Here we report the assignment of a family of tightly related proteins (designated eRF1) from lower and higher eukaryotes which are structurally and functionally similar to rabbit eRF. Two of these proteins, one from human(6) and the other from Xenopus laevis(7), have been expressed in yeast and Escherichia coli, respectively, purified and shown to be active in the in vitro RF assay. The other protein of this family, sup45 (sup1) of Saccharomyces cerevisiae, is involved in omnipotent suppression during translations(8-12). The amino-acid sequence of the eRF1 family is highly conserved. We conclude that the eRF1 proteins are directly implicated in the termination of translation in eukaryotes.	RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,MOSCOW 117984,RUSSIA; AARHUS UNIV,DEPT BIOL MOLEC,DK-800 AARHUS C,DENMARK; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE; UNIV RENNES 1,CNRS,URA 256,DEPT BIOL & GENET DEV,F-35042 RENNES,FRANCE; AARHUS UNIV,INST MED BIOCHEM,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DANISH CTR HUMAN GENOME RES,DK-8000 AARHUS C,DENMARK; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; CNRS,ERS0048,MOLEC ONCOL LAB,F-94802 VILLEJUIF,FRANCE	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Aarhus University; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; Aarhus University; Aarhus University; Russian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS)			Cheperegin, Sergey/R-6594-2018	LE GOFF, Xavier/0000-0002-5297-2421				BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BREINING P, 1986, NUCLEIC ACIDS RES, V14, P5187, DOI 10.1093/nar/14.13.5187; Caskey C T, 1974, Methods Enzymol, V30, P293; CRAIGEN WJ, 1990, MOL MICROBIOL, V4, P861, DOI 10.1111/j.1365-2958.1990.tb00658.x; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, EMBO J, V12, P4013; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P99, DOI 10.1073/pnas.67.1.99; GRENETT HE, 1992, GENE, V110, P239, DOI 10.1016/0378-1119(92)90655-9; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HIMMELFARB HJ, 1985, MOL CELL BIOL, V5, P816, DOI 10.1128/MCB.5.4.816; INGE-VECHTOMOV S G, 1970, Genetika, V6, P103; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; MUKINI O, 1994, P NATL ACAD SCI USA, V91, P5798; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; RASMUSSEN HH, 1991, ELECTROPHORESIS, V12, P873, DOI 10.1002/elps.1150121107; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; STANSFIELD I, 1992, MOL MICROBIOL, V6, P3469, DOI 10.1111/j.1365-2958.1992.tb01782.x; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TASSAN JP, 1993, MOL CELL BIOL, V13, P2815, DOI 10.1128/MCB.13.5.2815; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; TUITE MF, 1993, BIOCHEM SOC T, V21, P857, DOI 10.1042/bst0210857	25	350	371	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					701	703		10.1038/372701a0	http://dx.doi.org/10.1038/372701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990965				2022-12-01	WOS:A1994PX30700093
J	ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW				ERICKSON, SL; DESAUVAGE, FJ; KIKLY, K; CARVERMOORE, K; PITTSMEEK, S; GILLETT, N; SHEEHAN, KCF; SCHREIBER, RD; GOEDDEL, DV; MOORE, MW			DECREASED SENSITIVITY TO TUMOR-NECROSIS-FACTOR BUT NORMAL T-CELL DEVELOPMENT IN TNF RECEPTOR-2-DEFICIENT MICE	NATURE			English	Article							FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; ENDOTOXIC-SHOCK; MONOCYTOGENES; RESISTANT; INFECTION; BINDING; DOMAIN; LINES	TUMOUR necrosis factor (TNF) elicits multiple biological effects through two distinct cell surface receptors, TNF-R1 (p55) and TNF-R2 (p75). Most TNF-mediated biological responses, such as cell death, gene induction, antiviral activity and cytokine production, have been attributed to TNF-R1 (refs 1-5). Gene targeting of this receptor confirms its role in the lethality attributable to low doses of lipopolysaccharide after sensitization with D-galactosamine(6,7); surprisingly, the toxicity of high doses of lipopolysaccharide was unaffected. The function of TNF-R2 is less well understood, although there are data supporting a role in T-cell development and the proliferation of cytotoxic T lymphocytes(8,9). To clarify the physiological role of TNF-R2, we have generated mice deficient in this receptor by gene targeting. The TNF-R2(-/-) mice show normal T-cell development and activity, but we find that they have increased resistance to TNF-induced death. Additionally, such mice injected subcutaneously with TNF show a dramatic decrease in tissue necrosis, indicating that this receptor plays a role in the necrotic effects of TNF.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES & PHARMACOL,S SAN FRANCISCO,CA 94080; WASHINGTON UNIV,SCH MED,CTR IMMUNOL,DEPT PATHOL,ST LOUIS,MO 63110	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Washington University (WUSTL)			Schreiber, Robert D/A-1276-2013; de Sauvage, Frederic/ABE-8400-2020; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; de Sauvage, Frederic/0000-0002-5275-2584; Schreiber, Robert/0000-0003-1590-2341				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542	22	540	557	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					560	563		10.1038/372560a0	http://dx.doi.org/10.1038/372560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990930				2022-12-01	WOS:A1994PW08200055
J	BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL				BOTTASSO, OA; INGLEDEW, N; KENI, M; MORINI, J; PIVIDORI, JF; ROOK, GAW; STANFORD, JL			CELLULAR IMMUNE-RESPONSE TO COMMON MYCOBACTERIAL ANTIGENS IN SUBJECTS SEROPOSITIVE FOR TRYPANOSOMA-CRUZI	LANCET			English	Note							CHAGAS-DISEASE; TUBERCULOSIS; SUPPRESSION; LEPROSY	The immune response is impaired in the silent stage of Chagas' disease. We used quadruple skin-testing with new tuberculins in 37 adults who were symptom-free but seropositive for Trypanosoma cruzi and in 37 matched seronegative controls. Whereas 19% of controls responded to common mycobacterial antigens, none of the Chagas' seropositive group responded to them (p<0.006), demonstrating specificity in their unresponsiveness. The enhanced tuberculin reactivity after BCG vaccination in the control group was suppressed in seropositive subjects (p<0.002). Selective loss of response to common mycobacterial antigens may have implications for the autoimmune pathology of Chagas' disease, and for susceptibility to tuberculosis, leprosy, and HIV disease.	UCL, SCH MED, DEPT MED MICROBIOL, LONDON W1P 7LD, ENGLAND; UNIV NACL ROSARIO, FAC CIENCIAS MED, DIV INMUNOL, RA-2000 ROSARIO, SANTA FE, ARGENTINA; PROGRAMA PROV LUCHA CONTRA ENFERMADAD CHAGAS, RECONQUISTA, SANTA FE, ARGENTINA	University of London; University College London; UCL Medical School; National University of Rosario				Rook, Graham/0000-0002-8041-8110				BOTTASSO OA, 1982, MEDICINA-BUENOS AIRE, V42, P136; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; KHOO SH, 1993, 9 INT C AIDS BERL; LOCKWOOD DNJ, 1987, EUR J RESPIR DIS, V71, P348; MOSCA W, 1991, MEM I OSWALDO CRUZ, V86, P147, DOI 10.1590/S0074-02761991000200002; SHIELD MJ, 1977, J HYG-CAMBRIDGE, V78, P331, DOI 10.1017/S0022172400056230; STANFORD JL, 1974, TUBERCLE, V55, P143, DOI 10.1016/0041-3879(74)90008-7; VOLTARELLI JC, 1987, T ROY SOC TROP MED H, V81, P169, DOI 10.1016/0035-9203(87)90324-5; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267	10	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1540	1541		10.1016/S0140-6736(94)90351-4	http://dx.doi.org/10.1016/S0140-6736(94)90351-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983955				2022-12-01	WOS:A1994PV01700011
J	VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA				VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA			EFFECTS OF PRACTICE STYLE IN MANAGING BACK PAIN	ANNALS OF INTERNAL MEDICINE			English	Article						PHYSICIANS PRACTICE PATTERNS; BACK PAIN; SELF CARE; COST-BENEFIT ANALYSIS; BED REST	PHYSICIAN EDUCATION INTERVENTION; IMPROVE PRIMARY CARE; DISABILITY; IMPACT	Objective: To assess the effects of a practice style of back pain management consistent with self-care (infrequent prescribing of pain medications and bed rest) on long-term functional outcomes, costs of care, and patient satisfaction. Design: A quasi-experimental observational study in which primary care physicians (n = 44) were categorized according to one of three practice style groups defined by a low, moderate, or high frequency of prescribing pain medications and bed rest for many patients (average, 24 patients per physician). Setting: Primary care practices of a large, staff model health maintenance organization, Group Health Cooperative of Puget Sound. Patients: Consecutive patients with back or neck pain of participating primary care physicians. Patients were interviewed 1 month (n = 1071) and 1 year and 2 years (n = 911) after their index visits. Results: Patients in the three practice style groups rated similarly the quality of medical care received for back pain. Patients treated by physicians who infrequently prescribed pain medications and bed rest were more satisfied with education about back pain. On a scale of 0 to 10, the mean rating of agreement with the statement, ''After your visit with the doctor, you fully understood how to take care of your back problem,'' was 5.6 +/- 3.6 among patients of physicians who frequently prescribed medication and rest and was 6.6 +/- 3.5) among those who infrequently prescribed medication and bed rest. At 1 month, 30% of patients of physicians who infrequently prescribed medications and bed rest were graded as having moderate to severe activity limitation because of back pain, whereas 37% of patients in the moderate group had this grading, and 46% of patients of physicians who frequently prescribed were graded as having moderate to severe activity limitation. Differences in activity limitation by practice style group were no longer evident at 1 or 2 years of follow-up. The total 1-year costs of back care were higher among patients seen by physicians who frequently prescribed bed rest and pain medications (cost, $768 +/- $1592) than among those seen by physicians who infrequently prescribed (cost, $428 +/- $665), due largely to differences in inpatient and specialty care costs. The adjusted difference in costs, after controlling for case-mix variables, was $277 (95% Cl, $85.50 to $471.32). Conclusions: A practice style consistent with back pain self-care yielded similar long-term pain and functional outcomes at lower cost and was associated with higher satisfaction with patient education compared with a practice style characterized by more frequent prescribing of pain medications and bed rest.			VONKORFF, M (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, 1730 MINOR AVE, SUITE 1600, SEATTLE, WA 98101 USA.			VonKorff, Michael/0000-0001-5386-8477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006168, P01HS006344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS06168, P01 HS06344] Funding Source: Medline; NIDCR NIH HHS [P01 DE08773] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHERKIN D, 1991, SPINE, V16, P1168, DOI 10.1097/00007632-199110000-00007; CHERKIN D, 1991, SPINE, V16, P1173, DOI 10.1097/00007632-199110000-00008; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; FORDYCE WE, 1976, BEHAVIORAL METHODS C; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P; Osterweis M., 1987, PAIN DISABILITY CLIN; PHILIPS HC, 1991, BEHAV RES THER, V29, P435, DOI 10.1016/0005-7967(91)90127-O; PHILIPS HC, 1991, BEHAV RES THER, V29, P443, DOI 10.1016/0005-7967(91)90128-P; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; VONKORFF M, IN PRESS 7TH P WORLD, V2; Waddell G, 1991, Neurosurg Clin N Am, V2, P719; WHITNEY CW, 1992, PAIN, V50, P281, DOI 10.1016/0304-3959(92)90032-7; 1989, SAS USERS GUIDE STAT; 1987, SPINE S1, V12, pS1	23	98	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					187	195		10.7326/0003-4819-121-3-199408010-00005	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017745				2022-12-01	WOS:A1994NY33800005
J	LIU, DJ; DAY, LA				LIU, DJ; DAY, LA			PF1 VIRUS STRUCTURE - HELICAL COAT PROTEIN AND DNA WITH PARAXIAL PHOSPHATES	SCIENCE			English	Article							LASER RAMAN-SPECTROSCOPY; FILAMENTOUS BACTERIOPHAGE-PFL; BACTERIAL VIRUS-PF1; NEUTRON-DIFFRACTION; LINEAR DICHROISM; ELECTRON-DENSITY; XF; FD; RESOLUTION; IKE	The helical path of the DNA in filamentous bacteriophage Pf1 was deduced from different kinds of existing structural information, including results from x-ray fiber diffraction. The DNA has the same pitch, 16 angstroms, as the surrounding helix of protein subunits; the rise and rotation per nucleotide are 6.1 angstroms and 132 degrees, respectively; and the phosphates are 2.5 angstroms from the axis. The DNA in Pf1 is, therefore, the most extended and twisted DNA structure known. On the basis of the DNA structure and extensive additional information about the protein, a model of the virion is proposed. In the model, the DNA bases reach out, into the protein, and the lysine and arginine side chains reach in, between the DNA bases, to stabilize the paraxial phosphate charges; the conformation of the protein subunit is combination of alpha and 3(10) helices.			LIU, DJ (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRYAN RK, 1983, P NATL ACAD SCI-BIOL, V80, P4728, DOI 10.1073/pnas.80.15.4728; CASADEVALL A, 1983, BIOCHEMISTRY-US, V22, P4831, DOI 10.1021/bi00289a033; CASADEVALL A, 1988, BIOCHEMISTRY-US, V27, P3599, DOI 10.1021/bi00410a010; CLACK BA, 1992, BIOPOLYMERS, V32, P795, DOI 10.1002/bip.360320708; CROSS TA, 1983, BIOCHEMISTRY-US, V22, P721, DOI 10.1021/bi00273a002; DAY LA, 1979, NUCLEIC ACIDS RES, V7, P1393, DOI 10.1093/nar/7.6.1393; DAY LA, 1988, ANNU REV BIOPHYS BIO, V17, P509; FRITZSCHE H, 1986, STUD BIOPHYS, V116, P175; GREULICH KO, 1984, BIOCHIM BIOPHYS ACTA, V782, P446, DOI 10.1016/0167-4781(84)90053-8; HILL DF, 1991, J MOL BIOL, V218, P349, DOI 10.1016/0022-2836(91)90717-K; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P199, DOI 10.1107/S0365110X58000517; KOSTRIKIS LG, 1994, BIOCHEMISTRY-US, V33, P1694, DOI 10.1021/bi00173a011; MAKOWSKI L, 1981, J MOL BIOL, V145, P611; MARVIN DA, 1992, PHASE TRANSIT, V39, P45, DOI 10.1080/01411599208203472; MARVIN DA, 1987, J MOL BIOL, V193, P315, DOI 10.1016/0022-2836(87)90222-1; MARZEC CJ, 1988, BIOPHYS J, V53, P425, DOI 10.1016/S0006-3495(88)83119-9; MARZEC CJ, 1993, J BIOMOL STRUCT DYN, V10, P1091, DOI 10.1080/07391102.1993.10508697; MARZEC CJ, UNPUB; NAKASHIMA Y, 1980, J MOL BIOL, V138, P493, DOI 10.1016/S0022-2836(80)80014-3; NAMBUDRIPAD R, 1991, J MOL BIOL, V220, P359, DOI 10.1016/0022-2836(91)90019-3; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; NAVE C, 1981, J MOL BIOL, V149, P675, DOI 10.1016/0022-2836(81)90353-3; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; REISBERG SA, 1989, THESIS NEW YORK U; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; STARK W, 1988, J MOL BIOL, V199, P171, DOI 10.1016/0022-2836(88)90387-7; TAKEYA K, 1966, VIROLOGY, V28, P163, DOI 10.1016/0042-6822(66)90317-5; THOMAS GJ, 1983, J MOL BIOL, V165, P321, DOI 10.1016/S0022-2836(83)80260-5; THOMAS GJ, 1988, BIOCHEMISTRY-US, V27, P4350, DOI 10.1021/bi00412a023; THOMAS GJ, 1985, SPECTROCHIM ACTA A, V41, P217, DOI 10.1016/0584-8539(85)80100-8; TORBET J, 1981, BIOPOLYMERS, V20, P2657, DOI 10.1002/bip.1981.360201212; WISEMAN RL, 1977, J MOL BIOL, V116, P607, DOI 10.1016/0022-2836(77)90088-2	34	84	86	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					671	674		10.1126/science.8036516	http://dx.doi.org/10.1126/science.8036516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036516				2022-12-01	WOS:A1994NZ53800036
J	RING, BZ; ROBERTS, JW				RING, BZ; ROBERTS, JW			FUNCTION OF A NONTRANSCRIBED DNA STRAND SITE IN TRANSCRIPTION ELONGATION	CELL			English	Article							COLI RNA-POLYMERASE; PHAGE-LAMBDA; PAUSE SITE; Q-PROTEIN; TERMINATION; RHO; REGION; ANTITERMINATION; SEQUENCE; PROMOTER	A prolonged pause in transcription elongation at positions +16 and +17 of the phage lambda late gene operon has an important role in the modification of RNA polymerase by the lambda gene Q transcription antiterminator. Mutations included in the transcription bubble of the paused transcription complex, particularly at +2 and +6, abolish pausing and the ability of Q protein to modify RNA polymerase. By transcribing heteroduplex templates made in vitro, we show that the sites identified by these mutations act through the nontranscribed strand of DNA. This result suggests unexpected regulatory functions of the nontranscribed DNA strand in transcription.			RING, BZ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; Dahlberg JE, 1973, VIRUS RES, P533; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GILBERT W, 1974, COLD SPRING HARB SYM, V38, P845; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, THESIS CORNELL U ITH; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; Sambrook J., 1989, MOL CLONING LAB MANU; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T	25	57	57	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					317	324		10.1016/0092-8674(94)90300-X	http://dx.doi.org/10.1016/0092-8674(94)90300-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044843				2022-12-01	WOS:A1994NZ24200014
J	LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF				LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF			CYCLIC ADP RIBOSE ACTIVATION OF THE RYANODINE RECEPTOR IS MEDIATED BY CALMODULIN	NATURE			English	Article							SEA-URCHIN EGG; CALCIUM RELEASE; CA2+ RELEASE; MICROSOMES; MODULATION; CHANNEL; BINDING	CYCLIC ADP-ribose (cADPR) is a newly identified nucleotide(1,2) which can release calcium from a variety of cells(3-6), suggesting it is a messenger for mobilizing internal Ca2+ stores. Its cyclic structure has now been confirmed by X-ray crystallography(7). Available results are consistent with it being a modulator of Ca2+-induced Ca2+ releases(8-10). Here we report that sea urchin egg microsomes purified by Percoll gradients lose sensitivity to cADPR, but the response can be restored by a soluble protein in the supernatant. Purification and characterization of the protein indicate that it is calmodulin. It appears to be sensitizing the Ca2+ release mechanism because caffeine and strontium, agonists of Ca2+-induced Ca2+ release, can also mimic calmodulin in conferring cADPR-sensitivity. Although evidence indicates that cADPR may be an activator of the ryanodine receptor(8-10), present results point to the importance of accessory proteins such as calmodulin in modulating its activity.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011	Walseth, Timothy F/0000-0003-2558-7859; 				CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PAYNE ME, 1989, J BIOL CHEM, V262, P8051; SHEN SS, 1989, BIOCHEM BIOPH RES CO, V161, P1100, DOI 10.1016/0006-291X(89)91356-9; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; TAKASAWA S, SCIENCE, V370, P93; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WHITE A, 1993, FEBS LETT, V318, P21	19	209	213	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					307	309		10.1038/370307a0	http://dx.doi.org/10.1038/370307a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035880				2022-12-01	WOS:A1994NZ22900068
J	AMON, A; IRNIGER, S; NASMYTH, K				AMON, A; IRNIGER, S; NASMYTH, K			CLOSING THE CELL-CYCLE CIRCLE IN YEAST - G2 CYCLIN PROTEOLYSIS INITIATED AT MITOSIS PERSISTS UNTIL THE ACTIVATION OF G1 CYCLINS IN THE NEXT CYCLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; POSITIVE FEEDBACK; S-PHASE; PROTEIN; KINASE; CDC28; CLN1; PHOSPHORYLATION; DEGRADATION	It is thought that DNA replication and mitosis in yeast are triggered by oscillations in the level of G1-specific (CLN1 and CLN2) and G2-specific (CLB1-CLB4) cyclins, which determine the substrate specificity of the CDC28 protein kinase. It is not understood how the time and order of appearance of different cyclin types are determined. We show here that CLB2 proteolysis, which is important for transition from mitosis to G1, is not confined to a narrow window at the end of mitosis as previously thought but continues until reactivation of CDC28 by CLN cyclins toward the end of the subsequent G1 period. Thus, cell cycle-regulated proteolysis prevents accumulation of G2-specific CLB cyclins during G1 and thereby ensures that the CLN-associated forms of the CDC28 kinase are activated without interference from CLB cylins. Accumulation of CLN cyclins leads to inactivation of CLB cyclin proteolysis, which is a precondition for subsequent activation of G2-specific B-type cyclins.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; CHEREST H, 1985, GENE, V34, P269; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Maniatis T., 1982, MOL CLONING; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORTIMER RK, 1969, YEASTS, V1, P385; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1991, COLD SPRING HARB SYM, V56, P9; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSE MD, 1990, LABORATORY COURSE MA; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIMCHEN G, 1972, EXP CELL RES, V75, P207, DOI 10.1016/0014-4827(72)90538-1; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x	31	409	412	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1037	1050		10.1016/0092-8674(94)90443-X	http://dx.doi.org/10.1016/0092-8674(94)90443-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020094				2022-12-01	WOS:A1994NV42500012
J	BOUVET, P; WOLFFE, AP				BOUVET, P; WOLFFE, AP			A ROLE FOR TRANSCRIPTION AND FRGY2 IN MASKING MATERNAL MESSENGER-RNA WITHIN XENOPUS-OOCYTES	CELL			English	Article							RNA-BINDING-PROTEINS; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; HISTONE GENE CLUSTERS; POLYMERASE-III; LAEVIS OOCYTES; TRANSLATION; NUCLEAR; EMBRYOS; DNA; IDENTIFICATION	We find that mRNA synthesized within the Xenopus oocyte nucleus is translated with an efficiency 50 times less than that of mRNA injected into the oocyte cytoplasm. For histone H1 mRNA this effect is independent of mRNA splicing, nuclear export, and the promoter driving transcription. The mRNA synthesized in vivo is translationally competent but is masked from the translational machinery in the cytoplasm through association with proteins including frog Y-box protein 2 (FRGY2). We find that overexpression of FRGY2 facilitates the translational repression of mRNA synthesized within Xenopus oocytes. The requirement for transcription to occur in vivo before a translationally repressed state can be established suggests that these two events are functionally coupled in Xenopus oocytes.			BOUVET, P (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.		, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALDWELL DC, 1985, CELL, V42, P691, DOI 10.1016/0092-8674(85)90126-6; CHO H, 1994, IN PRESS GENE; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELAPENA P, 1987, CELL, V50, P613, DOI 10.1016/0092-8674(87)90034-1; DESCHAMPS S, 1991, FEBS LETT, V282, P110, DOI 10.1016/0014-5793(91)80456-D; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HARLAND R, 1988, DEVELOPMENT, V102, P837; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; OLD RW, 1982, NUCLEIC ACIDS RES, V10, P7561, DOI 10.1093/nar/10.23.7561; OSBORNE HB, 1991, EUR J BIOCHEM, V202, P575, DOI 10.1111/j.1432-1033.1991.tb16410.x; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1988, TRENDS BIOCHEM SCI, V13, P483, DOI 10.1016/0968-0004(88)90236-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUDERMAN JV, 1979, DEV BIOL, V71, P71, DOI 10.1016/0012-1606(79)90083-6; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1969, EUR J BIOCHEM, V10, P20; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167	70	175	183	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					931	941		10.1016/0092-8674(94)90141-4	http://dx.doi.org/10.1016/0092-8674(94)90141-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004679				2022-12-01	WOS:A1994NT33100017
J	GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT				GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT			LOCAL EFFECT OF SEROTONIN RELEASED DURING CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLIC FLOW VARIATIONS; VASOCONSTRICTOR ACTIVITY; ARTERIES; INVIVO; MEDIATORS; VASOSPASM; INJURY; DOGS; THROMBOXANE-A2; NITROGLYCERIN	Background. Serotonin is released after the aggregation of platelets, a phenomenon that may occur after coronary angioplasty. We sought to determine whether serotonin is released into the coronary circulation during coronary angioplasty and to assess whether serotonin can affect coronary-artery tone during angioplasty. Methods. Blood samples were drawn from the ascending aorta and the coronary sinus of eight patients scheduled to undergo angioplasty of the left anterior descending or circumflex coronary artery. Samples were obtained before angioplasty and after each balloon dilation. The dimensions of arterial segments distal to the site of dilation were measured angiographically before angioplasty and 5 and 15 minutes after the last dilation in these eight patients and in seven similar patients; the latter group was treated with ketanserin, a serotonin(2)-receptor antagonist, before angioplasty. Results. Before the eight patients underwent angioplasty, their mean (+/-SE) plasma serotonin level in the aorta was 2.5+/-0.7 ng per milliliter and that in the coronary sinus was 2.3+/-0.6 ng per milliliter (P = 0.34). The seretonin level in plasma from the coronary sinus rose significantly, to 31.5+/-13.5, 17.6+/-5.3, and 29.1+/-8.1 ng per milliliter after the first, second, and third dilations, respectively (P = 0.014 for the comparison with preoperative levels). In contrast, the serotonin level in plasma from the ascending aorta did not change. The cross-sectional area of the coronary artery was significantly reduced 5 and 15 minutes after the last dilation (from a preoperative value of 3.7+/-0.5 mm(2) to 2.7+/-0.4 mm(2) 15 minutes after the last dilation; P = 0.011). This vasoconstriction was significantly blunted in the seven patients who received ketanserin (from 3.7+/-0.5 mm(2) before angioplasty to 3.9+/-0.4 mm(2) after 15 minutes) (P = 0.017 for comparison with the eight patients who did not receive ketanserin). Conclusions. Serotonin is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction distal to the dilated site. The vasoconstriction is attenuated by ketanserin, a serotonin(2)-receptor antagonist.	UNIV NAPLES,SCH MED 2,DEPT INTERNAL MED,NAPLES,ITALY; UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR,DIV CARDIOL,HOUSTON,TX	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	GOLINO, P (corresponding author), UNIV NAPLES,SCH MED 2,DIV CARDIOL,VIA SERGIO PANSINI 5,I-80131 NAPLES,ITALY.			INDOLFI, Ciro/0000-0003-1241-6487; GOLINO, Paolo/0000-0002-3590-6983	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-1669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS GA, 1984, THROMB HAEMOSTASIS, V52, P45; ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; COHEN RA, 1987, CIRC RES, V61, P829, DOI 10.1161/01.RES.61.6.829; CRAGG A, 1983, AM J CARDIOL, V51, P1441, DOI 10.1016/0002-9149(83)90326-0; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; FISCHELL TA, 1988, CIRCULATION, V78, P1323, DOI 10.1161/01.CIR.78.6.1323; FISCHELL TA, 1990, J CLIN INVEST, V86, P575, DOI 10.1172/JCI114747; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HOLLMAN J, 1983, J AM COLL CARDIOL, V2, P1039, DOI 10.1016/S0735-1097(83)80327-1; HOLLMAN J, 1983, CIRCULATION, V68, P725, DOI 10.1161/01.CIR.68.4.725; HUSSAIN MN, 1987, BIOCHEM MED METAB B, V37, P314, DOI 10.1016/0885-4505(87)90042-9; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAM JYT, 1988, CIRCULATION, V78, P712, DOI 10.1161/01.CIR.78.3.712; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; MABIN TA, 1985, J AM COLL CARDIOL, V5, P198, DOI 10.1016/S0735-1097(85)80037-1; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SHIMOKAWA H, 1987, CIRC RES, V61, P256, DOI 10.1161/01.RES.61.2.256; SIGAL SL, 1991, ARTERIOSCLER THROMB, V11, P770, DOI 10.1161/01.ATV.11.3.770; SIMPFENDORFER C, 1987, AM J CARDIOL, V59, P267, DOI 10.1016/0002-9149(87)90797-1; SNEDECOR GW, 1980, STATISTICAL METHODS, P291; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; Tousoulis Dimitris, 1993, Journal of the American College of Cardiology, V21, p341A; TSCHOPP TB, 1977, THROMB RES, V11, P619, DOI 10.1016/0049-3848(77)90020-2; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; WALLER BF, 1984, AM J CARDIOL, V53, pC42, DOI 10.1016/0002-9149(84)90744-6; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198	32	138	149	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					523	528		10.1056/NEJM199402243300802	http://dx.doi.org/10.1056/NEJM199402243300802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8043066				2022-12-01	WOS:A1994MX43600002
J	CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; DOU, ZH; RAKEMAN, MA; ZHANG, ML; ODONNELL, K; MA, T; AMETTE, K; DELONG, N; DELONG, GR			TIMING OF VULNERABILITY OF THE BRAIN TO IODINE DEFICIENCY IN ENDEMIC CRETINISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IODIZED OIL; PREGNANCY; SUPPLEMENTATION; DISORDER	Background. Endemic cretinism, caused by severe iodine deficiency during pregnancy, is the world's most common preventable cause of mental retardation. It can be prevented by iodine treatment before conception, but whether it can be prevented or ameliorated by treatment during pregnancy or after delivery is not known. Methods. In a severely iodine-deficient area of the Xinjiang region of China, we systematically administered iodine to groups of children from birth to three years of age (n = 689) and women at each trimester of pregnancy (n = 295); we then followed the treated children and the babies born to the treated women for two years. We used three independent measures of neural development: the results of the neurologic examination, the head circumference (which correlates with brain weight in the first postnatal year), and indexes of cognitive and motor development. Untreated children one to three years of age, who were studied when first seen, served as control subjects. Results. The prevalence of moderate or severe neurologic abnormalities among the 120 infants whose mothers received iodine in the first or second trimester was 2 percent, as compared with 9 percent among the 752 infants who received iodine during the third trimester (through the treatment of their mothers) or after birth (P = 0.008). The prevalence of microcephaly (defined as a head circumference more than 3 SD below U.S. norms) decreased from 27 percent in the untreated children to 11 percent in the treated children (P = 0.006), and the mean (+/-SD) developmental quotient at two years of age increased (90 +/- 14, vs. 75 +/- 18 in the untreated children; P < 0.001). Treatment in the third trimester of pregnancy or after delivery did not improve neurologic status, but head growth and developmental quotients improved slightly. Treatment during the first trimester, which was technically problematic, improved the neurologic outcome. Conclusions. Up to the end of the second trimester, iodine treatment protects the fetal brain from the effects of iodine deficiency. Treatment later in pregnancy or after delivery may improve brain growth and developmental achievement slightly, but it does not improve neurologic status.	DUKE UNIV,MED CTR,DIV PEDIAT NEUROL,DURHAM,NC 27710; TIANJIN MED COLL,TIANJIN,PEOPLES R CHINA; XINJIANG ANTIEPIDEM & HLTH STN,URUMQI,PEOPLES R CHINA; INST ENDEM DIS RES,URUMQI,PEOPLES R CHINA	Duke University; Tianjin Medical University								Bayley N., 1969, BAYLEY SCALES INFANT; Bleichrodt N., 1989, IODINE BRAIN, P269; BOYAGES SC, 1989, MED J AUSTRALIA, V150, P676, DOI 10.5694/j.1326-5377.1989.tb136760.x; CAO XY, 1994, LANCET, V344, P107, DOI 10.1016/S0140-6736(94)91286-6; CHOUFOER JC, 1965, J CLIN ENDOCR METAB, V25, P385, DOI 10.1210/jcem-25-3-385; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; DOBBING J, 1974, SCI F PAEDIATRICS, P565; DUNN JT, 1993, ANN NY ACAD SCI, V678, P158; EAYRS JT, 1960, BRIT MED BULL, V16, P122, DOI 10.1093/oxfordjournals.bmb.a069810; GILLES FH, 1983, DEV HUMAN BRAIN GROW, P58; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HETZEL BS, 1989, J NUTR, V119, P145, DOI 10.1093/jn/119.2.145; KOCHUPILLAI N, 1986, IODINE NUTR THYROXIN, P87; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LIU JL, 1989, IODINE BRAIN, P249; MA T, 1993, ANN NEUROL, V34, P91, DOI 10.1002/ana.410340116; Ma T., 1989, IODINE BRAIN, P259, DOI 10.1007/978-1-4613-0765-5_24; MANO MT, 1989, ACTA ENDOCRINOL-COP, V121, P7, DOI 10.1530/acta.0.1210007; McCarrison R, 1908, LANCET, V2, P1275; Pharoah P O, 1972, Adv Exp Med Biol, V30, P201; PHAROAH POD, 1991, ARCH DIS CHILD, V66, P145, DOI 10.1136/adc.66.1.145; PHAROAH POD, 1971, LANCET, V1, P308; TONGLET R, 1992, NEW ENGL J MED, V326, P236, DOI 10.1056/NEJM199201233260405; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; 1981, LANCET, V2, P1095; [No title captured]	29	274	293	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1739	1744		10.1056/NEJM199412293312603	http://dx.doi.org/10.1056/NEJM199412293312603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ266	7984194				2022-12-01	WOS:A1994PZ26600003
J	PANKRATZ, L; JACKSON, J				PANKRATZ, L; JACKSON, J			HABITUALLY WANDERING PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; SERVICES; CARE	Background. Physicians are sometimes confronted with patients who gain admission to one hospital after another, sometimes referred to as ''wandering patients.'' Little is known about the presenting symptoms of these patients, their use of hospital resources, or the costs of their medical care, We analyzed the demographic and clinical characteristics of wandering patients served by Department of Veterans Affairs medical centers (VAMCs), Methods. For each patient they admit, all 159 hospitals in the Veterans Affairs medical system submit demographic and diagnostic information to a central data base at the Data Processing Center in Austin, Texas, We searched these records to identify patients who were admitted to four or more VAMCs within each year from fiscal year 1988 through 1992. Patients so identified in any one year were called ''wanderers''; those identified in all five years were designated ''habitual wanderers, Results. We identified 1013 wanderers in 1988. The number gradually declined each year to 729 in 1992, In 1991 there were 810 wandering patients, who averaged about eight admissions per year and more than 100 days of inpatient care; they accounted for about $26.5 million in costs for inpatient and outpatient care in that year. Only 35 patients wandered in all five years from 1988 through 1992. The most common discharge diagnoses of these 35 men were related to substance abuse (mostly alcoholism) and mental disorders. Their 2268 admissions and 7832 outpatient visits cost an estimated $6.5 million over the five-year period. Conclusions. Patients who are repeatedly admitted to different hospitals - wandering patients - accumulate high numbers of admissions, cause diagnostic confusion, and receive uncoordinated care. Because of the complexity of their disorders, such patients require case management on a regional or national basis.	OREGON HLTH SCI UNIV,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PSYCHOL MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	PANKRATZ, L (corresponding author), VET AFFAIRS MED CTR,PSYCHOL SERV 116B,POB 1034,PORTLAND,OR 97207, USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; BUCKLEY R, 1992, COMMUNITY MENT HLT J, V28, P43, DOI 10.1007/BF00756701; CATON CLM, 1981, HOSP COMMUNITY PSYCH, V32, P475; DRAKE RE, 1992, COMMUNITY MENT HLT J, V28, P5, DOI 10.1007/BF00756697; Durance P W, 1992, J Ment Health Adm, V19, P178, DOI 10.1007/BF02521318; FINK P, 1993, GEN HOSP PSYCHIAT, V15, P211, DOI 10.1016/0163-8343(93)90035-M; GELLER JL, 1992, AM J PSYCHIAT, V149, P1526; GELLER JL, 1992, HOSP COMMUNITY PSYCH, V43, P904; Gordon R E, 1975, J Fla Med Assoc, V62, P21; Gordon R E, 1973, JFMA, V60, P27; Hadley T R, 1990, Psychiatr Q, V61, P41, DOI 10.1007/BF01065163; McLean E K, 1990, Int J Soc Psychiatry, V36, P172, DOI 10.1177/002076409003600302; MECHANIC D, 1987, NEW ENGL J MED, V317, P1634, DOI 10.1056/NEJM198712243172605; PANKRATZ L, 1989, DRUG ALCOHOL DEPEN, V24, P115, DOI 10.1016/0376-8716(89)90073-2; PANKRATZ L, 1978, J OPER PSYCHIATR, V9, P42; PANKRATZ L, 1989, PERSPECT HEALTHCARE, V9, P5; PEPPER B, 1981, HOSP COMMUNITY PSYCH, V32, P463; ROSENHECK R, 1993, SCHIZOPHRENIA BULL, V19, P843, DOI 10.1093/schbul/19.4.843; SCHWARTZ SR, 1981, HOSP COMMUNITY PSYCH, V32, P470; SPARR L, 1983, AM J PSYCHIAT, V140, P1016; SURLES RC, 1987, HOSP COMMUNITY PSYCH, V38, P401; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725	22	25	26	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	1994	331	26					1752	1755		10.1056/NEJM199412293312606	http://dx.doi.org/10.1056/NEJM199412293312606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ266	7984197				2022-12-01	WOS:A1994PZ26600006
J	HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA				HUBBARD, SR; WEI, L; ELIS, L; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; AUTOPHOSPHORYLATION; PHOSPHOTRANSFERASE; PHOSPHORYLATION; IDENTIFICATION; INHIBITOR; FEATURES; FAMILY; CELLS	The X-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been determined by multiwavelength anomalous diffraction phasing and refined to 2.1 Angstrom resolution. The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1,162, is bound in the active site.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,WM KECK CTR GENOME INFORMAT,HOUSTON,TX 77030	Columbia University; Howard Hughes Medical Institute; Texas A&M University System	HUBBARD, SR (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							ACCILI D, 1992, J ENDOCRINOL INVEST, V15, P857, DOI 10.1007/BF03348820; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VERNON M, 1993, P NATL ACAD SCI USA, V90, P10618; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	47	929	972	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					746	754		10.1038/372746a0	http://dx.doi.org/10.1038/372746a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997262				2022-12-01	WOS:A1994PY21200043
J	BALICEGORDON, RJ; LICHTMAN, JW				BALICEGORDON, RJ; LICHTMAN, JW			LONG-TERM SYNAPSE LESS INDUCED BY FOCAL BLOCKADE OF POSTSYNAPTIC RECEPTORS	NATURE			English	Article							DEVELOPING NEUROMUSCULAR-JUNCTIONS; ACETYLCHOLINE-RECEPTOR; INVIVO VISUALIZATION; NERVE-TERMINALS; SKELETAL-MUSCLE; RAT MUSCLE; ELIMINATION; MOUSE; INNERVATION; PROTEIN	Focal application in vivo of alpha-bungarotoxin to block neurotransmission in a small region of a neuromuscular junction causes long-lasting synapse elimination at that site. In contrast, blockade of neurotransmission throughout a junction does not cause synapse elimination. These and related experiments indicate that active synaptic sites can destabilize inactive synapses in their vicinity.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Balice-Gordon, Rita/0000-0002-9950-7965				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1990, J NEUROSCI, V10, P2660; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BENOIT P, 1978, BRAIN RES, V149, P89, DOI 10.1016/0006-8993(78)90589-9; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; Burke RE, 1994, MYOLOGY, P464; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CHEN LL, 1991, J NEUROSCI, V11, P2920; COLMAN H, 1993, DEV BIOL, V156, P1, DOI 10.1006/dbio.1993.1054; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; Culican S. M., 1993, Society for Neuroscience Abstracts, V19, P1294; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRASER SE, 1982, CURR TOP DEV BIOL, V17, P77; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; HERRERA AA, 1990, J NEUROCYTOL, V19, P85, DOI 10.1007/BF01188441; HILL RR, 1991, J NEUROCYTOL, V20, P165, DOI 10.1007/BF01186990; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; LANGENFELDOSTER B, 1993, J NEUROCYTOL, V22, P517, DOI 10.1007/BF01189040; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LICHTMAN JW, 1985, NATURE, V314, P357, DOI 10.1038/314357a0; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LUTHER PW, 1985, J CELL BIOL, V100, P235, DOI 10.1083/jcb.100.1.235; MA J, 1993, J BIOL CHEM, V288, P25108; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; OBRIEN RAD, 1984, NEUROSCIENCE, V12, P637, DOI 10.1016/0306-4522(84)90079-4; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; POO MM, 1985, ANNU REV NEUROSCI, V8, P369; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RIBCHESTER RR, 1988, J PHYSL, V40, P53; RICH M, 1989, NEURON, V3, P677, DOI 10.1016/0896-6273(89)90236-5; RICH MM, 1994, NEUROLOGY, V44, P2138, DOI 10.1212/WNL.44.11.2138; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCOTT LJC, 1990, J NEUROSCI, V10, P346; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; VANMIER P, 1994, J NEUROSCI, V14, P5672; WERNIG A, 1980, J NEUROCYTOL, V9, P277, DOI 10.1007/BF01181538; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WIGSTON DJ, 1990, J NEUROSCI, V10, P1753; WIGSTON DJ, 1989, J NEUROSCI, V9, P639	49	223	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					519	524		10.1038/372519a0	http://dx.doi.org/10.1038/372519a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990923				2022-12-01	WOS:A1994PW08200043
J	YUN, MS; HO, PTP; LO, KY				YUN, MS; HO, PTP; LO, KY			A HIGH-RESOLUTION IMAGE OF ATOMIC-HYDROGEN IN THE M81 GROUP OF GALAXIES	NATURE			English	Article							NEUTRAL-HYDROGEN; KINEMATICS; NGC-3077	It has long been recognized that interactions between galaxies are important in determining their evolution. The distribution of gas-out of which new stars are formed-is strongly affected; in particular, gas may be concentrated near the nucleus, leading to a burst of star formation(1-4). Here we present a map of atomic hydrogen (H I) in the nearest interacting group of galaxies (that dominated by M81), obtained by combining 12 separate fields observed with the Very Large Array. The Hr that surrounds M81, M82 and NGC3077 (the most prominent galaxies in the group) is dominated by filamentary structures, clearly demonstrating the violent disruption of this system by tidal interactions. These observations should have detected all H I complexes more massive than 10(6) solar masses, meaning that our map contains all structures that might evolve into new dwarf galaxies.	CALTECH,PASADENA,CA 91125; UNIV ILLINOIS,DEPT ASTRON,URBANA,IL 61801	California Institute of Technology; University of Illinois System; University of Illinois Urbana-Champaign	YUN, MS (corresponding author), HARVARD SMITHSONIAN CTR ASTROPHYS,60 GARDEN ST,CAMBRIDGE,MA 02138, USA.		Ho, Paul/AAZ-5108-2020	Ho, Paul/0000-0002-3412-4306				APPLETON PN, 1988, MON NOT R ASTRON SOC, V234, P957, DOI 10.1093/mnras/234.4.957; APPLETON PN, 1981, MON NOT R ASTRON SOC, V195, P327, DOI 10.1093/mnras/195.2.327; ARP H, 1965, SCIENCE, V148, P363, DOI 10.1126/science.148.3668.363; BARBIERI C, 1974, ASTRON ASTROPHYS, V35, P463; Barnes J. E, 1988, APJ, V331, P669; BARNES JE, 1991, ASTROPHYS J, V370, pL65, DOI 10.1086/185978; BROUILLET N, 1992, ASTRON ASTROPHYS, V262, pL5; COTTRELL GA, 1977, MON NOT R ASTRON SOC, V178, P577, DOI 10.1093/mnras/178.4.577; COTTRELL GA, 1976, MON NOT R ASTRON SOC, V174, P455, DOI 10.1093/mnras/174.2.455; DEMOULIN M, 1960, ASTROPHYS J, V157, P81; FREEDMAN WL, 1994, ASTROPHYS J, V427, P628, DOI 10.1086/174172; GOTTESMAN ST, 1977, ASTROPHYS J, V211, P47, DOI 10.1086/154902; GOTTESMAN ST, 1975, ASTROPHYS J, V195, P23, DOI 10.1086/153301; HIBBARD JE, 1994, ASTRON J, V107, P67, DOI 10.1086/116835; KENT SM, 1987, ASTRON J, V93, P816, DOI 10.1086/114366; LIN CC, 1969, ASTROPHYS J, V155, P721, DOI 10.1086/149907; PEIMBERT M, 1981, ASTROPHYS J, V245, P845, DOI 10.1086/158860; PRICE JS, 1989, ASTROPHYS J, V337, P658, DOI 10.1086/167137; RIEKE GH, 1980, ASTROPHYS J, V238, P24, DOI 10.1086/157954; ROBERTS MS, 1972, EXTERNAL GALAXIES QU, P12; Rots A. H., 1980, Astronomy & Astrophysics Supplement Series, V41, P189; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P25; ROTS AH, 1975, ASTRON ASTROPHYS, V45, P43; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; SCOVILLE N, 1991, P C MASSIVE STARS ST, P233; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; VANDERHULST JM, 1979, ASTRON ASTROPHYS, V75, P97; VISSER HCD, 1978, STRUCTURE PROPERTIES, P105; WISNIEWSKI WZ, 1968, ASTRON J, V73, P866, DOI 10.1086/110721; YUN MS, 1993, ASTROPHYS J, V411, pL17, DOI 10.1086/186901	30	404	406	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					530	532		10.1038/372530a0	http://dx.doi.org/10.1038/372530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990925				2022-12-01	WOS:A1994PW08200045
J	PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D				PAROUSH, Z; FINLEY, RL; KIDD, T; WAINWRIGHT, SM; INGHAM, PW; BRENT, R; ISHHOROWICZ, D			GROUCHO IS REQUIRED FOR DROSOPHILA NEUROGENESIS, SEGMENTATION, AND SEX DETERMINATION AND INTERACTS DIRECTLY WITH HAIRY-RELATED BHLH PROTEINS	CELL			English	Article							HELIX-LOOP-HELIX; RULE GENE-EXPRESSION; OF-SPLIT COMPLEX; PAN-NEURAL GENE; FUSHI-TARAZU; DETERMINATION SIGNAL; ACHAETE-SCUTE; DNA-BINDING; ZYGOTIC CONTROL; SHOWS HOMOLOGY	We have used the interaction trap, a yeast two-hybrid system, to identify proteins interacting with hairy, a basic-helix-loop-helix (bHLH) protein that represses transcription during Drosophila embryonic segmentation. We find that the groucho (gro) protein binds specifically to hairy and also to hairy-related bHLH proteins encoded by deadpan and the Enhancer of split complex. The C-terminal WRPW motif present in all these bHLH proteins is essential for this interaction. We demonstrate that these associations reflect in vivo maternal requirements for gro during neurogenesis, segmentation, and sex determination, three processes regulated by the above bHLH proteins, and we propose that gro is a transcriptional corepressor recruited to specific target promoters by hairy-related bHLH proteins.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,DEV GENET LAB,OXFORD OX1 3PS,ENGLAND; UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,MOLEC EMBRYOL LAB,OXFORD OX1 3PS,ENGLAND; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	University of Oxford; University of Oxford; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Ingham, Philip W/E-6710-2010; Kidd, Thomas/AAT-9993-2020; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; Kidd, Thomas/0000-0001-7190-4208; Ish-Horowicz, David/0000-0001-5684-7129; Finley, Russ/0000-0003-1144-6887				Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega Jose A., 1993, P1091; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CARROLL SB, 1989, DEVELOPMENT, V107, P673; CLINE TW, 1988, GENETICS, V119, P829; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DELIDAKIS C, 1991, GENETICS, V129, P803; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, IN PRESS GENE PROBES; FORBES Z, 1993, ESSENTIAL DEV BIOL P, P3; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Howard K, 1990, Semin Cell Biol, V1, P161; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; INGHAM PW, 1985, GENETICS, V111, P643; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JACKLE H, 1992, J CELL SCI S, V16, pS39; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1992, GENETICS, V132, P505; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHRONS H, 1992, GENETICS, V132, P481; SMITH DB, 1988, GENE AMST, V76, P31; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VAVRA SH, 1989, DEVELOPMENT, V107, P663; WAINWRIGHT SM, 1992, MOL CELL BIOL, V12, P2475, DOI 10.1128/MCB.12.6.2475; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wieschaus E., 1986, P199; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	72	503	518	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					805	815		10.1016/0092-8674(94)90070-1	http://dx.doi.org/10.1016/0092-8674(94)90070-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001118				2022-12-01	WOS:A1994PW05400008
J	RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F				RUETER, P; RABUS, R; WILKES, H; AECKERSBERG, F; RAINEY, FA; JANNASCH, HW; WIDDEL, F			ANAEROBIC OXIDATION OF HYDROCARBONS IN CRUDE-OIL BY NEW TYPES OF SULFATE-REDUCING BACTERIA	NATURE			English	Article							HYDROTHERMAL VENT SITE; 16S RDNA ANALYSIS; MICROBIAL-DEGRADATION; GUAYMAS BASIN; NORTH-SEA; SULFATE; PETROLEUM; TOLUENE; SEDIMENTS	MANY crude oil constituents are biodegradable in the presence of oxygen; however, a substantial anaerobic degradation has never been demonstrated(1,2). An unusually low content of n-alkanes in oils of certain deposits is commonly attributed to selective utilization of these hydrocarbons by aerobic microorganisms(3,4). On the other hand, oil wells and production fluids were shown to harbour anaerobic sulphate-reducing bacteria(5-8), but their actual electron donors and carbon sources were unknown. On the basis of nutritional properties of various bacterial isolates it was assumed that fatty acids and H-2 are potential electron donors for sulphate reduction in situ(5-8). Here we demonstrate that hydrocarbons in crude oil are used directly by sulphate-reducing bacteria growing under strictly anoxic conditions. A moderately thermophilic pure culture selectively utilizes n-alkanes in oil for sulphate reduction to sulphide. In addition, a mesophilic sulphate-reducing enrichment culture is shown to oxidize alkylbenzenes in oil. Thus, sulphate-reducing bacteria utilizing aliphatic and aromatic hydrocarbons as electron donors may present a significant source of sulphide in oil deposits and oil production plants.	MAX PLANCK INST MARINE MIKROBIOL, D-28359 BREMEN, GERMANY; FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST ERDOL & ORGAN GEOCHEM ICG4, D-52428 JULICH, GERMANY; DEUTSCH SAMMLUNG MIKROORGANISMEN & ZELLKULTUREN, D-38124 BRAUNSCHWEIG, GERMANY; WOODS HOLE OCEANOG INST, WOODS HOLE, MA 02543 USA	Max Planck Society; Helmholtz Association; Research Center Julich; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Woods Hole Oceanographic Institution			Abu Laban, Nidal/E-5809-2011; Rainey, Fred A/C-8767-2013; Rainey, Fred/AAG-7996-2019	Rainey, Fred A/0000-0001-9129-6844; 				AECKERSBERG F, 1991, ARCH MICROBIOL, V156, P5, DOI 10.1007/BF00418180; ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; Balows A., 1992, PROKARYOTES, P3352, DOI [10.1007/978-1-4757-2191-1_21, DOI 10.1007/978-1-4757-2191-1_]; BAZYLINSKI DA, 1989, APPL ENVIRON MICROB, V55, P2832, DOI 10.1128/AEM.55.11.2832-2836.1989; BAZYLINSKI DA, 1988, ORG GEOCHEM, V12, P547, DOI 10.1016/0146-6380(88)90146-5; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; Blanc Ph., 1993, APPL PETROLEUM GEOCH, P151; CORDRUWISCH R, 1987, J PETROL TECHNOL, V39, P97, DOI 10.2118/13554-PA; DESOETE G, 1983, PSYCHOMETRIKA, V48, P621, DOI 10.1007/BF02293884; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P794, DOI 10.1128/AEM.58.3.794-800.1992; JORGENSEN BB, 1992, SCIENCE, V258, P1756, DOI 10.1126/science.258.5089.1756; Jukes T. H., 1969, MAMMALIAN PROTEIN ME; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; NAZINA TN, 1985, GEOMICROBIOL J, V4, P103, DOI 10.1080/01490458509385927; NIELSEN H, 1991, SCOPE, V43, P65; ORR WL, 1974, AAPG BULL, V58, P2295; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RABUS R, 1993, APPL ENVIRON MICROB, V59, P1444, DOI 10.1128/AEM.59.5.1444-1451.1993; RADKE M, 1980, ANAL CHEM, V52, P406, DOI 10.1021/ac50053a009; RAINEY FA, 1993, FEMS MICROBIOL LETT, V113, P125, DOI 10.1111/j.1574-6968.1993.tb06501.x; RAINEY FA, 1992, SYST APPL MICROBIOL, V15, P197, DOI 10.1016/S0723-2020(11)80092-5; ROSNES JT, 1991, APPL ENVIRON MICROB, V57, P2302, DOI 10.1128/AEM.57.8.2302-2307.1991; Schidlowski M., 1983, P149; SIMONEIT BRT, 1982, NATURE, V295, P198, DOI 10.1038/295198a0; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; Tissot B.P., 1984, PETROLEUM FORMATION, DOI DOI 10.1007/978-3-642-96446-6	26	341	367	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					455	458		10.1038/372455a0	http://dx.doi.org/10.1038/372455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984238				2022-12-01	WOS:A1994PV01200054
J	SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ				SMITH, ML; CHEN, IT; ZHAN, QM; BAE, IS; CHEN, CY; GILMER, TM; KASTAN, MB; OCONNOR, PM; FORNACE, AJ			INTERACTION OF THE P53-REGULATED PROTEIN GADD45 WITH PROLIFERATING CELL NUCLEAR ANTIGEN	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; EXCISION REPAIR; P53; PCNA	GADD45 is a ubiquitously expressed mammalian gene that is induced by DNA damage and certain other stresses. Like another p53-regulated gene, p21(WAF1/CIP1), whose product binds to cyclin-dependent kinases (Cdk's) and proliferating cell nuclear antigen (PCNA), GADD45 has been associated with growth suppression. Gadd45 was found to bind to PCNA, a normal component of Cdk complexes and a protein involved in DNA replication and repair. Gadd45 stimulated DNA excision repair in vitro and inhibited entry of cells into S phase. These results establish GADD45 as a link between the p53-dependent cell cycle checkpoint and DNA repair.	NCI, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21287 USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KILPATRICK KE, IN PRESS J BIOL CHEM; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MICHIELI P, 1994, CANCER RES, V54, P3391; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WASEEM NH, 1990, J CELL SCI, V96, P121; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	26	911	942	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1376	1380		10.1126/science.7973727	http://dx.doi.org/10.1126/science.7973727			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973727	Green Submitted			2022-12-01	WOS:A1994PT63200042
J	FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM				FICKER, E; TAGLIALATELA, M; WIBLE, BA; HENLEY, CM; BROWN, AM			SPERMINE AND SPERMIDINE AS GATING MOLECULES FOR INWARD RECTIFIER K+ CHANNELS	SCIENCE			English	Article							RECTIFYING POTASSIUM CURRENT; INTERNAL MG-2+; CELLS; RECTIFICATION; EXPRESSION; POLYAMINES; MYOCYTES; HEART; BLOCK	Inward rectifier K+ channels pass prominent inward currents, while outward currents are largely blocked. The inward rectification is due to block by intracellular Mg2+ and a Mg2+-independent process described as intrinsic gating. The rapid loss of gating upon patch excision suggests that cytoplasmic factors participate in gating. ''intrinsic'' gating can be restored in excised patches by nanomolar concentrations of two naturally occurring polyamines, spermine and spermidine. Spermine and spermidine may function as physiological blockers of inward rectifier K+ channels and ''intrinsic'' gating may largely reflect voltage-dependent block by these cations.	CASE WESTERN RESERVE UNIV,METRO HLTH SYST,RAMMELKAMP CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL,CLEVELAND,OH 44109; BAYLOR COLL MED,DEPT PHYSIOL & MOLEC BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT NEUROSCI,PHARMACOL SECT,I-80121 NAPLES,ITALY; BAYLOR COLL MED,DEPT OTORHINOLARYNGOL,HOUSTON,TX 77030	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Baylor College of Medicine; University of Naples Federico II; Baylor College of Medicine			Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044, HL36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ANUMONWO JMB, 1991, CARDIOVASC DRUG REV, V9, P299, DOI 10.1111/j.1527-3466.1991.tb00418.x; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROCK M, 1994, HEARING RES, V72, P37, DOI 10.1016/0378-5955(94)90203-8; BROWN ND, 1982, J CHROMATOGR, V245, P101, DOI 10.1016/S0021-9673(00)82479-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HARVEY RD, 1988, J GEN PHYSIOL, V91, P593, DOI 10.1085/jgp.91.4.593; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, J PHYSIOL-LONDON, V477P, pP86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; PEGG AE, 1988, CANCER RES, V48, P759; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; USHERWOOD PNR, 1991, PHARMACOL THERAPEUT, V52, P245, DOI 10.1016/0163-7258(91)90012-B; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WEIGER T, 1994, J MEMBRANE BIOL, V140, P133; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L	30	463	467	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1068	1072		10.1126/science.7973666	http://dx.doi.org/10.1126/science.7973666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973666				2022-12-01	WOS:A1994PQ92400053
J	PUVACIC, Z; WEINBERG, J				PUVACIC, Z; WEINBERG, J			IMPACT OF WAR ON INFECTIOUS-DISEASE IN BOSNIA-HERZEGOVINA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH		REPUBL INST PUBL HLTH, DEPT EPIDEMIOL, SARAJEVO, BOSNIA & HERCEG; WHO, HLTH MONITORING UNIT, ZAGREB AREA OFF, ZAGREB, CROATIA	World Health Organization								ARMENIAN HK, 1986, AM J EPIDEMIOL, V124, P28, DOI 10.1093/oxfordjournals.aje.a114367; SHEARS P, 1987, BMJ-BRIT MED J, V295, P314, DOI 10.1136/bmj.295.6593.314; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; 1990, LANCET, V336, P845; 1993, MMWR-MORBID MORTAL W, V42, P973	5	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1207	1208		10.1136/bmj.309.6963.1207	http://dx.doi.org/10.1136/bmj.309.6963.1207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987152	Green Published			2022-12-01	WOS:A1994PQ66200022
J	COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ				COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ			LINKAGE OF AUTOSOMAL-DOMINANT HEARING-LOSS TO THE SHORT ARM OF CHROMOSOME-1 IN 2 FAMILIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNDROME TYPE-I; WAARDENBURG SYNDROME; MOLECULAR-CLONING; COLLAGEN GENE; HUMAN GENOME; DEAFNESS; IMPAIRMENT; LOCALIZATION; ALPHA-1(XVI); MUTATIONS	Background. At least half of the cases of profound deafness of early onset are caused by genetic factors, but few of the genetic defects have been identified. This is particularly true of the most common hereditary forms of deafness, which occur in the absence of any associated syndrome. Methods. We studied a large Indonesian family in which hearing loss was inherited in an autosomal dominant pattern. The hearing loss first affects the high frequencies during the teens or 20s and becomes profound within 10 years. To locate the responsible gene, we performed genetic-linkage analysis, using microsatellite markers distributed over the entire genome. We then performed linkage analyses in an American family and a Dutch family with similar patterns of hereditary hearing loss. Results. In the extended Indonesian family, a gene linked to deafness mapped to chromosome Ip, with a multipoint rod score of more than 7. In the American family, deafness was linked to the same locus on chromosome 1p, with a multipoint rod score of more than 5. In the Dutch family, however, this locus was ruled out. The flanking markers D1S255 and D1S211 defined a region of 6 cM on chromosome 1p that is likely to contain the gene associated with deafness in the first two families. Conclusions. In some families with early-onset autosomal dominant hearing loss, the responsible gene is on chromosome 1p.	UNIV ANTWERP, DEPT MED GENET, B-2610 ANTWERP, BELGIUM; UNIV ANTWERP, DEPT OTORHINOLARYNGOL, B-2020 ANTWERP, BELGIUM; PADJADJARAN STATE UNIV, SCH MED, DEPT EAR NOSE & THROAT, BANDUNG, INDONESIA; BOYS TOWN NATL RES HOSP, CTR HEREDITARY COMMUN DISORDERS, BOYS TOWN, NE USA; LEIDEN UNIV, CTR GENET MED, DEPT HUMAN GENET, LEIDEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT NEUROL, NIJMEGEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT EAR NOSE & THROAT, NIJMEGEN, NETHERLANDS; ACAD HOSP UTRECHT, DEPT EAR NOSE & THROAT, UTRECHT, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3000 DR ROTTERDAM, NETHERLANDS	University of Antwerp; University of Antwerp; Universitas Padjadjaran; Boys Town National Research Hospital; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam			Cremers, C.W.R.J./L-4254-2015; Van Camp, Guy/F-3386-2013; Padberg, G.W.A.M./H-8079-2014	Van Camp, Guy/0000-0001-5105-9000; 	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P60DC000982] Funding Source: NIH RePORTER; NIDCD NIH HHS [P60-DC-00982] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BACH I, 1992, AM J HUM GENET, V51, P38; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; FREIMER NB, 1993, AM J HUM GENET, V52, P1102; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HUGHES AE, 1993, GENOMICS, V15, P433, DOI 10.1006/geno.1993.1083; Huizing E H, 1966, Acta Otolaryngol, V61, P161, DOI 10.3109/00016486609127053; Huizing E H, 1966, Acta Otolaryngol, V61, P35, DOI 10.3109/00016486609127040; HUIZING EH, 1983, ACTA OTO-LARYNGOL, V95, P620, DOI 10.3109/00016488309139453; HULL R, 1978, HDB CLIN AUDIOLOGY, P426; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KNOWLES JA, 1992, AM J HUM GENET, V51, P905; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; OTT J, 1992, AM J HUM GENET, V51, P283; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, J MED GENET, V29, P521, DOI 10.1136/jmg.29.8.521; ROBINSON D, 1992, HUM GENET, V90, P316; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P336; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P233; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YAMAGUCHI N, 1992, J BIOCHEM-TOKYO, V112, P856, DOI 10.1093/oxfordjournals.jbchem.a123989	35	106	108	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					425	431		10.1056/NEJM199408183310702	http://dx.doi.org/10.1056/NEJM199408183310702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035838	Green Published			2022-12-01	WOS:A1994PB50100002
J	MUHLRAD, D; PARKER, R				MUHLRAD, D; PARKER, R			PREMATURE TRANSLATIONAL TERMINATION TRIGGERS MESSENGER-RNA DECAPPING	NATURE			English	Article							MESSENGER-RNA DECAY; NONSENSE MUTATIONS; ENDONUCLEOLYTIC CLEAVAGE; SACCHAROMYCES-CEREVISIAE; RICH SEQUENCES; DEGRADATION; POLY(A); YEAST; DEADENYLATION; STEP	THE degradation of messenger RNA in eukaryotic cells is initiated by endonucleolytic cleavage(1,2) or by shortening of the poly(A) tail(3-6), which for some mRNAs activates a deadenylation-dependent decapping reaction(7). One type of rapid mRNA degradation in eukaryotes is caused by premature termination of translation(8,9). This turnover process prevents the translation of aberrant mRNAs(10,11), may affect the abundance and splicing pattern of nuclear transcripts(12,13), and may be involved in the aetiology of human genetic disease(14). Here we show that premature translational termination in yeast triggers decapping, independent of deadenylation, thereby exposing the transcript to 5'-to-3' degradation. Inactivation of the 5'-to-3' exonuclease reveals an additional 3'-to-5' pathway of mRNA turnover. These observations provide in vivo evidence for two new mechanisms of mRNA decay.			MUHLRAD, D (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,LIFE SCI S,TUCSON,AZ 85721, USA.							BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG H, 1992, MOL CELL BIOL, V12, P1553, DOI 10.1128/MCB.12.4.1553	23	329	333	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					578	581		10.1038/370578a0	http://dx.doi.org/10.1038/370578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052314				2022-12-01	WOS:A1994PC53700061
J	PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM				PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM			IDENTIFICATION OF 2 BONE MORPHOGENETIC PROTEIN TYPE-I RECEPTORS IN DROSOPHILA AND EVIDENCE THAT BRK25D IS A DECAPENTAPLEGIC RECEPTOR	CELL			English	Article							GROWTH-FACTOR-BETA; BIOCHEMICAL-CHARACTERIZATION; CYTOGENETIC ANALYSIS; GENE; MELANOGASTER; PATTERN; EMBRYO; MEMBER; FAMILY; SUPERFAMILY	Drosophila sequences at chromosomal positions 25D (Brk25D) and 43E (Brk43E) are similar to the TGF beta type I receptor serine/threonine kinases and are expressed broadly during embryogenesis. Brk25D binds dpp protein and bone morphogenetic protein 2 with high affinity. Mutations affecting Brk25D map to the gene thick veins and block the expression of two decapentaplegic-responsive (dpp-responsive) genes, dpp and labial, in the embryonic midgut. Defects in Brk25D receptor function combined with reduced expression of dpp ligand produce mutant phenotypes in the embryo and adult. Brk43E is the product of the gene saxophone, which also interacts with dpp. We conclude that dpp signaling in vivo is mediated by at least two receptors, Brk25D and Brk43E.	UNIV WISCONSIN, SCH MED, GENET LAB, MADISON, WI 53706 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; UNIV HORT & FOOD IND, DEPT GENET & PLANT BREEDING, H-1518 BUDAPEST, HUNGARY; UNIV TEXAS, DIV LIFE SCI, SAN ANTONIO, TX 78249 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Corvinus University Budapest; University of Texas System	PENTON, A (corresponding author), UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.		Wrana, Jeffrey/F-8857-2013; Cassill, Aaron/F-5467-2010	Massague, Joan/0000-0001-9324-8408; Hoffmann, F. Michael/0000-0002-2770-9656	NCI NIH HHS [CA09135, CA07175] Funding Source: Medline; NCRR NIH HHS [RR06610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KOENIG BB, 1994, IN PRESS MOL CELL BI; Lawrence P.A., 1986, P229; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1993, DEV BIOL, V159, P276, DOI 10.1006/dbio.1993.1240; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTO.K, 1994, IN PRESS DEV BIOL; STAEHLINGHAMPTO.K, 1994, IN PRESS CELL GROWTH; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TERRACOL R, 1994, IN PRESS GENETICS; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	47	235	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					239	250		10.1016/0092-8674(94)90294-1	http://dx.doi.org/10.1016/0092-8674(94)90294-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044838				2022-12-01	WOS:A1994NZ24200008
J	EDDY, DM				EDDY, DM			A CONVERSATION WITH MY MOTHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; HUMPHRY D, 1991, FINAL EXIT	3	49	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					179	181		10.1001/jama.272.3.179	http://dx.doi.org/10.1001/jama.272.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022025				2022-12-01	WOS:A1994NW18500001
J	AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T				AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T			FALLOUT FROM CHERNOBYL AND INCIDENCE OF CHILDHOOD LEUKEMIA IN FINLAND, 1976-92	BRITISH MEDICAL JOURNAL			English	Article							CANCER	Objective-To assess effects of fallout from Chernobyl on incidence of childhood leukaemia in Finland. Design-Nationwide cohort study. External exposure measured for 455 Finnish municipalities with instruments driven 19000 km throughout the country. Values specific to municipalities corrected for shielding due to houses and fallout from A bomb testing. Internal exposure estimated from whole body measurements on a random sample of 81 children. Mean effective dose for two years after incident calculated from these measurements. Data on childhood leukaemia obtained from Finnish cancer registry and verified through hospitals treating childhood cancers. Setting-Finland, one of the countries most heavily contaminated by the Chernobyl accident; the population was divided into fifths by exposure. Subjects-Children aged 0-14 years in 1976-92. Main outcome measures-Standardised incidence ratio of childhood leukaemia and relative excess risk of childhood leukaemia per mSv. From incidence data of Finnish cancer registry for 1976-85, expected numbers specific to sex and age group (0-4, 5-9, and 10-14 years) were calculated for each municipality for three periods (1976-85, 1986-8, and 1989-92) and pooled as exposure fifths. Dose response was estimated as regression slope of standardised incidence ratios on mean doses for fifths for each period. Results-Population weighted mean effective doses for first two years after the accident were 410 mu Sv for the whole country and 970 mu Sv for the population fifth with the highest dose. In all Finland the incidence of childhood leukaemia did not increase 1976-92. The relative excess risk 1989-92 was not significantly different from zero (7% per mSv; 95% confidence interval -27% to 41%). Conclusions-An important increase in childhood leukaemia can be excluded. Any effect is smaller than eight extra cases per million children per year in Finland. The results are consistent with the magnitude of effect expected.	FINNISH CTR RADIAT & NUCL SAFETY,SF-00101 HELSINKI,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND; KAROLINSKA INST,CANC EPIDEMIOL UNIT,S-10401 STOCKHOLM,SWEDEN	Radiation & Nuclear Safety Authority (STUK); Tampere University; Karolinska Institutet	AUVINEN, A (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAL-2111-2020; Auvinen, Anssi/AAD-9311-2020	Auvinen, Anssi/0000-0003-1125-4818; 				[Anonymous], 1988, SOURCES EFFECTS RISK; ARVELA H, 1990, RADIAT PROT DOSIM, V32, P177, DOI 10.1093/oxfordjournals.rpd.a080734; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Finck R., 1991, CHERNOBYL FALLOUT SW, P489; IVANOV EP, 1993, NATURE, V365, P702, DOI 10.1038/365702a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; MJONES L, 1986, SSI8622 SWED RAD PRO; PARKIN M, 1992, EUR J CANCER A, V29, P87; RAHOLA T, 1991, STUKA91 FINN CTR RAD; RAHOLA T, 1990, STUKA81 FINN CTR RAD; SAXEN E, 1978, FINNISH CANCER REGIS; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; 1991, BUILDINGS DWELLINGS; 1990, EUR12551 COMM EUR CO; 1992, CANCER SOC FINLAND P, V51	15	51	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					151	154		10.1136/bmj.309.6948.151	http://dx.doi.org/10.1136/bmj.309.6948.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044092	Green Published			2022-12-01	WOS:A1994NY22900017
J	CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP				CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP			CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; MUTANT P53; GENE AMPLIFICATION; BINDING DOMAIN; PROTEIN; CONFORMATION; RESOLUTION; CANCER; RECOGNITION	Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.			CHO, YJ (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NCI NIH HHS [NCI CA08748-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V2 1 MANUAL; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, IN PRESS NUCLEIC ACI; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1992, NATURE, V358, P83; ROULD MR, 1989, PROGRAM DSCALEAD; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; 1979, COLLABORATIVE COMPUT	64	2117	2167	3	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					346	355		10.1126/science.8023157	http://dx.doi.org/10.1126/science.8023157			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023157				2022-12-01	WOS:A1994NW81600027
J	WEINER, BM; KLECKNER, N				WEINER, BM; KLECKNER, N			CHROMOSOME PAIRING VIA MULTIPLE INTERSTITIAL INTERACTIONS BEFORE AND DURING MEIOSIS IN YEAST	CELL			English	Article								Fluorescence in situ hybridization analysis reveals that homologous chromosomes are paired in yeast cells about to enter meiosis. Fairing involves multiple interstitial interactions, one per similar to 65 kb. These observations exclude several classes of models for somatic/premeiotic pairing. The number of t = 0 pairing interactions is about the same as the number of subsequent meiotic recombination events. As cells enter meiosis, pairing disappears concomitant with DNA replication and then reappears, independent of synaptonemal complex. Mutant phenotypes suggest that formation of an individual meiotic pairing connection does not require a meiosis-specific double-stranded break (DSB). Mutants defective in recombination before or after DSBs exhibit pairing defects. These and other observations can be united by a model in which premeiotic pairing and early meiotic pairing occur by closely related paranemic DNA-DNA interactions between intact duplexes, with early meiotic interactions subsequently converted directly to plectonemic recombination intermediates via DSBs.			WEINER, BM (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014729] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44794, GM14729] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CAMPBELL AM, 1993, GENE, V135, P147, DOI 10.1016/0378-1119(93)90059-C; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHANDLEY AC, 1986, HUM GENET, V72, P50, DOI 10.1007/BF00278817; CHAUHAN KPS, 1968, CHROMOSOMA, V25, P297, DOI 10.1007/BF01183122; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; Jorgensen R., 1992, Agbiotech News and Information, V4, p265N; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEIN S, 1994, MYCOTA, V2; KOWALCZYKOWSKI SC, 1994, IN PRESS ANN REV BIO; LAWRENCE JB, 1988, CELL, V52, P51; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MAGUIRE MP, 1983, J HERED, V74, P93, DOI 10.1093/oxfordjournals.jhered.a109748; McCLINTOCK BARBARA, 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P191, DOI 10.1007/BF02462870; MCDERMOTT A, 1971, CAN J GENET CYTOL, V13, P536, DOI 10.1139/g71-079; MCGAVIN S, 1989, J THEOR BIOL, V136, P135, DOI 10.1016/S0022-5193(89)80221-8; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Rhoades MM, 1961, CELL, VIII, P1; RILEY R, 1977, PHILOS T R SOC B, V277, P191, DOI 10.1098/rstb.1977.0011; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STACK SM, 1969, NATURE, V222, P1275, DOI 10.1038/2221275a0; STERN H, 1987, P303; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANDALL A, 1985, CHROMOSOMA, V92, P254, DOI 10.1007/BF00329808; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615	66	328	332	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					977	991		10.1016/0092-8674(94)90438-3	http://dx.doi.org/10.1016/0092-8674(94)90438-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020104				2022-12-01	WOS:A1994NV42500007
J	EVANS, DB; JAMISON, DT				EVANS, DB; JAMISON, DT			ECONOMICS AND THE ARGUMENT FOR PARASITIC DISEASE-CONTROL	SCIENCE			English	Editorial Material							CHILDREN; AFRICA; MALARIA; COST		UNIV CALIF LOS ANGELES,CTR PACIFIC RIM STUDIES,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	EVANS, DB (corresponding author), UN DEV PROGRAM,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], [No title captured]; BRIEGER WR, 1990, J TROP MED HYG, V93, P106; CALLENDER JEM, 1992, LANCET, V339, P181, DOI 10.1016/0140-6736(92)90246-Y; COOPER BS, 1976, SOC SECUR BULL, V39, P21; GUYATT HL, 1992, PARASITOL TODAY, V8, P397, DOI 10.1016/0169-4758(92)90187-7; JAMISON D, 1992, ENCY ED RES, P399; JAMISON DT, 1993, DIS CONTROL PRIORITI, P3; KORTE R, 1992, SOC SCI MED, V34, P1, DOI 10.1016/0277-9536(92)90060-4; MAX E, 1989, INT J LEPROSY, V57, P476; Mooney G, 1992, EC MED HLTH CARE, V2nd; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; OVER M, 1992, HLTH ADULTS DEV WORL, P161; PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q; Prescott N., 1989, Demography and vector-borne diseases., P155; Psacharopoulos G., 1993, POLICY RES WORKING P, V1067; SHEPARD DS, 1991, TROP MED PARASITOL, V42, P199; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P445, DOI 10.4269/ajtmh.1989.41.445; 1993, 1993 WORLD BANK WORL	18	5	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1866	1867		10.1126/science.8009213	http://dx.doi.org/10.1126/science.8009213			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009213				2022-12-01	WOS:A1994NT84700026
J	MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M				MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M			FUNCTIONAL-ROLE OF TYPE-I AND TYPE-II INTERFERONS IN ANTIVIRAL DEFENSE	SCIENCE			English	Article							VESICULAR STOMATITIS; ALPHA-INTERFERON; INFLUENZA-VIRUS; MOUSE CELLS; MICE; EXPRESSION; RECEPTOR; GENES; PROTEIN; BETA	Mice lacking the known subunit of the type I interferon (IFN) receptor were completely unresponsive to type I IFNs, suggesting that this receptor chain is essential for type I IFN-mediated signal transduction. These mice showed no overt anomalies but were unable to cope with viral infections, despite otherwise normal immune responses. Comparison of mice lacking either type I or type II IFN receptors showed that, at least in response to some viruses, both IFN systems are essential for antiviral defense and are functionally nonredundant.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich			Reis, Luiz F. L./C-4556-2013; Pavlovic, Jovan/G-9669-2015; Li, Chia Cheng/D-9906-2015; Yang, Chen/G-1379-2010	Pavlovic, Jovan/0000-0003-4428-2487; Steinhoff, Ulrich/0000-0003-2141-7756; Reis, Luiz/0000-0002-4040-2456				BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BINDER D, 1991, J IMMUNOL, V146, P4301; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; DEMAEYER E, 1908, INTERFERONS OTHER RE; FAUCONNIER B, 1969, NATURE, V222, P185, DOI 10.1038/222185a0; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; FLORES I, 1991, J BIOL CHEM, V266, P19875; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLER AK, 1980, NATURE, V286, P266, DOI 10.1038/286266a0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; GRESSER I, 1976, J EXP MED, V144, P1316, DOI 10.1084/jem.144.5.1316; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MULLER U, UNPUB; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; ROBERTS RM, 1991, PHARMACOL THERAPEUT, V51, P329, DOI 10.1016/0163-7258(91)90064-S; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; RUTHERFORD MN, 1991, NUCLEIC ACIDS RES, V19, P1917, DOI 10.1093/nar/19.8.1917; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WEISS EH, 1984, NATURE, V310, P650, DOI 10.1038/310650a0; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZINKERNAGEL RM, 1993, IMMUNOL REV, V131, P199	35	1959	2018	22	299	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1918	1921		10.1126/science.8009221	http://dx.doi.org/10.1126/science.8009221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009221				2022-12-01	WOS:A1994NT84700041
J	VANDERWAL, G; DILLMANN, RJM				VANDERWAL, G; DILLMANN, RJM			EUTHANASIA IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							ASSISTED SUICIDE; FAMILY DOCTORS; LIFE	The practice of euthanasia in the Netherlands is often used as an argument in debates outside the Netherlands-hence a clear description of the Dutch situation is important. This article summarises recent data and discusses conceptual issues and relevant characteristics of the system of health care. Special emphasis is put on regulation, including relevant data on notification and prosecution. Besides the practice of euthanasia the Dutch are confronted with the gaps in reporting of cases to the public prosecutor and the existence of cases of ending a life without an explicit request. Nevertheless, the ''Dutch experiment'' need not inevitably lead down the slippery slope because of the visibility and openness of this part of medical practice. This will lead to increased awareness, more safeguards, and improvement of medical decisions concerning the end of life.	ROYAL DUTCH MED ASSOC,3502 LB UTRECHT,NETHERLANDS; HLTH PROV N HOLLAND,2001 DC HAARLEM,NETHERLANDS									ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BATTIN MP, 1990, PERSPECT BIOL MED, V34, P73; Bostrom B A, 1989, Issues Law Med, V4, P467; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DILLMANN RJM, 1994, EUROPEAN J HLTH LAW, V1, P81; FEBER HRG, 1989, NEDERLANDS JURISTEN, V64, P1441; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gomez Carlos F., 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; POLLARD BJ, 1991, MED J AUSTRALIA, V154, P613, DOI 10.5694/j.1326-5377.1991.tb121223.x; RIGTER H, 1988, BMJ-BRIT MED J, V297, P1593, DOI 10.1136/bmj.297.6663.1593; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; van Delden J J, 1992, Ned Tijdschr Geneeskd, V136, P644; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDELDEN JJM, 1993, BIOETHICS, V7, P323, DOI 10.1111/j.1467-8519.1993.tb00222.x; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; VANDERMAAS PJ, 1992, HLTH POLICY S1 S2, V22; VANDERWAL G, 1993, BIOETHICS, V7, P330, DOI 10.1111/j.1467-8519.1993.tb00223.x; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1992, FAM PRACT, V9, P135, DOI 10.1093/fampra/9.2.135; VANDERWAL G, 1992, EUTHANASIA ASSISTED; VANDERWAL G, IN PRESS J AM GERIAT; VANDERWAL G, 1993, NEDERLANDS JURISTEN, V68, P444; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y; 1987, BIOETHICS, V1, P163; 1991, MED BESLISSINGEN RON	29	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1346	1349		10.1136/bmj.308.6940.1346	http://dx.doi.org/10.1136/bmj.308.6940.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM989	8019226	Green Published			2022-12-01	WOS:A1994NM98900028
J	WEETMAN, AP				WEETMAN, AP			ENZYMES AS CATALYSTS OF AUTOIMMUNITY	LANCET			English	Editorial Material							HYDRALAZINE; PROPYLTHIOURACIL; LUPUS				WEETMAN, AP (corresponding author), NO GEN HOSP,DEPT MED,SHEFFIELD,S YORKSHIRE,ENGLAND.							BATCHELOR JR, 1980, LANCET, V1, P1107; CORNACCHIA E, 1988, J IMMUNOL, V140, P2197; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636; UCHIGATA Y, 1993, J CLIN ENDOCR METAB, V77, P249, DOI 10.1210/jc.77.1.249; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P1636; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1992, LANCET, V339, P779	11	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1716	1717		10.1016/S0140-6736(94)92881-9	http://dx.doi.org/10.1016/S0140-6736(94)92881-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996997				2022-12-01	WOS:A1994PY28100004
J	THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP				THIBODEAU, J; CLOUTIER, I; LAVOIE, PM; LABRECQUE, N; MOURAD, W; JARDETZKY, T; SEKALY, RP			SUBSETS OF HLA-DR1 MOLECULES DEFINED BY SEB AND TSST-1 BINDING	SCIENCE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; SHOCK SYNDROME TOXIN-1; CLASS-II MOLECULES; HLA-DR; T-CELLS; ANTIGEN; COMPLEX; SUPERANTIGEN; CHAIN; EXPRESSION	Superantigens bind to major histocompatibility complex class II molecules on antigen-presenting cells and stimulate T cells. Staphylococcus aureus enterotoxin B (SEB) and toxic shock syndrome toxin-1 (TSST-1) bind to the same region of human lymphocyte antigen (HL4)-DR1 but do not compete with each other, which indicates that they bind to different subsets of DR1 molecules. Here, a mutation in the peptide-binding groove disrupted the SEB and TSST-1 binding sites, which suggests that peptides can influence the interaction with bacterial toxins. in support of this, the expression of the DR1 molecule in various cell types differentially affected the binding of these toxins.	CLIN RES INST MONTREAL,IMMUNOL LAB,MONTREAL H2W 1R7,PQ,CANADA; UNIV MONTREAL,FAC MED,DEPT IMMUNOL & MICROBIOL,MONTREAL,PQ,CANADA; MCGILL UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,PQ,CANADA; CHU LAVAL,DEPT IMMUNOL & RHUMATOL,ST FOY G1V 4G2,PQ,CANADA; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; Laval University; Harvard University				Mourad, Walid/0000-0002-1859-9387; Lavoie, Pascal/0000-0002-2205-0362				ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LABRECQUE N, 1993, RES IMMUNOL, V144, P175, DOI 10.1016/0923-2494(93)80113-D; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MOLLICK JA, 1991, J IMMUNOL, V146, P463; NORCROSS MA, 1984, J EXP MED, V160, P1316, DOI 10.1084/jem.160.5.1316; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; SCHOLL PR, 1990, EUR J IMMUNOL, V20, P1911, DOI 10.1002/eji.1830200907; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHERMAN MA, 1994, J EXP MED, V179, P229, DOI 10.1084/jem.179.1.229; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAGI JJ, 1991, J IMMUNOL, V147, P1398	38	89	90	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1874	1878		10.1126/science.7997881	http://dx.doi.org/10.1126/science.7997881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997881				2022-12-01	WOS:A1994PX38300038
J	MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M				MINDEN, A; LIN, A; MCMAHON, M; LANGECARTER, C; DERIJARD, B; DAVIS, RJ; JOHNSON, GL; KARIN, M			DIFFERENTIAL ACTIVATION OF ERK AND JNK MITOGEN-ACTIVATED PROTEIN-KINASES BY RAF-1 AND MEKK	SCIENCE			English	Article							C-JUN ACTIVITY; MAP KINASE; PHOSPHORYLATION; CELLS; GROWTH; EXPRESSION; TYROSINE; CASCADE; DOMAIN; SERINE-63	Growth factors activate mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs) and Jun kinases (JNKs). Although the signaling cascade from growth factor receptors to ERKs is relatively well understood, the pathway leading to JNK activation is more obscure. Activation of JNK by epidermal growth factor (EGF) or nerve growth factor (NGF) was dependent on H-Ras activation, whereas JNK activation by tumor necrosis factor alpha (TNF-alpha) was Ras-independent. Ras activates two protein kinases, Raf-1 and MEK (MAPK, or ERK, kinase) kinase (MEKK). Raf-1 contributes directly to ERK activation but not to JNK activation, whereas MEKK participated in JNK activation but caused ERK activation only after overexpression. These results demonstrate the existence of two distinct Ras-dependent MAPK cascades-one initiated by Raf-1 leading to ERK activation, and the other initiated by MEKK leading to JNK activation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of California System; University of California San Diego; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Jewish Health; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; Lange, Carol/0000-0003-2751-3976				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AMERER G, 1994, CURR OPIN GENES DEV, V4, P90; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P664; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG T, COMMUNICATION; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1028; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gupta SK, UNPUB; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1986, MOL CELL BIOL, V6, P1979; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINDEN A, UNPUB; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WESTWICK JK, IN PRESS J BIOL CHEM; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	48	1049	1075	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1719	1723		10.1126/science.7992057	http://dx.doi.org/10.1126/science.7992057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992057				2022-12-01	WOS:A1994PW30800044
J	ROLDAN, ERS; MURASE, T; SHI, QX				ROLDAN, ERS; MURASE, T; SHI, QX			EXOCYTOSIS IN SPERMATOZOA IN RESPONSE TO PROGESTERONE AND ZONA-PELLUCIDA	SCIENCE			English	Article							RAM SPERM ACROSOME; PHOSPHOLIPASE-D; SUBSEQUENT EXOCYTOSIS; TYROSINE KINASE; BINDING-SITES; MOUSE SPERM; ACTIVATION; PROTEIN; CA-2+; DIACYLGLYCEROL	Exocytosis in mammalian spermatozoa (the acrosome reaction) is a process essential for fertilization. Both progesterone and zona pellucida induce exocytosis in spermatozoa, which may encounter both during penetration of the oocyte's vestments. When mouse spermatozoa were exposed first to progesterone and then to zona pellucida, exocytosis was enhanced to a greater degree than that seen when the agonists were presented together or in the inverse order, which suggests that the steroid exerts a priming effect. Progesterone similarly primed the generation of intracellular messengers evoked by zona pellucida. The effects triggered by progesterone were mimicked by gamma-aminobutyric acid (GABA) and were blocked by bicuculline, which indicates that the steroid acts on a GABA(A) receptor.			ROLDAN, ERS (corresponding author), BIOTECHNOL & BIOL SCI RES COUNCIL,BABRAHAM INST,DEPT DEV & SIGNALLING,CAMBRIDGE CB2 4AT,ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				BAULIEU EE, 1988, ANTIPROGESTIN STEROI; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; Bleil J.D., 1991, ELEMENTS MAMMALIAN F, V1, P133; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; DOMINO SE, 1989, J BIOL CHEM, V264, P9412; ERDO SL, 1990, LIFE SCI, V47, P1147, DOI 10.1016/0024-3205(90)90175-Q; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FRASER LR, 1989, J REPROD FERTIL, V86, P223, DOI 10.1530/jrf.0.0860223; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARINAUD J, 1992, FERTIL STERIL, V58, P599; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; ROLDAN E, UNPUB; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P108, DOI 10.1016/0005-2760(93)90273-C; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1993, BIOCHEM SOC T, V21, P284, DOI 10.1042/bst0210284; ROLDAN ERS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P48, DOI 10.1016/0005-2760(93)90048-E; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; ROLDAN ERS, 1990, SERONO S, P179; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; TESARIK J, 1993, MOL REPROD DEV, V34, P183, DOI 10.1002/mrd.1080340210; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; TURNER KO, 1994, MOL CELL ENDOCRINOL, V101, P221, DOI 10.1016/0303-7207(94)90238-0; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WISTROM CA, 1993, DEV BIOL, V159, P679; Yanagimachi R., 1994, P189; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893	37	284	299	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1578	1581		10.1126/science.7985030	http://dx.doi.org/10.1126/science.7985030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985030				2022-12-01	WOS:A1994PV01500049
J	SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; GEISSERT, D; GONT, LK; DEROBERTIS, EM			XENOPUS CHORDIN - A NOVEL DORSALIZING FACTOR-ACTIVATED BY ORGANIZER-SPECIFIC HOMEOBOX GENES	CELL			English	Article							SPEMANN ORGANIZER; LAEVIS EMBRYOS; MESODERM INDUCTION; INJECTED XWNT-8; BOX GENE; EXPRESSION; AXIS; DOMAIN; HYBRIDIZATION; ECTODERM	A Xenopus gene whose expression can be activated by the organizer-specific homeobox genes goosecoid and Xnot2 was isolated by differential screening. The chordin gene encodes a novel protein of 941 amino acids that has a signal sequence and four Cys-rich domains. The expression of chordin starts in Spemann's organizer subsequent to that of goosecoid, and its induction by activin requires de novo protein synthesis. Microinjection of chordin mRNA induces twinned axes and can completely rescue axial development in ventralized embryos. This molecule is a potent dorsalizing factor that is expressed at the right time and in the right place to regulate cell-cell interactions in the organizing centers of head, trunk, and tail development.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502, R01 HD021502, HD21502-09, R37 HD021502-13] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERHART J, 1991, BOD MAR LAB, P57; GILBERT SF, 1994, DEV BIOL, P597; GONT LK, 1993, DEVELOPMENT, V119, P991; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1991, METHOD CELL BIOL, V36, P62; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; STEWART RM, 1990, DEVELOPMENT, V109, P363; TADANO T, 1993, DEV GENET, V14, P204, DOI 10.1002/dvg.1020140307; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	47	932	976	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 2	1994	79	5					779	790		10.1016/0092-8674(94)90068-X	http://dx.doi.org/10.1016/0092-8674(94)90068-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001117	Green Accepted			2022-12-01	WOS:A1994PW05400006
J	TANIFUJI, M; SUGIYAMA, T; MURASE, K				TANIFUJI, M; SUGIYAMA, T; MURASE, K			HORIZONTAL PROPAGATION OF EXCITATION IN RAT VISUAL CORTICAL SLICES REVEALED BY OPTICAL IMAGING	SCIENCE			English	Article							INTRINSIC CONNECTIONS; ELECTRICAL-ACTIVITY; CORTEX; CAT; PROJECTIONS	Optical imaging with high spatial and temporal resolution of neural activity in rat cortical slices was used to investigate the dynamics of signal transmission through neural connections in the visual cortex. When inhibition due to gamma-aminobutyric acid was slightly suppressed, horizontal propagation of excitation in both the supra- and infragranular layers became prominent. This propagation was not affected by vertical cuts in either the supra- or infragranular layer, which suggests that excitation is at least partially conveyed horizontally by reciprocal vertical connections between neurons in these layers.			TANIFUJI, M (corresponding author), FUKUI UNIV,DEPT INFORMAT SCI,BUNKYO KU,FUKUI 910,JAPAN.		Tanifuji, Manabu/H-1744-2019; Murase, Kazuyuki/O-4881-2014	Tanifuji, Manabu/0000-0001-7754-7774; Murase, Kazuyuki/0000-0002-2358-995X				ALBOWITZ B, 1993, EXP BRAIN RES, V93, P213; BURKHALTER A, 1989, J COMP NEUROL, V279, P171, DOI 10.1002/cne.902790202; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; ICHIKAWA M, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P638; KOMATSU Y, 1988, BRAIN RES, V442, P359, DOI 10.1016/0006-8993(88)91526-0; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; KUROTANI T, 1993, DEV BRAIN RES, V71, P151, DOI 10.1016/0165-3806(93)90168-A; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; SUGITANI M, 1994, NEUROSCI LETT, V171, P175, DOI 10.1016/0304-3940(94)90633-5; SUGITANI M, 1994, NEUROSCI LETT, V165, P215, DOI 10.1016/0304-3940(94)90748-X; TANIFUJI M, 1991, Society for Neuroscience Abstracts, V17, P114; TANIFUJI M, UNPUB; TOYAMA K, 1991, BIOMED RES-TOKYO, V12, P145; NK3630 NIPP KANK SHI	21	136	136	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1057	1059		10.1126/science.7973662	http://dx.doi.org/10.1126/science.7973662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973662				2022-12-01	WOS:A1994PQ92400049
J	DALY, DA				DALY, DA			SPEECH CLUTTERING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALY, DA (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.							DALY D, 1988, FREEDOM FLUENCY; Daly D. A., 1993, STUTTERING RELATED D; DALY DA, 1986, ATYPICAL STUTTERER P; DALY DA, 1992, CLUTTERING CLIN PERS; Weiss D., 1964, CLUTTERING	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					565	565		10.1001/jama.272.7.565	http://dx.doi.org/10.1001/jama.272.7.565			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046816				2022-12-01	WOS:A1994PB22900040
J	GELMAN, B				GELMAN, B			THE LITTLE PICTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					417	417						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040961				2022-12-01	WOS:A1994PA27800001
J	DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G			THE EWING FAMILY OF TUMORS - A SUBGROUP OF SMALL-ROUND-CELL TUMORS DEFINED BY SPECIFIC CHIMERIC TRANSCRIPTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMITIVE NEUROECTODERMAL TUMORS; PERIPHERAL NEUROEPITHELIOMA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOME-TRANSLOCATION; CYTOGENETIC ANALYSIS; GENE FUSION; SARCOMA; BONE; HISTOGENESIS; EXPRESSION	Background. Precise diagnosis of small-round-cell tumors is often a challenge to the pathologist and the clinical oncologist. In Ewing's sarcomas and related peripheral primitive neuroectodermal tumors, a t(11;22) translocation or a (21,22) rearrangement is associated with hybrid transcripts of the EWS gene with the FLI1 or ERG gene. To investigate the diagnostic implication of this observation, we searched for these hybrid transcripts in tumors from patients with clinical and radiologic features of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Methods. Samples of RNA from 114 tumors were reverse transcribed and subjected to the polymerase chain reaction with primers designed to amplify the relevant chimeric transcripts. All amplified products were sequenced. Results. In-frame hybrid transcripts were observed in 89 cases. A hybrid transcript was found in 83 of 87 cases (95 percent) of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Samples of RNA from all of 12 tumors that had been proved to be other than Ewing's sarcoma or neuroectodermal tumors had no hybrid transcript. However, 6 of 15 undifferentiated tumors whose type was ambiguous (nonsecreting, poorly differentiated neuroblastoma or undifferentiated sarcoma) contained a hybrid transcript, suggesting that they might have to be reclassified. Conclusions. A subgroup of small-round-cell tumors identified as belonging to the Ewing family of tumors can be defined according to a specific molecular genetic lesion that is detectable by a rapid, reliable, and efficient method. This approach can be applied to small specimens obtained by fine-needle biopsies.	INST CURIE,GENET TUMEURS LAB,INSERM,CONTRAT JEUNE FORMAT 9201,F-75231 PARIS 05,FRANCE; INST CURIE,SERV ONCOL PEDIAT,PARIS,FRANCE; INST CURIE,SERV ANATOMOPATHOL,PARIS,FRANCE; CHILDRENS HOSP,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90027; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND; CNRS,URA 1462,CYTOGENET CANCEROL LAB,F-06034 NICE,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; INT AGCY RES CANC,F-69372 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Children's Hospital Los Angeles; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Saint Anna Children's Hospital; World Health Organization; International Agency for Research on Cancer (IARC)			zucman-rossi, Jessica/B-5098-2009; Sheer, Denise/C-6705-2011; Ambros, Peter/AAA-1266-2021; j, zucman-rossi/AAV-3594-2021; Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018	zucman-rossi, Jessica/0000-0002-5687-0334; Sheer, Denise/0000-0001-9067-1796; Ambros, Peter/0000-0002-5507-7211; j, zucman-rossi/0000-0002-5687-0334; Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; delattre, olivier/0000-0002-8730-2276	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BARR FG, 1991, GENE CHROMOSOME CANC, V3, P153, DOI 10.1002/gcc.2870030212; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; HAMILTON G, 1988, CANCER RES, V48, P6127; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; KISSANE JM, 1983, HUM PATHOL, V14, P773, DOI 10.1016/S0046-8177(83)80300-1; KOVAR H, 1990, ONCOGENE, V5, P1067; LIPINSKI M, 1987, CANCER RES, V47, P183; NASCIMENTO AG, 1980, AM J SURG PATHOL, V4, P29, DOI 10.1097/00000478-198004010-00003; NOGUERA R, 1992, LAB INVEST, V66, P143; PAPPO AS, 1993, HUM PATHOL, V24, P880, DOI 10.1016/0046-8177(93)90138-7; Sambrook J., 1989, MOL CLONING LAB MANU; TRICHE TJ, 1993, PRINCIPLES PRACTICE, P115; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	29	809	842	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					294	299		10.1056/NEJM199408043310503	http://dx.doi.org/10.1056/NEJM199408043310503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022439				2022-12-01	WOS:A1994NZ22700003
J	COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR				COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR			PRION PROTEIN IS NECESSARY FOR NORMAL SYNAPTIC FUNCTION	NATURE			English	Article							INTRAHIPPOCAMPAL TETANUS TOXIN; LONG-TERM POTENTIATION; RAT; HIPPOCAMPUS; INVITRO; DEPRESSION; INDUCTION; RECEPTOR; DISEASE	THE prion diseases are neurodegenerative conditions, transmissible by inoculation, and in some cases inherited as an autosomal dominant disorder. They include Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. The prion consists principally of a post-translationally modified form of a host-encoded glycoprotein (PrPc), designated PrPSc (ref. 1); the normal cellular function of PrPc is, however, unknown. Although PrP is highly conserved among mammals and widely expressed in early embryogenesis, mice homozygous for disrupted PrP genes appear developmentally and behaviourally normal(2). PrP is a protein anchored to the neuronal surface by glycosylphosphatidylinositol, suggesting a role in cell signalling or adhesion. Here we report that hippocampal slices from PrP null mice have weakened GABA(A) (gamma-aminobutyric acid type A) receptor-mediated fast inhibition and impaired long-term potentiation. This impaired synaptic inhibition may be involved in the epileptiform activity seen in Creutzfeldt-Jakob disease and we argue that loss of function of PrPc may contribute to the early synaptic loss(3) and neuronal degeneration seen in these diseases.	ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT NEUROL,LONDON W2 1NY,ENGLAND; UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND	Imperial College London; Imperial College London; University of Bristol	COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,LONDON W2 1PG,ENGLAND.		Smith, Corinne J/A-3170-2009; Jefferys, John G R/AAF-1164-2021; Jefferys, John/E-6132-2012	Smith, Corinne J/0000-0003-3364-7946; Jefferys, John G R/0000-0003-0106-4412; Jefferys, John/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALLAN RD, 1980, BRIT J PHARMACOL, V70, P609, DOI 10.1111/j.1476-5381.1980.tb09779.x; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRACE HM, 1985, J PHYSIOL-LONDON, V368, P343, DOI 10.1113/jphysiol.1985.sp015861; Brown D A, 1981, Adv Biochem Psychopharmacol, V29, P321; BUELERH, 1992, NATURE, V356, P577; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; EMPSON RM, 1993, J PHYSIOL-LONDON, V465, P595, DOI 10.1113/jphysiol.1993.sp019695; GROVERLM, 1993, J NEUROPHYSIOL, V69, P1541; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; JEFFERYS JGR, 1994, NEUROBIOL DIS, V1, P3; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SMITH TL, 1985, J PHARMACOL EXP THER, V232, P702; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0	23	664	676	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					295	297		10.1038/370295a0	http://dx.doi.org/10.1038/370295a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035877				2022-12-01	WOS:A1994NZ22900064
J	KHOURY, SJ; WEINER, HL				KHOURY, SJ; WEINER, HL			KAPPA-LIGHT-CHAINS IN SPINAL-FLUID FOR DIAGNOSING MULTIPLE-SCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CEREBROSPINAL-FLUID; NEUROLOGICAL DISEASES				KHOURY, SJ (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA, USA.							BOLLENGIER F, 1978, J CLIN CHEM CLIN BIO, V16, P165; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; GALLO P, 1989, J NEUROL SCI, V94, P241, DOI 10.1016/0022-510X(89)90234-7; LAURENZI MA, 1980, ANN NEUROL, V8, P241, DOI 10.1002/ana.410080304; LINK H, 1987, ITAL J NEUROL SCI S, V6, P57; RUDICK RA, 1986, ARCH NEUROL-CHICAGO, V43, P456, DOI 10.1001/archneur.1986.00520050036018; SINDIC CJM, 1991, J NEUROIMMUNOL, V33, P63, DOI 10.1016/0165-5728(91)90035-6; STANESCU GL, 1991, J CLIN LAB ANAL, V5, P206, DOI 10.1002/jcla.1860050310	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					242	243		10.1001/jama.272.3.242	http://dx.doi.org/10.1001/jama.272.3.242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022046				2022-12-01	WOS:A1994NW18500032
J	BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S				BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S			ATTACHMENT OF HELICOBACTER-PYLORI TO HUMAN GASTRIC EPITHELIUM MEDIATED BY BLOOD-GROUP ANTIGENS	SCIENCE			English	Article							GLYCOLIPID RECEPTORS; ULCER DISEASE; BACTERIA; GLYCOSPHINGOLIPIDS	Helicobacter pylori is associated with development of gastritis, gastric ulcers, and adenocarcinomas in humans. The Lewis(b) (Le(b)) blood group antigen mediates H. pylori attachment to human gastric mucosa. Soluble glycoproteins presenting the Le(b) antigen or antibodies to the Le(b) antigen inhibited bacterial binding. Gastric tissue lacking Le(b) expression did not bind H. pylori. Bacteria did not bind to Le(b) antigen substituted with a terminal GalNAcalpha1-3 residue (blood group A determinant), suggesting that the availability of H. pylori receptors might be reduced in individuals of blood group A and B phenotypes, as compared with blood group O individuals.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Sahlgrenska University Hospital; University of Gothenburg; Washington University (WUSTL); Washington University (WUSTL)	BOREN, T (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.		Larson, Göran/AAF-3404-2019	Roth, Kevin/0000-0002-0643-995X	FIC NIH HHS [TW04669-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004669] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BORIELLO S P, 1981, Journal of Antimicrobial Chemotherapy, V7, P53; CLARKE CA, 1955, BRIT MED J, V2, P643, DOI 10.1136/bmj.2.4940.643; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DESCAMPS J, 1968, CR ACAD SCI D NAT, V266, P1775; EVANS DG, 1993, J BACTERIOL, V175, P674, DOI 10.1128/JB.175.3.674-683.1993; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, IN PRESS METHODS ENZ; FAUCHERE JL, 1990, MICROB PATHOGENESIS, V9, P427, DOI 10.1016/0882-4010(90)90061-T; FINNE J, 1989, J BIOL CHEM, V264, P5720; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; LARSON G, 1988, J BIOL CHEM, V263, P10790; MARCUS DM, 1989, HUMAN IMMUNOGENETICS, P685; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SAITOH T, 1991, FEBS LETT, V282, P385, DOI 10.1016/0014-5793(91)80519-9; SAKAMOTO J, 1989, CANCER RES, V49, P745; SHARON N, 1986, LECTINS, P494; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WYATT JI, 1988, J PATHOL, V154, P113, DOI 10.1002/path.1711540203	27	936	979	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1892	1895		10.1126/science.8018146	http://dx.doi.org/10.1126/science.8018146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8018146				2022-12-01	WOS:A1993MM51100042
J	SAUNDERS, NJ				SAUNDERS, NJ			WHY MONITOR PEAK VANCOMYCIN CONCENTRATIONS	LANCET			English	Article							RENAL-FUNCTION; THERAPY	Peak and trough serum concentrations are routinely measured to monitor vancomycin therapy. Optimal therapy depends upon maintaining a concentration above that necessary for antibacterial activity and is therefore determined by the trough concentration. I determined the post dose increases in serum drug concentrations in routine clinical practice in adult patients without renal failure. Mean increases of 16.6 mg/L (SD 6.1) (peak samples collected 1 h post infusion) were measured from 165 paired samples. The results suggest that as long as trough concentrations do not exceed 15 mg/L, peak levels will not exceed normally accepted safe concentrations, and therefore do not need to be measured.			SAUNDERS, NJ (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT INFECT DIS & BACTERIOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		mouton, johan w/C-5915-2014; Saunders, Nigel J/W-6745-2019	mouton, johan w/0000-0001-6736-4149; Saunders, Nigel/0000-0002-0160-4573				ACKERMAN BH, 1992, ANTIMICROB AGENTS CH, V36, P1766, DOI 10.1128/AAC.36.8.1766; CANTU TG, 1994, CLIN INFECT DIS, V18, P533; EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652; ENG RHK, 1989, CHEMOTHERAPY, V35, P320, DOI 10.1159/000238688; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; FREEMAN CD, 1993, ANN PHARMACOTHER, V27, P594; GERACI JE, 1956, P STAFF M MAYO CLIN, V31, P564; GERACI JE, 1958, P STAFF M MAYO CLIN, V33, P172; HOOK EW, 1978, AM J MED, V65, P411, DOI 10.1016/0002-9343(78)90766-0; KIRBY WMM, 1960, NEW ENGL J MED, V262, P49, DOI 10.1056/NEJM196001142620201; MOELLERING RC, 1994, CLIN INFECT DIS, V18, P544, DOI 10.1093/clinids/18.4.544; PEETERMANS WE, 1990, ANTIMICROB AGENTS CH, V34, P1869, DOI 10.1128/AAC.34.10.1869; RODVOLD KA, 1987, CLIN PHARMACY, V6, P655; SORRELL TC, 1982, ANN INTERN MED, V97, P344, DOI 10.7326/0003-4819-97-3-344; TRABER PG, 1981, ANN INTERN MED, V95, P458, DOI 10.7326/0003-4819-95-4-458; VACANI PF, 1993, J CLIN PATHOL, V46, P890, DOI 10.1136/jcp.46.10.890; WAISBREN BA, 1960, ARCH INTERN MED, V106, P179, DOI 10.1001/archinte.1960.03820020019005	17	70	74	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 24	1994	344	8939-4					1748	1750		10.1016/S0140-6736(94)92890-8	http://dx.doi.org/10.1016/S0140-6736(94)92890-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7997005				2022-12-01	WOS:A1994PY28100013
J	STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M				STAEHLINGHAMPTON, K; HOFFMANN, FM; BAYLIES, MK; RUSHTON, E; BATE, M			DPP INDUCES MESODERMAL GENE-EXPRESSION IN DROSOPHILA	NATURE			English	Article							DORSAL VENTRAL AXIS; GERM LAYERS; CELL FATES; ACTIVIN-A; BOX GENES; PATTERN; EMBRYO; INDUCTION; HOMOLOG; MORPHOGENESIS	INDUCTIVE interactions between germ layers are an essential feature of the development of many organisms. In several species these interactions are mediated by members of the transforming growth factor-beta (TGF beta) family(1,2). In amphibians, different concentrations of activin can induce different types of mesoderm in the animal cap assay(3-5). In Drosophila, a member of the TGF beta family, decapentaplegic (dpp)(6,7), acts as an inductive signal. Midway through embryogenesis, dpp is expressed in the visceral mesoderm, and enhances the expression of the homeotic gene labial in the underlying midgut endoderm(8,9). Earlier in development, however, dpp expression is limited to the dorsal ectoderm(10). At this stage in development, thickveins, a dpp receptor(11-13), is expressed in the mesoderm(12,13), and this suggests that ectodermal dpp might not only be required for development of dorsal ectoderm(14,15), but could also act inductively to mediate pattern formation in the underlying mesoderm. Here we show, by expressing dpp ectopically in the ectoderm and mesoderm and by examining dpp null mutant embryos, that dpp regulates expression of mesodermal genes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	STAEHLINGHAMPTON, K (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.			Hoffmann, F. Michael/0000-0002-2770-9656	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BEER J, 1987, ROUX ARCH DEV BIOL, V196, P222, DOI 10.1007/BF00376346; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GOMEZ MR, 1993, EMBO J, V12, P1121; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAY RP, 1991, DEVELOPMENT, V113, P35; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	174	176	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					783	786						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997266				2022-12-01	WOS:A1994PY21200054
J	REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH				REDEKER, V; LEVILLIERS, N; SCHMITTER, JM; LECAER, JP; ROSSIER, J; ADOUTTE, A; BRE, MH			POLYGLYCYLATION OF TUBULIN - A POSTTRANSLATIONAL MODIFICATION IN AXONEMAL MICROTUBULES	SCIENCE			English	Article							ALPHA-TUBULIN; BETA-TUBULIN; TERMINAL DOMAIN; CELLS; PARAMECIUM; BRAIN; DETYROSINATION; NUCLEATION; SUBTILISIN; PROTEINS	A posttranslational modification was detected in the carboxyl-terminal region of axonemal tubulin from Paramecium. Tubulin carboxyl-terminal peptides were isolated and analyzed by Edman degradation sequencing, mass spectrometry, and amino acid analysis. All of the peptides, derived from both alpha and beta tubulin subunits, were modified by polyglycylation, containing up to 34 glycyl units covalently bound to the gamma carboxyl group of glutamyl residues. This modification, present in one of the most stable microtubular systems, may influence microtubule stability or axoneme function, or both.	INST ALFRED FESSARD,CNRS,UNITE PROPRE RECH 2212,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 11,BIOL CELLULAIRE LAB 4,CNRS,URA 1134,F-91405 ORSAY,FRANCE; ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 240,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)			Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388				ADOUTTE A, 1991, BIOL CELL, V71, P227, DOI 10.1016/0248-4900(91)90069-Y; ADOUTTE A, 1980, J CELL BIOL, V84, P717, DOI 10.1083/jcb.84.3.717; ADOUTTE A, 1985, J MOL EVOL, V22, P220, DOI 10.1007/BF02099751; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P327; BULINSKI JC, 1988, J CELL BIOL, V106, P1213, DOI 10.1083/jcb.106.4.1213; CALLEN AM, IN PRESS BIOL CELL; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; Dentler W.L., 1990, P31; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; DUPUIS P, 1992, THESIS U PARIS 11; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FACKENTHAL JD, 1993, DEV BIOL, V158, P213, DOI 10.1006/dbio.1993.1180; Fleury A., UNPUB; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GEUSS U, 1990, Journal of Protein Chemistry, V9, P299; GREER K, 1989, CELL MOVEMENT, V2, P47; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; Johnson Karl A., 1993, Trends in Cell Biology, V3, P156, DOI 10.1016/0962-8924(93)90136-O; KHAWAJA S, 1988, J CELL BIOL, V106, P2167; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEVILLIERS N, UNPUB; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; MATSUBARA H, 1970, METHOD ENZYMOL, V19, P642; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PIPERNO G, 1977, P NATL ACAD SCI USA, V74, P1600, DOI 10.1073/pnas.74.4.1600; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; REDEKER V, 1991, J BIOL CHEM, V266, P23461; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RUDIGER M, 1993, EUR J BIOCHEM, V218, P107, DOI 10.1111/j.1432-1033.1993.tb18357.x; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SACKETT DL, 1989, BIOCHEMISTRY-US, V28, P2662, DOI 10.1021/bi00432a045; SCHULZE E, 1987, J CELL BIOL, V105, P1020; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; WEHLAND J, 1987, J CELL SCI, V88, P185	39	219	228	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1688	1691		10.1126/science.7992051	http://dx.doi.org/10.1126/science.7992051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992051				2022-12-01	WOS:A1994PW30800035
J	BENEDETTI, J; COREY, L; ASHLEY, R				BENEDETTI, J; COREY, L; ASHLEY, R			RECURRENCE RATES IN GENITAL HERPES AFTER SYMPTOMATIC FIRST-EPISODE INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL; SENSORS, ARTIFICIAL; HEART RATE; ARRHYTHMIA	SIMPLEX VIRUS-INFECTION; CANADIAN MULTICENTER TRIAL; ORAL ACYCLOVIR; DOUBLE-BLIND; INTRAVENOUS ACYCLOVIR; TYPE-2 INFECTION; TRANSMISSION; SUPPRESSION; ANTIBODIES; THERAPY	Objective: To evaluate the frequency of reactivation of genital herpes infection and to identify predictors for recurrence. Design: Prospective, observational cohort study. Setting: Research clinic. Patients: 457 consecutive patients who did not have acute-phase serum antibodies to herpes simplex virus type 2 (HSV-2) but who did have herpes simplex vines (HSV) isolated from genital lesions. Results: Eighty-nine percent of patients with HSV-2 had at least one recurrence during follow-up (median, 391 days); the median monthly recurrence rate was 0.34. Thirty-eight percent had at least 6 recurrences during the first year and 20% had more than 10 recurrences. The median monthly recurrence rate was 0.43 for men and 0.33 for women (difference, 0.10 [95% CI, 0.03 to 0.19]; P < 0.01). Twenty-six percent of women and 8% of men had no or 1 recurrence in year 1 of follow-up, whereas 14% of women and 26% of men had more than 10 recurrences. Patients who had severe primary HSV-2 infection (duration, greater than or equal to 35 days) had recurrences nearly twice as often (0.66 compared with 0.36 recurrences per month [95% CI, 0.18 to 0.57]) and had a shorter time to first recurrence when compared with those who had shorter first episodes. Conclusions: Almost all persons with initially symptomatic HSV-2 infection have symptomatic recurrences. More than 35% of such patients have frequent recurrences. Recurrence rates are especially high in persons with an extended first episode of infection, regardless of whether they receive antiviral chemotherapy with acyclovir. Men with genital HSV-2 infection have about 20% more recurrences than do women, a factor that may contribute to the higher rate of HSV-2 transmission from men to women than from women to men and to the continuing epidemic of genital herpes in the United States.	UNIV WASHINGTON, DIV VIROL, SEATTLE, WA 98144 USA	University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30619, AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731, R01AI030619] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1993, SEX TRANSM DIS, V20, P230, DOI 10.1097/00007435-199307000-00009; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; Breimann L, 1984, CLASSIFICATION REGRE; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BURKE RL, 1991, VIROLOGY, V181, P793; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1978, NEW ENGL J MED, V299, P986, DOI 10.1056/NEJM197811022991805; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; COREY L, 1982, NEW ENGL J MED, V306, P1313, DOI 10.1056/NEJM198206033062201; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; JOHNSON R, 1993, US GENITAL HERPES TR; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1984, ANTIMICROB AGENTS CH, V26, P887, DOI 10.1128/AAC.26.6.887; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MINDEL A, 1987, LANCET, V1, P1171; MINDEL A, 1982, LANCET, V1, P697; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; SACKS SL, 1991, J INFECT DIS, V164, P665, DOI 10.1093/infdis/164.4.665; SACKS SL, 1987, J INFECT DIS, V155, P178, DOI 10.1093/infdis/155.2.178; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401	35	305	312	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					847	854		10.7326/0003-4819-121-11-199412010-00004	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978697				2022-12-01	WOS:A1994PT62800004
J	DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD				DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD			THE PUBLIC-HEALTH IMPLICATIONS OF AIDS RESEARCH IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; COTE-DIVOIRE; RISK-FACTORS; CROSS-REACTIVITY; CASE-DEFINITION; IVORY-COAST; TRANSMISSION	The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic has led to greatly increased international collaboration for medical research, mainly epidemiologic in nature, in Africa. Greater understanding of HIV/AIDS has resulted, and considerable training and technology transfer have occurred. However, analytic and descriptive research in countries heavily affected by AIDS has been slow to turn to assessment of interventions, and practical benefits to those countries' public health and policies have lagged behind scientific knowledge. This article considers the public health implications of selected HIV/AIDS research in sub-Saharan Africa and discusses opportunities for interventions and more applied research. Topics covered include HIV testing and its role, surveillance, control of sexually transmitted diseases, the vulnerability of youth and women, tuberculosis, HIV/AIDS care, and the inadequacy of resources currently committed to HIV/AIDS prevention and control in resource-poor countries. Research on HIV/AIDS in Africa has yielded crucial information but now should prioritize interventions and their evaluation. Specific goals that might limit the effects of the HIV/AIDS epidemic in resource-poor countries are achievable given vision, commitment, and resources.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; NATL AIDS CONTROL PROGRAMME,ABIDJAN,COTE IVOIRE; CHU TREICHVILLE,INFECT DIS SERV,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA								ACKAH A, 1993, 9TH INT C AIDS BERL; ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; AIDS S, 1991, PLUM, V5, pS65; AISU T, 1993, 9TH INT C AIDS BERL; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; [Anonymous], 1993, Wkly Epidemiol Rec, V68, P361; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BATTER V, 1993, 9TH INT C AIDS BERL; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BRATTEGAARD K, 1993, AIDS, V7, P883, DOI 10.1097/00002030-199306000-00019; BUEHLER JW, 1993, AIDS, V7, pS73, DOI 10.1097/00002030-199301001-00010; CAMERON D W, 1990, AIDS (London), V4, pS99; CAMERON DW, 1989, LANCET, V2, P403; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P529; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1989, LANCET, V2, P408; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; ECKHOLM E, 1991, NY TIMES        1029, pB6; EVANS LA, 1988, LANCET, V2, P1389; GARNETT GP, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90522-R; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GELBER RD, 1994, EXECUTIVE SUMMARY AC; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GHIJS P, 1993, 9TH INT C AIDS BERL; GRANT J, 1994, STATE WORLDS CHILDRE, P69; GURTLER LG, 1994, J VIROL, V68, P1581; HEYMANN DL, 1990, AIDS, V4, P469, DOI 10.1097/00002030-199005000-00017; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LACKRITZ EM, 1993, 9 INT C AIDS BERL; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1991, AIDS, V5, pS55; LAGA M, IN PRESS AIDS; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MANN J, 1992, AIDS WORLD, P421; MBOUP S, 1991, AIDS, V5, pS93; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; MUREKEZI C, 1993, 9TH INT C AIDS BERL; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MWINGA AG, 1993, TUBERCULOSIS BACK FU, P166; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PIOT P, 1991, AIDS, V5, pS1; PIOT P, 1990, HDB AIDS PREVENTION, P1; PLUMMER FA, 1991, AIDS, V5, pS169; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RICHARDS S, IN PRESS TUBER LUNG; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SCHULZER M, 1992, TUBERCLE LUNG DIS, V73, P52, DOI 10.1016/0962-8479(92)90080-4; SCHUTZ R, 1993, BRIT MED J, V307, P1517, DOI 10.1136/bmj.307.6918.1517; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO HT, 1990, SCIENCE, V250, P609, DOI 10.1126/science.250.4981.609; SPIELBERG F, 1989, LANCET, V1, P580; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TEDDER RS, 1988, LANCET, V2, P927; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TRAOREETTIEGNE V, 1993, 9 INT C AIDS BERL; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; 1993, 1993 WORLD BANK WORL, P103; 1993, HIV AIDS SURVEILLANC; 1986, WKLY EPIDEMIOL REC, V61, P72; 1993, INVESTING HLTH WORLD, P37; 1993, INVESTING HLTH WORLD, P99; 1994, WKLY EPIDEMIOL REC, V69, P5; 1992, MMWR-MORBID MORTAL W, V41, P1	90	29	29	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					481	486		10.1001/jama.272.6.481	http://dx.doi.org/10.1001/jama.272.6.481			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040984				2022-12-01	WOS:A1994PA27800031
J	ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J				ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J			LIMITED EFFECTS OF HIV COUNSELING AND TESTING FOR WOMEN - A PROSPECTIVE-STUDY OF BEHAVIORAL AND PSYCHOLOGICAL CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To assess the consequences of human immunodeficiency virus (HIV) counseling and testing for seronegative women in terms of sexual behavior and psychological outcomes. Design.-The design is prospective and longitudinal, using repeated measures. Participants were interviewed at recruitment, 2 weeks later (when tested women received results), and 3 months later. Setting.-Four community health clinics in southern Connecticut; all provide HIV counseling and testing and other specialized and primary health care services. Study Participants.-A sequential sample of women were recruited for two study groups: those seeking HIV counseling and testing (n=152), and a comparison group never tested for HIV (n=78), matched by clinic, race, and age. Main Outcome Measures.-A composite measure of sexual risk was developed, based on sexual activity, condom use, and partner risk factors. Psychometrically valid and reliable measures of general psychological functioning and acquired immunodeficiency syndrome (AIDS)-specific psychological indicators were also used. Results.-Average level of sexual risk was lower for tested than nontested women at all three interviews. For both groups, there was no significant change in sexual risk from baseline to 3-month follow-up. At the individual level, there was no difference in the number of women who decreased or increased sexual risk. For tested women, intrusive thoughts about AIDS and estimated chance of getting AIDS decreased after counseling and testing. Conclusions.-Behavioral and psychological consequences of HIV counseling and testing for women at risk for HIV were limited. These results have implications for further prevention interventions.	YALE UNIV, DEPT PSYCHOL, NEW HAVEN, CT 06520 USA	Yale University	ICKOVICS, JR (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, POB 208025, SHM IE-61 RWJ CLIN SCHOLARS, NEW HAVEN, CT 06520 USA.							ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; ANTONI MH, 1990, PSYCHOSOM MED, V52, P496, DOI 10.1097/00006842-199009000-00002; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; COATES TJ, 1987, JAMA-J AM MED ASSOC, V258, P1889, DOI 10.1001/jama.1987.03400140051006; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Crandall R., 1973, MEASURES SOCIAL PSYC, P45; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; DOLL LS, 1990, HEALTH PSYCHOL, V9, P253, DOI 10.1037/0278-6133.9.3.253; FOX R, 1987, AIDS, V1, P241; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; ICKOVICS JR, 1992, HEALTH PSYCHOL, V11, P1, DOI 10.1037/0278-6133.11.1.1; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; JOSEPH JG, 1987, J APPL SOC PSYCHOL, V17, P231, DOI 10.1111/j.1559-1816.1987.tb00312.x; KELLY JA, 1990, J CONSULT CLIN PSYCH, V58, P117, DOI 10.1037/0022-006X.58.1.117; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; PERRY SW, 1990, AIDS, V4, P145, DOI 10.1097/00002030-199002000-00008; RODIN J, 1989, ANNU REV PSYCHOL, V40, P533, DOI 10.1146/annurev.ps.40.020189.002533; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; Siegel S., 1956, NONPARAMETRIC STAT B; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WIKTOR SZ, 1990, J ACQ IMMUN DEF SYND, V3, P62; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395; 1992, MMWR-MORBID MORTAL W, V41, P613; 1993, HIV AIDS SURVEILLANC; 1988, 1988 PRES COMM HUM I	35	64	64	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					443	448		10.1001/jama.272.6.443	http://dx.doi.org/10.1001/jama.272.6.443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040979				2022-12-01	WOS:A1994PA27800025
J	OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P				OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P			ACTIVE ANAPHYLAXIS IN IGE-DEFICIENT MICE	NATURE			English	Article							PERTUSSIGEN PERTUSSIS TOXIN; IMMUNOGLOBULIN HEAVY-CHAIN; MAST-CELLS; CUTANEOUS ANAPHYLAXIS; HISTAMINE-RELEASE; MOUSE; LYMPHOCYTES; LETHALITY; MUTATION; ANTIGEN	The IgE-triggered release of mast cell mediators in response to antigen is thought to be the primary event in immediate hypersensitivity reactions such as systemic anaphylaxis(1). Although mast cells and basophils can be activated in vitro by non-IgE stimuli(2-5), it is not known whether these triggers lead to physiological changes in vivo. To investigate this possibility, we generated mice with a homozygous null mutation of the CE gene. Such mice make no IgE, but produce other immunoglobulin isotypes normally. We report that despite the IgE deficiency, sensitized mutant mice become anaphylactic on antigen challenge and display tachycardia and pulmonary function changes similar to those seen in wildtype animals. These responses are accompanied by vascular leak, sharply elevated plasma histamine and rapid death. IgE-independent anaphylaxis does not depend on complement activation, but, as indicated in studies using genetically immunodeficient RAG-2(-) and SCID mice, does require a functional immune system. Such results clearly demonstrate that non-IgE pathways for hypersensitivity reactions exist in mice.	CHILDRENS HOSP,DEPT PEDIAT,INA SUE PERLMUTTER LAB,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	OETTGEN, HC (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.		Drazen, Jeffrey M/E-5841-2012; deng, chuxia/N-6713-2016	Drazen, Jeffrey/0000-0003-2715-9890				ARIMURA A, 1990, IMMUNOL INVEST, V19, P227, DOI 10.3109/08820139009041837; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLAUSEN C R, 1970, Journal of Immunology, V104, P312; DAERON M, 1982, CELL IMMUNOL, V70, P27, DOI 10.1016/0008-8749(82)90130-7; DOMBROWICZ D, 1993, CELL, V75, P979; FOX PC, 1982, J IMMUNOL, V129, P314; HOOK WA, 1975, J IMMUNOL, V114, P1185; INAGAKI N, 1992, JPN J PHARMACOL, V59, P201, DOI 10.1254/jjp.59.201; KATZ HR, 1992, J IMMUNOL, V148, P868; KLERX JPAM, 1983, J IMMUNOL METHODS, V63, P215, DOI 10.1016/0022-1759(83)90425-8; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN TR, 1993, J IMMUNOL, V151, P367; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; MUNOZ JJ, 1987, INFECT IMMUN, V55, P1004, DOI 10.1128/IAI.55.4.1004-1008.1987; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Rothman P, 1989, Semin Immunol, V1, P65; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHIMIZU A, 1981, NATURE, V289, P149, DOI 10.1038/289149a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVERS WS, 1992, ANN ALLERGY, V68, P58; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUN SJ, 1992, J LAB CLIN MED, V120, P589; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBERG CW, 1991, J IMMUNOL METHODS, V136, P287, DOI 10.1016/0022-1759(91)90015-8; VAZ E M, 1970, International Archives of Allergy and Applied Immunology, V39, P459	30	337	348	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					367	370		10.1038/370367a0	http://dx.doi.org/10.1038/370367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047141				2022-12-01	WOS:A1994PA30400054
J	STEMMER, WPC				STEMMER, WPC			RAPID EVOLUTION OF A PROTEIN IN-VITRO BY DNA SHUFFLING	NATURE			English	Article							SEARCHING SEQUENCE SPACE; SPECTRUM BETA-LACTAMASES; MOLECULAR EVOLUTION; ENSEMBLE MUTAGENESIS	DNA shuffling is a method for in vitro homologous recombination of pools of selected mutant genes by random fragmentation and polymerase chain reaction (PCR) reassembly(1). Computer simulations called genetic algorithms(2-4) have demonstrated the importance of iterative homologous recombination for sequence evolution. Oligonucleotide cassette mutagenesis(5-11) and error-prone PCR are not combinatorial and thus are limited in searching sequence space(1,14). We have tested mutagenic DNA shuffling for molecular evolution(14-18) in a beta-lactamase model system(9,19). Three cycles of shuffling and two cycles of backcrossing with wild-type DNA, to eliminate non-essential mutations, were each followed by selection on increasing concentrations of the antibiotic cefotaxime. We report here that selected mutants had a minimum inhibitory concentration of 640 mu g ml(-1), a 32,000-fold increase and 64-fold greater than any published TEM-1 derived enzyme. Cassette mutagenesis and error-prone PCR resulted in only a 16-fold increase(9).			STEMMER, WPC (corresponding author), AFFYMAX RES INST,4001 MIRANDA AVE,PALO ALTO,CA 94304, USA.		Wood, David W/B-2992-2012					AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; ARKIN AP, 1992, P NATL ACAD SCI USA, V89, P7811, DOI 10.1073/pnas.89.16.7811; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DELAGRAVE S, 1993, BIO-TECHNOL, V11, P1548, DOI 10.1038/nbt1293-1548; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HOLLAND JH, 1992, SCI AM, V267, P66, DOI 10.1038/scientificamerican0792-66; HOLLAND JH, 1992, ADAPTATION NATURAL A; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kauffman S.A., 1993, ORIGINS ORDER; KAUFFMAN SA, 1992, J THEOR BIOL, V157, P1, DOI 10.1016/S0022-5193(05)80753-2; Leung DW, 1989, TECHNIQUE, V1, P11; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PALZKILL T, 1992, J BACTERIOL, V174, P5237, DOI 10.1128/JB.174.16.5237-5243.1992; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; STEMMER WPC, IN PRESS P NATN ACAD; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; [No title captured]	22	1454	2412	15	353	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					389	391		10.1038/370389a0	http://dx.doi.org/10.1038/370389a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047147				2022-12-01	WOS:A1994PA30400061
J	DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A				DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A			INTERACTION OF RAC WITH P67(PHOX) AND REGULATION OF PHAGOCYTIC NADPH OXIDASE ACTIVITY	SCIENCE			English	Article							GTP-BINDING-PROTEIN; CELL-FREE SYSTEM; RESPIRATORY BURST; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; COMPONENTS; RHO; CYTOCHROME-B558; TRANSLOCATION	Rho and Rac, two members of the Ras superfamily of guanosine triphosphate (GIP)-binding proteins, regulate a variety of signal transduction pathways in eukaryotic cells. Upon stimulation of phagocytic cells, Rac enhances the activity of the enzyme nicotinamide adenine dinucleotide phosphate (reduced) (NADPH) oxidase, resulting in the production of superoxide radicals. Activation of the NADPH oxidase requires the assembly of a multimolecular complex at the plasma membrane consisting of two integral membrane proteins, gp91(phox) and p2l(phox), and two cytosolic proteins, p67(phox) and p47(phox). Rac1 interacted directly with p67(phox) in GTP-dependent manner. Modified forms of Rac with mutations in the effector site did not stimulate oxidase activity or bind to p67(phox). Thus, p67(phox) appears to be the Rac effector protein in the NADPH oxidase complex.	UCL, CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP, MRC,MOLEC & CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; UCL, DEPT MED, LONDON WC1E 6JJ, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London				Tapon, Dagmar/0000-0003-3837-4764; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1986, J BIOL CHEM, V261, P963; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MORII N, 1992, J BIOL CHEM, V267, P20921; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SELF AJ, 1993, ONCOGENE, V8, P655; SELF AJ, UNPUB; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	32	352	361	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					531	533		10.1126/science.8036496	http://dx.doi.org/10.1126/science.8036496			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036496				2022-12-01	WOS:A1994NY21600032
J	CHOI, KW; BENZER, S				CHOI, KW; BENZER, S			ROTATION OF PHOTORECEPTOR CLUSTERS IN THE DEVELOPING DROSOPHILA EYE REQUIRES THE NEMO GENE	CELL			English	Article							PROTEIN-KINASE; IMAGINAL DISKS; NEURAL DEVELOPMENT; PATTERN-FORMATION; SCATTER FACTOR; CELL-DIVISION; RECEPTOR; TYROSINE; RETINA; PHOSPHORYLATION	The Drosophila eye consists of a reiterative hexagonal array of photoreceptor cell clusters, the ommatidia. During normal morphogenesis, the clusters in the dorsal or ventral halves of the disc rotate 90 degrees in opposite directions, forming mirror images across a dorsoventral equator. In the mutant nemo (nmo), there is an initial turning of approximately 45 degrees, but further rotation is blocked. Genetic mosaic analysis indicates that the nmo gene acts upon each cluster as a whole; normal nmo function in one or more photoreceptor cells appears to be sufficient to induce full rotation. The nmo gene sequence encodes a serine/threonine protein kinase homolog, suggesting that the kinase is required to initiate the second step of rotation. In another mutant, roulette, excessive rotation through varying angles occurs in many ommatidia. This defect is suppressed by nmo, indicating that nmo acts upstream in a rotation-regulating pathway.			CHOI, KW (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	NEI NIH HHS [EY0 9278] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABBOTT MK, 1991, GENETICS, V129, P783; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1992, J NEUROGENET, V8, P85, DOI 10.3109/01677069209084154; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DEUCHAR EM, 1971, J EMBRYOL EXP MORPH, V25, P189; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; ENGELS WR, 1986, FOCUS, V8, P6; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FRISTROM D, 1976, DEV BIOL, V54, P163, DOI 10.1016/0012-1606(76)90296-7; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gleichauf R, 1936, Z WISS ZOOL ABT A, V148, P1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HAMILTON L, 1969, J EMBRYOL EXP MORPH, V22, P253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIME G, 1992, DEVELOPMENT, V114, P165; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J., 1989, MOL CLONING LAB MANU; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITE K, 1978, DEV BIOL, V65, P298; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	53	156	158	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					125	136		10.1016/0092-8674(94)90579-7	http://dx.doi.org/10.1016/0092-8674(94)90579-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033204				2022-12-01	WOS:A1994NX32800015
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING AND WITHDRAWING LIFE-SUSTAINING TREATMENT FROM ELDERLY PEOPLE - TOWARDS FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							ETHICS	Clinicians often decide either to withhold or to withdraw lifesaving treatment in elderly patients. Considerable disagreement exists about the circumstances in which such actions can be defended. Debates about the scarcity of resources in the NHS add urgency to the need to resolve this disagreement. Competent elderly patients have a legal and moral right to decide whether to receive life sustaining treatment. Such treatment should not be withheld or withdrawn on the basis of a patient's age alone. Principles for making decisions about Life sustaining treatment in incompetent elderly patients can be defended and should exist as written guidelines.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEP HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), LONDON MED COLL,DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							[Anonymous], 1993, LANCET, V342, P1; ASPLUND K, 1989, STROKE, V20, P1107, DOI 10.1161/01.STR.20.8.1107; Buchanan AE., 1989, DECIDING OTHERS ETHI; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; DOYAL L, 1994, ARCH DIS CHILD, V70, P66; Doyal L., 1991, THEORY HUMAN NEED, DOI DOI 10.1007/978-1-349-21500-3; Dworkin R., 1993, LIFES DOMINION; EVANS JG, 1989, AGE AGEING, V18, P217, DOI 10.1093/ageing/18.4.217; FRASER M, 1987, DEMENTIA ITS NATURE; Harris J, 1985, VALUE LIFE; Parfit Derek., 1984, REASONS PERSONS; RACHELS J., 1986, END LIFE EUTHANASIA; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Wicclair M., 1993, ETHICS ELDERLY; WILLIAMS F, 1993, BRIT J HOSP MED, V50, P50; 1994, ENSURING EQUITY QUAL; 1994, REPORT; 1988, LIVING WILL CONSENT; 1994, BUTTERWORTHS MEDICOL, V15, P77	20	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1689	1692		10.1136/bmj.308.6945.1689	http://dx.doi.org/10.1136/bmj.308.6945.1689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025466	Green Published			2022-12-01	WOS:A1994NU48300031
J	ANDERSON, HR; BUTLAND, BK; STRACHAN, DP				ANDERSON, HR; BUTLAND, BK; STRACHAN, DP			TRENDS IN PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDREN; HEALTH	Objective-To test the null hypothesis that there has been no change in the prevalence or severity of childhood asthma over recent years. Design-Repeated population prevalence survey with questionnaires completed by parents followed by home interviews with parents. Setting-London borough of Croydon, 1978 and 1991. Subjects-All children in one year of state and private primary schools aged 71/2 to 81/2 years at screening survey. Main outcome measures-Trends in symptoms, acute severe attacks, and chronic disability. Results-For 1978 and 1991 respectively, the response rates were 4147/4763 and 3070/3786, and home interviews were obtained from 273/288 and 319/395 parents of currently wheezy children. Between 1978 and 1991 there were significant relative increases in prevalence ratios in the 12 month prevalence of attacks of wheezing or asthma (1.16; 95% confidence interval 1.02 to 1.31), the one month prevalence of wheezing episodes (1.78; 1.15 to 2.74), and the one month prevalence of night waking (1.81; 1.01 to 3.23) but not in frequent (greater than or equal to 5) attacks over the past year (1.05; 0.79 to 1.40). There were substantial and significant decreases in the 12 month prevalence of absence from school of more than 10 days due to wheezing (0.52; 0.30 to 0.90), any days in bed (0.67; 0.93 to 1.01), and restriction of activities at home (0.51; 0.31 to 0.83) and an equivalent but not significant fall in speech limiting attacks (0.51; 0.24 to 1.11). Conclusion-The small increase in the prevalence of wheezy children and relatively greater increase in persistent wheezing suggests a change in the environmental determinants of asthma. In contrast and paradoxically the frequency of wheezing attacks remains unchanged and there are indications that severe attacks and chronic disability have fallen by about half; this may be due to an improvement in treatment received by wheezy children.			ANDERSON, HR (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1983, J EPIDEMIOL COMMUN H, V37, P180, DOI 10.1136/jech.37.3.180; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ANDERSON HR, 1993, PAEDIATRIC RESPIRATO, V1, P6; ANDERSON HR, 1993, THORAX, V48, P451; AYRES JG, 1993, BRIT J GEN PRACT, V43, P361; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; STRACHAN DP, 1992, BRIT MED J, V304, P873; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; 1989, SAS STAT USERS GUIDE, V2, P846	16	196	199	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1600	1604		10.1136/bmj.308.6944.1600	http://dx.doi.org/10.1136/bmj.308.6944.1600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025426	Green Published			2022-12-01	WOS:A1994NT52800017
J	SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR				SAWADA, S; SCARBOROUGH, JD; KILLEEN, N; LITTMAN, DR			A LINEAGE-SPECIFIC TRANSCRIPTIONAL SILENCER REGULATES CD4 GENE-EXPRESSION DURING T-LYMPHOCYTE DEVELOPMENT	CELL			English	Article							CELL-SPECIFIC ENHANCER; TRANSGENIC MICE; EUKARYOTIC PROMOTERS; HOMEODOMAIN PROTEIN; NEGATIVE REGULATION; DROSOPHILA; REPRESSION; YEAST; ELEMENTS; IDENTIFICATION	During development of T lymphocytes, differential regulation of expression of the CD4 and CD8 glycoproteins is coupled to the choice of one of two pathways of differentiation. Thymocytes that express both of these coreceptors commit to either the helper lineage, shutting off CD8, or the cytotoxic lineage, shutting off CD4. We have used transgenic mice to identify an intronic regulatory region that controls CD4 gene expression during development. This region selectively extinguishes transgene expression in CD4(-)CD8(+), but not CD4(+)CD8(-) nor CD4(+)CD8(+) T cells. It also represses gene expression in CD4-CD8- immature thymocytes, indicating that the CD4 gene is derepressed during differentiation from the CD4(-)CD8(-) to the CD4(+)CD8(+) stage. The negative element(s) is both orientation and position independent and acts also on heterologous regulatory sequences. Its properties are functionally similar to those of silencers described in yeast and in Drosophila, suggesting that we have identified a developmentally regulated vertebrate transcriptional silencer.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SAWADA, S (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.							BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FRELS W I, 1990, New Biologist, V2, P1024; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOGAN B, 1986, MANIPULATING MOUSE E, P153; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, 1993, PHILOS T ROY SOC B, V342, P25, DOI 10.1098/rstb.1993.0131; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; RAICH N, 1992, BLOOD, V79, P861; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SANDS JF, 1992, INT IMMUNOL, V4, P1183, DOI 10.1093/intimm/4.10.1183; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SAYRE PH, 1987, P NATL ACAD SCI USA, V84, P2941, DOI 10.1073/pnas.84.9.2941; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	54	360	368	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					917	929		10.1016/0092-8674(94)90140-6	http://dx.doi.org/10.1016/0092-8674(94)90140-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004678				2022-12-01	WOS:A1994NT33100016
J	PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP				PLATT, OS; BRAMBILLA, DJ; ROSSE, WF; MILNER, PF; CASTRO, O; STEINBERG, MH; KLUG, PP			MORTALITY IN SICKLE-CELL DISEASE - LIFE EXPECTANCY AND RISK-FACTORS FOR EARLY DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GLOBIN GENE; FAT-EMBOLISM; PAIN CRISIS; CHILDREN; THALASSEMIA; ANEMIA	Background. Information on life expectancy and risk factors for early death among patients with sickle cell disease (sickle cell anemia, sickle cell-hemoglobin C disease, and the sickle cell-P-thalassemias) is needed to counsel patients, target therapy, and design clinical trials. Methods. We followed 3764 patients who ranged from birth to 66 years of age at enrollment to determine the life expectancy and calculate the median age at death. In addition, we investigated the circumstances of death for all 209 adult patients who died during the study, and used proportional-hazards regression analysis to identify risk factors for early death among 964 adults with sickle cell anemia who were followed for at least two years. Results. Among children and adults with sickle cell anemia (homozygous for sickle hemoglobin), the median age at death was 42 years for males and 48 years for females. Among those with sickle cell-hemoglobin C disease, the median age at death was 60 years for males and 68 years for females. Among adults with sickle cell disease, 18 percent of the deaths occurred in patients with overt organ failure, predominantly renal. Thirty-three percent were clinically free of organ failure but died during an acute sickle crisis (78 percent had pain, the chest syndrome, or both; 22 percent had stroke). Modeling revealed that in patients with sickle cell anemia, the acute chest syndrome, renal failure, seizures, a base-line white-cell count above 15,000 cells per cubic millimeter, and a low level of fetal hemoglobin were associated with an increased risk of early death. Conclusions. Fifty percent of patients with sickle cell anemia survived beyond the fifth decade. A large proportion of those who died had no overt chronic organ failure but died during an acute episode of pain, chest syndrome, or stroke. Early mortality was highest among patients whose disease was symptomatic. A high level of fetal hemoglobin predicted improved survival and is probably a reliable childhood forecaster of adult life expectancy.	CHILDRENS HOSP,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; NEW ENGLAND RES INST,WATERTOWN,MA; DUKE UNIV,SCH MED,DEPT MED,DURHAM,NC 27706; MED COLL GEORGIA,DEPT MED,AUGUSTA,GA 30912; HOWARD UNIV,CTR SICKLE CELL DIS,DEPT MED,WASHINGTON,DC; DEPT VET AFFAIRS MED CTR,HEMATOL ONCOL SECT,JACKSON,MS; UNIV MISSISSIPPI,SCH MED,DEPT MED,JACKSON,MS; TEXAS TECH UNIV,HLTH SCI CTR,DIV HEMATOL,AMARILLO,TX	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; HealthCore, Inc; Duke University; University System of Georgia; Augusta University; Howard University; University of Mississippi; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo				Steinberg, Martin/0000-0001-8800-8020; Brambilla, Donald/0000-0002-7276-4689				CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; DACIE J, 1960, HAEMOLYTIC ANAEMIA 1; DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; Diggs LMAH., 1973, SICKLE CELL DIS DIAG; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; DOZY AM, 1979, NATURE, V280, P605, DOI 10.1038/280605a0; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; HAUPT HM, 1982, CHEST, V81, P332, DOI 10.1378/chest.81.3.332; HUTCHINSON RM, 1973, J CLIN PATHOL, V26, P620, DOI 10.1136/jcp.26.8.620; LEIKIN SL, 1989, PEDIATRICS, V84, P500; ODENHEIMER DJ, 1984, AM J MED GENET, V18, P461, DOI 10.1002/ajmg.1320180316; PARFREY NA, 1985, AM J CLIN PATHOL, V84, P209, DOI 10.1093/ajcp/84.2.209; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POWARS D, 1990, SEMIN HEMATOL, V27, P360; SHAPIRO MP, 1984, ARCH INTERN MED, V144, P181, DOI 10.1001/archinte.144.1.181; STEINBERG MH, 1984, BLOOD, V63, P1353; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; 1988, DHHS PHS881101 PUBL	21	2184	2244	4	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	1994	330	23					1639	1644		10.1056/NEJM199406093302303	http://dx.doi.org/10.1056/NEJM199406093302303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP220	7993409				2022-12-01	WOS:A1994NP22000003
J	BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M				BAYNASH, AG; HOSODA, K; GIAID, A; RICHARDSON, JA; EMOTO, N; HAMMER, RE; YANAGISAWA, M			INTERACTION OF ENDOTHELIN-3 WITH ENDOTHELIN-B RECEPTOR IS ESSENTIAL FOR DEVELOPMENT OF EPIDERMAL MELANOCYTES AND ENTERIC NEURONS	CELL			English	Article							PROTEIN-KINASE-C; PROCESSING ENDOPROTEASES; SUBTILISIN FAMILY; NEURAL CREST; CLONING; CDNA; GENE; MICE; EXPRESSION; CELLS	Defects in the gene encoding the endothelin-B receptor produce aganglionic megacolon and pigmentary disorders in mice and humans. We report that a targeted disruption of the mouse endothelin-3 ligand (EDN3) gene produces a similar recessive phenotype of megacolon and coat color spotting. A natural recessive mutation that results in the same developmental defects in mice, lethal spotting (Is), failed to complement the targeted EDN3 allele. The Is mice carry a point mutation of the EDN3 gene, which replaces the Arg residue at the C-terminus of the inactive intermediate big EDN3 with a Trp residue. This mutation prevents the proteolytic activation of big EDN3 by ECE-1. These findings indicate that interaction of EDN3 with the endothelin-B receptor is essential in the development of neural crest-derived cell lineages. We postulate that defects in the human EDN3 gene may cause Hirschsprung's disease.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL,PQ H3G 1A4,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	BAYNASH, AG (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Emoto, Noriaki/0000-0001-6673-2616				ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DOUGLAS SA, 1994, TRENDS PHARMACOL SCI, V15, P313, DOI 10.1016/0165-6147(94)90019-1; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FABBRINI MS, 1993, P NATL ACAD SCI USA, V90, P3923, DOI 10.1073/pnas.90.9.3923; Hosoda K, 1994, CELL, V79; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KOSAKA T, 1994, J BIOCHEM-TOKYO, V116, P443, DOI 10.1093/oxfordjournals.jbchem.a124544; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Lyon MF, 1989, GENETIC VARIANTS STR; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MAYER TC, 1977, DEV BIOL, V56, P255, DOI 10.1016/0012-1606(77)90268-8; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; PUFFENBERGER EG, 1994, CELL, V79; RANDALL MD, 1994, LANCET, V344, P832, DOI 10.1016/S0140-6736(94)92819-3; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROTHMAN TP, 1993, DEV BIOL, V159, P559, DOI 10.1006/dbio.1993.1264; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHIBA R, 1992, BIOCHEM BIOPH RES CO, V186, P588, DOI 10.1016/S0006-291X(05)80849-6; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; STEINER DF, 1992, J BIOL CHEM, V267, P23435; SUZUKI N, 1990, BIOCHEM BIOPH RES CO, V169, P809, DOI 10.1016/0006-291X(90)90403-A; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	43	723	744	1	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1277	1285		10.1016/0092-8674(94)90018-3	http://dx.doi.org/10.1016/0092-8674(94)90018-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001160				2022-12-01	WOS:A1994PZ86000018
J	FAN, CM; TESSIERLAVIGNE, M				FAN, CM; TESSIERLAVIGNE, M			PATTERNING OF MAMMALIAN SOMITES BY SURFACE ECTODERM AND NOTOCHORD - EVIDENCE FOR SCLEROTOME INDUCTION BY A HEDGEHOG HOMOLOG	CELL			English	Article							FLOOR PLATE; CELL-DIFFERENTIATION; NEURAL-TUBE; GENE; MOUSE; SEGMENTATION; MORPHOGENESIS; SPECIFICATION; NEUROGENESIS; EXPRESSION	An early step in the development of vertebrae, ribs, muscle, and dermis is the differentiation of the semitic mesoderm into dermomyotome dorsally and sclerotome ventrally. To analyze this process, we have developed an in vitro assay for semitic mesoderm differentiation. We show that sclerotomal markers can be induced by a diffusible factor secreted by notochord and floor plate and that heterologous cells expressing Sonic hedgehog (shh/vhh-1) mimic this effect. In contrast, expression of dermomyotomal markers can be caused by a contact-dependent signal from surface ectoderm and a diffusible signal from dorsal neural tube. Our results extend previous studies by suggesting that dorsoventral patterning of somites involves the coordinate action of multiple dorsalizing and ventralizing signals and that a diffusible form of Shh/Vhh-1 mediates sclerotome induction.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							AOYAMA H, 1988, DEVELOPMENT, V104, P15; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1974, Verhandlungen der Anatomischen Gesellschaft, V68, P573; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Gallera J., 1966, Revue Suisse de Zoologie, V73, P492; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOHNSON RL, 1994, CELL, V79; JONES CM, 1991, DEVELOPMENT, V111, P531; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOURY JD, 1989, DEV BIOL, V141, P243; OFARRELL F, 1994, NATURE, V368, P188; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; PARR BA, 1993, DEVELOPMENT, V119, P247; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDDLE RD, 1993, CELL, V75, P1501; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RONG PM, 1992, DEVELOPMENT, V115, P657; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STERN CD, 1988, DEVELOPMENT, V104, P231; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; TESSIERLAVIGNE M, 1987, NATURE, V336, P775; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	49	507	542	0	19	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1175	1186		10.1016/0092-8674(94)90009-4	http://dx.doi.org/10.1016/0092-8674(94)90009-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001153				2022-12-01	WOS:A1994PZ86000009
J	MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP				MUSCATELLI, F; STROM, TM; WALKER, AP; ZANARIA, E; RECAN, D; MEINDL, A; BARDONI, B; GUIOLI, S; ZEHETNER, G; RABL, W; SCHWARZ, HP; KAPLAN, JC; CAMERINO, G; MEITINGER, T; MONACO, AP			MUTATIONS IN THE DAX-1 GENE GIVE RISE TO BOTH X-LINKED ADRENAL HYPOPLASIA CONGENITA AND HYPOGONADOTROPIC HYPOGONADISM	NATURE			English	Article							GLYCEROL KINASE-DEFICIENCY; RESTRICTION MAP; INDUCE PUBERTY; HEMOPHILIA-A; XP21; DELETION; FAILURE; CLONING; DISTAL; CONTIG	ADRENAL hypoplasia congenita (AHC) is an X-linked disorder characterized by primary adrenal insufficiency(1,2). Hypogonadotropic hypogonadism (HHG) is frequently associated with this disorder but is thought not to be caused by the low adrenal androgen levels due to adrenal hypoplasia(3,4). It is uncertain whether there are two distinct yet physically linked genes responsible for AHC and HHG or a single gene responsible for both diseases. AHC can occur as a part of a contiguous deletion syndrome together with Duchenne muscular dystrophy (DMD) and/or glycerol kinase deficiency (GKD). From the analysis of deletions, the following gene order has been deduced: Xpter-AHC-GKD-DMD-cen(5,6). An AHC critical region of 200-500 kilobases has been defined by physical mapping(7,8) and partially overlaps with a 160-kilobase dosage-sensitive sex (DSS) reversal critical region(9). The DAX-1 (DSS-AHC critical region on the X, gene 1) gene was isolated and found to encode a new member of the nuclear hormone receptor family(10). Here we report that DAX-1 is deleted in 14 patients and point mutations were found in the coding region in DNA from 12 unrelated individuals. All AHC patients over 14 years old and with only point mutations in DAX-1 mere also diagnosed with HHG, confirming that the DAX-1 gene is responsible for both X-linked AHC and HHG. But in four sporadic cases and a single familial case, no point mutations were found, suggesting genetic heterogeneity or differential expression of DAX-1.	UNIV MUNICH,KINDERPOLIKLIN,PADIAT GENET ABT,D-80336 MUNICH,GERMANY; UNIV PAVIA,I-27100 PAVIA,ITALY; HOP COCHIN,F-75014 PARIS,FRANCE; ICRF LABS,LONDON WC2A 3PX,ENGLAND; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHES KINDERSPITAL,D-80337 MUNICH,GERMANY	University of Munich; University of Pavia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Technical University of Munich; University of Munich	MUSCATELLI, F (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.		Bardoni, Barbara/F-9918-2013; Muscatelli, Françoise/P-4650-2016; Monaco, Anthony P/A-4495-2010; Walker, Ann P/C-1628-2008	Muscatelli, Françoise/0000-0003-4001-6528; Monaco, Anthony P/0000-0001-7480-3197; Guioli, Silvana/0000-0002-4920-7745; Bardoni, Barbara/0000-0001-6411-1517; Meitinger, Thomas/0000-0002-8838-8403	Telethon [B.05] Funding Source: Medline	Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; CHELLY J, 1988, HUM GENET, V78, P222, DOI 10.1007/BF00291665; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; COHEN HN, 1982, LANCET, V2, P1471; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; FRANCKE U, 1987, AM J HUM GENET, V40, P212; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; Kelch RP, 1984, PEDIATR ADOLESC ENDO, V13, P156; KIKUCHI K, 1987, ACTA ENDOCRINOL-COP, V114, P153, DOI 10.1530/acta.0.1140153; KLECZKOWSKA A, 1991, GENET COUNSELING, V1, P241; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MARHLENS F, 1987, HUM GENET, V77, P379; MATFIN G, 1994, CLIN ENDOCRINOL, V40, P807, DOI 10.1111/j.1365-2265.1994.tb02517.x; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; RACKWITZ HR, 1985, GENE, V40, P259, DOI 10.1016/0378-1119(85)90048-4; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; Sambrook J., 1989, MOL CLONING LAB MANU; SIZONENKO PC, 1978, AM J DIS CHILD, V132, P704, DOI 10.1001/archpedi.1978.02120320064015; WALKER AP, 1992, HUM MOL GENET, V1, P579, DOI 10.1093/hmg/1.8.579; WALKER AP, 1993, HUM MOL GENET, V2, P107, DOI 10.1093/hmg/2.2.107; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204; YATES JRW, 1987, CYTOGENET CELL GENET, V46, P723; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZEHETNER G, 1986, NUCLEIC ACIDS RES, V14, P335, DOI 10.1093/nar/14.1.335	29	585	608	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					672	676		10.1038/372672a0	http://dx.doi.org/10.1038/372672a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990958				2022-12-01	WOS:A1994PX30700085
J	STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP				STARK, K; VAINIO, S; VASSILEVA, G; MCMAHON, AP			EPITHELIAL TRANSFORMATION OF METANEPHRIC MESENCHYME IN THE DEVELOPING KIDNEY REGULATED BY WNT-4	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; WILMS-TUMOR GENE; MOUSE DEVELOPMENT; EXPRESSION; PROTOONCOGENE; EMBRYO; DISRUPTION; HOMOLOG	THE kidney has been widely exploited as a model system for the study of tissue inductions regulating vertebrate organogenesis(1,2). Kidney development is initiated by the ingrowth of the Wolfian duct-derived ureteric bud into the presumptive kidney mesenchyme. In response to a signal from the ureter, mesenchymal cells condense, aggregate into pretubular clusters and undergo an epithelial conversion generating a simple tubule. This then undergoes morphogenesis and is transformed into the excretory system of the kidney, the nephron. We report here that the expression of Wnt-4, which encodes a secreted glycoprotein, correlates with, and is required for, kidney tubulogenesis. Mice lacking Wnt-1 activity fail to form pretubular cell aggregates; however, other aspects of mesenchymal and ureteric development are unaffected. Thus, Wnt-4 appears to act as an autoinducer of the mesenchyme to epithelial transition that underlies nephron development.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, BIOLABS, CAMBRIDGE, MA 02138 USA	Harvard University			McMahon, Andrew P/ABE-7520-2020; Vassileva, Galya/A-6807-2009	Vainio, Seppo/0000-0001-9319-3566				ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; GUMBINER BM, 1993, J CELL SCI, P155; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT, V119, P97; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1993, DEVELOPMENT, V119, P247; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SAXEN L, 1971, EXP CELL RES, V66, P369, DOI 10.1016/0014-4827(71)90690-2; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	30	844	870	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					679	683		10.1038/372679a0	http://dx.doi.org/10.1038/372679a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990960				2022-12-01	WOS:A1994PX30700087
J	LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC				LAI, CG; LYMAN, RF; LONG, AD; LANGLEY, CH; MACKAY, TFC			NATURALLY-OCCURRING VARIATION IN BRISTLE NUMBER AND DNA POLYMORPHISMS AT THE SCABROUS LOCUS OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							PERIPHERAL NERVOUS-SYSTEM; STABILIZING SELECTION; MUTATION; GENETICS; BALANCE	The association between quantitative genetic variation in bristle number and molecular Variation at a candidate neurogenic locus, scabrous, was examined in Drosophila melanogaster. Approximately 32 percent of the genetic Variation in abdominal bristle number (21 percent for sternopleural bristle number) among 47 second chromosomes from a natural population was correlated with DNA sequence polymorphisms at this locus. Several polymorphic sites associated with large phenotypic effects occurred at intermediate frequency. Quantitative genetic variation in natural populations caused by alleles that have large effects at a few loci and that segregate at intermediate frequencies conflicts with the classical infinitesimal model of the genetic basis of quantitative variation.	N CAROLINA STATE UNIV, DEPT GENET, RALEIGH, NC 27695 USA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	University of North Carolina; North Carolina State University; McMaster University	LAI, CG (corresponding author), UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA.			Lai, Chao-Qiang/0000-0003-1107-8375; Long, Tony/0000-0002-5007-8514	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM045344, R01GM045146] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45146, GM45344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1994, P NATL ACAD SCI USA, V91, P4658, DOI 10.1073/pnas.91.11.4658; AGUADE M, 1989, GENETICS, V122, P607; AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; CLAYTON G. A., 1957, JOUR GENETICS, V55, P131, DOI 10.1007/BF02981620; Falconer D. S., 1989, Introduction to quantitative genetics.; Frankham R., 1980, Selection experiments in laboratory and domestic animals., P56; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HILL WG, 1990, 4TH WORLD C GEN APPL, P219; HOLM S, 1979, SCAND J STAT, V6, P65; KEARSEY MJ, 1970, HEREDITY, V25, P11, DOI 10.1038/hdy.1970.2; KEIGHTLEY PD, 1990, P ROY SOC B-BIOL SCI, V242, P95, DOI 10.1098/rspb.1990.0110; KEIGHTLEY PD, 1988, GENET RES, V52, P33, DOI 10.1017/S0016672300027282; KONDRASHOV AS, 1992, GENETICS, V132, P603; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Long A., UNPUB; LYNCH M, 1986, EVOLUTION, V40, P915, DOI 10.1111/j.1558-5646.1986.tb00561.x; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACKAY TFC, 1990, 4TH P WORLD C GEN AP; MARTIN R, 1990, BIOTECHNIQUES, V9, P762; MCBRIDE G, 1963, GENET RES, V4, P356, DOI 10.1017/S001667230000375X; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NUZHDIN SV, INPRESS GENETICS; ORR HA, 1992, AM NAT, V140, P725, DOI 10.1086/285437; POSAKONY JW, 1994, CELL, V76, P415, DOI 10.1016/0092-8674(94)90105-8; SHERIDAN A K, 1968, Theoretical and Applied Genetics, V38, P179, DOI 10.1007/BF00935264; SIMPSON P, 1990, DEVELOPMENT, V109, P509; TURELLI M, 1984, THEOR POPUL BIOL, V25, P138, DOI 10.1016/0040-5809(84)90017-0	33	135	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	1994	266	5191					1697	1702		10.1126/science.7992053	http://dx.doi.org/10.1126/science.7992053			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992053				2022-12-01	WOS:A1994PW30800038
J	STEVENSON, JC; GODSLAND, IF; WYNN, V				STEVENSON, JC; GODSLAND, IF; WYNN, V			CARDIOLOGISTS REBUKED	LANCET			English	Editorial Material											STEVENSON, JC (corresponding author), WYNN INST METAB RES, LONDON NW8 9SQ, ENGLAND.							BERG G, 1994, MODERN MANAGEMENT ME; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; LACROIX AZ, 1989, AM J EPIDEMIOL, V129, P669, DOI 10.1093/oxfordjournals.aje.a115183; LEY CJ, 1994, J AM COLL CARDIOL, V23, P377, DOI 10.1016/0735-1097(94)90423-5; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; ROBERTS WC, 1993, AM J CARDIOL, V72, P745, DOI 10.1016/0002-9149(93)90898-M; STEVENSON JC, 1994, HORIZONS MED, V5, P92; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; 1994, EUR HEART J S, V15	13	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	1994	344	8936					1557	1557		10.1016/S0140-6736(94)90356-5	http://dx.doi.org/10.1016/S0140-6736(94)90356-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983960				2022-12-01	WOS:A1994PV01700016
J	SCHNELL, DJ; KESSLER, F; BLOBEL, G				SCHNELL, DJ; KESSLER, F; BLOBEL, G			ISOLATION OF COMPONENTS OF THE CHLOROPLAST PROTEIN IMPORT MACHINERY	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ENVELOPE CONTACT SITES; TRANSIT PEPTIDE; PHOSPHATE TRANSLOCATOR; PRECURSOR PROTEINS; MEMBRANES; RECEPTOR; BINDING; IDENTIFICATION; SEQUENCE	Components of the protein import machinery of the chloroplast were isolated by a procedure in which the import machinery was engaged in vitro with a tagged import substrate under conditions that yielded largely chloroplast envelope-bound import intermediates. Subsequent detergent solubilization of envelope membranes showed that six envelope polypeptides copurified specifically and, apparently, stoichiometrically with the import intermediates. Four of these polypeptides are components of the outer membrane import machinery and are associated with early import intermediates. Two of these polypeptides have been characterized. One is a homolog of the heat shock protein hsp70; the other one is a channel-protein candidate.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	SCHNELL, DJ (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102, USA.		Kessler, Felix Henrique/AAO-1722-2020	Kessler, Felix/0000-0001-6409-5043				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CLINE K, 1985, PROTOPLASMA, V125, P111, DOI 10.1007/BF01297356; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODDENKOTTER B, 1993, P NATL ACAD SCI USA, V90, P2155, DOI 10.1073/pnas.90.6.2155; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; THEG SM, 1989, J BIOL CHEM, V264, P6730; TIANF, UNPUB; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	38	339	355	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 11	1994	266	5187					1007	1012		10.1126/science.7973649	http://dx.doi.org/10.1126/science.7973649			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973649				2022-12-01	WOS:A1994PQ92400033
J	WALCO, GA; CASSIDY, RC; SCHECHTER, NL				WALCO, GA; CASSIDY, RC; SCHECHTER, NL			PAIN, HURT, AND HARM - THE ETHICS OF PAIN CONTROL IN INFANTS AND CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SICKLE-CELL DISEASE; POSTOPERATIVE ANALGESIA; MORPHINE INFUSION; PEDIATRIC PAIN; ADOLESCENTS; MANAGEMENT; UNDERTREATMENT; PHYSICIANS; EFFICACY; PATIENT		UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103; LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11042; UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032	Rutgers State University New Brunswick; Rutgers State University Medical Center; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; University of Connecticut								ANAND K J S, 1987, Anesthesiology (Hagerstown), V67, pA502, DOI 10.1097/00000542-198709001-00502; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND R, 1987, LANCET, V2, P234; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; ARUNASALAM K, 1983, ANAESTHESIA, V38, P529; BEASLEY SW, 1987, AUST NZ J SURG, V57, P233, DOI 10.1111/j.1445-2197.1987.tb01346.x; BERDE C, 1990, PEDIATRICS, V86, pS818; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; CHAPMAN CR, 1989, CANCER, V63, P1636; DILWORTH NM, 1987, J PEDIATR SURG, V22, P264, DOI 10.1016/S0022-3468(87)80343-3; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Ferrell B R, 1991, J Clin Ethics, V2, P108; Fitzgerald M., 1993, PAIN INFANTS CHILDRE, P11; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; HAMMOND D, 1979, PERSPECT BIOL MED, V23, P152; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; ILOWITE NT, 1992, ANN RHEUM DIS, V51, P313; KOREN G, 1985, J PEDIATR-US, V107, P963, DOI 10.1016/S0022-3476(85)80205-5; LEVINE JD, 1982, PAIN, V14, P85, DOI 10.1016/0304-3959(82)90090-2; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MCCAFFERY M, 1993, PAIN INFANTS CHILDRE, P295; MCGRATH PA, 1987, PAIN, V31, P147, DOI 10.1016/0304-3959(87)90033-9; MCGRATH PJ, 1989, PEDIATR CLIN N AM, V36, P823; MECHANIC D, 1980, J HEALTH SOC BEHAV, V21, P146, DOI 10.2307/2136734; MIASKOWSKI C, 1993, 7TH WORLD C PAIN PAR, P2; MILLER RR, 1978, J CLIN PHARMACOL, V18, P180, DOI 10.1002/j.1552-4604.1978.tb01591.x; Morrison R A, 1991, Pediatr Nurs, V17, P503; Nolan K., 1993, PAIN INFANTS CHILDRE, P123; PEGELOW CH, 1992, CLIN PEDIATR, V31, P211, DOI 10.1177/000992289203100404; PETRIE A, 1967, INDIVIDUALITY PAIN S; SANDLER AN, 1992, ANESTHESIOL CLIN N A, V10, P271; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SCHECHTER NL, 1986, J DEV BEHAV PEDIATR, V7, P350; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; SCHECHTER NL, 1993, PAIN INFANTS CHILDRE; SHANNON M, 1989, PEDIATR CLIN N AM, V36, P855; VAMI JW, 1989, PEDIATRICIAN, V16, P56; WALCO GA, 1990, J PEDIATR PSYCHOL, V15, P643, DOI 10.1093/jpepsy/15.5.643; WILLIAMSON PS, 1983, PEDIATRICS, V71, P36; YASTER M, 1988, J PEDIATR-US, V113, P421, DOI 10.1016/S0022-3476(88)80622-X; YASTER M, 1993, PAIN INFANTS CHILDRE, P145; ZELTZER LK, 1990, PEDIATRICS, V86, pS826; 1990, CANCER PAIN RELIEF P; 1992, AHCPR920032 AG HLTH; 1992, PRINCIPLES ANALGESIC; 1993, ACCREDITATION MANUAL	49	136	137	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					541	544		10.1056/NEJM199408253310812	http://dx.doi.org/10.1056/NEJM199408253310812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041423				2022-12-01	WOS:A1994PD07200012
J	STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA				STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA			CRYSTAL-STRUCTURE OF YERSINIA PROTEIN-TYROSINE-PHOSPHATASE AT 2.5-ANGSTROM AND THE COMPLEX WITH TUNGSTATE	NATURE			English	Article							VIRULENCE DETERMINANT; PURIFICATION; INTERMEDIATE; CATALYSIS; CYSTEINE; CHARGES; LAR	PROTEIN tyrosine phosphatases (PTPases) and kinases coregulate the critical levels of phosphorylation necessary for intracellular signalling, cell growth and differentiation(1,2). Yersinia, the causative bacteria of the bubonic plague and other enteric diseases, secrete an active PTPase(3), Yop51, that enters and suppresses host immune cells(4,5). Though the catalytic domain is only similar to 20% identical to human PTP1B(6), the Yersinia PTPase contains all of the invariant residues present in eukaryotic PTPases(7), including the nucleophilic Cys 403 which forms a phosphocysteine intermediate during catalysis(3,8-10). We present here structures of the unliganded (2.5 Angstrom resolution) and tungstate-bound (2.6 Angstrom) crystal forms which reveal that Cys 403 is positioned at the centre of a distinctive phosphate-binding loop. This loop is at the hub of several hydrogen-bond arrays that not only stabilize a bound oxyanion, but may activate Cys 403 as a reactive thiolate. Binding of tungstate triggers a conformational change that traps the oxyanion and swings Asp 356, an important catalytic residue(7), by similar to 6 Angstrom into the active site. The same anion-binding loop in PTPases is also found in the enzyme rhodanese(11).	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,WALTHER CANC INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Walther Cancer Institute			Fauman, Eric/AAC-8275-2020	Fauman, Eric/0000-0002-9739-0249				AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; STEIGEMANN W, 1974, THESIS TU MUNICH; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIERENGA RK, 1986, T AM CRYSTALLOGR ASS, V22, P49; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	31	375	382	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					571	575		10.1038/370571a0	http://dx.doi.org/10.1038/370571a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052312	Green Submitted			2022-12-01	WOS:A1994PC53700059
J	KLEIN, PS; MELTON, DA				KLEIN, PS; MELTON, DA			INDUCTION OF MESODERM IN XENOPUS-LAEVIS EMBRYOS BY TRANSLATION INITIATION-FACTOR 4E	SCIENCE			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; 3' UNTRANSLATED REGION; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; ACTIVIN RECEPTOR; C-ELEGANS; MALIGNANT TRANSFORMATION; MIDBLASTULA TRANSITION; POLY(A) ADDITION	The microinjection of messenger RNA encoding the eukaryotic translation initiation factor 4E (elF-4E) into early embryos of Xenopus laevis leads to the induction of mesoderm in ectodermal explants. This induction occurs without a stimulation of overall protein synthesis and is blocked by the co-expression of a dominant negative mutant of the proto-oncogene ras or a truncated activin type II receptor. Although other translation factors have been studied in vertebrate and invertebrate embryos, none have been shown to play a direct role in development. The results here suggest a mechanism for relaying and amplifying signals for mesoderm induction.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BU X, 1993, J BIOL CHEM, V268, P4975; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1992, DEVELOPMENT, V115, P573; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMATIBRIVANLO.A, UNPUB; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; JONES EA, 1987, DEVELOPMENT, V101, P557; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KURIHARA K, 1981, DEV GROWTH DIFFER, V23, P361; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LOPO AC, 1988, BIOCHEMISTRY-US, V27, P351, DOI 10.1021/bi00401a053; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA O, 1970, P JPN ACAD, V46, P694, DOI 10.2183/pjab1945.46.694; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SAMBROOK J, 1990, MOL CLONING LABORATO; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; XU Z, 1990, CELL REGUL, V1, P1057, DOI 10.1091/mbc.1.13.1057	62	61	62	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					803	806		10.1126/science.8047887	http://dx.doi.org/10.1126/science.8047887			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047887				2022-12-01	WOS:A1994PA37200039
J	FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M				FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M			BENIGN ANAL LESIONS AND THE RISK OF ANAL CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CROHNS-DISEASE; CARCINOMA	Background. Benign anal lesions are often considered to cause a predisposition to anal cancer. To reexamine this association, we linked national data on hospital discharge and cancer in Denmark. Methods. After making certain exclusions, we used the Danish Central Hospital Discharge Register to identify 68,549 patients hospitalized with benign anal lesions between 1977 and 1989. Through computerized linkage to the Danish Cancer Registry, all incident cases of epidermoid anal cancer and colorectal cancer among these patients were identified. Follow-up for the occurrence of cancer started the month after the date of the first hospital discharge and continued until the patient died (10.6 percent of the sample), emigrated (0.7 percent), or was lost to follow-up (0.04 percent) or until December 31, 1989 (88.6 percent), whichever came first. Results. The median follow-up period was 6.2 years. There were 23 epidermoid anal cancers and 416 colorectal cancers. The overall relative risk of anal cancer (observed vs. expected cases) was 4.4 (95 percent confidence interval, 2.8 to 6.6). The relative risk was 12.0 (95 percent confidence interval, 5.2 to 23.6) within the first year after hospitalization for benign lesions, 4.6 (95 percent confidence interval, 2.3 to 8.3) from one to four years after hospitalization, and 1.8 (95 percent confidence interval, 0.5 to 4.7) five or more years after hospitalization. The risk of colorectal cancer was significantly increased only during the first year after hospitalization (relative risk, 2.6; 95 percent confidence interval, 2.1 to 3.1). Conclusions. There is a strong temporal association between the diagnosis of benign anal lesions and the diagnosis of anal cancer. Although we could not exclude the possibility of a moderate increase in the long-term risk of anal cancer, our data do not support the view that benign anal lesions cause anal cancer.	DANISH CANC SOC, RES CTR, DIV CANC EPIDEMIOL, COPENHAGEN, DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Olsen, Jorgen Helge/0000-0001-9633-5662				BACON HE, 1964, CANCER COLON RECTUM, P332; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; BROFELDT SA, 1927, ACTA SOC MED FENN DU, V8, P3; BUCKWALTER JA, 1957, ARCH SURG-CHICAGO, V75, P352; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; EWING J, 1940, NEOPLASTIC DISEASES, P726; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOULSTON KJ, 1986, LANCET, V2, P261; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HUGHES LE, 1992, DIS COLON RECTUM, V35, P928, DOI 10.1007/BF02253493; Keyes EL, 1937, ANN SURG, V106, P1046, DOI 10.1097/00000658-193712000-00008; KLINE RJ, 1964, ARCH SURG-CHICAGO, V89, P989; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Leichman L P, 1990, Curr Probl Cancer, V14, P117; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; PRESTON DM, 1983, BRIT J SURG, V70, P346, DOI 10.1002/bjs.1800700612; Rosser C., 1931, AM J SURG, V11, P328; Rothman KJ, 1982, CANCER EPIDEMIOLOGY, P15; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; Storm H H, 1991, IARC Sci Publ, P220; 1986, VEJLEDNING UDTRAEK	23	42	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					300	302		10.1056/NEJM199408043310504	http://dx.doi.org/10.1056/NEJM199408043310504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022440	Bronze			2022-12-01	WOS:A1994NZ22700004
J	STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S				STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S			THE MEDICAL AND SOCIAL-CONSEQUENCES OF LAND MINES IN CAMBODIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; EXPERIENCE; DEPRESSION		NYU,SCH MED,DEPT MED,NEW YORK,NY; AMER RED CROSS,WASHINGTON,DC 20006; AMER REFUGEE COMM,PHNOM PENH,CAMBODIA	New York University; American Red Cross	STOVER, E (corresponding author), PHYSICIANS HUMAN RIGHTS,100 BOYLSTON ST,SUITE 702,BOSTON,MA 02116, USA.							AKESODE FA, 1981, TROP GEOGR MED, V33, P71; ANDERSON K, 1993, HUMAN RIGHTS WATCH P; Becker Elizabeth, 1986, WAR WAS OVER CAMBODI; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FAZOL R, 1989, J CARDIOVASC SURG, V30, P39; FINE J, 1992, HIDDEN ENEMIES LAND; GARACHON A, 1993, 1993 S ANT MIN MONTR, P93; GEIGER HJ, 1993, JAMA-J AM MED ASSOC, V270, P616; HIRSCHHORN N, 1991, CLIN NEEDS ASSESSMEN, P37; JOHNSON DE, 1981, J TRAUMA, V21, P486; JOHNSON SR, 1981, J BACTERIOL, V146, P632, DOI 10.1128/JB.146.2.632-638.1981; KASHANI JH, 1983, J CLIN PSYCHIAT, V44, P256; KING F, 1992, THESIS LONDON SCH TR; MARTIN ES, 1985, EXPLOSIVE REMNANTS W; MCCOLLOUGH NC, 1992, ORTHOP CLIN N AM, V3, P136; MCGRATH R, 1991, REPORT AFGHANISTAN M; MCGRATH R, 1992, HIDDEN DEATH LAND MI; MCGRATH R, 1993, LAND MINES ANGOLA; MOLLICA RF, 1990, AM J PSYCHIAT, V147, P83; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RF, 1988, CLIN GUIDELINES CROS, P262; MYERS H, 1993, CAMBODIA CANT WAIT, P12; MYSLIWIEK E, 1988, PUNISHING POOR INT I, P42; PIERCE RO, 1993, ORTHOPEDICS, V16, P793; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; RONE J, 1986, LAND MINES EL SALVAD; Ryan J M, 1988, J R Army Med Corps, V134, P119; RYBARCZYK BD, 1992, ARCH PHYS MED REHAB, V73, P1169; SHUKLA GD, 1982, BRIT J PSYCHIAT, V141, P50, DOI 10.1192/bjp.141.1.50; STOVER E, 1991, LAND MINES CAMBODIA, P59; THOMPSON DM, 1988, INT REHABIL MED, V5, P165; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; 1990, CAMBODIA SITUATION C; 1980, UNDOCACONF9515 UN NA; 1993, HIDDEN KILLERS GLOBA; 1992, PERVERSE USE TECHNOL; 1994, LANDMINES UPDATE, P7; 1993, NY TIMES        1227, pA16; 1994, DEMINING SITUATION R; 1981, A36613 UN NAT PUBL; 1994, SECURITY REPORT	42	34	34	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					331	336		10.1001/jama.272.5.331	http://dx.doi.org/10.1001/jama.272.5.331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028149				2022-12-01	WOS:A1994NY90300001
J	WILSON, MA; MCNAUGHTON, BL				WILSON, MA; MCNAUGHTON, BL			REACTIVATION OF HIPPOCAMPAL ENSEMBLE MEMORIES DURING SLEEP	SCIENCE			English	Article							SYNAPTIC ENHANCEMENT; INFORMATION-STORAGE; ASSOCIATIVE MEMORY; UNIT ACTIVITY; PLASTICITY; POTENTIATION; DYNAMICS; RATES	Simultaneous recordings were made from large ensembles of hippocampal ''place cells'' in three rats during spatial behavioral tasks and in slow-wave sleep preceding and following these behaviors. Cells that fired together when the animal occupied particular locations in the environment exhibited an increased tendency to fire together during subsequent sleep, in comparison to sleep episodes preceding the behavioral tasks. Cells that were inactive during behavior, or that were active but had non-overlapping spatial firing, did not show this increase. This effect, which declined gradually during each post-behavior sleep session, may result from synaptic modification during waking experience. Information acquired during active behavior is thus re-expressed in hippocampal circuits during sleep, as postulated by some theories of memory consolidation.	UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85724 USA; UNIV ARIZONA, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona					NIMH NIH HHS [MH46823] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046823, R01MH046823] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AMIT DJ, 1989, P NATL ACAD SCI USA, V86, P7871, DOI 10.1073/pnas.86.20.7871; BARNES CA, 1985, BEHAV NEUROSCI, V99, P1040, DOI 10.1037/0735-7044.99.6.1040; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHROBAK JJ, IN PRESS J NEUROSCI; GERSTEIN GL, 1969, SCIENCE, V164, P828, DOI 10.1126/science.164.3881.828; GIBSON WG, 1992, NEURAL NETWORKS, V5, P645, DOI 10.1016/S0893-6080(05)80042-5; HEBB DO, 1949, ORG BEHAVIOR; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Landfield P. W., 1987, LONG TERM POTENTIATI; LEONARD BJ, 1987, BRAIN RES, V425, P174; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; McClelland J. L., 1992, Society for Neuroscience Abstracts, V18, P1216; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1990, NEUROSCIENCE CONNECT; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P609; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV, P150; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TREVES A, 1991, NETWORK-COMP NEURAL, V2, P371, DOI 10.1088/0954-898X/2/4/004; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; WOODY CD, 1972, J NEUROPHYSIOL, V35, P230, DOI 10.1152/jn.1972.35.2.230	32	1875	1904	4	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	1994	265	5172					676	679		10.1126/science.8036517	http://dx.doi.org/10.1126/science.8036517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036517				2022-12-01	WOS:A1994NZ53800038
J	KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S				KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S			INDUCTION OF AN OLFACTORY MEMORY BY THE ACTIVATION OF A METABOTROPIC GLUTAMATE-RECEPTOR	SCIENCE			English	Article							PREGNANCY BLOCK; BRAIN-FUNCTION; MESSENGER-RNA; RAT-BRAIN; BULB; MODULATION; INHIBITION; SYSTEM	Female mice form an olfactory memory of male pheromones at mating; exposure to the pheromones of a strange male after that mating will block pregnancy. The formation of this memory is mediated by the accessory olfactory system, in which an increase in norepinephrine after mating reduces inhibitory transmission of gamma-aminobutyric acid from the granule cells to the mitral cells. This study shows that the activation of mGluR2, a metabotropic glutamate receptor that suppresses the gamma-aminobutyric acid inhibition of the mitral cells, permits the formation of a specific olfactory memory without the occurrence of mating by infusion of mGluR2 agonists into the female's accessory olfactory bulb. This memory faithfully reflects the memory formed at mating.	KOCHI MED SCH,DEPT PHYSIOL,NANKO KU,KOCHI 783,JAPAN; KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kochi University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Kaba, Hideto/0000-0002-5187-1995				BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; BRENNAN PA, 1992, NEUROSCIENCE, V49, P277, DOI 10.1016/0306-4522(92)90095-J; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUCE HM, 1959, NATURE, V184, P105, DOI 10.1038/184105a0; HALASZ N, 1990, VERTEBRATE OLFACTORY; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; JAHR CE, 1982, NATURE, V297, P227, DOI 10.1038/297227a0; KABA H, 1989, NEUROSCIENCE, V32, P657, DOI 10.1016/0306-4522(89)90287-X; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KABA H, 1988, NEUROSCIENCE, V24, P93, DOI 10.1016/0306-4522(88)90314-4; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; TROMBLEY PQ, 1992, J NEUROSCI, V12, P3985	19	145	149	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					262	264		10.1126/science.8023145	http://dx.doi.org/10.1126/science.8023145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023145				2022-12-01	WOS:A1994NV95700045
J	GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K				GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K			DELETION OF A DNA-POLYMERASE-BETA GENE SEGMENT IN T-CELLS USING CELL-TYPE-SPECIFIC GENE TARGETING	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; TRANSGENIC MICE; EXPRESSION; BACTERIOPHAGE-P1; PATHWAYS; REGIONS	Deletion of the promoter and the first exon of the DNA polymerase beta gene (pol beta) in the mouse germ line results in a lethal phenotype. With the use of the bacteriophage-derived, site-specific recombinase Cre in a transgenic approach, the same mutation can be selectively introduced into a particular cellular compartment-in this case, T cells. The impact of the mutation on those cells can then be analyzed because the mutant animals are viable.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; MAX PLANCK INST IMMUNOBIOL, D-79011 FREIBURG, GERMANY	University of British Columbia; University of British Columbia; Max Planck Society	GU, H (corresponding author), UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY.			Rajewsky, Klaus/0000-0002-6633-6370				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; FRY M, 1983, ENZYMES NUCLEIC ACID, P39; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gu H.-Q., UNPUB; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Sambrook J., 1989, MOL CLONING LAB MANU; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAUER B, 1990, New Biologist, V2, P441; Sprent Jonathan, 1993, P75; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YAMAGUCHI M, 1987, MOL CELL BIOL, V7, P2012, DOI 10.1128/MCB.7.5.2012	21	1110	1265	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					103	106		10.1126/science.8016642	http://dx.doi.org/10.1126/science.8016642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016642				2022-12-01	WOS:A1994NV30100036
J	PRUDENT, JR; UNO, T; SCHULTZ, PG				PRUDENT, JR; UNO, T; SCHULTZ, PG			EXPANDING THE SCOPE OF RNA CATALYSIS	SCIENCE			English	Article							LIGANDS; ENZYME; ANTIBODIES; EVOLUTION; LIBRARY; TETRAHYMENA; MOLECULES; SELECTION; RIBOZYME; INVITRO	The basic notions of transition state theory have been exploited in the past to generate highly selective catalysts from the vast library of antibody molecules in the immune system. These same ideas were used to isolate an RNA molecule, from a large library of RNAs, that catalyzes the isomerization of a bridged biphenyl. The RNA-catalyzed reaction displays Michaelis-Menten kinetics with a catalytic rate constant (k(cat)) of 2.8 x 10(-5) per minute and a Michaelis constant (K-m) of 542 mu M; the reaction is competitively inhibited by the planar transition state analog with an inhibition constant (K-i) value of similar to 7 mu M. This approach may provide a general strategy for expanding the scope of RNA catalysis beyond those reactions in which the substrates are nucleic acids or nucleic acid derivatives.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08352A] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Criegee R, 1942, LIEBIGS ANN CHEM, V550, P99; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HALDANE JBS, 1930, ENZYMES, P182; HALL DM, 1950, J CHEM SOC, P711, DOI 10.1039/jr9500000711; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MISLOW K, 1962, J AM CHEM SOC, V84, P1449, DOI 10.1021/ja00867a022; MISLOW K, 1964, J AM CHEM SOC, V86, P1710, DOI 10.1021/ja01063a014; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI DOI 10.1021/CEN-V024N010.P1375; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; REBEK J, 1980, TETRAHEDRON LETT, V21, P2379, DOI 10.1016/S0040-4039(00)93154-X; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGEL IH, 1975, ENZYME KINETICS, P46; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	32	136	150	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1924	1927						4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009223				2022-12-01	WOS:A1994NT84700043
J	MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY				MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY			SCREENING FOR CERVICAL INTRAEPITHELIAL NEOPLASIA IN NORTH-EAST SCOTLAND SHOWS FALL IN INCIDENCE AND MORTALITY FROM INVASIVE CANCER WITH CONCOMITANT RISE IN PREINVASIVE DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DYSKARYOSIS; CYTOLOGY; WOMEN; SMEAR; MILD; CARCINOMA; TRENDS	Objective-To assess the effect of screening for cervical intraepithelial neoplasia on the incidence of and mortality from invasive squamous cell carcinoma of cervix in north east Scotland and to discover why cases of invasive cancer still occur. Design-(a) Analysis of data on cases of cervical intraepithelial neoplasia obtained from the cytology data bank; (b) analysis of data on 612 women presenting with invasive squamous cancer during 1968-91, obtained from cancer registry and hospital records; (c) analysis of death rates obtained from the registrar general's (Scotland) annual reports, the Information Services Division of the Home and Health Department (Scotland), and local records for 1974-91; (d) case-control studies on 282 cases of invasive cancer and 108 deaths which occurred in 1982-91. Cases were matched with two controls both for age and for having a negative smear test result at the time of presentation of the case. Setting-North east Scotland (Grampian region, Orkney, and Shetland). Subjects-Women (n=306 608) who had had cervical smear tests between 1960 and 1991. Results-There had been a substantial increase in cases of cervical intraepithelial neoplasia grade III since 1982. The incidence of invasive cancer has fallen since the start of screening in 1960, the fall occurring mainly in the well screened age group 40-69 years. There was a rise in women aged under 40 and over 70. Women with invasive disease seen between 1982 and 1991 mostly presented at stage I. Of these, half were unscreened, one third were poorly screened, 11% were found in retrospect to have had abnormal cells, 3% had recurrence of disease after treatment for cervical intraepithelial neoplasia grade III, and 3% were lost to follow up. Death rates had fallen, most noticeably in women aged 45-64, who had had the opportunity to be screened and rescreened. There was a disturbing rise in deaths among women under 45. Most deaths (65%) occurred in unscreened women. Case-control studies showed that the longer the time and absence of a smear test before presentation the higher was the risk of invasive cancer and of death. Conclusions-Screening has been effective in reducing the incidence of and mortality from cervical cancer in north east Scotland. Most cases and deaths occurred in unscreened women or in those who had had few smears at long intervals, An increase in cases of cervical intraepithelial neoplasia grade III in women screened for the first time occurred during 1982-91.	UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT PATHOL, ABERDEEN AB9 2ZD, SCOTLAND; GRAMPIAN AREA HLTH BOARD, ABERDEEN, SCOTLAND; ABERDEEN ROYAL HOSP, NHS TRUST, ABERDEEN, SCOTLAND; UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT GYNAECOL, ABERDEEN, SCOTLAND	University of Aberdeen; University of Aberdeen			Campbell, Marion/ABB-7063-2020					ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BERKELEY AS, 1980, LANCET, V2, P375; BETHWAITE P, 1992, BRIT J OBSTET GYNAEC, V99, P745, DOI 10.1111/j.1471-0528.1992.tb13877.x; COOK GA, 1984, BRIT J CANCER, V50, P367, DOI 10.1038/bjc.1984.185; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COTTON RE, 1986, BRIT MED J, V292, P799, DOI 10.1136/bmj.292.6523.799-a; CURLING M, 1992, ADV GYNAECOLOGICAL P, P62; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; GRAY M, 1992, GUIDELINES CLIN PRAC; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; JHA PKS, 1993, LANCET, V341, P1116, DOI 10.1016/0140-6736(93)93128-N; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; LAARA E, 1987, LANCET, V1, P1247; LAWSON JG, 1956, J OBSTET GYNAECOL, V63, P819; MACGREGOR JE, 1993, BRIT J OBSTET GYNAEC, V100, P801, DOI 10.1111/j.1471-0528.1993.tb14301.x; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; MACGREGOR JE, 1961, BRIT MED J, V1, P1631; ROBERTSON AJ, 1989, J CLIN PATHOL, V42, P231, DOI 10.1136/jcp.42.3.231; SILCOCKS PBS, 1988, BRIT J OBSTET GYNAEC, V95, P1111, DOI 10.1111/j.1471-0528.1988.tb06787.x; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; THOMPSON B, 1993, HLTH ED J, V52, P62; THOMPSON B, 1989, HAVING 1ST BABY EXPE; VANOORTMARSSEN GJ, 1992, BRIT MED J, V305, P449, DOI 10.1136/bmj.305.6851.449; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; 1992, REGISTRAR GENERAL AN; 1990, GRAMPIAN HLTH BOARD, P14; 1990, FACTS CANCER; 1990, GRAMPIAN HLTH PROFIL	31	97	106	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1407	1411		10.1136/bmj.308.6941.1407	http://dx.doi.org/10.1136/bmj.308.6941.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019250	Green Published			2022-12-01	WOS:A1994NP42000015
J	SETO, E; LEWIS, B; SHENK, T				SETO, E; LEWIS, B; SHENK, T			INTERACTION BETWEEN TRANSCRIPTION FACTORS SP1 AND YY1	NATURE			English	Article							SYNERGISTIC ACTIVATION; INITIATOR; ENHANCER; PROTEIN; DOMAINS; TRANSACTIVATOR; REPRESSION; EXPRESSION; ELEMENTS; INVITRO	A BASAL level of transcription is usually observed when all but a small region of DNA has been deleted from a eukaryotic gene promoter. These promoter elements, which are necessary and sufficient for specific transcription initiation, are referred to as minimal or core promoter elements. One element that is commonly present in a core promoter is the initiator. It has been demonstrated that the presence of Sp1 binding sites can greatly enhance the level of transcription initiation at initiator elements1-4. A binding site for the YY1 transcription factor, located at the initiation site of the adeno-associated virus P5 promoter, functions as an initiator element; a synergistic enhancement of its activity is observed in vitro when upstream Sp1 binding sites are present3. Here we report that this synergistic activation probably occurs through protein-protein interactions.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Howard Hughes Medical Institute; Princeton University	SETO, E (corresponding author), UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	20	259	263	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					462	464		10.1038/365462a0	http://dx.doi.org/10.1038/365462a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	8003102				2022-12-01	WOS:A1993LZ63300063
J	LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M				LUTHI, A; LAURENT, JP; FIGUROV, A; MULLER, D; SCHACHNER, M			HIPPOCAMPAL LONG-TERM POTENTIATION AND PLEURAL CELL-ADHESION MOLECULES L1 AND NCAM	NATURE			English	Article							IMMUNOELECTRON-MICROSCOPIC LOCALIZATION; PASSIVE-AVOIDANCE RESPONSE; N-CAM; NEURITE OUTGROWTH; MOUSE CEREBELLUM; MEMORY; CONSOLIDATION; ASSOCIATION; COMPONENT; MEMBRANES	SYNAPTIC membranes express cell adhesion molecules(1). Here we investigate the role of the neural cell adhesion molecules L1 and NCAM in hippocampal long-term potentiation (LTP), a sustained-use-dependent increase in synaptic efficacy that has been implicated in learning and memory(2). L1 and NCAM mediate cell interactions during neural development(3) and are strongly expressed in the hippocampus(4,5). They cooperate to strengthen L1-dependent cell adhesion(6-9) and are coupled to second messenger pathways(10-12). We show that LTP in CA1 neurons of rat hippocampal slices was reduced by application of various L1 and NCAM antibodies, recombinant L1 fragments, and upon dissociation of the L1/NCAM complex through oligomannosidic carbohydrates and NCAM peptides. Neither the activation of NMDA (N-methyl-D-aspartate) receptors nor the maintenance of LTP was affected. These results suggest that L1 and NCAM modulate the development or the stabilization of LTP(13).	CTR MED UNIV GENEVA,DEPT PHARMACOL,CH-1211 GENEVA 4,SWITZERLAND; ETH ZURICH,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND	University of Geneva; Swiss Federal Institutes of Technology Domain; ETH Zurich	LUTHI, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND.							APPEL F, 1993, J NEUROSCI, V13, P4764; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DOYLE E, 1992, J NEUROSCI RES, V31, P513, DOI 10.1002/jnr.490310315; DOYLE E, 1992, J NEUROCHEM, V59, P1570, DOI 10.1111/j.1471-4159.1992.tb08477.x; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HANSE E, 1994, NEUROSCI RES, V20, P15, DOI 10.1016/0168-0102(94)90018-3; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MILLER PD, 1993, J COMP NEUROL, V327, P341, DOI 10.1002/cne.903270303; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; RATHJEN FG, 1984, EMBO J, V3, P1; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SIMON H, 1991, EUR J NEUROSCI, V3, P634, DOI 10.1111/j.1460-9568.1991.tb00849.x; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; ZHANG H, 1992, J NEUROSCI, V12, P3107, DOI 10.1523/JNEUROSCI.12-08-03107.1992	25	451	459	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					777	779		10.1038/372777a0	http://dx.doi.org/10.1038/372777a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997264				2022-12-01	WOS:A1994PY21200052
J	LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH				LOMELI, H; MOSBACHER, J; MELCHER, T; HOGER, T; GEIGER, JRP; KUNER, T; MONYER, H; HIGUCHI, M; BACH, A; SEEBURG, PH			CONTROL OF KINETIC-PROPERTIES OF AMPA RECEPTOR CHANNELS BY NUCLEAR-RNA EDITING	SCIENCE			English	Article							GLUTAMATE-OPERATED CHANNELS; RAT HIPPOCAMPAL SLICES; CA2+ PERMEABILITY; BRAIN-SLICES; DESENSITIZATION; NEURONS; PATCHES; SUBUNIT; SWITCH; CELLS	AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor channels mediate the fast component of excitatory postsynaptic currents in the central nervous system. Site-selective nuclear RNA editing controls the calcium permeability of these channels, and RNA editing at a second site is shown here to affect the kinetic aspects of these channels in rat brain. In three of the four AMPA receptor subunits (GluR-B, -C, and -D), intronic elements determine a codon switch (AGA, arginine, to GGA, glycine) in the primary transcripts in a position termed the R/G site, which immediately precedes the alternatively spliced modules ''flip'' and ''flop.'' The extent of editing at this site progresses with brain development in a manner specific for subunit and splice form, and edited channels possess faster recovery rates from desensitization.	UNIV HEIDELBERG,CTR BIOL MOLEC,MOLEC NEUROENDOCRINOL LAB,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY; BASF AG,D-67056 LUDWIGSHAFEN,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society; BASF				Monyer, Hannah/0000-0002-9332-5749; Lomeli, Hilda/0000-0001-9659-0102				BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HIGUCHI M, UNPUB; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; JONAS P, 1994, CURR OPIN NEUROBIOL, V4, P365; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MOSBACHER J, IN PRESS SCIENCE; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SCHELL TJ, 1990, CELL, V61, P361; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STEIN E, 1992, MOL PHARMACOL, V42, P864; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TRUSSELL LO, 1994, SEMIN NEUROSCI, V6, P71; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	622	639	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1709	1713		10.1126/science.7992055	http://dx.doi.org/10.1126/science.7992055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992055				2022-12-01	WOS:A1994PW30800041
J	LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA				LEE, JJ; EKKER, SC; VONKESSLER, DP; PORTER, JA; SUN, BI; BEACHY, PA			AUTOPROTEOLYSIS IN HEDGEHOG PROTEIN BIOGENESIS	SCIENCE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; EXPRESSION; TRANSCRIPTION; MEMBER	Extracellular signaling proteins encoded by the hedgehog (hh) multigene family are responsible for the patterning of a variety of embryonic structures in vertebrates and invertebrates. The Drosophila hh gene has now been shown to generate two predominant protein species that are derived by an internal autoproteolytic cleavage of a larger precursor. Mutations that reduced the efficiency of autoproteolysis in vitro diminished precursor cleavage in vivo and also impaired the signaling and patterning activities of the HH protein. The two HH protein species exhibited distinctive biochemical properties and tissue distribution, and these differences suggest a mechanism that could account for the long- and short-range signaling activities of HH in vivo.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University				Ekker, Stephen/0000-0003-0726-4212				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG DT, IN PRESS DEVELOPMENT; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, UNPUB; Eugene O., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P1055, DOI 10.1007/BF00919788; FAN CM, IN PRESS CELL; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE J, 1993, DROSOPHILA RES C; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL H, METHODS CELL BIOL; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1993, CELL, V75, P761; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONKESSLER DP, UNPUB	37	440	477	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1528	1537		10.1126/science.7985023	http://dx.doi.org/10.1126/science.7985023			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985023				2022-12-01	WOS:A1994PV01500035
J	MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B				MEASDAY, V; MOORE, L; OGAS, J; TYERS, M; ANDREWS, B			THE PCL2 (ORFD)-PHO85 CYCLIN-DEPENDENT KINASE COMPLEX - A CELL-CYCLE REGULATOR IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MATING PHEROMONE; G1 CYCLINS; PHO SYSTEM; GENE; SWI4; PHOSPHATASE; CDC28; CLN1	Cyclin-dependent kinase (cdk) complexes are essential activators of cell cycle progression in all eukaryotes. In contrast to mammalian cells, in which multiple cdk's contribute to cell cycle regulation, the yeast cell cycle is largely controlled by the activity of a single cdk, CDC28. Analysis of the putative G(1) cyclin PCL2 (ORFD) identified a second cyclin-cdk complex that contributes to cell cycle progression in yeast. PCL2 interacted with the cdk PHO85 in vivo and in vitro and formed a kinase complex that had G(1)-periodic activity. Under genetic conditions in which the Start transition was compromised, PHO85 and its associated cyclin subunits were essential for cell cycle commitment. Because PHO85 and another cyclin-like molecule, PHO80, also take part in inorganic phosphate metabolism, this cdk enzyme may integrate responses to nutritional conditions with the cell cycle.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; STANFORD UNIV, CARNEGIE INST, STANFORD, CA 94305 USA	University of Toronto; University of Toronto; Carnegie Institution for Science; Stanford University			Tyers, Michael/ABE-3194-2021	Ogas, Joe/0000-0002-1332-7729				Andrews B., UNPUB; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ESPINOZA H, 1994, SCIENCE, V266, P1388; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARPER JW, 1993, CELL, V75, P805; Hunt T., COMMUNICATION; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, pCH5; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; MEASDAY V, UNPUB; MOORE L, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, 1992, THESIS U CALIFORNIA; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIKORSKI RS, 1989, GENETICS, V122, P19; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; TYERS M, 1992, EMBO J, V11, P1173; TYERS M, UNPUB; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	39	153	157	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1391	1395		10.1126/science.7973731	http://dx.doi.org/10.1126/science.7973731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973731				2022-12-01	WOS:A1994PT63200046
J	PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ				PIJNENBORG, L; VANDELDEN, JJM; KARDAUN, JWPF; GLERUM, JJ; van der Maas, PJ			NATIONWIDE STUDY OF DECISIONS CONCERNING THE END OF LIFE IN GENERAL-PRACTICE IN THE NETHERLANDS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY DOCTORS; PATIENT; PHYSICIAN; EUTHANASIA	Objective-To gain insight into decisions made in general practice about the end of life. Design-Study I: interviews with 405 physicians. Study II: analysis of death certificates with data obtained on 5197 cases in which decisions about the end of life may have been made. Study III: prospective study with doctors from study I: questionnaires used to collect information about 2257 deaths. The information was representative for all deaths in the Netherlands. Results-Over two fifths of all patients in the Netherlands die at home. General practitioners took fewer decisions about the end of life than hospital doctors and doctors in nursing homes (34%, 40%, and 56% of all dying patients, respectively). Specifically, decisions to withhold or withdraw treatment to prolong life were taken less often. Euthanasia or assisted suicide, however, was performed in 3.2% of all deaths in general practice compared with 1.4% in hospital practice. In over half of the cases concerning pain relief or non-treatment general practitioners did not discuss the decision with the patient, mostly because of incapacity of the patient, but in 20% of cases for ''paternalistic'' reasons. Older general practitioners discussed such decisions less often with their patients. Colleagues were consulted more often if the general practitioner worked in group practice. Conclusion-Differences in work situation between general practitioners and hospital doctors and differences between the group of general practitioners contribute to differences in the number and type of decisions about the end of life as well as in the decision making process.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							BATTIN MP, 1994, LEAST WORST DEATH ES, P130; Beauchamp T.L., 1989, PRINCIPLES BIOMEDICA, V3rd; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HOFFMASTER CB, 1991, SOC SCI MED, V33, P647, DOI 10.1016/0277-9536(91)90018-8; ORR RD, 1991, J FAM PRACTICE, V33, P500; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; SIEGLER M, 1985, ARCH INTERN MED, V145, P713, DOI 10.1001/archinte.145.4.713; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; 1987, BIOETHICS, V1, P163; 1992, END LIFE MED PRACTIC	13	15	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1994	309	6963					1209	1212		10.1136/bmj.309.6963.1209	http://dx.doi.org/10.1136/bmj.309.6963.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987154	Green Published			2022-12-01	WOS:A1994PQ66200024
J	GELLERT, GA				GELLERT, GA			PREPARING FOR EMERGING INFECTIONS	NATURE			English	Editorial Material											GELLERT, GA (corresponding author), PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA 22646, USA.							DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KILBOURNE ED, 1990, JAMA-J AM MED ASSOC, V264, P68, DOI 10.1001/jama.264.1.68; Lederberg J., 1992, EMERGING INFECT MICR; 1993, MMWR-MORBID MORTAL W, V4, P441; 1994, MMWR-MORBID MORTAL W, V43, P45	6	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					409	410		10.1038/370409a0	http://dx.doi.org/10.1038/370409a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047155	Green Published, Bronze			2022-12-01	WOS:A1994PB40700022
J	GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM				GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM			SINGLE MUTATION OF THE FUMARYLACETOACETATE HYDROLASE GENE IN FRENCH-CANADIANS WITH HEREDITARY TYROSINEMIA TYPE-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA; QUEBEC; IDENTIFICATION; DEFICIENT	Background. Hereditary tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. The disorder clusters in the Saguenay-Lac-St.-Jean area of Quebec. In this region, 1 of 1846 newborns is affected and 1 of every 22 persons is thought to be a carrier. Recently, we identified a splice mutation and two nonsense mutations in the fumarylacetoacetate hydrolase gene in two patients from Quebec with tyrosinemia type I. Methods. We used allele-specific-oligonucleotide hybridization to examine the frequency of these three candidate mutations in patients with tyrosinemia type I and in the population of Quebec. Results. The splice mutation was found in 100 percent of patients from the Saguenay-Lac-St.-Jean area and in 28 percent of patients from other regions of the world. Of 25 patients from the Saguenay-Lac-St.-Jean region, 20 (80 percent) were homozygous for this mutation, a guanine-to-adenine change in the splice-donor sequence in intron 12 of the gene, indicating that it causes most cases of tyrosinemia type I in the region. The frequency of carrier status, based on screening of blood spots from newborns, was about 1 per 25 in the Saguenay-Lac-St.-Jean population and about 1 per 66 overall in Quebec. Conclusions. This study identified the most prevalent mutation causing hereditary tyrosinemia in French Canada; it also showed the feasibility of DNA-based testing for carriers in the population at risk.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; CHU LAVAL,CTR RECH,GENET CELLULAIRE & MOLEC LAB,ST FOY,PQ,CANADA	Oregon Health & Science University; Laval University	GROMPE, M (corresponding author), OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,MAIL CODE L103,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Grompe, Markus/0000-0002-6616-4345	NICHD NIH HHS [HD-28585-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD028585] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGSTERIBBE E, 1990, NUCLEIC ACIDS RES, V18, P1887, DOI 10.1093/nar/18.7.1887; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; DEMERS SI, 1994, AM J HUM GENET, V55, P327; GROMPE M, 1993, HUM MUTAT, V2, P85, DOI 10.1002/humu.1380020205; HARTL DL, 1988, PRIMER POPULATION GE, P7; HECHTMAN P, 1990, AM J HUM GENET, V47, P815; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; John S. W. M., 1992, Human Mutation, V1, P72, DOI 10.1002/humu.1380010112; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Kvittingen E.A., 1986, SCAND J CLIN LAB I S, V184, P27; KVITTINGEN EA, 1983, PEDIATR RES, V17, P541, DOI 10.1203/00006450-198307000-00005; LABELLE Y, 1993, HUM MOL GENET, V2, P941, DOI 10.1093/hmg/2.7.941; LABERGE C, 1990, AM J HUM GENET, V47, P329; LABERGE C, 1969, AM J HUM GENET, V21, P36; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; MITCHELL GA, IN PRESS METABOLIC B, V1; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PARADISK, 1990, AM J HUM GENET, V47, P328; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; PHANEUF D, 1991, AM J HUM GENET, V48, P525; ROZEN R, 1992, AM J MED GENET, V42, P360, DOI 10.1002/ajmg.1320420322; SALT A, 1992, ACTA PAEDIATR, V81, P449, DOI 10.1111/j.1651-2227.1992.tb12270.x; Sambrook J., 1989, MOL CLONING LAB MANU; STLOUIS M, 1994, HUM MOL GENET, V3, P69, DOI 10.1093/hmg/3.1.69; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; TANGUAY RM, 1984, ADV GENE TECHNOLOGY, P250; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135; [No title captured]	31	91	94	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					353	357		10.1056/NEJM199408113310603	http://dx.doi.org/10.1056/NEJM199408113310603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028615				2022-12-01	WOS:A1994PA37400003
J	NELSON, S; TOTH, L; SHETH, B; SUR, M				NELSON, S; TOTH, L; SHETH, B; SUR, M			ORIENTATION SELECTIVITY OF CORTICAL-NEURONS DURING INTRACELLULAR BLOCKADE OF INHIBITION	SCIENCE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPAL SLICES; SYNAPTIC POTENTIALS; STRIATE CORTEX; SIMPLE CELLS; MECHANISMS; RESPONSES; EXCITATION; RECORDINGS; RECEPTOR	Neurons in the primary visual cortex of the cat are selectively activated by stimuli with particular orientations. This selectivity can be disrupted by the application of antagonists of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to a local region of the cortex. In order to determine whether inhibitory inputs are necessary for a single cortical neuron to show orientation selectivity, GABA receptors were blocked intracellularly during whole cell recording. Although the membrane potential, spontaneous activity, subfield antagonism, and directional selectivity of neurons were altered after they were perfused internally with the blocking solution, 18 out of 18 neurons remained selective for stimulus orientation. These results indicate that excitatory inputs are sufficient to generate orientation selectivity.			NELSON, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.			Nelson, Sacha/0000-0002-0108-8599	NATIONAL EYE INSTITUTE [U01EY006363, U10EY006363] Funding Source: NIH RePORTER; NEI NIH HHS [EY06363, EY07023] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1388, DOI 10.1152/jn.1989.62.6.1388; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; BORGGRAHAM LJ, 1992, THESIS MIT; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOKUBUN S, 1991, PFLUG ARCH EUR J PHY, V418, P204, DOI 10.1007/BF00370515; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; METHERATE R, 1993, J NEUROSCI, V13, P5312, DOI 10.1523/JNEUROSCI.13-12-05312.1993; NELSON SB, 1991, J NEUROSCI, V11, P369; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; SHIRASAKI T, 1992, J PHYSIOL-LONDON, V449, P551, DOI 10.1113/jphysiol.1992.sp019101; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; Somers D., 1993, Society for Neuroscience Abstracts, V19, P628; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; WHITE EL, 1989, CORTICAL CIRCUITS, P69; XING P, 1991, NEUROREPORT, V2, P485; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3	32	207	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					774	777		10.1126/science.8047882	http://dx.doi.org/10.1126/science.8047882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047882				2022-12-01	WOS:A1994PA37200031
J	FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC				FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC			NUP145P IS REQUIRED FOR NUCLEAR EXPORT OF MESSENGER-RNA AND BINDS HOMOPOLYMERIC RNA IN-VITRO VIA A NOVEL CONSERVED MOTIF	CELL			English	Article							XENOPUS-LAEVIS OOCYTES; PORE MEMBRANE DOMAIN; COLD-SHOCK PROTEIN; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN-PARTICLES; NUCLEOCYTOPLASMIC TRANSPORT; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE	An essential yeast protein, Nup145p, is identified via its genetic interaction with the nucleoporin Nsp1p. Nup145p contains GLFG repeats and localizes to nuclear pores. Depletion of Nup145p in vivo leads rapidly to nuclear retention of polyadenylated RNAs and more slowly to cytoplasmic accumulation of a nuclear reporter protein. A stretch of 140 amino acids within Nup145p is conserved in two other yeast nucleoporins, Nup116p and Nup100p, and in an uncharacterized C. elegans protein. Genetic experiments in yeast reveal that the three copies of the motif carry out an essential, redundant function. Fragments of Nup145p and Nup116p including this motif bind specifically to homopolymeric RNAs in vitro. Nup145p, Nup116p, and Nup100p thus represent a novel class of nucleoporins involved in nucleocytoplasmic transport.			FABRE, E (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Ed Hurt, Dr./AAE-8874-2019; Boelens, Wilbert/D-8877-2012	Ed Hurt, Dr./0000-0002-4535-8255; FABRE, Emmanuelle/0000-0002-0009-4604; Mattaj, Iain/0000-0002-5537-8284				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bossie MA, 1992, CURR OPIN GENET DEV, V2, P768, DOI 10.1016/S0959-437X(05)80137-6; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GOLDFARB DS, 1992, CELL, V70, P185, DOI 10.1016/0092-8674(92)90094-S; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITOH H, 1983, J BACTERIOL, V153, P163; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5466; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	87	123	129	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					275	289		10.1016/0092-8674(94)90297-6	http://dx.doi.org/10.1016/0092-8674(94)90297-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044840				2022-12-01	WOS:A1994NZ24200011
J	WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW				WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW			CRYSTAL-STRUCTURE OF THE CYSTEINE PROTEASE INTERLEUKIN-1-BETA-CONVERTING ENZYME - A (P20/P10)(2) HOMODIMER	CELL			English	Article							IL-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; TRIACYLGLYCEROL LIPASE; INTERLEUKIN 1-BETA; MOLECULAR-CLONING; TRIAD FORMS; RESOLUTION; FIBROBLASTS	Interleukin-1 beta-converting enzyme (ICE) proteolytically cleaves pro-IL-1 beta to its mature, active form. The crystal structure at 2.5 Angstrom resolution of a recombinant human ICE-tetrapeptide chloromethylketone complex reveals that the holoenzyme is a homodimer of catalytic domains, each of which contains a p20 and a p10 subunit. The spatial separation of the C-terminus of p20 and the N-terminus of pin in each domain suggests two alternative pathways of assembly and activation in vivo. ICE is homologous to the C. elegans cell death gene product, CED-3, and these may represent a novel class of cytoplasmic cysteine proteases that are important in programmed cell death (apoptosis). Conservation among members of the ICE/CED-3 family of the amino acids that form the active site region of ICE supports the hypothesis that they share functional similarities.	BASF BIORES CORP, WORCESTER, MA 01605 USA	BASF	WALKER, NPC (corresponding author), BASF AG, MAIN LAB, D-67056 LUDWIGSHAFEN, GERMANY.		Somani, ally-khan/AAA-9656-2020	Somani, Ally-Khan/0000-0003-2166-4896				BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P11; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NETT MA, 1992, J IMMUNOL, V149, P3254; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; POWERS JC, 1977, CHEM BIOCH AMINO ACI, V4, P65; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	60	518	556	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					343	352		10.1016/0092-8674(94)90303-4	http://dx.doi.org/10.1016/0092-8674(94)90303-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044845				2022-12-01	WOS:A1994NZ24200017
J	PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM				PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM			ASSOCIATION OF POLYOMAVIRUS MIDDLE TUMOR-ANTIGEN WITH 14-3-3-PROTEINS	SCIENCE			English	Article							SMALL T-ANTIGEN; CELLULAR PROTEINS; TRANSFORMATION; PHOSPHATASE-2A; COMPLEXES; FAMILY; CELLS	To carry out its transformation function, the middle tumor antigen (MT) of murine polyomavirus associates with a number of cellular proteins involved in regulation of cell proliferation, including pp60(c-Src), phosphatidylinositol 3-kinase, protein phosphatase 2A, Src homologous and collagen protein and growth factor receptor-binding protein 2. Here, two additional MT-associated proteins were identified as members of the 14-3-3 family of proteins. Yeast homologs of 14-3-3 proteins have recently been shown to play a role in the timing of mitosis. Thus, regulation of 14-3-3 protein function by MT may contribute to the development of neoplasia.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PALLAS, DC (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA030002, R29CA045285, P01CA050661, R01CA057327, R37CA030002] Funding Source: NIH RePORTER; NCI NIH HHS [CA50661, CA30002, CA45285, R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; PALLAS D, UNPUB; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	16	164	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					535	537		10.1126/science.8036498	http://dx.doi.org/10.1126/science.8036498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036498				2022-12-01	WOS:A1994NY21600034
J	PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J				PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J			DET1, A NEGATIVE REGULATOR OF LIGHT-MEDIATED DEVELOPMENT AND GENE-EXPRESSION IN ARABIDOPSIS, ENCODES A NOVEL NUCLEAR-LOCALIZED PROTEIN	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CHLOROPLAST DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; PLANT; SEQUENCE; YEAST; TRANSFORMATION; PATHWAYS; MUTANTS; DNA	The mechanisms by which plants integrate light signals to modify endogenous developmental programs are largely unknown. One candidate for a signal transduction component that may integrate light with developmental pathways is the Arabidopsis DET1 gene product. Here we report the positional cloning of the DET1 locus and show that DET1 is a unique nuclear-localized protein. An analysis of a number of det1 mutants indicates that mutants with partial DET1 activity develop as light-grown plants in the dark. det1 null mutants share this phenotype, but also display severe defects in temporal and spatial regulation of gene expression. These results suggest that DET1 acts in the nucleus to control the cell type-specific expression of light-regulated promoters.			PEPPER, A (corresponding author), SALK INST, PLANT BIOL LAB, SAN DIEGO, CA 92186 USA.		Delaney, Terrence P/A-2947-2008					ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LIN S, 1993, PLANT CELL, V5, P109, DOI 10.1105/tpc.5.1.109; Meer I. M. van der, 1993, Control of plant gene expression., P125; MISERA S, 1994, IN PRESS MOL GEN GEN; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROSE MD, 1990, METHODS YEAST GENETI; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946	36	242	250	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					109	116		10.1016/0092-8674(94)90577-0	http://dx.doi.org/10.1016/0092-8674(94)90577-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033202				2022-12-01	WOS:A1994NX32800013
J	ODOWD, TC; BOURNE, N				ODOWD, TC; BOURNE, N			INVENTING A NEW DIAGNOSTIC-TEST FOR VAGINAL INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL VAGINOSIS; CHLAMYDIA-TRACHOMATIS; WOMEN; FLUID	Bacterial vaginosis, which is underdiagnosed in clinical practice, has a characteristic fishy smell because of production of diamines. This smell is the basis of a visual rapid diagnostic test that is technically simple to perform. The test has been patented in Europe and America, and a licence agreement has been negotiated. This paper describes the process from idea to invention to patenting and licensing. The combined costs of research and patenting were met by a multinational company in return for rights to exploit the patented invention. The process has taken nine years and has needed clinical, scientific, legal, and commercial input to get the test to the marketplace.	UNIV WALES COLL CARDIFF, CARDIFF CF1 3XA, S GLAM, WALES	Cardiff University	ODOWD, TC (corresponding author), TRINITY COLL DUBLIN, DEPT COMMUNITY HLTH & GEN PRACTICE, DUBLIN 2, IRELAND.							[Anonymous], 1977, PATENTS ACT; CHEN KCS, 1982, J INFECT DIS, V145, P337, DOI 10.1093/infdis/145.3.337; DAVIS RH, 1991, Patent No. 2215044; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; GRAVETT M G, 1986, Journal of the American Medical Association, V256, P1899, DOI 10.1001/jama.256.14.1899; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MEAD G, 1992, FINANCIAL TIMES 0409, P11; ODOWD TC, 1988, BRIT MED J, V292, P1640; PEARSON H, 1990, COMMERCIAL EXPLOITAT, P1; THOMASON JL, 1988, OBSTET GYNECOL, V71, P67; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; 1992, PREPARE UK PATENT AP; 1992, INTELLECTUAL PROPERT, P1	16	6	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					40	42		10.1136/bmj.309.6946.40	http://dx.doi.org/10.1136/bmj.309.6946.40			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044068	Green Published			2022-12-01	WOS:A1994NV89100026
J	HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG				HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG			MEDIATION OF EPSTEIN-BARR-VIRUS EBNA2 TRANSACTIVATION BY RECOMBINATION SIGNAL-BINDING PROTEIN J(K)	SCIENCE			English	Article							RNA POLYMERASE-II; NUCLEAR ANTIGEN-2; DROSOPHILA HOMOLOG; J-KAPPA; PROMOTER; SEQUENCE; ELEMENT; GENE; DNA; PURIFICATION	The Epstein-Barr virus (EBV) transactivator protein, termed Epstein-Barr virus nuclear antigen 2 (EBNA2), plays a critical role in the regulation of latent viral transcription and in the immortalization of EBV-infected B cells. Unlike most transcription factors, EBNA2 does not bind directly to its cis-responsive DNA element but requires a cellular factor, termed C-promoter binding factor 1 (CBF1). Here, CBF1 was purified and was found to directly interact with EBNA2. CBF1 is identical to a protein thought to be involved in immunoglobulin gene rearrangement, RBPJ(k)appa. Contrary to previous reports, CBF1-RBPJ(k)appa did not bind to the recombination signal sequences but instead bound to sites in the EBV C-promoter and in the CD23 promoter.	TULARIK INC,S SAN FRANCISCO,CA 94080; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA42245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042245, R37CA042245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JIN XW, 1992, J VIROL, V66, P2846, DOI 10.1128/JVI.66.5.2846-2852.1992; KIEFF E, 1990, VIROLOGY, P1889; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MILLER G, 1990, VIROLOGY, P1921; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SUNG NS, 1991, J VIROL, V65, P2161; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	24	382	394	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					92	95		10.1126/science.8016657	http://dx.doi.org/10.1126/science.8016657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016657				2022-12-01	WOS:A1994NV30100032
J	KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S				KONDE, M; INGENBLEEK, Y; DAFFE, M; SYLLA, B; BARRY, O; DIALLO, S			GOITROUS ENDEMIC IN GUINEA	LANCET			English	Article							NUTRITIONAL-STATUS; DARFUR REGION; GOITER; MILLET; SUDAN; EPIDEMIOLOGY; ETIOLOGY	We identified a major goitrous area in the Republic of Guinea, characterised by an overall goitre prevalence of 70% in adults. Thyroid swelling was sometimes present at birth and affected 55% of schoolchildren. A difference between sexes appeared at puberty. Endemic cretinism, mainly in its myxoedematous form, was found in about 2% of goitrous patients. In this region, iodine deficiency is the primary causative factor (median urinary concentrations of 16 mu g/L, and in 69% of inhabitants below the critical threshold of 20 mu g/L). The diet contained substantial amounts of thiocyanate anions (median 6 mg/L in urine and in 27%, more than 10 mg/L) likely to further depress iodine bioavailability. Other dietary compounds, notably flavonoids were suspected to contribute. Overall nutritional and general health appeared satisfactory. The affected population is borderline euthyroid with a trend towards hypothyroidism in protracted disease. This area of Guinea may be regarded as the epicentre of the west African endemic acid as one of the most severely goitrous regions ever described, requiring urgent public health measures.	UNIV STRASBOURG 1,DEPT FOOD SCI,F-67400 ILLKIRCH GRAFFENS,FRANCE; DIRECT PUBL HLTH,CONAKRY,GUINEA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALDRIDGE WN, 1945, ANALYST, V70, P474; BEDIAKO BM, 1985, STUDIES PREVALENCE E, P1; BENMILOUD M, 1983, CASSAVA TOXICITY THY, P49; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; BOURDOUX P, 1986, PAHO SCI PUBL, V502, P115; COURTOIS P, 1982, NUTR FACTORS INVOLVE, P65; DEVISSCHER M, 1980, THYROID GLAND, P377; Dunn JT, 1990, ICCIDDUNICEFWHO3 TEC, P1; ELTOM M, 1985, ACTA ENDOCRINOL-COP, V108, P356, DOI 10.1530/acta.0.1080356; ELTOM M, 1984, ACTA MED SCAND, V215, P467; GAITAN B, 1986, PAHO WHO SCI PUBL, V502, P28; GAITAN E, 1989, J CLIN ENDOCR METAB, V68, P707, DOI 10.1210/jcem-68-4-707; HERSHMAN JM, 1986, PAHO WHO SCI PUBL, V502, P96; INGENBLEEK Y, 1980, LANCET, V1, P388; INGENBLEEK Y, 1975, METABOLISM, V24, P633, DOI 10.1016/0026-0495(75)90143-2; INGENBLEEK Y, 1985, INT J VITAM NUTR RES, V55, P91; INGENBLEEK Y, 1994, ANNU REV NUTR, V14, P495, DOI 10.1146/annurev.nu.14.070194.002431; INGENBLEEK Y, 1979, METABOLISM, V28, P9, DOI 10.1016/0026-0495(79)90162-8; Ingenbleek Y., 1980, THYROID GLAND, P499; KELLY FC, 1960, WHO MONOGR SER, V44, P117; KLOPFENSTEIN CF, 1983, NUTR REP INT, V27, P1039; KOUTRAS DA, 1980, ENDEMIC GOITER ENDEM, P255; LATAPIE JL, 1981, ANN ENDOCRINOL-PARIS, V42, P517; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; OLIVEIRA AL, 1991, B WORLD HEALTH ORGAN, V63, P347; OSMAN AK, 1981, ECOL FOOD NUTR, V11, P121, DOI 10.1080/03670244.1981.9990666; PEREZ C, 1960, WHO MONOGRAPHS SERIE, V44, P369; ROUX F, 1983, MED NUTR, V19, P339; Sandell E.B., 1937, MICROCHIM ACTA, V1, P9, DOI DOI 10.1007/BF01476194; Snedecor G. W., 1967, STATISTICAL METHODS, P91; STANBURY JB, 1980, IODINE NUTRITION HLT, P1; WILSON DC, 1954, T ROY SOC TROP MED H, V48, P481, DOI 10.1016/0035-9203(54)90083-8; WOLLMAN SH, 1962, AM J PHYSIOL, V203, P517, DOI 10.1152/ajplegacy.1962.203.3.517	33	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1675	1678		10.1016/S0140-6736(94)90461-8	http://dx.doi.org/10.1016/S0140-6736(94)90461-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996963				2022-12-01	WOS:A1994PX30200012
J	HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I				HARRISON, SL; MACLENNAN, R; SPEARE, R; WRONSKI, I			SUN EXPOSURE AND MELANOCYTIC NEVI IN YOUNG AUSTRALIAN CHILDREN	LANCET			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED NEVI; DYSPLASTIC NEVI; VANCOUVER MOLE; NEVOCYTIC NEVI; RISK-FACTORS; COMMON; PREVALENCE; SCHOOLCHILDREN; QUEENSLAND	Queensland, Australia, has the highest rates of melanoma in the world and Queensland children have the greatest numbers of melanocytic naevi, the strongest risk factor for melanoma. Although both melanoma and naevi are broadly related to sun exposure in childhood, the relation to individual exposure early in life is difficult to study retrospectively in adults. We surveyed 506 children aged 1-6 years who had been born in Townsville, North Queensland, Sun exposure was assessed by questionnaire and melanocytic naevi were counted using a standard international protocol. Very high counts (upper quarter) of melanocytic naevi were Significantly associated with sun exposure of more than 4 hours per day (adjusted relative risk ratio 3.29; 95% CI 1.12-9.69), and with a history of sunburn (1.89; 1.11-3.21). Melanocytic naevus counts increased with age, light skin reflectance, and freckling. With exposure to intense ultraviolet light in Townsville, children develop melanocytic naevi early in life and in large numbers. We found that both acute and chronic exposure to sun are associated with their development.	QUEENSLAND INST MED RES,EPIDEMIOL UNIT,BRISBANE,QLD 4006,AUSTRALIA	QIMR Berghofer Medical Research Institute	HARRISON, SL (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT PUBL HLTH & TROP MED,ANTON BREINI CTR,TOWNSVILLE,QLD 4811,AUSTRALIA.		Harrison, Simone Lee/U-3429-2018; Harrison, Simone Lee/CAF-2591-2022	Harrison, Simone Lee/0000-0001-5309-0773; Harrison, Simone Lee/0000-0001-5309-0773; Speare, Rick/0000-0002-9993-1213				ARMSTRONG BK, 1986, J NATL CANCER I, V77, P329; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P512; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P518; COOKE KR, 1985, INT J CANCER, V36, P175, DOI 10.1002/ijc.2910360208; ELWOOD JM, 1986, BRIT J CANCER, V53, P65, DOI 10.1038/bjc.1986.10; ENGLISH DR, 1994, AM J EPIDEMIOL, V139, P1; ENGLISH DR, 1990, IARC90002 INT AG RES; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P466, DOI 10.1001/archderm.126.4.466; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GREEN A, 1989, J AM ACAD DERMATOL, V20, P1054, DOI 10.1016/S0190-9622(89)70131-6; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P460; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; HORNBY F, 1986, TOWNSVILLE REGION SO; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; Kopf A W, 1978, J Dermatol Surg Oncol, V4, P153; KOPF AW, 1986, ARCH DERMATOL, V122, P1003, DOI 10.1001/archderm.122.9.1003; Lund CC., 1944, SURG GYNECOL OBSTET, V79, P352; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098, DOI 10.1056/nejm198710223171717; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; POPE DJ, 1992, ARCH DERMATOL, V128, P1201, DOI 10.1001/archderm.128.9.1201; RAMPEN FHJ, 1988, J AM ACAD DERMATOL, V18, P679, DOI 10.1016/S0190-9622(88)70090-0; SIGG C, 1989, DERMATOLOGICA, V179, P123, DOI 10.1159/000248337; SORAHAN T, 1990, J AM ACAD DERMATOL, V22, P747, DOI 10.1016/0190-9622(90)70102-N; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	30	163	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1529	1532		10.1016/S0140-6736(94)90348-4	http://dx.doi.org/10.1016/S0140-6736(94)90348-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983952				2022-12-01	WOS:A1994PV01700008
J	ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO				ESPINOZA, FH; OGAS, J; HERSKOWITZ, I; MORGAN, DO			CELL-CYCLE CONTROL BY A COMPLEX OF THE CYCLIN HCS26 (PCL1) AND THE KINASE PHO85	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; PHOSPHATASE; SYSTEM; GENE; G1; TRANSCRIPTION; REGULATORS; PHASE; CDC28	The events of the eukaryotic cell cycle are governed by cyclin-dependent kinases (cdk's), whose activation requires association with cyclin regulatory subunits expressed at specific cell cycle stages. In the budding yeast Saccharomyces cerevisiae, the cell cycle is thought to be controlled by a single cdk, CDC28. Passage through the G(1) phase of the cell cycle is regulated by complexes of CDC28 and G(1) cyclins (CLN1, CLN2, and CLN3). A putative G(1) cyclin, HCS26, has recently been identified. In a/alpha diploid cells lacking CLN1 and CLN2, HCS26 is required for passage through G(1). HCS26 does not associate with CDC28, but instead associates with PHO85, a closely related protein kinase. Thus, budding yeast, like higher eukaryotes, use multiple cdk's in the regulation of cell cycle progression.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Morgan, David/0000-0001-8753-4416; Ogas, Joe/0000-0002-1332-7729; Espinoza, Francisco/0000-0002-1855-1914	NATIONAL CANCER INSTITUTE [R01CA052481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER; NCI NIH HHS [CA52481] Funding Source: Medline; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ESPINOZA FH, UNPUB; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MURPHTY SM, 1993, MOL CELL BIOL, V19, P5290; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAS J, UNPUB; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	22	133	139	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1388	1391		10.1126/science.7973730	http://dx.doi.org/10.1126/science.7973730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973730				2022-12-01	WOS:A1994PT63200045
J	BOISMENU, R; HAVRAN, WL				BOISMENU, R; HAVRAN, WL			MODULATION OF EPITHELIAL-CELL GROWTH BY INTRAEPITHELIAL GAMMA-DELTA T-CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; ANTIGEN RECEPTORS; MURINE EPIDERMIS; EXPRESSION; LYMPHOCYTES; KGF	The role played in immune surveillance by gamma delta T cells residing in various epithelia has not been clear. It is shown here that activated gamma delta T cells obtained from skin and intestine express the epithelial cell mitogen keratinocyte growth factor (KGF). In contrast, intraepithelial alpha beta T cells, as well as all lymphoid alpha beta and gamma delta T cell populations tested, did not produce KGF or promote the growth of cultured epithelial cells. These results suggest that intraepithelial gamma delta T cells function in surveillance and in repair of damaged epithelial tissues.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032751, R01AI032751, R21AI032751] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ARSANOW D, 1989, NATURE, V341, P60; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BOISMENU R, UNPUB; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; FALCO JP, 1988, ONCOGENE, V2, P573; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; PAYER E, 1992, SPRINGER SEMIN IMMUN, V13, P315; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; ULICH TR, 1994, AM J PATHOL, V144, P862; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	26	549	558	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1253	1255		10.1126/science.7973709	http://dx.doi.org/10.1126/science.7973709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973709				2022-12-01	WOS:A1994PT13200057
J	PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS				PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS			MAJOR EXPANSION OF CD8+ T-CELLS WITH A PREDOMINANT V-BETA USAGE DURING THE PRIMARY IMMUNE-RESPONSE TO HIV	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VARIABLE REGION GENES; CD8+ LYMPHOCYTES-T; VACCINIA VIRUS; EXPRESSION VECTOR; INFECTION; CHAIN; RECOGNITION; SEQUENCES; DIVERSITY	A SIGNIFICANT proportion (up to 70%) of individuals experience an acute clinical syndrome of varying severity associated with primary infection with the human immunodeficiency virus (HIV)(1-4). We report here studies on six individuals who showed an acute HIV syndrome which generally resolved within four weeks, concomitant with a dramatic downregulation of viraemia(2-5). To characterize the T-cell-mediated primary immune response to HIV, we used combined semiquantitative polymerase chain reaction assay and cytofluorometry to analyse the T-cell antigen receptor repertoire in sequential peripheral blood mononuclear cells from the patients. We found major oligoclonal expansions in a restricted set of variable-domain beta-chain (V beta) families. Cells expressing the expanded V beta s predominantly expressed the CD8 T-cell differentiation antigen and mediated HIV-specific cytotoxicity. Major oligoclonal expansions of these CD8(+) T lymphocytes may represent an important component of the primary immune response to viral infections and may help to clarify both the immunopathogenic and the protective mechanisms of HIV infection.	INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, PQ, CANADA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, PQ, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL H3A 2B4, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute; Universite de Montreal; McGill University	PANTALEO, G (corresponding author), NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA.		graziosi, cecilia/M-1882-2019; Pantaleo, Giuseppe/K-6163-2016	Borrow, Persephone/0000-0002-3877-9780				BORROW P, IN PRESS J VIROL; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FERRADINI L, 1991, EUR J IMMUNOL, V21, P935, DOI 10.1002/eji.1830210412; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REBAI N, 1994, P NATL ACAD SCI USA, V91, P1529, DOI 10.1073/pnas.91.4.1529; SMITH TJ, 1993, BLOOD, V81, P1521; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514	26	566	584	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					463	467		10.1038/370463a0	http://dx.doi.org/10.1038/370463a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047166	Bronze			2022-12-01	WOS:A1994PB40700057
J	ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR				ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR			HIV AND TUBERCULOSIS INFECTION IN SAN-FRANCISCOS HOMELESS ADULTS - PREVALENCE AND RISK-FACTORS IN A REPRESENTATIVE SAMPLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; NEW-YORK-CITY; UNITED-STATES; SHELTER; WOMEN; MEN; HEALTH; EPIDEMIC; OUTBREAK	Objective.-To determine the prevalence and risk factors for human immunodeficiency virus (HIV) and tuberculosis (TB) infection and investigate the relationship between these two infections in homeless adults. Design.-Cross-sectional study. Setting.-Inner-city shelters and free meal programs. Participants.-A representative sample of 1226 adults (greater than or equal to 18 years) were enrolled from community sites. Main Outcome Measures.-Serum HIV-1 antibody status and tuberculin skin test reactivity. Results.-Human immunodeficiency virus seroprevalence was 8.5% (95% confidence interval [Cl], 7.0% to 10.1%) and the prevalence of TB infection was 32% (95% Cl, 30% to 37%). Nineteen percent of the HIV-seropositive subjects had positive tuberculin skin tests. Independent risk factors for HIV infection included younger age, black race, male homosexual contact, injection drug use, use of injection drugs in shooting galleries, and selling sex. Tuberculosis infection was associated with the duration of homelessness and living in crowded shelters or single-room-occupancy hotels. Injection drug use, a risk factor for HIV, was also a risk factor for TB, with a particularly strong association in women. No evidence of an association between TB and HIV infection was found, even after accounting for anergy. Conclusions.-The homeless population in the United States should be considered a group at high risk for HIV infection and TB. Given the constellation of risk factors present, the high prevalence of infection, and lack of access to medical services, we anticipate that these communicable diseases in this population will represent a growing public health problem.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,SAN FRANCISCO,CA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health			Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Pilote, Louise/0000-0002-6159-0628	NIDA NIH HHS [R01-DA04363-07] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004363] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLEN DM, 1992, 8TH INT C AIDS AMST, V2, pC297; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; BRUNDNEY K, 1991, AM REV RESPIR DIS, V144, P745; BURNAM MA, 1988, EVALUATION REV, V12, P117, DOI 10.1177/0193841X8801200202; CELENTANO DD, 1991, AM J PUBLIC HEALTH, V81, P1291, DOI 10.2105/AJPH.81.10.1291; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; COATES T, 1990, AIDS 2 DECADE, P38; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; ENGLE A, 1977, US DHEW HRA771649 PU; ERICKSON JR, 1992, 8TH INT C AIDS AMST, V2, pC297; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA, P638; Knopf SA, 1914, J AMER MED ASSOC, V63, P1720; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCADAM JM, 1990, SAFETY NET HLTH SOCI, P234; MOSS AR, 1992, BRIT J ADDICT, V87, P467; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; REICHMAN LB, 1978, AM REV RESPIR DIS, V117, P705; REICHMAN LB, 1992, NEW ENGL J MED, V326, P703; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHLAY J, 1992, 8TH INT C AIDS AMST, V2, pC298; SLUTKIN G, 1986, AM REV RESPIR DIS, V134, P1048, DOI 10.1164/arrd.1986.134.5.1048; TERRIS M, 1948, AM J PUBLIC HEALTH, V88, P1061; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P1394; 1979, TUBER LUNG DIS, V60, P191; 1991, MMWR-MORBID MORTAL W, V40, P859; 1991, MMWR-MORBID MORTAL W, V40, P869; 1985, MMWR-MORBID MORTAL W, V34, P429; 1993, HIV SEROPREVALENCE R, V4, P7; 1993, HIV SEROPREVALENCE R, V4, P6; 1991, MMWR-MORBID MORTAL W, V40, P865; 1989, MMWR-MORBID MORTAL W, V38, P236; 1992, MMWR-MORBID MORTAL W, V41, P1	49	200	203	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					455	461		10.1001/jama.272.6.455	http://dx.doi.org/10.1001/jama.272.6.455			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040981				2022-12-01	WOS:A1994PA27800027
J	ROSKIES, AL; OLEARY, DDM				ROSKIES, AL; OLEARY, DDM			CONTROL OF TOPOGRAPHIC RETINAL AXON BRANCHING BY INHIBITORY MEMBRANE-BOUND MOLECULES	SCIENCE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; POSITION-SPECIFIC PROPERTIES; TECTAL CELL-MEMBRANES; RETINOTECTAL PROJECTION; VISUAL-SYSTEM; XENOPUS TADPOLES; NEURITE GROWTH; MAP FORMATION; INVITRO; GUIDANCE	Retinotopic map development in nonmammalian vertebrates appears to be controlled by molecules that guide or restrict retinal axons to correct locations in their targets. However, the retinotopic map in the superior colliculus (SC) of the rat is developed instead by a topographic bias in collateral branching and arborization. Temporal retinal axons extending across alternating membranes from the topographically correct rostral SC or the incorrect caudal SC of embryonic rats preferentially branch on rostral membranes. Branching preference is due to an inhibitory phosphatidylinositol-linked molecule in the caudal SC. Thus, position-encoding membrane-bound molecules may establish retinotopic maps in mammals by regulating axon branching, not by directing axon growth.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute					NEI NIH HHS [NEI RO1 EY07025] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007025] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; COLELLO RJ, IN PRESS J NEUROSCI; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CORNEL E, 1992, NEURON, V9, P1001, DOI 10.1016/0896-6273(92)90061-H; COX EC, 1990, NEURON, V2, P31; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; Fraser S E, 1992, Curr Opin Neurobiol, V2, P83, DOI 10.1016/0959-4388(92)90167-J; FUJISAWA H, 1984, DEV GROWTH DIFFER, V26, P545; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1987, DEVELOPMENT, V101, P479; GODEMENT P, 1989, DEVELOPMENT, V106, P313; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATSUI K A, 1989, Society for Neuroscience Abstracts, V15, P1212; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; OLEARY DDM, 1992, SEMIN NEUROSCI, V4, P365; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; Roskies A. L., 1992, Society for Neuroscience Abstracts, V18, P222; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1993, CELL NEURON S, V72, P77; SIMON DK, 1992, J NEUROSCI, V12, P1212; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SIMON DK, 1992, NEURON, V9, P1; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; TUTTLE R, 1991, J NEUROSCI METH, V39, P193, DOI 10.1016/0165-0270(91)90085-E; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VIELMETTER J, 1989, NEURON, V2, P1331, DOI 10.1016/0896-6273(89)90071-8; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909	50	116	116	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					799	803		10.1126/science.8047886	http://dx.doi.org/10.1126/science.8047886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047886				2022-12-01	WOS:A1994PA37200038
J	NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC				NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC			MALARIA IN US MARINES RETURNING FROM SOMALIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PLASMODIUM-FALCIPARUM; PREVENTION; TRAVELERS; AFRICA	Objective.-To identify malaria in US Marines returning from Somalia and to determine their compliance with chemoprophylaxis. Design.-Case series. Setting.-The US Navy health care system. Patients.-Consecutive sample of 106 US Marines diagnosed with malaria after returning from Somalia in 1993. Main Outcome Measures.-Identification of the incidence and clinical features of imported malaria. Determination of compliance with chemoprophylaxis in this cohort. Results.-As of December 20, 1993, there were 112 cases of imported malaria in 106 US Marine Corps personnel returning from Somalia. Plasmodium vivax accounted for 97 (87%) of 112 malaria cases, and Plasmodium falciparum accounted for eight (7%) of 112 cases. Mixed infection with P vivax and P falciparum was noted in six (5%) of 112 cases, and a single case of Plasmodium malariae was identified. Patients with P falciparum malaria were diagnosed a mean of 20.9 days (range, 1 to 82 days) after returning to the United States compared with 91.8 days (range, 7 to 228 days) for P vivax infection (P<.0001). The self-reported chemoprophylaxis compliance rate was 56%; however, only 45 (50%) of 90 patients were given an optimal chemoprophylaxis regimen. Conclusions.-Noncompliance with personal protective measures and chemoprophylaxis contributed to the largest outbreak of imported malaria in US military personnel since the Vietnam conflict. Since military personnel frequently go on leave after deployment, health care providers throughout the United States must be aware of the presence of imported malaria from Somalia.	USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA 92134; USN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA; USN HOSP,DEPT INTERNAL MED,CAMP PENDLETON,CA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								BARRETT O, 1969, AM J TROP MED HYG, V18, P495, DOI 10.4269/ajtmh.1969.18.495; KEAN BH, 1976, AM J MED, V61, P159, DOI 10.1016/0002-9343(76)90164-9; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; LOBEL HO, 1985, J INFECT DIS, V152, P613, DOI 10.1093/infdis/152.3.613; LYNK A, 1989, PEDIATR INFECT DIS J, V8, P745, DOI 10.1097/00006454-198911000-00003; OLDFIELD EC, 1993, CLIN INFECT DIS S3, V16, pS131; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; WALLACE MR, 1993, CLIN INFECT DIS, V17, P510, DOI 10.1093/clinids/17.3.510; ZUCKER JR, 1993, INFECT DIS CLIN N AM, V7, P547; 1993, MMWR-MORBID MORTAL W, V42, P524; 1993, MMWR-MORBID MORTAL W, V42, P976; 1991, 1990 CTR DIS CONTR M	12	60	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					397	399		10.1001/jama.272.5.397	http://dx.doi.org/10.1001/jama.272.5.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028173				2022-12-01	WOS:A1994NY90300034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBLE ELECTROMAGNETIC-INTERFERENCE PROBLEMS WITH WHEELCHAIRS AND OTHER MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-01	WOS:A1994NY90300005
J	HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL				HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL			A PROPOSAL TO DEVELOP MEANINGFUL LABELING FOR CIGARETTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-YIELD CIGARETTES; CARBON-MONOXIDE; NICOTINE; SMOKING; TAR; BLOCKING; EXPOSURE; VENTS		PENN STATE UNIV,COLL HLTH & HUMAN DEV,PROGRAM BIOBEHAV HLTH,UNIV PK,PA 16802; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL & EXPTL THERAPEUT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HENNINGFIELD, JE (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							BENOWITZ NL, 1986, JAMA-J AM MED ASSOC, V256, P241; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, IN PRESS N ENGL J ME; Browne C. L., 1990, DESIGN CIGARETTES; COHEN JB, 1992, J PUBLIC POLICY MARK, V11, P82, DOI 10.1177/074391569201100109; HENNINGFIELD JE, 1984, ADV BEHAV PHARMACOL, V4, P131; KOZLOWSKI LT, 1980, SCIENCE, V209, P1550, DOI 10.1126/science.7433979; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; KOZLOWSKI LT, 1981, JAMA-J AM MED ASSOC, V245, P158, DOI 10.1001/jama.245.2.158; KOZLOWSKI LT, 1983, NATIONAL I DRUG ABUS, V48; PILLSBURY HC, 1969, J ASSOC OFF ANA CHEM, V52, P458; SHAPIRO E, 1994, WALL STREET J   0421, pB7; YOUNG JC, 1981, J TOXICOL ENV HEALTH, V7, P801, DOI 10.1080/15287398109530021; 1991, TAR NICOTINE CARBON; 1993, FED REG 4       0106; 1988, DHHS CDC888406 PUBL; 1986, DHHS CDC878398 PUBL	20	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					312	314		10.1001/jama.272.4.312	http://dx.doi.org/10.1001/jama.272.4.312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028146				2022-12-01	WOS:A1994NX80600035
J	SIMON, R; CARPENTER, R; DOYLE, S; COEN, E				SIMON, R; CARPENTER, R; DOYLE, S; COEN, E			FIMBRIATA CONTROLS FLOWER DEVELOPMENT BY MEDIATING BETWEEN MERISTEM AND ORGAN IDENTITY GENES	CELL			English	Article							FLORAL HOMEOTIC GENES; ANTIRRHINUM-MAJUS; ARABIDOPSIS; TRANSCRIPTION; TRANSPOSON; EXPRESSION; DEFICIENS	Two major classes of genes directing flower development have so far been described: early activated genes regulating meristem identity and later acting genes controlling organ identity. Here, we show that the fimbriata (fim) gene acts between these two classes in a sequence of gene activation. The fim gene, originally described in 1930, was cloned by transposon tagging from Antirrhinum majus and encodes a product with no detectable homology to other proteins. Mutations in fim result in partial homeotic transformations of floral organs and in reduced determinacy of the meristem. Expression and function of fim depends on the activity of meristem identity genes, and fim in turn controls the spatial and temporal expression of organ identity genes. The pattern of fim expression defines a new domain of the floral meristem that changes with time in a complementary manner to those of the meristem identity gene floricaula and the organ identity gene plena.			SIMON, R (corresponding author), JOHN INNES CTR PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Simon, Rudiger/T-6755-2018	Simon, Rudiger/0000-0002-1317-7716				BAUR ERWIN, 1930, ZEITSCHR BOT, V23, P676; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1993, PLANT CELL, V5, P1175, DOI 10.1105/tpc.5.10.1175; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; HARTE C, 1951, Z INDUKT ABSTAMM VER, V83, P392; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x	16	103	106	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					99	107		10.1016/0092-8674(94)90576-2	http://dx.doi.org/10.1016/0092-8674(94)90576-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033217				2022-12-01	WOS:A1994NX32800012
J	MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM				MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM			A TYROSYL-TRANSFER-RNA SYNTHETASE CAN FUNCTION SIMILARLY TO AN RNA STRUCTURE IN THE TETRAHYMENA RIBOZYME	NATURE			English	Article							GROUP-I INTRON; SECONDARY STRUCTURE; TERTIARY STRUCTURE; SEQUENCE; CORE; DOMAIN; SITES	GROUP I introns are highly structured RNAs which catalyse their own splicing by guanosine-initiated transesterification reactions(1,2). Their catalytic core is generally stabilized by RNA-RNA interactions within the core and with peripheral RNA structures(3,4). Additionally, some group I introns require proteins for efficient splicing in vivo(5). The Neurospora CYT-18 protein, the mitochondrial tyrosyl-transfer RNA synthetase (mt TyrRS), promotes splicing of the Neurospora mitochondrial large ribosomal RNA (LSU) and other group I introns by stabilizing the catalytically active structure of the intron core(6-8). We report here that CYT-18 functions similarly to a peripheral RNA structure, P5abc, that stabilizes the catalytic core of the Tetrahymena LSU intron. The CYT-18 protein and P5abc RNA bind to overlapping sites in the intron core, inducing similar conformational changes correlated with splicing activity. Our results show that a protein can play the role of an RNA structure in a catalytic RNA, a substitution postulated for the evolution of nuclear pre-messenger RNA introns from self-splicing introns(9,10).	OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHEMIACK AD, 1990, CELL, V62, P745; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; STREICHER B, 1993, NUCLEIC ACIDS RES, V21, P311; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	28	105	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					147	150		10.1038/370147a0	http://dx.doi.org/10.1038/370147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022484				2022-12-01	WOS:A1994NW80400059
J	WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN				WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN			INVOLVEMENT OF THE JAK-3 JANUS KINASE IN SIGNALING BY INTERLEUKIN-2 AND INTERLEUKIN-4 IN LYMPHOID AND MYELOID CELLS	NATURE			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR GAMMA-CHAIN; ERYTHROPOIETIN RECEPTOR; INTERFERON-ALPHA/BETA; TRANSDUCTION; PHOSPHORYLATION; PATHWAY; FAMILY; IL-2	MANY cytokines function through interaction with receptors of the cytokine receptor superfamily. Although lacking catalytic domains, cytokine receptors couple ligand binding to induction of protein tyrosine phosphorylation. Recent studie(1-10) have shown that one or more of the Janus kinase family members (Jaks) associate with cytokine receptors and are tyrosine phosphorylated and activated following ligand binding. Here we describe a new Jak family kinase, Jak-3, and demonstrate that Jak-3, and to a lesser extent Jak-1, are tyrosine phosphorylated and Jak-3 is activated in the responses to interleukin-2 and interleukin-4 in T cells and myeloid cells. Jak-3 activation requires the serine-rich, membrane-proximal domain of the interleukin-3 receptor beta-chain, but does not require the acidic domain that is required for association and activation of Src family kinases.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOL, CHAPEL HILL, NC 27599 USA	St Jude Children's Research Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill			witthuhn, bruce/GSE-3193-2022; Liu, Edison/C-4141-2008	Miura, Osamu/0000-0002-0981-3054				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARTGETSINGER LS, 1993, CELL, V74, P237; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	30	584	598	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					153	157		10.1038/370153a0	http://dx.doi.org/10.1038/370153a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022486				2022-12-01	WOS:A1994NW80400061
J	BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T				BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T			ABSORPTION OF NONHEME IRON FROM FOOD DURING NORMAL-PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							FOLATE SUPPLEMENTS; DIETARY IRON; ZINC	Objective-To determine whether the increased iron demands of pregnancy could be met by increased absorption from dietary sources. Design and setting-longitudinal prospective study in the research unit of a maternity hospital. Subjects-12 normal pregnant women. Interventions-At 12, 24, and 36 weeks' gestation (within one week) and 16-24 weeks after delivery women ate a breakfast of meat, bread, and orange juice (3.2 mg iron), extrinsically labelled with the stable isotope iron-54 (2.8 mg); the stable isotope iron-57 (200 mu g) was given intravenously. Main outcome measures-Serum samples were taken for 10 hours after administration of the isotopes; ratios of the isotopes were measured by inductively coupled plasma mass spectrometry, and the absorption of oral iron was calculated. Results-The geometric mean (95% confidence interval) absorption of iron at 12, 24, and 36 weeks' gestation was 7% (5% to 11%), 36% (28% to 47%), and 66% (57% to 76%) respectively. At 16-24 weeks after delivery the absorption was 11% (6% to 21%). The mean increase in absorption at 36 weeks (compared with that at 12 weeks) was 9.1 times (6.0 to 13.7). One pregnant woman developed iron deficiency anaemia but was otherwise indistinguishable from the others. Conclusions-An increase in the absorption of iron from food is a physiological consequence of normal pregnancy, not the result of developing anaemia during pregnancy, and such an increase is large enough to meet the increased requirements of pregnancy provided that the dietary intake is adequate.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT OBSTET & GYNAECOL,NEWCASTLE TYNE NE1 4LP,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,NERC,ICP MS FACIL,ASCOT SL5 7TE,BERKS,ENGLAND	Newcastle University - UK; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)								BARRETT JFR, IN PRESS CLIN SCI; BJORNRASMUSSEN E, 1976, AM J CLIN NUTR, V26, P1311; BLACK AE, 1986, BRIT J NUTR, V56, P59, DOI 10.1079/BJN19860085; BONNAR J, 1969, LANCET, V1, P457; Bothwell T.H., 1979, IRON METABOLISM MAN; COOK JD, 1991, AM J CLIN NUTR, V54, P717, DOI 10.1093/ajcn/54.4.717; CROFTON RW, 1989, AM J CLIN NUTR, V50, P141, DOI 10.1093/ajcn/50.1.141; DARKE SJ, 1980, BRIT J NUTR, V44, P243, DOI 10.1079/BJN19800037; Gibaldi M., 1982, PHARMACOKINETICS, V2nd, P145, DOI DOI 10.1111/jvp.12458; HAHN PF, 1951, AM J OBSTET GYNECOL, V61, P477, DOI 10.1016/0002-9378(51)91394-4; HAMBIDGE KM, 1987, OBSTET GYNECOL, V70, P593; HEINRICH HC, 1970, IRON DEFICIENCY, P213; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HYTTEN F, 1985, CLIN HAEMATOL, V14, P601; LIND T, 1983, NUTRITION PREGNANCY, P181; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRITCHARD JA, 1970, IRON DEFICIENCY, P173; Ramdath D D, 1989, Nutr Res Rev, V2, P29, DOI 10.1079/NRR19890006; REYNOLDS LG, 1985, S AFR MED J, V67, P680; ROSSANDER L, 1979, AM J CLIN NUTR, V32, P2484, DOI 10.1093/ajcn/32.12.2484; SCHOFIELD C, 1989, BRIT J NUTR, V62, P363, DOI 10.1079/BJN19890037; SOUTHON S, 1989, BRIT J NUTR, V62, P707, DOI 10.1079/BJN19890071; Svanberg B, 1975, Acta Obstet Gynecol Scand Suppl, V48, P43; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; WHITTAKER PG, 1991, BRIT J NUTR, V65, P457, DOI 10.1079/BJN19910104; 1979, 15 DEP HLTH SOC SEC; 1981, GEIGY SCI TABLES; 1991, PURE APPL CHEM, V63, P991; 1972, WHO TECH REP SER, V503, P29; 1993, JAMA-J AM MED ASSOC, V270, P2846; 1990, NUTRITION PREGNANCY, P272	34	115	116	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					79	82		10.1136/bmj.309.6947.79	http://dx.doi.org/10.1136/bmj.309.6947.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038670	Green Published			2022-12-01	WOS:A1994NW71600013
J	MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J				MORGAN, R; KING, D; PRAJAPATI, C; ROWE, J			VIEWS OF ELDERLY PATIENTS AND THEIR RELATIVES ON CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							ATTITUDES; DECISIONS		BROADGREEN HOSP,DEPT MED,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool								DAVIES KN, 1993, J ROY COLL PHYS LOND, V27, P127; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; STEWART K, 1990, BRIT MED J, V300, P785, DOI 10.1136/bmj.300.6727.785; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653	5	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1677	1678		10.1136/bmj.308.6945.1677a	http://dx.doi.org/10.1136/bmj.308.6945.1677a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	7993423	Green Published			2022-12-01	WOS:A1994NU48300022
J	BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D				BEHL, C; DAVIS, JB; LESLEY, R; SCHUBERT, D			HYDROGEN-PEROXIDE MEDIATES AMYLOID-BETA PROTEIN TOXICITY	CELL			English	Article							SUPEROXIDE-GENERATING OXIDASE; FAMILIAL ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; PRECURSOR PROTEIN; GLUTAMATE TOXICITY; GROWTH-FACTOR; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; CORTICAL-NEURONS; CELLS	Amyloid beta protein (A beta) is a 40-43 amino acid peptide that is associated with plaques in the brains of Alzheimer's patients and is cytotoxic to cultured neurons. Using both primary central nervous system cultures and clonal cell lines, it is shown that a number of antioxidants protect cells from A beta toxicity, suggesting that at least one pathway to A beta cytotoxicity results in free radical damage. A beta causes increased levels of H2O2 and lipid peroxides to accumulate in cells. The H2O2-degrading enzyme catalase protects cells from A beta toxicity. Clonal cell lines selected for their resistance to A beta toxicity also become resistant to the cytolytic action of H2O2. In addition, A beta induces the activity of NF-kappa B, a transcription factor thought to be regulated by oxidative stress. Finally, A beta-induced H2O2 production and A beta toxicity are blocked by reagents that inhibit flavin oxidases, suggesting that A beta activates a member of this class of enzymes. These results show that the cytotoxic action of A beta on neurons results from free radical damage to susceptible cells.			BEHL, C (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92186 USA.			Behl, Christian/0000-0001-8453-2378				ABE K, 1990, JPN J PHARMACOL, V53, P221, DOI 10.1254/jjp.53.221; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Halliwell B., 1989, FREE RADICAL BIO MED; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KIMURA H, 1992, J CELL BIOL, V116, P777, DOI 10.1083/jcb.116.3.777; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; LEES GJ, 1993, NEUROSCIENCE, V54, P287, DOI 10.1016/0306-4522(93)90254-D; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Schubert D., 1984, DEV BIOL CULTURED NE; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; VOGT M, 1963, P NATL ACAD SCI USA, V49, P171, DOI 10.1073/pnas.49.2.171; WOZNIAK A, 1989, IMMUNOLOGY, V68, P359; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	52	1952	2027	0	216	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					817	827		10.1016/0092-8674(94)90131-7	http://dx.doi.org/10.1016/0092-8674(94)90131-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004671				2022-12-01	WOS:A1994NT33100007
J	PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF				PTACEK, LJ; TAWIL, R; GRIGGS, RC; ENGEL, AG; LAYZER, RB; KWIECINSKI, H; MCMANIS, PG; SANTIAGO, L; MOORE, M; FOUAD, G; BRADLEY, P; LEPPERT, MF			DIHYDROPYRIDINE RECEPTOR MUTATIONS CAUSE HYPOKALEMIC PERIODIC PARALYSIS	CELL			English	Article							CHANNEL ALPHA-SUBUNIT; SLOW CALCIUM CURRENT; SKELETAL-MUSCLE; SODIUM-CHANNEL; PARAMYOTONIA-CONGENITA; MUSCULAR DYSGENESIS; GENE; MICE; LINKAGE; DNA	Hypokalemic periodic paralysis (hypoKPP) is an autosomal dominant skeletal muscle disorder manifested by episodic weakness associated with low serum potassium. Genetic linkage analysis has localized the hypoKPP gene to chromosome 1q31-q32 near a dihydropyridine (DHP) receptor gene. This receptor functions as a voltage-gated calcium channel and is also critical for excitation-contraction coupling in a voltage-sensitive and calcium-independent manner. We have characterized patient-specific DHP receptor mutations in 11 probands of 33 independent hypoKPP kindreds that occur at one of two adjacent nucleotides within the same codon and predict substitution of a highly conserved arginine in the S4 segment of domain 4 with either histidine or glycine. In one kindred, the mutation arose de novo. Taken together, these data establish this DHP receptor as the hypoKPP gene. We are unaware of any other human diseases presently known to result from DHP receptor mutations.	UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14642; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; MED ACAD WARSAW,DEPT NEUROL,PL-02097 WARSAW,POLAND	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Rochester; Mayo Clinic; University of California System; University of California San Francisco	PTACEK, LJ (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT NEUROL,SALT LAKE CITY,UT 84132, USA.			Griggs, Robert/0000-0001-7988-4854	NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHGRI NIH HHS [8 R01 HG00367] Funding Source: Medline; NICHD NIH HHS [1 K11 HD00940-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K11HD000940] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000367] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; CASLEY WL, 1992, GENOMICS, V14, P493, DOI 10.1016/S0888-7543(05)80249-6; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; ENGEL AG, 1970, MAYO CLIN PROC, V45, P774; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Fontaine B, 1991, Neuromuscul Disord, V1, P235, DOI 10.1016/0960-8966(91)90095-A; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GOUW L, 1994, IN PRESS NEUROLOGY; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GREGG RG, 1993, GENOMICS, V15, P107, DOI 10.1006/geno.1993.1017; GRIGGS RC, 1992, HOSP PRACT, V27, P123; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LEONARD JP, 1982, EXP NEUROL, V76, P121, DOI 10.1016/0014-4886(82)90106-6; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCLATCHEY AI, 1992, NAT GENET, V2, P148; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POWELL JA, 1973, J CELL PHYSIOL, V82, P21, DOI 10.1002/jcp.1040820104; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; PTACEK LJ, 1994, IN PRESS NEUROLOGY; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUDEL R, 1984, MUSCLE NERVE, V7, P110, DOI 10.1002/mus.880070205; RUDOLPH JA, 1992, NAT GENET, V2, P1144; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WROGEMANN K, 1976, LANCET, V27, P672	38	334	352	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					863	868						6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004673				2022-12-01	WOS:A1994NT33100011
J	JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM				JARVIS, WR; BOLYARD, EA; BOZZI, CJ; BURWEN, DR; DOOLEY, SW; MARTIN, LS; MULLAN, RJ; SIMONE, PM			RESPIRATORS, RECOMMENDATIONS, AND REGULATIONS - THE CONTROVERSY SURROUNDING PROTECTION OF HEALTH-CARE WORKERS FROM TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; NOSOCOMIAL TRANSMISSION; OUTBREAK	Recent nosocomial outbreaks of tuberculosis have increased concern about the occupational acquisition of tuberculosis by health care workers. The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, and the Occupational Safety and Health Administration, Department of Labor, have issued recommendations and regulations in an effort to decrease health care workers' risk for exposure to patients with infectious tuberculosis. Within the CDC, the National Center for Infectious Diseases, the National Center for Prevention Services, and the National Institute for Occupational Safety and Health collaborated to produce the 1994 Guidelines for Preventing the Transmission of Tuberculosis in Health-Care Facilities. As stated in the Draft Guidelines, the major components of health care worker protection from Mycobacterium tuberculosis infection include administration or source controls, engineering controls, and respiratory protective devices. We review the evolution of the seemingly conflicting recommendations for respiratory protective devices made by these Centers of the CDC and explain how the recommendations in the current CDC Guidelines were reached.	CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, NCPS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NIOSH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	JARVIS, WR (corresponding author), CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, 1600 CLIFTON RD NE, MS E-69, ATLANTA, GA 30333 USA.							Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LEIDEL NA, 1992, NIOSH RECOMMENDED GU; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; WENGER P, 1992, 1ST WORLD C TUB ROCK; 1982, CDC828371 US DEP HLT; 1993, MMWR-MORBID MORTAL W, V42, P696; 1987, DHHS NIOSH87116 PUBL; 1994, FED REG         0524, P26850; 1972, FED REGISTER, V37, P1910; 1993, DRAFT GUIDELINES PRE	18	43	44	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					142	146		10.7326/0003-4819-122-2-199501150-00011	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992989				2022-12-01	WOS:A1995QC05900011
J	CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS				CHANG, Y; CESARMAN, E; PESSIN, MS; LEE, F; CULPEPPER, J; KNOWLES, DM; MOORE, PS			IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA	SCIENCE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; HOMOSEXUAL MEN; CYTOMEGALO-VIRUS; BISEXUAL MEN; COHORT; INFECTION; COFACTORS; DISEASE; GENOME	Representational difference analysis was used lo isolate unique sequences present in more than 90 percent of Kaposi's sarcoma (KS) tissues obtained from patients with acquired immunodeficiency syndrome (AIDS). These sequences were not present in tissue DNA from non-AIDS patients, but were present in 15 percent of non-KS tissue DNA samples from AIDS patients. The sequences are homologous to, but distinct from, capsid and tegument protein genes of the Gammaherpesvirinae, herpesvirus saimiri and Epstein-Barr virus. These KS-associated herpesvirus-like (KSHV) sequences appear to define a new human herpesvirus.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT BIOL MOLEC,PALO ALTO,CA 94304; NEW YORK CITY DEPT HLTH,DIS INTERVENT COMMISS,NEW YORK,NY 10013; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10013	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; New York City Department of Health & Mental Hygiene; Columbia University	CHANG, Y (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Pessin, Melissa/0000-0003-3990-6494				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCHIBALD CP, 1992, EPIDEMIOLOGY, V3, P203, DOI 10.1097/00001648-199205000-00004; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BENDSOE N, 1990, EUR J CANCER, V26, P699, DOI 10.1016/0277-5379(90)90120-I; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BOVENZI P, 1993, LANCET, V341, P1288, DOI 10.1016/0140-6736(93)91198-U; DREW WL, 1982, LANCET, V2, P125; Giraldo G, 1983, Antibiot Chemother (1971), V32, P1; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; HOLMBERG SD, 1990, CANCER DETECT PREV, V14, P331; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; JOHNSTON GS, 1990, CANCER DETECT PREV, V14, P337; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KINGSLEY L, UNPUB; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; LIN JC, 1993, BLOOD, V81, P3372; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; PELLICI PG, 1985, J EXP MED, V162, P1015; PETERMAN TA, 1991, CANCER SURV, V10, P23; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SCHECHTER MT, 1991, AM J EPIDEMIOL, V134, P485, DOI 10.1093/oxfordjournals.aje.a116120; SIDDIQUI A, 1983, P NATL ACAD SCI-BIOL, V80, P4861, DOI 10.1073/pnas.80.15.4861; VANDENBERG F, 1989, J CLIN PATHOL, V42, P128, DOI 10.1136/jcp.42.2.128; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724	30	4578	4788	5	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1865	1869		10.1126/science.7997879	http://dx.doi.org/10.1126/science.7997879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997879	Green Submitted			2022-12-01	WOS:A1994PX38300036
J	DICKEY, W				DICKEY, W			EPILEPSY, CEREBRAL CALCIFICATIONS, AND CELIAC-DISEASE	LANCET			English	Editorial Material							CELIAC-DISEASE				DICKEY, W (corresponding author), ANTRIM HOSP,ANTRIM,NORTH IRELAND.							AMBROSETTO G, 1992, EPILEPSIA, V33, P476, DOI 10.1111/j.1528-1157.1992.tb01695.x; BARDELLA MT, 1994, ARCH DIS CHILD, V70, P211, DOI 10.1136/adc.70.3.211; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COOKE WT, 1966, BRAIN, V89, P683, DOI 10.1093/brain/89.4.683; ERRANZ E, 1994, GUT, V35, P476; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GOBBI G, 1992, LANCET, V340, P439; MAGAUDDA A, 1993, J NEUROL NEUROSUR PS, V56, P885, DOI 10.1136/jnnp.56.8.885; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; PIATTELLA L, 1993, CHILD NERV SYST, V9, P172; SAMMARITANO M, 1988, Neurology, V38, P239; TIACCI C, 1993, EPILEPSIA, V34, P528, DOI 10.1111/j.1528-1157.1993.tb02592.x; TORTORELLA G, 1993, NEUROPEDIATRICS, V24, P341, DOI 10.1055/s-2008-1071569	14	17	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1585	1586		10.1016/S0140-6736(94)90400-6	http://dx.doi.org/10.1016/S0140-6736(94)90400-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983988				2022-12-01	WOS:A1994PW05100003
J	URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M				URBANEK, P; WANG, ZQ; FETKA, I; WAGNER, EF; BUSSLINGER, M			COMPLETE BLOCK OF EARLY B-CELL DIFFERENTIATION AND ALTERED PATTERNING OF THE POSTERIOR MIDBRAIN IN MICE LACKING PAX5/BSAP	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; HOMEOBOX-CONTAINING GENE; PROTO-ONCOGENE INT-1; DNA-BINDING PROTEIN; IMMUNOGLOBULIN HEAVY; PAIRED BOX; CHAIN GENE; WAARDENBURG SYNDROME; TARGETED DISRUPTION; HINDBRAIN BOUNDARY	The Pax5 gene, coding for the transcription factor BSAP, was mutated in the mouse germline by targeted disruption. Homozygous mutant mice were born alive, became growth retarded, and usually died within three weeks. About 5% of mutants survived to adulthood and were fertile, but severely runted. Morphogenesis of the posterior midbrain was affected as early as embryonic day 16.5, leading to a reduction of the inferior colliculus near the midline and to altered foliation of the anterior cerebellum. Moreover, all mutants failed to produce small pre-B, B, and plasma cells owing to a complete arrest of B cell development at an early precursor stage. These data define a key role for Pax5 in early a lymphopoiesis and midbrain patterning.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Wagner, Erwin F/0000-0001-7872-0196				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOBER E, 1994, DEVELOPMENT, V120, P603; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BUCKWALTER MS, 1993, GENOMICS, V17, P279, DOI 10.1006/geno.1993.1322; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DUCHEN LW, 1964, BRAIN, V87, P367, DOI 10.1093/brain/87.2.367; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LIAO F, 1992, J IMMUNOL, V148, P2909; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MASTERTON RB, 1992, TRENDS NEUROSCI, V15, P280, DOI 10.1016/0166-2236(92)90077-L; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WURST W, 1994, DEVELOPMENT, V120, P2065; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; YOON C. H., 1957, JOUR HEREDITY, V48, P176; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	66	660	666	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					901	912		10.1016/0092-8674(94)90079-5	http://dx.doi.org/10.1016/0092-8674(94)90079-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001127				2022-12-01	WOS:A1994PW05400017
J	DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT				DOWNES, CS; CLARKE, DJ; MULLINGER, M; GIMENEZABIAN, JF; CREIGHTON, AM; JOHNSON, RT			A TOPOISOMERASE II-DEPENDENT G2 CYCLE CHECKPOINT IN MAMMALIAN-CELLS	NATURE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ULTRAVIOLET-IRRADIATION; MITOTIC CHROMOSOMES; STRAND BREAKS; EGG EXTRACTS; DNA; REPLICATION; SEPARATION; INHIBITION; CAFFEINE	THE enzyme DNA topoisomerase II, which removes the catenations formed between the DNA molecules of sister chromatids during replication(1) and is a structural component of chromosome cores(2), is needed for chromosome condensation in yeast(3) and in Xenopus extracts(4-6). Inhibitors of topoisomerase II arrest mammalian cells before mitosis in the G2 phase of the cell cycle(7), but also produce DNA damage, which causes arrest through established checkpoint controls(8). It is open to question whether cells need topoisomerase II to leave G2, or control late-cycle progression in response to its activity. Bisdioxopiperazines are topoisomerase II inhibitors that act without producing direct DNA damage(9); the most potent, ICRF-193, blocks mammalian entry into but not exit from mitosis. Here we show that checkpoint-evading agents such as caffeine override this block to produce abortively condensed chromosomes, indicating that topoisomerase II is needed for complete condensation. We find that exit from G2 is regulated by a catenation-sensitive checkpoint mechanism which is distinct from the G2-damage checkpoint.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT REPROD PHYSIOL,MED CHEM LAB,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	DOWNES, CS (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,CRC,MAMMALIAN CELL DNA REPAIR RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Abián, Juan F Giménez/E-6372-2015	Abián, Juan F Giménez/0000-0002-9220-286X; Clarke, Duncan/0000-0002-7795-3294				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AHNSTROM G, 1974, INT J RADIAT BIOL, V26, P493, DOI 10.1080/09553007414551511; CLARKE DJ, 1993, J CELL SCI, V105, P563; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; CREIGHTON AM, 1969, NATURE, V222, P384, DOI 10.1038/222384a0; CREIGHTON AM, 1979, ADV MED ONCOL RES ED, V5, P83; Downes CS, 1991, P NATL ACAD SCI USA, V88, P2616; GORBSKY GJ, 1994, CANCER RES, V54, P1042; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; ISHIDA R, 1991, CANCER RES, V51, P4909; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Johnson Robert David, 1994, CELL CYCLE PRACTICAL, P1; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KALWINSKY DK, 1983, CANCER RES, V43, P1592; LOCK RB, 1990, CANCER RES, V50, P3761; MA XJ, 1993, J BIOL CHEM, V268, P6182; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MUSK SRR, 1990, BIOCHIM BIOPHYS ACTA, V1052, P53, DOI 10.1016/0167-4889(90)90057-K; MUSK SRR, 1988, J CELL SCI, V90, P591; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; RUFAS JS, 1987, GENOME, V29, P706, DOI 10.1139/g87-121; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHARPE HBA, 1970, NATURE, V226, P524, DOI 10.1038/226524a0; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	30	281	287	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					467	470		10.1038/372467a0	http://dx.doi.org/10.1038/372467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984241				2022-12-01	WOS:A1994PV01200058
J	HOOPER, JE				HOOPER, JE			DISTINCT PATHWAYS FOR AUTOCRINE AND PARACRINE WINGLESS SIGNALING IN DROSOPHILA EMBRYOS	NATURE			English	Article							CELL-CELL COMMUNICATION; HEDGEHOG GENE; PATCHED GENE; PROTEIN; TRANSCRIPTION; SECRETION; PRODUCT; EXPRESSION; EPIDERMIS; MUTATIONS	Two secreted proteins, Wingless(1,2) and Hedgehog(3,4), instruct cell fates within the segmented epidermis of Drosophila embryos (reviewed in ref. 5). Wingless (Wg) is expressed by the most posterior cells in each parasegment; Hedgehog (Hh) is expressed in the most anterior cells of the next parasegment. Immediately after gastrulation, the two cell types are mutually dependent(6,7). Local Wg signalling stabilizes Hh expression(8-10) and local Hh signalling stabilizes Wg expression(11,12). Direct Wg autoregulation (autocrine signalling) is masked by its paracrine role in maintaining hh, which in turn maintains wg. I have used zeste-white3 (zw3)(13) and patched (ptc)(11,14) mutant backgrounds to uncouple genetically this positive-feedback loop and to study autocrine Wg signalling. I report here that direct Wg autoregulation differs from Wg signalling to adjacent cells in the importance of fused (fu), smoothened (smo) and cubitus interruptus (ci) relative to zw3 and armadillo (arm). I also find that Wg autoregulation during this early hh-dependent phase differs from later Wg autoregulation(15) by lack of gooseberry (gsb) participation.			HOOPER, JE (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FORBES AJ, 1993, DEVELOPMENT, P115; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042	31	117	121	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					461	464		10.1038/372461a0	http://dx.doi.org/10.1038/372461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984239				2022-12-01	WOS:A1994PV01200056
J	OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K				OUBRIDGE, C; ITO, N; EVANS, PR; TEO, CH; NAGAI, K			CRYSTAL-STRUCTURE AT 1.92 ANGSTROM RESOLUTION OF THE RNA-BINDING DOMAIN OF THE U1A SPLICEOSOMAL PROTEIN COMPLEXED WITH AN RNA HAIRPIN	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; X-RAY-DIFFRACTION; HNRNP-C-PROTEINS; A-PROTEIN; PREMESSENGER RNA; SYNTHETASE; SNRNA; RECOGNITION; POLYADENYLATION; CRYSTALLOGRAPHY	The crystal structure of the RNA-binding domain of the small nuclear ribonucleoprotein U1A bound to a 21-nucleotide RNA hairpin has been determined at 1.92 Angstrom resolution. The ten-nucleotide RNA loop binds to the surface of the beta-sheet as an open structure, and the AUUGCAC sequence of the loop interacts extensively with the conserved RNP1 and RNP2 motifs and the C-terminal extension of the RNP domain. These interactions include stacking of RNA bases with aromatic side chains of proteins and many direct and water-mediated hydrogen bonds. The structure reveals the stereochemical basis for sequence-specific RNA recognition by the RNP domain.			OUBRIDGE, C (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Oubridge, Chris/0000-0001-8492-8305				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; COSIER J, 1986, J APPL CRYSTALLOGR, V19, P105, DOI 10.1107/S0021889886089835; GALT MJ, 1991, OLIGONUCLEOTIDE SYNT, P25; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LESLIE AGW, 1992, JOINT CCP4 AND ESF E; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGAI K, 1991, ISOMORPHOUS REPLACEM, P141; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013	50	800	816	2	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					432	438		10.1038/372432a0	http://dx.doi.org/10.1038/372432a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984237				2022-12-01	WOS:A1994PV01200047
J	SURRIDGE, C				SURRIDGE, C			FOREWARNED IS 4-ARMED	NATURE			English	Editorial Material							BINDING; P53							Surridge, Christopher/0000-0003-4264-5176				CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581	5	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					482	482		10.1038/372482a0	http://dx.doi.org/10.1038/372482a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984245	Bronze			2022-12-01	WOS:A1994PV01200062
J	WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF				WANG, ZQ; FUNG, MR; BARLOW, DP; WAGNER, EF			REGULATION OF EMBRYONIC GROWTH AND LYSOSOMAL TARGETING BY THE IMPRINTED IGF2/MPR GENE	NATURE			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II; TME LOCUS; MOUSE; CELLS; ACTIVATION; DISRUPTION; PROTEINS; BINDING; DEFECTS	THE receptor for insulin-like growth factor type 2, also known as the cation-independent mannose-6-phosphate receptor (Igf2/Mpr), is a multifunctional receptor thought to play a role in lysosomal targeting, cell growth and signal transduction(1-8). Igf2/Mpr has been mapped to the mouse Tme(9) locus and shown to be an imprinted gene(10), which further suggests a role in embryonic growth regulation. To define the functions of Igf2/Mpr, we have generated mice lacking this gene. We report here that maternal inheritance of an Igf2/Mpr null allele (-/+) as well as homozygosity for the inactive allele (-/-) is generally lethal at birth and mutants are about 30% larger, indicating that maternal expression of Igf2/Mpr is essential for late embryonic development and growth regulation. The phenotype is probably caused by an excess of Igf2 because the introduction of an Igf2 null allele rescued the Igf2/Mpr mutant mice. Mutant mice also have organ and skeletal abnormalities and missort mannose-6-phosphate-tagged proteins. A few (-/+) mice reactivated their paternal Igf2/Mpr allele in some tissues and survived to adults. But no (-/-) mice survived, indicating a role for the reactivated paternal allele in postnatal survival.			WANG, ZQ (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHLARA TM, 1990, CELL, V64, P849; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FILSON A, 1993, DEVELOPMENT, V116, P731; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FRANKEL HA, 1977, PEDIATR RES, V11, P811, DOI 10.1203/00006450-197707000-00007; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; JOHNSON DR, 1974, GENETICS, V76, P795; Kaufman M.H., 1992, ATLAS MOUSE DEV; KORNFELD S, 1992, REV BIOCH, V61, P307; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OKA Y, 1985, J BIOL CHEM, V260, P9435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VOGLER C, 1990, AM J PATHOL, V136, P2207; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	30	397	416	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 1	1994	372	6505					464	467		10.1038/372464a0	http://dx.doi.org/10.1038/372464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984240				2022-12-01	WOS:A1994PV01200057
J	KOFF, WC				KOFF, WC			THE NEXT STEPS TOWARD A GLOBAL AIDS VACCINE	SCIENCE			English	Editorial Material							ENVELOPE; ANTIBODIES; INDUCTION; IMMUNITY; ISSUES				KOFF, WC (corresponding author), UNITED BIOMED,VACCINE RES & DEV,25 DAVIDS DR,HAUPPAUGE,NY 11790, USA.							CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; COHEN J, 1994, SCIENCE, V264, P1839, DOI 10.1126/science.8009201; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DIXON DO, 1993, J ACQ IMMUN DEF SYND, V6, P485; ESPARZA J, 1993, CURR OPIN INFECT DIS, V6, P218, DOI 10.1097/00001432-199304000-00014; ESPARZA J, 1993, AIDS RES HUM RETR S1, V9, pS1133; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; KARZON DT, 1992, VACCINE, V10, P1039, DOI 10.1016/0264-410X(92)90114-Y; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; Mariner W K, 1987, Law Med Health Care, V15, P17; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MYERS G, 1993, HUMAN RETROVIRUSES A; PETRICCIANI JC, 1993, VACCINE, V11, P873, DOI 10.1016/0264-410X(93)90364-4; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; STEIN RE, 1992, VACCINE RES DEV, V1, P223; VERMUND SH, 1994, CURR OPIN INFECT DIS, V7, P82, DOI 10.1097/00001432-199402000-00014; VERMUND SH, 1993, EFFICACY HIV VACCINE, P187; WEININGER BG, IN PRESS AIDS; 1994, HIV VACCINES ACCELER; 1993, HUMAN IMMUNODEFICIEN; 1985, VACCINE SUPPLY INNOV; 1991, VACCINE, V9, P703	32	16	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 25	1994	266	5189					1335	1337		10.1126/science.7973724	http://dx.doi.org/10.1126/science.7973724			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7973724				2022-12-01	WOS:A1994PT63200030
J	CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR				CHIRUVOLU, S; WARRINER, HE; NARANJO, E; IDZIAK, SHJ; RADLER, JO; PLANO, RJ; ZASADZINSKI, JA; SAFINYA, CR			A PHASE OF LIPOSOMES WITH ENTANGLED TUBULAR VESICLES	SCIENCE			English	Article							THERMAL FLUCTUATIONS; MEMBRANES; LECITHIN; TRANSITION; ADHESION; SYSTEM; L3	An equilibrium phase belonging to the family of bilayer liposomes in ternary mixtures of dimyristoylphosphatidylcholine (DMPC), water, and geraniol (a biological alcohol derived from oil-soluble vitamins that acts as a cosurfactant) has been identified. Electron and optical microscopy reveal the phase, labeled L(tv), to be composed of highly entangled tubular vesicles. In situ x-ray diffraction confirms that the tubule walls are multilamellar with the lipids in the chain-melted state. Macroscopic observations show that the L(tv) phase coexists with the well-known L(4) phase of spherical vesicles and a bulk L(alpha) phase. However, the defining characteristic oi the L(tv) phase is the Weissenberg rod climbing effect under shear, which results from its polymer-like entangled microstructure.	UNIV CALIF SANTA BARBARA, DEPT CHEM ENGN,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT MAT,MAT RES LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOLEC BIOL PROGRAM, SANTA BARBARA, CA 93106 USA; EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Exxon Mobil Corporation			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bangham A.D., 1973, METHODS MEMBR BIOL, V1, P1; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Ben-Shaul A., 1994, MICELLES MEMBRANES M; Bird RB, 1977, DYNAMICS POLYM LIQUI, V1; CANTU L, 1990, EUROPHYS LETT, V13, P561, DOI 10.1209/0295-5075/13/6/015; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; COULON C, 1991, PHYS REV LETT, V66, P1709, DOI 10.1103/PhysRevLett.66.1709; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; HARBICH W, 1990, J PHYS-PARIS, V51, P1027, DOI 10.1051/jphys:0199000510100102700; HARBICH W, 1984, CHEM PHYS LIPIDS, V36, P39, DOI 10.1016/0009-3084(84)90089-6; HELFRICH W, 1985, CHEM SCRIPTA, V25, P32; HELFRICH W, 1986, J PHYS-PARIS, V47, P321, DOI 10.1051/jphys:01986004702032100; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HERVE P, 1993, J PHYS II, V3, P1255, DOI 10.1051/jp2:1993196; HOFFMANN H, 1992, LANGMUIR, V8, P2629, DOI 10.1021/la00047a011; Israelachvili J., 1992, INTERMOLECULAR SURFA; JANIAK MJ, 1979, J BIOL CHEM, V254, P6068; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KLOSGEN B, 1993, EUR BIOPHYS J, V22, P340; LASIC DD, 1993, LIPOSOMES PHYSICS AP; MCINTOSH TJ, 1989, BIOPHYS J, V55, P897, DOI 10.1016/S0006-3495(89)82888-7; Papahadjopoulos D., 1978, ANN NY ACAD SCI, V308, P1, DOI [10.1111/j.1749-6632.1978.tb22009.x, DOI 10.1111/J.1749-6632.1978.TB22009.X]; PORTE G, 1988, EUROPHYS LETT, V7, P713, DOI 10.1209/0295-5075/7/8/008; PORTE G, 1989, J PHYS-PARIS, V50, P1335, DOI 10.1051/jphys:0198900500110133500; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Safran S. A., 1994, STAT THERMODYNAMICS; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SCHNEIDER MB, 1984, BIOPHYS J, V45, P891, DOI 10.1016/S0006-3495(84)84235-6; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SERVUSS RM, 1987, PHYSICS COMPLEX SUPR; SPECTOR M, UNPUB; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	36	88	90	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1222	1225		10.1126/science.7973704	http://dx.doi.org/10.1126/science.7973704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973704	Green Submitted			2022-12-01	WOS:A1994PT13200049
J	FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D				FESKENS, EJM; HAVEKES, LM; KALMIJN, S; DEKNIJFF, P; LAUNER, LJ; KROMHOUT, D			APOLIPOPROTEIN E4 ALLELE AND COGNITIVE DECLINE IN ELDERLY MEN	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ALZHEIMER-DISEASE; CORONARY HEART-DISEASE; E POLYMORPHISM; TYPE-4 ALLELE; CHROMOSOME-19; STATE; GENE; APOE; RISK	Objectives-To determine whether polymorphism of apolipoprotein E-notably, the e4 allele- predicts cognitive deterioration in the general population. Design-Population based cohort investigated in 1990 and in 1993. Setting-Zutphen, the Netherlands. Subjects-Representative cohort of 538 Dutch men aged 70-89 at baseline. Main outcome measures-Cognitive function assessed by mini mental state examination, change in cognitive function and incidence of impaired cognitive function at three years. Results-The baseline prevalence of impaired cognitive function (mini mental state examination score less than or equal to 25) was higher among carriers of the e4 allele compared wth men without the allele (41.0% (55) v 31.1% (122) P=0.03), and this result was still valid after adjustment for age, occupation, smoking, alcohol use, and cardiovascular diseases. The decline in cognitive function at three years was largest in men homozygous for e4 (-2.4 points), intermediate in those heterozygous for e4 (-0.7 points), and lowest in men without e4 (-0.1 points), and it was independent of other risk factors (P=0.02). The risk of developing impaired cognitive function during follow up was significantly increased in allele carriers compared with non-carriers (27.6% (16/58) v 15.5% (32/207)). The adjusted odds ratio was 2.87 (95% confidence interval 1.29 to 6.42). Twenty two per cent of the risk of developing impaired cognitive function in this population may be attributable to the e4 allele. Conclusions-The apolipoprotein e4 allele predisposes to cognitive decline in a general population of elderly men.	TNO,INST PREVENT HLTH RES PG TNO,GAUBIUS LAB,LEIDEN,NETHERLANDS; ROTTERDAM MED SCH,DEPT EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Netherlands Organization Applied Science Research	FESKENS, EJM (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRONIC DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Feskens, Edith/ABI-1446-2020; Kromhout, Daan/A-8566-2014; Feskens, Edith JM/A-3757-2012; de Knijff, Peter/Y-2519-2018	Feskens, Edith/0000-0001-5819-2488; de Knijff, Peter/0000-0002-0899-771X				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAS HK, 1985, J BIOL CHEM, V260, P6240; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FILTENBAUM GG, 1988, PSYCHOL MED, V18, P1023; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HAVEKES LM, 1987, J LIPID RES, V28, P445; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KEYS A, 1967, ACTA MED SCAND, V460, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, pS12; LAUNER LJ, 1993, J GERONTOL, V48, P271; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PIORIER J, 1993, LANCET, V342, P697; REBECK GW, 1993, NEURON, V11, P575; Rose G, 1968, CARDIOVASCULAR SURVE; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIU AL, 1991, ANN INTERN MED, V134, P1303; SMIT M, 1988, HUM GENET, V80, P287, DOI 10.1007/BF01790099; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; 1990, STAT USERS GUIDE; 1993, LANCET, V342, P737; 1978, TECHNICAL REPORT SER, V628	34	151	153	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1202	1206		10.1136/bmj.309.6963.1202	http://dx.doi.org/10.1136/bmj.309.6963.1202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7987151	Green Published			2022-12-01	WOS:A1994PQ66200020
J	CHANG, PC; COHEN, SN				CHANG, PC; COHEN, SN			BIDIRECTIONAL REPLICATION FROM AN INTERNAL ORIGIN IN A LINEAR STREPTOMYCES PLASMID	SCIENCE			English	Article							DNA FRAGMENTS	Commonly, linear replicons that have protein covalently attached to 5' DNA termini replicate by protein-primed, strand-displacing, continuous synthesis of full-length strands. The synthesis of DNA in pSLA2, a 17-kilobase linear plasmid of Streptomyces rochei containing 5' terminal protein, occurs bidirectionally from an internally located replication origin. The replication intermediates are linear duplex molecules that have recessed (similar to 280 nucleotides) 5' ends rather than full-length single strands. The 3' over-hangs may serve as templates for the non-displacing synthesis of the lagging strand terminus primed by the covalently attached 5' DNA binding protein.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; HARDING NE, 1980, VIROLOGY, V104, P323, DOI 10.1016/0042-6822(80)90337-2; HINNEBUSCH J, 1993, MOL MICROBIOL, V10, P917, DOI 10.1111/j.1365-2958.1993.tb00963.x; HIROCHIKA H, 1982, PLASMID, V7, P59, DOI 10.1016/0147-619X(82)90027-0; HIROCHIKA H, 1984, EMBO J, V3, P761, DOI 10.1002/j.1460-2075.1984.tb01881.x; Hopwood D. A., 1985, GENETIC MANIPULATION; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KINASHI H, 1987, NATURE, V328, P454, DOI 10.1038/328454a0; LECHNER RL, 1977, CELL, V12, P1007, DOI 10.1016/0092-8674(77)90165-9; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEINHARDT F, 1990, CURR GENET, V17, P89, DOI 10.1007/BF00312851; SAKAGUCHI K, 1990, MICROBIOL REV, V54, P66, DOI 10.1128/MMBR.54.1.66-74.1990; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 1989, MOL CLONING LAB MANU; SHIFFMAN D, 1992, P NATL ACAD SCI USA, V89, P6129, DOI 10.1073/pnas.89.13.6129; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGIMOTO K, 1968, P NATL ACAD SCI USA, V60, P1356, DOI 10.1073/pnas.60.4.1356; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WU XN, 1993, J BACTERIOL, V175, P37, DOI 10.1128/JB.175.1.37-52.1993	21	87	95	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					952	954		10.1126/science.8052852	http://dx.doi.org/10.1126/science.8052852			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052852				2022-12-01	WOS:A1994PB49900042
J	GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC				GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC			ACTIVATION OF TRANSFORMING GROWTH-FACTOR-BETA IS INHIBITED IN TRANSGENIC APOLIPOPROTEIN(A) MICE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; EXPRESSING HUMAN APOLIPOPROTEIN(A); LIPOPROTEIN(A); PROLIFERATION; OSTEOPONTIN; CULTURE; INVITRO	A HIGH concentration of serum lipoprotein(a) is a risk factor for atherosclerosis(1-3). Lipoprotein(a) consists of low-density lipoprotein with the additional protein component, apolipoprotein(a), a homologue of plasminogen(4). Lipoprotein(a) and apolipoprotein(a) enhance proliferation of human vascular smooth muscle cells (hVSMCs) in culture by inhibiting activation of plasminogen to plasmin, thus blocking the proteolytic activation of transforming growth factor-beta (TGF-beta)(5), an autocrine inhibitor of hVSMC proliferation(5,6). The hypothesis that this pathway is a key step in atherogenesis(5) is tested on transgenic mice expressing the human apolipoprotein(a) gene. We show here that the activation of TGF-beta is inhibited in the aortic wall and serum of mice expressing apolipoprotein(a), as a consequence of apolipoprotein(a) inhibition of plasminogen activation. These effects are closely correlated with VSMC activation.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University	GRAINGER, DJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.			Kemp, Paul/0000-0001-8975-7293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; KIRSCHENLOHR HL, 1993, AM J PHYSIOL, V265, pC571, DOI 10.1152/ajpcell.1993.265.2.C571; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RINDERKNECHT H, 1960, EXPERIENTIA, V16, P430, DOI 10.1007/BF02178856; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631	21	337	352	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					460	462		10.1038/370460a0	http://dx.doi.org/10.1038/370460a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047165				2022-12-01	WOS:A1994PB40700056
J	EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC				EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC			THE CRYSTAL-STRUCTURE OF HUMAN HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE WITH BOUND GMP	CELL			English	Article							LESCH-NYHAN; NUCLEOSIDE HYDROLASE; TRANSITION-STATE; DEFICIENCY; PATIENT; EXPRESSION; STABILITY; PURINE; GENE	The crystal structure of HGPRTase with bound GMP has been determined and refined to 2.5 Angstrom resolution, The enzyme has a core alpha/beta structure resembling the nucleotide-binding fold of dehydrogenases, and a second lobe composed of residues from the amino and carboxy termini. The GMP molecule binds in an anti conformation in a solvent-exposed cleft of the enzyme. Lys-165, which forms a hydrogen bond to O6 of GMP, appears to be critical for determining the specificity for guanine and hypoxanthine over adenine. The location of active site residues also provides evidence for a possible mechanism for general base-assisted HGPRTase catalysis. A rationalization of the effects on stability and activity of naturally occurring single amino acid mutations of HGPRTase is presented, including a discussion of several mutations at the active site that lead to Lesch-Nyhan syndrome.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; FELS INST CANC RES, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	EADS, JC (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048623] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA12227] Funding Source: Medline; NIGMS NIH HHS [GM48623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1983, J BIOL CHEM, V258, P6450; ARNOLD WJ, 1971, J BIOL CHEM, V246, P7398; BLABER M, 1994, J MOL BIOL, V235, P600, DOI 10.1006/jmbi.1994.1016; BOUWENSROMBOUTS AGM, 1993, HUM GENET, V91, P451, DOI 10.1007/BF00217770; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; DAVIDSON BL, 1988, GENE, V68, P85, DOI 10.1016/0378-1119(88)90601-4; DAVIDSON BL, 1989, J BIOL CHEM, V264, P520; DAVIDSON BL, 1988, GENE, V63, P331, DOI 10.1016/0378-1119(88)90536-7; DOVEY HF, 1984, MOL BIOCHEM PARASIT, V11, P157, DOI 10.1016/0166-6851(84)90062-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUJIMORI S, 1991, ADV EXP MED BIOL, V309, P101; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIACOMELLO A, 1978, J BIOL CHEM, V253, P6038; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GORDON RB, 1991, ADV EXP MED BIOL, V309, P95; Gutteridge W, 1977, BIOCH PARASITIC PROT, P69, DOI 10.1007/978-1-349-15809-6_6; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSON GG, 1979, SCIENCE, V203, P174, DOI 10.1126/science.569362; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1263; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MAIN P, 1993, SQUASH SUITE PROGRAM; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NICHOLLS A, 1993, GRASP; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P72; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STOUT JT, 1989, METABOLIC BASIS INHE, P1007; STRAUSS M, 1978, EUR J BIOCHEM, V90, P89, DOI 10.1111/j.1432-1033.1978.tb12578.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VELLIEUX FMD, 1993, DEMON PROGRAM SUITE; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WILSON JM, 1983, NEW ENGL J MED, V309, P900; WILSON JM, 1982, J BIOL CHEM, V257, P978; WILSON JM, 1986, J CLIN INVEST, V77, P188, DOI 10.1172/JCI112275; YAMADA Y, 1991, ADV EXP MED BIOL, V309, P121	47	211	214	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					325	334		10.1016/0092-8674(94)90301-8	http://dx.doi.org/10.1016/0092-8674(94)90301-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044844				2022-12-01	WOS:A1994NZ24200015
J	ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M				ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M			ACTIVATION OF CAMP AND MITOGEN RESPONSIVE GENES RELIES ON A COMMON NUCLEAR FACTOR	NATURE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION; CREB; FOS; PROMOTERS; COMPLEX; KINASE; DOMAIN; BINDS	A NUMBER of Signalling pathways stimulate transcription of target genes through nuclear factors whose activities are primarily regulated by phosphorylation. Cyclic AMP regulates the expression of numerous genes, for example, through the protein kinase-A (PKA)-mediated phosphorylation of transcription factor CREB at Ser133(1,2) Although phosphorylation may stimulate transcriptional activators by modulating their nuclear transport or DNA-binding affinity(3), CREB belongs to a class of proteins whose phosphorylation appears specifically to enhance their trans-activation potential(1,2,4). Recent work describing a phospho-CREB binding protein (CBP)(5) which interacts specifically with the CREB trans-activation domain prompted us to examine whether CBP is necessary for cAMP regulated transcription. We report here that microinjection of an anti-CBP antiserum into fibroblasts can inhibit transcription from a cAMP responsive promoter. Surprisingly, CBP also cooperates with upstream activators such as c-Jun, which are involved in mitogen responsive transcription(6). We propose that CBP is recruited to the promoter through interaction with certain phosphorylated factors, and that CBP may thus play a critical role in the transmission of inductive signals from cell surface receptor to the transcriptional apparatus.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Cancer Research UK	ARIAS, J (corresponding author), SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Brindle, Paul/0000-0001-7172-8478				ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	21	689	705	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	1994	370	6486					226	229		10.1038/370226a0	http://dx.doi.org/10.1038/370226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028671				2022-12-01	WOS:A1994NX97100056
J	BOUVIER, M; WILEY, DC				BOUVIER, M; WILEY, DC			IMPORTANCE OF PEPTIDE AMINO AND CARBOXYL TERMINI TO THE STABILITY OF MHC CLASS-I MOLECULES	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; VIRUS MATRIX PROTEIN; VIRAL PEPTIDES; THERMAL-STABILITY; BINDING; HLA-A2; RECOGNITION; ANTIGENS; HLA-B27; IDENTIFICATION	An influenza virus matrix peptide in which either the charged amino or carboxyl terminus was substituted by methyl groups promoted folding of the class I human histocompatibility antigen (HLA-A2). A peptide modified at both termini did not promote stable folding. The thermal stability of HLA-A2 complexed with peptides that did not have either terminus was similar to 22 degrees C lower than that of the control peptide, whereas matrix peptide in which both anchor positions were substituted by alanines had its stability decreased by only 5.5 degrees C. Thus, the conserved major histocompatibility complex class I residues at both ends of the peptide binding site form energetically important sites for binding the termini of short peptides.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLLINS EJ, UNPUB; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Ghosh P., UNPUB; GUO H, UNPUB; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; Heinrikson R L, 1977, Methods Enzymol, V47, P175; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; OLSEN AC, 1994, EUR J IMMUNOL, V24, P385, DOI 10.1002/eji.1830240218; OSAPAY G, 1991, TECHNIQUES PROTEIN C, V2, P221; PARKER KC, 1992, J IMMUNOL, V149, P3580; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAUMA SY, 1993, HUM IMMUNOL, V37, P252, DOI 10.1016/0198-8859(93)90508-X; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; UTZ U, 1992, J IMMUNOL, V149, P214; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	44	231	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					398	402		10.1126/science.8023162	http://dx.doi.org/10.1126/science.8023162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023162				2022-12-01	WOS:A1994NW81600041
J	CHEN, Y; EBRIGHT, YW; EBRIGHT, RH				CHEN, Y; EBRIGHT, YW; EBRIGHT, RH			IDENTIFICATION OF THE TARGET OF A TRANSCRIPTION ACTIVATOR PROTEIN BY PROTEIN-PROTEIN PHOTO-CROSS-LINKING	SCIENCE			English	Article							COLI RNA-POLYMERASE; CAP-DNA COMPLEX; ESCHERICHIA-COLI; ALPHA-SUBUNIT; RECEPTOR PROTEIN; POSITIVE CONTROL; CAMP-CRP; PROMOTER; REGION; MUTATIONS	Here it is shown, with the use of protein-protein photocrosslinking, that the carboxyl-terminal region of the alpha subunit of RNA polymerase (RNAP) is in direct physical proximity to the activating region of the catabolite gene activator protein (CAP) in the ternary complex of the lac promoter, RNAP, and CAP, These results strongly support the proposal that transcription activation by CAP involves protein-protein contact between the carboxyl-terminal region of the alpha subunit and the activating region of CAP.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Niu W., UNPUB; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x; [No title captured]	25	114	117	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					90	92		10.1126/science.8016656	http://dx.doi.org/10.1126/science.8016656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016656				2022-12-01	WOS:A1994NV30100031
J	SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH				SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH			RECEPTOR AND LIGAND DOMAINS FOR INVASION OF ERYTHROCYTES BY PLASMODIUM-FALCIPARUM	SCIENCE			English	Article							BINDING ANTIGEN; GLYCOPHORIN-A; MALARIA PARASITES; AMINO-ACID; GLYCOPROTEIN; MEMBRANE; POLYMORPHISM; KNOWLESI; PROTEINS; SEQUENCE	A 175-kilodalton erythrocyte binding protein, EBA-175, of the parasite Plasmodium falciparum mediates the invasion of erythrocytes. The erythrocyte receptor for EBA-175 is dependent on sialic acid. The domain of EBA-175 that binds erythrocytes was identified as region II with the use of truncated portions of EBA-175 expressed on COS cells. Region II, which contains a cysteine-rich motif, and native EBA-175 bind specifically to glycophorin A, but not to glycophorin B, on the erythrocyte membrane. Erythrocyte recognition of EBA-175 requires both sialic acid and the peptide backbone of glycophorin A. The identification of both the receptor and ligand domains may suggest rational designs for receptor blockade and vaccines.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; UNIV LOUISVILLE,DEPT MED,LOUISVILLE,KY 40292; POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,DEPT IMMUNOCHEM,PL-53114 WROCLAW,POLAND	National Institutes of Health (NIH) - USA; University of Louisville; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences				Chitnis, Chetan/0000-0002-8773-9865; Wasniowska, Kazimiera/0000-0001-7629-2589				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; BLUMENFELD OO, 1981, P NATL ACAD SCI-BIOL, V78, P747, DOI 10.1073/pnas.78.2.747; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; BREUER WV, 1983, BIOCHIM BIOPHYS ACTA, V755, P263, DOI 10.1016/0304-4165(83)90213-1; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; CHITNIS CE, IN PRESS J EXP MED; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; KLOTZ FW, 1992, MOL BIOCHEM PARASIT, V51, P49, DOI 10.1016/0166-6851(92)90199-T; LISOWSKA E, 1987, MOL IMMUNOL, V24, P605, DOI 10.1016/0161-5890(87)90041-1; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PERKINS M, 1981, J CELL BIOL, V90, P563, DOI 10.1083/jcb.90.3.563; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; WARREN L, 1959, J BIOL CHEM, V234, P1971; Wasniowska K, 1985, GLYCOCONJUGATE J, V2, P163; 1989, SAS STAT USERS GUIDE, V2, P1135	24	451	476	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1941	1944		10.1126/science.8009226	http://dx.doi.org/10.1126/science.8009226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009226				2022-12-01	WOS:A1994NT84700048
J	HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA				HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA			USE OF SINUS X-RAY-FILMS BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT OTOLARYNGOL HEAD & NECK SURG,GLASGOW G31 2ER,SCOTLAND; ROYAL INFIRM,DEPT RADIOL,GLASGOW G31 2ER,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh				wilson, janet/0000-0002-6416-5870				FASCENELLI FW, 1969, ARCH OTOLARYNGOL, V90, P98; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; PFLEIDERER AG, 1986, CLIN OTOLARYNGOL, V11, P455, DOI 10.1111/j.1365-2273.1986.tb00151.x; WILSON PS, 1990, J LARYNGOL OTOL, V104, P694, DOI 10.1017/S0022215100113647; 1993, MAKING BEST USE DEPA	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1608	1609		10.1136/bmj.308.6944.1608	http://dx.doi.org/10.1136/bmj.308.6944.1608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025428	Green Published			2022-12-01	WOS:A1994NT52800019
J	WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB				WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB			SEQUENCES SPECIFIC FOR ENTEROVIRUS DETECTED IN SPINAL-CORD FROM PATIENTS WITH MOTOR-NEURON DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE; TISSUE	Objective-To investigate the association enteroviruses with motor neurone disease, known as amyotrophic lateral sclerosis. Design-Analysis by enterovirus polymerase chain reaction of wax embedded material from spinal cords taken at necropsy from subjects with motor neurone disease and from age and sex matched controls. Setting-Specimens were collected in the west of Scotland and in London between 1982 and 1992. Results-Sequences specific for a non-poliovirus type enterovirus were detected in spinal cord tissue from subjects with motor neurone disease. Amplification of a 414 base RNA target sequence in the conserved enterovirus 5' untranslated region from wax embedded tissue sections was successful in tissue from eight of 11 cases of sporadic motor neurone disease, one of two cases of familial motor neurone disease, and the one case of poliomyelitis, but not in the six matched controls or one case of antecedent poliomyelitis. In addition, sequences were detected in spinal cords from one monkey infected with wild type poliovirus and one monkey infected with polio vaccine. Comparison of sequences from cases of motor neurone disease with sequences of corresponding regions of the 5' untranslated regions of known picornaviruses showed them to be tightly grouped within the enterovirus genus closely related to coxsackievirus type B but not to polioviruses. Sequences derived from different parts of the spinal cord of the same subjects were identical, but sequences differed between individual subjects. Conclusions-Conserved enteroviral sequences closely related to coxsackie B virus sequences were detectable in spinal cords from subjects with sporadic motor neurone disease and from one subject with possible familial motor neurone disease.	RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PATHOL,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,SCOTTISH SERUM BANK,GLASGOW G20 9NB,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND	University of Edinburgh; University of Glasgow								[Anonymous], 1990, LANCET, V336, P1033; BRAHIC M, 1985, ANN NEUROL, V18, P337, DOI 10.1002/ana.410180311; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HEIMANPATTERSON TD, 1986, AMYOTROPHIC LATERAL, P85; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; MARTYN CN, 1988, LANCET, V1, P1319, DOI 10.1016/S0140-6736(88)92129-0; MINOR PD, 1990, TOPLEY WILSONS PRINC, V4, P324; NORBY E, 1990, VIROLOGY, P1028; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; PALMENBERG AC, 1988, MOL ASPECTS PICORNAV, P211; POSKANZER DC, 1969, MOTOR NEURON DISEASE, P286; ROOS RP, 1980, ARCH NEUROL-CHICAGO, V37, P312, DOI 10.1001/archneur.1980.00500540090016; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUECKERT R R, 1990, P507; STANWAY G, 1990, J GEN VIROL, V71, P2483, DOI 10.1099/0022-1317-71-11-2483; VIOLA MV, 1980, ANN NEUROL, V5, P402; WEINER LP, 1980, NEUROLOGY, V30, P1319, DOI 10.1212/WNL.30.12.1319; WOODALL CJ, 1993, J CLIN PATHOL, V46, P276, DOI 10.1136/jcp.46.3.276; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZILKHA K J, 1962, Proc R Soc Med, V55, P1028; 1991, PROGRAM MANUAL GCG P	23	73	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1541	1543		10.1136/bmj.308.6943.1541	http://dx.doi.org/10.1136/bmj.308.6943.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019310	Green Published			2022-12-01	WOS:A1994NR11000023
J	MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ				MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ			PROLONGED BREAST-FEEDING, DIARRHEAL DISEASE, AND SURVIVAL OF CHILDREN IN GUINEA-BISSAU	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTECTION; DIARRHEAL; COMMUNITY; STATE	Objective-To analyse the impact of breast feeding on diarrhoeal disease and survival in children above 1 year of age in Guinea-Bissau, west Africa. Design-A community study of an open cohort followed up weekly by interviews over 15 months. Data on feeding practices, anthropometry, and survival were recorded for three years. Setting-301 randomly selected houses in a semiurban area in the capital, Bissau. Subjects-849 children aged less than 3 years. Main outcome measures-Incidence and duration of diarrhoea, weight for age, and death of a child. Results-The incidence of diarrhoea was higher in weaned children than in partially breast fed children, both in 1 year olds (relative risk 1.41; 95% confidence interval 1.23 to 1.62) and in 2 year olds (1.67; 1.29 to 2.15). The mean duration of an episode of diarrhoea was 5.3 days in breast fed children compared with 6.3 days in weaned children (P= 0.001). Independent of the age of weaning, a similar increase was found in an analysis comparing, for each child, the rate and duration of diarrhoea one month before and one month after weaning. Children with low weight for age were breast fed longer than the better nourished children (P=0.02). Children aged 12-35 months who were not breast fed had a 3.5 times higher mortality (1.4 to 8.3) than breast fed children. Conclusions-The beneficial effects of breast feeding are not restricted to infancy. Though children who are partially breast fed after infancy may have a lower state of nutrition than the weaned ones, the benefit in terms of lower morbidity may be more important for child survival in places with a high morbidity from diarrhoea and with high mortality.	STATENS SERUM INST, DEPT STAT, DK-2300 COPENHAGEN, DENMARK; STATENS SERUM INST, DEPT INFECT IMMUNOL, PARASITOL LAB, DK-2300 COPENHAGEN, DENMARK; NATL PUBL HLTH LAB, BISSAU, GUINEA BISSAU	Statens Serum Institut; Statens Serum Institut	MOLBAK, K (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, DK-2300 COPENHAGEN S, DENMARK.			Aaby, Peter/0000-0001-8331-1389; Molbak, Kare/0000-0002-3100-4990				BRAKOHIAPA LA, 1988, LANCET, V2, P416; BRIEND A, 1988, BRIT MED J, V296, P879, DOI 10.1136/bmj.296.6626.879; BROWN KH, 1989, PEDIATRICS, V83, P31; CLEMENS JD, 1986, AM J EPIDEMIOL, V123, P710, DOI 10.1093/oxfordjournals.aje.a114291; DETTWYLER KA, 1987, SOC SCI MED, V24, P633, DOI 10.1016/0277-9536(87)90306-6; Diarrhoea Kirkwood B., 1991, DIS MORTALITY SUBSAH, P134; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1983, ACTA PAEDIATR SCAND, V72, P133, DOI 10.1111/j.1651-2227.1983.tb09679.x; HABICHT JP, 1986, AM J EPIDEMIOL, V123, P279, DOI 10.1093/oxfordjournals.aje.a114236; HUTTLY SRA, 1987, T ROY SOC TROP MED H, V81, P865, DOI 10.1016/0035-9203(87)90055-1; Jelliffe D. B., 1978, HUMAN MILK MODERN WO; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P497; Mata L J, 1976, Ciba Found Symp, P311; MICHAELSEN KF, 1988, LANCET, V2, P788; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566, DOI 10.1097/00006454-199008000-00008; TANGERMANN RH, 1988, LANCET, V2, P1016, DOI 10.1016/S0140-6736(88)90761-1; VICTORA CG, 1984, AM J CLIN NUTR, V39, P307, DOI 10.1093/ajcn/39.2.307; VICTORA CG, 1987, LANCET, V2, P319; Wyatt R G, 1972, Arch Latinoam Nutr, V22, P629	20	95	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1403	1406		10.1136/bmj.308.6941.1403	http://dx.doi.org/10.1136/bmj.308.6941.1403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019249	Green Published			2022-12-01	WOS:A1994NP42000014
J	FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D				FERRANDON, D; ELPHICK, L; NUSSLEINVOLHARD, C; STJOHNSTON, D			STAUFEN PROTEIN ASSOCIATES WITH THE 3'UTR OF BICOID MESSENGER-RNA TO FORM PARTICLES THAT MOVE IN A MICROTUBULE-DEPENDENT MANNER	CELL			English	Article							MESSENGER-RNA LOCALIZATION; EARLY DROSOPHILA EMBRYO; POLE CELL-FORMATION; POSTERIOR DETERMINANT; ANTERIOR LOCALIZATION; SECONDARY STRUCTURE; MOLECULAR ANALYSIS; MATERNAL GENE; PATTERN; OSKAR	Staufen protein is required in order to anchor bicoid (bcd) mRNA at the anterior pole of the Drosophila egg. Here we show that staufen protein colocalizes with bcd mRNA at the anterior, and that this localization depends upon Its association with the mRNA. Upon injection into the embryo, bcd transcripts specifically interact with staufen, and we have mapped the sequences required to three regions of the 3'UTR, each of which is predicted to form a long stem-loop. The resulting staufen-bcd 3'UTR complexes form particles that show a microtubule-dependent localization. Since staufen is also transported with oskar (osk) mRNA during oogenesis, staufen associates specifically with both osk and bcd mRNAs to mediate their localizations, but at two distinct stages of development.	WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND		FERRANDON, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-III,D-72076 TUBINGEN,GERMANY.		St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301; FERRANDON, Dominique/0000-0001-7680-7773	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DEBRABANDER M, 1986, INT REV CYTOL, V101, P215; DRIEVER W, 1990, DEVELOPMENT, V109, P811; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GANS M, 1975, GENETICS, V81, P683; GAVIS ER, 1992, CELL, V71, P310; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; KARR TL, 1991, MECH DEVELOP, V34, P101, DOI 10.1016/0925-4773(91)90047-A; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cb.09.110193.000435; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON EC, 1987, DEV BIOL, V124, P1, DOI 10.1016/0012-1606(87)90453-2; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	49	350	358	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1221	1232		10.1016/0092-8674(94)90013-2	http://dx.doi.org/10.1016/0092-8674(94)90013-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001156				2022-12-01	WOS:A1994PZ86000013
J	WILKINSON, HA; FITZGERALD, K; GREENWALD, I				WILKINSON, HA; FITZGERALD, K; GREENWALD, I			RECIPROCAL CHANGES IN EXPRESSION OF THE RECEPTOR LIN-12 AND ITS LIGAND LAG-2 PRIOR TO COMMITMENT IN A C-ELEGANS CELL FATE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-NOTCH; GENE; HOMOLOG; SEQUENCES; AUTONOMY; ENCODES; MOTCH; SET	During development of the C. elegans hermaphrodite gonad, two cells interact with each other, so that one chooses to become the anchor cell (AC) and the other becomes a ventral uterine precursor cell (VU). This interaction is mediated by the receptor LIN-12 and its apparent ligand LAG-2. We show that initially lin-12 and lag-2 are expressed in both cells, but prior to commitment, the expression patterns change in a reciprocal manner, so that lin-12 expression becomes restricted to the presumptive VU and lag-2 expression becomes restricted to the presumptive AC. In addition, lin-12 activity promotes expression of lin-12 and represses expression of lag-2. Furthermore, we show that positive autoregulation of lin-12 transcription in the presumptive VU is mediated by a cis-acting 5' regulatory sequence and is necessary to specify the VU fate. Our results suggest that transcriptional control is a component of the feedback mechanism involved in specifying the AC and VU fates.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	WILKINSON, HA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FIRE A, 1993, GENET ANAL TECH APPL, V9, P151; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD J, 1994, CURR OPIN GENET DEV, V4, P556; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1989, GENETICS, V123, P301; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TAX FE, 1994, THESIS U WASHINGTON; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILKINSON HA, 1994, THESIS PRINCETON U P; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	44	212	216	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1187	1198		10.1016/0092-8674(94)90010-8	http://dx.doi.org/10.1016/0092-8674(94)90010-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001154				2022-12-01	WOS:A1994PZ86000010
J	CARPENTER, L; BARTLEY, M				CARPENTER, L; BARTLEY, M			FAT, FEMALE, AND POOR	LANCET			English	Editorial Material							ADULTHOOD; OBESITY		UNIV OXFORD NUFFIELD COLL,OXFORD,ENGLAND	University of Oxford	CARPENTER, L (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND.							Blaxter M., 1990, HLTH LIFESTYLES; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Dex S., 1987, WOMENS OCCUPATIONAL; Erikson Robert, 1992, CONSTANT FLUX; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; JOSHI H, 1988, LONGITUDINAL DATA AN; LEON D, 1994, LANCET; POWER C, 1988, INT J OBESITY, V12, P445; SARGENT JD, 1994, ARCH PEDIAT ADOL MED, V148, P681, DOI 10.1001/archpedi.1994.02170070019003; SITTHIAMORN C, 1994, LANCET; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; 1991, HLTH NATION	12	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1715	1716		10.1016/S0140-6736(94)92880-0	http://dx.doi.org/10.1016/S0140-6736(94)92880-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7996996				2022-12-01	WOS:A1994PY28100003
J	PETTIT, DL; PERLMAN, S; MALINOW, R				PETTIT, DL; PERLMAN, S; MALINOW, R			POTENTIATED TRANSMISSION AND PREVENTION OF FURTHER LTP BY INCREASED CAMKII ACTIVITY IN POSTSYNAPTIC HIPPOCAMPAL SLICE NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; DENSITY PROTEIN; FASCIA DENTATA; SYNAPTIC ENHANCEMENT; SYNTHETIC MACHINERY; NMDA RECEPTORS; CA1 NEURONS; CALMODULIN; ACTIVATION	Calcium-calmodulin-dependent protein kinase II (CaMKII) is a necessary component of the cellular machinery underlying learning and memory. Here, a constitutively active form of this enzyme, CaMKII(1-290), was introduced into neurons of hippocampal slices with a recombinant vaccinia virus to test the hypothesis that increased postsynaptic activity of this enzyme is sufficient to produce long-term synaptic potentiation (LTP), a prominent cellular model of learning and memory. Postsynaptic expression of CaMKII(1-290) increased CaMKII activity, enhanced synaptic transmission, and prevented more potentiation by an LTP-inducing protocol. These results, together with previous studies, suggest that postsynaptic CaMKII activity is necessary and sufficient to generate LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,NEUROSCI PROGRAM,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,NEUROSCI PROGRAM,DEPT MICROBIOL,IOWA CITY,IA 52242	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa								AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; ASZTELY F, 1992, SYNAPSE, V11, P342, DOI 10.1002/syn.890110409; BAILINGER C, 1990, J CELL BIOL, V111, P1763; BLISS TVP, 1983, J PHYSIOL-LONDON, V334, P475, DOI 10.1113/jphysiol.1983.sp014507; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Dingledine R., 1984, BRAIN SLICES; FUKANAGA K, 1993, J BIOL CHEM, V268, P7863; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACKETT M, 1985, DNA CLONING PRACTICA; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALENKA RC, 1986, NATURE, V319, P774; MALENKA RC, 1986, NATURE, V321, P695; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULLER D, 1988, P NATL ACAD SCI USA, V85, P6997, DOI 10.1073/pnas.85.18.6997; MULLER W, 1992, J NEUROPHYSIOL, V68, P2264, DOI 10.1152/jn.1992.68.6.2264; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; PETTIT DL, 1983, COLD SPRING HARB SYM, V48, P745; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REYMANN KG, 1986, BRAIN RES BULL, V17, P291, DOI 10.1016/0361-9230(86)90234-0; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEWARD O, 1988, J NEUROSCI, V8, P176; STEWARD O, 1986, J NEUROSCI, V6, P3079; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	53	256	258	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1881	1885		10.1126/science.7997883	http://dx.doi.org/10.1126/science.7997883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7997883				2022-12-01	WOS:A1994PX38300040
J	GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A				GRAHAM, A; FRANCISWEST, P; BRICKELL, P; LUMSDEN, A			THE SIGNALING MOLECULE BMP4 MEDIATES APOPTOSIS IN THE RHOMBENCEPHALIC NEURAL CREST	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; HINDBRAIN; CELLS	THE pattern of skeletal structures and muscles in the branchial region of the head is profoundly influenced by the neural crest whose cells arise at discrete segmental levels of the chick hindbrain: specifically, rhombomeres (r)1 + 2, r4 and r6, whereas r3 and r5 are crest-depleted(2). We have demonstrated that an interaction between even-numbered rhombomeres and r3/r5 effects this depletion of neural crest, resulting in the sculpting of discrete migratory streams of neural crest(3). This mechanism acts through increased expression of msx2 and the induction of apoptosis in dorsal cells of r3 and r5 (ref. 3) (Fig. 1A). Here we demonstrate that the signalling molecule Bmp4 is expressed in r3 and r5 and is dependent on the neighbouring rhombomeres. Addition of recombinant BMP4 protein to explant cultures of r3 or r5, which produce neural crest when isolated from their neighbouring rhombomeres, upregulates msx2 and reinstates apoptosis in the neural crest population.	UCL, SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	GRAHAM, A (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DIV ANAT & CELL BIOL, MRC, LONDON SE1 9RT, ENGLAND.		graham, anthony/B-1864-2008; Lumsden, Andrew/C-5146-2009	graham, anthony/0000-0003-2011-7188; 				ACHESON A, 1993, SOC NEUR ABSTR, V19; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; DALE L, 1992, DEVELOPMENT, V115, P573; DELANNET M, 1992, DEVELOPMENT, V116, P275; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GRAHAM A, 1993, DEVELOPMENT, V119, P233; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; JONES CM, 1992, DEVELOPMENT, V115, P639; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; VANIO S, 1993, CELL, V75, P45	12	441	448	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					684	686		10.1038/372684a0	http://dx.doi.org/10.1038/372684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990961				2022-12-01	WOS:A1994PX30700088
J	FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y				FUJITA, A; OKA, C; ARIKAWA, Y; KATAGAI, T; TONOUCHI, A; KUHARA, S; MISUMI, Y			A YEAST GENE NECESSARY FOR BUD-SITE SELECTION ENCODES A PROTEIN SIMILAR TO INSULIN-DEGRADING ENZYMES	NATURE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; EXPRESSION; SEQUENCE; CLONING; DISRUPTION	CELLS Of the yeast Saccharomyces cerevisiae choose bud sites in a non-random spatial pattern that depends on mating type: axial for haploid cells and bipolar for ala diploid cells(1,2). We identified a mutant yeast, axl1, in which the budding pattern is altered from axial to bipolar. Expression of the AXL1 gene is repressed in a/alpha diploid cells. With the ectopic expression of AXL1, a/alpha cells exhibited an axial budding pattern, thus AXL1 is a key morphological determinant that distinguishes the budding pattern of haploid cells from that of ala diploid cells(2). AXL1 encodes a protein similar in sequence to the human and Drosophila insulin-degrading enzymes(3,4) and to the Escherichia coli ptr gene product(5). The axial budding pattern might result from degradation of a target protein by the putative Axl1 protease.	IND RES INST CHIBA PREFECTURE, WAKABA KU, CHIBA 264, JAPAN; NAGANO STATE LAB FOOD TECHNOL, NAGANO 380, JAPAN; KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, FUKUOKA 812, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, JONAN KU, FUKUOKA 81401, JAPAN	Kyushu University; Fukuoka University	FUJITA, A (corresponding author), AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, 1-1 HIGASHI, TSUKUBA, IBARAKI 305, JAPAN.							AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FUJITA A, 1990, GENE, V89, P93, DOI 10.1016/0378-1119(90)90210-I; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RINE J, 1987, GENETICS, V116, P9; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; STILLMAN DJ, 1992, GENE DEV, V6, P93; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035	21	117	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	1994	372	6506					567	570		10.1038/372567a0	http://dx.doi.org/10.1038/372567a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7990931				2022-12-01	WOS:A1994PW08200057
J	DEVINCENZI, I				DEVINCENZI, I			LONGITUDINAL-STUDY OF HUMAN-IMMUNODEFICIENCY-VIRUS TRANSMISSION BY HETEROSEXUAL PARTNERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL TRANSMISSION; HIV; DISEASE; WOMEN; MEN	Background. Worldwide, the predominant mode of human immunodeficiency virus (HIV) transmission is heterosexual intercourse, but the risk of heterosexual transmission and the effectiveness of measures to prevent it are not well defined. Methods. We conducted a prospective study of HIV-negative subjects whose only risk of HIV infection was a stable heterosexual relationship with an HIV-infected partner. Every six months the subjects were interviewed, tested for HIV, and counseled about safe sexual practices. Results. A total of 304 HIV-negative subjects (196 women and 108 men) were followed for an average of 20 months. During the study, 130 couples (42.8 percent) ended their sexual relationships, most often because of the HIV-infected partner's illness or death. Of the 256 couples who continued to have sexual relations for more than three months after enrollment in the study, only 124 (48.4 percent) used condoms consistently for vaginal and anal intercourse. Among these couples, none of the seronegative partners became infected with HIV, despite a total of about 15,000 episodes of intercourse. Among the 121 couples who used condoms inconsistently, the rate of seroconversion was 4.8 per 100 person-years (95 percent confidence interval, 2.5 to 8.4). Eleven couples refused to answer questions about condom use. The risk of transmission increased with advanced stages of HIV infection in the index partners (P<0.02) and with genital infection in the HIV-negative partners (P<0.04). Withdrawal to avoid ejaculation in the vagina had a protective effect in uninfected women (P<0.02). Conclusions. Consistent use of condoms for heterosexual intercourse is highly effective in preventing the transmission of HIV. Among couples not using condoms regularly, the risk of HIV transmission varies widely.			DEVINCENZI, I (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; CHANCHEE C, 1991, GENITOURIN MED, V67, P173; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P739; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1990, J ACQ IMMUN DEF SYND, V3, P55; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; ROSENBERG MJ, 1992, AM J PUBLIC HEALTH, V82, P1473, DOI 10.2105/AJPH.82.11.1473; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; SIDDIQUI NS, 1992, AIDS, V6, P1529, DOI 10.1097/00002030-199212000-00017; SIDDIQUI NS, 1993, AIDS, V7, P444; VOELLER B, 1990, AIDS SEX INTEGRATED, P276; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; 1986, MMWR-MORBID MORTAL W, V35, P334; 1992, BRIT MED J, V304, P809	19	505	512	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					341	346		10.1056/NEJM199408113310601	http://dx.doi.org/10.1056/NEJM199408113310601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA374	8028613				2022-12-01	WOS:A1994PA37400001
J	WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M				WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M			A PROTEIN COMPLEX REQUIRED FOR SIGNAL-SEQUENCE-SPECIFIC SORTING AND TRANSLOCATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; LARGE RIBOSOMAL-SUBUNIT; RECOGNITION PARTICLE; NASCENT PREPROLACTIN; ESCHERICHIA-COLI; CROSS-LINKING; POLYPEPTIDE-CHAINS; RECEPTOR; TRANSCRIPTION; CELL	We have purified a nascent-polypeptide-associated complex (NAC) which prevents short ribosome-associated nascent polypeptides from inappropriate interactions with proteins in the cytosol. NAC binds nascent-polypeptide domains emerging from ribosomes unless a signal peptide is fully exposed. Depletion of cytosolic proteins (including NAC) from ribosomes carrying nascent polypeptides allows the signal recognition particle (SRP) to crosslink to polypeptides irrespective of whether or not they contain signal peptides. In the absence of cytosol, proteins lacking signal peptides can be mistranslocated into the endoplasmic reticulum in vitro, albeit with low efficiency. Readdition of NAC restores the specificity of SRP and fidelity of translocation.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center								BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; KANNO M, 1992, GENE, V117, P219, DOI 10.1016/0378-1119(92)90732-5; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	30	331	349	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					434	440		10.1038/370434a0	http://dx.doi.org/10.1038/370434a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047162				2022-12-01	WOS:A1994PB40700048
J	ROSENTHAL, N				ROSENTHAL, N			TOOLS OF THE TRADE - RECOMBINANT-DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				LEWIN B, 1993, GENES, V5; WATSON J, 1992, RECOMBINANT DNA SHOR	2	27	27	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					315	317		10.1056/NEJM199408043310508	http://dx.doi.org/10.1056/NEJM199408043310508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022444				2022-12-01	WOS:A1994NZ22700008
J	NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC				NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC			THE COST OF A SUCCESSFUL DELIVERY WITH IN-VITRO FERTILIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL INTENSIVE-CARE; LOW-BIRTH-WEIGHT; INVITRO FERTILIZATION; ASSISTED CONCEPTION; MULTIPLE BIRTHS; OVARIAN-CANCER; TRIPLET; PREGNANCIES; INFERTILITY; RISKS	Background. The use of in vitro fertilization has engendered considerable debate about who should have the procedure, whether health insurance should cover the cost, and if so, to what extent. We investigated the cost of a successful delivery with in vitro fertilization. Methods. We calculated the cost per successful delivery with in vitro fertilization (defined as at least one live birth) for a general population of couples undergoing in vitro fertilization and for two subgroups: couples with a diagnosis of tubal disease (who have a better chance of success), and couples in which the woman is over the age of 40 years and the man has a low sperm count (who have a lower chance of success). Information on charges per cycle of in vitro fertilization was obtained from six facilities across the country; delivery rates with this procedure were estimated from the literature. Results. On average, the cost incurred per successful delivery with in vitro fertilization increases from $66,667 for the first cycle of in vitro fertilization to $114,286 by the sixth cycle. The cost increases because with each cycle in which fertilization fails, the probability that a subsequent effort will be successful declines. Sensitivity analyses indicated that the cost per delivery ranges from $44,000 to $211,940. For couples with a better chance of successful in vitro fertilization (i.e., those with a diagnosis of tubal disease), it costs $50,000 per delivery for the first cycle and $72,727 for the sixth. For couples in which the woman is older and there is a diagnosis of male-factor infertility, the cost rises from $160,000 for the first cycle to $800,000 for the sixth. Conclusions. The debate about insurance coverage for in vitro fertilization must take into account ethical judgments and social values. But analyses of costs and cost effectiveness help elucidate the economic implications of using in vitro fertilization and thus inform the policy discussion.	BRIGHAM & WOMENS HOSP, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	NEUMANN, PJ (corresponding author), PROJECT HOPE CTR HLTH AFFAIRS, SUITE 600, 7500 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BONNICKSEN AL, 1989, IN VITRO FERTILIZATI; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BRANDES JM, 1992, PEDIATRICS, V90, P424; BROMWICH P, 1989, LANCET, V2, P1327; DALTON M, 1989, LANCET, V2, P1327; DEMOUZON J, 1993, FERTIL STERIL, V59, P587; EDWARDS RG, 1989, LANCET, V2, P1328; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HERSHLAG A, 1991, FERTIL STERIL, V56, P913; HOWE RS, 1988, FERTIL STERIL, V49, P726; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; JOHANNES CB, 1993, FERTIL STERIL, V59, P250, DOI 10.1016/S0015-0282(16)55656-8; KELLY TE, 1986, CLIN GENETICS GENETI, P218; KINGSLAND CR, 1990, EUR J OBSTET GYN R B, V34, P197, DOI 10.1016/0028-2243(90)90071-8; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LEVRAN D, 1990, NEW ENGL J MED, V323, P1153, DOI 10.1056/NEJM199010253231701; NEUMANN PJ, 1994, MED CARE, V32, P686, DOI 10.1097/00005650-199407000-00003; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PAGE H, 1989, J ROY SOC MED, V82, P99, DOI 10.1177/014107688908200216; Petrikovsky B M, 1989, Obstet Gynecol Surv, V44, P578, DOI 10.1097/00006254-198908000-00002; SASSOON DA, 1990, OBSTET GYNECOL, V75, P817; SCHENKER JG, 1994, FERTIL STERIL, V61, P411; SEOUD MAF, 1992, FERTIL STERIL, V57, P825; SMITH BH, 1991, BRIT MED J, V302, P127, DOI 10.1136/bmj.302.6769.127; SPIRTAS R, 1993, FERTIL STERIL, V59, P291; TAN SL, 1992, LANCET, V339, P1390, DOI 10.1016/0140-6736(92)91205-M; TRAVERS B, 1992, BRIT MED J, V305, P50, DOI 10.1136/bmj.305.6844.50-c; WAGNER MG, 1989, LANCET, V2, P1027; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; 1993, INFERTILITY NATIONAL; 1990, ANN CLIN SPECIFIC RE; 1991, STATE LAWS INFERTILI; 1989, CLIN GYNECOLOGIC END, P611; 1987, 38 OFF TECHN ASS HLT	39	184	184	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					239	243		10.1056/NEJM199407283310406	http://dx.doi.org/10.1056/NEJM199407283310406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015571				2022-12-01	WOS:A1994NY33500006
J	ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS				ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS			ADAPTIVE MUTATION BY DELETIONS IN SMALL MONONUCLEOTIDE REPEATS	SCIENCE			English	Article							ESCHERICHIA-COLI; FRAMESHIFT MUTATION; MISMATCH REPAIR; TUMOR-CELLS; RECOMBINATION; RECD; GENE; MUTANTS; ORIGIN; CANCER	Adaptive reversion of a +1 frameshift mutation in Escherichia coli, which requires homologous recombination functions, is shown here to occur by -1 deletions in regions of small mononucleotide repeats. This pattern makes improbable recombinational mechanisms for adaptive mutation in which blocks of sequences are transferred into the mutating gene, and it supports mechanisms that use DNA polymerase errors. The pattern appears similar to that of mutations found in yeast cells and in hereditary colon cancer cells that are deficient in mismatch repair. These results suggest a recombinational mechanism for adaptive mutation that functions through polymerase errors that persist as a result of a deficiency in post-synthesis mismatch repair.	UNIV ALBERTA, DEPT GENET, EDMONTON T6G 2E9, AB, CANADA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of Alberta; University of California System; University of California Berkeley	ROSENBERG, SM (corresponding author), UNIV ALBERTA, FAC MED, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA.			Rosenberg, Susan M./0000-0003-1444-473X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; DEMEREC M, 1962, P NATL ACAD SCI USA, V48, P1696, DOI 10.1073/pnas.48.10.1696; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLEACH FS, 1993, CELL, V75, P1215; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; GRAFEN A, 1988, NATURE, V336, P525, DOI 10.1038/336525b0; HALL BG, 1990, GENETICS, V125, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAYARAMAN R, 1992, J GENET, V71, P23, DOI 10.1007/BF02927873; Luria SE, 1943, GENETICS, V28, P491; MAGNI GE, 1962, GENETICS, V47, P1097; MAIZELS N, 1991, CELL, V48, P359; MCGILL C, 1993, CURR GENET, V23, P430; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASZEWSKI A, 1964, NATURE, V204, P809, DOI 10.1038/204809a0; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; ROTH J, 1992, GENETICS, V132, P865; ROTHENFLUH H, 1993, TODAYS LIFE SCI, V5, P8; STAHL FW, 1989, NATURE, V355, P112; Steele E.J., 1979, SOMATIC SELECTION AD; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAUSS BS, 1992, CANCER RES, V52, P249; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THALER DS, 1994, TRENDS ECOL EVOL, V9, P108, DOI 10.1016/0169-5347(94)90208-9; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1990, BACTERIAL CHROMOSOME, P445	35	193	199	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					405	407		10.1126/science.8023163	http://dx.doi.org/10.1126/science.8023163			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023163				2022-12-01	WOS:A1994NW81600043
J	BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A				BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A			CARDIOVASCULAR-DISEASE AND DISTRIBUTION OF COGNITIVE FUNCTION IN ELDERLY PEOPLE - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL-STATE; ARTERIAL-DISEASE; SENILE DEMENTIA; POPULATION	Objective-To investigate the distribution of cognitive function in elderly people and to assess the impact of clinical manifestations of atherosclerotic disease on this distribution. Design-Single centre population based cross sectional door to door study. Setting--Ommoord, a suburb of Rotterdam, the Netherlands. Subjects-4971 subjects aged 55 to 94 years. Main outcome measure-Cognitive function as measured by the mini mental state examination. Results-The overall participation rate in the study was 80%. Cognitive test data were available for 90% of the participants. Increasing age and lower educational level were associated with poorer cognitive function. Previous vascular events, presence of plaques in the carotid arteries, and presence of peripheral arterial atherosclerotic disease were associated with worse cognitive performance independent of the effects of age and education. On average the differences were moderate; however, they reflected the net result of a shift of the total population distribution of cognitive function towards lower values. Thereby, they resulted in a considerable increase in the proportion of subjects with scores indicative of dementia. Conclusions-These findings are compatible with the view that atherosclerotic disease accounts for considerable cognitive impairment in the general population.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT NEUROL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	BRETELER, MMB (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS.		Breteler, Monique M.B./J-5058-2014; Grobbee, Diederick/C-7651-2014	Breteler, Monique M.B./0000-0002-0626-9305; Grobbee, Diederick/0000-0003-4472-4468				BRAYNE C, 1988, LANCET, V1, P1265; BRAYNE C, 1990, AGE AGEING, V19, P91, DOI 10.1093/ageing/19.2.91; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; DEWEY ME, 1990, CASE FINDING DEMENTI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; HACHINSKI V, 1992, LANCET, V340, P645; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; RAPP PR, 1992, TRENDS NEUROSCI, V15, P340, DOI 10.1016/0166-2236(92)90051-9; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; Rose G., 1992, STRATEGY PREVENTIVE; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STEWART RB, 1991, GERONTOLOGY, V37, P2272; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; 1987, SOI1978 NETH CENTR B	20	418	426	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1604	1608		10.1136/bmj.308.6944.1604	http://dx.doi.org/10.1136/bmj.308.6944.1604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025427	Green Published			2022-12-01	WOS:A1994NT52800018
J	PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R				PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R			DISTAL FOREARM FRACTURE AS RISK FACTOR FOR VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,ENGLAND; NO GEN HOSP,DEPT DIAGNOST IMAGING,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT ORTHOPAED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	University of Sheffield; Northern General Hospital; Northern General Hospital			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				KLEINBAUM DJ, 1978, APPLIED REGRESSION A; OWEN RA, 1982, CLIN ORTHOPAEDICS, V171, P37; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919	4	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1543	1544		10.1136/bmj.308.6943.1543	http://dx.doi.org/10.1136/bmj.308.6943.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019311	Green Published			2022-12-01	WOS:A1994NR11000024
J	CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR				CAULEY, JA; SEELEY, DG; ENSRUD, K; ETTINGER, B; BLACK, D; CUMMINGS, SR			ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; FRACTURES; OSTEOPOROSIS, POSTMENOPAUSAL; AGE FACTORS; BONE DENSITY	POST-MENOPAUSAL WOMEN; HIP FRACTURE; ELDERLY WOMEN; POSTMENOPAUSAL OSTEOPOROSIS; BONE-DENSITY; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; TRABECULAR BONE; RISK; DISEASE	Objective: To determine the relation between estrogen replacement therapy and fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Participants: 9704 ambulatory, nonblack women 65 years of age or older. Measurements: Estrogen use, medical history, and anthropometric data were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident fractures were validated by radiographic report. Results: After adjustment for potential confounders, current estrogen use was associated with a decrease int he risk for wrist fractures (relative risk [RR], 0.39; 95% Cl, 0.24 to 0.64) and for all nonspinal fractures (RR, 0.66; Cl, 0.54 to 0.80) when compared with no estrogen use. Results were similar for women using unopposed estrogen or estrogen plus progestin, for women younger or older than 75 years of age, and for current smokers or nonsmokers. The effect of estrogen remained after adjustment was made for appendicular bone mass. The relative risk for hip fracture tended to be lower among current users (RR, 0.60; Cl, 0.36 to 1.02) than among never-users. Estrogen was most effective in preventing hip fracture among those older than 75 years. Current users who started estrogen within 5 years of menopause had a decreased risk for hip fractures (RR, 0.29; Cl, 0.09 to 0.92), wrist fractures (RR, 0.29; Cl, 0.13 to 0.68), and all nonspinal fractures (RR, 0.50; Cl, 0.36 to 0.70) when compared with women who had never used estrogen. Previous use of estrogen for more than 10 years or use begun soon after menopause had no substantial effect on the risk for fractures. Conclusions: Current use of estrogen appears to decrease the risk for fracture in older women. These results suggest that for protection against fractures, estrogen should be initiated soon after menopause and continued indefinitely.	UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, DEPT MED, MINNEAPOLIS, MN 55417 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA 94611 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities	CAULEY, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, A524 CRABTREE HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582] Funding Source: Medline; NIA NIH HHS [1-R01-AG05395] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005395] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1991, 31ST ANN C CARD DIS; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1994, IN PRESS OSTEOPOROSI; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PECK WA, 1993, AM J MED, V94, P646; PHILLIPS SK, 1993, CLIN SCI, V84, P95, DOI 10.1042/cs0840095; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SEELEY DG, 1994, IN PRESS ARCH INTERN; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VOGEL JM, 1987, OSTEOPOROSIS UPDATE, P219; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695	43	680	689	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					9	16		10.7326/0003-4819-122-1-199501010-00002	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7985914				2022-12-01	WOS:A1995PY50200002
J	LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P				LETOURNEUR, F; GAYNOR, EC; HENNECKE, S; DEMOLLIERE, C; DUDEN, R; EMR, SD; RIEZMAN, H; COSSON, P			COATOMER IS ESSENTIAL FOR RETRIEVAL OF DILYSINE-TAGGED PROTEINS TO THE ENDOPLASMIC-RETICULUM	CELL			English	Article							CLATHRIN-COATED VESICLES; ALPHA-PHEROMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEINS; SECRETORY PATHWAY; POLYACRYLAMIDE GELS; YEAST COATOMER; GOLGI-COMPLEX; BETA-COP; SUBUNIT	Dilysine motifs in cytoplasmic domains of transmembrane proteins are signals for their continuous retrieval from the Golgi back to the endoplasmic reticulum (ER). We describe a system to assess retrieval to the ER in yeast cells making use of a dilysine-tagged Ste2 protein. Whereas retrieval was unaffected in most sec mutants tested (sec7, sec12, sec13, sec16, sec17, sec18, sec19, sec22, and sec23), a defect in retrieval was observed in previously characterized coatomer mutants (sec21-1, sec27-1), as well as in newly isolated retrieval mutants (sec21-2, ret1-1). RET1 was cloned by complementation and found to encode the alpha subunit of coatomer. While temperature-sensitive for growth, the newly isolated coatomer mutants exhibited a very modest defect in secretion at the nonpermissive temperature. Coatomer from beta'-COP (sec27-1) and alpha-COP (ret1-1) mutants, but not from gamma-COP (sec21) mutants, had lost the ability to bind dilysine motifs in vitro. Together, these results suggest that coatomer plays an essential role in retrograde Golgi-to-ER transport and retrieval of dilysine-tagged proteins back to the ER.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Berkeley; University of Basel	LETOURNEUR, F (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Duden, Rainer/C-8917-2011; Duden, Rainer/GXH-3206-2022	Letourneur, Francois/0000-0003-2232-6127; Riezman, Howard/0000-0003-4680-9422				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, IN PRESS J BIOL CHEM, V269; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HARTER C, 1993, FEBS LETT, V332, P71, DOI 10.1016/0014-5793(93)80487-F; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cb.07.110191.003411; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	43	678	687	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1199	1207		10.1016/0092-8674(94)90011-6	http://dx.doi.org/10.1016/0092-8674(94)90011-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001155				2022-12-01	WOS:A1994PZ86000011
J	PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A				PUFFENBERGER, EG; HOSODA, K; WASHINGTON, SS; NAKAO, K; DEWIT, D; YANAGISAWA, M; CHAKRAVARTI, A			A MISSENSE MUTATION OF THE ENDOTHELIN-B RECEPTOR GENE IN MULTIGENIC HIRSCHSPRUNGS-DISEASE	CELL			English	Article							CHROMOSOMAL ASSIGNMENT; AGANGLIONIC MEGACOLON; FUNCTIONAL EXPRESSION; CLONING; IDENTIFICATION; ORGANIZATION; CDNA; ASSOCIATION; ANTAGONIST; DELETION	Hirschsprung's disease (HSCR) is characterized by an absence of enteric ganglia in the distal colon and a failure of innervation in the gastrointestinal tract. We recently mapped a recessive susceptibility locus (HSCR2) to human chromosome 13q22, which we now demonstrate to be the endothelin-B receptor gene (EDNRB). We identified in HSCR patients a G-->T missense mutation in EDNRB exon 4 that substitutes the highly conserved Trp-276 residue in the fifth transmembrane helix of the G protein-coupled receptor with a Cys residue (W276C). The mutant W276C receptor exhibited a partial impairment of ligand-induced Ca2+ transient levels in transfected cells. The mutation is dosage sensitive, in that W276C homozygotes and heterozygotes have a 74% and a 21% risk, respectively, of developing HSCR. Genotype analysis of patients in a Mennonite pedigree shows HSCR to he a multigenic disorder.	CASE WESTERN RESERVE UNIV,SCH MED,CTR HUMAN GENET,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,CLEVELAND,OH 44106; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; KYOTO UNIV,SCH MED,DEPT MED,DIV 2,KYOTO 606,JAPAN	Case Western Reserve University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kyoto University	PUFFENBERGER, EG (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106, USA.			Puffenberger, Erik/0000-0002-6388-9148	NICHD NIH HHS [HD-28088] Funding Source: Medline; NIGMS NIH HHS [T32GM08056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; ARINAMI T, 1991, AM J HUM GENET, V48, P990; BADNER JA, 1990, AM J HUM GENET, V46, P568; BADNER JA, 1990, AM J MED GENET, V35, P100, DOI 10.1002/ajmg.1320350119; BAYNASH AG, 1994, CELL, V79; BECKER A, 1994, EUR J BIOCHEM, V221, P951, DOI 10.1111/j.1432-1033.1994.tb18810.x; Bergey LL, 1992, PA MENNON HERIT, V15, P9; BOTTANI A, 1991, HUM GENET, V87, P748; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHAKRAVARTI A, 1992, CYTOGENET CELL GENET, V59, P99, DOI 10.1159/000133212; CLAPHAM DE, 1994, NATURE, V371, P109, DOI 10.1038/371109a0; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; EARLAM RJ, 1972, AM J DIG DIS, V17, P255, DOI 10.1007/BF02232298; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEYL DL, 1993, PEPTIDE RES, V6, P238; HOSODA K, 1992, J BIOL CHEM, V267, P18797; Hosoda K, 1994, CELL, V79; IKADAI H, 1979, Congenital Anomalies, V19, P31; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; JACOBSCOHEN RJ, 1987, J COMP NEUROL, V255, P425, DOI 10.1002/cne.902550309; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPUR RP, 1993, DEVELOPMENT, V117, P993; KARNE S, 1993, J BIOL CHEM, V268, P19126; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KISS P, 1989, J MED GENET, V26, P793, DOI 10.1136/jmg.26.12.793; KUMAR C, 1994, J BIOL CHEM, V269, P13414; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAMONT MA, 1989, J MED GENET, V26, P100, DOI 10.1136/jmg.26.2.100; LANE PW, 1984, J HERED, V75, P435, DOI 10.1093/oxfordjournals.jhered.a109980; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MCCABE L, 1990, AM J MED GENET, V36, P336, DOI 10.1002/ajmg.1320360319; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; REPASKE R, 1985, J VIROL, V54, P764, DOI 10.1128/JVI.54.3.764-772.1985; ROMEO G, 1994, NATURE, V357, P377; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SOGABE K, 1993, J PHARMACOL EXP THER, V264, P1040; SPARKES RS, 1984, HUM GENET, V68, P258, DOI 10.1007/BF00418397; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	54	729	796	2	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1257	1266		10.1016/0092-8674(94)90016-7	http://dx.doi.org/10.1016/0092-8674(94)90016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	8001158				2022-12-01	WOS:A1994PZ86000016
J	KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB				KEHLENBACH, RH; MATTHEY, J; HUTTNER, WB			XL-ALPHA-S IS A NEW-TYPE OF G-PROTEIN	NATURE			English	Article							CONSTITUTIVE SECRETORY VESICLES; SYNAPTIC-LIKE MICROVESICLES; TRANS-GOLGI NETWORK; GTP-BINDING; RECEPTOR; MEMBRANE; MUTATIONS; ENDOSOMES; SUBUNITS; P100	THE GTP-binding proteins are well-known regulators of cellular functions(1-4), including vesicular transport(5-7). Cholera toxin, which is known to catalyse ADP-ribosylation of the as subunit of heterotrimeric G proteins, stimulates secretory vesicle formation from the trans-Golgi network(8). Here we describe a new cholera toxin target, an 'extra large' G protein (XLas; M(r) 92K) which consists of a new 51K XL-portion linked to a Gas truncated at the amino terminus. XLas is specifically associated with the trans-Golgi network and occurs selectively in cells containing both the regulated and the constitutive pathway of protein secretion. Hence, XLas may mediate the effects of cholera toxin on secretory vesicle formation.	UNIV HEIDELBERG, INST NEUROBIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018	Kehlenbach, Ralph/0000-0003-4920-9916				Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; GILL DM, 1991, METHOD ENZYMOL, V195, P267; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Sambrook J., 1989, MOL CLONING LAB MANU; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1991, BIOCHEM J, V280, P171, DOI 10.1042/bj2800171; TRAUB LM, 1990, BIOCHEM J, V272, P453, DOI 10.1042/bj2720453; UDRISAR D, 1990, P NATL ACAD SCI USA, V87, P6321, DOI 10.1073/pnas.87.16.6321; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	35	186	189	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					804	809						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997272				2022-12-01	WOS:A1994PY21200060
J	ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR				ZHANG, GH; TANEJA, KL; SINGER, RH; GREEN, MR			LOCALIZATION OF PRE-MESSENGER-RNA SPLICING IN MAMMALIAN NUCLEI	NATURE			English	Article							INSITU HYBRIDIZATION; NASCENT TRANSCRIPTS; CELL-NUCLEUS; POLY(A) RNA; RIBONUCLEOPROTEINS; ORGANIZATION; IDENTIFICATION; DOMAINS; PROTEIN; INTERPHASE	IN mammalian nuclei, precursor messenger RNA splicing factors are distributed non-uniformly. Antibodies directed against structural polypeptides of small nuclear ribonucleoprotein particles (snRNPs)(1) and some non-snRNP splicing factors(2) have shown that these components are concentrated in about 20-50 nuclear 'speckles'. These and other non-homogeneous distributions have been proposed to indicate nuclear 'compartments' that are distinct from the sites of transcription and in which RNA processing (3-9). We have tested this idea using a new approach. Previous structural(10-13) and biochemical(14-16) data have shown that splicing can occur in association with transcription. Nascent RNA of specific genes can be detected by in situ hybridization as intense spots of nuclear stain which map to the sites of transcription(17-19). Here we identify active pre-mRNA splicing sites by localizing the nascent spliced mRNA of specific genes. We find that splicing occurs at the sites of transcription, which are not coincident with intranuclear speckles. We conclude that the nucleus is not compartmentalized with respect to transcription and pre-mRNA splicing.	UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	ZHANG, GH (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.							AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BRIDGE E, 1993, J VIROL, V67, P5792, DOI 10.1128/JVI.67.10.5792-5802.1993; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TURNER BM, 1987, J CELL SCI, V87, P269; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; VOELKERDING K, 1986, J VIROL, V60, P353, DOI 10.1128/JVI.60.2.353-362.1986; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729	30	229	234	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					809	812						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997273				2022-12-01	WOS:A1994PY21200061
J	BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C				BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C			THE RISK OF DYING IN ALCOHOL-RELATED AUTOMOBILE CRASHES AMONG HABITUAL DRUNK DRIVERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; DRINKING	Background. Reports suggest that people who drive while intoxicated by alcohol may do so repeatedly. We hypothesized that persons arrested for driving while impaired might be at increased risk for death in an alcohol-related motor vehicle crash. To evaluate this possibility, we studied the deaths of drivers in alcohol-related motor vehicle accidents in North Carolina over a 10-year period. Methods. We compared drivers who died in motor vehicle crashes from 1980 through 1989 and who had blood alcohol concentrations of at least 20 mg per deciliter (4.3 mmol per liter), referred to as the case drivers, with those who died in crashes but had blood alcohol concentrations below 20 mg per deciliter, referred to as the control drivers. We identified case drivers and control drivers through the state Medical Examiner System. We then searched North Carolina driver-history. files for the five years before each death to identify arrests for driving while impaired. Results. We linked a total of 1646 case drivers and 1474 control drivers to their driver-history files. Case drivers were more likely than control drivers to have been arrested for driving while impaired (26 percent vs. 3 percent). After we controlled for potential confounding variables, case drivers 21 to 34 years of age were 4.3 times more likely (95 percent confidence interval, 2.7 to 6.8) than control drivers to have been arrested for driving while impaired; case drivers 35 years of age or older were 11.7 times more likely (95 percent confidence interval, 6.8 to 20.1). The strength of the association appeared to increase with the number of prior arrests. Case drivers were also more likely than the general population of currently licensed drivers to have been arrested. Conclusions. Arrests for driving while impaired substantially increase the risk of eventual death in an alcohol-related crash. Aggressive intervention in the cases of people arrested for driving while impaired may decrease the likelihood of a future fatal alcohol-related crash.	CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, INJURY CONTROL SECT, RALEIGH, NC USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, DIV STAT & INFORMAT SERV, RALEIGH, NC USA; UNIV N CAROLINA, HIGHWAY SAFETY RES CTR, CHAPEL HILL, NC USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill	BREWER, RD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, DIV UNINTENT INJURY PREVENT, ATLANTA, GA 30341 USA.				PHS HHS [H28/CCH401640011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARSTEINKERSLAKE GW, 1985, TYPOLOGICAL ANAL CAL; CLARK CD, 1972, HIT LAB REP, V2, P1; Clark WB, 1991, ALCOHOL AM DRINKING; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DEAN AD, 1991, EPI INFO VERION 5 0; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; FILKINS LD, 1970, ALCOHOL ABUSE TRAFFI; FINE EW, 1976, ANN NY ACAD SCI, V273, P637, DOI 10.1111/j.1749-6632.1976.tb52938.x; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V50, P54, DOI 10.15288/jsa.1989.50.54; Richman A, 1985, J Stud Alcohol Suppl, V10, P21; SELZER ML, 1969, BEHAV SCI, V14, P1, DOI 10.1002/bs.3830140102; SHORE ER, 1988, EVAL PROGRAM PLANN, V11, P245, DOI 10.1016/0149-7189(88)90020-1; SLEET DA, 1989, HEALTH EDUC QUART, V16, P329, DOI 10.1177/109019818901600302; SMITH PF, 1989, HEALTH EDUC QUART, V16, P345, DOI 10.1177/109019818901600304; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; STERLINGSMITH RS, 1974, PSYCHOSOCIAL ANAL OP; Vaillant G.E., 1995, WISDOM EGO; 1992, NHTSA23 TECHN TRANSF; 1992, DHHS PHS921232 PUBL; 1989, SAS RELEASE 6 03; 1993, MMWR-MORBID MORTAL W, V42, P905; 1992, STATISTICAL ABSTRACT	26	90	93	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					513	517		10.1056/NEJM199408253310806	http://dx.doi.org/10.1056/NEJM199408253310806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041418				2022-12-01	WOS:A1994PD07200006
J	CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G				CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG HEALTH-CARE WORKERS WHO DONATE BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; HEALTH PERSONNEL; BLOOD DONORS; BLOOD BANKS; OCCUPATIONAL EXPOSURE	HIV-INFECTION; MEMBERS	Objective: To estimate the prevalence of human immunodeficiency virus (HIV) infection among health care workers who donate blood. Design: Point prevalence survey of blood donors. Setting: 20 U.S. blood centers that participate in an ongoing interview study of HIV-seropositive blood donors. Measurements: Prevalence rates for HIV in persons who reported being health care workers were measured directly for 6 of the 20 blood centers. For the other 14 centers, we derived the numerator from the interview study in the same manner used for the 6 centers; we estimated the denominator using blood collection logs at those centers and extrapolations from the survey completed at the 6 blood centers. Results: Between March 1990 and August 1991, 8519 health care workers donated blood at 6 hospitals and other medical facilities. Three persons were HIV seropositive: Two reported being health care workers and having nonoccupational risk factors for HIV infection; the occupation and other possible risk factors of the third seropositive donor could not be determined. Therefore, the highest overall prevalence of HIV infection among health care worker donors at these 6 centers was 0.04% (3 of 8519; upper limit of 95% CI, 0.1%). We estimated that during the same period, approximately 36 329 health care workers were tested for HIV at all 20 centers. Twenty-seven persons infected with HIV who donated at hospitals were identified; 7 did not return for interviews, so their health care occupations could not be verified. Thus, the highest estimated overall prevalence of HIV infection among health care worker donors at the 20 centers was 0.07% (27 of 36 329; upper limit of CI, 0.1%). Of the 20 known health care worker donors, 11 reported nonoccupational risks for HIV infection; 3 of the remaining 9 health care workers described occupational blood exposures that could have resulted in transmission of HIV. Conclusions: Blood donors can serve as a sentinel cohort when evaluating the risk for occupationally acquired HIV infection. These findings suggest that among the many health care worker donors in this study, HIV infection attributable to occupational exposure was uncommon.	IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; AMER RED CROSS, ATLANTA, GA USA; AMER RED CROSS, PHILADELPHIA, PA USA; AMER RED CROSS, BALTIMORE, MD USA; AMER RED CROSS, DETROIT, MI USA; UNIV CALIF LOS ANGELES HOSP, LOS ANGELES, CA USA	American Red Cross; American Red Cross; American Red Cross; American Red Cross; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GRUNINGER SE, 1992, J AM DENT ASSOC, V123, P57, DOI 10.14219/jada.archive.1992.0075; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; PETERSEN LR, 1990, PUBLIC HEALTH REP, V105, P153; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; 1987, MMWR-MORBID M     S2, V36, pS1; 1993, PHS HIVNCID1193036 D; 1992, HIV AIDS SURVEILLANC	12	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					269	273		10.7326/0003-4819-121-4-199408150-00006	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037407				2022-12-01	WOS:A1994PB10200006
J	GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ				GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ			AN OSMOSENSING SIGNAL-TRANSDUCTION PATHWAY IN MAMMALIAN-CELLS	SCIENCE			English	Article							C-JUN ACTIVITY; ACTIVATION DOMAIN; PHOSPHORYLATION; OSMOREGULATION; KINASE; SERINE-63; YEAST	The osmotic balance between the cytoplasmic and extracellular compartments of cells is critical for the control of cell volume. A mammalian protein kinase, Jnk, which is a distant relative of the mitogen-activated protein kinase group, was activated by phosphorylation on threonine and tyrosine in osmotically shocked cells. The activation of Jnk may be relevant to the biological response to osmotic shock because the expression of human Jnk in the yeast Saccharomyces cerevisiae rescued a defect in growth on hyper-osmolar media. These data indicate that related protein kinases may mediate osmosensing signal transduction in yeast and mammalian cells.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINKENZELLER G, 1994, FEBS LETT, V340, P163, DOI 10.1016/0014-5793(94)80129-0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAMAMURA M, 1992, BRAIN RES, V572, P42, DOI 10.1016/0006-8993(92)90448-I; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JILL LE, 1987, AM J PHYSIOL, V252, pF1; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PAREDES A, 1992, AM J PHYSIOL, V263, pC1282, DOI 10.1152/ajpcell.1992.263.6.C1282; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TILLY BC, 1993, J BIOL CHEM, V268, P19919; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	22	538	556	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					806	808		10.1126/science.8047888	http://dx.doi.org/10.1126/science.8047888			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047888				2022-12-01	WOS:A1994PA37200040
J	HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			MILLER-DIEKER LISSENCEPHALY GENE ENCODES A SUBUNIT OF BRAIN PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							FACTOR ACETYLHYDROLASE; FACTOR PAF; CHROMOSOME-17P13; PURIFICATION; RECEPTOR; REPEATS; CLONES; PCR	PLATELET-ACTIVATING factor (PAF) is involved in a variety of biological and pathological processes(1) and PAF acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is widely distributed in plasma and tissue cytosols(2,3). One isoform of PAP acetylhydrolase present in bovine brain cortex is a heterotrimer comprising subunits with relative molecular masses of 45K, 30K and 29K (ref. 4). We have now isolated the complementary DNA for the 45K subunit. Sequence analysis revealed a striking identity (99%) of the subunit with a protein encoded by the causative gene (LIS-1) for MiUer-Dieker lissencephaly(5), a human brain malformation manifested by a smooth cerebral surface and abnormal neuronal migration. This indicates that the LIS-1 gene product is a human homologue of the 45K subunit of intracellular PAF acetylhydrolase. Our results raise the possibility that PAF and PAF acetylhydrolase are important in the formation of the brain cortex during differentiation and development.	SUNTORY INST BIOMED RES,MISHIMA 618,OSAKA,JAPAN	Suntory Holdings Ltd	HATTORI, M (corresponding author), UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN.		Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; CATALAN RE, 1992, BIOCHEM BIOPH RES CO, V183, P300, DOI 10.1016/0006-291X(92)91643-5; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOGOS V, 1990, J NEUROSCI RES, V27, P706, DOI 10.1002/jnr.490270431; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; VANDERNVOORN L, 1992, FEBS LETT, V507, P131	18	434	443	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					216	218		10.1038/370216a0	http://dx.doi.org/10.1038/370216a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028668				2022-12-01	WOS:A1994NX97100052
J	OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A				OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A			OUTCOME OF CHILDHOOD ASTHMA IN MID-ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT THORAC MED,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,CTR ADOLESCENT HLTH,MELBOURNE,VIC,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	4	100	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					95	96		10.1136/bmj.309.6947.95	http://dx.doi.org/10.1136/bmj.309.6947.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038676	Green Published			2022-12-01	WOS:A1994NW71600019
J	HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ				HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ			PEPTIDE-SYNTHESIS CATALYZED BY AN ANTIBODY CONTAINING A BINDING-SITE FOR VARIABLE AMINO-ACIDS	SCIENCE			English	Article							REACTIVITY	Monoclonal antibodies, induced with a phosphonate diester hapten, catalyzed the coupling of p-nitrophenyl esters of N-acetyl valine, leucine, and phenylalanine with tryptophan amide to form the corresponding dipeptides. All possible stereoisomeric combinations of the ester and amide substrates were coupled at comparable rates. The antibodies did not catalyze the hydrolysis of the dipeptide product nor hydrolysis or racemization of the activated esters. The yields of the dipeptides ranged from 44 to 94 percent. The antibodies were capable of multiple turnovers at rates that exceeded the rate of spontaneous ester hydrolysis. This achievement suggests routes toward creating a small number of antibody catalysts for polypeptide syntheses.	UNIV PENN,MONELL CHEM SENSES CTR,DEPT CHEM,RES STRUCT MATTER LAB,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT CHEM,UNIV PK,PA 16802	Monell Chemical Senses Center; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	HIRSCHMANN, R (corresponding author), UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104, USA.		Taylor, Carol/B-4841-2012	Taylor, Carol/0000-0002-6262-0796	NIGMS NIH HHS [GM-45611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAHMSER L, 1991, BIOCHEMISTRY-US, V30, P4151; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; BENOITON NL, 1983, PEPTIDES, V5, pCH4; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; FERSHT AR, 1970, J AM CHEM SOC, V92, P5442, DOI 10.1021/ja00721a024; GREEN BS, 1991, CATALYTIC ANTIBODIES, V159, P139; GUTTE B, 1969, J AM CHEM SOC, V91, P501, DOI 10.1021/ja01030a050; HEARD AL, 1963, J CHEM SOC, V1963, P5807; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P509; HIRSCHMANN R, UNPUB; HOEGER C, 1989, J CHROMATOGR, V404, P307; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; Jakubke HD., 1987, PEPTIDES ANAL SYNTHE, V9, P103; KAISER ET, 1989, SCIENCE, V243, P187, DOI 10.1126/science.2492114; KIRBY DA, 1993, J CHROMATOGR, V648, P257, DOI 10.1016/0021-9673(93)83309-G; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOULT J, 1976, J MOL BIOL, V74, P137; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; RIVIER JE, 1978, J LIQ CHROMATOGR, V1, P343, DOI 10.1080/01483917808060004; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCHWYZER R, 1966, HELV CHIM ACTA, V49, P134, DOI 10.1002/hlca.660490120; SIEPKE G, 1986, ANGEW CHEM INT EDIT, V25, P535; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213	27	395	405	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					234	237		10.1126/science.8023141	http://dx.doi.org/10.1126/science.8023141			4	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023141				2022-12-01	WOS:A1994NV95700037
J	SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M				SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M			A MATRIX METALLOPROTEINASE EXPRESSED ON THE SURFACE OF INVASIVE TUMOR-CELLS	NATURE			English	Article							IV COLLAGENASE; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; ACTIVATION; FIBROBLASTS; GELATINASE; ASSOCIATION; METASTASIS; CARCINOMA; PRECURSOR	GELATINASE A (type-IV collagenase; M(r) 72,000) is produced by tumour stroma cells and is believed to be crucial for their invasion and metastasis, acting by degrading extracellular matrix macromolecules such as type IV collagen(1-3). An inactive precursor of gelatinase A (pro-gelatinase A) is secreted and activated in invasive tumour tissue(4-7) as a result of proteolysis which is mediated by a fraction of tumour cell membrane that is sensitive to metalloproteinase inhibitors(4,5). Here we report the cloning of the complementary DNA encoding a new matrix metalloproteinase with a potential transmembrane domain. Expression of the gene product on the cell surface induces specific activation of pro-gelatinase A in vitro and enhances cellular invasion of the reconstituted basement membrane. Tumour cells of invasive lung carcinomas, which contain activated forms of gelatinase A, were found to express the transcript and the gene product. The new metalloproteinase may thus trigger invasion by tumour cells by activating pro-gelatinase A on the tumour cell surface.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT ORAL SURG,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; FUJI CHEM IND CO LTD,RES INST,DEPT BIOCHEM,TAKAOKA,TOYAMA 933,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			TAKINO, Takahisa/D-8460-2015; SATO, Hiroshi/D-8454-2015; Okada, Yasunori/B-5550-2014; Seiki, Motoharu/K-9443-2015	Okada, Yasunori/0000-0001-9208-4755; 				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; BROWN PD, 1993, CLIN EXP METASTAS, V11, P183, DOI 10.1007/BF00114976; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; POULSOM R, 1992, AM J PATHOL, V141, P389; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TEMPLETON NS, 1990, CANCER RES, V50, P5431; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	30	2349	2440	5	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					61	65		10.1038/370061a0	http://dx.doi.org/10.1038/370061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015608				2022-12-01	WOS:A1994NV71100059
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P			CHANGES IN RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NORTH-KARELIA; DECLINE	Objective-To estimate the extent to which changes in the main coronary risk factors (serum cholesterol concentration, blood pressure, and smoking) explain the decline in mortality from ischaemic heart disease and to evaluate the relative importance of change in each of these risk factors. Design-Predicted changes in ischaemic heart disease mortality were calculated by a logistic regression model using the risk factor levels assessed by cross sectional population surveys, in 1972, 1977, 1982, 1987, and 1992. These predicted changes were compared with observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-14257 men and 14786 women aged 30-59 randomly selected from the national population register. Main outcome measures-Levels of the risk factors and predicted and observed changes in mortality from ischaemic heart disease. Results-The observed changes in the risk factors in the population from 1972 to 1992 predicted a decline in mortality from ischaemic heart disease of 44% (95% confidence interval 37% to 50%) in men and 49% (37% to 59%) in women. The observed decline was 55% (51% to 58%) and 68% (61 to 74) respectively. Conclusion-An assessment of the data on the risk factors for ischaemic heart disease and mortality suggests that most of the decline in mortality from ischaemic heart disease can be explained by changes in the three main coronary risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.							ALROOMI KA, 1989, AM J EPIDEMIOL, V129, P503, DOI 10.1093/oxfordjournals.aje.a115161; DWYER T, 1980, INT J EPIDEMIOL, V9, P65, DOI 10.1093/ije/9.1.65; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; JACKSON R, 1987, INT J EPIDEMIOL, V16, P377, DOI 10.1093/ije/16.3.377; NICOLOSI A, 1988, INT J EPIDEMIOL, V17, P766, DOI 10.1093/ije/17.4.766; Ovcarov V K, 1978, World Health Stat Q, V31, P208; PIETINEN P, 1990, LIPIDS HLTH; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; SALONEN JT, 1979, BRIT MED J, V2, P1178, DOI 10.1136/bmj.2.6199.1178; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAO SC, 1989, INT J EPIDEMIOL, V18, pS159; TUOMILEHTO J, 1986, BRIT MED J, V293, P1068, DOI 10.1136/bmj.293.6554.1068; Uemura K, 1985, World Health Stat Q, V38, P142; UESHIMA H, 1987, AM J EPIDEMIOL, V125, P62, DOI 10.1093/oxfordjournals.aje.a114512; VARTIAINEN E, 1991, INT J EPIDEMIOL, V20, P651, DOI 10.1093/ije/20.3.651; 1992, MINISTRY AGR FORESTR, V11; 1988, J CLIN EPIDEMIOL, V41, P105, DOI [10.1016/0895-4356(88)90084-4, DOI 10.1016/0895-4356(88)90084-4]; 1987, AM J EPIDEMIOL, V1, P95	20	344	351	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					23	27		10.1136/bmj.309.6946.23	http://dx.doi.org/10.1136/bmj.309.6946.23			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044063	Green Published			2022-12-01	WOS:A1994NV89100019
J	WARD, BJ; TATE, PA				WARD, BJ; TATE, PA			ATTITUDES AMONG NHS DOCTORS TO REQUESTS FOR EUTHANASIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore NHS doctors' attitudes to competent patients' requests for euthanasia and to estimate the proportion of doctors who have taken active steps to hasten a patient's death. Design-Anonymous postal questionnaire, with no possibility of follow up. The survey was conducted from December 1992 to March 1993. Subjects-All (221) general practitioners and 203 hospital consultants in one area of England. Results-273 doctors responded to a question on whether a patient had ever asked them to hasten death. Of these, 163 had been asked to; 124 of these had been asked to take active steps to hasten death; 38 of 119 (32%) of these had complied with such a request (95% confidence interval 23% to 40%). This proportion represented 12% of all those who returned a completed questionnaire and 9% of all those who had been sent a questionnaire (95% confidence interval 6.3% to 11.7%). A larger proportion of the respondents (142/307 (46%)), however, would consider taking active steps to bring about the death of a patient if it was legal to do so. Conclusions-Many doctors face difficult decisions about euthanasia. For the benefit of both patients and doctors euthanasia should be discussed more openly.	UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	University of Cambridge								KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; 1988, BRIT MED J, V296, P1376; 1987, ATTITUDES EUTHANASIA	5	112	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1332	1334		10.1136/bmj.308.6940.1332	http://dx.doi.org/10.1136/bmj.308.6940.1332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019219	Green Published			2022-12-01	WOS:A1994NM98900020
J	OWENS, DM; NELSON, DK; TALLEY, NJ				OWENS, DM; NELSON, DK; TALLEY, NJ			THE IRRITABLE-BOWEL-SYNDROME - LONG-TERM PROGNOSIS AND THE PHYSICIAN-PATIENT INTERACTION	ANNALS OF INTERNAL MEDICINE			English	Article						COLONIC DISEASES, FUNCTIONAL; PHYSICIAN-PATIENT RELATIONS; DIARRHEA; ABDOMINAL PAIN	ALTERNATIVE MEDICINE; EPIDEMIOLOGY; ENCOUNTERS; DISCOURSE; CRITIQUE	Objective: To evaluate the long-term course and prognosis associated with the irritable bowel syndrome (IBS) and to determine the influence of an effective physician-patient relationship on subsequent health care use. Design: Prospective review of medical records. Setting: Tertiary referral center. Patients: 112 consecutive Olmsted County, Minnesota, residents who were first diagnosed with IBS at the Mayo Clinic during the period 1961-1963. Results: The median follow-up was 29 years (range, 1 to 32 years) and patients made a median of 2 return visits for IBS-related symptoms (range, 0 to 12 visits). In addition to abdominal pain, diarrhea (reported by 50% of patients) was the predominant bowel symptom at diagnosis. Organic gastrointestinal disease occurred in 10 patients a median of 15 years after diagnosis of IBS. Survival in patients with IBS did not differ from expected survival (27 deaths; median survival > 30 years after initial diagnosis). A positive physician-patient interaction, defined a priori using objective criteria in the written record, was associated with fewer return visits for IBS. Of the eight variables examined, notations in the medical record about psychosocial history, precipitating factors, and discussion of diagnosis and treatment with patients were associated with fewer return visits for IBS-related symptoms. Conclusions: When diagnosed according to current criteria, IBS is associated with a good prognosis and the diagnosis is unlikely to be changed to that of an organic disease during follow-up. A positive physician-patient interaction may be related to reduced use of ambulatory health services by patients with IBS.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092	NIA NIH HHS [R01 AG099440] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLPORT GW, 1942, B SOCIAL SCI RES COU, V49, pR12; BARFOOT M, 1990, PSYCHOL MED, V20, P263, DOI 10.1017/S0033291700017591; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; CAMILLERI M, 1992, ANN INTERN MED, V116, P1001, DOI 10.7326/0003-4819-116-12-1001; CHAUDHARY NA, 1962, Q J MED, V31, P307; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FREEMON B, 1971, PEDIATR RES, V5, P298; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HARVEY RF, 1987, LANCET, V1, P963; HOLMES KM, 1982, BRIT MED J, V285, P1533, DOI 10.1136/bmj.285.6354.1533; Houston WR, 1938, ANN INTERN MED, V11, P1416, DOI 10.7326/0003-4819-11-8-1416; INUI TS, 1982, MED CARE, V20, P535, DOI 10.1097/00005650-198206000-00001; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUPTON D, 1992, AUST J PUBLIC HEALTH, V16, P145; PAGANO MP, 1992, COMMUNICATING EFFECT; PHILLIPS SF, 1992, MOTILITY DISORDERS G, P299; PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008; Roter DL, 1992, DOCTORS TALKING PATI; Ryle JA, 1928, LANCET, V2, P1115; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SVENDSEN JH, 1985, SCAND J GASTROENTERO, V20, P415, DOI 10.3109/00365528509089673; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; WALLER SL, 1969, LANCET, V2, P753	29	247	251	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					107	+		10.7326/0003-4819-122-2-199501150-00005	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7992984				2022-12-01	WOS:A1995QC05900005
J	HIROSE, K; IINO, M				HIROSE, K; IINO, M			HETEROGENEITY OF CHANNEL DENSITY IN INOSITOL-1,4,5-SENSITIVE TRISPHOSPHATE-SENSITIVE CA2+ STORES	NATURE			English	Article							VASCULAR SMOOTH-MUSCLE; CALCIUM RELEASE; FLUORESCENT INDICATOR; INTRACELLULAR STORES; 1,4,5-TRISPHOSPHATE; CELLS; MECHANISM; MOBILIZATION; DEPENDENCE	INOSITOL-1,4,5-trisphosphate (InsP(3))-induced Ca2+ release is a key mechanism for intracellular Ca2+ mobilization(1). The rate of Ca2+ release declines progressively with time until a higher concentration of InsP(3) is added, which is referred to as the incremental detection mechanism(2). Two hypotheses have been postulated to explain these complex kinetics: (1) Ca2+ stores consist of multiple compartments (quanta) with different sensitivities to InsP(3) (refs 3-7), and (2) the rate of Ca2+ release is modulated by the Ca2+ concentration in the lumen of Ca2+ stores(8-12). We studied this phenomenon by real-time measurement of the luminal Ca2+ concentration of Ca2+ stores using a Ca2+-sensitive fluorescent dye, but our results were not explained by either of these hypotheses. Here we report that the complex kinetics of Ca2+ release results from the heterogeneous density of equally InsP(3)-sensitive channels on the Ca2+ stores. This heterogeneity creates Ca2+ stores with apparently different sensitivities to InsP(3), which may have different functions in Ca2+ mobilization.			HIROSE, K (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.			Hirose, Kenzo/0000-0002-8944-6513				AHNERTHILGER G, 1988, TRENDS PHARMACOL SCI, V9, P195, DOI 10.1016/0165-6147(88)90081-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HIROSE K, 1993, BIOCHEM BIOPH RES CO, V194, P726, DOI 10.1006/bbrc.1993.1882; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1993, J BIOL CHEM, V268, P25206; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SHORT AD, 1993, J BIOL CHEM, V268, P25887; Somlyo AV, 1980, HDB PHYSL          2, P33; SWILLENS S, 1992, MOL PHARMACOL, V41, P110; UYAMA Y, 1992, BRIT J PHARMACOL, V106, P208, DOI 10.1111/j.1476-5381.1992.tb14316.x	29	114	116	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	1994	372	6508					791	794						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7997268				2022-12-01	WOS:A1994PY21200056
J	NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR				NELSON, HD; NEVITT, MC; SCOTT, JC; STONE, KL; CUMMINGS, SR			SMOKING, ALCOHOL, AND NEUROMUSCULAR AND PHYSICAL FUNCTION OF OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; CIGARETTE-SMOKING; MAINTAINING MOBILITY; POSTMENOPAUSAL WOMEN; ARTERIAL-DISEASE; ALAMEDA COUNTY; HEART-DISEASE; BREAST-CANCER; LATE-LIFE; CONSUMPTION	Objective.-To determine the associations of current and lifetime smoking and alcohol use with physical function in an older population. Design.-Survey. Setting.-Four clinic centers in the United States. Participants.-A total of 9704 community-dwelling, ambulatory white women 65 years or older recruited from four areas of the United States. Main Outcome Measures.-Twelve performance tests of muscle strength, agility and coordination, gait and balance, and self-reported functional status. Results.-Compared with women who never smoked, current smokers had significantly poorer function on all of the performance measures except grip strength after adjusting for age, history of stroke, body mass index, clinic site, physical activity, and alcohol use (P<.05). This decrease in function was 50% to 100% as great as that associated with a 5-year increase in age, and most measures worsened with increasing numbers of pack-years. Compared with current moderate drinkers, nondrinkers had significantly poorer function on all of the performance measures except tandem walk (P<.05). Evaluation of a dose effect with alcohol was limited by the small number of heavy drinkers in the study. Conclusions.-In this population, women who currently smoke are weaker and have poorer balance and poorer performance on measures of integrated physical function than nonsmokers. Smoking is associated with a decline in physical function. Current moderate drinkers have better physical function compared with nondrinkers, but associations of function with heavy drinkers could not be assessed.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD	University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	NELSON, HD (corresponding author), OREGON HLTH SCI UNIV,DIV GEN INTERNAL MED,3181 SW SAM JACKSON PK RD,L475,PORTLAND,OR 97201, USA.			Ensrud, Kristine/0000-0002-9069-3036; Cauley, Jane A/0000-0003-0752-4408				ADAMS RD, 1977, PRINCIPLES NEUROLOGY, P812; ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ARMOR D, 1982, ENCY HDB ALCOHOLISM; BAER L, 1985, AM J MED, V78, P564, DOI 10.1016/0002-9343(85)90396-1; BALFOUR DJK, 1982, PHARMACOL THERAPEUT, V16, P269, DOI 10.1016/0163-7258(82)90058-4; BELCH JJF, 1984, THROMB HAEMOSTASIS, V51, P6; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOHANNON RW, 1986, PHYS THER, V66, P206, DOI 10.1093/ptj/66.2.206; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BUSBY WJ, 1988, J AM GERIATR SOC, V36, P301, DOI 10.1111/j.1532-5415.1988.tb02355.x; CASSIDENTI DL, 1990, AM J OBSTET GYNECOL, V163, P1953, DOI 10.1016/0002-9378(90)90780-B; CAULEY JA, 1987, J CHRON DIS, V40, P115, DOI 10.1016/0021-9681(87)90062-2; CERHAN JR, 1993, AM J EPIDEMIOL, V137, P870, DOI 10.1093/oxfordjournals.aje.a116748; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; CRIQUI MH, 1989, AM J EPIDEMIOL, V129, P1110, DOI 10.1093/oxfordjournals.aje.a115233; FITTI JE, 1987, VITAL HEALTH STAT, V21, P1; FORTMANN SP, 1986, AM J EPIDEMIOL, V124, P706, DOI 10.1093/oxfordjournals.aje.a114445; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GARG R, 1993, ARCH INTERN MED, V153, P1211, DOI 10.1001/archinte.153.10.1211; GAVALER JS, 1985, J STUD ALCOHOL, V46, P495, DOI 10.15288/jsa.1985.46.495; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HATCHER EM, 1977, ALCOHOL CLIN EXP RES, V1, P371; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KIRCH DG, 1988, CELL MOL NEUROBIOL, V8, P285, DOI 10.1007/BF00711170; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; Leveille S. G., 1992, J WOMENS HEALTH, V1, P53; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; NEVITT JC, 1990, 2ND 50 YEARS PROMOTI, P263; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TARTER RE, 1975, DIS NERV SYST, V36, P185; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1980, HLTH CONSEQUENCES SM	57	144	148	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1825	1831		10.1001/jama.272.23.1825	http://dx.doi.org/10.1001/jama.272.23.1825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PW980	7990216				2022-12-01	WOS:A1994PW98000030
J	DIAMOND, J				DIAMOND, J			HIV TESTING IN PRISON - WHATS THE CONTROVERSY	LANCET			English	Editorial Material							INMATES				DIAMOND, J (corresponding author), MERRITHEW MEM HOSP,MARTINEZ,CA 94553, USA.							ALBERT P, 1992, AIDS PRACTICE MANUAL, P14; ANDRUS JK, 1989, AM J PUBLIC HEALTH, V79, P840, DOI 10.2105/AJPH.79.7.840; BEHRENDT C, 1994, AM J EPIDEMIOL, V139, P918, DOI 10.1093/oxfordjournals.aje.a117098; CASTRO K, 1991, 7 INT C AIDS FLOR; GREENBERG R, 1994, 10 INT C AIDS YOK; HAMMETT T, 1994, 1992 UPDATE HIV AIDS; HARDING TW, 1992, WHO GLOBAL PROGRAMME, P15; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; HOXIE NJ, 1990, AM J PUBLIC HEALTH, V80, P1129, DOI 10.2105/AJPH.80.9.1129; MAUER M, 1994, AM BARS INT USE INCA; 1994, MIDYEAR PRISONER STA; 1994, HIV AIDS SURVEILLANC, V6, P15; 1990, MMWR-MORBID MORTAL W, V39, P273; 1993, WHO GUIDELINES HIV I	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1650	1651		10.1016/S0140-6736(94)90451-0	http://dx.doi.org/10.1016/S0140-6736(94)90451-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX302	7996954				2022-12-01	WOS:A1994PX30200002
J	LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K				LUNDBERG, JON; HELLSTROM, PM; LUNDBERG, JM; ALVING, K			GREATLY INCREASED LUMINAL NITRIC-OXIDE IN ULCERATIVE-COLITIS	LANCET			English	Note								A role for nitric oxide (NO) in ulcerative colitis has been suggested because mucosal NO synthase activity, measured by indirect assays, is increased in this disorder. We directly measured luminal NO in the colons of twelve controls and six patients with active ulcerative colitis. During colonoscopy, gas was aspirated from different parts of the colon and immediately analysed by a chemiluminescence technique. NO concentrations were more than 100 times higher in the patients than in the controls. Luminal NO is rapidly and easily measurable and may be used to monitor inflammatory bowel disease.	KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	LUNDBERG, JON (corresponding author), KAROLINSKA INST,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN.		; Alving, Kjell/M-4579-2014	Hellstrom, Per/0000-0001-8428-0772; Lundberg, Jon/0000-0002-0174-5210; Alving, Kjell/0000-0003-0784-0443				ALVING K, 1993, EUR RESPIR J, V6, P1368; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; HARTLEY MG, 1992, J MED MICROBIOL, V36, P96, DOI 10.1099/00222615-36-2-96; JI XB, 1989, BIOCHEM ARCH, V5, P61; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; TEPPERMAN BL, 1993, AM J PHYSIOL, V265, pG214, DOI 10.1152/ajpgi.1993.265.2.G214; WHITTLE BJR, 1994, NITRIC OXIDE GASTROI, P267	10	224	236	2	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1673	1674		10.1016/S0140-6736(94)90460-X	http://dx.doi.org/10.1016/S0140-6736(94)90460-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996962				2022-12-01	WOS:A1994PX30200011
J	BENEZRA, R				BENEZRA, R			AN INTERMOLECULAR DISULFIDE BOND STABILIZES E2A HOMODIMERS AND IS REQUIRED FOR DNA-BINDING AT PHYSIOLOGICAL TEMPERATURES	CELL			English	Article							LOOP-HELIX PROTEINS; NF-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; MYOD; INVIVO; GENE; DAUGHTERLESS; REGULATOR; MUTATIONS; SUBUNITS	It is demonstrated in this report that purified E2A helix-loop-helix (HLH) proteins spontaneously form homodimers that are linked by an intermolecular disulfide bond. These homodimers bind DNA at physiological temperatures but fail to associate with either Id or MyoD. When the disulfide bond is reduced by an activity present in muscle cell lysates or disrupted by site-directed mutagenesis, the monomeric form of the protein is strongly favored at 37 degrees C. These E2A monomers cannot bind DNA but heterodimerize efficiently with Id and MyoD. It is also shown that an intermolecular disulfide bond cross-links E2A homodimers in B cells but not in muscle cells in which only heterodimers have been detected. These results suggest a novel mechanism for regulating the dimerization status and DNA binding properties of E2A HLH transcription factors.			BENEZRA, R (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1990, CELL, V60, P773; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; HARA E, 1994, J BIOL CHEM, V269, P2139; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHUE GL, 1994, J BIOL CHEM, V269, P2707; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TOLEDANO N, 1994, CELL, V78, P897; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XANTHOUDAKIS S, 1992, EMBO J, V121, P3323	39	90	90	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1057	1067		10.1016/0092-8674(94)90036-1	http://dx.doi.org/10.1016/0092-8674(94)90036-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001133				2022-12-01	WOS:A1994PY08600015
J	XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S				XU, M; HU, XT; COOPER, DC; MORATALLA, R; GRAYBIEL, AM; WHITE, FJ; TONEGAWA, S			ELIMINATION OF COCAINE-INDUCED HYPERACTIVITY AND DOPAMINE-MEDIATED NEUROPHYSIOLOGICAL EFFECTS IN DOPAMINE D1 RECEPTOR MUTANT MICE	CELL			English	Article							RAT NUCLEUS-ACCUMBENS; DISCRIMINATIVE STIMULUS PROPERTIES; LOCOMOTOR HYPERACTIVITY; STIMULATION ENABLES; ADENYLATE-CYCLASE; VENTRAL STRIATUM; XENOPUS OOCYTES; BASAL GANGLIA; D2 RECEPTORS; BRAIN	The brain mesoaccumbens dopamine system is intricately Involved in the psychomotor stimulant activities of cocaine. However, the extent to which different dopamine receptors mediate these effects has not yet been firmly established. The present study used dopamine D1 receptor mutant mice produced by gene targeting to investigate the role of this receptor in the effects induced by cocaine. In contrast with wild-type mice, which showed a dose-dependent increase in locomotion, D1 mutant mice exhibited a dose-dependent decrease. Electrophysiological studies of dopamine-sensitive nucleus accumbens neurons demonstrated a marked reduction in the inhibitory effects of cocaine on the generation of action potentials. In addition, the inhibitory effects of dopamine as well as D1 and D2 agonists were almost completely abolished, whereas those of serotonin were unaffected. DS-like dopamine receptor binding was also normal. These results demonstrate the essential role of the D1 receptor in the locomotor stimulant effects of cocaine and in dopamine-mediated neurophysiological effects within the nucleus accumbens.	MIT, CTR LEARNING & MEM, DEPT BIOL, CAMBRIDGE, MA 02139 USA; FINCH UNIV HLTH SCI, CHICAGO MED SCH, DEPT NEUROSCI, NEUROPSYCHOPHARMACOL LAB, N CHICAGO, IL 60064 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Chicago Medical School; Massachusetts Institute of Technology (MIT)	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015	Moratalla, Rosario V/0000-0002-7623-8010; Graybiel, Ann/0000-0002-4326-7720	NIDA NIH HHS [DA 04093, DA 08037, DA 00207] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004093, R01DA008037, R01DA004093] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARNT J, 1987, EUR J PHARMACOL, V133, P137, DOI 10.1016/0014-2999(87)90144-0; ARNT J, 1992, EUR J PHARMACOL, V213, P259, DOI 10.1016/0014-2999(92)90690-6; BARRETT RL, 1989, PSYCHOPHARMACOLOGY, V99, P13, DOI 10.1007/BF00634445; Bergman J., 1990, Behav Pharmacol, V1, P355; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BHAT RV, 1993, J PHARMACOL EXP THER, V267, P496; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BRADBERRY CW, 1993, J NEUROCHEM, V60, P1429, DOI 10.1111/j.1471-4159.1993.tb03305.x; BRIGGS CA, 1991, BRIT J PHARMACOL, V104, P1038, DOI 10.1111/j.1476-5381.1991.tb12546.x; BRITTON DR, 1991, PHARMACOL BIOCHEM BE, V39, P911, DOI 10.1016/0091-3057(91)90052-4; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CALLAHAN PM, 1994, PSYCHOPHARMACOLOGY, V115, P110, DOI 10.1007/BF02244759; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHURCH WH, 1987, EUR J PHARMACOL, V139, P345, DOI 10.1016/0014-2999(87)90592-9; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.ne.15.030192.001441; GEYER MA, 1976, BRAIN RES, V106, P257, DOI 10.1016/0006-8993(76)91024-6; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GREEN AR, 1976, NATURE, V260, P487; HU XT, 1990, J NEUROSCI, V10, P2318; HU XT, 1994, SYNAPSE, V17, P43, DOI 10.1002/syn.890170106; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; JACOBS BL, 1976, LIFE SCI, V19, P777, DOI 10.1016/0024-3205(76)90303-9; JOHANSEN PA, 1991, J NEURAL TRANSM-GEN, V86, P97, DOI 10.1007/BF01250571; JOYCE EM, 1983, NEUROPHARMACOLOGY, V22, P1141, DOI 10.1016/0028-3908(83)90051-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MALDONADO R, 1993, PHARMACOL BIOCHEM BE, V45, P239, DOI 10.1016/0091-3057(93)90112-7; Marsden C. D., 1992, SEMIN NEUROSCI, V4, P171; MCQUADE RD, 1988, LIFE SCI, V43, P1861, DOI 10.1016/S0024-3205(88)80003-1; MOGENSON GJ, 1980, PROG NEUROBIOL, V14, P69, DOI 10.1016/0301-0082(80)90018-0; MOGENSON GJ, 1987, PROG PSYCHOB PHYSIOL, V12, P117; MURRAY AM, 1989, EUR J PHARMACOL, V160, P377, DOI 10.1016/0014-2999(89)90093-9; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PHILLIPS AG, 1983, PROG NEURO-PSYCHOPH, V7, P585, DOI 10.1016/0278-5846(83)90029-5; PRADHAN SN, 1978, COMMUN PSYCHOPHARMAC, V2, P481; PYCOCK CJ, 1980, NATURE, V286, P74, DOI 10.1038/286074a0; RAPPAPORT MS, 1993, BRAIN RES, V616, P242, DOI 10.1016/0006-8993(93)90215-9; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEGAL DS, 1987, PSYCHOPHARMACOL BULL, V23, P417; SIMON H, 1988, BRAIN RES, V447, P335, DOI 10.1016/0006-8993(88)91136-5; Spano P F, 1978, Adv Biochem Psychopharmacol, V19, P155; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STOOF JC, 1984, LIFE SCI, V35, P2281, DOI 10.1016/0024-3205(84)90519-8; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; SVENSSON K, 1994, J NEURAL TRANSM-GEN, V95, P71, DOI 10.1007/BF01283032; TASSIN JP, 1978, BRAIN RES, V141, P267, DOI 10.1016/0006-8993(78)90197-X; TAYLOR D, 1979, RES COMMUN PSYCH PSY, V4, P447; TELLA SR, 1994, PHARMACOL BIOCHEM BE, V48, P151, DOI 10.1016/0091-3057(94)90511-8; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; VEZINA P, 1991, EUR J NEUROSCI, V3, P1001, DOI 10.1111/j.1460-9568.1991.tb00036.x; WACHTEL SR, 1992, PSYCHOPHARMACOLOGY, V109, P41, DOI 10.1007/BF02245478; WACHTEL SR, 1989, SYNAPSE, V4, P327, DOI 10.1002/syn.890040409; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WALAAS I, 1981, NEUROSCIENCE, V6, P399, DOI 10.1016/0306-4522(81)90132-9; WALTERS JR, 1987, SCIENCE, V236, P719; WATERS N, 1993, J NEURAL TRANSM-GEN, V94, P11, DOI 10.1007/BF01244979; White F.J., 1990, Behav Pharmacol, V1, P303; WHITE FJ, 1986, J NEUROSCI, V6, P274; WHITE FJ, 1988, PHARMACOL BIOCHEM BE, V30, P189, DOI 10.1016/0091-3057(88)90442-X; WHITE FJ, 1987, EUR J PHARMACOL, V135, P101, DOI 10.1016/0014-2999(87)90764-3; WHITE FJ, 1993, J PHARMACOL EXP THER, V266, P1075; WHITE FJ, 1994, IN PRESS NEUROBIOLOG; WHITE FJ, 1993, D1 D2 DOPAMINE RECEP, P79; WHITE FJ, 1992, COCAINE PHARM PHYSL, P261; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WOOD DM, 1989, PHARMACOL BIOCHEM BE, V33, P453, DOI 10.1016/0091-3057(89)90529-7; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	83	292	297	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					945	955		10.1016/0092-8674(94)90026-4	http://dx.doi.org/10.1016/0092-8674(94)90026-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001143				2022-12-01	WOS:A1994PY08600005
J	LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A				LEVY, HL; WAISBREN, SE; LOBBREGT, D; ALLRED, E; SCHULER, A; TREFZ, FK; SCHWEITZER, SM; SARDHARWALLA, IB; WALTER, JH; BARWELL, BE; BERLIN, CM; LEVITON, A			MATERNAL MILD HYPERPHENYLALANINEMIA - AN INTERNATIONAL SURVEY OF OFFSPRING OUTCOME	LANCET			English	Article							HEAD CIRCUMFERENCE; PHENYLKETONURIA; INTELLIGENCE; PREGNANCIES; FETUS; BIRTH	Maternal phenylketonuria (PKU) has adverse effects on the offspring including microcephaly, mental retardation, congenital heart disease, and intrauterine growth retardation. Maternal non-PKU mild hyperphenyalaninaemia (MHP) is believed to be benign, but whether there may be long-term consequences to offspring is unclear. In an international survey we have obtained information about 86 MHP mothers with MHP (blood phenylalanine 167-715 mu mol/L), their 219 untreated pregnancies, and 173 offspring. Spontaneous fetal loss (13% of pregnancies), congenital heart disease (2.3% of offspring), and severe non-cardiac anomalies (2.9% of offspring) occurred at frequencies within expected limits for the general population. For weight and length at birth the median percentile was the 50th but that for birth head circumference was the 25th. Median z-scores for birth length and head circumference were significantly lower for offspring of mothers with phenylalanine concentrations above 400 mu mol/L than for those whose mothers had lower values (p=0.05 and p=0.005, respectively). The median intelligence quotient (IQ) of the offspring (3-27 years) was 100 for those whose mothers had higher phenylalanine concentrations and 108 for those of the lower phenylalaninaemia group. However, offspring IQ correlated slightly more closely with maternal IQ (r=0.53, p<0.01) than with maternal phenylalanine concentration (r=0.45, p=0.02). Maternal MHP does not seem to have serious consequences for the fetus. A maternal phenylalanine concentration of less than 400 mu mol/L does not warrant intervention. Nevertheless, maternal blood phenylalanine above this value is associated with slightly lower birth measurements and offspring IQ than lower maternal blood phenylalanine concentrations.	HARVARD UNIV,SCH MED,BOSTON,MA; PKU LAB,BUDAPEST,HUNGARY; UNIV HEIDELBERG,HEIDELBERG,GERMANY; CHILDRENS HOSP,HANNOVER,GERMANY; ROYAL MANCHESTER CHILDRENS HOSP,MANCHESTER,LANCS,ENGLAND; SHEFFIELD CHILDRENS HOSP,REG NEONATAL SCREENING LAB,SHEFFIELD,S YORKSHIRE,ENGLAND; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Royal Manchester Children's Hospital; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	LEVY, HL (corresponding author), CHILDRENS HOSP,IC SMITH ROOM 106,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD023149] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-2-3149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARTIER L, 1982, AM J PUBLIC HEALTH, V72, P1386, DOI 10.2105/AJPH.72.12.1386; COSTELLO PM, 1994, EUR J PEDIATR, V153, P260; DORMAN C, 1991, DEV MED CHILD NEUROL, V33, P267; DROGARI E, 1987, LANCET, V2, P927; GARDINER RM, 1990, J INHERIT METAB DIS, V13, P627, DOI 10.1007/BF01799517; GUTTLER F, 1980, ACTA PAEDIATR SC   S, V280, P7; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P65; KOCH R, 1993, AM J DIS CHILD, V147, P1224, DOI 10.1001/archpedi.1993.02160350098015; LENKE RR, 1980, NEW ENGL J MED, V303, P1202, DOI 10.1056/NEJM198011203032104; LEVITON A, 1993, J CHILD NEUROL, V8, P64, DOI 10.1177/088307389300800109; LEVY HL, 1987, ENZYME, V38, P312, DOI 10.1159/000469221; LEVY HL, 1992, AM J MED GENET, V44, P439, DOI 10.1002/ajmg.1320440411; LEVY HL, 1983, NEW ENGL J MED, V309, P1269, DOI 10.1056/NEJM198311243092101; LEVY HL, 1984, J PEDIATR-US, V104, P245, DOI 10.1016/S0022-3476(84)81003-3; LYNN R, 1987, NATURE, V328, P797, DOI 10.1038/328797a0; Matarazzo J. D., 1972, WECHSLERS MEASUREMEN; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; NISWANDER KR, 1972, DHEW NIH73379 PUBL; PLATT LD, 1992, AM J OBSTET GYNECOL, V166, P1150, DOI 10.1016/S0002-9378(11)90601-2; ROCHE AF, 1987, PEDIATRICS, V79, P706; SCHOONHEYT WE, 1994, CLIN CHIM ACTA, V225, P165, DOI 10.1016/0009-8981(94)90044-2; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; VENTURA SJ, 1992, MONTHLY VITAL ST 6 S, V41; WAISBREN SE, 1990, J PEDIATR-US, V116, P926, DOI 10.1016/S0022-3476(05)80654-7; WAISBREN SE, 1988, AM J PUBLIC HEALTH, V78, P789, DOI 10.2105/AJPH.78.7.789; [No title captured]; 1994, J PEDIATR, V124, P383	28	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1589	1594		10.1016/S0140-6736(94)90404-9	http://dx.doi.org/10.1016/S0140-6736(94)90404-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7983992				2022-12-01	WOS:A1994PW05100007
J	OBRIEN, E				OBRIEN, E			THE LAND MINE CRISIS - A GROWING EPIDEMIC OF MUTILATION	LANCET			English	Editorial Material											OBRIEN, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,DUBLIN,IRELAND.							Cahill K. M., 1995, CLEARING FIELDS SOLU; MCGRATH R, 1993, LANCET, V342, P628, DOI 10.1016/0140-6736(93)91751-7	2	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 3	1994	344	8936					1522	1522		10.1016/S0140-6736(94)90345-X	http://dx.doi.org/10.1016/S0140-6736(94)90345-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV017	7983950				2022-12-01	WOS:A1994PV01700005
J	HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G				HAHNE, K; HAUCKE, V; RAMAGE, L; SCHATZ, G			INCOMPLETE ARREST IN THE OUTER-MEMBRANE SORTS NADH-CYTOCHROME-B(5) REDUCTASE TO 2 DIFFERENT SUBMITOCHONDRIAL COMPARTMENTS	CELL			English	Article							MITOCHONDRIAL PROTEIN IMPORT; AMINO-TERMINAL REGION; RAT-LIVER MICROSOMES; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; NADH-CYTOCHROME-B5 REDUCTASE; ENDOPLASMIC-RETICULUM; GEL-ELECTROPHORESIS	The S. cerevisiae gene MCR1 encodes two mitochondrial isoforms of NADH-cytochrome b(5) reductase. The primary translation product has an amino-terminal matrix-targeting signal, followed by a stretch of 21 uncharged amino acids. This precursor protein is inserted into the outer membrane, but only about one-third of the molecules become firmly anchored to the outer face of that membrane. The remaining molecules pass through the outer membrane into the inner membrane, are cleaved by inner membrane protease 1, and are released into the intermembrane space. Incomplete translocation arrest in the outer membrane is a novel mechanism by which the product of a single gene is sorted into different compartments of the same organelle.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Haucke, Volker/0000-0003-3119-6993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 RO1 GM37803] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BIBUS CR, 1988, J BIOL CHEM, V263, P13097; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; BORGESE N, 1990, BIOCHEM J, V266, P341, DOI 10.1042/bj2660341; BORGESE N, 1986, BIOCHEM J, V239, P393, DOI 10.1042/bj2390393; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CSUKAI M, 1994, EUR J BIOCHEM, V219, P441, DOI 10.1111/j.1432-1033.1994.tb19957.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESANTIS A, 1984, ARCH BIOCHEM BIOPHYS, V232, P354; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASE T, 1986, FEBS LETT, V197, P199, DOI 10.1016/0014-5793(86)80326-X; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HINES V, 1993, J BIOL CHEM, V268, P449; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P187, DOI 10.1093/oxfordjournals.jbchem.a131434; Maniatis T., 1982, MOL CLONING; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAKAI M, 1993, J BIOL CHEM, V268, P24262; NAKAI M, 1989, J BIOCHEM-TOKYO, V106, P181, DOI 10.1093/oxfordjournals.jbchem.a122811; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; OZOLS J, 1985, J BIOL CHEM, V260, P1953; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P62, DOI 10.1016/0005-2728(72)90024-2; PERIMAN D, 1984, MOL CELL BIOL, V4, P1682; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; REDDY VVR, 1977, J BIOL CHEM, V252, P2797; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V34, P584, DOI 10.1016/0006-3002(59)90324-5; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIESS M, 1989, J BIOL CHEM, V264, P19117; TOMATSU S, 1989, GENE, V80, P353; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCH, V99, P401	70	106	107	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					829	839		10.1016/0092-8674(94)90072-8	http://dx.doi.org/10.1016/0092-8674(94)90072-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001120				2022-12-01	WOS:A1994PW05400010
J	SCHIESTL, RH; KHOGALI, F; CARLS, N				SCHIESTL, RH; KHOGALI, F; CARLS, N			REVERSION OF THE MOUSE PINK-EYED UNSTABLE MUTATION INDUCED BY LOW-DOSES OF X-RAYS	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; INTRACHROMOSOMAL RECOMBINATION; IONIZING-RADIATION; CHROMOSOME-ABNORMALITIES; MOLECULAR-GENETICS; SPOT-TEST; CANCER; CELLS; CARCINOGENS; FREQUENCY	Deletions and other genome rearrangements can be caused by radiation and are associated with carcinogenesis and inheritable diseases. The pink-eyed unstable (p(un)) mutation in the mouse is caused by a gene duplication and reverts to wild type by deletion of one copy. Reversion events in the mouse embryo were detected as black spots on the fur of the animals or microscopically as partially black hair in a background of colorless hair. The frequency of partially black hair was increased by x-rays at very low doses. A linear dose-response relation was found between 1 and 100 centigray.			SCHIESTL, RH (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006593] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06593] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOCHER D, 1982, INT J RADIAT BIOL, V42, P317, DOI 10.1080/09553008214551231; BRENNAN RJ, 1994, MUTAT RES, V308, P159, DOI 10.1016/0027-5107(94)90151-1; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; CAIRNS J, 1981, NATURE, V289, P353, DOI 10.1038/289353a0; CARLS N, 1994, MUTAT RES, V320, P293, DOI 10.1016/0165-1218(94)90082-5; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; FAHRIG R, 1975, MOL GEN GENET, V138, P309, DOI 10.1007/BF00264800; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; GROSOVSKY AJ, 1985, P NATL ACAD SCI USA, V82, P2092, DOI 10.1073/pnas.82.7.2092; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HIROBE T, 1984, ANAT REC, V208, P589, DOI 10.1002/ar.1092080414; LITTLE JB, 1993, HEMATOL ONCOL CLIN N, V7, P337, DOI 10.1016/S0889-8588(18)30244-2; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MITELMAN F, 1990, CANCER DETECT PREV, V14, P527; MODAN B, 1992, EUR J CANCER, V28A, P1010, DOI 10.1016/0959-8049(92)90442-5; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL LB, 1981, MUTAT RES, V86, P355, DOI 10.1016/0165-1110(81)90011-7; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; RUSSELL WL, 1962, P NATL ACAD SCI USA, V48, P1724, DOI 10.1073/pnas.48.10.1724; SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K; SCHIESTL RH, 1988, GENETICS, V119, P237; SCHIESTL RH, 1989, NATURE, V337, P285, DOI 10.1038/337285a0; SCHIESTL RH, 1989, CARCINOGENESIS, V10, P1445, DOI 10.1093/carcin/10.8.1445; SCHLAGER G, 1967, GENETICS, V57, P319; SEARLE AG, 1982, MUTAT RES, V92, P205, DOI 10.1016/0027-5107(82)90224-X; STEPHENSON DA, 1988, MUTAT RES, V197, P101, DOI 10.1016/0027-5107(88)90145-5; STYLES JA, 1985, MUTAT RES, V154, P183, DOI 10.1016/0165-1110(85)90017-X; THACKER J, 1986, MUTAT RES, V160, P267, DOI 10.1016/0027-5107(86)90137-5; UPTON AC, 1992, ANNU REV PUBL HEALTH, V13, P127, DOI 10.1146/annurev.pu.13.050192.001015; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WARD JF, 1987, INT C ANTICARCINOGEN, P321; WINTERSBERGER U, 1982, NATURWISSENSCHAFTEN, V69, P107, DOI 10.1007/BF00376714; ZHANG LH, 1992, CARCINOGENESIS, V13, P609, DOI 10.1093/carcin/13.4.609	38	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1573	1576		10.1126/science.7985029	http://dx.doi.org/10.1126/science.7985029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985029				2022-12-01	WOS:A1994PV01500047
J	STEINER, NC; CLARKE, L				STEINER, NC; CLARKE, L			A NOVEL EPIGENETIC EFFECT CAN ALTER CENTROMERE FUNCTION IN FISSION YEAST	CELL			English	Article							POSITION-EFFECT VARIEGATION; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CHROMOSOME; DNA; SEQUENCE; REGIONS; INHERITANCE; CEREVISIAE	A novel epigenetic mechanism that can affect minichromosome centromere function in vivo has been identified in S. pombe. This epigenetic system can result in the conversion of a nonfunctional centromere to a functional one without changes in the content, structural arrangement, or chemical modification state of the minichromosomal DNA. The conversion from a centromere-inactive to an active state, which is evident with minichromosomes carrying abbreviated centromeric DNA constructions, occurs with a relatively high frequency during mitotic cell divisions and readily provides an in vivo essay for proper centromere formation. The centromere-targeted epigenetic system supports a model for centromere function that involves specific de novo folding of centromeric components into a higher order chromatin structure.	UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara					NIGMS NIH HHS [GM-33783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.genet.19.1.29; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KENDAL WS, 1988, CANCER RES, V48, P1060; Kohli J, 1989, MOL BIOL FISSION YEA, P75; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Luria SE, 1943, GENETICS, V28, P491; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; Maniatis T., 1982, MOL CLONING; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NAKASEKO Y, 1987, NUCLEIC ACIDS RES, V15, P4705, DOI 10.1093/nar/15.12.4705; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHAFFER CD, 1993, TRENDS GENET, V9, P35, DOI 10.1016/0168-9525(93)90171-D; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M	38	132	135	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					865	874		10.1016/0092-8674(94)90075-2	http://dx.doi.org/10.1016/0092-8674(94)90075-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001123				2022-12-01	WOS:A1994PW05400013
J	WALKER, S; HAYES, S; OHARE, P				WALKER, S; HAYES, S; OHARE, P			SITE-SPECIFIC CONFORMATIONAL ALTERATION OF THE OCT-1 POU DOMAIN-DNA COMPLEX AS THE BASIS FOR DIFFERENTIAL RECOGNITION BY VMW65 (VP16)	CELL			English	Article							IMMEDIATE-EARLY GENE; TYPE-1 TRANSACTIVATOR VMW65; OCTAMER-BINDING-PROTEIN; TRANSCRIPTION COMPLEX; REGULATORY PROTEIN; CELLULAR FACTOR; HOMEO DOMAIN; SEQUENCES; INTERACTS; SUBDOMAINS	We show that the presence of a regulatory cis-acting element that flanks the core octamer site and dictates selectivity in the response to Vmw65 (VP16), while dispensable for POU binding per se, induces a conformational alteration in the nature of the POU domain in the DNA complex. A single substitution in the flanking signal distorts the POU complex and without affecting overall POU binding prevents Vmw65 interaction. Alternatively, substitution of a residue in the homeodomain predicted to contact the GARAT region prevents its recognition even on a wild-type motif, causing a reversion to the DNA binding pattern seen on a cellular motif and at the same time inefficient recognition by Vmw65. The results indicate that Vmw65 recognizes a particular POU domain conformation induced by the presence of the flanking GARAT region.			WALKER, S (corresponding author), MARIE CURIE RES INST,CHART,OXTED RH8 OTL,SURREY,ENGLAND.							APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OHARE P, 1993, ALPHA HERPESVIRUSES, P145; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PRESTON CM, 1984, J VIROL, V50, P708, DOI 10.1128/JVI.50.3.708-716.1984; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	33	76	77	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 2	1994	79	5					841	852		10.1016/0092-8674(94)90073-6	http://dx.doi.org/10.1016/0092-8674(94)90073-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001121				2022-12-01	WOS:A1994PW05400011
J	MALINOW, R				MALINOW, R			LTP - DESPERATELY SEEKING RESOLUTION	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; GLUTAMATE RELEASE; NMDA RECEPTORS; HIPPOCAMPUS; PROBABILITY; PLASTICITY; SYNAPSE				MALINOW, R (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.							BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; MURPHY TH, 1994, NATURE, V263, P529; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0	21	53	55	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1195	1196		10.1126/science.7973700	http://dx.doi.org/10.1126/science.7973700			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973700				2022-12-01	WOS:A1994PT13200041
J	ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C				ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C			ERADICATION OF HEPATITIS-C VIRUS-RNA AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							LIVER-DISEASE; HCV; MULTICENTER; VIREMIA; SERUM		CHU NECKER, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	ROMEO, R (corresponding author), UNIV MILAN, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.			Romeo, Raffaella/0000-0002-7858-4670				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRILLANTI S, 1993, LANCET, V341, P464, DOI 10.1016/0140-6736(93)90210-8; BROUWER JT, 1993, HEPATOLOGY, V18, pA110; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; GIL B, 1993, HEPATOLOGY, V18, P1050; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; ROMEO R, 1993, TRANSFUSION, V33, P629, DOI 10.1046/j.1537-2995.1993.33893342742.x; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	11	67	67	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					276	277		10.7326/0003-4819-121-4-199408150-00008	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037409				2022-12-01	WOS:A1994PB10200008
J	ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J				ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J			DIRECTIONAL MOTION OF BROWNIAN PARTICLES INDUCED BY A PERIODIC ASYMMETRIC POTENTIAL	NATURE			English	Article								STRUCTURES possessing spatial asymmetry should act as pumps in the presence of dissipation alone(1-4), without the need for macroscopic forces or temperature differences(5) to drive vectorial motion. It has been shown theoretically(2-4,6,7) that particles subjected to an asymmetric periodic potential can display net directional motion even if the space-averaged forte is zero. Here we demonstrate such behaviour experimentally. We have studied the behaviour of colloidal particles suspended in solution and exposed to a sawtooth dielectric potential which is turned on and off periodically. The particles exhibit net motion with a velocity that depends on their size, suggesting applications in separation processes for objects in the size range 0.1-5 mu m-a range that includes biological structures such as viruses, cells and chromosomes(8). We furthermore point out the analogy between our device and motor protein assemblies.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, CNRS, URA 1382, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	ROUSSELET, J (corresponding author), CTR RECH PAUL PASCAL, AVE A SCHWEITZER, F-33600 PESSAC, FRANCE.			SALOME, Laurence/0000-0001-9667-4154				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; AJDARI A, 1993, Patent No. 9311346; AJDARI A, 1992, THESIS U PARIS 6; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; CORDOVA NJ, 1991, NATO ADV SCI I B-PHY, V263, P207; Curie P., 1894, J PHYS-PARIS, V3, P393, DOI DOI 10.1051/JPHYSTAP:018940030039300; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; FELICI N, 1971, CR ACAD SCI B PHYS, V273, P1004; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; PESKIN CS, 1994, CELL MECHANICS CELLU; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652	12	574	594	5	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					446	448		10.1038/370446a0	http://dx.doi.org/10.1038/370446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047163				2022-12-01	WOS:A1994PB40700051
J	KIM, DS; BONHOEFFER, T				KIM, DS; BONHOEFFER, T			REVERSE OCCLUSION LEADS TO A PRECISE RESTORATION OF ORIENTATION PREFERENCE MAPS IN VISUAL-CORTEX	NATURE			English	Article							MONOCULAR DEPRIVATION; STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; KITTENS; CAT; ORGANIZATION; SELECTIVITY; DOMAINS; AREA-18	In the visual system of young kittens, the layout of the cortical maps for ocular dominance and orientation preference converges to an equilibrium state within the first few weeks of life and normally remains largely unchanged. If during the critical period, however, patterned visual experience is restricted to only one eye for a few days, cortical neurons lose their ability to respond to stimulation of the deprived eye. We used the 'reverse occlusion' protocol together with chronical optical imaging to investigate how the profound anatomical changes accompanying monocular deprivation(1) affect the spatial pattern of the cortical orientation preference map. We report here that after 1 week of monocular deprivation, cortical orientation maps for the deprived eye had vanished, But we also discovered that after subsequent reverse occlusion the restored orientation maps were very similar to the original maps. This demonstrates that in spite of functional disconnection of one eye after monocular deprivation, the layout of cortical orientation maps, when re-established for this eye, is not formed from scratch but is strongly influenced by previous experience.	MAX PLANCK INST PSYCHIAT,D-82152 MUNCHEN MARTINSRI,GERMANY; MAX PLANCK INST BRAIN RES,D-60528 FRANKFURT,GERMANY	Max Planck Society; Max Planck Society			Bonhoeffer, Tobias/B-9481-2009; Kim, Dae-Shik/C-2071-2011	Bonhoeffer, Tobias/0000-0001-7897-6634; 				ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KOSSUT M, 1991, EXP BRAIN RES, V85, P519; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; VANSLUYTERS RC, 1978, J PHYSIOL-LONDON, V284, P1	19	75	75	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					370	372		10.1038/370370a0	http://dx.doi.org/10.1038/370370a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047142				2022-12-01	WOS:A1994PA30400055
J	LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G				LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G			SUBARACHNOID HEMORRHAGE AND HORMONAL FACTORS IN WOMEN - A POPULATION-BASED CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						SUBARACHNOID HEMORRHAGE; HORMONE REPLACEMENT THERAPY, POSTMENOPAUSAL; MENSTRUATION; ESTROGENS	ORAL-CONTRACEPTIVES; CIGARETTE-SMOKING; REPLACEMENT THERAPY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PROXY RESPONDENTS; FOLLOW-UP; STROKE; HYPERTENSION	Objective: To determine the degree to which endogenous and exogenous hormonal factors influence the risk for subarachnoid hemorrhage in women. Design: A population-based case-control study. Setting: King County, Washington. Participants: 103 women with an incident, spontaneous subarachnoid hemorrhage and 2 age- and sex-matched controls per case-patient who were identified through random-digit dialing. Measurements: Information on exposures was collected during in-person interviews of case-patients, controls, and their surrogates. Results: Premenopausal women, especially those without a history of smoking or hypertension, were at a reduced risk for subarachnoid hemorrhage compared with age-matched postmenopausal women (odds ratio, 0.24; 95% CI, 0.09 to 0.68). The use of hormone replacement therapy was associated with a reduced risk (odds ratio, 0.47; CI, 0.26 to 0.86); the reduction was significantly greater in women who had smoked than in those that had never smoked. Of the 23 premenopausal case-patients, 74% were either menstruating when hemorrhaging occurred or had had their last menstrual period 21 or more days before hemorrhaging compared with the expected 43% (difference, 31%; CI, 4% to 58%). Conclusions: Premenopausal women are at reduced risk for subarachnoid hemorrhage, especially those without a history of smoking or hypertension. Hormone replacement therapy reduced the risk only in postmenopausal women who had ever smoked. Among women still menstruating, the risk for hemorrhage was greatest in the perimenstrual period.	UNIV WASHINGTON, SCH MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Nelson, Lorene M/D-1305-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022690] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS22690] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; DAVIES OL, 1980, STATISTICAL METHODS, V1; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FISCH IR, 1977, JAMA-J AM MED ASSOC, V237, P2499, DOI 10.1001/jama.237.23.2499; GANGAR KF, 1991, LANCET, V338, P839; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GILL JS, 1987, CLIN SCI, V73, pP57; HANDA H, 1983, STROKE, V14, P857, DOI 10.1161/01.STR.14.6.857; HEYMAN A, 1976, NEUROLOGY, V26, P358; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; LINDEGARD B, 1987, ACTA NEUROL SCAND, V76, P37, DOI 10.1111/j.1600-0404.1987.tb03541.x; LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377; LONGSTRETH WT, 1992, STROKE, V23, P1242, DOI 10.1161/01.STR.23.9.1242; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; MARSHALL JC, 1989, ENDOCRINOLOGOY, P1940; MASHCHAK CA, 1985, J REPROD MED, V30, P805; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NELSON LM, 1994, EPIDEMIOLOGY, V5, P204, DOI 10.1097/00001648-199403000-00011; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; Paik, 2003, STAT METHODS RATES P, P598; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1991, ADV CONTRACEPTION S3, V7, P65; PRENTICE RL, 1987, ADV CANCER RES, V49, P285, DOI 10.1016/S0065-230X(08)60801-5; PRENTICE RL, 1988, AM J EPIDEMIOL, V127, P213, DOI 10.1093/oxfordjournals.aje.a114797; ROBINSON RW, 1977, NEW ENGL J MED, V86, P597; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; SHAMMA F, 1992, Neurology, V42, P272; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STOBER T, 1985, J NEUROL, V232, P67, DOI 10.1007/BF00313903; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; TORNER JC, 1984, SEMIN NEUROL, V4, P354, DOI 10.1055/s-2008-1041565; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WALKER AM, 1988, AM J EPIDEMIOL, V127, P905, DOI 10.1093/oxfordjournals.aje.a114893; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; WREN BG, 1992, MED J AUSTRALIA, V157, P204, DOI 10.5694/j.1326-5377.1992.tb137091.x; 1982, JAMA-J AM MED ASSOC, V247, P633	45	142	144	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					168	173		10.7326/0003-4819-121-3-199408010-00002	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017743				2022-12-01	WOS:A1994NY33800002
J	FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM				FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM			14-3-3-PROTEIN HOMOLOGS REQUIRED FOR THE DNA-DAMAGE CHECKPOINT IN FISSION YEAST	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; KINASE-C; GENE; CLONING; REPLICATION; THIAMINE; MITOSIS; REPAIR; FAMILY	During the cell cycle, DNA is replicated and segregated equally into two daughter cells. The DNA damage checkpoint ensures that DNA damage is repaired before mitosis is attempted. Genetic studies of the fission yeast Schizosaccharomyces pombe have identified two genes, rad24 and rad25, that are required for this checkpoint. These genes encode 14-3-3 protein homologs that together provide a function that is essential for cell proliferation. In addition, S. pombe rad24 null mutants, and to a lesser extent rad25 null mutants, enter mitosis prematurely, which indicates that 14-3-3 proteins have a role in determining the timing of mitosis.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AITKEN A, 1990, NATURE, V344, P594; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHELDRICK KS, UNPUB; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	23	319	325	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					533	535		10.1126/science.8036497	http://dx.doi.org/10.1126/science.8036497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036497				2022-12-01	WOS:A1994NY21600033
J	PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC				PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC			A MOLECULAR APPROACH TO THE STRATIFICATION OF CARDIOVASCULAR RISK IN FAMILIES WITH MARFANS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; FIBRILLIN GENES; MISSENSE MUTATION; CALCIUM-BINDING; SYNDROME LOCUS; CHROMOSOME-15; DIAGNOSIS; LINKAGE; DISORDER; SEQUENCE	Background. The fibrillin gene encodes a protein in the extracellular matrix, and this protein is widely distributed in elastic tissues. The fibrillin gene is the site of mutations causing Marfan's syndrome. This disorder shows a high degree of clinical variability both between and within families. Each family appears to have a unique mutation in the fibrillin gene, which precludes the routine use of mutation screening for presymptomatic diagnosis of the disorder. The goal of this study was to develop a widely applicable method of molecular diagnosis. Methods. We used three newly characterized intragenic sites of normal DNA repeat-sequence variation (i.e., polymorphisms) as markers to follow the inheritance pattern of specific copies (alleles) of the fibrillin gene in multiple kindreds with various clinical features of Marfan's syndrome. Results. The polymorphic markers allowed identification of the particular copy of the fibrillin gene that cosegregated with Marfan's syndrome in 13 of the 14 families tested. In 11 families a definite presymptomatic diagnosis of Marfan's syndrome could be made in family members who had only equivocal manifestations of the disorder. In two other families, some family members demonstrated either classic Marfan's syndrome or a milder but closely related phenotype. The copy of the fibrillin gene that cosegregated with classic Marfan's syndrome was not inherited by family members with the latter, atypical, form of the disease. These milder phenotypes, previously diagnosed as Marfan's syndrome, were not associated with aortic involvement. Conclusions, These results document the usefulness of novel polymorphic DNA repeat sequences in the presymptomatic diagnosis of Marfan's syndrome. Our findings also demonstrate that the various clinical phenotypes seen in selected families may be due not to single fibrillin mutations, but rather to different genetic alterations. These findings underscore the need for a modification of the current diagnostic criteria for Marfan's syndrome in order to achieve accurate risk assessment.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,HEADINGTON,OXON,ENGLAND; ALLEGHENY SINGER RES INST,DEPT HUMAN GENET,PITTSBURGH,PA 15212; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT CARDIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,BALTIMORE,MD 21205	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oxford; Johns Hopkins University; Johns Hopkins University			Pyeritz, Reed/A-1364-2010; Pereira, Lygia V/C-1049-2012	Pereira, Lygia V/0000-0002-0002-725X	NCRR NIH HHS [RR-007722] Funding Source: Medline; NHLBI NIH HHS [HL-02815, HL-35877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BOILEAU C, 1993, AM J HUM GENET, V53, P46; CLARK BA, 1991, NUCLEIC ACIDS RES, V19, P4309, DOI 10.1093/nar/19.15.4309; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; GODFREY M, 1993, AM J HUM GENET, V53, P472; GOTT VL, 1991, ANN THORAC SURG, V52, P38, DOI 10.1016/0003-4975(91)91414-Q; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KAINULAINEN K, 1991, AM J HUM GENET, V49, P662; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SARFARAZI M, 1992, J MED GENET, V29, P75, DOI 10.1136/jmg.29.2.75; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; [No title captured]	30	100	106	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					148	153		10.1056/NEJM199407213310302	http://dx.doi.org/10.1056/NEJM199407213310302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008028	Bronze			2022-12-01	WOS:A1994NW79700002
J	WEI, N; CHAMOVITZ, DA; DENG, XW				WEI, N; CHAMOVITZ, DA; DENG, XW			ARABIDOPSIS COP9 IS A COMPONENT OF A NOVEL SIGNALING COMPLEX MEDIATING LIGHT CONTROL OF DEVELOPMENT	CELL			English	Article							GENE-EXPRESSION; REGULATED DEVELOPMENT; HYPOCOTYL ELONGATION; PROTEIN; PHYTOCHROME; MUTANTS; ENCODES	Environmental light signals are sensed by multiple families of photoreceptors and transduced by largely unknown mechanisms to regulate plant development. In this report, genetic analysis suggested that light signals perceived by both phytochromes and a blue light receptor converge to repress the action of Arabidopsis COP9 in suppressing seedling photomorphogenesis. Molecular cloning of the gene revealed that COP9 encodes a novel protein of 197 amino acids whose expression is not regulated by light. COP9 functions as a large (>560 kDa) complex(es) that is probably subjected to light modulation. In addition, COP8 and COP11 are required for either the COP9 complex formation or its stability. Therefore COP9, together with COP8 and COP11, defines a novel signaling step in mediating light control of plant development.			WEI, N (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.		Deng, Xing Wang/ABF-4107-2020; Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1992, DEVELOPMENT, V115, P337; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GLASS DB, 1986, J BIOL CHEM, V261, P2987; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MISERA S, 1994, IN PRESS MOL GEN GEN; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757	25	285	303	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					117	124		10.1016/0092-8674(94)90578-9	http://dx.doi.org/10.1016/0092-8674(94)90578-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033203				2022-12-01	WOS:A1994NX32800014
J	FISHER, P; WARD, A				FISHER, P; WARD, A			MEDICINE IN EUROPE .8. COMPLEMENTARY MEDICINE IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; PRACTITIONERS	Complementary or unconventional treatments are used by many doctors and other therapists throughout Europe, The major forms are acupuncture, homoeopathy, manual therapy or manipulation, and phytotherapy or herbal medicine. The relative popularity of therapies differs between countries, but public demand is strong and growing. Regulation of practitioners varies widely: in most countries only registered health professionals may practice, but in the United Kingdom practice is virtually unregulated. Germany and some Scandinavian countries have intermediate systems. Legal reforms are in progress in the Netherlands and the United Kingdom. European institutions are starting to influence the development of complementary medicine. Harmonisation of training and regulation of practitioners is the challenge for the future.			FISHER, P (corresponding author), ROYAL LONDON HOMOEOPATH HOSP,GREAT ORMOND ST,LONDON WC1N 3HR,ENGLAND.							ANDERSON E, 1988, J R COLL GEN PRACT, V38, P511; BOUCHAYER F, 1991, COMPLEMENTARY MED EU; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FULDER S, 1981, STATUS COMPLEMENTARY; FULDER SJ, 1985, LANCET, V2, P542; HALPERN S, 1985, HLTH SOCIAL SER 0606, P702; HUGGON T, 1990, J ALTERNATIVE CO JAN; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; MATTHIESSEN P, 1992, MATERIALIEN GESUNDHE, V21; PIETRONI PC, 1992, BRIT MED J, V305, P564, DOI 10.1136/bmj.305.6853.564; RASMUSSEN N, 1991, COMPLEMENTARY MED EU; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; SERMEUS G, 1991, COMPLEMENTARY MED EU; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; VANDIJK P, 1993, GENEWIJZEN NEDERLAND; VASKILAMPI T, 1991, COMPLEMENTARY MED EU; VISSER J, 1991, COMPLEMENTARY MED EU; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1992, OFFICIAL J EURO 1013; 1992, DOCTOR          0716, P17; 1992, EEC MARKET HOMOEOPAT; 1989, REPORT ALTERNATIVE M; 1993, COMPLEMENTARY MED NE; 1993, HOMEOPATHIE 1993; 1993, COMPLEMENTARY THERAP; 1992, REGULATON PRACTITION	27	495	511	2	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					107	111		10.1136/bmj.309.6947.107	http://dx.doi.org/10.1136/bmj.309.6947.107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038643	Green Published			2022-12-01	WOS:A1994NW71600028
J	VINCENT, JP; LAWRENCE, PA				VINCENT, JP; LAWRENCE, PA			DROSOPHILA WINGLESS SUSTAINS ENGRAILED EXPRESSION ONLY IN ADJOINING CELLS - EVIDENCE FROM MOSAIC EMBRYOS	CELL			English	Article							SEGMENT-POLARITY GENE; FUSHI-TARAZU; PROTEIN; PARASEGMENTS; EPIDERMIS; SECRETION; PATTERN; WNT-1	The wingless protein is secreted, but it is not known whether it acts only on cells near to its site of synthesis or whether it has a longer range. Here, we use mosaic Drosophila embryos to estimate the range of wingless as it acts to maintain expression of the engrailed gene. We find that expression of engrailed is often sustained in those wingless(-) cells that are located near a wildtype patch of tissue, but this is not invariably so. Also, the numbers of cells maintaining engrailed expression are small. From these findings, we argue that wing less-expressing cells sustain engrailed expression only in adjoining cells. The wingless gene is also needed for maintenance of its own expression; using mosaics, we find that the range of this action is short as well.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology				Lawrence, Peter/0000-0002-9554-8268				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FOE VE, 1989, DEVELOPMENT, V107, P1; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LAWRENCE PA, 1989, DEVELOPMENT, V107, P847; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1993, DEVELOPMENT, V119, P971; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VINCENT JP, 1994, IN PRESS DEV BIOL; ZALOKAR M, 1971, P NATL ACAD SCI USA, V68, P1539, DOI 10.1073/pnas.68.7.1539	37	54	54	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					909	915		10.1016/0092-8674(94)90139-2	http://dx.doi.org/10.1016/0092-8674(94)90139-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004677				2022-12-01	WOS:A1994NT33100015
J	CZEIZEL, AE; KODAJ, I; LENZ, W				CZEIZEL, AE; KODAJ, I; LENZ, W			SMOKING DURING PREGNANCY AND CONGENITAL LIMB DEFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							MATCHED CASE-CONTROL; MULTIVARIATE-ANALYSIS; REDUCTION DEFECTS; HUNGARY; FAMILY	Objective-To examine genetic and environmental factors in the origin of isolated congenital limb deficiencies. Design-Case-control study with questionnaire at a family interview of cases of isolated congenital Limb deficiencies (six types), negative controls (matched for age, sex, and place of residence), and positive controls (cases of sentinel anomalies). Setting-The database of the Hungarian Congenital Abnormality Registry, 1975-84, complemented by three other sources of ascertainment (1 575 904 births). Subjects-537 case-control pairs; 392 positive controls. Main outcome measures-smoking during pregnancy, congenital limb deficiencies. Results-The adjusted rate of smoking during pregnancy was significantly higher in the mothers of cases of terminal transverse defect (relative odds 1.48; 95% confidence interval 0.98 to 2.23; P=0.017). This finding supports the hypothesis of vascular disruption as a cause of congenital limb deficiency. Conclusions-Maternal smoking during pregnancy raises the relative odds for terminal transverse limb deficiencies.	NATL INST HYG,DEPT HUMAN GENET & TERATOL,WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DI,BUDAPEST,HUNGARY; STATE HOSP,DEPT OBSTET & GYNAECOL,BUDAPEST,HUNGARY; UNIV MUNSTER,INST HUMAN GENET,W-4400 MUNSTER,GERMANY	World Health Organization; University of Munster								ARO T, 1984, INT J EPIDEMIOL, V13, P459, DOI 10.1093/ije/13.4.459; ARO T, 1983, EARLY HUM DEV, V9, P49, DOI 10.1016/0378-3782(83)90101-9; BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623; CZEIZEL A, 1991, Acta Morphologica Hungarica, V39, P229; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; CZEIZEL A, 1988, World Health Statistics Quarterly, V41, P219; CZEIZEL A, 1980, ACTA MORPHOL HUNG, V28, P177; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; CZEIZEL AE, 1993, TERATOLOGY, V48, P323, DOI 10.1002/tera.1420480405; CZEIZEL AE, 1993, AM J MED GENET, V46, P372, DOI 10.1002/ajmg.1320460406; CZEIZEL AE, 1993, AM J MED GENET, V46, P427, DOI 10.1002/ajmg.1320460416; CZEIZEL AE, 1993, CLIN GENET, V44, P32; CZEIZEL AE, 1992, ACTA MORPHOL HUNG, V40, P49; EVANS JA, 1994, IN PRESS AM J MED; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; HARLOW SD, 1989, AM J EPIDEMIOL, V33, P159; HOLFORD TR, 1978, AM J EPIDEMIOL, V107, P245, DOI 10.1093/oxfordjournals.aje.a112531; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; KOBOR J, 1988, Orvosi Hetilap, V129, P21; KULLANDER S, 1971, ACTA OBSTET GYN SCAN, V50, P83, DOI 10.3109/00016347109157292; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LOWE CR, 1959, BRIT MED J, V2, P673, DOI 10.1136/bmj.2.5153.673; MACKENZIE SG, 1989, AM J EPIDEMIOL, V129, P65, DOI 10.1093/oxfordjournals.aje.a115125; MASTROIACOVO P, 1991, LANCET, V337, P1091, DOI 10.1016/0140-6736(91)91735-D; MENGES RW, 1970, ENVIRON RES, V3, P285, DOI 10.1016/0013-9351(70)90022-8; OAKLEY A, 1990, J BIOSOC SCI, V22, P477, DOI 10.1017/S0021932000018885; OLSEN J, 1988, SCAND J SOC MED, V16, P49, DOI 10.1177/140349488801600108; SHIONO PH, 1986, TERATOLOGY, V34, P65, DOI 10.1002/tera.1420340109	28	67	71	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1473	1476		10.1136/bmj.308.6942.1473	http://dx.doi.org/10.1136/bmj.308.6942.1473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019281	Green Published			2022-12-01	WOS:A1994NQ22900017
J	DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG				DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG			MANAGEMENT OF FEMALE PRISONERS WITH ABNORMAL CERVICAL CYTOLOGY	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MOGHISSI KS, 1968, AM J OBSTET GYNECOL, V100, P607, DOI 10.1016/S0002-9378(15)33386-X; WILL M, 1970, Scottish Medical Journal, V15, P219	3	17	18	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1412	1413		10.1136/bmj.308.6941.1412	http://dx.doi.org/10.1136/bmj.308.6941.1412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019252	Green Published			2022-12-01	WOS:A1994NP42000017
J	PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA				PEREGO, M; HANSTEIN, C; WELSH, KM; DJAVAKHISHVILI, T; GLASER, P; HOCH, JA			MULTIPLE PROTEIN ASPARTATE PHOSPHATASES PROVIDE A MECHANISM FOR THE INTEGRATION OF DIVERSE SIGNALS IN THE CONTROL OF DEVELOPMENT IN BACILLUS-SUBTILIS	CELL			English	Article							BACILLUS-SUBTILIS; SPORULATION GENE; PHOSPHORYLATION; INITIATION; EXPRESSION; SYSTEM; TRANSCRIPTION; PHOSPHORELAY; CHROMOSOME; MUTATIONS	The initiation of sporulation in B. subtilis is regulated by the SpoOA transcription factor, which is activated by phosphorylation to central developmental switching from the vegetative to the sporulation state. The level of phosphorylation of SpoOA is regulated by the phosphorelay, a signal transduction system based on the protein-histidine kinase-response regulator two-component paradigm. To initiate sporulation, the cell must recognize and interpret a large variety of environmental, metabolic, and cell cycle signals that influence the phosphorylation level of SpoOA. We describe here a family of protein-aspartate phosphatases with activity on SpoOF similar to P, a response regulator component of the phosphorelay, that provide a mechanism for signal recognition and interpretation. These phosphatases function to drain the phosphorelay, lower SpoOA similar to P levels, and prevent sporulation, The integration of diverse environmental signals that affect the initiation of sporulation likely occurs through the competition between opposing activities of protein kinases and protein phosphatases.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV, I-27100 PAVIA, ITALY; INST PASTEUR, DEPT REGULAT GENET EXPRESS, F-75724 PARIS, FRANCE; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	University of Pavia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Scripps Research Institute	PEREGO, M (corresponding author), UNIV PARMA, DIPARTIMENTO FARMACEUT, VIA SCI, I-43100 PARMA, ITALY.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045727, R37GM019416, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45727, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DEDONDER RA, 1977, APPL ENVIRON MICROB, V33, P989, DOI 10.1128/AEM.33.4.989-993.1977; DUBNAU D, 1991, MOL MICROBIOL, V5, P11, DOI 10.1111/j.1365-2958.1991.tb01820.x; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Miller JH., 1972, EXPT MOL GENETICS; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; Perego Marta, 1993, P615; SANDMAN K, 1987, GENETICS, V117, P603; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1993, MOL MICROBIOL, V7, P967, DOI 10.1111/j.1365-2958.1993.tb01188.x; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	35	253	256	2	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1047	1055		10.1016/0092-8674(94)90035-3	http://dx.doi.org/10.1016/0092-8674(94)90035-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	8001132				2022-12-01	WOS:A1994PY08600014
J	BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C				BAIN, G; MAANDAG, ECR; IZON, DJ; AMSEN, D; KRUISBEEK, AM; WEINTRAUB, BC; KROP, I; SCHLISSEL, MS; FEENEY, AJ; VANROON, M; VANDERVALK, M; TERIELE, HPJ; BERNS, A; MURRE, C			E2A PROTEINS ARE REQUIRED FOR PROPER B-CELL DEVELOPMENT AND INITIATION OF IMMUNOGLOBULIN GENE REARRANGEMENTS	CELL			English	Article							TRANSCRIPTION FACTOR BSAP; DNA-BINDING PROTEINS; HEAVY-CHAIN ENHANCER; FUNCTIONAL-ANALYSIS; LYMPHOCYTES-B; IGH ENHANCER; STEM-CELLS; EXPRESSION; PROMOTER; SEQUENCE	E12 and E47 are two helix-loop-helix transcription factors that arise by alternative splicing of the E2A gene. Both have been implicated in the regulation of immunoglobulin gene expression. We have now generated E2A (-/-) mice by gene targeting. E2A-null mutant mice fail to generate mature B cells. The arrest of B cell development occurs at an early stage, since no immunoglobulin DJ rearrangements can be detected in homozygous mutant mice. While immunoglobulin germline I-mu RAG-1, mb-1, CD19, and lambda 5 transcripts are dramatically reduced in fetal livers of E2A (-/-) mice, B29 and mu degrees transcripts are present, but at lower levels. In addition, we show that Pax-5 transcripts are significantly reduced in fetal livers of E2A (-/-) mice. These data suggest a crucial role for E2A products as central regulators in early B cell differentiation.	NETHERLANDS CANC INST, DEPT IMMUNOL, 1066 CX AMSTERDAM, NETHERLANDS; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; NETHERLANDS CANC INST, DEPT MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Scripps Research Institute; Johns Hopkins University; Johns Hopkins University; Netherlands Cancer Institute	BAIN, G (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0116, LA JOLLA, CA 92130 USA.				NCI NIH HHS [CA54198-01] Funding Source: Medline; NHLBI NIH HHS [HL48702] Funding Source: Medline; NIAID NIH HHS [R01 AI34088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA054198, R01CA054198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	53	635	642	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					885	892		10.1016/0092-8674(94)90077-9	http://dx.doi.org/10.1016/0092-8674(94)90077-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	8001125				2022-12-01	WOS:A1994PW05400015
J	ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C				ERIE, DA; YANG, GL; SCHULTZ, HC; BUSTAMANTE, C			DNA BENDING BY CRO PROTEIN IN SPECIFIC AND NONSPECIFIC COMPLEXES - IMPLICATIONS FOR PROTEIN SITE RECOGNITION AND SPECIFICITY	SCIENCE			English	Article							SCANNING FORCE MICROSCOPY; TATA-BOX COMPLEX; CRYSTAL-STRUCTURE; GEL-ELECTROPHORESIS; RNA-POLYMERASE; OPERATOR DNA; TRANSCRIPTION; ENDONUCLEASE; REPRESSOR; BINDING	Scanning force microscopy was used to resolve lambda Cro protein when bound as a single dimer or multiple dimers to its three operator (O-R) sites. The bend angles induced by binding of Cro to specific and nonspecific sites were determined and are 69 degrees +/- 11 degrees for specific and 62 degrees +/- 23 degrees for nonspecific complexes. Bending of the nonspecific sites is advantageous for a protein such as Cro that bends its specific site, because it increases the binding specificity of the protein and it can be used by the protein to sample contacts required for the recognition of its target sequence. It is proposed here that bending of nonspecific DNA may be a general property among DNA binding proteins that bend their specific sites.	UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM032543, R01GM032543, R37GM015792, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-32543, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; BUSTAMANTE JF, 1994, SCIENCE, V265, P1599; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; GARCIA R, UNPUB; HATS JB, 1969, BIOPOLYMERS, V8, P531; HERMAN S, UNPUB; Hermann S., UNPUB; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; JOANICOT M, 1987, BIOPOLYMERS, V26, P315, DOI 10.1002/bip.360260211; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Landau L D., 1980, STATISTICAL PHYSIC 1, V5, P396; LANDAU LD, 1970, THEORY ELASTICITY, V7, P82; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; MATTHEW JB, 1985, J BIOL CHEM, V260, P5860; MEYERALMES FJ, 1994, J MOL BIOL, V236, P1, DOI 10.1006/jmbi.1994.1112; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; PTASHNE M, 1992, GENETIC SWITCH GENE; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; SCHELLMAN JA, 1974, BIOPOLYMERS, V13, P217, DOI 10.1002/bip.1974.360130115; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STARR DE, UNPUB; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STOVER T, 1993, J BIOL CHEM, V268, P8645; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; ZAUG AJ, 1985, BIOCHEMISTRY-US, V24, P6211, DOI 10.1021/bi00343a027; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	54	158	160	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1562	1566		10.1126/science.7985026	http://dx.doi.org/10.1126/science.7985026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7985026				2022-12-01	WOS:A1994PV01500044
J	BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH				BLUMENFELD, JD; SEALEY, JE; SCHLUSSEL, Y; VAUGHAN, ED; SOS, TA; ATLAS, SA; MULLER, FB; ACEVEDO, R; ULICK, S; LARAGH, JH			DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM	ANNALS OF INTERNAL MEDICINE			English	Review							ATRIAL NATRIURETIC FACTOR; ALDOSTERONE-PRODUCING ADENOMA; CALCIUM-CHANNEL BLOCKADE; PLASMA-RENIN ACTIVITY; ESSENTIAL-HYPERTENSION; PEPTIDE; RADIOIMMUNOASSAY; RESPONSES	Objective: To characterize the clinical and laboratory features of primary aldosteronism and to evaluate which diagnostic tests can discriminate surgically curable forms of this syndrome. Design: Retrospective analysis of the following data from 82 patients with primary aldosteronism: blood pressure, serum electrolytes, urinary aldosterone anti electrolytes, computed tomographic scans, plasma renin and aldosterone before and during upright posture, atrial natriuretic peptide, and adrenal vein aldosterone and cortisol. Clinical outcomes assessed after treatment included blood pressure, serum electrolytes, anti plasma renin activity. Results: Drug therapy was discontinued before diagnostic tests were done in 56 of 82 patients (34 with adenomas and 22 with hyperplasia). Compared with patients with hyperplasia, those with adenomas had higher systolic (184 mm Hg and 161 mm Hg, respectively; P < 0.001) and diastolic blood pressures (112 mm Hg and 105 mm Hg; P = 0.03), lower serum potassium levels (3.0 mmol/L and 3.5 mmol/L; P < 0.001), and higher serum CO, (P = 0.001), atrial natriuretic peptide (P = 0.008), and urinary 18-methyl oxygenated cortisol metabolite levels (P = 0.02). In patients with adenomas, aldosterone secretion lateralized to one adrenal gland and did not increase during the postural stimulation test; preoperative urinary aldosterone levels were correlated with diastolic pressures (r = 0.58; P = 0.001). Hypertension was ''cured'' postoperatively in approximately 35% of patients with adenomas and those with hyperplasia (P > 0.2) but was ''improved'' more frequently in those with adenomas (P= 0.002). Cured patients from both groups were younger than those not cured (mean ages, 43 years anti 54 years, respectively; P = 0.002) and had lower preoperative mean plasma renin activity (0.17 ng/mL per hour and 0.50 ng/mL per hour; P < 0.001). All patient!; with adenomas in whom aldosterone secretion lateralized were either cured or improved. Conclusion: Of the 51 patients with primary aldosteronism who had adrenalectomy (43 patients with adenomas and 8 with hyperplasia), those most likely to be cured were younger and had lower plasma renin activity. In patients with adenomas who were cured or improved, aldosterone secretion was more likely to lateralize. Tests that distinguished adenomas from adrenal hyperplasia included the postural stimulation test, urinary excretion rates of 18-oxocortisol and 18-hydroxycortisol, and adrenal vein sampling.	VET AFFAIRS MED CTR, HYPERTENS RES LAB 151, BRONX, NY 10468 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BLUMENFELD, JD (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP,CTR CARDIOVASC, 520 E 70TH ST, STARR 4, NEW YORK, NY 10021 USA.		Acevedo, Romina/HCI-4706-2022; Blumenfeld, Jon/ABC-1107-2021; Sealey, Jean/A-9562-2009		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00047] Funding Source: Medline; NHLBI NIH HHS [HL 18323] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEEVERS DG, 1976, Q J MED, V45, P401; BOLLI P, 1980, J CARDIOVASC PHARM, V2, pS399, DOI 10.1097/00005344-198002003-00013; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1988, HYPERTENSION, V11, P207; BRAVO EL, 1986, HYPERTENSION, V8, P191; BRAVO EL, 1985, HYPERTENSION, V7, P90, DOI 10.1161/01.HYP.7.1.90; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; BUHLER FR, 1974, HYPERTENSION MANUAL, P655; BURSZTYN M, 1988, AM J HYPERTENS, V1, pS88, DOI 10.1093/ajh/1.3.88S; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; Conn JW., 1968, HARVEY LECT, V62, P257; FARMER RW, 1974, CLIN CHEM, V20, P411; FONTES RG, 1991, AM J HYPERTENS, V4, P786, DOI 10.1093/ajh/4.9.786; GANGULY A, 1973, J CLIN ENDOCR METAB, V36, P401, DOI 10.1210/jcem-36-2-401; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1990, AM J HYPERTENS, V3, P576, DOI 10.1093/ajh/3.7.576; IWAOKA T, 1990, ENDOCRINOL JAPON, V37, P151; LJUNGMAN S, 1990, AM J HYPERTENS, V3, P956, DOI 10.1093/ajh/3.12.956; MCLEOD MK, 1989, SURGERY, V106, P1161; MELBY JC, 1984, KIDNEY INT, V26, P769, DOI 10.1038/ki.1984.215; MELBY JC, 1967, NEW ENGL J MED, V277, P1050, DOI 10.1056/NEJM196711162772002; NADLER JL, 1985, J CLIN ENDOCR METAB, V60, P896, DOI 10.1210/jcem-60-5-896; NAKADA T, 1989, J UROLOGY, V142, P13, DOI 10.1016/S0022-5347(17)38650-0; PEDRINELLI R, 1988, HYPERTENSION, V12, P192, DOI 10.1161/01.HYP.12.2.192; RADIN DR, 1992, AM J ROENTGENOL, V158, P553, DOI 10.2214/ajr.158.3.1738993; SCOGGINS BA, 1972, ANN INTERN MED, V76, P891, DOI 10.7326/0003-4819-76-6-391; SEALEY JE, 1991, CLIN CHEM, V37, P1811; SEALEY JE, 1972, CIRC RES, V31, P367, DOI 10.1161/01.RES.31.3.367; STREETEN DHP, 1990, AM J HYPERTENS, V3, P360, DOI 10.1093/ajh/3.5.360; TORRES VE, 1990, NEW ENGL J MED, V322, P345, DOI 10.1056/NEJM199002083220601; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; TUNNY TJ, 1986, CLIN EXP PHARMACOL P, V13, P341, DOI 10.1111/j.1440-1681.1986.tb00360.x; ULICK S, 1993, J CLIN ENDOCR METAB, V76, P873, DOI 10.1210/jc.76.4.873; ULICK S, 1989, ADRENAL HYPERTENSION, P313; WEIBNERGER MH, 1984, ANN INTERN MED, V90, P386; YAMAJI T, 1986, J CLIN ENDOCR METAB, V63, P815, DOI 10.1210/jcem-63-4-815; 1990, NEW ENGL J MED, V323, P29	40	213	224	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					877	885		10.7326/0003-4819-121-11-199412010-00010	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7978702				2022-12-01	WOS:A1994PT62800010
J	PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S				PARSELL, DA; KOWAL, AS; SINGER, MA; LINDQUIST, S			PROTEIN DISAGGREGATION MEDIATED BY HEAT-SHOCK PROTEIN HSP104	NATURE			English	Article							RNA-POLYMERASE; YEAST-CELLS; DNAK; BINDING; HSP70; CHAPERONES; ORIGIN; REPA	THE heat-inducible members of the Hsp100 (or Clp) family of proteins share a common function in helping organisms to survive extreme stress, but the basic mechanism through which these proteins function is not understood(1-5) Hsp104 protects cells against a variety of stresses, under many physiological conditions(6,7) and its function has been evolutionarily conserved, at least from Saccharomyces cerevisiae to Arabidopsis thaliana(25). Homology with the Escherichia coli ClpA protein suggests that Hsp104 may provide stress tolerance by helping to rid the tell of heat-denatured proteins through proteolysis(1). But genetic analysis indicates that Hsp104 may function like Hsp70 as a molecular chaperones(8). Here we investigate the role of Hsp104 in vivo using a temperature-sensitive Vibrio harveyi luciferase-fusion protein as a test substrate(9). We find that Hsp104 does not protect luciferase from thermal denaturation, nor does it promote proteolysis of luciferase. Rather, Hsp104 functions in a manner not previously described for other heat-shock proteins: it mediates the resolubilization of heat-inactivated luciferase from insoluble aggregates.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago								BYERS B, 1991, METHOD ENZYMOL, V194, P602; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; KRUGER E, 1994, J BACTERIOL, V176, P3360; KURTZ S, 1985, SEQUENCE SPECIFICITY, P611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, IN PRESS PL CELL; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TRECO DA, 1989, CURRENT PROTOCOLS MO; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WEBSTER DL, 1993, YEAST, V9, P1165, DOI 10.1002/yea.320091103; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473	25	726	742	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					475	478		10.1038/372475a0	http://dx.doi.org/10.1038/372475a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7984243				2022-12-01	WOS:A1994PV01200060
J	ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F				ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F			RIBOSOMAL HETEROGENEITY FROM CHROMATIN DIMINUTION IN ASCARIS-LUMBRICOIDES	SCIENCE			English	Article							PROTEIN GENES; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; TURNER SYNDROME; RNA; S19; ORGANIZATION; EXPRESSION; GENOME; YEAST	The genome of Ascaris lumbricoides encodes both germline- and soma-specific proteins homologous to the eukaryotic small ribosomal protein (Rp) S19. The two Ascaris homologs differ by 24 amino acid substitutions and are both components of the small ribosomal subunits. In oocytes, the germline RpS19 homolog (RpS19G) predominates. During chromatin diminution, however, the gene is eliminated from all presomatic cells, and RpS19G is replaced by the product of the somatic gene (RpS19S). Chromatin diminution in A. lumbricoides causes a change in the protein composition of ribosomes during development and represents an alternative means of gene regulation.	UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								AEBY P, 1986, EMBO J, V5, P3353, DOI 10.1002/j.1460-2075.1986.tb04650.x; BAUMGARTNER S, 1993, NUCLEIC ACIDS RES, V21, P3897, DOI 10.1093/nar/21.16.3897; BRADSHAW RE, 1991, GENE, V108, P157, DOI 10.1016/0378-1119(91)90502-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONOVAN DM, 1990, MOL CELL BIOL, V10, P6097, DOI 10.1128/MCB.10.11.6097; ETTER A, 1991, P NATL ACAD SCI USA, V88, P1593, DOI 10.1073/pnas.88.5.1593; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GODAY C, 1993, PARASITOL TODAY, V9, P319, DOI 10.1016/0169-4758(93)90229-9; GORENSTEIN C, 1976, P NATL ACAD SCI USA, V73, P1547, DOI 10.1073/pnas.73.5.1547; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARLOW E, 1988, ANTIBODIES LABORATOR; KIMURA J, 1987, FEBS LETT, V224, P65, DOI 10.1016/0014-5793(87)80423-4; KONDOH N, 1992, CANCER RES, V52, P791; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MOLENAAR CMT, 1984, NUCLEIC ACIDS RES, V12, P7345, DOI 10.1093/nar/12.19.7345; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; MULLER F, 1982, NUCLEIC ACIDS RES, V10, P7493, DOI 10.1093/nar/10.23.7493; MULLER F, 1991, CELL, V67, P815, DOI 10.1016/0092-8674(91)90076-B; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; Poinar GO., 1983, NATURAL HIST NEMATOD; RAMAGOPAL S, 1993, TRANSLATIONAL APPARATUS, P713; Sambrook J., 1989, MOL CLONING LAB MANU; Spedding G, 1990, RIBOSOMES PROTEIN SY, P9; SPICHER A, 1994, DEV BIOL, V164, P72, DOI 10.1006/dbio.1994.1181; STORTKUHL KF, 1994, CELL TISSUE RES, V275, P27, DOI 10.1007/BF00305373; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1990, BIOCHIMIE, V72, P299, DOI 10.1016/0300-9084(90)90088-X; TOBLER H, 1992, TRENDS GENET, V8, P427, DOI 10.1016/0168-9525(92)90326-Y; TOBLER H, 1986, RESULTS PROBLEMS CEL, V13; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	33	45	47	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					954	956		10.1126/science.8052853	http://dx.doi.org/10.1126/science.8052853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052853				2022-12-01	WOS:A1994PB49900043
J	OROURKE, B; RAMZA, BM; MARBAN, E				OROURKE, B; RAMZA, BM; MARBAN, E			OSCILLATIONS OF MEMBRANE CURRENT AND EXCITABILITY DRIVEN BY METABOLIC OSCILLATIONS IN HEART-CELLS	SCIENCE			English	Article							PURINE NUCLEOTIDE CYCLE; SENSITIVE K+ CHANNELS; CALCIUM CHANNELS; GLYCOLYTIC OSCILLATIONS; POTENTIAL OSCILLATIONS; INTRACELLULAR CALCIUM; MUSCLE EXTRACTS; ATP; MYOCYTES; MODULATION	Periodic changes in membrane ionic current linked to intrinsic oscillations of energy metabolism were identified in guinea pig cardiomyocytes. Metabolic stress initiated cyclical activation of adenosine triphosphate-sensitive potassium current and concomitant suppression of depolarization-evoked intracellular calcium transients. The oscillations in membrane current and excitation-contraction coupling were linked to oscillations in the oxidation state of pyridine nucleotides but were not driven by pacemaker currents or alterations in the concentration of cytosolic calcium. Interventions that altered the rate of glucose metabolism modulated the oscillations, suggesting that the rhythms originated at the level of glycolysis. The energy-driven oscillations in potassium currents produced cyclical changes in the cardiac action potential and thus may contribute to the genesis of arrhythmias during metabolic compromise.	JOHNS HOPKINS UNIV, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 36957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES V, 1990, J BIOL CHEM, V265, P21441; AON MA, 1991, J CELL SCI, V99, P325; BACKX PH, 1991, AM J HYPERTENS, V4, pS416, DOI 10.1093/ajh/4.7.416S; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHANCE B, 1964, BIOCHEMISTRY-US, V52, P337; CHEN V, 1985, BIOCHIM BIOPHYS ACTA, V846, P398, DOI 10.1016/0167-4889(85)90012-6; COLLATZ KG, 1990, COMP BIOCHEM PHYS B, V96, P771, DOI 10.1016/0305-0491(90)90229-M; CONNOR JA, 1979, J EXP BIOL, V81, P153; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; FRENKEL R, 1966, ARCH BIOCHEM BIOPHYS, V115, P112, DOI 10.1016/S0003-9861(66)81046-9; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GOLDBETER A, 1980, MATH MODELS MOL CELL, P260; GOLDMAN YE, 1982, NATURE, V300, P701, DOI 10.1038/300701a0; GOOCH VD, 1974, BIOCHIM BIOPHYS ACTA, V346, P245, DOI 10.1016/0304-4173(74)90002-0; GWILT M, 1993, EUR J PHARMACOL, V236, P107, DOI 10.1016/0014-2999(93)90232-7; HESS B, 1983, H-S Z PHYSIOL CHEM, V364, P1; Hess B, 1979, Ann N Y Acad Sci, V316, P203, DOI 10.1111/j.1749-6632.1979.tb29470.x; KEUNG EC, 1991, J CLIN INVEST, V88, P1772, DOI 10.1172/JCI115497; KORT AA, 1985, J PHYSIOL-LONDON, V367, P291, DOI 10.1113/jphysiol.1985.sp015825; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MARKUS M, 1984, FEBS LETT, V172, P235, DOI 10.1016/0014-5793(84)81132-1; MEECH RW, 1979, J EXP BIOL, V81, P93; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; OROURKE B, 1992, SCIENCE, V257, P245, DOI 10.1126/science.1321495; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; Stryer L, 1981, BIOCHEMISTRY; TORNHEIM K, 1974, J BIOL CHEM, V249, P3241; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TSIEN RW, 1979, J EXP BIOL, V81, P205; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; Wit A. L., 1993, VENTRICULAR ARRHYTHM	38	212	222	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					962	966		10.1126/science.8052856	http://dx.doi.org/10.1126/science.8052856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052856				2022-12-01	WOS:A1994PB49900046
J	KAO, CM; KATZ, L; KHOSLA, C				KAO, CM; KATZ, L; KHOSLA, C			ENGINEERED BIOSYNTHESIS OF A COMPLETE MACROLACTONE IN A HETEROLOGOUS HOST	SCIENCE			English	Article							METHYLMALONYL-COA EPIMERASE; COENZYME-A MUTASE; POLYKETIDE SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA; ESCHERICHIA-COLI; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; PROPIONIBACTERIUM-SHERMANII; PHYSICOCHEMICAL PROPERTIES; NUCLEOTIDE-SEQUENCE	Macrocyclic polyketides have been subjects of great interest in synthetic and biosynthetic chemistry because of their structural complexity and medicinal activities. With expression of the entire 6-deoxyerythronolide B synthase (DEBS) (10,283 amino acids) in a heterologous host, substantial quantities of 6-deoxyerythronolide B (6dEB), the aglycone of the macrolide antibiotic erythromycin, and 8,8a-deoxyoleandolide, a 14-membered lactone ring identical to 6dEB except for a methyl group side chain in place of an ethyl unit, were synthesized in Streptomyces coelicolor. The biosynthetic strategy utilizes a genetic approach that facilitates rapid structural manipulation of DEBS or other modular polyketide synthases (PKSs), including those found in actinomycetes with poorly developed genetic methods. From a technological viewpoint, this approach should allow the rational design of biosynthetic products and may eventually lead to the generation of diverse polyketide libraries by means of combinatorial cloning of naturally occurring and mutant PKS modules.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; ABBOTT LABS,ANTIINFECT DISCOVERY RES,ABBOTT PK,IL 60064	Stanford University; Abbott Laboratories				Khosla, Chaitan/0000-0001-6529-495X				ALBERSSCHONBERG G, 1981, J AM CHEM SOC, V103, P4216, DOI 10.1021/ja00404a040; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; DORMAN DE, 1976, HELV CHIM ACTA, V59, P2625, DOI 10.1002/hlca.19760590802; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FU H, IN PRESS BIOCHEMISTR; FU H, 1993, IN PRESS J AM CHEM S, V115, P11671; FULLER JQ, 1983, BIOCHEM J, V213, P643, DOI 10.1042/bj2130643; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hopwood D. A., 1985, GENETIC MANIPULATION; HSIEH YJ, 1994, J BACTERIOL, V176, P714, DOI 10.1128/jb.176.3.714-724.1994; HUNAITI AA, 1984, ANTIMICROB AGENTS CH, V25, P173, DOI 10.1128/AAC.25.2.173; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KATZ L, UNPUB; KIBWAGE IO, 1987, J ANTIBIOT, V40, P1; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; Maniatis T., 1982, MOL CLONING; MARDSEN AFA, 1994, SCIENCE, V263, P378; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL RG, UNPUB; NOURSE JG, 1975, J AM CHEM SOC, V97, P4584, DOI 10.1021/ja00849a021; O'Hagan D., 1991, POLYKETIDE METABOLIT; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; OMURA S, 1983, J ANTIBIOT, V36, P614, DOI 10.7164/antibiotics.36.614; ONO M, 1983, J ANTIBIOT, V36, P509, DOI 10.7164/antibiotics.36.509; PIEPER R, UNPUB; POSPISIL S, 1983, J ANTIBIOT, V36, P617, DOI 10.7164/antibiotics.36.617; REYNOLDS KA, 1988, J CHEM SOC PERK T 1, P3195, DOI 10.1039/p19880003195; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHERMAN MM, 1986, J ANTIBIOT, V39, P1135, DOI 10.7164/antibiotics.39.1135; TAKIGUCHI Y, 1983, J ANTIBIOT, V36, P502, DOI 10.7164/antibiotics.36.502; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994	49	212	252	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					509	512		10.1126/science.8036492	http://dx.doi.org/10.1126/science.8036492			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036492				2022-12-01	WOS:A1994NY21600025
J	CAELLES, C; HELMBERG, A; KARIN, M				CAELLES, C; HELMBERG, A; KARIN, M			P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES	NATURE			English	Article							REPLICATION FACTOR-A; DNA-REPLICATION; THYMOCYTE APOPTOSIS; CELL-DEATH; WILD-TYPE; P53; PROTEIN; MUTANT; TRANSFORMATION; LOCALIZATION	THE tumour suppressor p53 is required to induce programmed cell death (apoptosis) by DNA-damaging agents(1,2). As p53 is a transcriptional activator(3) that mediates gene induction after DNA damage(4), it has been proposed to be a genetic switch that activates apoptosis-mediator genes(5). Here we evaluate the role of p53 in DNA-damage-induced apoptosis by establishing derivatives of GHFT1 cells, that are somatotropic progenitors immortalized by expression of SV40 T-antigen(6), which express a temperature-sensitive p53 mutant(7). In these cells induction of apoptosis by DNA damage depends strictly on p53 function. A shift to the permissive temperature triggers apoptosis following DNA damage, but this is independent of new RNA or protein synthesis. The extent of apoptotic DNA cleavage is directly proportional to the period during which p53 is functional. These results do not support the proposal that p53 is an activator of apoptosis-mediator genes but rather indicate that p53 either represses genes necessary for cell survival(8) or is a component of the enzymatic machinery for apoptotic cleavage or repair of DNA(5).	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HIBI M, 1993, GENE DEV, V7, P2134; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEVINE AJ, 1993, BIOL CHEM H-S, V374, P227; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	852	868	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					220	223		10.1038/370220a0	http://dx.doi.org/10.1038/370220a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028670				2022-12-01	WOS:A1994NX97100054
J	KONDRASHOV, AS				KONDRASHOV, AS			THE ASEXUAL PLOIDY CYCLE AND THE ORIGIN OF SEX	NATURE			English	Article							CELL-FUSION; EVOLUTION; MEIOSIS; AMEBA; DNA; REPRODUCTION; GYMNAMOEBIA; SELECTION; MUTATIONS; ADVANTAGE	SEX involves syngamy (gamete fusion), which doubles the amount of DNA in a cell, and meiosis(1), which halves it. The result is a 'ploidy cycle' of alternating diploid and haploid phases. Asexual reproduction does not require changes of ploidy, and yet asexual forms may have ploidy cycles. Here I show that such cycles lessen the mutation load, compared with permanent diploidy or polyploidy, and are thus likely to evolve in cases where it is always advantageous to have more than one copy of the genome per cell. The asexual ploidy cycle could have facilitated the origin of sex, by providing a means of orderly genetic reduction available immediately after the origin of syngamy.			KONDRASHOV, AS (corresponding author), CORNELL UNIV,ECOL & SYSTEMAT SECT,ITHACA,NY 14853, USA.							AFONKIN SJ, 1986, ARCH PROTISTENKD, V131, P101, DOI 10.1016/S0003-9365(86)80067-7; [Anonymous], 1988, SEX DEATH PROTOZOA H; Bernstein C., 1991, AGING SEX DNA REPAIR; BRUGEROLLE G, 1993, J EUKARYOT MICROBIOL, V40, P616, DOI 10.1111/j.1550-7408.1993.tb06118.x; BYERS TJ, 1986, INT REV CYTOL, V99, P311; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CLEVELAND LR, 1947, SCIENCE, V105, P287, DOI 10.1126/science.105.2724.287; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DICKSON DPE, 1984, HEREDITY, V53, P717, DOI 10.1038/hdy.1984.129; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P1905, DOI 10.1093/nar/19.8.1905; HAIG D, 1993, J THEOR BIOL, V163, P15, DOI 10.1006/jtbi.1993.1104; HASIMOTO T, 1994, MOL BIOL EVOL, V11, P65; HURST LD, 1993, NATURE, V365, P206, DOI 10.1038/365206a0; HURST LD, 1991, J THEOR BIOL, V150, P561, DOI 10.1016/S0022-5193(05)80447-3; KIMURA M, 1966, GENETICS, V54, P1337; KIRKPATRICK M, 1989, NATURE, V339, P300, DOI 10.1038/339300a0; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, GENETICS, V137, P311; KONDRASHOV AS, 1982, GENET RES, V40, P325, DOI 10.1017/S0016672300019194; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LEWIS WM, 1985, AM NAT, V125, P692, DOI 10.1086/284372; MAGUIRE MP, 1992, J THEOR BIOL, V154, P43, DOI 10.1016/S0022-5193(05)80187-0; Margulis L, 1990, HDB PROTOCTISTA; Margulis L, 1986, ORIGINS SEX; MULLER DG, 1967, PLANTA, V75, P39, DOI 10.1007/BF00380838; Raikov I.B., 1989, Progress in Protistology, V3, P21; SERAVIN LN, 1983, TSITOLOGIYA+, V25, P194; SERAVIN LN, 1984, TSITOLOGIYA+, V26, P123; SERAVIN LN, 1985, ZOOL ZH, V64, P1090; WILLUMSEN NBS, 1987, ARCH PROTISTENKD, V134, P303, DOI 10.1016/S0003-9365(87)80002-7; [No title captured]; [No title captured]	34	72	80	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					213	216		10.1038/370213a0	http://dx.doi.org/10.1038/370213a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028667				2022-12-01	WOS:A1994NX97100051
J	ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE				ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE			LATE DEATHS AND SURVIVAL AFTER CHILDHOOD-CANCER - IMPLICATIONS FOR CURE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TUMORS	Objectives-To investigate causes of death and survival in subjects who had survived at least five years after diagnosis of childhood cancer; to compare observed mortality with that expected in the general population; and to compare results with a corresponding cohort diagnosed earlier. Design-Retrospective cohort study. Setting-Population based National Register of Childhood Tumours. Subjects-9080 five year survivors of childhood cancer diagnosed in Britain during 1971-85, of whom 793 had died. Comparison with corresponding cohort diagnosed during 1940-70. Main outcome measures-Cause of death established from all available sources of information (including hospital and general practitioner records and postmortem reports) and underlying cause of death coded on death certificate. Results-Of the 781 deaths for which sufficient information was available, death was attributed to recurrent tumour in 578 (74%) cases, treatment related effect in 121 (15%), second primary tumour 52 (7%), and other causes in 30 (4%). Comparison of observed mortality with that expected in the general population indicated a fourfold excess of deaths from non-neoplasic causes. The risk of dying of recurrent tumour in the next 10 years after surviving five years from diagnosis during 1940-70 and 1971-85 fell from 12% to 8%. The risk of dying from a treatment related effect increased slightly from 1% to 2%. Conclusion-Improvements in five year survival after childhood cancer have been accompanied by a reduction in risk of dying from recurrent tumour during the subsequent 10 years and by a slight increase in risk of dying from treatment related effects. The results provide information relevant to decisions concerning balance between effective treatments and their potentially harmful effects.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND	University of Oxford								ALASIRI RH, 1992, MED PEDIATR ONCOL, V20, P315, DOI 10.1002/mpo.2950200409; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow N. E., 1987, STATISTICAL METHODS, VII; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; NICHOLSON HS, 1994, CANCER, V73, P3094; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTSON CM, 1992, ARCH DIS CHILD, V67, P1378, DOI 10.1136/adc.67.11.1378; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; [No title captured]; 1965, MANUAL INT STATISTIC	17	95	97	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					162	166		10.1136/bmj.309.6948.162	http://dx.doi.org/10.1136/bmj.309.6948.162			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044095	Green Published			2022-12-01	WOS:A1994NY22900021
J	WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH				WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH			THE ONCOGENIC CYSTEINE-RICH LIM DOMAIN PROTEIN RBTN2 IS ESSENTIAL FOR ERYTHROID DEVELOPMENT	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; MOUSE EMBRYO; ERYTHROPOIETIN RECEPTOR; MESSENGER-RNAS; SCL GENE; C-MYC; DIFFERENTIATION; EXPRESSION	The LIM domain protein rbtn2 is associated with T cell acute leukemias. We demonstrate that rbtn2 is a nuclear protein expressed in the erythroid lineage in vivo, and using homologous recombination, we show that it is essential for erythroid development in mice. The homozygous rbtn2 null mutation leads to failure of yolk sac erythropoiesis and embryonic lethality around E10.5. Moreover, in vitro differentiation of yolk sac tissue from homozygous mutant mice and sequentially targeted double-mutant ES cells demonstrates a block to erythroid development. This shows a pivotal role for a LIM domain protein in lineage specification during mammalian development and suggests that RBTN2 and GATA-1 are critical at similar stages of erythroid differentiation.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge	WARREN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Colledge, William/X-4976-2019; Rabbitts, Terence/D-6262-2016	Colledge, William/0000-0002-9603-4429; Rabbitts, Terence/0000-0002-4982-2609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, ONCOGENE, V3, P691; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHENG JT, 1993, ONCOGENE, V8, P667; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1975, BRIT J HAEMATOL, V29, P553, DOI 10.1111/j.1365-2141.1975.tb02742.x; CHUI DHK, 1974, DEV BIOL, V40, P256, DOI 10.1016/0012-1606(74)90128-6; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCH P, 1993, ONCOGENE, V8, P3271; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN SM, 1989, ONCOGENE, V4, P737; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1993, BLOOD, V81, P2237; RIBEIRO RC, 1991, BLOOD, V78, P466; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUSSELL ES, 1968, GENETICS, V58, P259; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOFRONIEW MV, 1983, HDB CHEM NEUROANATOM, V1, P210; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILES MV, 1991, DEVELOPMENT, V111, P259; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	65	534	551	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					45	57		10.1016/0092-8674(94)90571-1	http://dx.doi.org/10.1016/0092-8674(94)90571-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033210				2022-12-01	WOS:A1994NX32800007
J	HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S				HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S			PARTHENOGENETIC ACTIVATION OF OOCYTES IN C-MOS-DEFICIENT MICE	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS OOCYTES; MOUSE-TISSUES; MEIOSIS-II; EGGS; PROTOONCOGENE; TRANSCRIPTS; EXPRESSION; FEATURES	IN Xenopus the c-mos proto-oncogene product (Mos) is essential for the initiation of oocyte maturation(1), for the progression from meiosis I to meiosis II2,3 and for the second meiotic metaphase arrest, acting as an essential component of the cytostatic factor CSF4,5. Its function in mouse oocytes is unclear(6-9), however, as is the biological significance of c-mos mRNA expression in testes(1,10) and several somatic tissues(1,10,11). We have generated c-mos-deficient mice by gene targeting in embryonic stem cells. These mice grew at the same rate as their wild-type counterparts and reproduction was normal in the males, but the fertility of the females was very low. The c-mos-deficient female mice developed ovarian teratomas at a high frequency. Oocytes from these females matured to the second meiotic metaphase both in vivo and in vitro, but were activated without fertilization. The results indicate that in mice Mos plays a role in the second meiotic metaphase arrest, but does not seem to be essential for the initiation of oocyte maturation, spermatogenesis or somatic cell cycle.	MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,KURUME,FUKUOKA 830,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,TOKYO 113,JAPAN	RIKEN; Kurume University; Tokyo Medical & Dental University (TMDU)			Okazaki, Kenji/H-4393-2012; Watanabe, Nobumoto/N-6959-2015	Watanabe, Nobumoto/0000-0002-2130-1334				DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; EPPIG JJ, 1977, NATURE, V269, P517, DOI 10.1038/269517a0; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HASHIMOTO N, 1990, DEV GROWTH DIFFER, V32, P197; HERZOG NK, 1989, ONCOGENE, V4, P1307; HOGAN B, 1986, MANIPULATING MOUSE E, V106; INOUE M, 1975, BIOL REPROD, V13, P546, DOI 10.1095/biolreprod13.5.546; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; WOLF DP, 1978, DEV BIOL, V64, P1, DOI 10.1016/0012-1606(78)90056-8; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [10.1262/jrd1955.16.147, DOI 10.1262/JRD1955.16.147]; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43	24	394	412	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					68	71		10.1038/370068a0	http://dx.doi.org/10.1038/370068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015610				2022-12-01	WOS:A1994NV71100061
J	BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R				BARLOWE, C; ORCI, L; YEUNG, T; HOSOBUCHI, M; HAMAMOTO, S; SALAMA, N; REXACH, MF; RAVAZZOLA, M; AMHERDT, M; SCHEKMAN, R			COPII - A MEMBRANE COAT FORMED BY SEC PROTEINS THAT DRIVE VESICLE BUDDING FROM THE ENDOPLASMIC-RETICULUM	CELL			English	Article							YEAST SECRETORY PATHWAY; GOLGI TRANSPORT VESICLES; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; VESICULAR TRANSPORT; BETA-COP; ESCHERICHIA-COLI; COMPLEX; CLATHRIN; ER	In vitro synthesis of endoplasmic reticulum-derived transport vesicles has been reconstituted with washed membranes and th ree soluble proteins (Sar1p, Sec13p complex, and Sec23p complex). Vesicle formation requires GTP but can be driven by nonhydrolyzable analogs such as GMP-PNP. However, GMP-PNP vesicles fail to target and fuse with the Golgi complex whereas GTP vesicles are functional. All the cytosolic proteins required for vesicle formation are retained on GMP-PNP vesicles, while Sar1p dissociates from GTP vesicles. Thin section electron microscopy of purified preparations reveals a uniform population of 60-65 nm vesicles with a 10 nm thick electron dense coat. The subunits of this novel coat complex are molecularly distinct from the constituents of the nonclathrin coatomer involved in intra-Golgi transport. Because the overall cycle of budding driven by these two types of coats appears mechanistically similar, we propose that the coat structures be called COPI and COPII.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	BARLOWE, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Salama, Nina Reda/AAG-2437-2019	Salama, Nina Reda/0000-0003-2762-1424				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BARLOWE C, J BIOL CHEM, V268, P87393; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Parks R. E., 1973, ENZYMES, V8, P307, DOI 10.1016/S1874-6047(08)60069-4; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	60	1040	1055	0	135	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 17	1994	77	6					895	907		10.1016/0092-8674(94)90138-4	http://dx.doi.org/10.1016/0092-8674(94)90138-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	8004676				2022-12-01	WOS:A1994NT33100014
J	MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA				MACKEWICZ, CE; YANG, LC; LIFSON, JD; LEVY, JA			NONCYTOLYTIC CD8 T-CELL ANTI-HIV RESPONSES IN PRIMARY HIV-1 INFECTION	LANCET			English	Note							PLASMA; VIRUS	Acute HIV infection is accompanied by a sharp rise in virus titres that soon fall, but the role of humoral and cellular immunity is not clear in the control of initial virus replication. We have found seven HIV-1 infected subjects who had CD8 T-cell non-cytolytic anti-HIV activity in plasma many months before neutralising antibodies can be detected. We observed an inverse relation between the extent of this CD8 cell response and the level of plasma viraemia in some subjects. These results suggest that a cellular immune response controls viral replication soon after HIV infection.	UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; GENELABS TECHNOL INC,REDWOOD CITY,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI35467, R01-AI30350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030350, R01AI035467, R37AI035467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P629; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SHEPPARD HW, 1993, J ACQ IMMUN DEF SYND, V6, P1339; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001	10	102	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1671	1673						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7996961				2022-12-01	WOS:A1994PX30200010
J	ORENGO, CA; JONES, DT; THORNTON, JM				ORENGO, CA; JONES, DT; THORNTON, JM			PROTEIN SUPERFAMILIES AND DOMAIN SUPERFOLDS	NATURE			English	Article							STRUCTURE ALIGNMENT; GLOBULAR-PROTEINS; SEQUENCES; FOLD; SIMILARITIES; FAMILIES	As the protein sequence and structure databases expand rapidly a better understanding of the relationships between proteins is required. A classification is considered that extends the sequence-based superfamilies to include proteins with similar function and three-dimensional structures but no sequence similarity. So far there are only nine protein folds known to recur in proteins having neither sequence nor functional similarity. These folds dominate the structure database, representing more than 30 per cent of all determined structures. This observation has implications for protein-fold recognition.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	ORENGO, CA (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDROV NN, 1994, PROTEIN SCI, V3, P866; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; FINKELSTEIN AV, 1994, CURR OPIN STRUC BIOL, V4, P422, DOI 10.1016/S0959-440X(94)90112-0; FLORES TP, 1993, PROTEIN SCI, V2, P1811, DOI 10.1002/pro.5560021104; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; HILBERT M, 1993, PROTEINS, V17, P138, DOI 10.1002/prot.340170204; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; ORENGO CA, 1993, PROTEIN ENG, V6, P485, DOI 10.1093/protein/6.5.485; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RACKOVSKY S, 1990, PROTEINS, V7, P378, DOI 10.1002/prot.340070409; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; YEE DP, 1993, PROTEIN SCI, V2, P884, DOI 10.1002/pro.5560020603	27	652	677	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					631	634		10.1038/372631a0	http://dx.doi.org/10.1038/372631a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990952				2022-12-01	WOS:A1994PX30700074
J	ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK				ROMANEK, CS; GRADY, MM; WRIGHT, IP; MITTLEFEHLDT, DW; SOCKI, RA; PILLINGER, CT; GIBSON, EK			RECORD OF FLUID-ROCK INTERACTIONS ON MARS FROM THE METEORITE ALH84001	NATURE			English	Article							ISOTOPE FRACTIONATIONS; STABLE ISOTOPES; SNC METEORITES; CARBON-DIOXIDE; OXYGEN; CALCITE; EVOLUTION	ALLAN HILLS (ALH) 84001 is the most recently recognized(1) member of a suite of meteorites-the SNCs-that almost certainly originated on Mars(2). Several factors distinguish ALH84001 from the other SNC meteorites. Preliminary studies(3,4) suggest that it may be older than other martian meteorites. Moreover, it contains abundant, zoned domains of calcium-iron-magnesium carbonate that are indigenous to the sample(1) and thus may hold important clues regarding near-surface processes on Mars and the evolution of the martian atmosphere. We report here analyses of the carbon and oxygen stable-isotope Compositions of the carbonates that place constraints on their formation conditions. Our results imply the presence of at least two chemically distinct carbonates-one Ca,Fe-rich, the other Mg-rich-that are enriched in C-13 relative to terrestrial carbonates (delta(13)C approximate to + 41%parts per thousand), consistent with martian atmospheric CO2 as the carbon source. The oxygen isotope compositions of the carbonates indicate that they precipitated from a low-temperature fluid in the martian crust. Combined with textural and bulk geochemical considerations, the isotope data suggest that carbonate deposition took place in an open-system environment in which the ambient temperature fluctuated.	BRITISH MUSEUM NAT HIST,DEPT MINERAL,LONDON SW7 5BD,ENGLAND; OPEN UNIV,DEPT EARTH SCI,PLANETARY SCI UNIT,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND; LOCKHEED ENGN & SCI CO,HOUSTON,TX 77058	British Museum of Natural History; Open University - UK; Lockheed Martin	ROMANEK, CS (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,PLANETARY SCI BRANCH SN4,HOUSTON,TX 77058, USA.			Grady, Monica/0000-0002-4055-533X				ALASAM IS, 1990, CHEM GEOL, V80, P119; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; CHIBA H, 1989, GEOCHIM COSMOCHIM AC, V53, P2985, DOI 10.1016/0016-7037(89)90174-9; Clayton R., 1993, ANTARCT METEORITE NE, V16, P4; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; GRADY MM, 1994, METEORITICS, V29, P469; JAGOUTZ E, 1994, METEORITICS, V29, P478; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JULL AJT, 1994, METEORITICS, V29, P479; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MOZLEY PS, 1993, J SEDIMENT PETROL, V63, P73; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; SWART PK, 1991, CHEM GEOL, V86, P89, DOI 10.1016/0168-9622(91)90055-2; TREIMAN AH, 1994, METEORITICS, V29, P542; VEIZER J, 1983, REV MINERAL, V11, P265; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; [No title captured]	25	198	201	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 15	1994	372	6507					655	657		10.1038/372655a0	http://dx.doi.org/10.1038/372655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7990956				2022-12-01	WOS:A1994PX30700079
J	DANON, A; MAYFIELD, SP				DANON, A; MAYFIELD, SP			LIGHT-REGULATED TRANSLATION OF CHLOROPLAST MESSENGER-RNAS THROUGH REDOX POTENTIAL	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; CO2 ASSIMILATION; HIGHER-PLANTS; MUTATIONS; NUCLEAR; PSBA; BIOGENESIS; PROTEINS	Translation of key proteins in the chloroplast is regulated by light. Genetic and biochemical studies in the unicellular alga Chlamydomonas reinhardtii suggest that light may regulate translation by modulating the binding of activator proteins to the 5' untranslated region of chloroplast messenger RNAs. in vitro binding of the activator proteins to psbA messenger RNA and in vivo translation of psbA messenger RNA is regulated by the redox state of these proteins, suggesting that the light stimulus is transduced by the photosynthesis-generated redox potential.	Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON AD, UNPUB; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GRANT DM, 1980, P NATL ACAD SCI-BIOL, V77, P6067, DOI 10.1073/pnas.77.10.6067; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MATTOO AK, 1981, P NATL ACAD SCI-BIOL, V78, P1572, DOI 10.1073/pnas.78.3.1572; MAYFIELD SP, 1994, J CELL BIOL, V127, P6; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; WETTERN M, 1984, ISRAEL J BOT, V33, P253; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	23	279	284	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1717	1719		10.1126/science.7992056	http://dx.doi.org/10.1126/science.7992056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7992056				2022-12-01	WOS:A1994PW30800043
J	SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H				SAINTRUF, C; UNGEWISS, K; GROETTRUP, M; BRUNO, L; FEHLING, HJ; VONBOEHMER, H			ANALYSIS AND EXPRESSION OF A CLONED PRE-T CELL-RECEPTOR GENE	SCIENCE			English	Article							BETA-CHAIN GENE; THYMOCYTE DEVELOPMENT; TRANSGENIC MICE; IMMATURE THYMOCYTES; REARRANGEMENT; TCR; RESTORATION; CD3-EPSILON; PROTEINS; SURFACE	The T cell antigen receptor (TCR) beta chain regulates early T cell development in the absence of the TCR alpha chain. The developmentally controlled gene described here encodes the pre-TCR alpha (pT alpha) chain, which covalently associates with TCR beta and with the CD3 proteins forms a pre-TCR complex that transduces signals in immature thymocytes. Unlike the lambda 5 pre-B cell receptor protein, the pT alpha chain is a type I transmembrane protein whose cytoplasmic tail contains two potential phosphorylation sites and a Src homology 3 (SH3)-domain binding sequence. Pre-TCR alpha transfection experiments indicated that surface expression of the pre-TCR is controlled by additional developmentally regulated proteins. Identification of the pT alpha gene represents an essential step in the structure-function analysis of the pre-TCR complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		SAINTRUF, C (corresponding author), INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.							ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FENG DF, 1987, J MOL EVOL, V35, P359; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GROETTRUP M, 1993, THESIS U BASEL; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P6101; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; RODEWALD HR, UNPUB; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHORES EW, 1991, EUR J IMMUNOL, V21, P973, DOI 10.1002/eji.1830210417; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; YU H, 1994, STRUCTURAL BIOL, V1, P417	38	362	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 18	1994	266	5188					1208	1212		10.1126/science.7973703	http://dx.doi.org/10.1126/science.7973703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7973703	Green Submitted			2022-12-01	WOS:A1994PT13200045
J	GRAZIANO, MSA; YAP, GS; GROSS, CG				GRAZIANO, MSA; YAP, GS; GROSS, CG			CODING OF VISUAL SPACE BY PREMOTOR NEURONS	SCIENCE			English	Article							PARIETAL NEURONS; CORTEX; MOVEMENTS; REPRESENTATION; ORGANIZATION; MONKEY	In primates, the premotor cortex is involved in the sensory guidance of movement. Many neurons in ventral premotor cortex respond to visual stimuli in the space adjacent to the hand or arm. These visual receptive fields were found to move when the arm moved but not when the eye moved; that is, they are in arm-centered, not retinocentric, coordinates. Thus, they provide a representation of space near the body that may be useful for the visual control of reaching.			GRAZIANO, MSA (corresponding author), PRINCETON UNIV, DEPT PSYCHOL, PRINCETON, NJ 08544 USA.				NIMH NIH HHS [MH 19420] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH019420] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; BRUCE CJ, 1990, NEUROSCI IN, P261; CAMINITI R, 1990, J NEUROSCI, V10, P2039; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GOLDMANRAKIC PS, 1990, COLD SPRING HARB SYM, V55, P1025; GRAZIANO MS, 1992, BEHAV BRAIN SCI, V15, P750; GRAZIANO MS, ATTENTION PERFORMANC, V16; GRAZIANO MSA, 1993, EXP BRAIN RES, V97, P96; GRAZIANO MSA, 1994, CURR DIR PSYCHOL SCI, V3, P164, DOI 10.1111/1467-8721.ep10770670; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; GROSS CG, IN PRESS NEUROSCIENT; HE SQ, 1993, J NEUROSCI, V13, P952; MILLER EK, 1993, BRAIN RES, V616, P25, DOI 10.1016/0006-8993(93)90187-R; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; Rosenthal R., 1985, CONTRAST ANAL FOCUSE; SPARKS DL, 1991, BRAIN SPACE, P3; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	23	551	558	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1054	1057		10.1126/science.7973661	http://dx.doi.org/10.1126/science.7973661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7973661	Green Published			2022-12-01	WOS:A1994PQ92400048
J	ROSENTHAL, N				ROSENTHAL, N			MOLECULAR MEDICINE - STALKING THE GENE - DNA LIBRARIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; WATSON J, 1992, RECOMBINANT DNA SHOR	2	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					599	600		10.1056/NEJM199409013310908	http://dx.doi.org/10.1056/NEJM199409013310908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047086				2022-12-01	WOS:A1994PD69900008
J	HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG				HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG			HUMAN HERPESVIRUS-6 INFECTION IN CHILDREN - A PROSPECTIVE-STUDY OF COMPLICATIONS AND REACTIVATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SUBITUM ROSEOLA INFANTUM; CENTRAL-NERVOUS-SYSTEM; EXANTHEM-SUBITUM; IDENTIFICATION; ANTIBODY; MENINGOENCEPHALITIS; TRANSMISSION; PREVALENCE; POLYMERASE	Background. Infect with human herpesvirus-6 (HHV-6) is nearly universal in infancy or early childhood. However, the-course of this infection, its complications, and its potential for persistence or reactivation remain unclear. Methods. We studied infants and children under the age of three years who presented to our emergency department with acute illnesses. Infants and young children without acute illness were studied as controls. HHV-6 infection was identified by blood-mononuclear-cell culture, serologic testing, and the polymerase chain reaction (PCR). Results. No primary HHV-6 infection was found among 582 infants and young children with acute nonfebrile illnesses or among 352 controls without acute illness. Of 1653 infants and young children with acute febrile illnesses, 160 (9.7 percent) had primary HHV-6 infection, as documented by viremia and seroconversion. They ranged in age from 2 weeks to 25 months; 23 percent were under the age of 6 months. HHV-6 infections accounted for 20 percent of 365 visits to the emergency department for febrile illnesses among children 6 to 12 months old. Of the 160 infants and young children with acute HHV-6 infections, 21 (13 percent) were hospitalized, and 21 had seizures. Often the seizures appeared late and were prolonged or recurrent. HHV-6 infections accounted for one third of all febrile seizures in children up to the age of two years. In follow-up studies over a period of one to two years, the HHV-6 genome persisted in blood mononuclear cells after primary infection in 37 of 56 children (66 percent). Reactivation, sometimes with febrile illnesses, was suggested by subsequent increases in antibody titers in 16 percent (30 of 187) and by PCR in 6 percent (17 of 278). No recurrent viremia was detected. Of 41 healthy newborns studied, 12 (29 percent) had the HHV-6 genome in their blood mononuclear cells; nevertheless, 6 of these newborns subsequently had primary HHV-6 infections. Conclusions. In infants and young children HHV-6 infection is a major cause of visits to the emergency department, febrile seizures, and hospitalizations. Perinatal transmission may occur, with possible asymptomatic, transient, or persistent neonatal infection.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester	HALL, CB (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642, USA.			Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033020] Funding Source: NIH RePORTER; NCRR NIH HHS [5-MO1-RR-000-44] Funding Source: Medline; NIAID NIH HHS [R01 AI33020-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ablashi D V, 1991, In Vivo, V5, P193; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1991, NEW ENGL J MED, V324, P634; AUBIN JT, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91801-E; BERENBERG W, 1949, NEW ENGL J MED, V241, P253, DOI 10.1056/NEJM194908182410701; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BURNSTINE RC, 1959, AMA J DIS CHILD, V98, P144, DOI 10.1001/archpedi.1959.02070020146002; CASERTA MT, 1993, ANNU REV MED, V44, P377, DOI 10.1146/annurev.med.44.1.377; CASERTA MT, 1993, CLIN INFECT DIS, V17, P557; CHANDRAN B, 1992, J MED VIROL, V37, P247, DOI 10.1002/jmv.1890370403; CHERRY JD, 1992, TXB PEDIATRIC INFECT, V2, P1789; CHOU SW, 1993, J LAB CLIN MED, V121, P388; CLEMENS HH, 1945, J PEDIATR-US, V26, P66, DOI 10.1016/S0022-3476(45)80135-X; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; Dean A. G., 1990, EPI INFO VERSION 5 W; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416, DOI 10.1128/JCM.31.2.416-418.1993; DEWHURST S, 1992, VIROLOGY, V190, P490, DOI 10.1016/0042-6822(92)91240-U; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DUNNE WM, 1992, LANCET, V340, P121; DUNNE WM, 1993, J INFECT DIS, V168, P250, DOI 10.1093/infdis/168.1.250; EFSTATHIOU S, 1992, J GEN VIROL, V73, P1661, DOI 10.1099/0022-1317-73-7-1661; ENDERS G, 1990, INFECTION, V18, P12, DOI 10.1007/BF01644173; HALL CB, 1991, PEDIATR RES, V29, pA173; Huang L M, 1991, J Formos Med Assoc, V90, P579; HUANG LM, 1992, J INFECT DIS, V165, P1163, DOI 10.1093/infdis/165.6.1163; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; KAWAGUCHI S, 1992, PEDIATRICS, V90, P628; KEMPE CH, 1950, J PEDIATR-US, V37, P561, DOI 10.1016/S0022-3476(50)80266-4; KONDO K, 1993, J INFECT DIS, V167, P1197, DOI 10.1093/infdis/167.5.1197; KUSUHARA K, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91800-N; LINNAVUORI K, 1992, PEDIATRICS, V89, P103; MOLLER K L, 1956, Acta Paediatr, V45, P534, DOI 10.1111/j.1651-2227.1956.tb06912.x; OKADA K, 1993, PEDIATR INFECT DIS J, V12, P204, DOI 10.1097/00006454-199303000-00006; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; PELLETT PE, 1993, VIROLOGY, V195, P521, DOI 10.1006/viro.1993.1403; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2; PORTOLANI M, 1993, J MED VIROL, V39, P146, DOI 10.1002/jmv.1890390211; POSSON DD, 1949, J PEDIATR-US, V35, P235, DOI 10.1016/S0022-3476(49)80239-3; PREZIOSO PJ, 1992, J PEDIATR-US, V120, P921, DOI 10.1016/S0022-3476(05)81962-6; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SUGA S, 1992, MICROBIOL IMMUNOL, V36, P495, DOI 10.1111/j.1348-0421.1992.tb02047.x; SUGA S, 1992, J MED VIROL, V38, P278, DOI 10.1002/jmv.1890380409; SUGA S, 1993, ANN NEUROL, V33, P597, DOI 10.1002/ana.410330607; TAKIKAWA T, 1992, LANCET, V340, P1288, DOI 10.1016/0140-6736(92)92989-S; YAMANISHI K, 1992, MICROBIOL IMMUNOL, V36, P551, DOI 10.1111/j.1348-0421.1992.tb02055.x; YAMANISHI K, 1988, LANCET, V1, P1065; YANAGI K, 1990, J INFECT DIS, V161, P153, DOI 10.1093/infdis/161.1.153-a; YOSHIKAWA T, 1991, BLOOD, V78, P1381; YOSHIKAWA T, 1990, PEDIATR INFECT DIS J, V9, P589, DOI 10.1097/00006454-199008000-00013; YOSHIKAWA T, 1992, PEDIATRICS, V89, P888	54	428	448	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					432	438		10.1056/NEJM199408183310703	http://dx.doi.org/10.1056/NEJM199408183310703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035839				2022-12-01	WOS:A1994PB50100003
J	WOLFENDEN, R; RADZICKA, A				WOLFENDEN, R; RADZICKA, A			ON THE PROBABILITY OF FINDING A WATER MOLECULE IN A NONPOLAR CAVITY	SCIENCE			English	Article							MUTATIONS	Measurements of solubility and vapor pressure indicate that the cost of making a cavity in a nonpolar solvent that is large enough to accommodate a single water molecule is just balanced by the attraction between the water molecule and the walls of the cavity. As a result of this unexpected coincidence, the equilibrium constant for entry of an isolated water molecule from the vapor phase into cyclohexane is almost exactly unity at room temperature. Molecules smaller than water prefer the vapor phase, whereas molecules larger than water prefer cyclohexane. In equilibrium with liquid water, the tendency of single water molecules to enter small nonpolar cavities, such as may be present in mutant proteins, is expected to be vanishingly small.			WOLFENDEN, R (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM-18325] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018325, R01GM018325] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; CHRISTIAN SD, 1970, Q REV CHEM SOC, V24, P20, DOI 10.1039/qr9702400020; DORSEY NE, 1950, PROPERTIES ORDINARY; DOYLE D, UNPUB; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FINKELSTEIN A, 1987, WATER TRANSPORT LIPI, P94; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; PASCUALAHUIR JL, 1990, J COMPUT CHEM, V11, P1047, DOI 10.1002/jcc.540110907; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; UNGEMACH SR, 1974, J AM CHEM SOC, V96, P7898, DOI 10.1021/ja00833a010; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WADE RC, 1991, BIOPOLYMERS, V31, P919, DOI 10.1002/bip.360310802; WASHBURN EW, 1928, INT CRIT TABLES, V3, P210; WILHELM E, 1973, CHEM REV, V73, P1, DOI 10.1021/cr60281a001; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004	18	91	91	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					936	937		10.1126/science.8052849	http://dx.doi.org/10.1126/science.8052849			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052849				2022-12-01	WOS:A1994PB49900036
J	BOSS, LP; TOOLE, MJ; YIP, R				BOSS, LP; TOOLE, MJ; YIP, R			ASSESSMENTS OF MORTALITY, MORBIDITY, AND NUTRITIONAL-STATUS IN SOMALIA DURING THE 1991-1992 FAMINE - RECOMMENDATIONS FOR STANDARDIZATION OF METHODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REFUGEES; DISEASE; MALNUTRITION; RATES; SUDAN	Objectives.-To evaluate the various survey methods used in Somalia between 1991 and early 1993 while assessing documentation of mortality and malnutrition rates and common causes of morbidity and mortality. Data Sources.-Twenty-three population surveys were identified from the Center for Public Health Surveillance for Somalia, the United Nations Children's Fund, and other humanitarian organizations. Study Selection.-Only surveys with defined populations and apparently systematic methodology that focused on mortality, morbidity, and/or nutritional status were included. Results.-Extensive methodological differences were found among the 23 surveys. Target populations and sampling strategies varied widely. Twelve studies were considered not reproducible. Of the 16 studies assessing mortality, only eight assessed cause of death. Use of units of measurement and inclusion of denominators in rate calculations were inconsistent. None of the studies provided confidence intervals around the point estimates of the rates. Of the 11 studies providing information on morbidity, none provided case definitions. And in the 16 studies reporting nutritional status, a variety of measurement methods and definitions of malnutrition were used. Three studies presented information based on mid-upper-arm circumference measurements, and 10 presented weight-for-height data below 70% and 80% of the reference median; only four studies presented z scores.			BOSS, LP (corresponding author), CTR DIS CONTROL & PREVENT, MS F-57, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							ALLEN P, 1991, INTERAGENCY MOH NUTR; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BOSS LP, 1987, INT J EPIDEMIOL, V16, P556, DOI 10.1093/ije/16.4.556; BROWN V, 1993, HODDUR SOMALIE IMPAC; DEWAAL A, 1989, POP STUD-J DEMOG, V43, P5, DOI 10.1080/0032472031000143826; GLASS RI, 1980, LANCET, V1, P868; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MEIJMAN B, 1993, MED NEWS         AUG, V2, P5; MERCER A, 1993, HLTH SURVEILLANCE RE; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OREILLY F, 1992, NUTRITIONAL SURVEY B; RUTHERFORD GW, 1985, J TROP PEDIATRICS, V31, P143, DOI 10.1093/tropej/31.3.143; SANDLER RH, 1991, JAMA-J AM MED ASSOC, V266, P638, DOI 10.1001/jama.266.5.638; SEAMAN J, 1978, INT J EPIDEMIOL, V7, P31, DOI 10.1093/ije/7.1.31; SHEARS P, 1987, INT MIGR REV, V21, P783, DOI 10.2307/2546622; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; WOODRUFF BA, 1990, DISASTERS, V14, P151, DOI 10.1111/j.1467-7717.1990.tb01056.x; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1993, UNPUB NUTRITION MORT; 1992, MMWR-MORBID MORTAL W, V41, P913; 1992, REPORT CONSULTATION; 1989, MMWR-MORBID MORTAL W, V38, P461; 1989, MMWR-MORBID MORTAL W, V38, P455; 1993, SURVEY RESULTS BELET; 1991, MMWR-MORBID MORTAL W, V40, P443; IN PRESS REPORT SUBC; 1991, MMWR-MORBID MORTAL W, V40, P13; 1992, UNPUB HLTH MORTALITY; 1988, MASURING CHANGE NUTR; 1992, CTR PUBLIC HLTH SURV, V2, P1; 1988, MMWR-MORBID MORTAL W, V37, P641; 1993, UNPUB RESULTS MORBID; 1990, MMWR-MORBID MORTAL W, V39, P707; 1992, MMWR MORB MORT SRR13, V41, P1; 1992, REPORT UNICEF RMO NU; 1990, MMWR-MORBID MORTAL W, V39, P715; 1992, HLTH MORTALITY ASSES; 1993, MMWR-MORBID MORTAL W, V42, P304; UNPUB RESULTS MORBID; 1993, NUTRITION HLTH ASSES; 1993, RESULTS MORBIDITY MO	43	40	40	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					371	376						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028168				2022-12-01	WOS:A1994NY90300029
J	DEHAENELAMBERTZ, G; DEHAENE, S				DEHAENELAMBERTZ, G; DEHAENE, S			SPEED AND CEREBRAL CORRELATES OF SYLLABLE DISCRIMINATION IN INFANTS	NATURE			English	Article							1ST YEAR; PERCEPTION; ATTENTION; BRAIN; LIFE	THE remarkable linguistic abilities of human neonates are well documented(1-5). Young infants can discriminate phonemes even if they are not used in their native language(2-4), an ability which regresses during the first year of life(4,5). This ability to discriminate is often studied by repeating a stimulus for several minutes until some behavioural response of the infant habituates, and later examining whether the response recovers when the stimulus is changed(6). This method, however, does not reveal how fast infants can detect phonetic changes, nor what brain mechanisms are involved. We describe here high-density recordings of event-related potentials in three-month-old infants listening to syllables whose first consonants differed in place of articulation Two processing stages, corresponding to an increasingly refined analysis of the auditory input, were identified and localised to the temporal lobes. A late frontal response to novelty was also observed. The infant brain recognizes a phonetic change in less than 400 ms.	CNRS,SCI COGNIT & PSYCHOLINGUIST LAB,INSERM,F-75270 PARIS 06,FRANCE; EHESS,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	DEHAENELAMBERTZ, G (corresponding author), UNIV OREGON,INST COGNIT & DECIS SCI,EUGENE,OR 97405, USA.		Dehaene, Ghislaine/O-3633-2017	Dehaene, Ghislaine/0000-0003-2221-9081				BERTONCINI J, 1989, BRAIN LANG, V37, P591, DOI 10.1016/0093-934X(89)90113-2; BEST CT, 1988, J EXP PSYCHOL HUMAN, V14, P345, DOI 10.1037/0096-1523.14.3.345; BEST CT, 1982, PERCEPT PSYCHOPHYS, V31, P75, DOI 10.3758/BF03206203; CHI JG, 1977, ANN NEUROL, V1, P86, DOI 10.1002/ana.410010109; Courchesne E, 1983, TUTORIALS EVENT RELA, P329; EIMAS PD, 1971, SCIENCE, V171, P303, DOI 10.1126/science.171.3968.303; EMIAS PD, 1987, CATEGORICAL PERCEPTI, P161; JUSCZYK PW, 1985, MEASUREMENT AUDITION, P195; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; MILLS DL, 1993, J COGNITIVE NEUROSCI, V5, P317, DOI 10.1162/jocn.1993.5.3.317; MOLFESE DL, 1991, CEREBRAL LATERALITY, P71; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1983, ADV PSYCHOL, P119, DOI DOI 10.1016/S0166-4115(08)62036-1; NELSON CA, 1992, DEV NEUROPSYCHOL, V8, P119, DOI 10.1080/87565649209540521; NOVAK GP, 1989, ELECTROEN CLIN NEURO, V73, P295, DOI 10.1016/0013-4694(89)90108-9; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Rothbart M. K., 1990, ADV PSYCHOL, V69, P47; SCHERG M, 1990, BESA BRAIN ELECTRICA; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; VARGHAKHADEM F, 1979, BRAIN LANG, V8, P19; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WOODS DL, 1986, ELECTROEN CLIN NEURO, V65, P447, DOI 10.1016/0168-5597(86)90024-9; [No title captured]	25	234	235	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					292	295		10.1038/370292a0	http://dx.doi.org/10.1038/370292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ229	8035876				2022-12-01	WOS:A1994NZ22900063
J	LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B				LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B			THE HIGH-RESOLUTION CRYSTAL-STRUCTURE OF A PARALLEL-STRANDED GUANINE TETRAPLEX	SCIENCE			English	Article							TELOMERIC DNA; COMPLEX; OLIGONUCLEOTIDE; SEQUENCE; RNA	Repeat tracts of guanine bases found in DNA and RNA can form tetraplex structures in the presence of a variety of monovalent cations. Evidence suggests that guanine tetraplexes assume important functions within chromosomal telomeres, immunoglobulin switch regions, and the human immunodeficiency virus genome. The structure of a parallel-stranded tetraplex formed by the hexanucleotide d(TG(4)T) and stabilized by sodium cations was determined by x-ray crystallography to 1.2 angstroms resolution. Sharply resolved sodium cations were found between and within planes of hydrogen-bonded guanine quartets, and an ordered groove hydration was observed. Distinct intra- and intermolecular stacking arrangements were adopted by the guanine quartets. Thymine bases were exclusively involved in making extensive lattice contacts.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN, NUCL ACID RES GRP, DUNDEE DD1 4HN, SCOTLAND; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Dundee; University of York - UK	LAUGHLAN, G (corresponding author), UNIV GLASGOW, MRC, VIROL UNIT, CHURCH ST, GLASGOW G11 5JR, SCOTLAND.		Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; ABOULELA F, IN PRESS J MOL BIOL; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARLE IL, 1974, BIOCHEMISTRY-US, V13, P2155, DOI 10.1021/bi00707a025; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHELDRICK GM, SHELX 93; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WANG Y, 1991, J MOL BIOL, V222, P819, DOI 10.1016/0022-2836(91)90513-6; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	29	494	503	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					520	524		10.1126/science.8036494	http://dx.doi.org/10.1126/science.8036494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036494	Green Submitted			2022-12-01	WOS:A1994NY21600029
J	ZIMMERMAN, GC; GRABSKI, WJ				ZIMMERMAN, GC; GRABSKI, WJ			MALIGNANT-MELANOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ZIMMERMAN, GC (corresponding author), BROOKE ARMY MED CTR,FT SAM HOUSTON,TX 78234, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					168	168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008030				2022-12-01	WOS:A1994NW79700005
J	FOSTER, PL; TRIMARCHI, JM				FOSTER, PL; TRIMARCHI, JM			ADAPTIVE REVERSION OF A FRAMESHIFT MUTATION IN ESCHERICHIA-COLI BY SIMPLE BASE DELETIONS IN HOMOPOLYMERIC RUNS	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; SEQUENCE-ANALYSIS; MISMATCH REPAIR; DNA; HOMOLOG; CANCER; OCCUR	Spontaneous mutations are thought to occur primarily in growing cells. However, spontaneous mutations also arise in nutritionally deprived cells, and in some cases this process appears to be adaptive. Here it is reported that when a Lac(-) strain of Escherichia coli is under selection for lactose use, the spectrum of Lac(+) mutations that arises is different, and simpler, than that arising without selection. Mutations appearing during selection were mainly one-base deletions in runs of iterated bases. Similar mutations occurring in repetitive DNA elements are associated with a variety of human hereditary diseases and are increased in cells that cannot correct heteroduplex DNA.	BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	FOSTER, PL (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02118, USA.			Foster, Patricia/0000-0002-7236-4378; Trimarchi, Jeffrey/0000-0001-7923-1538	NIGMS NIH HHS [R01 GM054084-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CALOS MP, 1981, J MOL BIOL, V153, P39, DOI 10.1016/0022-2836(81)90525-8; CUPPLES CG, 1990, GENETICS, V125, P275; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; HALL BG, 1991, GENETICA, V84, P73, DOI 10.1007/BF00116545; HALL BG, 1990, GENETICS, V126, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Miller JH., 1972, EXPT MOL GENETICS; MULLERHI.B, 1974, NATURE, V249, P561, DOI 10.1038/249561a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRIVAL MJ, 1992, GENETICS, V132, P303; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Roth Jurgen, COMMUNICATION; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEELE DF, 1992, GENETICS, V132, P9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	35	169	174	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					407	409		10.1126/science.8023164	http://dx.doi.org/10.1126/science.8023164			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023164	Green Accepted			2022-12-01	WOS:A1994NW81600044
J	GODAL, T				GODAL, T			FIGHTING THE PARASITES OF POVERTY - PUBLIC RESEARCH, PRIVATE INDUSTRY, AND TROPICAL DISEASES	SCIENCE			English	Editorial Material											GODAL, T (corresponding author), UNDP,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA,SWITZERLAND.							ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; HENDERSON RH, 1994, 4TH ANN PUBL HLTH FO; 1994, WKLY EPIDEMIOL REC, V69, P145; 1993, 1993 WORLD BANK WORL, P329; 1990, HLTH RES ESSENTIAL L, P136	5	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1864	1866		10.1126/science.8009212	http://dx.doi.org/10.1126/science.8009212			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009212				2022-12-01	WOS:A1994NT84700025
J	SOUTTER, WP; FLETCHER, A				SOUTTER, WP; FLETCHER, A			INVASIVE CANCER OF THE CERVIX IN WOMEN WITH MILD DYSKARYOSIS FOLLOWED UP CYTOLOGICALLY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMEAR; COLPOSCOPY; MANAGEMENT; ATYPIA	Mildly dyskaryotic smears are common, and women with such results are often followed up with further cervical smear tests. An important consideration in evaluating this practice would be the annual incidence of invasive cervical cancer. A reanalysis of five previous studies of the cytological follow up of women with mildly abnormal smear test results was undertaken to calculate this incidence. The annual incidence of invasive cancer in these women ranged from 0 to 420 per 100 000 women years. The large studies providing the most precise estimates had annual rates of 143 to 420 per 100 000 women years. This is 16 to 47 times greater than in-women aged 15-34 years in England and Wales. The average rate was 208 per 100 000 women years. Women with mild dyskaryosis are at high risk of developing invasive cervical cancer despite cytological follow up. A full appraisal of the costs and benefits of colposcopy in this situation is urgently required.	LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT STUDIES, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	SOUTTER, WP (corresponding author), ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND.							ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BOLGER BS, 1988, BRIT J OBSTET GYNAEC, V95, P1117, DOI 10.1111/j.1471-0528.1988.tb06788.x; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; KESIC VI, 1993, INT J GYNECOL CANCER, V3, P395, DOI 10.1046/j.1525-1438.1993.03060395.x; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SIGURDSSON K, 1989, INT J CANCER, V43, P1, DOI 10.1002/ijc.2910430102; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; SOUTTER WP, 1992, REPORT WORKSHOP MILD; WALKER EM, 1986, LANCET, V2, P672; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; 1990, SERIES MB1, V18; 1987, INTERCOLLEGIATE WORK	20	59	60	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1421	1423		10.1136/bmj.308.6941.1421	http://dx.doi.org/10.1136/bmj.308.6941.1421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019256	Green Published			2022-12-01	WOS:A1994NP42000022
J	BINCHY, JM; MOLYNEUX, EM; MANNING, J				BINCHY, JM; MOLYNEUX, EM; MANNING, J			ACCIDENTAL INGESTION OF METHADONE BY CHILDREN IN MERSEYSIDE	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,LIVERPOOL L12 2AP,ENGLAND; WIRRAL HOSP,ARROWE PK L49 5PE,MERSEYSIDE,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								ARONOW R, 1973, CLIN TOXICOL, V6, P175, DOI 10.3109/15563657308990515; ARONOW R, 1972, J AMER MED ASSOC, V219, P321, DOI 10.1001/jama.219.3.321; BALTMAN S, 1971, PEDIATRICS, V48, P173; DIMAIO D J, 1973, Journal of Forensic Sciences, V18, P130; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516	5	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1335	1336		10.1136/bmj.308.6940.1335	http://dx.doi.org/10.1136/bmj.308.6940.1335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019221	Green Published			2022-12-01	WOS:A1994NM98900022
